<SEC-DOCUMENT>0001564590-22-009702.txt : 20220310
<SEC-HEADER>0001564590-22-009702.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310171510
ACCESSION NUMBER:		0001564590-22-009702
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oncternal Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001260990
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				621715807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50549
		FILM NUMBER:		22730084

	BUSINESS ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 434-1113

	MAIL ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GTX INC /DE/
		DATE OF NAME CHANGE:	20030822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>onct-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T22:05:06.8745341+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : e954f1db574f4cdbb446abea68e107eb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:onct="http://www.oncternal.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
onct-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:EntityCentralIndexKey" contextRef="C_0001260990_20210101_20211231">0001260990</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:AmendmentFlag" contextRef="C_0001260990_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001260990_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001260990_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="onct:CollaborativeArrangementPotentialMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20211231" decimals="-6">0</ix:nonFraction>
			<ix:nonNumeric id="F_000292" name="onct:ResearchAgreementTerm" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000293" name="onct:ResearchAgreementTerm" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20211202_20220101">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000385" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000475" name="onct:PeriodForCumulativeChangeInOwnership" contextRef="C_0001260990_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="C_0001260990_20210101_20211231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001260990_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001260990_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:PreferredStockValue" contextRef="C_0001260990_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:PreferredStockValue" contextRef="C_0001260990_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000376" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20190101_20191231">P2Y9M0D</ix:nonNumeric>
			<ix:nonNumeric id="F_000377" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20200101_20201231">P4Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000378" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20210101_20211231">P3Y3M22D</ix:nonNumeric>
			<ix:nonNumeric id="F_000398" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231">P8Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000399" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231">P6Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000410" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001260990_20210101_20211231">P6Y2M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000411" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001260990_20200101_20201231">P6Y8M12D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="onct-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001260990_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20220310">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_onctsegment">
				<xbrli:measure>onct:segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-05-22</xbrli:startDate>
					<xbrli:endDate>2019-05-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-17</xbrli:startDate>
					<xbrli:endDate>2021-03-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:ChiefFinancialOfficerSonMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-05-01</xbrli:startDate>
					<xbrli:endDate>2016-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:RegentsLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20211202_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-12-02</xbrli:startDate>
					<xbrli:endDate>2022-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyTwoMember_20211202_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-12-02</xbrli:startDate>
					<xbrli:endDate>2022-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyThreeMember_20211202_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-12-02</xbrli:startDate>
					<xbrli:endDate>2022-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyFourMember_20211202_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementTwoThousandTwentyFourMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-12-02</xbrli:startDate>
					<xbrli:endDate>2022-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-08-01</xbrli:startDate>
					<xbrli:endDate>2017-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210801_20210831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-08-01</xbrli:startDate>
					<xbrli:endDate>2021-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-10-02</xbrli:startDate>
					<xbrli:endDate>2021-11-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20210525">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_onctAtTheMarketFacilityMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketFacilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-07-01</xbrli:startDate>
					<xbrli:endDate>2015-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;<ix:nonNumeric id="F_000002" name="dei:DocumentType" contextRef="C_0001260990_20210101_20211231">10-K</ix:nonNumeric></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="width:4.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:40%;text-indent:0pt;;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:95.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:40%;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.08%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.92%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(D)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000003" name="dei:DocumentPeriodEndDate" contextRef="C_0001260990_20210101_20211231" format="ixt:datemonthdayyearen">December&#160;31,<ix:nonNumeric id="F_000005" name="dei:DocumentFiscalYearFocus" contextRef="C_0001260990_20210101_20211231"> 2021</ix:nonNumeric></ix:nonNumeric></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="width:4.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.82%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(D)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000018" name="dei:EntityFileNumber" contextRef="C_0001260990_20210101_20211231">000-50549</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0001260990_20210101_20211231">Oncternal Therapeutics,&#160;Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.22%;"></td>
<td style="width:0.97%;"></td>
<td style="width:48.81%;"></td>
</tr>
<tr style="height:11.15pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001260990_20210101_20211231">62-1715807</ix:nonNumeric></p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or <span style="font-size:8pt;">other jurisdiction</span> of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine1" contextRef="C_0001260990_20210101_20211231">12230 El Camino Real</ix:nonNumeric>, <ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine2" contextRef="C_0001260990_20210101_20211231">Suite 300</ix:nonNumeric><br /><ix:nonNumeric id="F_000022" name="dei:EntityAddressCityOrTown" contextRef="C_0001260990_20210101_20211231">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000023" name="dei:EntityAddressStateOrProvince" contextRef="C_0001260990_20210101_20211231">CA</ix:nonNumeric> <ix:nonNumeric id="F_000024" name="dei:EntityAddressPostalZipCode" contextRef="C_0001260990_20210101_20211231">92130</ix:nonNumeric><br />(<ix:nonNumeric id="F_000025" name="dei:CityAreaCode" contextRef="C_0001260990_20210101_20211231">858</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000026" name="dei:LocalPhoneNumber" contextRef="C_0001260990_20210101_20211231">434-1113</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)<span style="font-size:3pt;font-weight:normal;">&#160;</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:8.65pt;">
<td valign="top" style="width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title&#160;of&#160;Each&#160;Class</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:25.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol (s)</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name&#160;of&#160;Each&#160;Exchange&#160;on&#160;Which&#160;Registered</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="width:35.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:Security12bTitle" contextRef="C_0001260990_20210101_20211231">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:25.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:TradingSymbol" contextRef="C_0001260990_20210101_20211231">ONCT</ix:nonNumeric></p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:35.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000029" name="dei:SecurityExchangeName" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes <span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001260990_20210101_20211231">No</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span>.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.&#160;&#160;&#160;&#160;Yes <span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001260990_20210101_20211231">No</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span>.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric id="F_000014" name="dei:EntityCurrentReportingStatus" contextRef="C_0001260990_20210101_20211231">Yes</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric id="F_000027" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001260990_20210101_20211231">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:9.9pt;">
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntitySmallBusiness" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span> &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000031" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined by Rule&#160;12b of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;Yes <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No <span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000017" name="dei:EntityPublicFloat" contextRef="C_0001260990_20210630" decimals="-5" scale="6">212.2</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Capital Market on June&#160;30, 2021 of $4.75 per share.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of outstanding shares of the registrant&#8217;s common stock as of March 10, 2022 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000016" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001260990_20220310" decimals="INF" format="ixt:numdotdecimal">49,429,054</ix:nonFraction>.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000034" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001260990_20210101_20211231">Portions of the Registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#8217;s 2022 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2021. </ix:nonNumeric></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics,&#160;Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;10-K &#8212; ANNUAL REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Fiscal Year Ended December&#160;31,&#160;2021</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:93.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:none;">PART I</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM1_BUSINESS"><span style="text-decoration:none;">Business</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:none;">Risk Factors</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:none;">Properties</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGSFROM_Q3_FORM_10Q"><span style="text-decoration:none;">Legal Proceedings</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:93.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:none;">PART II</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:none;">[Reserved]</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7A.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 8.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENT_OR_SUPPLEMENT"><span style="text-decoration:none;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9A.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9B.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:none;">Other Information</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9C.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR"><span style="text-decoration:none;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:93.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:none;">PART III</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 10.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 11.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 12.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 13.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 14.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"><span style="text-decoration:none;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:93.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:none;">PART IV</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:none;">Form 10-K Summary</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:83.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:93.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:none;">Signatures</span></a></p></td>
<td valign="top" style="width:6.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART&#160;I</p>
<p style="margin-top:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form&#160;10-K, or this Annual Report, including the sections entitled &#8220;Summary,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; contains forward-looking statements. We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to obtain and maintain regulatory approvals for our product candidates, including zilovertamab (formerly cirmtuzumab) and ONCT-216 (formerly TK-216)&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">our ability to identify and advance into the clinic product candidates, including ONCT-808, our ROR1-targeted CAR-T cell therapy candidate, and ONCT-534 (formerly GTX-534), our dual-action androgen receptor inhibitor, or DAARI, candidate</span><span style="color:#000000;">&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the expected timing for achieving key milestones, including </span><span style="color:#000000;">commencing, </span><span style="color:#000000;">completing and announcing clinical trial results of </span><span style="color:#000000;">our product candidates</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing or likelihood of regulatory filings and approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the estimated size of the patient population and anticipated market potential for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the impact of products that compete with our product candidates that are or may become available&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain favorable regulatory designations for our product candidates and preclinical programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing upon the intellectual property rights of others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">our commercialization, marketing and reliance on third-party manufacturing capabilities and strategy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the impact the COVID-19 pandemic has had on our business and the U.S. and global economies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the plans and objectives of management for future operations and future results of anticipated products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing. </span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We qualify </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the forward-looking statements in this Annual Report by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
<p style="margin-top:14pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY OF RISK FACTORS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock is subject to numerous risks and uncertainties, including those described in Part I, Item 1A, &#8220;Risk Factors&#8221; of this Annual Report. The principal risks and uncertainties affecting our business include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The COVID-19 pandemic may adversely impact our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We depend heavily on the success of our product candidates, which are in clinical or preclinical development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the foreseeable future. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not be able to maintain orphan drug designations for some of our product candidates, and may be unable to leverage the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fast Track designation by the FDA for ONCT-216 or our other product candidates may not actually lead to a faster development or regulatory review or approval process.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to Good Laboratory Practices, Good Clinical Practices, and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:7pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademarks, trade names, and service marks referenced in this Annual Report include Oncternal<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, which is protected under intellectual property laws and is our property. All other trademarks, trade names and service marks are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report appear without the <sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;&#65039;</sup>, <sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>, or <sup style="font-size:85%;line-height:120%;vertical-align:top">sm</sup> symbols, but such references should not be construed as any indication that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.<br /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM1_BUSINESS">Item 1.<span style="font-weight:normal;margin-left:36pt;color:#000000;"></span>Business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc., or Oncternal, is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal focuses drug development on promising, yet untapped biological pathways implicated in cancer generation or progression. The following figure summarizes our current development programs:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000001.jpg" title="" alt="" style="width:596px;height:268px;" /></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Zilovertamab </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zilovertamab (formerly cirmtuzumab or UC-961) is an investigational, humanized, potentially first-in-class monoclonal antibody designed to: (i) inhibit Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, a growth factor receptor that is widely expressed on many tumors and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance&#59; and (ii) bind to a specific functionally important epitope of ROR1. ROR1 is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, a protein typically expressed during embryogenesis that may confer a survival and fitness advantage when reactivated and expressed by tumor cells. ROR1 overexpression in multiple tumor types, including mantle cell lymphoma, or MCL, chronic lymphocytic leukemia, or CLL, prostate cancer and breast cancer, and its expression has been associated with more aggressive disease, resistance to therapy and shorter progression-free survival, or PFS, and overall survival, or OS. In preclinical models, inhibition of ROR1 has shown anti-tumor activity, and we believe this may have additive or synergistic effects when combined with either targeted therapy or chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies demonstrated that zilovertamab bound with high affinity and specificity to ROR1, sparing healthy, non-cancerous tissues. When zilovertamab bound to ROR1, it blocked growth factor Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of CLL tumor cells. Zilovertamab was developed in the laboratory of one of our scientific advisors, Professor Thomas Kipps, M.D., Ph.D., Professor of Medicine and Evelyn and Edwin Tasch Chair in Cancer Research at the University </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of California San Diego</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or UC San Diego,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with support </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Institute for Regenerative Medicine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CIRM. We have an exclusive</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, worldwide</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> license to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zilovertamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutic uses from UC San Diego.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Food and Drug Administration, or FDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> granted orphan drug designations for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zilovertamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the treatment of patients with MCL and for the treatment of patients with CLL/small lymphocytic lymphoma</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or SLL,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in 2020. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zilovertamab is currently being evaluated in an ongoing Phase 1/2 clinical trial in combination with ibrutinib (Imbruvica) known as CIRM-0001 or the CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) study for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. In December 2021, we presented interim clinical data from this study at the American Society of Hematology (ASH) 2021 Virtual Annual Meeting. The objective response rate, or ORR, of 81%, complete response, or CR, rate of 35%, and median progression-free survival, or PFS, of 35.9 months we reported for patients with relapsed/refractory MCL treated with zilovertamab plus ibrutinib compared favorably to the historical ORR of 66%, CR rate of 20% and median PFS of 12.8 months previously published for patients with MCL treated with ibrutinib alone. The combination of zilovertamab and ibrutinib was well tolerated, with a safety profile consistent with or improved compared with historical data for ibrutinib monotherapy. As of January 31, 2022, we have completed enrollment of patients with MCL and CLL in the Phase 1/2 CIRLL study, and those patients are completing therapy or are in long-term follow-up. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, we announced that following a successful End-of-Phase 2 meeting with the FDA for zilovertamab, we and the FDA agreed on key elements of our potentially pivotal Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory MCL. The FDA has also reviewed and agreed upon the key design features and operational details of our Phase 3 clinical trial protocol and statistical analysis plan. <span style="color:#000000;">We expect to initiate a global Phase 3 study in the second quarter of 2022. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are supporting two investigator-sponsored studies being conducted at UC San Diego: (i)&#160;a Phase 1b clinical trial for metastatic castration-resistant prostate cancer, or mCRPC, study, which has an Investigational New Drug Application, or IND, in effect, and (ii)&#160;a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, which is open for enrollment. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional preclinical activities to evaluate zilovertamab in other cancer types, including hematologic malignancies, are ongoing. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ROR1 Cell Therapy Program</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-808, our lead cell therapy product candidate, is an autologous chimeric antigen receptor, or CAR, T cell, or CAR-T, therapy that targets ROR1, which is in preclinical development as a potential treatment for hematologic malignancies and solid tumors. ONCT-808 utilizes the binding domain of zilovertamab as a single-chain variable region fragment, or scFv. Because zilovertamab has been shown to bind specifically to multiple tumor tissues but not to normal adult tissues in preclinical studies, we believe that zilovertamab-based CAR-T cells may be selective in distinguishing cancer from normal tissues. ONCT-808 was initially developed in collaboration with UC San Diego and is being further evaluated in preclinical studies in collaboration with the Karolinska Institutet in Stockholm, Sweden and the MD Anderson Cancer Center in Houston, Texas. We are working with Lentigen Technology, Inc. (lentivirus manufacturing), or Lentigen, and Miltenyi Biotec B.V. &#38; Co. KG (cell processing) on the manufacturing aspects of the program. We have developed manufacturing production processes for both the lentivirus containing the CAR gene, and the ROR1 CAR-T cell drug product, along with all suitable release test methods enabling the submission to the FDA of an IND for the treatment of patients with relapsed/refractory B-cell malignancies, which we expect to occur in mid-2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our ROR1 cell therapy strategy includes the potential development of a next-generation cell therapy, which could include CAR-expressing immune cells bearing additional features to overcome barriers in the tumor microenvironment. targeting ROR1-expressing cancer cells in solid tumors Also, we are evaluating &#8220;off-the-shelf&#8221; or allogeneic CAR-expressing immune cells, such as chimeric antigen receptor natural killer, or CAR-NK, cell therapies. We expect partnerships and collaborations to be essential for implementing our next-generation ROR1 cell therapy strategy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ONCT-534 </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dual-Action Androgen Receptor Inhibitor</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, or </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DAARI</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Program</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-534 (formerly GTX-534), our lead dual-action androgen receptor inhibitor, or DAARI, product candidate, is in preclinical development as a potential treatment for advanced castration-resistant prostate cancer, or CRPC, and <span style="color:#000000;">other androgen receptor, or </span>AR, driven diseases. DAARIs interact with both the N-terminal domain, or NTD, and the ligand-binding domain, or LBD, of the AR inducing AR degradation, and have demonstrated preclinical activity in prostate cancer tumor models resistant to approved AR-targeting therapies. We believe ONCT-534 has the potential to address significant unmet needs related to important tumor resistance mechanisms, including AR amplification, splice variants and LBD mutations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ONCT-216</p>
<p style="margin-top:10pt;margin-bottom:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216 (formerly TK-216) is a targeted inhibitor of E26 Transformation-Specific, or ETS oncoproteins, including certain overexpressed fusion proteins. Tumorigenic fusion proteins involving the Ewing sarcoma, or EWS, protein and an ETS protein can be found in virtually all cases of Ewing sarcoma. ETS-related translocations or overexpression are also found in many other tumors, such as diffuse large B-cell lymphoma, or DLBCL, prostate cancer and acute myeloid leukemia, or AML. Researchers in the laboratory of Jeffrey Toretsky, M.D., at Georgetown Lombardi Comprehensive Cancer Center, identified the precursor to ONCT-216 using a novel chemical screening assay they developed based on a deep understanding of the underlying biological mechanism of ETS factors. Following this early work, we generated ONCT-216, which is designed to be a specific inhibitor of ETS factors, through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction. In preclinical models, ONCT-216 inhibited the interaction between ETS family members and RNA helicase A, or RHA, and by doing so, repressed excessive cell proliferation. We own intellectual property related to ONCT-216 and have an exclusive license to product candidates targeting ETS oncoproteins for therapeutic, diagnostic or research tool purposes from Georgetown University. The FDA has granted rare pediatric disease designation, as well as orphan drug and fast track designations for ONCT-216 for the treatment of Ewing sarcoma.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216 is currently being investigated as a single agent and in combination with vincristine in <span style="color:#000000;">an open-label, multicenter</span> Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma. <span style="color:#000000;">In the third quarter of 2021, we added a new Phase 2 expansion cohort targeting up to 21 Ewing sarcoma patients to evaluate clinical responses to single agent ONCT-216 at 175 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>/day, treating patients for 28 days per cycle with the next cycle starting immediately after the prior one, to intensify the amount of ONCT-216 administered over time. The expansion cohort is actively enrolling patients. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our team</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled a management team, board of directors and scientific founders who have significant experience in successfully developing and commercializing therapeutics in oncology and orphan diseases, having worked or served on the Board of companies such as Amgen, Inc., Bavarian Nordic, Inc. (lead cancer asset acquired by Bristol Meyers Squibb Company), Baxalta Incorporated (acquired by Shire PLC), Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc), Dynavax Technologies Corporation, Elan Corporation (acquired by Perrigo), Eli Lilly and Company, Gilead Sciences, Inc., Innocrin Precision Therapeutics, Inc., Johnson &#38; Johnson, Merck, Micromet, Inc. (acquired by Amgen, Inc.), Pfizer, Inc., Roche Holding AG, Sorrento Therapeutics, Inc., Tracon Pharmaceuticals, Inc., and Zavante Therapeutics, Inc. (acquired by Nabriva Therapeutics plc).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our strategy</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs. We believe our investigational agents target novel cancer pathways and have unique mechanisms of action. Our current pipeline is derived from our ability to identify therapeutic candidates that have generated promising, late-stage preclinical results or clinical data, and in-license them for further development. We are particularly focused on therapeutic approaches for which there is a genetic or protein biomarker that can be used to identify populations of patients most likely to respond. We prioritize targets that we believe have the potential to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transform the treatment </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">paradigm</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of difficult-to-treat cancers with either single agent or combination therapy. As is the case for many oncology products, we believe that potential efficacy in one indication suggests the potential for application in other indications that carry the same target.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our focus is on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hematological malignanc</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es and prostate cancer as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we believe our product pipeline can have the greatest impact in addressing unmet needs of patients </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnosed with</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> these diseases</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key elements of our strategy are as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.15pt;color:#000000;">advance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">zilovertamab</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">through</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">clinical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">development in multiple indications,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">with a primary focus</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">MCL as we expect to initiate a potentially pivotal Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory MCL in the second quarter of 2022&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.15pt;color:#000000;">advance ONCT-808, our ROR1-targeting autologous CAR-T cell therapy candidate, into clinical development for the treatment of patients with hematological malignancies, as we expect to submit a U.S. IND application in mid-2022&#59;</span><span style="color:#000000;"><br /></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance ONCT-534, our lead DAARI product candidate, into IND-enabling studies and subsequently </span><span style="letter-spacing:0.15pt;color:#000000;">into clinical development for the treatment of patients with</span><span style="color:#000000;"> advanced prostate cancer&#59;<br /></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance ONCT-216 through clinical development for the treatment of patients with relapsed/refractory Ewing sarcoma, including completion of the ongoing Phase 1/2 clinical trial&#59; and<br /></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.15pt;color:#000000;">evaluate </span><span style="color:#000000;">our product pipeline</span><span style="letter-spacing:0.05pt;color:#000000;"> in preclinical studies </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">additional</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tumors</span><span style="letter-spacing:-0.3pt;color:#000000;"> with a focus on hematological malignancies and prostate cancer. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and continues to affect economies, financial markets and business operations around the world. The pandemic may continue to directly or indirectly affect the timeline for our manufacturing activities, planned IND submissions and clinical trials, including our global Phase 3 study of zilovertamab that we plan to initiate in the second quarter of 2022. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of ongoing vaccination programs worldwide, the emergence and spread of additional variants of COVID-19, as well as the economic impact on local, regional, national and international markets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Zilovertamab - monoclonal antibody targeting ROR1</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab scientific background: inhibition of ROR1 as a therapeutic strategy in cancer</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROR1 is an onco-embryonic protein essential for normal fetal development whose expression is suppressed at birth unless reactivated as a survival factor by many different cancers. The switching-on of ROR1 is consistent with the general process of de-differentiation in cancer, in which normal cells lose their highly differentiated functions and return to a more primitive state, where they exhibit a greatly increased capacity for invasion, metastasis and resistance to treatment. This de-differentiation is associated with expression of a number of genes normally restricted to fetal development, one of which is ROR1. Cancer cells with the highest potential for self-renewal are sometimes referred to as tumor-initiating cells or cancer stem cells and are capable of invading other tissues or metastasizing to form tumors in distant sites in the body. These tumor-initiating cells are also the cells that have been found to be the most resistant to standard cancer therapies including chemotherapy and radiation therapy. Cancer cells that overexpress ROR1 have been shown to have increased survival, migration and resistance to chemotherapy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over-expression of ROR1 has been reported in multiple hematological and solid tumor types. Histological staining of over 350 human tumor samples identified that a majority expressed ROR1, including 90% or more of uterine cancers, lymphomas and prostate cancers.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cancer type</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROR1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expressed (%)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cancer type</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROR1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expressed (%)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uterus</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adrenal</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCL</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#62;95%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLL</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lymphoma</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Testicular</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colon</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovarian</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreas</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bladder</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High ROR1 expression on patients&#8217; tumor cells in a variety of cancers is associated with the development of metastases, and early relapse after therapy. ROR1 expression levels on patients&#8217; tumor cells is higher in cancers that are more advanced or poorly differentiated. For example, whereas Grade 1 or 2 ovarian tumors were found to be 21% positive for ROR1, Grade 3 or 4 tumors were found to be 62% positive for ROR1. High expression of ROR1 has been associated with more aggressive disease and shorter patient survival in multiple tumor types, including CLL, breast cancer and ovarian cancer. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inhibition of ROR1 signaling or silencing of ROR1 expression in multiple preclinical cancer models including breast cancer, ovarian cancer and glioblastoma, was associated with suppressing the expression of genes characteristic of tumor-initiating cells, and with repression of cancer migration and metastasis. Preclinical models have also demonstrated that inhibition of ROR1, or blocking of Wnt5a-induced signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells &#8211; resulting in fewer metastases and improved survival. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inhibition of ROR1 has been demonstrated in preclinical models to be additive to, or synergistic with, chemotherapy agents such as paclitaxel, and with targeted therapy agents such as ibrutinib and venetoclax. In addition, inhibition of ROR1 has been shown to enhance sensitivity of cancer cells to targeted therapy with agents, such as erlotinib and may increase apoptosis and decrease proliferation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, we believe that ROR1 is an attractive therapeutic target in oncology for several reasons:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ROR1 is widely expressed </span><span style="letter-spacing:0.15pt;color:#000000;">on </span><span style="color:#000000;">many tumors, </span><span style="letter-spacing:0.2pt;color:#000000;">including </span><span style="letter-spacing:0.15pt;color:#000000;">hematologic malignancies </span><span style="letter-spacing:0.1pt;color:#000000;">and solid </span><span style="color:#000000;">tumors&#59;<br /></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expression of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">high</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">levels</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">of</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">ROR1</span><span style="letter-spacing:0.1pt;color:#000000;"> on patients&#8217; tumors is </span><span style="color:#000000;">associated with</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rapid</span><span style="letter-spacing:0.05pt;color:#000000;"> disease </span><span style="color:#000000;">progression, resistance to therapy</span><span style="letter-spacing:0.1pt;color:#000000;"> and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">shorter</span><span style="letter-spacing:-0.45pt;color:#000000;"> patient </span><span style="letter-spacing:0.1pt;color:#000000;">survival</span><span style="color:#000000;">, and therefore may represent an especially high unmet medical need</span><span style="letter-spacing:0.1pt;color:#000000;">&#59;<br /></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Blocking of ROR1 activity in preclinical models inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells, thus depriving the cancer of essential functionalities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inhibition of ROR1 has been observed in preclinical models to be synergistic with certain chemotherapies and targeted therapies, potentially allowing for safer and more efficacious combination therapies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Clinical data presented for MK-2140 (formerly VLS-101) a ROR1-targeting antibody-drug conjugate, or ADC, presented at the ASH 2021 Annual Meeting did not reveal any unusual or unexpected off-tumor organ toxicity and are consistent with our clinical observations. Zilovertamab is the ROR1 antibody used in the MK-2140 product candidate. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two notable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisitions in 2020 involved companies developing product candidates targeting ROR1: Merck &#38; Co. acquired </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VelosBio</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Inc. and its ROR1-targeting ADC (which was initially developed at Oncternal), and Boehringer-Ingelheim acquired NBE Therapeutics and its ROR1-targeting ADC.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab development in MCL and CLL</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">MCL disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCL is an aggressive form of non-Hodgkin&#8217;s lymphoma. There are approximately 4,200 new cases of MCL each year in the U.S., with the average age at diagnosis in the mid-60s. MCL is an aggressive lymphoma and carries a poor prognosis, with a median survival of about two to five years. The 10-year survival rate is only approximately 5-10%. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are several therapeutic options available to treat patients with relapsed or refractory MCL, we believe none of these options offers curative benefit, with most patients relapsing in less than 20 months. Inhibitors of Bruton&#8217;s Tyrosine kinase, or BTK, such as ibrutinib (Imbruvica), are emerging as a standard of care in patients who have failed other therapies. Most patients progress after 1-2 years of BTK inhibitor monotherapy (Rule et al 2017). As a result, we believe that more effective and better tolerated therapies with shorter treatment periods represent a significant unmet need.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CLL disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLL is the most common form of leukemia in adults, accounting for 25-30% of all leukemias in the U.S. According to The Surveillance, Epidemiology, and End Results (SEER) Program, an estimated 21,250 new cases of CLL were expected to occur in the U.S. in 2021, and in 2018 the prevalence of CLL in the U.S. was estimated to be 195,129 patients. CLL is primarily a disease of older adults. The median age at diagnosis is 71 years of age. Most patients are diagnosed as a result of routine blood work when elevated levels of lymphocytes are detected.</p>
<p style="margin-top:10pt;margin-bottom:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BTK inhibitor therapy has emerged as a standard of care for CLL and is recommended by the National Comprehensive Cancer Network (NCCN) guidelines as first-line therapy. Patients with CLL can experience a substantial period of disease control, but the disease eventually recurs, and is more likely to do so for patients with previous CLL therapy. Adverse events have been shown in a real-world analysis to limit ibrutinib treatment duration for almost half of all patients. An acceptable safety profile may be particularly important for patients with CLL who are older and may have multiple co-morbidities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to Evaluate Pharma, the global market for CLL therapies was estimated to be $9.1 billion in 2021, largely driven by targeted therapies, including ibrutinib, venetoclax, and acalabrutinib. We believe that CLL represents an attractive clinical and commercial opportunity for <span style="color:#000000;">zilovertamab</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab preclinical summary in MCL and CLL</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROR1 is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, which is a protein typically expressed during embryogenesis that may confer a survival and fitness advantage when reactivated and expressed by tumor cells. ROR1 is over-expressed in many different cancers, including MCL, CLL, breast cancer and prostate cancer, and has been reported to be associated with more aggressive disease, resistance to therapy and shorter PFS or OS. In preclinical models, inhibition of ROR1 has shown anti-tumor activity and we believe may have additive or synergistic effects when combined with either targeted therapy or chemotherapy.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zilovertamab is an investigational, humanized monoclonal antibody designed to bind to a specific functionally important epitope of ROR1. The ligand for ROR1 in hematologic malignancies is Wnt5a, a secreted glycoprotein that has a critical role in embryonic and fetal development. Researchers at the UC San Diego School of Medicine discovered that targeting a critical epitope on ROR1 was key to inhibiting Wnt5a activation, specifically targeting ROR1 expressing tumors. This led to the development of <span style="color:#000000;">zilovertamab</span>, which binds this critical epitope of ROR1. Preclinical studies demonstrated that zilovertamab binds with high affinity and specificity to ROR1, sparing healthy, non-cancerous tissues. Z<span style="color:#000000;">ilovertamab</span> was not observed to bind to normal adult tissues in a Good Laboratory Practice, or GLP, tissue cross-reactivity study.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tudies have shown that ROR1 expression on tumor cells accelerated the development and progression of leukemia in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">animal </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">models of CLL</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and that Wnt5a enhanced CLL cell viability, migration and proliferation in a ROR1-dependent manner. Patients with high levels of ROR1 on their CLL cells have more aggressive disease and have a significant reduction in survival</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An analysis of MCL and CLL patient samples has shown that ROR1 surface expression, as well as secreted Wnt5a levels, were comparable between patients with MCL and CLL.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies also showed that when zilovertamab bound to ROR1, it blocked growth factor Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of CLL tumor cells. Preclinical studies with zilovertamab showed that treating MCL or CLL patient&#8217;s tumor cells with a combination of zilovertamab and ibrutinib led to reduced proliferation. Additional in vitro studies showed that the combination of zilovertamab plus BTK inhibitor remains active in certain MCL cells that had become insensitive to BTK inhibitor alone. In vivo<span style="font-style:italic;"> </span>studies conducted in mouse models of human CLL have shown that ibrutinib and zilovertamab exerted antitumor activities through independent pathways&#59; that is, inhibition of BTK by ibrutinib did not alter ROR1 signaling, nor did it impair the rate at which zilovertamab blocked ROR1 signaling. The combination of both drugs reduced the size of the spleen, the primary site of leukemic disease in these mice, as well as the number of CLL cells in these spleens. Further preclinical studies suggested that zilovertamab was synergistic with venetoclax in vitro. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab clinical development in MCL and CLL</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Zilovertamab Phase 1 clinical trial in patients with CLL</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 dose escalation clinical trial of zilovertamab, which was funded primarily by Oncternal and CIRM, was conducted in 26 patients with actively progressing CLL who had relapsed or refractory disease. Patients received four doses of zilovertamab administered every two weeks in cohorts of three, with patients receiving escalating doses ranging from 0.15 to 20 mg/kg/dose. Zilovertamab infusions were generally well tolerated. There were no dose-limiting toxicities, no serious adverse events, and no discontinuations related to adverse events. The most common adverse events included anemia, thrombocytopenia, and neutropenia, which were primarily attributed to the underlying CLL. Pharmacokinetic data showed a plasma half-life of approximately 32 days following four doses of zilovertamab at 16 mg/kg. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this clinical trial, 22 patients were evaluable for response assessment&#59; four patients who discontinued zilovertamab early without meeting criteria for progressive disease were not considered evaluable. No patients met criteria for complete or partial remission following this brief treatment. Seventeen of 22 evaluable patients had stable disease, or SD. Five patients had progressive disease. Most patients experienced reductions in their leukemic lymphocyte counts and were able to delay initiation of further treatments for an average of 262 days, at which point plasma levels of zilovertamab were undetectable. Although zilovertamab therapy was limited to four doses, one patient who received zilovertamab at 20 mg/kg had a greater than 50% reduction in lymphadenopathy. Analysis of blood samples from these patients prior to treatment showed significantly higher plasma levels of Wnt5a compared to healthy matched controls. Patients also had high levels of expression of ROR1 on their CLL cells. In addition, when compared to baseline, cells from zilovertamab treated patients showed a reduction in expression of a panel of genes identified as being highly correlated with stem cells and oncogenic dedifferentiation. These results were consistent with preclinical observations that zilovertamab-induced ROR1 inhibition may drive cells away from a stem-cell-like profile.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab CIRLL Phase 1/2 clinical trial in combination with ibrutinib in patients with MCL and CLL</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal and UC San Diego, with funding from CIRM, and a donation of ibrutinib product from Pharmacyclics LLC, are conducting a Phase 1/2 trial of zilovertamab in combination with ibrutinib in patients with relapsed/refractory MCL, or patients with CLL who are either relapsed/refractory or treatment-na&#239;ve (the CIRLL study). This clinical trial was designed to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of zilovertamab in combination with ibrutinib in adult patients with adequate performance status and organ function. The study has 3 parts:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part 1</span><span style="font-weight:normal;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dose Finding</span><span style="font-weight:normal;"> is a Phase 1b, open-label, sequential allocation, dose-finding evaluation of the sequential administration of </span><span style="font-weight:normal;">zilovertamab</span><span style="font-weight:normal;"> monotherapy for 4 weeks followed by </span><span style="font-weight:normal;">zilovertamab</span><span style="font-weight:normal;"> plus ibrutinib therapy in patients with relapsed/refractory MCL or CLL/SLL. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part 2<span style="font-weight:normal;"> </span>Expansion<span style="font-weight:normal;"> is a Phase 2, open-label evaluation of the concurrent administration of zilovertamab plus ibrutinib in patients with relapsed/refractory MCL or CLL/SLL, using the recommended dose regimen for zilovertamab derived from Part 1. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part 3<span style="font-weight:normal;"> is a 2:1 randomized Phase 2 open-label, controlled, 2-arm, parallel group evaluation of the clinical activity and safety of zilovertamab plus ibrutinib versus ibrutinib alone in patients with treatment-na&#239;ve or relapsed/refractory CLL/SLL only. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed enrollment of patients with CLL in Parts 1, 2 and 3, and those patients are completing therapy or are in long-term follow-up. Following an evaluation of safety and PK data from Part 1, the recommended dose regimen, or RDR, of zilovertamab for Part 2 was determined to be 600 mg of zilovertamab administered intravenously every two weeks for three doses, followed by dosing every four weeks until disease progression or intolerance develop. This zilovertamab regimen was designed and chosen to be used in combination with 560 mg of ibrutinib once daily for patients with MCL, or 420 mg of ibrutinib administered once daily for patients with CLL, which are the FDA-approved doses of ibrutinib in these indications. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab CIRLL Phase 1/2 clinical trial interim data in MCL</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In December 2021, we presented updated interim data from the CIRLL trial in patients with MCL and CLL at the ASH 2021 Annual Meeting. As of the October 1, 2021 data cutoff date, 26 of the 31 patients with relapsed/refractory MCL enrolled in the dose-finding and dose-expansion cohorts of the CIRLL Phase 1/2 clinical trial were evaluable for efficacy. These patients had high-risk factors and were heavily pre-treated at study entry, 52% with a high Ki-67 proliferative index (&#8805;30%), or High Ki-67 Patients, and 45% with intermediate/high simplified MCL international prognostic impact (sMIPI) score. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The majority of drug-related treatment-emergent adverse event, or TEAES, and all Grade 3 or higher TEAEs in this study were deemed to be related to ibrutinib by the Investigators. No Grade 3 or higher TEAEs were deemed to be related to zilovertamab alone, and no new events were deemed to be unique to the combination therapy. The adverse event profile for ibrutinib plus zilovertamab was consistent with the published literature and prescribing information for single&#8209;agent ibrutinib. Encouraging TEAEs related to myelosuppression appeared to be lower than expected for ibrutinib treatment, so quantitative analysis of complete blood count data for MCL was undertaken. Grade 3 or greater neutrophil decrease and platelets decrease of 9.7% for zilovertamab plus ibrutinib, respectively, appear to be qualitatively lower than the 29% Grade 3 or greater neutrophils decreased and 17% platelets decreased reported for the ibrutinib MCL registration study. This could be related to the observation that residual tumor cells during ibrutinib treatment express ROR1, which is activated by its ligand Wnt5a, leading to cross-activation of inflammatory pathways including JAK/STAT and secretion of inflammatory chemokines and cytokines including IL6 and IFN-gamma. Zilovertamab has been shown to inhibit this inflammatory activity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The clinical outcomes reported for patients with MCL in Study CIRM-0001 were very encouraging. The ORR was 81% (21 of 26 evaluable patients) and: (i) nine (35%) achieved a CR&#59; (ii) 12 (46%) achieved a partial response, or PR&#59; and (iii) three (12%) had SD, for a total clinical benefit rate (CR, PR, SD) of 92% as of the data cutoff date. CRs have remained durable for up to 32 months. The ORR and median duration of response were favorable in patients with high-risk features associated with difficult to treat disease. High Ki-67 Patients had an ORR of 85% and a median duration of response of 14 months (95% confidence interval 13.7 months - not evaluable). Patients that had received more than one systemic prior therapy had an ORR of 82%, with the median duration of response not reached for patients receiving two prior lines of systemic therapy and 34 months (95% confidence interval 13.7 months to 34.1 months) for patients receiving three or more prior lines of systemic therapy. Five patients had received prior treatment with ibrutinib, with two achieving CRs and two achieving PRs. One patient that received prior treatment with ibrutinib had SD. Median PFS was 35.9 months, after a median follow-up of 14.4 months (95% confidence interval 11.4 months to 19.3 months), regardless of the number of prior systemic therapies. Median PFS had not been reached for patients achieving a CR. We believe these clinical results have the potential to translate into significantly improved clinical outcomes because they compare favorably with published historical data of a merged analysis of 370 patients with relapsed/refractory MCL from three clinical trials who had received a median of two prior therapies (Rule et al., 2017, British Journal of Haematology), which showed an ORR of 66%, CR rate of 20%, and median PFS of 12.8 months (95% confidence interval 8.5 &#8211; 16.6 months) for patients with MCL who were treated with single agent ibrutinib. Results from the ASH 2021 Annual Meeting poster presentation for patients with MCL treated with zilovertamab plus ibrutinib are shown in the figures below. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 1. Study CIRM-0001. Best Tumor Response from Baseline (Percentage Reduction)&#59; Patients with MCL&#59; Evaluable Population Administered Zilovertamab and Ibrutinib.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000002.jpg" title="" alt="" style="width:564px;height:433px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 2. Study CIRM-0001. Progression Free Survival in Patients with MCL&#59; Evaluable Population Administered Zilovertamab and Ibrutinib.</p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000003.jpg" title="" alt="" style="width:574px;height:309px;" /></p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 3. Study CIRM-0001. Progression Free Survival by Prior Systemic Therapy&#59; in Patients with MCL&#59; Evaluable Population Administered Zilovertamab and Ibrutinib.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000004.jpg" title="" alt="" style="width:603px;height:343px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 4. Study CIRM-0001. Progression Free Survival by p53 Mutation in Patients with MCL&#59; Evaluable Population Administered Zilovertamab and Ibrutinib. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000005.jpg" title="" alt="" style="width:607px;height:355px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 5. Study CIRM-0001. Progression Free Survival by sMIPI Subtypes in Patients with MCL&#59; Evaluable Population Administered Zilovertamab and Ibrutinib.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000006.jpg" title="" alt="" style="width:606px;height:324px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab CIRLL Phase 1/2 clinical trial interim data in CLL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The interim CIRM-0001 study results for patients with CLL reported at ASH 2021 were also encouraging.&#160;&#160;As of the&#160;October 1,&#160;2021&#160;data cutoff date, all 34 patients with CLL enrolled in the dose-finding and dose-confirming cohorts of this clinical trial were evaluable for efficacy. Patients had high-risk factors, and most were heavily pre-treated at study entry, with&#160;71% having RAI staging II or higher&#160;and a median of two systemic prior therapies&#160;(range 1-15). The ORR was 91% (31&#160;of 34 evaluable patients),&#160;consistent with prior published results.&#160;The CR rate was&#160;6% (two&#160;of 34 evaluable patients). Twenty-nine&#160;patients (85%) achieved a PR and&#160;three&#160;patients (9%) had SD, for a total clinical benefit rate (CR, PR, SD) of 100%. Median PFS&#160;in patients with two or fewer prior therapies had&#160;not been reached, and patients with more than two prior therapies had a median&#160;PFS&#160;of 36.1 months after a median follow-up of 29.0&#160;months (95% confidence interval 27.6 months to 31.6 months) in this&#160;high risk and mostly heavily pre-treated CLL population.&#160;Based on the Kaplan-Meier curve, landmark progression-free survival, or PFS, of&#160;approximately&#160;85% and&#160;approximately&#160;65% at 24 and 36 months, respectively,&#160;for CLL patients&#160;who had previously received&#160;two or more&#160;prior lines of therapy compared favorably to historical ibrutinib monotherapy of&#160;approximately&#160;65% and&#160;approximately&#160;50%, respectively&#160;(Byrd&#160;2019). Landmark PFS&#160;was 100%&#160;at 36 months for CLL patients with&#160;two or fewer prior lines of therapy, which&#160;compares&#160;favorably to historical ibrutinib monotherapy of&#160;approximately&#160;75%&#160;(Byrd&#160;2019). </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thirty-one&#160;patients&#160;with CLL have also been&#160;enrolled in the (2:1) randomized efficacy cohort of the clinical trial, of which 22 were evaluable for efficacy.&#160;Data&#160;on&#160;this cohort&#160;are maturing, and&#160;median PFS&#160;for both arms had&#160;not been reached&#160;as of the October 1,&#160;2021&#160;cutoff date. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 6. Study CIRM-0001. Best Tumor Response from Baseline (Percentage Reduction)&#59; Patients with CLL&#59; Evaluable Population Administered Zilovertamab and Ibrutinib.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000007.jpg" title="" alt="" style="width:572px;height:419px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 7. Study CIRM-0001. PFS in the CLL Cohort in Phase 1/2 Clinical Trial of Zilovertamab in Combination with Ibrutinib, as of October 1, 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000008.jpg" title="" alt="" style="width:497px;height:320px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to announce a data update from this Phase 1/2 clinical trial in the second quarter of 2022.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab Phase 3 Study ZILO-301 in patients with Relapsed/Refractory MCL<span style="font-size:15pt;font-style:normal;"><br /></span></p>
<p style="margin-bottom:5pt;margin-top:5pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, we announced that following a successful End-of-Phase 2 meeting with the FDA for zilovertamab, we and the FDA agreed on key elements of the company&#8217;s potentially pivotal Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory MCL. The FDA has also reviewed and agreed upon the key design features and operational details of our Phase 3 clinical trial protocol and statistical analysis plan. Based on these agreements, we plan to conduct ZILO-301, a Phase 3 clinical trial entitled &#8220;Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study of Zilovertamab Plus Ibrutinib Versus Ibrutinib Plus Placebo in Patients with Relapsed or Refractory Mantle Cell Lymphoma.&#8221; The study will randomize patients with relapsed or refractory MCL who have experienced SD or achieved a PR after receiving four months of oral ibrutinib therapy to receive either blinded zilovertamab or placebo, and all patients will continue receiving oral ibrutinib. The primary endpoint, intended to support submission of a Biologics License Application, or BLA, seeking regular FDA approval, will be PFS. An interim analysis potentially supporting submission of a BLA seeking accelerated FDA approval will be conducted with a primary endpoint of ORR, plus Duration of Response, or DOR. The FDA previously provided positive feedback on the sufficiency of the preclinical and pharmacology studies of zilovertamab needed to support a BLA submission.</p>
<p style="margin-bottom:5pt;margin-top:5pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study ZILO-301 will be conducted internationally in at least 50 centers with demonstrated expertise treating MCL, with initiation expected in the second quarter of 2022. The Phase 3 trial is designed to evaluate up to 250 randomized patients.</p>
<p style="margin-bottom:5pt;margin-top:5pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also planning to conduct Study ZILO-302, an open-label companion clinical trial to Study ZILO-301. Patients who have progressive disease during the initial four months of ibrutinib monotherapy from Study ZILO-301 will be enrolled and treated with zilovertamab plus ibrutinib, to determine whether ROR1 inhibition can sensitize patients to ibrutinib therapy. If successful, Study ZILO-302 could result in an additional approval or label expansion for this underserved patient population.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab</span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;"> development in </span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">prostate</span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;"> cancer</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prostate cancer disease overview</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate cancer is the second most frequently diagnosed cancer among men in the U.S. behind skin cancer, according to the American Cancer Society. While patients with localized prostate adenocarcinoma have 5-year survivals that approach 100% according to the SEER Program database, outcomes are much more dismal in the metastatic setting, with an estimated 5-year survival of 30%. Much of this mortality is attributed to castrate resistant disease, in which the malignancy develops the ability to progress despite androgen deprivation or blockade. In its castrate resistant state, the disease is characterized by impaired quality of life and diminished survival. Current management strategies include hormonal and cytotoxic therapies. Though these approved therapeutic agents have slightly prolonged survival for patients with this disease, responses are not durable and nearly all patients develop resistance. Moreover, many of these therapies are not targeted and in the case of cytotoxic therapies, are associated with toxicity and poor tolerability. Despite a growing understanding of the molecular signaling associated with prostate cancer growth, there remains a paucity of targeted therapies in the management of prostate adenocarcinoma.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROR1 is expressed by approximately 90% of prostate cancers, and the Wnt5a signaling pathway is activated in patients with advanced prostate cancer that is progressing while on treatment with an AR inhibitor. Treatment of prostate cancer cell lines with an AR inhibitor was found to increase the expression of Wnt5a, and the addition of Wnt5a attenuated the antiproliferative effect of AR inhibition. The expression of Wnt5a in the tumors of patients with mCRPC has been associated with poor OS. Notably, ROR1 expression has also been shown on certain prostate cancer cell lines that had lost dependence on the AR signaling pathway, an important mechanism of resistance development in advanced prostate cancer. We are collaborating with academic investigators to investigate the potential effects of zilovertamab on this disease.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Zilovertamab clinical development in prostate cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An investigator-sponsored prospective, open-label, non-randomized, one-arm Phase 1b study to evaluate the safety and efficacy of, and to determine the recommended Phase 2 dose, or RP2D, of, docetaxel combined with zilovertamab in patients with mCRPC is about to open at UC San Diego, with an IND in effect.  During the treatment period, zilovertamab and docetaxel will be administered by IV infusion on an outpatient basis. Initially, zilovertamab be given as a series of loading doses with biweekly IV infusions on days 1, 15, and 29 of cycle 1. Following this, zilovertamab will be given concurrently with docetaxel (cycles 2 up to 6 depending on tolerance to docetaxel) and each cycle will be 21 days in length. Patients will be treated for a maximum of six cycles with combination therapy. Following completion or discontinuation of docetaxel, cycle length will be 28 days and zilovertamab will be administered day 1 of every 28-day cycle starting at cycle 8 (or earlier depending on tolerance). Zilovertamab will be administered IV on day 1 of the cycle. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Zilovertamab development in breast cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.78%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Zilovertamab was evaluated in an investigator-sponsored single-arm, open-label, Phase 1b trial of zilovertamab in combination with paclitaxel in patients with locally advanced, unresectable or metastatic HER2-negative breast cancer. The primary objective of this trial was to determine the safety and tolerability during the first four weeks of fixed dose zilovertamab when administered in combination with weekly standard of care paclitaxel to patients with metastatic, or locally advanced, unresectable breast cancer. The treatment regimen was zilovertamab at a dose of 600 mg on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle, and paclitaxel weekly at a dose of 80 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>. The study was completed by UC San Diego and analyzed based on a data cutoff of August 12, 2021. Twenty-three patients were screened, and 16 were treated with paclitaxel and zilovertamab. Adverse events were consistent with the known safety profile of paclitaxel alone. There was no dose limiting toxicity, no discontinuations and no serious adverse events attributed to zilovertamab. Adverse events possibly related to zilovertamab included nausea, neutrophil count decreased, and constitutional symptoms. Among the 16 patients in the intent-to-treat population, the ORR was 37.5% (95% confidence interval 15.2% - 64.6%) with six patients experiencing PR, and the best response rate, including SD, was 75.0% (95% confidence interval 47.6% - 92.7%). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">A</span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">dditional </span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">p</span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">otential clinical opportunities for </span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">zilovertamab</span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">in </span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">other </span><span style="font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">solid tumors</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Lung cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 77% to 93% of lung cancers. In adenocarcinoma of the lung, higher levels of ROR1 expression were correlated with advanced stages of disease and with positive lymph node metastases. In addition, Kaplan-Meier survival analysis indicated an association of high ROR1 expression with worse OS in lung adenocarcinoma patients. ROR1 expression has been shown to be correlated with the presence of other negative prognostic factors such as phosphorylated AKT, or p-AKT, or phosphorylated CREB, or p-CREB. Inhibition of ROR1 in lung cancer cell lines induced apoptosis and cell cycle arrest and led to a reduction in levels of p-CREB and p-AKT. Notably, a recent preclinical study has shown that downregulating ROR1 expression re-sensitizes erlotinib-resistant lung cancer cells to an EGFR inhibitor drug.  </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ovarian cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 54% of ovarian cancers, which is the most lethal gynecologic malignancy among women worldwide. Analysis of ROR1 expression on ovarian cancer patient samples revealed that disease-free survival and OS rate in patients with high ROR1 expression were significantly lower than in patients with low or no ROR1 expression. In a preclinical study, it was shown that a ROR1 antibody inhibited growth of ovarian cancer cell lines in vitro and slowed tumor growth in a mouse model. Zilovertamab also demonstrated an anti-proliferative effect on certain ovarian and endometrial cancer cell lines in vitro.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pancreatic cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 83% of pancreatic cancers. A recent preclinical study has shown that blocking ROR1 led to apoptotic cell death, which was further enhanced in combination with chemotherapeutic drugs such as erlotinib and ibrutinib, when tested against a panel of pancreatic cancer cell lines.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROR1 CAR-T Cell Therapy Program</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We are developing our CAR-T cell therapy candidate based on the ROR1 binding domain of zilovertamab to treat patients with aggressive hematological malignancies or solid tumors. We believe that the selective expression of ROR1 on many tumor cells and its absence on normal cells make it an ideal target for a CAR-T cell therapy approach. In addition, we believe that ROR1-negative relapses might be less likely to develop after ROR1 CAR-T cell therapy, because the survival benefit imparted on cancer cells by ROR1-associated activities may limit the development of ROR1-negative tumors, such that tumor cells that lose or mutate ROR1 to escape CAR-T cell treatment may be less aggressive than the parental cells. Our ROR1-targeting CAR-T cell therapy candidate, ONCT-808, is in preclinical development and we expect to submit to the FDA our first IND for the treatment of patients with relapsed/refractory B-cell malignancies in mid-2022. We are pursuing a two-pronged development strategy for our ROR1 CAR-T cell therapy program. The first part of the strategy is to demonstrate evidence of safety and clinical activity of our ROR1 CAR-T cell therapy in humans while seeking to reduce the development risks by using an established autologous CAR-T approach and targeting hematological indications that are known to be susceptible to CAR-T cell therapy. The second part of the strategy will be to develop next-generation cell therapies targeting ROR1 by introducing more advanced cell therapy technologies, which could include CAR-T cells bearing additional features to overcome the solid tumor microenvironment, as well as &#8220;off-the-shelf&#8221; or allogeneic CAR-T cell or CAR-NK cell therapies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We expect partnerships and collaborations to be essential for implementing our next-generation strategy. In January 2021, we announced a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells from the laboratory into the clinic. In September 2021, we announced a research collaboration with Celularity Inc., or Celularity, to evaluate placental derived-cellular therapies targeting ROR1. As part of the collaboration,&#160;Celularity&#160;will explore in preclinical studies: (i) the use of zilovertamab in combination with Celularity&#8217;s natural killer cells, and (ii) ROR1-targeted chimeric antigen receptor, or CAR, gene modification in Celularity&#8217;s CYNK natural killer cell and CyCAR-T cell platforms.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We are also collaborating with SPH for our CAR-T cell therapy program, through its U.S. subsidiary Shanghai Pharmaceutical (USA) Inc., or SPH USA. SPH USA </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">entered into</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> the SPH USA License Agreement with us to develop ROR1-targeted CAR-T cell therapy product candidates in greater China. </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">One of </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SPH USA</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s affiliates </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intend</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> to conduct one or more initial clinical trials of </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the licensed ROR1 </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cell therapy candidate at hospitals in China that have experience with processing cellular immunotherapy materials and conducting CAR-T </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">cell therapy </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">clinical trials.</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Scientific background: CAR-T cell therapy overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immuno-oncology approaches to treating cancer involve redirecting one of the pillars of the immune system, the adaptive immune system, so that it specifically and efficaciously recognizes cancerous cells that might previously have escaped immune recognition. A key element in the adaptive immune response is the T cell that can recognize and kill infected and abnormal cells. T cells also act to signal other immune cells to respond to threats. T cells recognize their targets because they are selected in a way that allows them to specifically recognize foreign antigens on the surface of other cells.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T cells are well suited for immuno-oncology applications based on several characteristics. They have evolved to be exquisitely specific and avid killers. One T cell can eliminate numerous target cells. T cells are extremely specific, able to recognize a cancer cell and kill it, while ignoring an almost identical healthy cell. T cells are thought to be vigilant all the time, eliminating cancer cells from the body before they can form tumors. However, tumor cells sometimes evolve to escape T cell killing by activating a number of pathways that suppress T cell function. Adoptive T cell therapies, and specifically CAR-T cells, are being developed to provide methods to generate large quantities of T cells capable of specifically recognizing and killing tumor cells despite tumor suppressive mechanisms.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cells are generated by isolating T cells from patients and modifying them to recognize specific antigens on tumors. T cells have potent cell killing activity that is directed to target cells that are recognized by specific T cell receptors, or TCRs, that are expressed on the surface of these T cells. While some T cells have TCRs that can recognize cancer cells leading to their killing, potent T cells do not develop against all tumor targets. In some cases, the potential cancer cell target is also a protein that has an essential role in other tissues or at other stages of development, and TCRs that recognize these targets are eliminated during normal T cell development.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cell therapy has emerged as a way to engineer T cells to recognize specific targets, such as those that are selectively expressed on cancer cells. A gene encoding a chimeric protein is constructed that contains a single antigen-binding domain of an antibody that specifically recognizes the target, which is coupled to a T cell costimulatory domain and a portion of the T cell receptor.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cell therapies are typically produced from a patient&#8217;s own T cells, which are isolated by leukapheresis. These cells are then genetically modified with the chimeric antigen gene construct which can be delivered by various mechanisms, such as lentiviral gene delivery vectors. Transduced cells are then expanded and undergo quality testing before being reintroduced into the same patient. This approach is also known as autologous CAR-T cell therapy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;font-weight:bold;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 8. CAR-T Production and Patient Treatment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000009.jpg" title="" alt="" style="width:323px;height:214px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DAARI Program&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-534, our lead DAARI program candidate, is a novel investigational, potentially first-in-class, orally bioavailable, AR dual-action inhibitor, for the treatment of patients with mCRPC and other AR-driven diseases. Based on preclinical studies, we believe ONCT-534 has the potential to be a novel treatment option for patients with advanced prostate cancer. We licensed ONCT-534 and certain other DAARI program rights from the University of Tennessee Research Foundation, or UTRF, under an exclusive, worldwide license agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 9. <span style="color:#000000;">Schematic Representation of Clinically Relevant Domains of the Androgen Receptor.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000010.jpg" title="" alt="" style="width:534px;height:141px;" />&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have chosen AR antagonism and degradation as our target mechanism of action focus due to the well-documented biology of AR signaling as the principal driver of prostate cancer. ONCT-534 has demonstrated activity in preclinical models of AR overexpression, AR mutations, as well as AR splice variants, all common mechanisms of resistance to current standard of care agents in advanced prostate cancer. ONCT-534 has a potentially novel and unique mechanism of action: interacting with both the NTD and LBD of the AR, inhibiting AR function as well as inducing AR protein degradation. We believe that this NTD binding is relevant to the activity of ONCT-534 against tumors expressing AR splice-variants that do not contain an LBD. Current standard of care treatment options, such as enzalutamide or apalutamide, bind only to the LBD of the AR, which may explain their reduced efficacy in patients with AR-SV-expressing tumors, as these AR variants lack the LBD. We believe that the differentiated dual-action pharmacology of ONCT-534 has the potential to translate into improved clinical outcomes over current standard of care agents.&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Prostate cancer overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately one-third of all prostate cancer patients who have been treated for local disease with curative intent will subsequently have rising serum levels of prostate-specific antigen, or PSA, which is an indication of recurrent disease with or without development of distant metastasis. Patients with recurrent disease as indicated by rising PSA usually undergo androgen deprivation therapy, or ADT. While most of these patients initially respond to ADT, many experience a recurrence in tumor growth despite the reduction of testosterone to castrate levels, and at that point are considered to have castrate resistant prostate cancer, or CRPC. Following diagnosis of CRPC, patients have generally been treated with anti-androgens that competitively </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">block the binding of androgens (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">darolutamide</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, enzalutamide, apalutamide or bicalutamide) to the AR resulting in functional inhibition of the AR signaling </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pathway, or</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> inhibit synthesis of androgens (abiraterone). More recently, significant improvements in PFS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and OS have been achieved by utilizing this latest generation of antiandrogens in combination with ADT earlier in the disease natural history, such as hormone-sensitive prostate cancer, or&#160;HSPC,&#160;and non-metastatic CRPC, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nmCRPC</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The growth of prostate tumors is in large part mediated by an activated AR pathway. Generally, there are three means of activating the AR. First, androgens, such as dihydrotestosterone, can activate the AR by binding to its LBD. Second, CRPC can be driven by variants of AR that lack an LBD, are constitutively activated, and consequently do not require androgens for activation. A third mechanism may involve certain signaling pathways that activate AR independent of androgen activity. Generally, current drugs for the treatment of prostate cancer are directly inhibiting activation of the AR pathway by: (i) interfering with the production of androgen, or (ii) preventing androgen from binding to the LBD. Over time, these approaches will eventually fail due to mechanisms of resistance, which involve the LBD end of the receptor, whether at the DNA level via AR amplification, or via LBD mutations, or at the RNA level via the emergence of AR splice variants. With respect to the development of alternative pathway mechanisms of AR activation, tumors might also be insensitive to antiandrogen activity. Lastly, in patients who have been treated for years with various antiandrogen therapies, genomic changes may lead to additional, non-AR-related oncogenic drivers, also insensitive to inhibition of AR pathway biology.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mechanism of Action&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a DAARI, ONCT-534 has a potentially novel and unique mechanism of action: it interacts with both the NTD and the LBD of the AR (shown in the figure above), inhibiting AR function and leading to AR protein degradation. We believe that this NTD binding is relevant to the activity of ONCT-534 against tumors expressing AR splice-variants by preventing AR activation. In this respect, ONCT-534 is designed to mechanistically differ from classical non-steroid antiandrogens that interfere with androgen synthesis, such as abiraterone, and to differ from current standard of care treatment options, such as darolutamide, enzalutamide, or apalutamide, that bind only to the LBD of the AR, which may explain their reduced efficacy in patients with AR-SV-expressing tumors, as these AR variants lack the certain parts of the LBD. We believe that the potentially differentiated dual-action pharmacology of ONCT-534 has the potential to translate into significantly improved clinical outcomes over current standard of care agents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our mechanism of action offers potential for DAARI therapeutic development in other AR-driven diseases, such as luminal AR-positive triple-negative breast cancer, or LAR-TNBC, as well as non-oncology indications, such as&#160;Spinal Bulbar Muscular Atrophy, or SBMA.&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-534 development in prostate cancer&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating ONCT-534 as a potential therapy for patients with advanced CRPC and other AR-driven diseases. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, ONCT-534 demonstrated antagonism and degradation of full-length AR, mutant LBD AR, and AR-splice variants. ONCT-534 additionally has shown strong in vivo activity in models of prostate cancer in both castrated and intact animals that are resistant to AR antagonists, such as enzalutamide, as detailed below.&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the ability of ONCT-534 to treat enzalutamide-resistant cancers, we conducted in vivo studies in an enzalutamide-resistant MDVR VCaP cell line xenograft model. This treatment resistance can be seen in the figures below for both castrated and intact animals, as tumors in mice dosed with enzalutamide grew at nearly the same rate as tumors in mice dosed only with the drug vehicle, a control similar to dosing with a placebo. Orally delivered ONCT-534 significantly inhibited tumor growth, described as tumor growth inhibition, or TGI, in these enzalutamide-resistant MDVR tumors.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 10. DAARIs Exhibit AR-specific Anti-tumor Activity in ENZA-resistant Preclinical Model.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000011.jpg" title="" alt="" style="width:537px;height:218px;" />&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a mouse xenograft model of human prostate cancer in intact animals, tumor growth of LnCAP human prostate cancer cells that overexpress AR (LnCAP-AR) was significantly inhibited by treatment with ONCT-534, as shown in the figure below.<span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 11. DAARIs Exhibit AR-specific Anti-tumor Activity in AR-overexpressing Preclinical Model.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Segoe UI;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000012.jpg" title="" alt="" style="width:410px;height:190px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AR-V7 is a splice variant of AR that lacks the LBD and hinge region and is expressed in 22Rv1 cells, which are human prostate carcinoma epithelial cells derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent xenograft. As shown in the figure below, enzalutamide is not efficacious against these tumors that lack the LBD. Treatment with ONCT-534 however, resulted in tumor growth inhibition as well as significant reduction in PSA in this model, demonstrating activity at the NTD.<span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.13%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 12. DAARIs Exhibit Anti-tumor Activity in AR Splice-variant Preclinical Model.<span style="font-size:12pt;font-weight:normal;">&#160;&#160;</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000013.jpg" title="" alt="" style="width:492px;height:167px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preclinical IND-enabling activities are ongoing for ONCT-534. The manufacturing process has been established and transferred to the lead manufacturer. We are also evaluating potential Phase 1/2&#160;clinical study designs to demonstrate safety, determine the RP2D and efficacy, including the effect on patient PSA levels of ONCT-534 in patients with relapsed or refractory mCRPC regardless of their mutational status.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216 - ETS oncoprotein inhibitor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.71%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216 is an investigational, potentially first-in-class, targeted small-molecule inhibitor of the ETS family of oncoproteins, including fusion proteins. Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in virtually all cases of Ewing sarcoma. ETS-related translocations or overexpression are also found in many other tumors, such as DLBCL, prostate cancer and AML. Researchers in the laboratory of one of our scientific advisors, Jeffrey Toretsky, M.D. of Georgetown Lombardi Comprehensive Cancer Center, identified the precursor to ONCT-216 by using a novel chemical screening assay that they developed based on a deep understanding of the underlying biological mechanism of ETS factors. Following this early work, ONCT-216, which is designed to be a specific, high-affinity inhibitor of ETS factors, was created by us through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction. In preclinical models, ONCT-216 has inhibited the interaction between ETS family members and RNA Helicase A, RHA and by doing so, shut down excessive cell proliferation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating ONCT-216 as a single agent and in combination with vincristine, in heavily pretreated patients in a Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma. The dose-finding portion of the study was completed in 2019. We completed enrollment of the Phase 2 expansion cohort to evaluate the clinical response of treatment with ONCT-216 in combination with vincristine using the <span style="color:#000000;">RP2D regimen</span>, and we are currently enrolling patients in <span style="color:#000000;">a new Phase 2 expansion cohort to evaluate clinical responses to single agent ONCT-216 using an optimized dosing regimen, treating patients for 28 days per cycle with the next cycle starting immediately after the prior one, to intensify the amount of ONCT-216 administered over time</span>. Ewing sarcoma is a rare pediatric cancer that has historically been very challenging to treat effectively, particularly for recurrent and metastatic disease. The FDA has granted rare pediatric disease designation, as well as orphan drug and fast track designations for ONCT-216 for the treatment of Ewing sarcoma.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-216 scientific background: ETS transcription factors and oncogenesis</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216 targets the ETS family of oncoproteins known to be associated with both solid tumors and hematological malignancies. In normal development and physiology, ETS transcription factors govern processes such as cell cycle control, differentiation, proliferation, apoptosis, tissue remodeling and angiogenesis. However, when alterations in the functions of ETS factors develop, through overexpression, gene fusion or modulation, they have been shown to lead to tumor initiation, progression, and metastasis. Fusion proteins are a well-known category of targets for small molecule cancer therapy that have been cited in the scientific literature as providing a number of diagnostic and therapeutic advantages because of their tumor-specific expression. <br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fusion proteins involving ETS factors have been implicated in various solid tumors, including Ewing sarcoma and prostate cancer. For example, approximately 85% of Ewing sarcomas contain a genomic </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rearrangement between chromosomes 11 and 22. DNA is exchanged between these chromosomes in a pathological manner, and this exchange results in a fusion of two genes: the </span><span style="font-style:italic;">FLI1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene, an ETS family member, and the </span><span style="font-style:italic;">EWSR1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene, an unrelated transcription factor. This gene fusion, known as </span><span style="font-style:italic;">EWS/FLI1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, functions as a transcription activator that is no longer controlled by the relevant regulatory machinery in the cell. In addition to escaping regulation, the dysregulated function of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resultant </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EWS/FLI1 fusion </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protein </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">causes a series of abnormalities in RNA processing including aberrant mRNA expression and splicing, where it leads to defects in the synthesis of proteins</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such as BRCA1, a DNA repair protein. EWS/FLI1 fusion </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proteins </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also cause the formation of abnormal and potentially deleterious DNA and RNA structures known as R-loops that are associated with replication and transcriptional blocks as well as being prone to increased DNA damage.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple other tumors contain gene fusions of other ETS factors. For example, over 50% of metastatic prostate cancers carry a <span style="font-style:italic;">TMPRSS2-ETS</span> gene fusion. Other tumors have genetic changes that result in overexpression of ETS factors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="bottom" style="width:47.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ETS Fusions</p></td>
<td valign="bottom" style="width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:44.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ETS Overexpression</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing<span style="letter-spacing:-0.55pt;"> </span>sarcoma</p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AML</p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EWS-FLI1</p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLI1, ERG, ETV5,<span style="letter-spacing:0.75pt;"> </span>ETS2</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLBCL</p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TMPRSS2-ERG</p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV1, FLI1, ETV4,<span style="letter-spacing:0.65pt;"> </span>SPIB</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AML</p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6-various<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">(20+)</span></p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ERG, <span style="letter-spacing:0.1pt;">ETV1, ETV4,</span><span style="letter-spacing:0.8pt;"> </span>ETV6</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALL</p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6-RUNX1</p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV5, ETV1, FLI1,<span style="letter-spacing:0.7pt;"> </span>ETS1</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secretory breast<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6-NTRK3</p></td>
<td valign="top" style="width:8.06%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6, ETV4, SPIB,<span style="letter-spacing:0.65pt;"> </span>ETV5</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:3.64%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the genetic associations between ETS factors and tumorigenesis and the reported correlation between high levels of ETS factor expression and survival, there are currently no approved therapeutics available that target these factors. We believe that our approach of inhibiting protein-protein interactions is novel and that our product candidate ONCT-216 targeting ETS factors could fill an important gap in the treatment landscape for both solid tumors and hematological malignancies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-216 development in Patients with Ewing sarcoma</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ewing sarcoma disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma is the second most common bone tumor of children, and it occurs most often in adolescents, accounting for approximately 2% of all childhood cancer diagnoses. The incidence of Ewing sarcoma for all ages is approximately 1.3 cases per 1 million people in the U.S., corresponding to approximately 430 new patients diagnosed per year in the U.S. The median age at diagnosis of patients with Ewing sarcoma is 15.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nearly all Ewing sarcoma cases are driven by translocations of <span style="font-style:italic;">ETS</span> family oncogenes, including 85-90% of cases driven by the <span style="font-style:italic;">EWS-FLI1</span> fusion, and approximately 10% by <span style="font-style:italic;">EWS-ERG</span>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma typically develops in the pelvis, femur, and bones of the head and trunk, but its diagnosis often takes months as other causes for non-specific symptoms such as localized pain, fever, fatigue, weight loss, or anemia are ruled out. The five-year survival of patients who are diagnosed with non-metastatic disease is between 50% and 70%. Patients diagnosed with metastatic disease have five-year survival between 18% and 30%. The prognosis for patients with recurrent Ewing sarcoma is particularly poor, and five-year survival after recurrence is approximately 10 to 15%.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma is usually treated systemically due to the fact that local treatments, even in patients without overt metastases, have an 80% to 90% relapse rate. The current standard therapy for patients with localized Ewing sarcoma in the U.S. is a combination of chemotherapy agents, including vincristine, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">doxorubicin and cyclophosphamide, with alternating cycles of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ifosfamide</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and etoposide &#8211; a therapy known as VDC/IE. Patients that respond to this therapy may be candidates for tumor resection and continued treatment for a total of 14 to 17 cycles. This therapeutic regimen, however, is associated with significant toxicities. Patients with metastatic disease are often treated with VDC/IE or variations of this therapy with higher or more compressed dosing. This may also be supplemented by local radiation therapy or systemic radiation followed by autologous hematopoietic stem cell transplant. We believe that more effective therapies are needed for this rare and severe pediatric disease.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-216 preclinical data in Ewing sarcoma </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216 was the product of a novel approach based on developing small molecule inhibitors of a critical protein-protein interaction linked to the ETS family of transcription factors. Researchers at Georgetown University identified YK-4-279, the precursor to ONCT-216, by using a novel chemical screening assay. Following this early work, ONCT-216, a specific inhibitor of ETS factors, was then created by Oncternal through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction linked to the ETS family of transcription factors. ONCT-216 is a structural analog of YK-4-279 that has shown increased potency in biochemical, cellular and xenograft tumor models. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 13. ONCT-216 Inhibits Interaction of ETS Fusion Protein EWS/FLI1 with RHA.</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:15pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000014.jpg" title="" alt="" style="width:615px;height:151px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Ewing sarcoma, a key heterodimer between EWS/FLI1 and RHA forms the core of a transcriptome complex causing activated oncogenes, inhibited tumor suppressors, abnormal RNA transcription and abnormal RNA splicing. ONCT-216 was developed to disrupt that heterodimer, thereby potentially preventing transcription and leading to inhibition of the oncogenic activity of EWS/FLI1, by decreasing oncogene expression, increasing tumor suppressor function, and apoptotic cell death. In preclinical models, ONCT-216 inhibited the interaction between ETS family members and RHA and by doing so, shut down excessive cell proliferation and caused apoptotic cell death.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-216 clinical development in Ewing sarcoma</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating ONCT-216 as a single agent and in combination with vincristine in <span style="color:#000000;">an open-label, multicenter</span> Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma. <span style="color:#000000;">Ewing sarcoma is a rare pediatric cancer that has historically been very challenging to treat effectively, particularly for recurrent and metastatic disease. ETS fusion proteins have been shown to be present in over 90% of Ewing sarcoma cases. </span>The dose escalation portion of the study was completed in 2019, and we completed enrollment of the Phase 2 expansion cohort to evaluate the clinical response of treatment with ONCT-216 in combination with vincristine using the <span style="color:#000000;">RP2D regimen. The RP2D for the combination had been established to be 200 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>/day of ONCT-216 for 14 days, with vincristine 0.75-1.5 mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> on the first day of each 28-day treatment cycle. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we announced updated interim clinical data from our ongoing open-label, multicenter Phase 1/2 clinical trial evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma. Patients entering the trial had previously been treated with a median of three, and as many as nine prior lines of systemic therapy. The presentation included interim data for 60 evaluable patients, including 37 evaluable patients treated at the RP2D as of the October 1, 2021 efficacy cutoff date. Two of the 37 patients treated at the RP2D (5.4%) achieved a CR. One patient achieved a CR after resection of a residual non-target lung lesion at Cycle 6 and completed &#62;2-years of treatment with no evidence of disease, and one patient remains on treatment with no evidence of disease at </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#62;20 months on study as of the cutoff date. The best ORR was 8.1% for patients treated with RP2D. Twelve additional patients treated at the RP2D had SD, for a disease control rate (CR, PR or SD) of 40.5%. The median duration of response for patients treated at the RP2D was 14.7 months. In the third quarter of 2021, we added a new Phase 2 expansion cohort targeting up to 21 Ewing sarcoma patients to evaluate clinical responses to single agent ONCT-216 </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at 175 mg/m</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/day</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, treating patients for 28 days per cycle with the next cycle starting immediately after the prior one, to intensify the amount of ONCT-216 administered over time. The new Phase 2 expansion cohort is actively enrolling patients. </span><span style="color:#000000;">Results from the CTOS 2021 Annual Meeting presentation for patients with relapsed or refractory Ewing sarcoma treated with ONCT-216 as a single agent and in combination with vincristine are shown in the figures below.</span><span style="color:#000000;"><br /></span><span style="color:#000000;"><br /></span><span style="font-weight:bold;color:#000000;">Figure 1</span><span style="font-weight:bold;color:#000000;">4</span><span style="font-weight:bold;color:#000000;">. ONCT-216 Patient Overview: Swimmer&#8217;s Plot.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000015.jpg" title="" alt="" style="width:616px;height:377px;" /></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2022, we expect to announce additional interim clinical data from this Phase 1/2 clinical trial in patients with Ewing sarcoma, including data from the expanded cohort with the intensified dosing regimen.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential additional clinical opportunities for ONCT-216</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Diffuse Large B-Cell Lymphoma, <span style="font-style:normal;">or DLBCL. DLBCL is a form of non-Hodgkin lymphoma, or NHL, that is the most common blood&#160;cancer. Lymphomas occur when cells of the&#160;immune system grow and multiply uncontrollably. B cells are a type of lymphocyte that is responsible for producing antibodies. DLBCL occurs mostly in adults and is a fast-growing (aggressive) B-cell lymphoma. It can start in the&#160;lymph nodes&#160;or outside of the&#160;lymphatic system&#160;in the gastrointestinal tract,&#160;testes, thyroid, skin, breast, bone, or brain.&#160;Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETS transcription factors have been implicated in the development of lymphoid tissues and immune system control. ETS1 and FLI1 have been shown to regulate important mechanisms in B-cell development and maturation, such as the B-cell specific activator PAX5 as well as the regulator of plasma cell differentiation, PDRM1. DLBCL </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the most common subtype of NHL </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has been shown to have high expression of these transcription factors. Nearly one-quarter of 166 DLBCL cases were characterized by a recurrent lesion on chromosome 11q24.3, which contains the transcription factors ETS1 and FLI1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In a published report, ONCT-216 demonstrated anti-lymphoma activity in vitro and in vivo when used either alone or in combination with certain other lymphoma therapies, including </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venetoclax</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or lenalidomide. Notably, ONCT-216 was administered orally in the in vivo studies suggesting the potential for an oral dose development.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Prostate cancer.<span style="font-style:normal;"> Approximately 174,650 new cases of prostate cancer are diagnosed annually in the U.S. The incidence of metastatic prostate cancer is increasing, causing an estimated 31,620 deaths per year in the U.S. New therapeutic options are needed after failure of androgen antagonism and prior to chemotherapy. Approximately 55% of men with advanced prostate cancer carry the ETS family fusion gene </span>TMPRSS2-ERG<span style="font-style:normal;"> that is related to androgen resistance.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe ONCT-216 may provide a novel therapeutic strategy for the treatment of patients with advanced prostate cancer, in particular those who carry the ETS family fusion gene <span style="font-style:italic;">TMPRSS2-ERG</span>. In a preclinical in vivo study, YK-4-279, which is an analog of ONCT-216, showed anti-tumor activity against a prostate cancer cell line harboring the ETS-family translocation, while growth of a prostate cancer cell without the translocation was not inhibited.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acute myeloid leukemia, or AML.<span style="font-style:normal;"> AML is a hematologic malignancy characterized by dysregulated maturation of myeloid or blood stem cells and failure of the bone marrow to properly function, leaving patients with anemia and immune deficiency, and at high risk of infections and bleeding. AML is the most common type of acute leukemia in adults. Approximately 21,450 new AML cases and 10,920 AML associated deaths occur annually in the U.S. The average age of an AML patient is 68 years. The National Cancer Institute estimated in 2018 that the five-year survival rate for adult patients with AML was approximately 27%. We believe that there is a need for more effective and less toxic therapies for AML.<br /></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETS overexpression or fusion proteins incorporating ETS family member have been observed in about 30% of AML cases. The ETS family member ERG is overexpressed in many cancers, such as AML. In a retrospective analysis of patients with AML, the quartile of patients with the highest levels of ERG expression had a significantly higher rate of relapse and poorer OS than patients with lower levels of ERG expression. Those with the highest levels of ERG had a five-year survival rate of 20%, while those with lower levels of ERG had a survival rate of approximately 50%. ERG overexpression was an independent negative prognostic factor. Similarly, AML patients with high levels of ETS2, another ETS family member, had a significantly lower five-year survival rate of approximately 15% compared to 40% for patients with lower levels of ETS2. ETS2 overexpression was an independent negative prognostic factor. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure<span style="letter-spacing:-0.45pt;"> 15</span><span style="letter-spacing:0.2pt;">.</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:0.1pt;">Survival</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.7pt;"> Patients with AML is Related to Expression of ETS Oncoproteins </span>ERG<span style="letter-spacing:-0.6pt;"> </span>(left)<span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:0.15pt;">or</span><span style="letter-spacing:-0.45pt;"> </span>ETS2<span style="letter-spacing:-0.25pt;"> </span>(right).<span style="letter-spacing:-0.75pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="ggtc45pq2o35000016.jpg" title="" alt="" style="width:551px;height:120px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:1.71%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple AML cell lines have been shown to be sensitive to being killed by ONCT-216, with sensitivity proportional to ETS expression. ONCT-216 may provide a novel therapeutic strategy for the treatment of patients with relapsed and refractory AML, a patient population known to express, in certain cases, fusion proteins involving ETV6, and to have overexpression of ETS family members including FLI1, ERG, ETS2, and ETV5.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure<span style="letter-spacing:-0.45pt;"> 16</span><span style="letter-spacing:0.2pt;">.</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:0.1pt;">Prostate Cancer Sensitivity was Associated with an ETS-family Fusion Protein in Human Prostate Cancer Xenograft Models.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:15pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="ggtc45pq2o35000017.jpg" title="" alt="" style="width:525px;height:133px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />Competition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are intensely competitive and characterized by rapid technology evolution. Our potential competitors include large pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as government, academic and other research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. <span style="color:#000000;">These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our programs. </span>Our commercial opportunities may be reduced or eliminated if our competitors develop and commercialize similar products that are safer, more effective, have fewer side effects or are less expensive than any products that we or our collaborators may develop. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In particular, we compete with other companies that are developing and commercializing treatments for patients with cancer. Competing therapies include chemotherapies, targeted therapies and immunotherapies and may represent various therapeutic modalities including small molecules, antibodies, cell therapies, gene therapies, and cancer vaccines. These companies may compete with us for clinical trial sites and eligible patient populations, scientific and management talent, outsourced manufacturing capacity and healthcare budgets for commercial-stage products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;" id="ca74401_sards_for_the_potential_">Zilovertamab competition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several therapeutic options available to treat patients with relapsed or refractory MCL, including BTK inhibitors. In an open-label Phase 2 clinical trial, ibrutinib (Imbruvica), a BTK inhibitor that is approved by the FDA for the treatment of patients with relapsed MCL, demonstrated an ORR of 66% and a CR rate of 17%, with a median DOR of 17.5 months. In an open-label Phase 2 clinical trial, acalabrutinib (Calquence), another BTK inhibitor approved by the FDA for the treatment of patients with relapsed MCL, demonstrated an ORR of 80% and CR rate of 40%. Another BTK inhibitor approved in 2019, zanubrutinib (Brukinsa), demonstrated an ORR of 84% and CR rate of 59%, with a median DOR of 19.5 months in an open-label Phase 2 clinical trial. These therapies are given continuously for prolonged periods of time, and their use can be associated with significant toxicity. The majority of patients with MCL are older, and remissions are not durable with most patients relapsing in less than 20 months. As a result, we believe that more effective and better tolerated therapies with shorter treatment periods represent a significant unmet need. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three classes of targeted therapies have been approved for the treatment of patients with CLL: inhibitors of BTK, a key component of cell signaling in B-cells, such as ibrutinib, which is marketed as Imbruvica by AbbVie, Inc., and Johnson &#38; Johnson, and acalabrutinib, which is marketed as Calquence by AstraZeneca PLC&#59; inhibitors of the protein B-cell lymphoma-2, or Bcl-2, such as venetoclax, which is marketed as Venclexta and Venclyxto by AbbVie, Inc., and Roche/Genentech&#59; and inhibitors of Phosphoinositide 3-kinase, or PI3K, which include idelalisib, which is marketed as Zydelig by Gilead Sciences, Inc., and duvelisib, which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is marketed as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Copiktra</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Verastem</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Inc. These targeted therapies are now the core of the recommended treatment regimens for patients with both </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">first-line</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and relapsed or refractory CLL, and have achieved objective response rates of 85-90%, two-year PFS of 65-90%, and two-year overall survival of 75-95%. The outcomes are worse for patients with certain prognostic factors, such as 17p or 11q chromosome deletions&#59; for such patients with relapsed or refractory CLL treated with ibrutinib, the reported PFS is 50-75%.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved products targeting the ROR1 receptor, we are aware of therapeutics in clinical development that target ROR1, including MK-2140, an ADC being developed by Merck &#38; Co., an ADC being developed by NBE-Therapeutics (acquired by Boehringer Ingelheim in 2020), and a ROR1 CAR-T therapy being developed by Bristol-Myers Squibb Company. MK-2140, originally designed and developed by Oncternal, binds to the same epitope on ROR1, and utilizes zilovertamab to target ROR1. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">There are numerous companies developing or marketing treatments for the same oncology indications that we are targeting with our zilovertamab program. Therapies approved or in clinical development for the treatment of patients with treatment-na&#239;ve or relapsed/refractory CLL and relapsed/refractory MCL include BTK inhibitors, Bcl-2 inhibitors, PI3K inhibitors, anti-CD20 antibodies, and cell therapies that are being marketed or developed by companies including AbbVie, Inc., AstraZeneca PLC, BeiGene, Ltd., Eli Lilly and Company, Gilead Sciences, Inc., Johnson &#38; Johnson, MEI Pharma, Merck, Novartis Pharmaceuticals Corporation, Roche Holding AG&#8217;s Genentech subsidiary, TG Therapeutics, Inc., and Verastem, Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ROR1 CAR-T competition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved cell therapy products targeting the ROR1 receptor, we are aware of an autologous CAR-T cell therapy clinical program targeting ROR1 sponsored by Bristol-Myers Squibb for patients with hematological malignancies. Precigen, Inc. announced plans to initiate a Phase 1/1b clinical trial of PRGN-3007, an autologous CAR-T cell therapy targeting ROR1, in patients with hematological malignancies and solid tumors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous companies developing or marketing cell therapy treatments for the same oncology indications that we may target with our ROR1 CAR-T program including AbbVie, Inc., Adicet, Allogene Therapeutics, Atara Biotherapeutics, Inc., Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Therapeutics, Fate Therapeutics, Gilead Sciences, Inc., Johnson &#38; Johnson, Legend Biotech, Merck, NantKwest, Nkarta Therapeutics, Novartis Pharmaceuticals Corporation, Poseida Therapeutics, Roche Holding AG, and others. <br />Six CAR-T cell therapies have been approved by the FDA, Yescarta and Tecartus are marketed by Gilead Sciences, Inc., Kymriah is marketed by Novartis Pharmaceuticals Corporation, Abcema and Breyanzi are marketed by Bristol-Myers Squibb Company, and Carvykti, developed by Legend Biotech. Yescarta, Tecartus, Kymriah and Breyanzi target the CD19 protein, a protein expressed on the surface of the majority of B cells, including B cell tumorigenic cells. <br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-534 competition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved drugs with similar mechanism of action as our DAARI program, ONCT-534, the competition in the advanced prostate cancer market is very high. Several therapies have already been approved and many more are currently in development. Second-generation antiandrogens including Xtandi (Astellas and Pfizer), Zytiga/Erleada (Johnson &#38; Johnson), and Nubeqa (Bayer) have become the preferred regimens for first line therapy in this indication. Other therapeutic modalities, such as checkpoint inhibitors are being evaluated in combination with either antiandrogen or chemotherapies. Bispecific antibodies and CAR-T therapies targeted towards prostate-specific member antigen are also in early development. Other approaches to interfering with AR signaling include strategies to: (i) blocking AR activation via NTD binding as being pursued by ESSA Pharma, Inc., and (ii) degrading the AR such as that being pursued by Arvinas, Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ONCT-216 competition</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved drugs targeting ETS oncoproteins, there are numerous companies developing or marketing treatments for the same oncology indications that we are targeting with our ONCT-216 program. Investigational therapies in clinical development for the treatment of patients with relapsed/refractory Ewing sarcoma include kinase inhibitors,<span style="font-weight:bold;"> </span>LSD1 inhibitor and other targeted therapies, therapeutic antibodies and cell therapies that are being developed by companies including Bayer AG, Bristol-Meyers Squibb Company, Eisai Co., Ltd., Epizyme, Inc., Gradalis, Inc., Eli Lilly and Company, Johnson &#38; Johnson, Exelixis, Inc., NantCell, Inc., Pharmamar S.A., Pfizer, Inc., Salarius Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and others.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licenses and Collaborative Relationships</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UC San Diego</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, we entered into a license agreement with the Regents of the University of California, or the Regents, represented by UC San Diego, which was amended and restated in August 2018, and amended on March 25, 2019, May 15, 2019 and February 5, 2021 (the &#8220;Regents License Agreement&#8221;), for the development, manufacturing and distribution rights to naked antibodies, including zilovertamab and genetically engineered cellular therapy products, including CAR-T products that are covered by licensed patents for all human therapeutic, diagnostic and preventive applications in all indications. The Regents License Agreement requires us to pay certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, low single-digit royalties including potential future minimum annual royalties on net sales of each product, certain annual patent costs, and annual license maintenance fees. Unless terminated earlier, the Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the first commercial sale of a licensed product. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UC San Diego may terminate the Regents License Agreement if a material breach by us is not cured within a reasonable time, we file a claim asserting the licensed patent rights are invalid or unenforceable, or we file for bankruptcy. We may terminate the agreement at any time upon at least 90 days&#8217; written notice. In July 2016, we entered into a research agreement with the Regents (the &#8220;Regents Research Agreement&#8221;), for further research on the ROR1 therapeutic development program. Under this five-year agreement that expired in June 2021, UC San Diego was paid $3.6 million, with $125,000 payable quarterly. The costs paid to UC San Diego under the Regents Research Agreement are included as part of our annual diligence obligations under the Regents License Agreement. As of December 31, 2021, we believe we have met our obligations under the Regents License Agreement. Effective January 1, 2022, we entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this four-year agreement that expires on December 31, 2025, the Regents will have an aggregate budget of $1.6 million, with quarterly payments of $125,000 in 2022, $131,250 in 2023, and $137,813 in 2024.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CIRM</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, <span style="color:#000000;">and as amended and restated in December 2020,</span> the California Institute for Regenerative Medicine, or CIRM, awarded an $18.3 million grant to researchers at UC San Diego to advance the CIRLL study. We have received approximately $13.9 million in development milestones under research subaward agreements, and expect to receive an additional $0.5 million prior to the expiration of the award project period on March 31, 2022. We are required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. As of December 31, 2021, we believe we have met our obligations under the CIRM award and UC San Diego subawards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CIRM may suspend or permanently cease disbursements of funds under the research subaward agreements, or pursue other remedies as allowed by law, if CIRM determines that UC San Diego has not complied with the terms and conditions of the award, or if there are unexpected, substantial manufacturing failure leading to delayed enrollment in the clinical trial, failure to enroll the trial, or if FDA issues a clinical hold order with respect to the clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Celularity</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we entered into a research collaboration with Celularity to evaluate placental derived-cellular therapies targeting ROR1. Under the collaboration, Celularity will explore in preclinical studies: (i) the use of zilovertamab in combination with Celularity&#8217;s natural killer cells, or CYNK-101, a placental derived-allogeneic NK cell therapy that has been genetically engineered to synergize with therapeutic antibodies, and (ii) ROR1-targeted CAR gene modification in Celularity&#8217;s CYNK natural killer cell and CyCART T cell platforms.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Georgetown University</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, we entered into an exclusive license agreement, or the Georgetown License Agreement, with Georgetown University, or Georgetown, pursuant to which we licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes. Under the Georgetown License Agreement, we are solely responsible for all development and commercialization activities and costs in our respective territories and are also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights. We are also obligated to pay Georgetown an annual license maintenance fee until the first commercial sale occurs, make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and will be required to pay low single digit royalties based on annual net product sales. The term of the Georgetown License Agreement continues until the expiration of the last valid claim within the patent rights covering the product but may be terminated by either party upon material breach, or by us as to one or more countries with 90 days written notice of termination. Additionally, Georgetown may terminate the agreement in the event we fail to pay any amount and fails to cure such failure within 30 days after receipt of notice, default in our obligation to obtain and maintain insurance and fail to remedy such breach within 60 days after receipt of notice or declare insolvency or bankruptcy. We may terminate the agreement at any time upon at least 60 days&#8217; written notice. As of December 31, 2021, we believe we have met our obligations under the Georgetown License Agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into a license agreement with SPH USA, or the SPH USA License Agreement, under which we granted exclusive rights to SPH USA to manufacture, develop, market, distribute and sell in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (the &#8220;SPH USA Territory<span style="color:#000000;">&#8221; or "Greater China"),</span> our product candidates under the Georgetown License Agreement and the UC San Diego License Agreement. Under the SPH USA License Agreement, SPH USA is solely responsible for all preclinical and clinical development activities specific to obtaining regulatory approval for such product candidates in the SPH USA Territory, any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the UC San Diego License Agreement and paying us a low single digit royalty on net sales of licensed products in the SPH USA Territory. The SPH USA License Agreement will expire on a licensed product-by-licensed product and country/region-by-country/region basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country/region. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SPH USA License Agreement may be terminated by SPH USA, on a country/region-by-country/region or product-by-product basis with 180 days written notice following the first anniversary of the effective date of the agreement or at any time on a product-by-product basis for a safety concern with respect to such product. Either party may terminate the SPH USA License Agreement in its entirety or on a licensed product-by-licensed product basis upon material breach that is not cured within 90 days, or in its entirety the event the other party becomes insolvent or enters into bankruptcy proceedings. We may terminate the agreement with 60 days written notice if SPH USA or its affiliates or sublicensees commence an action challenging the validity or enforceability of any licensed patent, or with 10 days written notice if SPH USA fails to own at least 20% of the voting securities of any assignee of the SPH USA License Agreement. Upon termination of the agreement for any reason all rights and licenses granted to SPH USA under the agreement will terminate, and in the event of termination for reasons other than our material breach, SPH USA would </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grant us non-exclusive, royalty-free, worldwide license to any intellectual property rights controlled by SPH USA or its affiliates to exploit the terminated program in the SPH USA Territory.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, we entered into a license agreement with UTRF (the &#8220;DAARI License Agreement&#8221;), which was amended and restated in March 2022. Under the DAARI License Agreement, we were granted exclusive worldwide rights in all proprietary DAARI technologies owned or controlled by UTRF, including all improvements thereto. We are obligated to use commercially reasonable efforts to develop and commercialize one or more licensed products, including by achieving a certain milestone event. We are obligated to pay UTRF annual license maintenance fees in the mid five digits and low single-digit royalties on aggregate net sales of licensed products. We are also obligated to pay UTRF tiered royalties ranging from a low single digit to low double digit percentage of consideration received by our sublicensees, excluding royalties, such percentage dependent on the stage of development of a clinical product candidate at the time it is sublicensed. Our obligation to pay UTRF royalties expires on a country-by-country and licensed product-by-licensed product basis on the last-to-expire valid patent claim of a licensed patent covering such licensed product in such country.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the term of the DAARI License Agreement will continue, on a country-by-country basis, until the expiration of the last-to-expire valid claim of any licensed patent covering a licensed product in such country. Either party may terminate the DAARI License Agreement for the other party&#8217;s uncured material breach, subject to certain notice and cure periods. UTRF may terminate the DAARI License Agreement for our bankruptcy or insolvency. We may terminate the Amended and Restated UTRF Agreement with advance written notice to UTRF, provided we have satisfied our payment obligations to UTRF prior to such termination.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a manufacturing strategy of contracting with third parties to manufacture API, drug substance and drug product in accordance with current Good Manufacturing Practices, or cGMPs, and additional manufacturers are used to label, package and distribute investigational drug products. This strategy allows us to maintain a more flexible infrastructure while focusing our expertise on the development of our products.<br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on third parties for the production, characterization, and release testing of clinical and commercial quantities of all product candidates and associated critical reagents. For example, we are working with Lentigen on lentivirus manufacturing and Miltenyi Biotec B.V. &#38; Co. KG on cell processing for our ONCT-808 program. There are no unusually complicated biochemistries or equipment required in the manufacturing process for zilovertamab, ONCT-808, ONCT-534 or ONCT-216, which we believe allows for potential manufacturing flexibility.<br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a quality control and quality assurance program, which includes a set of standard operating procedures and specifications designed to ensure that our products are manufactured in accordance with cGMPs, and other applicable domestic and foreign regulations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or acquired or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the U.S and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology, continuing innovation, and acquisition and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of cancer therapeutics.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success may depend in part on our ability to: (i) obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements&#59; (ii) preserve the confidentiality of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our trade secrets&#59; (iii) defend and enforce our proprietary rights, including our patents&#59; and (iv) operate without infringing the valid and enforceable patents and other proprietary rights of third parties.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed, licensed and acquired numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of healthcare products and services. As of February 4, 2022, our owned and in-licensed patent portfolio consisted of approximately 42 issued U.S. patents and 42 pending U.S. patent applications related to certain of our proprietary technology, inventions, and improvements, and 57 issued patents and 66 pending patent applications in jurisdictions outside of the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ROR1 Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an exclusive, commercial, worldwide, transferrable license to a portfolio of patents and patent applications directed to ROR1 antibodies and CAR-T therapies for all therapeutic indications. This portfolio is licensed from the Regents of the University of California. We have know-how and trade secrets related to compositions of matter for treating cancers, methods for treating cancer, and methods of screening for additional compositions of matter used for treating cancer, as well as to additional antibodies and molecules that modulate ROR1 signaling. We have also developed certain patents and patent applications directed to ROR1 based therapies, which are owned by Oncternal.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 4, 2022, our licensed patent portfolio included patents related to our zilovertamab clinical candidate currently in Phase 1 and Phase 2 clinical trials. Zilovertamab is a humanized monoclonal antibody that specifically binds to the ROR1 receptor. We have two issued U.S. patents directed to the zilovertamab composition of matter: U.S. Pat. No. 9,217,040, with a patent term not due to expire before 2032&#59; and U.S. Patent No. 9,758,591, with a patent term not due to expire before March 2033. We have one patent issued in the U.S. directed to methods of using zilovertamab to treat cancer, U.S. Pat, No. 10,344,096, with a patent term not due to expire before March 2033. We have one patent application pending in the U.S. related to single chain variable region fragments derived from zilovertamab which, if issued, would have a patent term not due to expire before 2033. We also have patents issued in Australia, China, Europe, Israel, Japan, Korea, Macao, Canada and Mexico directed to zilovertamab compositions of matter. In Europe patents directed to zilovertamab compositions of matter have been validated in jurisdictions including France, Germany, Italy, UK, Spain, Turkey, Belgium, Poland, Netherlands, Greece, Switzerland, Sweden, Austria, Denmark, and Ireland. We have applications pending in foreign jurisdictions related to zilovertamab compositions of matter and methods of use in treating cancer, including Australia, China, Europe, Japan, Mexico, and Thailand. Patents, if issued from these pending foreign applications, would not be due to expire before 2033. The validity of one of our issued European patents EP Patent No. 3604339 is being challenged in an opposition proceeding. This patent is directed to methods of treating cancer using antibodies that bind to the epitope bound by zilovertamab. We believe we have meritorious defenses against the opposition. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 4, 2022, we have approximately 29 licensed patent applications pending in the U.S. and in jurisdictions outside the U.S. related to methods of treating cancer using a combination of zilovertamab and small-molecule chemotherapeutics. We have one issued patent, U.S. Patent No. 10,688,181, directed to methods of treating cancer with the combination of zilovertamab and a BTK inhibitor. Patents, if issued from these pending non-provisional applications, would not be due to expire before dates ranging from 2037 to 2041. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 4, 2022, we have licensed patents and patent applications related to additional ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-zilovertamab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors. We have six issued U.S. patents directed to non-zilovertamab ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-zilovertamab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors: U.S. Pat. No. 8,212,009, with a patent term not due to expire before November 2026&#59; U.S. Patent No. 9,242,014, with a patent term not due to expire before June 2031&#59; U.S. Patent No. 9,938,350, with a patent term not due to expire before June 2031&#59; U.S. Patent No. 9,217,040, with a patent term not due to expire before January 2032&#59; U.S. Patent No. 10,627,409 with a patent term not due to expire before January 2032&#59; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Patent No. 10,900,973 with a patent term not due to expire before January 2032. We have two patent applications pending in the U.S. related to additional non-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zilovertamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zilovertamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ROR1 binding antibodies, polypeptides and chimeric antigen receptors, which, if issued, would have a patent term not due to expire before dates ranging from 2031 to 2032. We also have patents issued in Europe and Canada directed to additional ROR1 binding antibodies. We have one patent application pending in Europe related to additional ROR1 binding antibodies specific for ROR1. Any patent issued from this pending foreign application, would not be due to expire before 2032.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 4, 2022, we have licensed patents and patent applications related to methods of screening for antibodies that specifically bind to ROR1. We have two issued U.S. patents, U.S. Pat. Nos. 9,523,695, and 9,933,434, with patent terms not due to expire before January 2032, directed to methods of screening for antibodies that specifically bind to ROR1. We additionally have one issued U.S. patent and one patent application issued in Japan directed to methods of screening for modulators of ROR1 signaling&#59; additionally, we have applications pending in the U.S., Australia, Canada, China, Hong Kong, and Europe directed to methods of screening for modulators of ROR1 signaling.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 4, 2022, <span style="letter-spacing:0.15pt;">we also own one patent application filed </span>under the Patent Cooperation Treaty directed to methods of treating cancer using a combination of zilovertamab and small molecule cancer chemotherapeutics. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">DAARI Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have exclusive worldwide rights to a portfolio of patents and patent applications related to Dual-Action Androgen Receptor Inhibitor, or DAARI, compounds for use in therapeutics. We hold a portfolio of patents and patent applications related to DAARIs and jointly owned with <span style="color:#000000;">UTRF</span><span style="Background-color:#FFFFFF;">, including ten issued U.S. patents directed to DAARI ligands and methods of use thereof: </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">9,814,698, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,017,471, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,035,763, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,441,570, U.S. Pat. No. </span><span style="color:#000000;">10,865,184, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">9,815,776, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">9,834,507, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,093,613, U.S. Pat. No. </span>10,597,354, and U.S. Pat. No. <span style="color:#000000;">10,806,720, as well as six</span> issued patents in Australia, Japan, China, Europe (validated in Great Britain, France and Germany) and Russia,<span style="Background-color:#FFFFFF;"> and approximately three pending U.S. patent applications and nine pending patent applications outside of the U.S., each with a patent term </span>not due to expire before April 2036. <span style="Background-color:#FFFFFF;">We also have a portfolio of </span>patents and patent applications licensed from <span style="color:#000000;">UTRF</span><span style="Background-color:#FFFFFF;"> including five issued U.S. patent directed to DAARI ligands and methods of use thereof: </span>U.S. Pat. No. 10,314,797, U.S. Pat. No. 10,654,809, U.S. Pat. No. 10,806,719, U.S. Pat. No. 11,230,523, and U.S. Pat. No. 11,230,531, issued patents in Japan and Israel, two pending U.S. patent applications and thirteen patent applications outside of the U.S., each with a patent term not due to expire before June 2037. A third portfolio for the DAARI program includes approximately thirteen patent applications licensed from UTRF including two pending patent applications in the U.S. and eleven pending patent applications outside of the U.S.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the U.S. are effective for 20 years from the earliest effective and non-provisional filing date. The patent term may be adjusted to compensate for delayed patent issuance when such delays are caused by the patent office or successful appeals against patent office actions. There is no limit on this patent term adjustment. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The extended restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following the date of FDA approval of the applicable drug product. The duration of patents outside of the U.S. varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective non-provisional filing date. Our issued patents are due to expire on dates ranging from 2026-2037. If patents are issued on our pending patent applications, the resulting patents would be due to expire on dates ranging from 2026-2041. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">availability of legal remedies in a particular country, and the validity and enforceability of the patent. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most countries require a patent owner to pay maintenance fees or annuities in order to extend the patent to the full length of its term.&#160;If these fees and annuities are not paid timely, our patents will expire prior to the expiration dat</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ONCT-216 Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have exclusive worldwide rights to a portfolio of patents and patent applications related to small molecules, including ONCT-216, targeting EWS-FLI1 for use in therapeutics and companion diagnostics. We hold a portfolio of patents and patent applications, the Oncternal Portfolio, related to ONCT-216, analogs thereof, and uses thereof, as well as the Georgetown Licensed Portfolio, which is licensed from Georgetown University.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of </span><span style="color:#000000;">February 4, 2022</span><span style="Background-color:#FFFFFF;">, the Oncternal Portfolio directed to the new chemical entity ONCT-216 contained approximately </span>eight<span style="Background-color:#FFFFFF;"> U.S. issued patents and </span>two<span style="Background-color:#FFFFFF;"> pending applications in the U.S., as well as approximately 14 patents and approximately 21 pending patent applications in jurisdictions outside of the U.S. As of February 4, 2022, we had two U.S. patents directed to ONCT-216: U.S. Pat. No. 9,604,927, with a patent term not due to expire before October 2035, and U.S. Pat. No. 9,987,251, with a patent term not due to expire before October 2035. We also had a patent with claims directed to methods of inhibiting proliferation of a cell that overexpresses an ETS gene or comprises an ETS fusion gene, or inhibiting growth of or killing neoplastic cells: U.S. Pat. No. 9,895,352, with a patent term not due to expire before October 2035. We had approximately one pending U.S. application and approximately 19 patents or pending applications in jurisdictions outside the U.S., including Australia, Canada, China, Eurasia, Europe, Hong Kong, India, Israel, Japan, Korea, </span><span style="color:#000000;">Macao, </span><span style="Background-color:#FFFFFF;">Mexico, New Zealand, and Taiwan. These patents have a patent term not due to expire before October 2035, and patents, if issued from these applications, would not be due to expire before October 2035. We also had a patent with claims covering compositions of ONCT-216 in combination with venetoclax and associated methods of inducing apoptosis in cells in AML and DLBCL: U.S. Pat. No. 10,159,660, with a patent term not due to expire before July 2037, and a patent covering ONCT-216 in combination with lenalidomide and associated methods for inducing apoptosis in a lymphocyte produced in mantle cell lymphoma: U.S. Pat. No. 10,646,470, with a patent term not due to expire before July 2037. We had approximately one pending U.S. application and approximately thirteen pending applications filed in jurisdictions outside the U.S., including Canada, China, Europe, Hong Kong, Japan, Korea, Mexico, Singapore, and Taiwan directed to ONCT-216 combination therapies. Patents, if issued from these applications, would not be due to expire before July 2037. The Oncternal Portfolio further contained additional patents and pending applications related to indoline derivative compounds, which are analogs of ONCT-216. We had two issued U.S. patents directed to compounds and methods of inhibiting proliferation of a cell expressing an ETS gene or comprising an ETS fusion gene: U.S. Pat. No. 9,822,122, with a patent term not due to expire before March 2037, and U.S. Pat. No. 10,351,569, with a patent term not due to expire before March 2037. We also had</span><span style="color:#000000;"> an </span><span style="Background-color:#FFFFFF;">issued U.S.</span><span style="color:#000000;"> patent with claims directed to killing or inhibiting the growth of a neoplastic cell and methods of treating specific cancers by administering an analogue of ONCT-216:</span><span style="Background-color:#FFFFFF;"> U.S. Pat. No. 10,711,008, with a patent term not due to expire before March 2037. There were also approximately eight patents or applications pending outside the U.S. in China, Europe </span><span style="color:#000000;">(including a European patent validated in Austria, Belgium, Denmark, France, Germany, Great Britain, Ireland, Italy, Spain, Sweden, and Switzerland)</span><span style="Background-color:#FFFFFF;">, Japan, Korea, and Taiwan. Patents, if issued from these applications, would not be due to expire before March 2037.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 4, 2022, the Georgetown Licensed Portfolio contained patents directed to other EWS-FLI1 inhibitor compounds. We had three U.S. patents directed to compounds and methods for treating Ewing sarcoma or pancreatic cancer: U.S. Pat. No. 8,232,310, with a patent term not due to expire before November 2028, U.S. Pat. No. 9,045,415, with a patent term not due to expire before August 2028, and U.S. Pat. No. 9,758,481, with a patent term not due to expire before December 2027. We had four issued patents in jurisdictions outside the U.S., including Australia, Canada, Europe (validated in Germany, France and Great Britain), and Hong Kong. These patents are not due to expire before December 2027. We had two issued U.S. patents directed to compounds and methods for treating pancreatic cancer or Ewing sarcoma: U.S. Pat. No. 9,290,449, with a patent term not due to expire before April 2033, and U.S. Pat. No. 9,714,222, with a patent term not due to expire before April 2033. There are approximately seventeen patents outside the U.S. in Australia, Canada, China, Europe (validated in Great Britain, France and Germany), Hong Kong, India, Israel, Japan, Korea, Macao, Mexico, and New Zealand. These patents have a patent term not due to expire before </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 2033, and patents, if issued from these applications, would not be due to expire before April 2033. The Georgetown Licensed Portfolio contained additional patents related to methods of treating cancers. We had one issued U.S. patent directed to methods of treating lung cancer or glioblastoma multiforme: U.S. Pat. No. 9,511,050, with a patent term not due to expire before October 2034. There were approximately two patents issued outside the U.S. in China and Japan. These patents have a patent term not due to expire before October 2034.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record&#8209;keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process and a new biologic must be approved by the FDA through the biologics license application, or BLA, process before it may be legally marketed in the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United States Drug Development Process</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and in the case of biologics, also under the Public Health Service Act, or PHSA, and their implementing regulations. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following steps are usually required by the FDA before a drug or biologic may be marketed in the U.S.:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP requirements and other applicable regulations&#59; submission to the FDA of an Investigational New Drug Application, or IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approval by an independent Institutional Review Board, or IRB, or Ethics Committee associated with each clinical site before patients can be enrolled into each trial at that particular clinical site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practices, or GCP, requirements to establish the safety and efficacy of the proposed drug, or safety, purity and potency of the proposed biologic, for its intended use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of an NDA or BLA after substantial information is available from pivotal clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a determination by the FDA within 60 days of its receipt of an NDA or BLA whether to file the application for review&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential review of the product application by an FDA advisory committee, where appropriate and if applicable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality and purity, and audits of selected clinical trial sites to ensure compliance with GCP&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA review and approval of the NDA or BLA.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies usually include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. Prior to beginning the first clinical trial with a product candidate in the U.S., a Sponsor must submit an IND to the FDA, which is a request for authorization from the FDA to administer an investigational new drug product to humans. The U.S. IND submission contains the general investigational plan, the clinical protocol, protocols and results from preclinical studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls, or CMC, information, and any available human data or literature to support the use of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigational product. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA will review the IND, and if the information is adequate, the IND goes into effect and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">human clinical trials may begin. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The IND automatically </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goes into </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect 30 days after receipt by the FDA, unless the FDA </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requires additional information which may result in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a clinical hold </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if the data are insufficient.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In such a case, the IND </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. The FDA may also impose clinical holds on a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny drug or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one or more </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials may not recommence </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or continue </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without FDA authorization </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated with agreed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or changes agreed between </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Sponsor</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA, supervision of certain human gene transfer trials may also require evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of a product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study Sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, patient selection and exclusion criteria, and the parameters to be used to monitor patient safety, including stopping rules that assure a clinical study will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations including GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical study must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical study will be conducted. The FDA, the IRBs, or the Sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or if a trial is unlikely to meet its stated objectives. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the Sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase&#160;1</span><span style="color:#000000;">: The product candidate is initially administered to healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase&#160;2</span><span style="color:#000000;">: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine the appropriate dosage for further clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase&#160;3</span><span style="color:#000000;">: The product candidate is administered to an expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the safety and efficacy of the product and the overall risk benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling and commercial use of the product.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as Phase&#160;4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of an NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a new drug or biologic, Sponsors are given opportunities to meet with the FDA at certain points. These meetings may be prior to submission of an IND, at the end of Phase&#160;2, and before an NDA or BLA is submitted, or at other times important in product candidate development. These meetings can provide an opportunity for the Sponsor to share information about the clinical, preclinical or CMC data gathered to date, for the FDA to provide advice, and for the Sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase&#160;2 trial to discuss Phase&#160;2 clinical results and present plans for the pivotal Phase&#160;3 clinical trial that they believe will support approval of the new drug or biologic.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsors</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <span style="font-style:italic;">in vitro</span> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA&#8209;regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United States Review and Approval Process</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product development, preclinical and other preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from several alternative sources, including studies initiated and sponsored by investigators. The submission of an NDA or BLA is subject to the payment of user fees&#59; a waiver of such fees may be obtained under certain limited circumstances (eg., indication for a product with orphan drug designation).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews all NDAs and BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the submission is accepted for filing, the FDA will determine the type of review (standard or priority) and the FDA begins an in&#8209;depth substantive review. The FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP&#8209;compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may refer the NDA or BLA to an advisory committee so that independent advice can be provided to contribute to the FDA&#8217;s decision-making and lends credibility to the review process. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or BLA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facilities </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">follow</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, it will issue an Approval Letter or a Complete Response Letter, or CRL. An Approval Letter authorizes commercial marketing of the drug and is accompanied with the approved U.S. Prescribing Information, or USPI. A CRL indicates that the review cycle of the NDA or BLA is complete and the application will not be approved with the information provided by the Sponsor. A CRL usually describes the specific deficiencies in the NDA or BLA identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time&#8209;consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a CRL is issued, the Sponsor must resubmit the NDA or BLA, addressing all of the deficiencies identified in the CRL Since the re-submission of the NDA and BLA may address all deficiencies, there is no guarantee that the FDA would approve the NDA or BLA as the circumstances may have changed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives FDA approval for marketing authorization, the approval may be significantly limited to a specific disease subset, dosages, or use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to require post-marketing information including additional information from certain trials, perform Phase&#160;4 clinical trials designed to further assess a products safety and effectiveness after NDA or BLA approval, may require testing and surveillance programs to monitor the safety of approved products which have been commercialized, additional CMC information or preclinical studies. The FDA may also place other conditions on approval including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the Sponsor of the NDA or BLA must submit a proposed REMS program.&#160;The FDA will not approve the NDA without an approved REMS program, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non&#8209;compliance with regulatory requirements or if problems occur following initial marketing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA Safety and Innovation Act, or FDASIA, made permanent the Pediatric Research Equity Act, or PREA, which requires a sponsor to conduct pediatric clinical trials for most drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the Sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S. or, if it affects more than 200,000 individuals in the U.S., there is no reasonable expectation that the cost of developing and making a drug or biologic product available in the U.S. for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug or biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;fee waivers. However, competitors, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA offers several expedited development and review programs for qualifying product candidates. For example, the FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs or biologics are eligible for Fast Track designation if they are intended for the treatment of a serious or life-threatening disease or condition and which demonstrate the potential to address an unmet medical need for the disease or condition. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy. The Sponsor of a Fast Track product candidate has opportunities for more frequent meetings with the FDA review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. With regard to a Fast Track product candidate, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the Sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the Sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation (BTD) to expedite its development and review. A product candidate can receive BTD if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate submitted to the FDA for approval, including a product with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and Accelerated Approval. A BLA or NDA for a product candidate is eligible for priority review if the product candidate has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. A serious disease or condition is a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning. Short-lived and self-limiting morbidity will usually not be sufficient, but the morbidity need not be irreversible if it is persistent or recurrent. The FDA will attempt to direct additional resources to the evaluation of a BLA or NDA designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six&#160;months of the filing date as compared to ten&#160;months for review of original BLAs and new molecular entity NDAs under its standard review goals.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a product candidate may be eligible for Accelerated Approval. Drugs and biologics intended to treat serious or life-threatening diseases or conditions may be eligible for Accelerated Approval upon a determination that the product candidate has an effect on a surrogate endpoint, is a marker such as a laboratory measurement, radiographic image, physical sign, or other measure, that is thought to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a Sponsor of a drug receiving Accelerated Approval perform adequate and well-controlled </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">postmarketing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> confirmation clinical trials. As a condition of Accelerated Approval, the FDA will generally require the Sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products approval using the Accelerated Approval pathway may be subject to expedited withdrawal procedures if the Sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for Accelerated Approval preapproval of promotional materials, which could adversely impact the commercial launch of the product. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the FDA established the regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug or biologic. Regenerative medicine therapies to treat, modify, reverse, or cure serious conditions are eligible for FDA&#8217;s expedited programs, including fast track designation, breakthrough therapy designation, RMAT designation, Accelerated Approval, and priority review designation, if they meet the criteria for such programs. that meets the following criteria: (i) the drug or biologic qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions&#59; (ii) the drug or biologic is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition&#59; and (iii) preliminary clinical evidence indicates that the drug or biologic has the potential to address unmet medical needs for such a disease or condition. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, Breakthrough Therapy designation, RMAT designation, priority review and Accelerated Approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time for FDA review or approval will not be shortened.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rare Pediatric Disease Priority Review Voucher Program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#201F1E;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#201F1E;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, the U.S. Congress authorized the FDA to award priority review vouchers to Sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product. The Sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the Sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents&#59; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the Sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any Rare Pediatric Disease Priority Review Voucher.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Post</span><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8209;approval requirements</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval of marketing authorization is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug and biologics manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations.<span style="font-family:Calibri;"> </span>Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any drug products we or our partners manufacture or distribute pursuant to FDA marketing authorization approvals will be subject to continuing regulation by the FDA, irrespective of the country of manufacture, including, among other things, recordkeeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug and biologics manufacturers, such as those related to direct to consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry sponsored scientific and educational activities, and promotional activities involving the internet. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and consistent with the provisions of the approved label. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications about off-label use of their products. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications or supplements to approved applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Marketing Exclusivity </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of marketing exclusivity available in the U.S. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the Sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Biosimilars and Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being addressed by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12 year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the Sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can also obtain pediatric market exclusivity in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FDA Regulation of Companion<span style="font-weight:bold;"> </span>Diagnostics<span style="font-weight:bold;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may require use of an <span style="font-style:italic;">in vitro</span> diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the U.S., the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA, approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If use of companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&#160;6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;<span style="font-style:italic;">In Vitro</span> Companion Diagnostic Devices.&#8221; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the Sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of <span style="font-style:italic;">in vitro</span> companion diagnostic devices on issues related to co-development of these products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these <span style="font-style:italic;">in vitro</span> companion diagnostics in conjunction with the review of therapeutic candidates such as those we are developing involves coordination of review by the FDA&#8217;s Center for Drug Evaluation and Research and by the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are also subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains several conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained, or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Approval Process Outside of the United States</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, marketing authorization, post-marketing requirements and any commercial sales and distribution of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. In addition, ethical, social, and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may want to use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product candidates in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Regulations Governing Marketing Authorization of Medicinal Products in the European Union<span style="color:#000000;font-weight:normal;"> </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical studies and clinical trials</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly to the U.S., the various phases of preclinical and clinical research in the European Union, or EU, are subject to significant regulatory controls.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Preclinical studies must be conducted in compliance with the principles of GLP as set forth in EU Directive 2004/10/EC. In particular, preclinical studies, both <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span>, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for preclinical studies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transitional basis for three years. Additionally, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier, or IMPD, containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the Sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorization</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.7%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, to obtain regulatory approval of an investigational chemical or biological product under EU regulatory systems, a marketing authorization application, or MAA, must be submitted. Medicinal product candidates can only be placed on the market after obtaining a marketing authorization, or MA. The process for doing this depends, among other things, on the nature of the medicinal product. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medical Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid <span style="color:#000000;">throughout </span>the EU. The centralized procedure is compulsory for certain types of medicinal medicines, such as: (i) medicinal products derived from biotechnology processes, such as genetic engineering, (ii) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicines, and (iv) Advanced Therapy Medicinal Products, or ATMPs, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. It is very likely that the centralized procedure would apply to the products we are developing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs&#59; the manufacturing and control information that should be submitted in a marketing authorization application&#59; and post-approval measures required to monitor patients and evaluate the long-term efficacy and potential adverse reactions of ATMPs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure and in exceptional cases, the CHMP might perform an accelerated review of a MA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and are expected to be of major public health interest may be eligible for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. In March 2016, the EMA launched an initiative, the Priority Medicines, or PRIME, scheme, a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;standard&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data and Marketing Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU also provides opportunities for market exclusivity. Upon receiving MA, reference medicinal products generally qualify for eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two&#8209;year period of market exclusivity, a generic/biosimilar MA can be submitted, and the innovator&#8217;s data may be referenced, but no generic/biosimilar product can be marketed until 10 years have elapsed from the initial authorization of the reference product in the EU. The overall ten-year market exclusivity period may be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Medicinal Products</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the U.S. A medicinal product may be designated as orphan if its Sponsor can establish that: (1)&#160;the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The application for orphan drug designation must be submitted before the application for MA. Orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and access to the centralized procedure. Once authorized, orphan medicinal products are entitled to ten&#160;years of market exclusivity for the approved therapeutic indication. During the ten-year market exclusivity period, the competent authorities cannot accept a MAA, or grant a MA, or accept an application to extend a MA, for the same indication, in respect of a similar medicinal product. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MAA is submitted. The period of market exclusivity is extended by two&#160;years for orphan medicinal products that have also complied with an agreed pediatric investigation plan, or PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10&#8209;year market exclusivity may be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold. In addition, MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; (2) the applicant consents to a second orphan medicinal product application&#59; or (3) the applicant cannot supply enough quantities of the orphan medicinal product. A company may voluntarily remove a product from the orphan register.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.64%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulation of Companion Diagnostics in the EU</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, <span style="font-style:italic;">in vitro</span> diagnostic medical devices are regulated by Directive 98/79/EC, or IVDD, which regulates the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufactures and devices as well as the vigilance procedure. <span style="font-style:italic;">In vitro</span> diagnostic medical devices must comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulation of companion diagnostics will be subject to further requirements once the in-vitro diagnostic medical devices Regulation No 2017/746, or IVDR, will become applicable on May 26, 2022. However, on October 14, 2021, the European Commission proposed a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of <span style="font-style:italic;">in vitro</span> diagnostic medical devices. The European Parliament and Council adopted the proposed regulation on December 15, 2021. The IVDR will fully apply on May 26, 2022, but there will be a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The IVDR introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a MAA for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">national competent authorities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or the EMA.</span></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aforementioned EU rules are generally applicable in the EEA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.64%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.64%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Brexit and the Regulatory Framework in the United Kingdom</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United Kingdom, or UK, left the EU on January 31, 2020, following which existing EU medicinal product legislation continued to apply in the UK during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December 31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. The transition period provided time for the UK and EU to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement, or TCA, and became effective on the January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. However, new legislation such as the EU CTR will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, Great Britain, or GB&#59; broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the UK. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019, or the Exit Regulations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder chooses to opt-out. In order to use the centralized procedure to obtain a MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, after Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization&#59; or use the MHRA&#8217;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Foreign Regulations Governing Marketing Authorization of Medicinal Products</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the U.S. federal and state governments and by authorities in the foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. Violation of these laws or other governmental regulations may result in penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the U.S., and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that may require companies to provide scientific and clinical support for the use of a product to each payor separately. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. Lastly, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic (or biosimilar) products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity, and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The U.S. and some foreign jurisdictions are considering or have enacted several reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of containing healthcare costs, improving quality or expanding access. In the </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the Affordable Care Act, or ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the U.S., and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular importance to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. <span style="color:#000000;">On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. </span>Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020, through March 31, 2022, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the way manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Data Privacy and Security Laws</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous state, federal and foreign laws, regulations, and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information and could apply now or in the future to our operations or the operations of our partners. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, the European Union General Data Protection Regulation, or GDPR, imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, companies have had to comply with the GDPR and the United Kingdom GDPR, or UK GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in United Kingdom, or UK, national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 6, 2019, we, then operating as GTx, Inc., or GTx, entered into an Agreement and Plan of Merger and Reorganization, as amended, or the Merger Agreement, with privately-held Oncternal Therapeutics, Inc., or Private Oncternal, and Grizzly Merger Sub, Inc., our wholly-owned subsidiary, or Merger Sub. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as our wholly-owned subsidiary (the &#8220;Merger&#8221;). On June 7, 2019, the Merger was completed.&#160; GTx changed its name to Oncternal </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics, Inc., and Private Oncternal, which remains as our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wholly-owned</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subsidiary, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;&#160; </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Human Capital</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March <span style="color:#000000;">4, 2022</span>, we had 26 full-time employees, <span style="color:#000000;">three</span> part-time employees, and several consultants, most of whom are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our management team and our clinical, scientific, and other employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel through the granting of stock-based and cash-based compensation awards, to align our interests and the interests of our stockholders with those of our employees and consultants.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are in San Diego, California, where we currently lease 4,677 square feet of office space available for corporate, research, development, clinical, regulatory, manufacturing and quality functions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the name Genotherapeutics, Inc. in Tennessee in September 1997.&#160; We changed our name to GTx, Inc. in 2001 and reincorporated in Delaware in 2003.&#160;On June 7, 2019, the Merger was completed and GTx, Inc. changed its name to Oncternal Therapeutics, Inc.&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are located at 12230 El Camino Real, Suite 300, San Diego, CA 92130, and our telephone number is (858) 434-1113. Our website address <span style="text-decoration:none;">is www.oncternal.com.</span> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form&#160;10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. We make available on our website at <span style="text-decoration:none;">www.oncternal.com</span>, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of that website is <span style="text-decoration:none;">www.sec.gov</span>. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.48%;text-indent:-10.48%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_RISK_FACTORS"><span style="color:#000000;">Risk Factors.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should consider carefully the following risk factors, together with the other information contained in this Annual Report, including our financial statements and the related notes and &#8220;Management Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business operations or financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring and&#160;in-licensing&#160;our product candidates and conducting preclinical studies and early-stage clinical trials. Zilovertamab and ONCT-216 are in clinical development, while our ROR1 CAR-T and DAARI programs are in the preclinical stage. We have not yet demonstrated an ability to successfully obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third-party to do so on our behalf, or embark on sales and marketing activities necessary for successful post regulatory approval product commercialization, and have not developed any companion diagnostic test for our product candidates. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since our inception. If our product candidates are not successfully developed and approved, we may never generate any revenue. Our net losses were $<span style="color:#000000;">31.3 million and $</span>17.2 million for the years ended December 31, 2021, and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $114.1 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and anticipate these losses will increase substantially as we continue to develop, seek regulatory approval for and potentially commercialize any of our product candidates, and seek to identify, assess, acquire, in-license or develop additional product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in our company&#8217;s value could also cause stockholders to lose all or part of their investment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of zilovertamab and ONCT-216, continue research and development and initiate clinical trials of our other development programs<span style="color:#000000;">, including our preclinical ROR1 CAR-T and DAARI programs,</span> and seek regulatory approval for our current product candidates and any future product candidates we may develop. In addition, as our product candidates progress through development and toward commercialization, we will need to make milestone payments to the licensors and other third parties from whom we have in-licensed or acquired our product candidates, including zilovertamab, ONCT-216, and any candidates from our ROR1 CAR-T and DAARI programs. If we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution<span style="color:#000000;"> and we will need to make royalty payments to the licensors and / or other third parties from whom we have in-licensed or acquired our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, we incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based our estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through a combination of equity financings, debt financings, government funding or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our&#160;day-to-day&#160;activities, which may adversely affect our ability to develop our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs incurred as a result of the COVID-19 pandemic, including clinical trial delays and impacts on our supply chain activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the type, number, scope, progress, expansions, results, costs and timing of our clinical trials of zilovertamab and ONCT-216, and preclinical studies or clinical trials of our ROR1 CAR-T and DAARI programs or additional indications of our current product candidates as well as other product candidates that we may choose to pursue in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of obtaining ibrutinib, for which we currently obtain supply at no cost under our clinical supply agreement with Pharmacyclics LLC, to conduct our clinical trials of zilovertamab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and capacity for CAR-T development and lentivirus manufacturing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs, timing and outcome of regulatory review of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs associated with hiring additional personnel, contract research organizations, or CROs and consultants as our clinical and other development activities increase&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of the milestone or other payments we must make to the licensors and other third parties from whom we have in-licensed&#160;or acquired our product candidates or technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of establishing or securing sales and marketing capabilities if any of our product candidates are approved&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs associated with any products or technologies that we may&#160;in-license&#160;or acquire.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting clinical trials and preclinical studies is a time consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:7.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.7%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, our Form S-3 registration statement became effective. Future sales under a Form S-3, if any, will depend on a variety of factors including, but not limited to, the effectiveness of a Form S-3, prevailing market conditions, the trading price of our common stock and our capital needs. If we are successful in filing a Form S-3 in the future, there can be no assurance that we will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate<span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, government funding or other capital sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect stockholders&#8217; rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend heavily on the success of our product candidates, which are in clinical or preclinical development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.<span style="font-weight:normal;font-style:normal;"><br /></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our two clinical-stage product candidates are zilovertamab, which we expect to initiate a Phase 3 clinical study in the second quarter of 2022, and ONCT-216 which is in a Phase 1/2 clinical study. In addition, zilovertamab is being evaluated in two investigator-sponsored studies being conducted at UC San Diego, a: (i) Phase 1b clinical trial in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer is about to open at UC San Diego, has an Investigational New Drug Application, or IND, in effect, to evaluate the safety and efficacy of, and to determine the RP2D, and (ii)&#160;a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL is open for enrollment. We are also developing ONCT-216, an investigational small molecule that is designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. ONCT-216 is being evaluated in a Phase 1/2 clinical trial as a single agent and in combination with vincristine </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. In addition, we are developing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-808, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a chimeric antigen receptor T cell, or CAR-T, therapy candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pipeline also includes&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-534</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n investigational</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> dual-action androgen receptor inhibitor, that is in preclinical development as a potential treatment for castration resistant prostate cancer and other androgen-receptor dependent diseases.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of our product candidates have advanced into a pivotal or registrational study for the indications for which we are studying them</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, although</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we expect the planned Phase 3 trial of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zilovertamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the treatment of patients with MCL to be a potentially pivotal trial</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on various factors, including the following:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful completion of preclinical and clinical studies with favorable results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of investigation new drug applications, or INDs, by the FDA, or similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed designs for future clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">demonstrating safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receiving marketing approvals from applicable regulatory authorities, including Biologics License Applications, or BLAs, or new drug applications, or NDAs, from the FDA, and maintaining such approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">making arrangements with our third-party manufacturers for commercial manufacturing capabilities and manufacturing process optimization for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing sales, marketing and distribution capabilities and launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the demonstration of an acceptable safety profile of our products following approval, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing, in-licensing or acquiring companion diagnostics to our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintaining and growing an organization for people who can develop our product candidates and technology.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business, including our ability to finance the company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any of our product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early<span style="color:#000000;">-</span>stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.</p>
<p style="margin-top:6pt;margin-bottom:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while zilovertamab was well tolerated and showed favorable results in the Phase 1 portion of our ongoing Phase 1/2 clinical trial as well as the inhibition of ROR1 signaling in patients with CLL in early clinical trials, we do not know how zilovertamab will perform in the Phase 2 portion of the clinical trial and one or more of the reported clinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outcomes may materially change as patient enrollment continues in such trial, and such results may not be replicated in any other future clinical trials, including as a result of any differences in the target population, drug interactions or other differences in our trial design.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, this and any future preclinical and clinical data may be susceptible to varying interpretations and analyses. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, we cannot assure you that we will be able to successfully progress our preclinical programs from candidate identification to Phase&#160;1 clinical development.</span></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union, or EU, recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the Sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.&#160;&#160; </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is currently unclear to what extent the United Kingdom, or UK, will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic may adversely impact our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration, extent, and impact of the ongoing COVID-19 pandemic remains uncertain, has presented substantial public health and economic challenges and continues to affect economies, financial markets and business operations around the world. International and U.S. governmental authorities have taken actions since late 2019 in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. We expect that COVID-19 precautions may continue to directly or indirectly affect the timeline for our clinical trials, including our global Phase 3 study of zilovertamab that we plan to initiate in the second quarter of 2022 and our expected submission of an IND for our ROR1 CAR-T program during the middle of 2022. Patients with MCL or CLL may be at increased risk of severe disease if they develop COVID-19 because of advanced age and/or immunosuppression, and so may be unwilling to travel to our study centers to enroll in our clinical trials. For our existing patients, we continue to work all of our clinical trial sites to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">minimize disruptions and address concerns on an individual site or patient basis in order to allow participating patients to continue to receive treatment at home or in alternate healthcare settings while minimizing their potential exposure to the virus that causes COVID-19.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the present time, we believe we have sufficient quantities of our zilovertamab and ONCT-216 clinical trial materials to continue to treat patients in our clinical trials through at least the end of 2022. However, if our third-party manufacturers, including those located in China, experience additional manufacturing difficulties due to the COVID-19 pandemic or as a result of natural disasters, labor disputes, unstable political environments, or other public health emergencies, our ability to provide our product candidates to patients in clinical trials, or to provide product for treatment of patients if approved, would be jeopardized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic may cause disruptions that could severely impact our business, clinical trials and manufacturing and supply chains, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>interruptions or delays in the operations of the FDA or other regulatory authorities, which may delay receiving feedback or approvals from the FDA or other regulatory authorities with respect to future clinical trials or regulatory submissions&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>further delays or difficulties in enrolling patients in our clinical trials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial patient visits and study procedures, which may impact the integrity of patient data and clinical study endpoints&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>limiting our ability to interact with our clinical trial investigators, present our data in person at scientific and investor conferences, develop and renew contracts due to travel limitations or cancellations of scientific or investor conferences&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, including interruption of supply of zilovertamab or ONCT-216&#59;<span style="color:#000000;"><br /></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and interruption in global shipping that may affect the transport of clinical trial materials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees&#59; and</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.48%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the spread of COVID-19 may have impacted, and may continue to impact, the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis, or at all, or enter into partnerships with pharmaceutical companies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The situation continues to rapidly evolve. The extent to which the COVID-19 may impact our business, including our clinical trials, manufacturing and supply chains and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the identification of new variants, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section.</p>
<p style="margin-top:18pt;margin-bottom:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue, and adversely affect our commercial prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. We are conducting a Phase 1/2 clinical trial of zilovertamab in combination with ibrutinib in patients with treatment-na&#239;ve or relapsed or refractory CLL and previously treated patients with MCL. Additionally, we are evaluating ONCT-216 as a single agent and in combination with vincristine in a Phase 1 clinical trial in patients with relapsed or refractory Ewing sarcoma.&#160;&#160;We will have to follow the same procedure for our other preclinical product candidates that we plan to advance to clinical development, and would also be required to submit regulatory filings to foreign regulatory authorities if we decide to initiate clinical trials outside of the U.S.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in recruiting clinical trial investigators with the appropriate competencies and experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in obtaining approval from one or more institutional review boards, or IRBs, or ethics committees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional patients, or withdrawing their approval of the trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes to clinical trial protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical sites deviating from trial protocols or dropping out of a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">challenges in manufacturing sufficient quantities of product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patients failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment&#160;follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">lack of adequate funding to continue clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patients experiencing severe or unexpected drug-related adverse effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">occurrence of serious adverse events in clinical trials of the same class of agents conducted by other companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">cGMP regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing </span><span style="color:#000000;">process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any changes to our manufacturing process that may be necessary or desired&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials in a timely manner or consistent with applicable clinical trial protocols, GCP, or other regulatory requirements&#59; third-party contractors not performing data collection or analysis in a timely or accurate manner&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if our clinical trials are suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial, or by the FDA or comparable foreign regulatory authorities. Regulatory authorities may suspend or terminate clinical trials due to a number of factors, including failure to conduct clinical trials in accordance with regulatory requirements or the applicable clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, if we decide to conduct clinical trials of our product candidates in foreign countries additional risks may arise that may delay completion of those clinical trials. These risks include the failure of enrolled patients in other countries to adhere to clinical protocol as a result of differences in healthcare practices or cultural customs, managing additional administrative burdens associated with the regulatory schemes of other countries, as well as political and economic risks relevant to other countries.&#160;&#160;Under our license and development agreement with SPH USA, SPH USA has the right to manufacture, develop, market, distribute and sell our zilovertamab, ROR1 CAR-T, and ONCT-216 product candidates in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan, or Greater China, and the obligation to perform all preclinical and clinical development activities required to obtain regulatory approvals for such product candidates in Greater China. In the event that SPH USA&#8217;s preclinical studies or clinical trials of our product candidates raise new safety or efficacy concerns, the prospects for obtaining regulatory approval of our product candidates in the U.S. and other countries, and our business, could be adversely impacted.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the completion of, or termination of, clinical trials of our product candidates, the commercial prospects of such product candidates may be harmed, and our ability to generate product revenues from such product candidates may be delayed. Moreover, delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many of the factors that cause, or lead to, the termination, suspension or delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. If we make formulation or manufacturing changes to our product candidates or revise the route of administration or dosing regimen for our product candidates, we may be required to conduct additional preclinical or clinical studies to bridge our modified product candidates to earlier versions or to bridge the new dosing regimens to dosing regimens used in our clinical trials. The need to conduct additional preclinical or clinical studies could result in delays in the approval or commercialization of our product candidates, which could shorten any period during which we may have the exclusive right to commercialize our product candidates and enable our competitors to bring products to market before we do. In such an event, the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the availability of competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. For example, a limited number of patients are affected by CLL, MCL and particularly Ewing sarcoma, which are our initial target indications for zilovertamab and ONCT-216. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for our planned clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing patients may prove costly. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required&#160;follow-up&#160;periods. For certain of our product candidates, including zilovertamab and ONCT-216, the conditions which we currently plan to evaluate are orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. If patients are unwilling to participate in our clinical trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of approved therapies, or if we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure stockholders that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of the label for an approved product candidate, or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with oncology drugs generally, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence, or unexpected characteristics of side effects. For example, our ongoing clinical trials of zilovertamab in combination with ibrutinib, and ONCT-216 in combination with vincristine, and the ongoing investigator-initiated clinical trial of zilovertamab in combination with paclitaxel, may reveal adverse events based on the combination therapy under evaluation. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, result in a more restrictive label for the product candidate, or delay or cause the denial of regulatory approval of the product candidate by the FDA or comparable foreign regulatory authorities. The drug-related side effects could also affect patient recruitment for our clinical trials, or the ability of enrolled patients to complete the trials, or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial prospects for the product candidate if approved. We may also be required to modify our plans for future studies based on findings in our ongoing clinical trials.&#160;&#160;Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as the use of our product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may withdraw, suspend or limit approvals of such product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to recall a product or change the way such product is administered to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients or </span><span style="color:#000000;">similar risk management measures</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we could be sued and held liable for harm caused to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of the product may decrease significantly or the product could become less competitive&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reputation could suffer.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to maintain orphan drug designations for certain of our product </span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates, and</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the U.S. and EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of greater than 200,000 individuals in the U.S., but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S.<span style="color:#000000;"> In the EU, orphan drug designation is granted by the European Commission based on a scientific opinion of the European Medicines Agency&#8217;s, or EMA, Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its Sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment&#59; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application for orphan designation must be submitted before the application for marketing authorization.</span> In June 2020, we announced that we had obtained orphan drug designations in the U.S. for zilovertamab for treatment of MCL and for treatment of CLL/small lymphocytic lymphoma. We have also received orphan drug designation in the U.S. for ONCT-216 for patients with Ewing sarcoma. We may seek additional orphan drug designations for zilovertamab or ONCT-216 or for certain of our other product candidates. There can be no assurance that the FDA or the European Commission will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a NDA or BLA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in the EU, but such exclusivity period can be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory landscape that will apply to development of gene therapy or cell-based therapeutic product candidates by us or by our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing products involving gene therapy treatment have changed frequently and will likely continue to change in the future. Approvals by one regulatory agency may not be indicative of what any other regulatory agency may require for approval, and there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of gene therapy products, cell therapy products and other products created with genome editing technology. For example, in addition to the submission of an IND to the FDA, before initiation of a clinical trial in the U.S., certain human clinical trials for cell therapy products and gene therapy are subject to the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NIH Guidelines call for the supervision of human gene transfer trials including an evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. We will therefore be subject to significant regulatory oversight by the FDA, and in addition to the government regulators, the applicable IBC and IRB of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, would need to review and approve the proposed clinical trial.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar requirements apply in the EU. The EMA, has a Committee for Advanced Therapies, or CAT, that is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products, or ATMPs. ATMPs include gene therapy medicine, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the EU, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any of our gene therapy product candidates such as CAR-T, but that remains uncertain at this point.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for product candidates involving gene therapy can be more lengthy, rigorous and expensive than the process for other better known or more extensively studied product candidates and technologies. Since we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or comparable regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. This may be a particularly significant risk for many of the genetically defined diseases for which we may develop product candidates alone or with collaborators due to small patient populations for those diseases, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene therapy in a timely manner or under technically or commercially feasible conditions. Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene therapy, either of which could materially harm our business. Furthermore, regulatory action or private litigation could result in increased expenses, delays or other impediments to our research programs or the development or commercialization of current or future product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient product revenue to maintain our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As an organization, we have limited experience in the process of enrolling patients in our clinical trials, have never conducted later-stage clinical trials or submitted a BLA or an NDA, and may be unable to do so for any of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar requirements apply in the EU. The EMA, has a Committee for Advanced Therapies, or CAT, that is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products, or ATMPs. ATMPs include gene therapy medicine, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate that is submitted to the EMA. In the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any of our gene therapy product candidates such as CAR-T, but that remains uncertain at this point.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. We are not permitted to market any of our product candidates in the U.S. until we receive approval of a BLA or an NDA from the FDA. Similar risks exist in foreign jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses, and in the case of biological products, that such product candidates are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may disagree with the design or execution of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approval may be granted only for indications that are significantly more limited than those sought by us, and/or may include significant restrictions on distribution and use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which we contract for clinical and commercial supplies&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failure to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually complete clinical trials and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS or <span style="color:#000000;">similar risk management measures</span>, which may be required because the FDA or the comparable foreign regulatory authority believes it is necessary to ensure safe use of the drug after approval. The FDA or the comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there are a greater likelihood of success.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we are focused on specific product candidates, indications and development programs. As a result, we may forgo or delay the pursuit of opportunities with other indications or other product candidates that could have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we could relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements, when it might be more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fast Track designation by the FDA for ONCT-216 or our other product candidates may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted a Fast Track designation for ONCT-216 in the U.S. for the treatment of Ewing sarcoma and may seek Fast Track designation for zilovertamab or our other product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing new product candidates that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. With a Fast Track product candidate, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the Sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the Sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining a Fast Track designation does not change the standards for product approval, but may expedite the development or approval process. Even though the FDA has granted such designation for ONCT-216, it may not actually result in faster clinical development or regulatory review or approval. Furthermore, such a designation does not increase the likelihood that ONCT-216 or any other product candidate that may be granted Fast Track designation will receive marketing approval in the U.S.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek PRIME designation by EMA or other designations, schemes or tools in the EU, including the conditional marketing authorization or marketing authorization under exceptional circumstances, for one or more of our product candidates, which we may not receive. Such designations may not lead to a faster development or regulatory review or approval process and do not increase the likelihood that our product candidates will receive marketing authorization.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek EMA PRIME (Priority Medicines) designation or other designations, schemes or tools for one or more of our product candidates. In the EU, innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the Breakthrough Therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. The benefits of a PRIME designation include the appointment of a rapporteur before submission of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we believe one of our product candidates is eligible for PRIME, the EMA may disagree and instead determine not to make such designation. The EMA PRIME scheme or other schemes, designations, or tools, even if obtained or used for any of our product candidates may not lead to a faster development, regulatory review or approval process compared to therapies considered for approval under conventional procedures and do not assure ultimate approval. In addition, even if one or more of our product candidates is eligible to the PRIME scheme, the EMA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for review or approval will not be shortened.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product developers that benefit from PRIME designation may be eligible for accelerated assessment (in 150 days instead of 210 days), which may be granted for medicinal products of major interest from a public health perspective or that target an unmet medical need, but this is not guaranteed. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, in the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. <span style="text-transform:uppercase;">A</span> conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed. Furthermore, marketing authorizations may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to the introduction of specific procedures. This may arise when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This type of marketing authorization is close to a conditional marketing authorization as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a marketing authorization. However, unlike a conditional marketing authorization, the applicant does not have to provide the missing data and will never have to. Although a marketing authorization &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the marketing authorization may be withdrawn where the risk-benefit ratio is no longer favorable. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The competent regulatory authorities in the EU have broad discretion whether to grant such an accelerated assessment, conditional marketing authorization or marketing authorization under exceptional circumstances, and, even if such assessment or authorization is granted, we may not experience a faster development process, review or authorization compared to conventional procedures. Moreover, the removal or threat of removal of such designation or marketing authorizations may create uncertainty or delay in the clinical development of our product candidates and threaten the commercialization prospects of our product candidates, if approved. Such an occurrence could materially impact our business, financial condition and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future choose to conduct one or more of our clinical trials or a portion of our clinical trials for our product candidates outside the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice&#59; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations&#59; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which are based on preliminary analyses of then-available data. Such preliminary or topline results and related findings and conclusions are subject to change following more comprehensive reviews of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.&#160;As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated.&#160;Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary or topline data should be viewed with caution until the final data are available. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may also disclose interim data from our clinical studies. Interim data from this clinical trial and future clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available. Adverse differences between topline, preliminary or interim data and final data could significantly harm our business prospects<span style="color:#000000;">.</span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of data from preclinical studies or clinical trials of its product candidates, or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or prospects for commercialization of the product candidate, or our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Information that we decide not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the interim, topline or preliminary data that we disclose differ from actual results, or if others, including regulatory authorities, disagree with the conclusions we reach based on our analyses of such data, our ability to obtain approval for, and commercialize our product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any Breakthrough Therapy designation that we may receive from the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Breakthrough Therapy designation for some of our product candidates, including zilovertamab and ONCT-216. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For drugs or biologics that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the Sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The designation also includes the same program features as Fast Track designation, including eligibility for rolling review of a submitted NDA or BLA. Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification and rescind the designation.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although we have obtained a rare pediatric disease designation for ONCT-216, there is no guarantee that FDA approval of ONCT-216 will result in a priority review voucher.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The Sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor.&#160;&#160;The voucher may be further transferred any number of times before the voucher is used, as long as the Sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained a rare pediatric disease designation for ONCT-216 for the treatment of Ewing&#8217;s sarcoma, however, there is no guarantee that we will be able to obtain a priority review voucher, even if ONCT-216 is approved by the FDA.&#160;&#160;Moreover, Congress included a sunset provision in the statute authorizing the rare pediatric disease priority review voucher program.&#160; On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the Sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any rare pediatric disease priority review vouchers.<br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to GLPs, GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on third parties to conduct our clinical trials and preclinical studies, including our ongoing clinical trials for zilovertamab and ONCT-216 and preclinical studies for our ROR1 cell therapy and DAARI programs. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and applicable regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of its clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations or similar foreign requirements outside the U.S. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any BLA or NDA we submit to the FDA. Similar risks may exist in foreign jurisdictions where we decide to conduct clinical trials. Any such delay or rejection could prevent us from commercializing our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates and related raw materials for clinical and preclinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA or other regulatory agencies pursuant to inspections that will be conducted after we submit a BLA or an NDA to the FDA or their equivalent to other regulatory agencies. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or similar foreign </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements for manufacture of our drug products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency and pure compounds or other products, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if regulatory authorities withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or a third-party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms, or to comply with cGMP or similar foreign requirements could adversely affect our business in a number of ways, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an inability to initiate or continue clinical trials of zilovertamab, ONCT-216 or any future product candidates under development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">requirements to cease development or to recall batches of our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product candidates.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">breach of the manufacturing agreement by the third-party&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to manufacture our product according to our specifications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to manufacture our product according to our schedule, or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">misappropriation of our proprietary information, including our trade secrets and&#160;know-how&#59;&#160;and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP or foreign regulations and that might be capable of manufacturing for us.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we currently rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees, consultants and contractors prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our&#160;know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into and may seek to enter into additional collaborations, licenses and other similar arrangements, and we may not be successful in doing so, and we may not realize the benefits of such relationships.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints, in addition to our collaboration with Shanghai Pharmaceutical Holding Co., Ltd., SPH USA and Celularity Inc. We may not be successful in our efforts to establish such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into a clinical trial and supply agreement with Pharmacyclics in support of our clinical trial to evaluate the combination of zilovertamab with ibrutinib. Ibrutinib is an<span style="color:#000000;"> inhibitor of Bruton&#8217;s tyrosine kinase, a key component of cell signaling in B-cells,</span> and is marketed by Pharmacyclics for treatment in patients with CLL and MCL. We initiated a Phase 1/2 clinical trial in May 2018 to assess zilovertamab in combination with ibrutinib in patients with CLL and MCL. Pursuant to the agreement, Pharmacyclics has supplied ibrutinib up to a maximum aggregate amount at no cost to us for part 1 (a dose-finding arm) and part 2 (dose expansion arm) of the ongoing Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib.&#160;&#160;Under the clinical trial and supply agreement with Pharmacyclics, we are required to provide periodic reports to Pharmacyclics, including safety data reports, and to collaborate with Pharmacyclics in relation to any interactions with regulatory authorities regarding ibrutinib. The agreement includes no upfront costs, milestone or royalty payment commitments. In August 2019, Pharmacyclics agreed to provide additional quantities of ibrutinib at no cost to us for part 3 of the clinical trial, and so that patients who participated in parts 1 and 2 of the study may continue to receive ibrutinib in combination with zilovertamab for as long as their disease is responding. In the event the clinical supply agreement is terminated, we would likely incur substantial additional costs in order to obtain and purchase ibrutinib from a source other than Pharmacyclics and the Phase 2 part 3 of the Phase 1/2 clinical trial may be delayed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved, and may not conduct those activities in the same manner as we would. Any termination of collaborations we </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enter into</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization of Our Product Candidates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following potential approval of any of our product candidates, the FDA or comparable foreign regulatory authorities may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA or comparable foreign regulatory authorities may also require a REMS or <span style="color:#000000;">similar risk management measures</span> or as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs or similar foreign requirements and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications we filed or suspension or revocation of approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention, or refusal to permit the import or export of our products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if any of our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA and comparable foreign regulatory authorities strictly regulate the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA or comparable foreign regulatory authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such&#160;off-label&#160;uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses, and a company that is found to have improperly promoted&#160;off-label&#160;uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in&#160;off-label&#160;promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and comparable foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies<span style="color:#000000;">, such as the EMA, following its relocation to Amsterdam and resulting staff changes,</span> may also slow the time necessary for new drugs and biologics, or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities outside the U.S. have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">demonstration of clinical efficacy and safety compared to other more-established products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the indications for which our product candidates are approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the limitation of our targeted patient population and other limitations or warnings contained in any&#160;FDA-approved&#160;labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of a new drug for the relevant indication by healthcare providers and their patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of patients to pay all, or a portion of,&#160;out-of-pocket&#160;costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">any restrictions on the use of our products, and the prevalence and severity of any adverse </span><span style="color:#000000;">effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential product liability claims&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of market introduction of our products as well as competitive drugs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effectiveness of our or any of our potential future collaborators&#8217; sales and marketing strategies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unfavorable publicity relating to the product.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for our product candidates may be limited to patients who are ineligible for or have failed prior treatments and may be small or different from our estimates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, including targeted therapy, immunotherapy, chemotherapy, hormone therapy, surgery or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. In markets with approved therapies, there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive later stage therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. In addition, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first- or second-line therapy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the Sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. Similar risks may exist in foreign jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our future product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reference products in a way that is </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses. If we are found or alleged to have improperly promoted&#160;off-label&#160;uses, we may become subject to significant liability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as our product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such&#160;off-label&#160;uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in&#160;off-label&#160;promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion and avoid off-label promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require&#160;co-payments&#160;that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require&#160;pre-approval&#160;of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates as we are targeting certain defined populations for our treatments. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement sought for our product candidates, once approved. While we, or our collaborators, have not yet developed any companion diagnostic test for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain approval, coverage and adequate reimbursement for the same reasons applicable to our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the U.S, the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the fields of immunology, inflammation and oncology. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and&#160;in-licensing&#160;new product candidates. Smaller or early<span style="color:#000000;">-</span>stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved in oncology indications such as CLL or MCL, they will compete with small molecule therapies, biologics, cell-based therapies and vaccines, either approved or under development, that are intended to treat the same cancers that we are targeting, including through approaches that may prove to be more effective, have fewer side effects, be less costly to manufacture, be more convenient to administer or have other advantages over any product candidates we develop. In addition to competing with other therapies targeting similar indications, there are numerous other companies and academic institutions focused on similar targets as our product candidates and/or different scientific approaches to treating the same indications. We face competition from such companies in seeking any future potential collaborations to partner our product candidates, as well as potentially competing commercially for any approved products. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant progress has been made in the treatment of CLL since the advent of targeted therapies and FDA approval of ibrutinib for CLL in 2014. Three classes of targeted therapies have now been approved for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treatment of patients with CLL: inhibitors of BTK a key component of cell signaling in B-cells, such as ibrutinib, which is marketed as Imbruvica by AbbVie, Inc., and Johnson &#38; Johnson, and acalabrutinib, which is marketed as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calquence</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by AstraZeneca PLC&#59; inhibitors of the protein B-cell lymphoma-2, or Bcl-2, such as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venetoclax</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which is marketed as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Venclexta</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Venclyxto</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by AbbVie, Inc., and Roche/Genentech&#59; and inhibitors of Phosphoinositide 3-kinase, or PI3K, which include </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">idelalisib</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which is marketed as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zydelig</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by Gilead Sciences, Inc., and duvelisib, which is marketed as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Copiktra</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Verastem</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Inc. These targeted therapies are now the core of the recommended treatment regimens for patients with both </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">first-line</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and relapsed or refractory CLL, and have achieved objective response rates of 85-90%, two-year PFS of 65-90%, and two-year overall survival of 75-95%. The outcomes are worse for patients with certain prognostic factors, such as 17p or 11q chromosome deletions&#59; for such patients with relapsed or refractory CLL treated with ibrutinib, the reported PFS is 50-75%. While CLL is treatable, it generally remains incurable, and patients with CLL will generally experience a recurrence of their cancer. </span><span style="color:#000000;">Additionally, clinicians are investigating their potential in earlier stage disease in multiple clinical trials.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several therapeutic options available to treat MCL. Newly diagnosed patients are typically treated with rituximab combined with a chemotherapy regimen known as CHOP, comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone. Alternative chemotherapy regimens include bortezomib or bendamustine. Patients with clinical responses to chemotherapy may become candidates for another therapeutic approach, autologous stem cell transplantation, a procedure in which radiation and/or chemotherapy is used to eliminate the patient&#8217;s immune cells, including residual MCL cells. Recently, ibrutinib was granted Accelerated Approval by the FDA for the treatment of relapsed MCL. Additionally, two other BTK inhibitors, acalabrutinib (Calquence) and zanubrutinib (Brukinsa) have been approved by the FDA for the treatment of patients with relapsed MCL. These therapies are given continuously for prolonged periods of time, and their use can be associated with significant toxicity.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current standard therapy for patients with localized Ewing sarcoma in the U.S. is a combination of chemotherapy agents, including vincristine, doxorubicin and cyclophosphamide, with alternating cycles of ifosfamide and etoposide &#8211; a therapy known as VDC/IE. Patients that respond to this therapy may be candidates for tumor resection and continued treatment for a total of 14 to 17 cycles. This therapeutic regimen, however, is associated with significant toxicities. Patients with metastatic disease are often treated with VDC/IE or variations of this therapy with higher or more compressed dosing. This may also be supplemented by local radiation therapy or systemic radiation followed by autologous hematopoietic stem cell transplant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of products we may develop, if approved, could be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, the number who have the specific indicated stage or treatment history we believe will be the approved indication, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indication approved by regulatory agencies and the diagnostic criteria included in the final label for each of our product candidates approved for sale for these </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in most other countries, we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, manufacturing, pricing and distribution of our product candidates. If we receive regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different regulatory requirements for approval of drugs in foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced protection for intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the existence of additional third-party patent rights of potential relevance to our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unexpected changes in tariffs, trade barriers and regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">economic weakness, including inflation, public health emergencies, or political instability in particular foreign economies and markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign reimbursement, pricing and insurance regimes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce uncertainty in countries where labor unrest is common&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geopolitical actions, including war and terrorism, public health emergencies, such as the outbreak of a novel strain of coronavirus affecting the People&#8217;s Republic of China and elsewhere or natural disasters including earthquakes, typhoons, floods and fires.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business Operations and Industry</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and any manufacturing issues or challenges requiring additional manufacturing activities, and the terms of our agreements with third-party manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters such as earthquakes, typhoons, floods and fires or public health emergencies or pandemics such as the recent coronavirus (COVID-19) pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of any milestone or other payments we must make to the licensors and other third parties from whom we have&#160;in-licensed&#160;or acquired our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of demand for any approved products, which may vary significantly&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">future accounting pronouncements or changes in our accounting policies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a&#160;period-to-period&#160;basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on the services of our management and if we are not able to retain these individuals or recruit additional management or other key personnel, our business will suffer.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our Chief Executive Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned operations, planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter difficulties in managing our growth and expanding our operations successfully.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 4, <span style="color:#000000;">2022</span>, we had twenty-six full-time employees and three part-time employees. As we continue research and development activities and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to expand our financial, research, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for the company. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to various foreign, federal, and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services, CMS, information related to payments and other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors)</span><span style="color:#000000;">, certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives)</span><span style="color:#000000;"> and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">analogous U.S. state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by&#160;non-&#160;governmental third-party payors, including private insurers, or by the patients themselves&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities&#59; and state and local laws that require the registration of pharmaceutical sales representatives. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our consulting arrangements with physicians and other healthcare providers, some of whom received stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, referred to collectively as the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, was enacted in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Among the provisions of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of importance to our potential product candidates, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: establishe</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents&#59; extend</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59; expands eligibility criteria for Medicaid programs&#59; expand</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the entities eligible for discounts under the Public Health program&#59; increase</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program&#59; create</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a new Medicare Part D coverage gap discount program&#59; establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research&#59; and establishe</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there has been heightened governmental scrutiny in the U.S. of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients with life-threatening diseases or conditions to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. There is no obligation for a drug manufacturer to make our drug products available to eligible patients as a result of the Right to Try Act.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended. Any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or<span style="letter-spacing:-0.4pt;"> </span>conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive health-related or other personal information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the California Consumer Privacy Act, or CCPA, went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the California Privacy Rights Act, or CPRA, was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> become enforceable on July 1, 2023.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EU and the U.S. remains uncertain. For example, Court of Justice of the EU, or the CJEU, limited how organizations could lawfully transfer personal data from the EEA, to the U.S. by invalidating an agreed upon framework for data transferred from the EU to the U.S., called the Privacy Shield, for purposes of international transfers and imposing further restrictions on the use of the standard contractual clauses.  To the extent we are unable to transfer personal data between and among regions in which we operate or intend to operate as a result of regulatory authorities issuing further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, it could affect the manner in which we operate and could adversely affect our financial results.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Further, since January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or/ extends that decision. and remains under review by the Commission during this period. In September 2021, the UK government launched a consultation on its proposals for wide-ranging reform of UK data protection laws following Brexit. There is a risk that any material changes which are made to the UK data protection regime could result in the European Commission reviewing the UK adequacy decision, and the UK losing its adequacy decision if the European Commission deems the UK to no longer provide adequate protection for personal data. The relationship between the UK and the EU in relation to certain aspects of data protection law remains uncertain, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. If we or our third-party CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our historical operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injury to our reputation and significant negative media attention&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs to defend the related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a diversion of management&#8217;s time and our resources&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to trial participants or patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant negative financial impact&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decline in our stock price.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold $10.0 million in product liability insurance coverage in the aggregate. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we and any of our potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of health-related and other personal information, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personal or other confidential information, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personal information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and&#160;follow-up&#160;actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third- party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a&#160;man-made&#160;or natural disaster or other business interruption. In addition, our corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1)&#160;the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2)&#160;manufacturing standards, including cGMP and similar foreign requirements, (3)&#160;federal, state and foreign data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad or (4)&#160;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and&#160;out-licensing&#160;or&#160;in-licensing&#160;of intellectual property, products or technologies, similar to our approach in&#160;in-licensing&#160;and acquiring our current product candidates. Any future transactions could increase our near and long-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired&#160;in-process&#160;research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by licensing or filing patent applications in the U.S. and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our or our licensor&#8217;s patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our or our licensor&#8217;s patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we own and license issued patents in the U.S. and foreign countries, we cannot be certain that the claims in our or our licensor&#8217;s other U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the U.S. Patent and Trademark Office, or USPTO, courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our or our licensor&#8217;s issued patents will not be found invalid or unenforceable if challenged.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we, our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patent applications may not result in any patents being issued&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.7%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.78%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is also expensive and time consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensor in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license,&#160;and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we enter into&#160;non-disclosure&#160;and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensees, collaboration partners, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including with respect to zilovertamab and ONCT-216, or otherwise experiences disruptions in our business relationships with our licensors, we could lose license rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to several license agreements under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future. For example, in March 2014, we entered into an exclusive license agreement with Georgetown University, or Georgetown, to obtain an exclusive license to certain intellectual property rights to develop and commercialize compounds targeting EWS-FLI1.&#160;&#160;In March 2016, we entered into an exclusive license agreement with the Regents of the University of California to obtain an exclusive license to certain intellectual property rights to develop and commercialize zilovertamab and other ROR1 related naked antibodies.&#160;&#160;We are also party to a license agreement with the University of Tennessee Research Foundation pursuant to which we have exclusive rights to certain intellectual property rights to develop and commercialize product candidates in our DAARI program.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These license agreements impose, and we expect that any future license agreements where we&#160;in-license&#160;intellectual property, will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are able to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> obtain a license, it may be&#160;non-exclusive,&#160;thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to sublicense patents and other rights to third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to transfer or assign the license&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ownership of inventions and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensor&#8217;s patent rights are highly uncertain. Our and our licensor&#8217;s pending and future patent applications may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our or our licensor&#8217;s patents by developing similar or alternative technologies or products in a&#160;non-infringing&#160;manner which could materially adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our and our licensor&#8217;s patents may not cover our product candidates or may be challenged in the courts or patent offices in the U.S. and abroad. Our and our licensor&#8217;s patents may be subject to a third-party&#160;pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and&#160;inter partes&#160;review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our or our licensor&#8217;s patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors or our licensor and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we, our predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our or our licensor&#8217;s patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our or our licensor&#8217;s patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The patent protection and patent prosecution for some of our product candidates may be dependent on third parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we or our licensors may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our or our licensor&#8217;s patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our or our licensor&#8217;s patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. If we or our licensors, whether current or future, fail to establish, maintain or protect our patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to our assuming control over patent prosecution.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical&#160;in-licensed&#160;technology, we may be unable to successfully develop,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out-license,&#160;market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop,&#160;out-license&#160;or market and sell our product candidates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as&#160;&#8220;march-in&#8221;&#160;rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with&#160;non-U.S.&#160;manufacturers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work on zilovertamab and ONCT-216 was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a&#160;non-exclusive,&#160;non-transferable,&#160;irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or&#160;non-exclusive&#160;licenses to any of these inventions to a third-party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention&#59; (ii)&#160;government action is necessary to meet public health or safety needs&#59; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as&#160;&#8220;march-in&#160;rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the U.S. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with&#160;non-U.S.&#160;product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. With respect to state funding, specifically funding via the California Institute of Regenerative Medicine, or CIRM which has granted funds for the study of zilovertamab in combination with ibrutinib and a novel anti-cancer stem cell targeted therapy, the grantee has certain obligations and the state or CIRM&#160;has certain rights. For example, the grantee has an obligation to share intellectual property, including research results, generated by CIRM-funded research, for research use in California. In addition, the California government can exercise march-in rights if it determines that action is necessary because we or the grantee failed to achieve practical application of the CIRM-funded technology, because we failed to comply with agreed to access and pricing requirements, or because action is necessary to address a public health emergency declared by the governor of California.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications that we own or license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our licensors or predecessors might not have been the first to file patent applications covering certain of our inventions&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">it is possible that our or our licensor&#8217;s pending patent applications will not lead to issued patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not develop additional proprietary technologies that are patentable&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patents of others may have an adverse effect on our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on licensee relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including milestone payments and future royalty revenues.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully, our product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates and could delay, interrupt or terminate the collaborative research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. In addition, a significant downturn or deterioration in the business or financial condition of our collaborators or partners could result in a loss of expected revenue and our expected returns on investment. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our or our licensee&#8217;s research, development and commercialization activities may be subject to claims that we or our licensee infringes or otherwise violates patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our or our licensee&#8217;s ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">result in costly litigation that may cause negative publicity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">divert the time and attention of our technical personnel and management&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cause development delays&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subject us to an injunction preventing us from making, using, selling, offering for sale, or importing our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require us to develop&#160;non-infringing&#160;technology, which may not be possible on a cost-effective basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subject us to significant liability to third parties&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be&#160;non-exclusive,&#160;which could result in our competitors gaining access to the same technology.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although no third-party has asserted a claim of patent infringement against us as of December 31, 2021, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially reasonable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third-party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our or our licensor&#8217;s patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or&#160;non-enablement.&#160;Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to our or our licensor&#8217;s intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We or our licensor may not have sufficient financial or other resources to conduct or participate in such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we or our licensor can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivation or interference proceedings provoked by third parties or brought by us or our licensors or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our licensor&#8217;s patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensor&#8217;s defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the U.S. transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third-party was first to invent the claimed invention. A third-party that files a patent application in the USPTO after March 2013 but before we could therefore be awarded a patent covering an invention of our even if we had made the invention before it was made by such third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the U.S. and most </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other countries are confidential for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a period of time</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after filing or until issuance, we cannot be certain that we or our licensor was the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our or our licensor&#8217;s patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensor&#8217;s patent applications and the enforcement or defense of our or our licensor&#8217;s issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property rights and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our or our licensor&#8217;s patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensor&#8217;s ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensor&#8217;s ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.&#160;non-provisional&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount of time required for the development, testing and regulatory review of product candidates, patents protecting our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension for our product candidates, our business may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our or our licensor&#8217;s U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our or our licensor&#8217;s patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we and our licensors have issued patents and pending patent applications in the U.S. and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we or our licensor has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our and our licensor&#8217;s patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensor may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensor&#8217;s efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensor is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our and our licensors&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent office&#8217;s require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on the protection of our trade secrets, including unpatented&#160;know-how,&#160;technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented&#160;know-how,&#160;including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The trading price of the shares of our common stock may be highly volatile, and purchasers of our common stock may incur substantial losses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above their purchase price. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="color:#000000;"> or our collaborators</span><span style="color:#000000;"> ability to enroll patients in our ongoing and planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of our clinical trials and preclinical studies, and the results of the trials of our competitors or those of other companies in our market sector&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments in the U.S. and foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success or failure of our efforts to acquire, license or develop additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">innovations or new products developed by us or our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements regarding the results of discovery efforts and preclinical, clinical and commercial activities by us, or those of our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing, supply or distribution delays or shortages&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achievement of expected product sales and profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trading volume of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishment of short positions by holders or non-holders of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an inability to obtain additional funding&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our stock by insiders and stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic, industry and market conditions or other events or factors, many of which are beyond our control&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key personnel&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">intellectual property, product liability or other litigation against us.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders, if they choose to act together, will continue to control or significantly influence all matters submitted to stockholders for approval. Furthermore, two of our directors have been appointed by one of our principal stockholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, our executive officers, directors and greater than 5% stockholders, in the aggregate, owned approximately 9.30% of our outstanding common stock. Furthermore, two of our directors are affiliated with our largest stockholder, SPH USA. As a result, such persons or their appointees to our board of directors, acting together, will have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock by our stockholders in the public market could cause our stock price to fall.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. As of December 31, 2021, 44,830,509 shares of our outstanding common stock are freely tradable, without restriction, in the public market, unless they are purchased by one of our affiliates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, up to 12,522,086 shares of common stock that are either subject to outstanding warrants, options or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the exclusive right of our board of directors, unless the board of directors&#8217; grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prohibition on removal of directors without cause due to the classified board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the required approval of at least&#160;66-2/3%&#160;of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal certain provisions of our amended and restated certificate of incorporation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive </span><span style="color:#000000;">officer</span><span style="color:#000000;"> or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.74%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use net operating loss (&#8220;NOL&#8221;) carryforwards and other tax attributes may be limited.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all). As of December&#160;31, 2021, we had federal and state NOL carryforwards of approximately $81.5 million and $59.4 million, respectively. Approximately $55.2 million of NOLs do not expire and the remaining federal and state NOL carryforward will begin to expire in 2033 and 2029, respectively, unless previously utilized. <span style="color:#000000;">As of December 31, 2021, we had federal and state research and development credit carryforwards of approximately $2.1 million and $1.3 million, respectively. The federal research and development credit carryforwards will begin expiring in 2034, unless previously utilized. The state research and development credits do not expire.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Tax Act, federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely but federal NOLs generated in taxable years beginning after December 31, 2017 may only be used to offset 80% of our taxable income annually. Under Sections&#160;382 and 383 of the Code, our NOL and research and development tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including changes resulting from our Merger, as described elsewhere. We have not yet determined the amount of the cumulative change in our ownership resulting from the Merger or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stockholders prior to the Merger who hold CVRs may not receive any payment on the CVRs and the CVRs may otherwise expire valueless.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to a <a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex101.htm"><span style="text-decoration:none;">CVR Agreement, dated as of June 7, 2019 and as amended on November 1, 2021, or </span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the CVR Agreement, pursuant to which, for each share of GTx common stock held, stockholders of record as of immediately prior to the Merger received one contingent value right, or CVR, entitling such holders to receive in the aggregate 50% of any net proceeds received during the 15-year period after the closing of the Merger from the grant, sale or transfer of rights to our DAARI program that occurs during the 10-year period after the closing of the Merger (or in the 11th&#160;year if based on a term sheet approved during the initial 10-year period) and, if applicable, to receive royalties on the sale of any DAARI products or SARM products by us during the 15-year period after the closing of the Merger.&#160;&#160;</span><span style="color:#000000;">As of December 31, 2021, no transactions or net sales relating to the DAARI technology had occurred.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CVRs are not transferable, will not have any voting or dividend rights, and interest will not accrue on any amounts potentially payable on the CVRs. Accordingly, the right of any stockholder of record as of immediately prior to the Merger to receive any future payment on or derive any value from the CVRs will be contingent solely upon the achievement of the foregoing events within the time periods specified in the CVR Agreement and if these events are not achieved for any reason within the time periods specified in the CVR Agreement, no payments will be made under the CVRs, and the CVRs will expire valueless. In addition, we (as successor in interest to GTx) have agreed only to use commercially reasonable efforts to develop DAARI products, subject to certain limitations, which allows for the consideration of a variety of factors in determining the efforts that we are required to use to develop DAARI products, and we are not required to take all possible actions to continue efforts to develop DAARI products. Accordingly, under certain circumstances we may not be required to continue efforts to develop DAARI products, or may allocate resources to other projects, which would have an adverse effect on the value, if any, of the CVRs. Furthermore, the CVRs will be unsecured obligations of our company and all payments under the CVRs, all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all of our current or future senior obligations. Finally, the U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the IRS, would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, or Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action we take to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future&#160;non-compliance&#160;with Nasdaq&#8217;s listing requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that apply to us. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manner in which</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we operate our business in ways we cannot currently anticipate.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our common stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of Sarbanes-Oxley, we are required to report upon the effectiveness of our internal control over financial reporting. Additionally, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been required to upgrade our information technology systems&#59; implement additional financial and management controls, reporting systems and procedures&#59; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;"> may become involved in the future, in securities class action litigation that could divert management&#8217;s attention, adversely affect our business and subject us to significant liabilities.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following volatility in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.81%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future lawsuits to which we may become a party are subject to inherent uncertainties and will likely be expensive and time-consuming to investigate, defend and resolve, and will divert our management&#8217;s attention and financial and other resources. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of future lawsuits, and we may not prevail. Any litigation to which we may become a party may result in an onerous or unfavorable judgment that may not be reversed upon appeal or in payments of substantial monetary damages or fines, or we may decide to lawsuits on similarly unfavorable terms, which could adversely affect our business, financial condition, results of operations or stock price.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the U.S. and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unresolv</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ed Staff Comments</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_PROPERTIES">Properties.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are <span style="color:#000000;">located in San Diego, California, where we lease 4,677 square feet of office space used primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. Such lease expires on May 31, 2022.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_LEGAL_PROCEEDINGSFROM_Q3_FORM_10Q">Legal Proceedings.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Mine Safety Disclosures.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART&#160;II</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT&#8221;. As of March 3, 2022, there were approximately 117 holders of record of our common stock.&#160;&#160;<span style="color:#000000;">This number was derived from our stockholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_RESERVED">[Reserved].</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion should be read in conjunction with the consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and future financial performance, includes forward-looking statements that are based upon current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should review the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that could cause our actual results and the timing of selected events to differ materially from those described in or implied by the forward-looking statements contained in the following discussion and analysis. Please also see the section within Part&#160;I of this Annual Report entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for cancers with critical unmet medical need. Our development efforts are focused on promising, yet untapped, biological pathways implicated in cancer generation or progression. Our pipeline includes: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226; Zilovertamab (formerly cirmtuzumab or UC-961) is an investigational, humanized, potentially first-in-class, monoclonal antibody designed to: (i) inhibit Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, a growth factor receptor that is widely expressed on many tumors and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance, and (ii) bind to a specific functionally important epitope of ROR1. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After reaching an agreement regarding the study design and major details with the U.S. Food and Drug Administration (FDA), zilovertamab is planned to be evaluated in our potentially pivotal Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory MCL, which is expected to be initiated in the second quarter of 2022. The Phase 3 clinical trial ZILO-301 is entitled, &#8220;Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study of Zilovertamab (A ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Patients with Relapsed or Refractory Mantle Cell Lymphoma.&#8221; Zilovertamab is currently being evaluated in the Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia, or CIRLL, study, a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma, or MCL, and chronic lymphocytic leukemia, or CLL. As of January 31, 2022, we have completed the enrollment of patients with MCL and CLL in the Phase 1/2 CIRLL study, and those patients are completing therapy or are in long-term follow-up. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are supporting two investigator-sponsored studies being conducted at the UC San Diego School of Medicine, or UC San Diego, a: (i) Phase 2 clinical trial for metastatic castration-resistant prostate cancer study, and (ii) Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226; ONCT-808, our lead cell therapy product candidate, is: (i) an autologous chimeric antigen receptor T cell, or CAR-T, therapy that targets ROR1, (ii) in preclinical development as a potential treatment for hematologic malignancies and solid tumors, (iii) highly expressed by multiple solid tumors and hematological malignancies and confers both an aggressive phenotype and survival advantage to tumor cells, and (iv) being developed in collaboration with the Karolinska Institutet and under agreements with Lentigen Technology, Inc. (lentivirus manufacturing) and Miltenyi Biotec B.V. &#38; Co. KG. (cell processing). We are performing preclinical activities to support the submission to the FDA of an Investigational New Drug Application, or IND, which we expect to submit in mid-2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226; ONCT-534 (formerly GTX-534), a dual action androgen receptor inhibitor, or DAARI, product candidate is in preclinical development as a potential treatment for advanced castration-resistant prostate and other androgen-receptor cancers. This program was acquired in the GTx Merger (described below) and was previously known as the selective androgen receptor degrader, or SARD, program. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226; ONCT-216 (formerly TK216) is an investigational small molecule that is designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins, has shown in preclinical studies to alter gene transcription and RNA processing and leads to increased cell proliferation and invasion. ONCT-216 is being evaluated in a Phase 1/2 clinical trial as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. The active Phase 2 expansion cohort targeting up to 21 evaluable Ewing sarcoma patients is designed to evaluate clinical responses to single agent ONCT-216 using an optimized dosing regimen, treating patients for 28 days per cycle with the next cycle starting immediately after the prior one, to intensify the amount of ONCT-216 administered over time.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the inception of privately-held Oncternal Therapeutics, Inc. in 2013, we have devoted most of our resources to organizing and staffing, business planning, raising capital, acquiring product candidates and securing related intellectual property rights and advancing our zilovertamab and ONCT-216 clinical development programs as well as our ONCT-808 and ONCT-534 preclinical programs. Under research subaward agreements between us and UC San Diego, we are eligible to receive approximately $14.4 million in development milestones during the award project period, estimated to be from October 1, 2017 to March 31, 2022. Through December 31, 2021, we have funded our operations primarily through: (i) gross proceeds of $125.0 million from the issuance of common stock, (ii) gross proceeds of $49.0 million from the issuance of convertible preferred stock, (iii) receipt of $13.9 million in subaward grant payments received from UC San Diego, and (iv) cash proceeds of $18.3 million received in connection with the closing of the merger with GTx, Inc. in June 2019, or the GTx Merger. As of December 31, 2021, we had cash and cash equivalents of $90.8 million and no debt.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each year since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss was $31.3 million for the year ended December 31, 2021. As of December 31, 2021, we had an accumulated deficit of $114.1 million. Substantially all of our net losses have resulted from costs incurred in connection with: (i) advancing our research and development programs, (ii) general and administrative costs associated with our operations, including the costs associated with operating as a public company, and (iii) in-process research and development costs associated with the GTX Merger. We expect to continue to incur significant and increasing operating losses for at least the next several years. We expect that our expenses and capital funding requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance zilovertamab through clinical development in multiple indications, with a primary focus in MCL&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance our ROR-1 targeting cell therapy program, which includes ONCT-808 to clinical development, initially in hematological malignancies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>generate clinical proof-of-concept data with ONCT-216 in Ewing sarcoma, an orphan pediatric cancer indication&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance ONCT-534 into clinical development, initially in castration resistant prostate cancer and then other AR-driven diseases&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>respond to the impacts of the COVID-19 pandemic, which has slowed enrollment into our clinical trials and impacted our supply chain activities&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluate zilovertamab in additional ROR1-positive hematologic malignancies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluate ONCT-216 in additional malignancies with ETS fusion proteins or overexpression&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue to develop additional product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>acquire or in&#8209;license other product candidates and technologies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintain, expand and protect our intellectual property portfolio&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek regulatory approvals for any product candidates that successfully complete clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>add operational, financial and management information systems and personnel, including personnel to support our planned product development and future commercialization efforts. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not generate product sales revenue unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. If we obtain regulatory approval for any of our product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates and do not </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enter into</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. In addition, we expect to incur additional costs associated with operating as a public company. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we believe we will need substantial additional funding to support our continuing operations and pursue our business strategy. Until such time as we can generate significant product sales revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements. We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in licenses or acquisitions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Beyond that point, we will need to raise additional capital to finance our operations, which cannot be assured.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and continues to affect economies, financial markets and business operations around the world. The pandemic may continue to directly or indirectly affect the timeline for our manufacturing activities, planned IND submissions and clinical trials, including our global Phase 3 study of zilovertamab that we plan to initiate in the second quarter of 2022. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact the our business results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of ongoing vaccination programs worldwide, the emergence and spread of additional variants of COVID-19, as well as the economic impact on local, regional, national and international markets.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our grant revenue has been derived from a California Institute for Regenerative Medicine, or CIRM, grant subaward with UC San Diego and research and development grants from the National Institutes of Health, or NIH.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance our Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. Oncternal is conducting this study in collaboration with UC San Diego and estimates it will receive approximately $14.4 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022. In addition, we are committed to certain co-funding requirements and are required to provide UC San Diego progress and financial update reports throughout the award project period. We received subaward payments of $2.2 million and $1.4 million in the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we believe we have met our obligations under the CIRM award and UC San Diego subawards.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the NIH awarded the Company two research and development grants for up to $2.2 million to support preclinical activities for the Company&#8217;s ONCT-216 and ONCT-534 programs, including $0.7 million payable to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subawardees</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-refundable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the Company is required to provide periodic progress performance reports. During the year ended December 31, 2021, the Company received no award payments from the NIH and recorded $143,000 in grant revenue and unbilled receivables which has been included in prepaid and other assets.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for the preclinical and clinical development of our product candidates, zilovertamab, ONCT-216, ONCT-808 and ONCT-534, which include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>expenses under agreements with third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs related to develop and manufacture preclinical study and clinical trial material&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>salaries and employee-related costs, including stock-based compensation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs incurred under our collaboration and third-party licensing agreements&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>laboratory and vendor expenses related to the execution of preclinical and clinical trials.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accrue all research and development costs in the period for which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred and then expensed as the related goods are delivered and as services are performed. Any unearned advances would be refunded when known. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially for the foreseeable future as we: (i) continue to invest in developing our product candidates preclinically, advance preclinical assets into the clinic and as we begin to conduct larger global clinical trials, and (ii) invest in additional operational personnel to support our planned product development efforts. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, especially for global studies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct research and development expenses are tracked by product candidate and consist primarily of external costs, such as fees paid under third-party license agreements and to outside consultants, contract research organizations, or CROs, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by product candidate unless we can include them as subaward costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development, including any potential expanded dosing beyond the original protocols based in part on ongoing clinical success and the potential effects of the COVID-19 pandemic. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments of each product candidate&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related costs, insurance costs, facility costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. Personnel-related costs consist of salaries, benefits and stock-based compensation. We expect our general and administrative expenses will increase significantly as we: (i) incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs, (ii) hire additional personnel, and (iii) protect our intellectual property.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Income</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, we received a $0.3 million loan under the Paycheck Protection Program, or PPP, a program implemented by the U.S. Small Business Administration, or SBA, under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. The loan forgiveness was recorded as other income in the consolidated statement of operations for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our cash equivalents, which consist of money market funds. Our interest income has not been significant due to low interest earned on invested balances.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2021 and 2020</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,315</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">940</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,086</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,544</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,542</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,595</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,373</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,222</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,681</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,917</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,764</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,366</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,542</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,824</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(301</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(284</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,333</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,225</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,108</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Revenue </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue for the year ended December 31, 2021 was $4.3 million, compared to $3.4 million for the year ended December 31, 2020. The increase of $0.9 million was primarily due to an increase in clinical and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing activities under the CIRM grant subaward and partially due to new operating activities under the NIH awards received in August 2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the periods indicated (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase/</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zilovertamab</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,735</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,359</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,376</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-216</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,048</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-808</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,273</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCT-534</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,543</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,157</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,086</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,544</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,542</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the years ended December 31, 2021 and 2020 were $24.0 million and $12.5 million, respectively, an increase of $11.5 million. The increase was due to: (i) a $6.3 million net increase in direct product candidate costs, and (ii) a $5.2 million increase in unallocated research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for zilovertamab increased $3.4 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, primarily due to the following partially offsetting factors: (i) a $0.2 million increase in preclinical costs, (ii) a $0.7 million increase in clinical trial costs primarily related to our ongoing <span style="color:#000000;">Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib</span>, (iii) a $2.2 million increase in manufacturing development costs related to the supply of clinical drug product, and (iv) a $0.3 million increase in license and milestone fees under the Regents License Agreement, as defined below.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for ONCT-216 increased $0.7 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, due primarily to the following offsetting factors: (i) a $0.2 million decrease in clinical trial costs related to our ongoing Phase 1/2 clinical trial of ONCT-216 in refractory Ewing sarcoma, and (ii) a $0.9 million increase in manufacturing development costs related to the supply of clinical drug product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for ONCT-808 increased $2.3 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, primarily due to a: (i) $1.9 million increase in manufacturing and preclinical development costs and, (ii) $0.4 million increase in collaboration agreement costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for ONCT-534 increased by a nominal amount for the year ended December 31, 2021, compared to the year ended December 31, 2020, primarily due to an increase in preclinical costs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated expenses increased $5.2 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, primarily due to higher personnel costs, including higher non-cash share-based compensation expense of $2.6 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the years ended December 31, 2021 and 2020 were $11.6 million and $8.4 million, respectively, an increase of $3.2 million. The increase is primarily due to higher: (i) personnel and professional related costs of $2.5 million, <span style="color:#000000;">including higher non-cash share-based compensation expense of $1.7 million,</span> (ii) director&#8217;s and officer&#8217;s insurance costs of $0.4 million, and (iii) public company and other expenses of $0.3 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses and negative cash flows from operations since inception. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we had an accumulated deficit of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114.1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and anticipate that we will continue to incur net losses for the foreseeable future.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">As of December 31, 2021, we had $90.8 million in cash and cash equivalents</span><span style="color:#000000;"> and no debt</span><span style="color:#000000;">. We believe we have sufficient cash to</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> fund our </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">projected operating requirements into mid-2023</span><span style="color:#000000;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our net cash flow activity for each of the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:76.28%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,589</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,495</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,181</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,972</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,686</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, net cash used in operating activities was $26.6 million, resulting from our net loss of $31.3 million and changes in our operating assets and liabilities of $1.3&#160;million, partially offset by net non-cash charges of $6.0 million related to stock-based compensation and lease expense. The net loss of $31.3 million was driven by our ongoing clinical development activities partially offset by grant revenue.&#160;&#160;The $1.3 million change in operating assets and liabilities primarily consisted of the following activities, a: (i) $1.6 million decrease in deferred revenue, (ii) $0.9 million increase in prepaid and other assets and operating lease liability, and (iii) $1.2 million increase in accounts payable and accrued expenses.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, operating activities used $17.5 million, resulting from our net loss of $17.2 million, which included net non-cash charges of $1.4 million related to stock-based compensation, lease expense, and forgiveness of the paycheck protection program loan, offset by a $1.7 million change in our operating assets and liabilities. <span style="color:#000000;">The net loss of $17.2 million was driven by our ongoing clinical development activities partially offset by grant revenue.&#160;&#160;</span>The $1.7 million change in operating assets and liabilities primarily consisted of the following partially offsetting activities: (i) a $2.0 million decrease in deferred revenue, (ii) a $0.7 million increase in prepaid and other assets and operating lease liability, and (iii) a $1.0 million increase in accounts payable and accrued expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No cash was used or provided by investing activities for the years ended December 31, 2021 and December 31, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities provided net cash of $0.6 million for year ended December 31, 2021, which consisted of net proceeds from the exercise of common stock options and warrants. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities provided net cash of $114.2 million for the year ended December 31, 2020, which primarily consisted of $113.9 million in net proceeds received from various public offerings. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Capital Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to increase as we continue the research and development of, and seek regulatory approvals for, our product candidates and conduct additional research and development activities. Our product candidates have not yet achieved regulatory approval and we may not be successful in achieving commercialization of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing cash and cash equivalents as of March </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will be sufficient to fund our projected operating requirements into mid-2023. However, our forecast of the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period of time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> through which our financial resources will be adequate to support our planned operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. For example, the FDA or other regulatory authorities may require us to generate additional data or conduct additional preclinical studies or clinical </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may impose other requirements beyond those that we currently anticipate. Additionally, it is possible for a product candidate to show promising results in preclinical studies or in clinical </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials, but</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> fail to establish sufficient safety and efficacy data necessary to obtain regulatory approvals. As a result of these and other risks and uncertainties and the probability of success, the duration and the cost of our research and development activities required to advance a product candidate cannot be accurately estimated and are subject to considerable variation. We may encounter difficulties, complications, delays and other unknown factors and unforeseen expenses </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the course of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our research and development activities, any of which may significantly increase our capital requirements and could adversely affect our liquidity.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require additional capital for the research and development of our product candidates, and we may be forced to seek additional funds sooner than expected to pursue our research and development activities. We expect to finance our capital requirements in the foreseeable future through a combination of the sale of public or private equity or debt securities, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements. There can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. Any of these events could significantly harm our business, operations, financial condition and prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our forecast of the period of time through which our existing cash and cash equivalents and investments will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs incurred as a result of the COVID-19 pandemic, including clinical trial delays&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the type, number, scope, progress, expansions, results, costs and timing of our clinical trials of <span style="color:#000000;">zilovertamab and ONCT-216, and </span>preclinical studies or clinical trials of our ROR1 CAR-T and DAARI product candidates or additional indications of our current product candidates as well as other product candidates that we may choose to pursue in the future&#59;<span style="font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs of obtaining ibrutinib, for which we currently obtain supply at no cost under our clinical supply agreement with Pharmacyclics, to conduct our clinical trials of zilovertamab&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs and capacity for CAR-T development and lentivirus manufacturing&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs, timing and outcome of seeking and obtaining worldwide regulatory approvals for our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs associated with hiring additional personnel, CROs and consultants as our preclinical and clinical activities increase&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements, including milestone or other payments under our existing in-license agreements and any in-license agreements that we may enter into in the future&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs associated with any products or technologies that we may in-license or acquire&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities for, and the pricing and reimbursement of, any products for which we may receive regulatory approval.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot continue or expand our research and development operations, or otherwise capitalize on our business opportunities, because we lack sufficient capital, our business, operations, financial condition and prospects could be materially adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2021, we entered into the ATM Sales Agreement, pursuant to which we </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are able to</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million.&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. Through December 31, 202</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we have not sold any shares under the Sales Agreement.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under current SEC regulations, if at any time our public float is less than $75.0 million, and for so long as our public float remains less than $75.0 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the baby shelf rules. As of December 31, 2021, our calculated public float exceeded $75.0 million. In April 2021, our Form S-3 registration statement became effective. Future sales of our common stock, if any, will depend on a variety of factors including, but not limited to, the expected timing for achieving key milestones, including initiating, completing and announcing results of clinical trials of zilovertamab and ONCT-216 and announcing the first-in-human dosing of our CAR-T product candidate targeting ROR-1, currently in preclinical development, prevailing market conditions, the trading price of our common stock and our capital needs. There can be no assurance that we will be successful in consummating future sales of our securities based on prevailing market conditions or in the quantities or at the prices that we deem appropriate.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to a number of license agreements, pursuant to which we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements. As of December 31, 2021, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. See Notes 3 and 4 to our consolidated financial statements included elsewhere in this Annual Report for a description of these agreements. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies &#38; Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of the financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimates are based on our historical trends and other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our significant accounting policies are described in more detail in Note 1, &#8220;<span style="font-style:italic;">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</span>,&#8221; in the notes to our consolidated financial statements as of December 31, 2021 and 2020 and for each of the years ended December 31, 2021 and 2020, appearing elsewhere in this Annual Report. However, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. Certain service providers invoice us in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to us at that time. We periodically confirm the accuracy of our estimates with the service providers and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make adjustments</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if necessary. Examples of estimated accrued research and development expenses include fees paid to: (</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) CROs and other third parties in connection with clinical studies and preclinical development activities&#59; (ii) investigative sites in connection with clinical studies&#59; and (iii) third parties related to product manufacturing, development and distribution of clinical supplies.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from certain grant awards or a subaward (the &#8220;Grant Awards&#8221;) (see Note 4), which provide us with payments in return for certain research and development activities over a contractually defined period. Revenue from Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Grant Awards are on a best-effort basis and do not require scientific achievement as a performance obligation. The Grant Awards are nonrefundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the Grant Awards are recorded as revenue as we are the principal participant in the arrangement because the activities under the Grant Awards are part of our development programs. In those instances where we first receive consideration in advance of providing underlying services, we classify such consideration as deferred revenue until (or as) we provide the underlying services. In those instances where we first provide the underlying services prior to receipt of consideration, we record a grant receivable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Quantitative and Qualitative Disclosures About Market Risk.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.48%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_8_FINANCIAL_STATEMENT_OR_SUPPLEMENT">Financial Statement and Other Supplementary Information.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Consolidated Financial Statements and supplementary data of Oncternal Therapeutics, Inc. required by this Item are described in Item 15 of this Annual Report and are presented beginning on page F-1.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORTINDEPENDENTREGISTEREDPUBLICACC">Report of Independent Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders and Board of Directors </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended<span style="font-weight:bold;">,</span> in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material <span style="color:#auto;">misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an </span>opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Accruals</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Notes 1 and 2 to the consolidated financial statements, the Company has recorded $0.5 million for accrued clinical trial expenses for the estimated costs incurred but not yet billed or paid as of December 31, 2021. When payment terms under the related contracts do not align with the pattern of costs incurred, the Company is required to make estimates of the outstanding obligations as of period end. When evaluating the adequacy of the accrued clinical trial liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs, which could involve significant judgements, estimates, and specialized knowledge. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified clinical trial accruals as a critical audit matter due to the application of significant management judgement over the estimate of services provided as of year-end. Specifically, the amount of accrued clinical trial expenses recognized is sensitive to the availability of information to make the estimate, including the estimate of the progress of the clinical trial and the level of effort expended including patient enrollment and follow-up activity as of the balance sheet date and the associated cost of such services. Auditing these elements involved especially subjective auditor judgment due to the nature of the audit evidence available to address these matters.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary procedures we performed to address this critical audit matter included:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Reviewing the Company&#8217;s contractual agreements with third parties and any change orders to assess the impact to the amounts recorded including changes in scope and timing. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Testing clinical accrual cutoff and evaluating the completeness and valuation of clinical accruals by comparing invoices received by the Company subsequent to December 31, 2021 to the amounts recognized by the Company as of that date. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Testing clinical accrual for completeness and accuracy by confirming amounts due at December 31, 2021 directly with clinical research organizations (CROs) including total expenses incurred for all services provided by the CRO during 2021. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <ix:nonNumeric id="F_000035" name="dei:AuditorName" contextRef="C_0001260990_20210101_20211231">BDO USA, LLP</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2016.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000036" name="dei:AuditorLocation" contextRef="C_0001260990_20210101_20211231">San Diego, California</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except par value)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AssetsCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AssetsCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001260990_20211231" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001260990_20201231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001260990_20211231" decimals="-3" scale="3">657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Assets" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Assets" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20211231" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000059">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000060">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000073" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000074" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20201231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, authorized shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000075" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000076" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction></ix:nonFraction> at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December&#160;31, 2021 and 2020&#59; issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000077" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001260990_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001260990_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000061">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000062">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000081" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001260990_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000082" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001260990_20201231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; authorized shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">120,000</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; at December&#160;31, 2021 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">60,000</ix:nonFraction> at 2020&#59; issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001260990_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">49,429</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">48,802</ix:nonFraction></ix:nonFraction> at December&#160;31, 2021 and 2020,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:CommonStockValue" contextRef="C_0001260990_20211231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:CommonStockValue" contextRef="C_0001260990_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">202,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">114,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">82,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(thousands, except per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:Revenues" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:Revenues" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:OperatingExpenses" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:OperatingExpenses" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000106" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001260990_20210101_20211231" decimals="2" sign="-">0.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000107" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001260990_20200101_20201231" decimals="2" sign="-">0.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000108" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000109" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:ProfitLoss" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ProfitLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on forgiveness of payroll protection program loan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:ShareBasedCompensation" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:ShareBasedCompensation" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash lease expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="onct:NoncashLeaseExpense" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="onct:NoncashLeaseExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" scale="3">169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred grant revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from payroll protection loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options and common stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="onct:ProceedsFromStockOptionsExercisedAndWarrantExercises" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="onct:ProceedsFromStockOptionsExercisedAndWarrantExercises" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock and common stock warrants,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="onct:CashlessExerciseOfWarrants" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of warrants issued to placement agent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="onct:FairValueOfWarrantsIssuedToPlacementAgent" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on forgiveness of payroll protection program loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of 2019 bonus awards with stock options in lieu of cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockIssued1" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF">Consolidated Statements of Stockholders' Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">15,387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options for cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000153" name="onct:ExerciseOfCashlessWarrantShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting related to repurchase liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of issuance cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="onct:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">33,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of 2019 bonus awards with stock option in lieu of cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000166" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">48,802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">82,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options for cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000171" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000174" name="onct:ExerciseOfCashlessWarrantShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" scale="3">459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants for cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000175" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting related to repurchase liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000184" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">49,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">202,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">114,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">Notes to<span style="color:#000000;"> </span>Consolidated Financial Statements</p><ix:nonNumeric id="F_000190" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000190_dcnt_59a961a1-ac50-419d-a8c8-fdb9aeff0af9">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Business,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">Basis</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Presentation<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>Summary<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.45pt;"> </span>Significant<span style="letter-spacing:-0.5pt;"> </span>Accounting<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">Policies</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Oncternal,&#8221; or the &#8220;combined company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.</p><ix:nonNumeric id="F_000199" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric id="F_000200" name="onct:LiquidityAndGoingConcernPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20211231" decimals="-5" scale="6">90.8</ix:nonFraction> million in cash and cash equivalents and no debt. The Company believes it has sufficient cash to<span style="color:#000000;"> fund its projected operating requirements for at least twelve months from the date of issuance</span>. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20211231" decimals="-5" sign="-" scale="6">114.1</ix:nonFraction> million as of December 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has capacity to issue $<ix:nonFraction unitRef="U_xbrlishares" id="F_000224" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" scale="3">50.0</ix:nonFraction> million of additional shares of common stock under its recently established and unused ATM program. There can be no assurance that the Company will be able to sell any shares of its common stock under the ATM Program or regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM Program may be at prices that result in additional dilution to existing stockholders of the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000190_dcnt_59a961a1-ac50-419d-a8c8-fdb9aeff0af9" continuedAt="F_000190_dcnt_67383e61-94e7-4571-bbea-c821653a8cab"><ix:nonNumeric id="F_000201" name="us-gaap:UseOfEstimates" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP.</span><span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>preparation<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">accompanying</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">notes</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities. </span><span style="letter-spacing:0.1pt;">Significant </span>estimates <span style="letter-spacing:0.1pt;">consist </span><span style="letter-spacing:0.15pt;">of those </span>used to determine <span style="letter-spacing:0.15pt;">the </span>fair <span style="letter-spacing:0.15pt;">value of the </span><span style="letter-spacing:0.1pt;">Company&#8217;s </span>stock-based awards<span style="letter-spacing:0.15pt;">, </span><span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">those </span>used to determine grant <span style="letter-spacing:0.1pt;">revenue and </span>accruals for research <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">development </span>costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000202" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p></ix:nonNumeric><ix:nonNumeric id="F_000203" name="onct:ConcentrationRiskCreditRiskPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></ix:nonNumeric><ix:nonNumeric id="F_000204" name="onct:PatentCostsPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p></ix:nonNumeric><ix:nonNumeric id="F_000205" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of December 31, 2021, the Company&#8217;s clinical trial accrual balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20211231" decimals="-5" scale="6">0.5</ix:nonFraction> million is included in accrued liabilities. The Company&#8217;s related clinical trial expenses are included in research and development expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20210101_20211231" decimals="-5" scale="6">24.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">12.5</ix:nonFraction> million at December 31, 2021 and December 31, 2020, respectively.</p></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000190_dcnt_67383e61-94e7-4571-bbea-c821653a8cab" continuedAt="F_000190_dcnt_12abcac2-7c74-4c63-8c86-2a040bf2fd29">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000206" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000207" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from certain grant awards or a research subaward (the &#8220;Grant Awards&#8221;)(see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2021 and 2020, the Company had a grant receivable of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:GrantsReceivable" contextRef="C_0001260990_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:GrantsReceivable" contextRef="C_0001260990_20211231" decimals="-5" scale="6">0.4</ix:nonFraction></ix:nonFraction> million and deferred grant revenue of <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20211231" decimals="-5" scale="6">1.6</ix:nonFraction></ix:nonFraction> </span>million, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000208" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p></ix:nonNumeric><ix:nonNumeric id="F_000209" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000209_dcnt_a53ef048-0ef3-4c6c-a8c2-0e952d7ba722">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000190_dcnt_12abcac2-7c74-4c63-8c86-2a040bf2fd29" continuedAt="F_000190_dcnt_dd224b5a-025f-4a05-88c2-506a7d6fbffd"><ix:continuation id="F_000209_dcnt_a53ef048-0ef3-4c6c-a8c2-0e952d7ba722">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been included in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements. Under this method, deferred tax assets and liabilities are determined </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the basis of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p></ix:continuation><ix:nonNumeric id="F_000210" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="U_onctsegment" id="F_000232" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001260990_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment in the United States.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000211" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of <ix:nonFraction unitRef="U_xbrlishares" id="F_000233" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001260990_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">7,000</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000234" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction> shares from the weighted-average number of common shares outstanding for the years ended December 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p><ix:nonNumeric id="F_000213" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares&#59; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000235" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">4,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000236" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">5,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000237" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">6,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000238" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">2,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000239" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231" decimals="INF" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000240" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">10,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">7,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000212" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000212_dcnt_f7877091-c6ed-4b76-8450-fca85ad201a1">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2021-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;). The FASB issued the ASU to improve transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements.&#160;&#160;The disclosure requirements in ASU 2021-10 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard (IAS) 20,&#160;Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model.&#160;ASU 2021-10 requires the entity to disclose the nature and significant terms and conditions of the transaction, accounting policies used to account for the transaction, and line items in the financial statements affected by the transaction. ASU 2021-10 is effective for annual periods beginning </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000190_dcnt_dd224b5a-025f-4a05-88c2-506a7d6fbffd"><ix:continuation id="F_000212_dcnt_f7877091-c6ed-4b76-8450-fca85ad201a1">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after December 15, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Early adoption is permitted, including adoption in an interim period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASU 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the prospective method of transition effective </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> determined that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there was no cumulative effect to be recognized </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">early adoption.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Standards Not Yet Adopted&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#8239;<span style="font-style:italic;">Financial Instruments - Credit Losses</span>: <span style="font-style:italic;">Measurement of Credit Losses on Financial Statements </span>(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU 2021-04, <span style="font-style:italic;">Earnings Per Share</span> (Topic 260), <span style="font-style:italic;">Debt-Modifications and Extinguishments</span> (Subtopic 470-50), <span style="font-style:italic;">Compensation-Stock Compensation</span> (Topic 718), and <span style="font-style:italic;">Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity </span>(Subtopic 815-40):<span style="font-style:italic;"> Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>, which intends to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000191" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000191_dcnt_66ba4a13-e3c4-4bb8-9c3a-62e64bc0fff5">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Details</p></td></tr></table></div><ix:nonNumeric id="F_000214" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000214_dcnt_761cb02e-b262-428b-807c-39facb95da1d">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="onct:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001260990_20211231" decimals="-3" scale="3">779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="onct:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001260990_20201231" decimals="-3" scale="3">412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20211231" decimals="-3" scale="3">518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20201231" decimals="-3" scale="3">980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001260990_20211231" decimals="-3" scale="3">154</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested share liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="onct:AccruedUnvestedShareLiability" contextRef="C_0001260990_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001260990_20211231" decimals="-3" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000191_dcnt_66ba4a13-e3c4-4bb8-9c3a-62e64bc0fff5"><ix:continuation id="F_000214_dcnt_761cb02e-b262-428b-807c-39facb95da1d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000192" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments, Contingencies and Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="onct:RentExpense" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="onct:RentExpense" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20211231" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million for the years ended December 31, 2021 and 2020. On May 22, 2019, the Company entered into an office sublease agreement for <ix:nonFraction unitRef="U_utrsqft" id="F_000257" name="us-gaap:NetRentableArea" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522" decimals="0" format="ixt:numdotdecimal">4,677</ix:nonFraction> square feet in San Diego, California (&#8220;San Diego Lease&#8221;) which expired on <ix:nonNumeric id="F_000258" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522" format="ixt:datemonthdayyearen">March 31, 2021</ix:nonNumeric>. On March 17, 2021, the Company entered into a direct lease with the landlord for the same facility (the &#8220;San Diego Lease&#8221;) which expires on <ix:nonNumeric id="F_000259" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317" format="ixt:datemonthdayyearen">May 31, 2022</ix:nonNumeric>. Base rent under the San Diego Lease is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="onct:RemainderOfLeaseTermBaseRent" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="onct:RemainderOfLeaseTermBaseRent" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317" decimals="0" format="ixt:numdotdecimal">77,000</ix:nonFraction></ix:nonFraction> for the remainder of the lease term and the monthly rent expense is being recognized on a straight-line basis over the lease term. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a <ix:nonFraction unitRef="U_xbrlipure" id="F_000262" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231" decimals="3" scale="-2">10.0</ix:nonFraction>% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. As of December 31, 2021, the Company has recognized a net operating lease right-of-use asset and a lease liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction> that matures in May 2022, which has a weighted average remaining lease term of <ix:nonNumeric id="F_000264" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231" format="ixt-sec:duryear">0.42</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Transactions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company engaged Newfront Insurance as its primary insurance broker. The son of Richard Vincent, the Company&#8217;s Chief Financial Officer, acted as the Company&#8217;s agent at Newfront Insurance. During the years ended December 31, 2021 and 2020, the Company paid total related policy premiums of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:GeneralInsuranceExpense" contextRef="C_0001260990_20210101_20211231" decimals="-5" scale="6">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:GeneralInsuranceExpense" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million, respectively, for which Mr. Vincent&#8217;s son received a commission of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:InsuranceCommissions" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;) entered into a Materials Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During the year ended December&#160;31, 2021, the Company recorded amounts receivable from SPH USA related to statements of work totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:AccountsReceivableRelatedParties" contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20211231" decimals="-5" scale="6">0.4</ix:nonFraction> million (see Note 4). SPH USA is the Company&#8217;s largest stockholder and an affiliate of two of the Company&#8217;s directors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the securities purchase agreements and underwritten offering, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner and Michael G. Carter (see Note 6).</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000193" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000193_dcnt_c4dcbcb3-b5d0-4d39-ad5b-cb6bb66514e9">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration, Research Subaward Agreement and CVR Agreements</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Georgetown University (&#8220;Georgetown&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an Exclusive License Agreement (the &#8220;Georgetown License Agreement&#8221;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="onct:LicenseMaintenanceFeeToBePaidAndPaymentMade" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction> until the first commercial sale occurs, (ii) is required to make up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="onct:CollaborativeArrangementPotentialMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231" decimals="INF" scale="6">0.2</ix:nonFraction> million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of December 31, 2021, the Company had not triggered or made any milestone payments under the Georgetown License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with <ix:nonNumeric id="F_000272" name="onct:NumberOfDaysInWrittenNoticeOfTermination" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231" format="ixt-sec:durday">90</ix:nonNumeric> days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within <ix:nonNumeric id="F_000273" name="onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231" format="ixt-sec:durday">30</ix:nonNumeric> days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within <ix:nonNumeric id="F_000274" name="onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231" format="ixt-sec:durday">60</ix:nonNumeric> days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least <ix:nonNumeric id="F_000275" name="onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company entered into a collaboration agreement (as amended, the &#8220;Collaboration&#8221;) with MD Anderson, which provides for the conduct of preclinical and clinical research for ONCT-216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231" decimals="-5" scale="6">1.0</ix:nonFraction> million based on net product sales. In July 2020 and September 2021, the Company entered into two research agreements with MD Anderson for certain services up to an aggregate cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731" decimals="-5" scale="6">0.8</ix:nonFraction> million. The amount recorded as research and development expense for the year ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction> million.<span style="color:#000000;"> </span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000193_dcnt_c4dcbcb3-b5d0-4d39-ad5b-cb6bb66514e9" continuedAt="F_000193_dcnt_847af458-3dac-463c-ac67-79a456aba5d6">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, and as amended and restated in August 2018, and as amended in March and May 2019 and February 2021, the Company entered into a license agreement (as amended and restated, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="onct:UpfrontLicenseFeesPaid" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="-5" scale="6">0.5</ix:nonFraction> million was paid and <ix:nonFraction unitRef="U_xbrlishares" id="F_000281" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="INF" format="ixt:numdotdecimal">107,108</ix:nonFraction> shares of common stock were issued, (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="onct:AnnualLicenseMaintenanceFees" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain&#160;annual patent costs, (iv) certain development and regulatory milestones aggregating from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531" decimals="INF" scale="6">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531" decimals="INF" scale="6">12.5</ix:nonFraction> million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="-5" scale="6">75.0</ix:nonFraction> million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="onct:AdvanceLicensedAssets" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531" decimals="INF" scale="6">1.0</ix:nonFraction> million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: <span style="letter-spacing:0.15pt;">(i) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></ix:nonFraction> in </span><span style="letter-spacing:0.1pt;">license</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">maintenance</span><span style="letter-spacing:-0.3pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>research<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">development</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">expense for each of the</span> years ended December 31, 2021 and 2020, and (ii)<span style="letter-spacing:-0.6pt;"> approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million and</span> $<ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">costs</span> as general <span style="letter-spacing:0.1pt;">and administrative </span><span style="letter-spacing:0.15pt;">expense </span>for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company believes it has met its obligations under the Regents License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the first commercial sale of a licensed product. <span style="color:#000000;">The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. </span>The Company may terminate the agreement at any time upon at least <ix:nonNumeric id="F_000291" name="onct:NumberOfDaysInWrittenNoticeOfTermination" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20211231" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000292">five-year</span> agreement that expired in 2021, the Regents was paid an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="onct:ResearchAgreementResearchFundingAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231" decimals="-5" scale="6">3.6</ix:nonFraction> million. The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million in research and development expense under this agreement&#160;for each of the years ended December 31, 2021 and 2020, respectively. Such costs are includable as part of the Company&#8217;s annual diligence obligations under the Regents License Agreement. Effective January 1, 2022, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000293">four-year</span> agreement that expires on December 31, 2025, the Regents will have an aggregate budget of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="onct:ResearchAgreementResearchFundingAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20211202_20220101" decimals="-5" scale="6">1.6</ix:nonFraction> million, with quarterly payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="onct:ResearchAgreementResearchFundingAmountPayable" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyTwoMember_20211202_20220101" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction> in 2022, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="onct:ResearchAgreementResearchFundingAmountPayable" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyThreeMember_20211202_20220101" decimals="0" format="ixt:numdotdecimal">131,250</ix:nonFraction> in 2023, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="onct:ResearchAgreementResearchFundingAmountPayable" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyFourMember_20211202_20220101" decimals="0" format="ixt:numdotdecimal">137,813</ix:nonFraction> in 2024. &#160;&#160;  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2015, and as amended and restated in March 2022, the Company and UTRF entered into a license agreement (the &#8220;DAARI License Agreement&#8221;&#59; formerly known as the SARD License Agreement) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader technologies owned or controlled by UTRF, including all improvements thereto, which is now known as the dual action androgen receptor inhibitor, or DAARI program. Under the DAARI License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expenses under this agreement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million for each of the years ended December 31, 2021 and 2020, respectively. <span style="color:#000000;">As of December 31, 2021, the Company believes it has met its obligations under the DAARI License Agreement.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000193_dcnt_847af458-3dac-463c-ac67-79a456aba5d6" continuedAt="F_000193_dcnt_05e52602-15a6-44fe-baa1-aa977c6de884">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Award<span style="font-size:6pt;font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017,<span style="color:#000000;"> and as amended and restated in December 2020,</span> CIRM awarded an $<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831" decimals="-5" scale="6">18.3</ix:nonFraction> million grant to researchers at UC San Diego to advance the Company&#8217;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia (&#8220;CLL&#8221;) and mantle cell lymphoma (&#8220;MCL&#8221;). <span style="color:#000000;">This study is known as CIRM-0001, or Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia </span>(&#8220;CIRLL&#8221;)<span style="color:#000000;"> study</span>. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831" decimals="-5" scale="6">14.4</ix:nonFraction> million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received subaward payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="onct:SubawardPaymentsReceived" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231" decimals="-5" scale="6">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="onct:SubawardPaymentsReceived" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million in the years ended December 31, 2021 and 2020, respectively, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the years ended December 31, 2021 and 2020, the Company&#8217;s grant revenue was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:Revenues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231" decimals="-5" scale="6">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:Revenues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231" decimals="-5" scale="6">3.4</ix:nonFraction> million, respectively. Related qualifying subaward costs for the years ended December 31, 2021 and 2020 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="onct:RelatedQualifyingSubawardCosts" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231" decimals="-5" scale="6">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="onct:RelatedQualifyingSubawardCosts" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231" decimals="-5" scale="6">5.2</ix:nonFraction> million, respectively. As of December 31, 2021, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031" decimals="-5" scale="6">5.8</ix:nonFraction> million grant to the researchers at the University of California San Diego School of Medicine (&#8220;UC San Diego&#8221;) to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="onct:AmountAgreedToBeProvidedInContingencyFunds" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031" decimals="INF" scale="6">1.0</ix:nonFraction> million in contingency funds if required during the grant period. The Company recorded <ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_20210101_20211231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction> research and development expense, and no contingency funds have been provided under such CIRM award for the years ended December 31, 2021 and 2020. The grant expired in 2021 and the Company believes there are no obligations as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The National Institutes of Health (&#8220;NIH&#8221;) Grant Awards<span style="font-size:12pt;font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the NIH awarded the Company two research and development grants for up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210801_20210831" decimals="-5" scale="6">2.2</ix:nonFraction> million to support preclinical activities for the Company&#8217;s ONCT-216 and ONCT-534 programs, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="onct:AccruedClinicalTrials1" contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210831" decimals="-5" scale="6">0.7</ix:nonFraction> million payable to subawardees. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the year ended December 31, 2021, the Company received <ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:Revenues" contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210101_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> award payments from the NIH and recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="onct:AwardPaymentsReceived" contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">143,000</ix:nonFraction> in grant revenue and unbilled receivables which has been included in prepaid and other assets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial and Supply Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, and as amended in August 2019, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#8220;Pharmacyclics&#8221;) to supply ibrutinib for the Company&#8217;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SPH USA, a Related Party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Development Agreement (&#8220;LDA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018,<span style="color:#000000;"> and as amended in August 2020, </span>the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000193_dcnt_05e52602-15a6-44fe-baa1-aa977c6de884">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) SPH USA on a country</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/region-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/region</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) </span><span style="letter-spacing:0.15pt;">either</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">event</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">other</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">declares</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">insolvency</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">bankruptcy. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no significant activity under this agreement for the years ended December 31, 2021 and 2020. See Note 3.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the GTx merger agreement entered into in June 2019 (the &#8220;Merger&#8221;), the Company, a representative of holders of the CVRs, and Computershare, Inc. as rights agent entered into the CVR Agreement. Pursuant to the CVR Agreement, the Company&#8217;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#8217;s common stock held immediately prior to the Merger. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i)&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000319" name="onct:PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101" decimals="2" scale="-2">50</ix:nonFraction>% of certain net proceeds received by the Company during the <ix:nonNumeric id="F_000321" name="onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101" format="ixt-sec:duryear">15</ix:nonNumeric>-year period after the closing of the Merger (the &#8220;CVR Term&#8221;) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the <ix:nonNumeric id="F_000322" name="onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101" format="ixt-sec:duryear">10</ix:nonNumeric>-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period)&#59; and (ii) <ix:nonFraction unitRef="U_xbrlipure" id="F_000320" name="onct:PercentageOfNetSales" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101" decimals="2" scale="-2">5</ix:nonFraction>% of net sales of products by Parent or its affiliates during the CVR Term incorporating the DAARI technology. As of December 31, 2021, no transactions or net sales relating to the DAARI technology had occurred.</p></ix:continuation><ix:nonNumeric id="F_000194" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Debt</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531" decimals="-5" scale="6">0.3</ix:nonFraction> million unsecured loan, bearing interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000324" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531" decimals="INF" scale="-2">1</ix:nonFraction>%, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;), a program implemented by the U.S. Small Business Administration (the &#8220;SBA&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) (the &#8220;PPP Loan&#8221;). In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. <span style="color:#000000;">The loan forgiveness was recorded as other income of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million in the consolidated statement of operations.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000195" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000195_dcnt_557e6b48-a635-42b9-bb33-cabd22b0b6f8">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amended and Restated Articles of Incorporation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 25, 2021, the Company&#8217;s certificate of incorporation was amended and restated to authorize <ix:nonFraction unitRef="U_xbrlishares" id="F_000326" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20210525" decimals="INF" format="ixt:numdotdecimal">120,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_000327" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20210525" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of undesignated preferred stock, each with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000328" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20210525" decimals="INF">0.001</ix:nonFraction> per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities Purchase Agreements <span style="color:#000000;">and </span>Underwritten Offering</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company entered into a Securities Purchase Agreement (the &#8220;May Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000329" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" decimals="INF" format="ixt:numdotdecimal">1,943,636</ix:nonFraction> shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" decimals="-5" scale="6">4.4</ix:nonFraction> million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000331" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="INF" format="ixt:numdotdecimal">971,818</ix:nonFraction> shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000332" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="4">2.5725</ix:nonFraction>. In addition, the Company<span style="color:#000000;"> issued </span>warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000333" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="INF" format="ixt:numdotdecimal">116,618</ix:nonFraction> <span style="color:#000000;">shares of </span>common <span style="color:#000000;">stock at </span>an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000334" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="4">3.2156</ix:nonFraction><span style="color:#000000;"> per share </span>to the placement agent, H.C. Wainwright &#38; Co., LLC (&#8220;Wainwright&#8221; or the &#8220;placement agent&#8221;) as part of its compensation, which warrants were immediately exercisable and expire on <span style="color:#000000;"><ix:nonNumeric id="F_000335" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" format="ixt:datemonthdayyearen">May 21, 2025</ix:nonNumeric></span>. <span style="color:#000000;">An investor participating in the transaction included an entity affiliated with David F. Hale, the chairman of the Company&#8217;s board of directors.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a Securities Purchase Agreement (the &#8220;July Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000336" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">2,581,867</ix:nonFraction> shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" decimals="-5" scale="6">5.7</ix:nonFraction> million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000195_dcnt_557e6b48-a635-42b9-bb33-cabd22b0b6f8" continuedAt="F_000195_dcnt_68aa1669-a558-459b-bab1-71134c1db460">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants, and (ii) unregistered warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000338" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="INF" format="ixt:numdotdecimal">1,290,933</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000339" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="4">2.3825</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000340" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="2">2.32</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share and expire on </span><span style="color:#000000;"><ix:nonNumeric id="F_000341" name="onct:CommonStockWarrantsExpirationDate" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" format="ixt:datemonthdayyearen">January 21, 2026</ix:nonNumeric></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company issued warrants to purchase </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000342" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="INF" format="ixt:numdotdecimal">154,912</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock at an exercise price of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000343" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="4">2.9781</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on </span><span style="color:#000000;"><ix:nonNumeric id="F_000344" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" format="ixt:datemonthdayyearen">July 21, 2025</ix:nonNumeric></span><span style="color:#000000;">.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, and Daniel L. Kisner, a member of the Company&#8217;s board of directors.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;August Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000345" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" decimals="INF" format="ixt:numdotdecimal">2,428,886</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000348" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="2">2.10</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" decimals="-5" scale="6">4.4</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000347" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="INF" format="ixt:numdotdecimal">145,733</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000349" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="3">2.625</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000350" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" format="ixt:datemonthdayyearen">August 27, 2025</ix:nonNumeric>. An investor participating in the transaction included Michael G. Carter, a member of the Company&#8217;s board of directors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;November Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000351" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" decimals="INF" format="ixt:numdotdecimal">7,258,065</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000354" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="2">3.10</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" decimals="-5" scale="6">20.4</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000353" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="INF" format="ixt:numdotdecimal">435,484</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000355" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="3">3.875</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <span style="color:#000000;"><ix:nonNumeric id="F_000356" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" format="ixt:datemonthdayyearen">November 17, 2025</ix:nonNumeric></span>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;December Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000357" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" decimals="INF" format="ixt:numdotdecimal">19,161,667</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000360" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="2">4.50</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" decimals="-5" scale="6">79.0</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000359" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,149,700</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000361" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="3">5.625</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <span style="color:#000000;"><ix:nonNumeric id="F_000362" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" format="ixt:datemonthdayyearen">December 9, 2025</ix:nonNumeric></span>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, <span style="color:#000000;">which expired in 2021</span>. <span style="color:#000000;">In December 2021, the Company executed an at-the-market (&#8220;ATM&#8221;) facility of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="onct:AmountForAtTheMarketFacility" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_onctAtTheMarketFacilityMember_20210101_20211231" decimals="-5" scale="6">50.0</ix:nonFraction> million.</span> During the year ended December 31, 2021, the Company did not sell shares under the ATM. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Warrants</p><ix:nonNumeric id="F_000215" name="onct:ScheduleOfWarrantActivityTableTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:85.12%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Underlying Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2019</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000364" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">841,424</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000370" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20191231" decimals="INF">37.97</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000376">2.75</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000365" name="onct:WarrantsIssued" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">4,265,198</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000371" name="onct:WarrantIssuedPricePerShare" contextRef="C_0001260990_20200101_20201231" decimals="INF">3.47</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000366" name="onct:ExerciseOfWarrants" contextRef="C_0001260990_20200101_20201231" decimals="INF" sign="-" format="ixt:numdotdecimal" scale="3">74,781</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000372" name="onct:WarrantExercisedPricePerShare" contextRef="C_0001260990_20200101_20201231" decimals="INF">3.22</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2020</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000367" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">5,031,841</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000373" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20201231" decimals="INF">9.25</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000377">4.40</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000368" name="onct:ExerciseOfWarrants" contextRef="C_0001260990_20210101_20211231" decimals="INF" sign="-" format="ixt:numdotdecimal" scale="3">796,931</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000374" name="onct:WarrantExercisedPricePerShare" contextRef="C_0001260990_20210101_20211231" decimals="INF">2.56</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000369" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">4,234,910</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000375" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20211231" decimals="INF">10.50</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000378">3.31</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, all warrants met the criteria for classification in stockholders&#8217; equity.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000195_dcnt_68aa1669-a558-459b-bab1-71134c1db460" continuedAt="F_000195_dcnt_617e8da7-9fa7-4e4b-b775-d593eef9719e">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneous with the Merger&#160;&#160;closing: (i) Private Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) <ix:nonFraction unitRef="U_xbrlishares" id="F_000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607" decimals="INF" format="ixt:numdotdecimal" scale="3">1,678,571</ix:nonFraction>&#160;shares of common stock, (b) <ix:nonFraction unitRef="U_xbrlishares" id="F_000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607" decimals="INF" format="ixt:numdotdecimal" scale="3">275,579</ix:nonFraction> shares of common stock previously outstanding under the GTx 2013 Equity Incentive Plan that were cancelled became available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) <ix:nonFraction unitRef="U_xbrlipure" id="F_000381" name="onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607" decimals="2" scale="-2">5</ix:nonFraction>% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At December&#160;31, <span style="color:#000000;">2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000382" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">1,842,432</ix:nonFraction></span> shares remain available for future issuance under the 2019 Plan and Inducement Plan (as defined below).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000383" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731" decimals="INF" format="ixt:numdotdecimal">631,120</ix:nonFraction> shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire <ix:nonNumeric id="F_000384" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant and vest over a <span style="-sec-ix-hidden:F_000385">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan was terminated as to new grants in June 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire ten years from the date of grant and vest over a four-year period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 11, 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan. As amended on May 25, 2021 and December 16, 2021, the Company has reserved 2,800,000 shares of common stock under the Inducement Plan.</p><ix:nonNumeric id="F_000216" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:84.7%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">2,107,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000392" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="2">4.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">4,884,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000393" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231" decimals="2">5.78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000388" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">439,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000394" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231" decimals="2">5.46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000389" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">107,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000395" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231" decimals="2">3.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">6,444,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000396" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="2">5.28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000398">8.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">613,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000391" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">1,440,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000397" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="2">3.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000399">6.8</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">488,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of option grants for the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000402" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20211231" decimals="2">4.35</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000403" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231" decimals="2">2.53</ix:nonFraction> per share, respectively.&#160;&#160;The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at the time of the option exercise and the exercise price of that stock option. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">419,755</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,413</ix:nonFraction>. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000195_dcnt_617e8da7-9fa7-4e4b-b775-d593eef9719e" continuedAt="F_000195_dcnt_e982381e-624f-4435-963b-cb25de1a31c9">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p><ix:nonNumeric id="F_000217" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000406" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001260990_20210101_20211231" decimals="3" scale="-2">0.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000407" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001260990_20200101_20201231" decimals="3" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000408" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001260990_20210101_20211231" decimals="3" scale="-2">92.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000409" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001260990_20200101_20201231" decimals="3" scale="-2">91.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000410">6.2</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000411">6.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected term assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term</span><span style="font-size:9pt;font-family:Segoe UI;font-style:normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <span style="font-style:normal;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield. <span style="font-style:normal;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><ix:nonNumeric id="F_000218" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,136</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" scale="3">544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, the total compensation cost related to nonvested awards not yet recognized was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001260990_20211231" decimals="-5" scale="6">17.4</ix:nonFraction> million and the weighted-average period over which it is expected to be recognized was <ix:nonNumeric id="F_000419" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001260990_20210101_20211231" format="ixt-sec:duryear">3.2</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p><ix:nonNumeric id="F_000219" name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000420" name="onct:CommonStockWarrantsReservedForFutureIssuance" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="onct:CommonStockWarrantsReservedForFutureIssuance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000422" name="onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000423" name="onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000424" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000425" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="-3" scale="3">938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000426" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000427" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000195_dcnt_e982381e-624f-4435-963b-cb25de1a31c9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000196" name="onct:COVID19PandemicAndCARESActDisclosureTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#FF0000;"></span>COVID-19 Pandemic and CARES Act</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#8220;COVID-19&#8221;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., the Company expects that COVID-19 precautions may directly or indirectly impact the timeline for some of its clinical trials. For example, some of its clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Additionally, the Company&#8217;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy in China has been delayed. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its consolidated financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at December&#160;31, 2021. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP), and authorized the PPP (see Note 5).&#160; The CARES Act had no material impact on the Company&#8217;s income tax provision for the years ended December&#160;31, 2021 or 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000197" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true" continuedAt="F_000197_dcnt_f5756370-aa4b-45a9-b0b5-a361a9deb9d5">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.78%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div><ix:nonNumeric id="F_000220" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,579</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="onct:IncomeTaxReconciliationPermanentItems" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="onct:IncomeTaxReconciliationPermanentItems" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" scale="3">65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" contextRef="C_0001260990_20210101_20211231" decimals="-3" scale="3">512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_0001260990_20210101_20211231" decimals="-3" sign="-" scale="3">131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000197_dcnt_f5756370-aa4b-45a9-b0b5-a361a9deb9d5" continuedAt="F_000197_dcnt_23bfd6be-9b17-476d-bc6f-0d3887897af1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000221" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,852</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_0001260990_20211231" decimals="-3" scale="3">484</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_0001260990_20201231" decimals="-3" scale="3">367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research and development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001260990_20201231" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001260990_20211231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001260990_20201231" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,540</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001260990_20211231" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001260990_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="onct:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="C_0001260990_20211231" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="onct:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="C_0001260990_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001260990_20211231" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001260990_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company's deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of the Company's deferred tax assets, management considers all available evidence, both positive and negative.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#8220;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#8221; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2021. Accordingly, a valuation allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20211231" decimals="-5" scale="6">41.8</ix:nonFraction> million has been recorded to offset this deferred tax asset.&#160;&#160;The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001260990_20210101_20211231" decimals="-5" scale="6">9.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">5.0</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, the Company had federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">81.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">59.4</ix:nonFraction> million, respectively. Of the federal net operating losses at December&#160;31, 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="onct:OperatingLossCarryforwardsNonExpirePortion" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">55.2</ix:nonFraction> million do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in <ix:nonNumeric id="F_000469" name="onct:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2033</ix:nonNumeric> and <ix:nonNumeric id="F_000470" name="onct:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">2029</ix:nonNumeric>, respectively, unless previously utilized. At December&#160;31, 2021, the Company also had federal and state research and development credit carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">1.3</ix:nonFraction> million, respectively. The federal research and development credit carryforwards will begin expiring in <ix:nonNumeric id="F_000473" name="onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2034</ix:nonNumeric> unless previously utilized. The state research and development credits do not expire. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000474" name="onct:CumulativeChangeInOwnershipPercentage" contextRef="C_0001260990_20210101_20211231" decimals="2" scale="-2">50</ix:nonFraction>% occurs within a <span style="-sec-ix-hidden:F_000475">three-year</span> period. The Company has not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study and the fact that there may be additional such ownership changes in the future. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000197_dcnt_23bfd6be-9b17-476d-bc6f-0d3887897af1">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December 31, 2021 and 2020, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001260990_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#8217;s 2014 through 2021 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated statements of operations since inception.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000198" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001260990_20210101_20211231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style=" clear:both;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9A_CONTROLS_PROCEDURES">Controls and Procedures.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Controls and Procedures </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosures. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2021, the end of the period covered by this Annual Report. Based on the evaluation of these disclosure controls and procedures, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2021. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management's Report on Internal Control Over Financial Reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, as management of Oncternal Therapeutics, Inc., are responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Securities Exchange Act Rule&#160;13a-15(f). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles. Any system of internal control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and misstatements due to error or fraud may occur and not be detected. Also, because of changes in conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance that the objectives of the internal control system are met. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021 using the criteria for effective internal control over financial reporting as described in "Internal Control&#160;&#8212; Integrated Framework," issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this evaluation, we concluded that, as of December 31, 2021, our internal control over financial reporting was effective. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.46%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9B_OR_INFORMATION">Other Information.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 9, 2022, we entered into the amended and restated DAARI License Agreement.&#160; For a description of the DAARI License Agreement, see &#8220;Business&#8212;Licenses and Collaborative Relationships&#8212;University of Tennessee Research.&#8221; The description of the DAARI License Agreement does not purport to be complete and is qualified in its entirety by reference to the DAARI License Agreement that is filed as an exhibit to this Annual Report.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART&#160;III</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Directors, Executive Officers and Corporate Governance.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive Proxy Statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2022 Annual Meeting of Stockholders or the Proxy Statement, which is expected to be filed not later than 120&#160;days after the end of our fiscal year ended December 31, 2021, under the headings &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; and &#8220;Delinquent Section&#160;16(a) Reports,&#8221; and is incorporated herein by reference.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_11_EXECUTIVE_COMPENSATION">Executive Compensation.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; in our Proxy Statement.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the information set forth in the section titled &#8220;Executive Compensation&#8221; in our Proxy Statement.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Certain Relationships and Related Transactions, and Director Independence.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding certain relationships and related transactions and director independence is incorporated by reference to the information set forth in the sections titled &#8220;Transactions with Related Parties&#8221; and &#8220;Election of Directors &#8211; Independence of the Board of Directors,&#8221; respectively, in our Proxy Statement.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC">Principal Accountant Fees and Services.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding principal accountant fees and services is incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART&#160;IV</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Exhibits and Financial Statement Schedules.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Documents filed as part of this report.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Financial Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of Oncternal Therapeutics,&#160;Inc. listed below are set forth in Item 8 of this Annual Report for the year ended December&#160;31,&#160;2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:92.31%;"></td>
<td style="width:1.92%;"></td>
<td style="width:5.77%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORTINDEPENDENTREGISTEREDPUBLICACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (BDO USA, LLP&#59; San Diego, California&#59; PCAOB ID#<ix:nonNumeric id="F_000037" name="dei:AuditorFirmId" contextRef="C_0001260990_20210101_20211231">243</ix:nonNumeric>)</span></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><span style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:none;">Consolidated Notes to Financial Statements</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Financial Statement Schedules</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These schedules have been omitted because the required information is included in the financial statements or notes thereto or because they are not applicable or not required.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Exhibits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Annual Report and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;16.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_16_FORM_10K_SUMMARY"><span style="font-weight:normal;"></span>FORM 10-K SUMMARY</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="middle" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporation by Reference</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="middle" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File no.</p></td>
<td valign="middle" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="middle" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;2.2<span style="color:#000000;">&#94;</span></p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465919013252/a19-5973_1ex2d1.htm"><span style="text-decoration:none;">Agreement and Plan of Merger and Reorganization (&#8220;Merger Agreement&#8221;) dated March 6, 2019, among the Registrant, Oncternal Therapeutics, Inc. (N/K/A Oncternal Oncology, Inc.) (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc. (&#8220;Merger Sub&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7-Mar-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;2.2.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465919025348/a19-9089_1ex2d1.htm"><span style="text-decoration:none;">Amendment No. 1 to Merger Agreement dated April 30, 2019, among the Registrant, Private Oncternal and Merger Sub</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095013405014821/f11069orexv4w1.htm"><span style="text-decoration:none;">Restated Certificate of Incorporation of the Registrant dated February 6, 2004 (&#8220;Restated Certificate&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-127175</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4-Aug-05</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095012311046639/c16700exv3w2.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated May 6, 2011</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-May-11</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465914037092/a14-12275_1ex3d3.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated May 6, 2014</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9-May-14</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.3</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465915036849/a15-7744_1ex3d4.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated May 6, 2015</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11-May-15</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.4</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465916160637/a16-22576_1ex3d1.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated December 5, 2016</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-Dec-16</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.5</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex31.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated June 7, 2019 related to the Reverse Stock Split of the Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Jun-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.6</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex32.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated June 7, 2019 related to the Name Change of the Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Jun-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1.7</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312521177174/d173882dex31.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate dated May 25, 2021</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28-May-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex33.htm"><span style="text-decoration:none;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Jun-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex42_392.htm"><span style="text-decoration:none;">Specimen of Common Stock Certificate</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9-Aug-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465917063137/a17-24206_1ex4d9.htm"><span style="text-decoration:none;">Form of Common Stock Warrant, issued by Registrant pursuant to the Purchase Agreement dated September 25, 2017, between Registrant and the purchasers identified in Exhibit A therein</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-221040</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20-Oct-17</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex411.htm"><span style="text-decoration:none;">Form of Warrant to purchase shares of Series B-2 Preferred Stock of Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex41_414.htm"><span style="text-decoration:none;">Form of Amendment to Warrant to Purchase shares of Series B-2 Preferred Stock of Private Oncternal</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9-Aug-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.4</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex41_7.htm"><span style="text-decoration:none;">Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement dated May 19, 2020, between the Registrant and the purchasers signatory thereto (&#8220;May 2020 Purchase Agreement&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21-May-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.5</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex42_8.htm"><span style="text-decoration:none;">Form of Placement Agent Warrant, issued by Registrant pursuant to the May 2020 Purchase Agreement</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21-May-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.6</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex41.htm"><span style="text-decoration:none;">Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement dated July 17, 2020, between the Registrant and the purchasers signatory thereto (the &#8220;July 2020 Purchase Agreement&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21-Jul-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.7</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex42.htm"><span style="text-decoration:none;">Form of Placement Agent Warrant, issued by Registrant pursuant to the July 2020 Purchase Agreement.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21-Jul-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.8</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520236278/d32449dex41.htm"><span style="text-decoration:none;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated August 27, 2020, between the Registrant and H.C. Wainwright &#38; Co., LLC (&#8220;H.C. Wainright&#8221;)&#160;</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31-Aug-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.9</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520298237/d76696dex41.htm"><span style="text-decoration:none;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated November 17, 2020, between the Registrant and H.C. Wainwright&#160;</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19-Nov-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.10</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520315323/d67428dex41.htm"><span style="text-decoration:none;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement dated December 9, 2020, between the Registrant and H.C. Wainwright &#160;</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11-Dec-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.11*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex411_404.htm"><span style="text-decoration:none;">Description of Securities of the Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex101.htm"><span style="text-decoration:none;">Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;) dated June 7, 2019, between the Registrant, Marc S. Hanover, as the Holders&#8217; Representative (&#8220;Holders&#8217; Representative&#8221;), and Computershare Investor Services, as Rights Agent (&#8220;Rights Agent&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Jun-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.1.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021054536/onct-ex101_100.htm"><span style="text-decoration:none;">First Amendment to CVR Agreement dated November 1, 2021, between the Registrant, Holders&#8217; Representative, and Rights Agent</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4-Nov-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.2&#8224;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1047.htm"><span style="text-decoration:none;">Exclusive License Agreement between Georgetown University and the Registrant dated March 26, 2014 (the &#8220;Georgetown License Agreement&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.2.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1048.htm"><span style="text-decoration:none;">Amendment to the Georgetown License Agreement dated March 17, 2016</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.48</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.3&#8224;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1054.htm"><span style="text-decoration:none;">License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC dated February 6, 2018</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.54</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.4&#8224;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1055.htm"><span style="text-decoration:none;">Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and UC San Diego dated August 31, 2018 (the &#8220;UCSD License Agreement&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.55</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.4.1&#8224;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1056.htm"><span style="text-decoration:none;">Amendment #1 to the UCSD License Agreement Amended dated March 25, 2019</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.56</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.4.2&#8224;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1013_766.htm"><span style="text-decoration:none;">Amendment #2 to the UCSD License Agreement dated May 15, 2019</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16-Mar-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.4.3&#8224;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021012588/onct-ex1014_496.htm"><span style="text-decoration:none;">Amendment #3 to the UCSD License Agreement dated February 5, 2021</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11-Mar-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15.75pt;">
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.5&#8224;*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex105_807.htm"><span style="text-decoration:none;">Amended and Restated License Agreement between the University of Tennessee Research Foundation and the Registrant Oncternal Therapeutics, Inc. dated March 9, 2022</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.6#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1063.htm"><span style="text-decoration:none;">Restricted Stock Purchase Agreement dated May 9, 2018, between the Registrant and Charles Theuer, M.D., Ph.D.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.63</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.7#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex101_210.htm"><span style="text-decoration:none;">Employment Agreement dated August 26, 2019 between the Registrant and Frank Hsu, M.D.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Nov-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.7.1#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021025109/onct-ex103_248.htm"><span style="text-decoration:none;">Employment Transition Agreement between Frank Hsu, M.D. and Registrant, dated February 24, 2021</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-May-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.8#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex102_215.htm"><span style="text-decoration:none;">Employment Agreement dated September 5, 2019 between the Registrant and Gunnar F. Kaufmann, Ph.D.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Nov-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.9#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex104_212.htm"><span style="text-decoration:none;">Employment Agreement dated September 12, 2019 between the Registrant and James B. Breitmeyer, M.D.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Nov-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.10#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex105_211.htm"><span style="text-decoration:none;">Employment Agreement dated September 5, 2019 between the Registrant and Richard G. Vincent</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Nov-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.11#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021041698/onct-ex101_51.htm"><span style="text-decoration:none;">Amended and Restated Employment Agreement dated January 6, 2021 between the Registrant and Raj Krishnan, Ph.D.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-Aug-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.12#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021041698/onct-ex102_52.htm"><span style="text-decoration:none;">Employment Agreement dated April 12, 2021 between the Registrant and Chase Leavitt</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-Aug-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.13#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021041698/onct-ex103_49.htm"><span style="text-decoration:none;">Employment Agreement dated May 17, 2021 between the Registrant and Salim Yazji, M.D.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-Aug-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.14#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex107_307.htm"><span style="text-decoration:none;">Annual Incentive Plan of the Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Nov-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.15#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1031_767.htm"><span style="text-decoration:none;">Form of Indemnification Agreement</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16-Mar-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.16#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021025109/onct-ex102_247.htm"><span style="text-decoration:none;">Non-Employee Director Compensation Program of Registrant</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-May-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.17#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1057.htm"><span style="text-decoration:none;">2015 Equity Incentive Plan of Private Oncternal, as amended (the &#8220;2015 Plan&#8221;)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.57</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.17.1#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1058.htm"><span style="text-decoration:none;">Form of Stock Option Agreement under the 2015 Plan</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.58</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.17.2#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1059.htm"><span style="text-decoration:none;">Form of Early Exercise Stock Option Agreement under the 2015 Plan</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.59</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-Apr-19</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.18*#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex1018_739.htm"><span style="text-decoration:none;">2019 Incentive Award Plan of the Registrant effective June 7, 2019 (the &#8220;2019 Plan&#8221;)&#160;</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.18.1*#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex10181_736.htm"><span style="text-decoration:none;">Form of Stock Option Agreement under the 2019 Plan</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.18.2*#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex10182_1014.htm"><span style="text-decoration:none;">Form of Restricted Stock Unit under the 2019 Plan</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.19#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021006178/onct-ex101_8.htm"><span style="text-decoration:none;">2021 Employment Inducement Incentive Award Plan of the Registrant (the &#8220;Inducement Plan&#8221;) </span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17-Feb-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.19.1*#</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex10191_735.htm"><span style="text-decoration:none;">Form of Stock Option under the Inducement Plan</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.19.2#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312521177174/d173882dex101.htm"><span style="text-decoration:none;">Amendment No. 1 to the Inducement Plan dated May 28, 2021</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25-May-21</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;10.19.3*#</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex10193_738.htm"><span style="text-decoration:none;">Amendment No. 2 to the Inducement Plan dated December 15, 2021</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;21.1</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex211_764.htm"><span style="text-decoration:none;">Subsidiaries</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16-Mar-20</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;23.1*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex2310_945.htm"><span style="text-decoration:none;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;24.1*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:none;">Power of Attorney (see Signature Page)</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;31.1*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex311_8.htm"><span style="text-decoration:none;">Certification of Chief Executive Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.&#160;</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;31.2*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex312_6.htm"><span style="text-decoration:none;">Certification of Chief Financial Officer of the Registrant, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;32.1&#8225;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex321_7.htm"><span style="text-decoration:none;">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;32.2&#8225;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex322_9.htm"><span style="text-decoration:none;">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;101.INS*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;101.SCH*</span></p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;101.CAL*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;101.DEF*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;101.LAB*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;101.PRE*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;104*</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="width:0.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#94;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The schedules and exhibits to the merger agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;*</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed herewith</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#8225;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnished herewith</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;#</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management contract or compensatory plan</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#8224;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">Signatures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Section&#160;13 or 15(d)&#160;of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:48.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics,&#160;Inc.</p></td>
</tr>
<tr>
<td valign="top" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:44.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:44.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;James B. Breitmeyer, M.D., PH.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:44.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS<span style="font-weight:normal;">, that each person whose signature appears below constitutes and appoints Dr.&#160;James B. Breitmeyer, M.D., Ph.D. and Richard G. Vincent, and each of them, as his or her true and. lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Member of the Board of Directors</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard G. Vincent</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard G. Vincent</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David F. Hale</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David F. Hale</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael G. Carter</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael G. Carter, M.B., ChB, FRCP</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jinzhu Chen</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jinzhu Chen</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Daniel L. Kisner</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daniel L. Kisner</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William R. LaRue</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William R. LaRue</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rosemary Mazanet</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosemary Mazanet, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:6.3pt;">
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nakanishi, Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Robert Wills</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Wills, Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Charles P. Theuer</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charles P. Theuer, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>2
<FILENAME>onct-ex411_404.htm
<DESCRIPTION>EX-4.11
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex411_404.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.11</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Description of the Registrant&#8217;s SECURITIES Registered Pursuant to Section 12 Of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (&#8220;<font style="font-weight:bold;font-style:italic;">we</font>,&#8221; &#8220;<font style="font-weight:bold;font-style:italic;">us</font>,&#8221; and &#8220;<font style="font-weight:bold;font-style:italic;">our</font>&#8221;) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTIONOFCAPITALSTOCK_121431"></a>Description of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary of the terms of our common stock does not purport to be complete and is subject to and qualified in its entirety by reference to our Restated Certificate of Incorporation, as amended (the &#8220;<font style="font-weight:bold;font-style:italic;">certificate of incorporation</font>&#8221;), and Amended and Restated Bylaws (&#8220;<font style="font-weight:bold;font-style:italic;">bylaws</font>&#8221;), which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our certificate of incorporation and our bylaws for additional information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our certificate of incorporation, the total number of shares of all classes of stock that we have authority to issue is 125,000,000, consisting of 120,000,000 shares of common stock, par value $0.001 per share and 5,000,000 shares of preferred stock, par value $0.001 per share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 5, 2016, we effected a one-for-ten reverse stock split of our outstanding common stock. At the effective time of the reverse stock split, every ten shares of our issued and outstanding common stock was automatically combined and reclassified into one issued and outstanding share of common stock. No fractional shares of our common stock were issued and each holder of our common stock who would otherwise have been entitled to a fraction of a share of our common stock received a cash payment. In addition, as a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, restricted stock units and warrants issued by us and outstanding immediately prior to the effective time of the reverse stock split, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportionate increase in the exercise price of all such stock options and warrants. The number of shares reserved for issuance under our equity compensation plans immediately prior to the effective time of the reverse stock split was reduced proportionately.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, we effected a seven-for-one reverse stock split of our outstanding common stock. At the effective time of the reverse stock split, every seven shares of our issued and outstanding common stock was automatically combined and reclassified into one issued and outstanding share of common stock. No fractional shares of our common stock were issued and each holder of our common stock who would otherwise have been entitled to a fraction of a share of our common stock received a cash payment. In addition, as a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, restricted stock units and warrants issued by us and outstanding immediately prior to the effective time of the reverse stock split, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportionate increase in the exercise price of all such stock options and warrants. The number of shares reserved for issuance under our equity compensation plans immediately prior to the effective time of the reverse stock split was reduced proportionately. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary description of our capital stock is based on the provisions of our certificate of incorporation and bylaws, the applicable provisions of the General Corporation Law of the State of Delaware (&#8220;<font style="font-weight:bold;font-style:italic;">DGCL&#8221;)</font>, and the agreements described below. This information may not be complete in all respects and is qualified entirely by reference to the provisions of our certificate of incorporation and bylaws, the DGCL and such agreements. For information on how to obtain copies of our certificate of incorporation, bylaws and such agreements, which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this Exhibit is a part.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Common Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our common stock are entitled to one vote for each share held of record on all matters properly submitted to a vote of stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the certification of incorporation that relates to solely to the terms of any outstanding series of preferred stock if the holders such preferred stock are entitled to vote thereon by law or pursuant to the certification of incorporation. The holders of our common stock do not have cumulative voting rights in the election of directors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dissolution, Liquidation or Winding Up</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rights and Preferences</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. The rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any preferred stock that we may designate and issue in the future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Listing</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ONCT.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. Its address is 150 Royall Street, Canton, MA 02021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="DESCRIPTIONOFWARRANTS_121440"></a><a name="PLANOFDISTRIBUTION_121446"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Provisions of Delaware Law and Our Charter Documents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Delaware Takeover Statute<font style="font-style:normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation such as us from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that the stockholder became an interested stockholder, unless:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">at or </font><font style="color:#000000;font-size:10pt;">subsequent to</font><font style="color:#000000;font-size:10pt;"> the time the stockholder became an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 203 defines a business combination to include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">any merger or consolidation involving the corporation and the interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority-owned subsidiary);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Charter Documents<font style="font-style:normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation and bylaws provide that our board of directors be divided into three classes of directors, as nearly equal in number as possible, with each class serving a staggered three-year term. The classification system of electing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us since the classification of the board of directors generally increases the difficulty of replacing a majority of directors. In addition, our certificate of incorporation and bylaws:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">provide that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">provide that the authorized number of directors may be changed only by resolution of the board of directors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote is required to amend a corporation&#8217;s bylaws, unless a corporation&#8217;s certificate of incorporation requires a greater percentage or also confers the power upon the corporation&#8217;s directors. Our bylaws may be amended or repealed by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">the affirmative vote of a majority of our directors then in office; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">the affirmative vote of the holders of at least 66-2/3% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally in the election of directors</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing provisions of our certificate of incorporation may be amended or repealed only with the affirmative vote of a majority of our directors and the affirmative vote of the holders of at least 66-2/3% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally in the election of directors. These and other provisions contained in our certificate of incorporation and bylaws could delay or discourage some types of transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares over then current prices, and may limit the ability of stockholders to remove current management or approve transactions that stockholders may deem to be in their best interests and, therefore, could adversely affect the price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>onct-ex105_807.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex105_807.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.5</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION AND ONCTERNAL THERAPEUTICS, INC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amended and Restated License Agreement (&#8220;<font style="text-decoration:underline;">Amended Agreement</font>&#8221;) is made and entered into this 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of March, 2022 (&#8220;<font style="text-decoration:underline;">Amended Effective Date</font>&#8221;) by and between the UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, having an office at 910 Madison Avenue, Suite 827 Memphis, Tennessee 38163 (&#8220;<font style="text-decoration:underline;">UTRF</font>&#8221;), and Oncternal Therapeutics, Inc., having an office at 12230 El Camino Real, Suite 300, San Diego CA 92130 (&#8220;<font style="text-decoration:underline;">LICENSEE</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, UT (defined below) has submitted the Invention Disclosure (defined below) to UTRF for administration;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, LICENSEE desires to utilize and commercialize the Licensed Patents (defined below) and is willing to expend its reasonable efforts and resources to do so if it can obtain a license to use the Licensed Patents under the terms and conditions set forth herein; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, UTRF desires to transfer the Licensed Patents for the ultimate benefit of the public and believes that such transfer will be facilitated by the grant of a license to LICENSEE under the terms and conditions set forth herein;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, UTRF and GTx, Inc. executed a license agreement on March 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>, 2015 (as previously amended, &#8220;Original License Agreement&#8221;), subsequent to which GTx, Inc. was acquired by LICENSEE; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, UTRF and LICENSEE now seek to amend and restate the Original License Agreement with mutual consent, and that this Amended Agreement will supersede and replace in its entirety the Original License Agreement and any previous amendments or modifications to the same as applicable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:7.55%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the recitals, covenants, conditions, and undertakings contained herein, the parties hereto amend and restate the Original License Agreement to read in its entirety as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 1 DEFINITIONS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When used in this Amended Agreement, the following terms shall have the meanings set out below. The singular shall be interpreted as including the plural and vice versa, unless the context clearly indicates otherwise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Active Ingredient</font><font style="font-weight:normal;">&#8221; means the material(s) in a pharmaceutical product which provide its pharmacological activity (excluding formulation components such as coatings, stabilizers or controlled release technologies).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Affiliate</font><font style="font-weight:normal;">&#8221; means any corporation, partnership, or other entity that at any time during the Term of this Amended Agreement, directly or indirectly Controls or is Controlled by or is under common Control with a party to this Amended Agreement, but only for so long as the relationship exists. A corporation or other entity shall no longer be an Affiliate when through loss, divestment, dilution or other reduction of ownership, the requisite Control no longer exists.</font></p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Combination Product</font><font style="font-weight:normal;">&#8221;</font><font style="font-weight:normal;"> means either (</font><font style="font-weight:normal;">i</font><font style="font-weight:normal;">) any pharmaceutical product that consists of a SAR</font><font style="font-weight:normal;">D</font><font style="font-weight:normal;"> and at least one other </font><font style="font-weight:normal;">Active </font><font style="font-weight:normal;">Ingredient that is</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">not a</font><font style="font-weight:normal;"> SAR</font><font style="font-weight:normal;">D</font><font style="font-weight:normal;">, or (ii</font><font style="font-weight:normal;">) any combination of</font><font style="font-weight:normal;"> a SAR</font><font style="font-weight:normal;">D</font><font style="font-weight:normal;"> and another pharmaceutical product that contains at least one other Active Ingredient that is not a SAR</font><font style="font-weight:normal;">D</font><font style="font-weight:normal;"> where such products are not formulated together but are sold together as a single product and invoiced as one product.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.4<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Control</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Controls</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Controlled</font><font style="font-weight:normal;">&#8221; means: in the case of a corporation, ownership or control, directly or indirectly, of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors; or (ii) in the case of an entity other than a corporation, ownership or control, directly or indirectly, of more than fifty percent (50%) of the assets of such entity.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.5<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dispute</font><font style="font-weight:normal;">&#8221; means any and all claims, disputes, or controversies arising under, out of, or in connection with this Amended Agreement, including any dispute relating to patent validity or infringement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.6<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Invention Disclosure</font><font style="font-weight:normal;">&#8221; means the UTRF file numbers: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[***].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[***].</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.7<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Patents</font><font style="font-weight:normal;">&#8221; means, to the extent now or hereinafter owned (solely or partially) or controlled by UTRF and which are described as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any United States and foreign patents and/or patent applications and/or provisional patents listed in Appendix&#160;A;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any divisionals and continuations of any United States or foreign patent applications listed in Appendix&#160;A; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any United States and foreign patents issued from any applications described in (a) or (b) above; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any claims of United States and foreign patent applications (including, without limitation, continuations-in-part of patent applications or patents described in (a) or (b) above), and of the resulting patents (i) that are directed to subject matter described in or claimed in the patents or patent applications described in (a), (b), or (c) above or (ii) that are directed to subject matter described in the Invention Disclosure; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any reissue or extension of any United States patent described in (a), (b), (c), or (d) above or any patent resulting from equivalent foreign procedures with respect to any foreign patent described in (a), (b), (c), or (d) above.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Product</font><font style="font-weight:normal;">&#8221;</font><font style="font-weight:normal;"> means any product</font><font style="font-weight:normal;">, </font><font style="font-weight:normal;">method</font><font style="font-weight:normal;">, procedure or</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">service,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">or process </font><font style="font-weight:normal;">thereof</font><font style="font-weight:normal;">, whose manufactu</font><font style="font-weight:normal;">re, use, sale, lease, or import i</font><font style="font-weight:normal;">s covered by a Valid Claim of the Licensed Patents in the country in which such product, method, procedure, service, process, or part thereof is manufactured, use</font><font style="font-weight:normal;">d, sold, leased, or imported.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.9<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Net Sales</font><font style="font-weight:normal;">&#8221; means: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The gross receipts received by LICENSEE or any Sublicensees from the sale, lease, or other transfer or disposition to Third Parties (hereinafter &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sale</font><font style="font-weight:normal;">&#8221;) of a Licensed Product (hereinafter &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Gross Receipts</font><font style="font-weight:normal;">&#8221;) less the following deductions, provided they actually pertain to the Sale of Licensed Product and are separately invoiced:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[***];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[***];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[***]; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[***];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[***]; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[***].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">For purposes of the calculation of Net Sales:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">no deductions shall be made for any other costs or expenses, including commissions paid to individuals who are employees of LICENSEE, a Sublicensee, or their respective Affiliates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Net Sales shall not include the gross amounts from the Sale of any Licensed Products to any Sublicensee unless such Sublicensee is an end-user of such Licensed Products (i.e., Sublicensee&#8217;s purchase of Licensed Products is not for the purpose of resale). If such Sublicensee is an end-user, such consideration shall be included in Net Sales at the greater of the actual selling price or the average selling price charged to a third party. Net Sales also shall not include Sales of Licensed Product for use in conducting clinical trials of a Licensed Product candidate in a country.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;font-weight:normal;">Combination </font><font style="text-decoration:underline;letter-spacing:0.6pt;font-weight:normal;">Product</font><font style="font-weight:normal;">: In</font><font style="letter-spacing:0.95pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:1.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">event</font><font style="letter-spacing:1.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">one</font><font style="letter-spacing:1.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">or</font><font style="letter-spacing:0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">more</font><font style="letter-spacing:0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">Licensed</font><font style="letter-spacing:0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">Products</font><font style="letter-spacing:1.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">are</font><font style="letter-spacing:1.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">sold</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">part</font><font style="letter-spacing:1pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">a</font><font style="letter-spacing:1.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">Combination</font><font style="letter-spacing:1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Product</font><font style="letter-spacing:1.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:0.95pt;font-weight:normal;"> </font><font style="font-weight:normal;">a particular</font><font style="letter-spacing:0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">country,</font><font style="letter-spacing:0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Net</font><font style="letter-spacing:0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sales</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">such</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">Licensed</font><font style="letter-spacing:0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">Product(s),</font><font style="letter-spacing:0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">purposes</font><font style="letter-spacing:0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">determining</font><font style="letter-spacing:0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">payments</font><font style="letter-spacing:0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">based</font><font style="letter-spacing:0.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">on Net</font><font style="letter-spacing:0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sales,</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">shall</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">be</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">determined</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">by</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">multiplying the</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">Net</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sales</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Combination</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Product</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">such</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">country,</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">during</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">the applicable</font><font style="letter-spacing:-0.95pt;font-weight:normal;"> </font><font style="font-weight:normal;">Net</font><font style="letter-spacing:-0.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">Sales</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">reporting</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">period,</font><font style="letter-spacing:-0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">by</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">fraction,</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">A/(A+B),</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">where:</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:22.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="letter-spacing:-0.35pt;"> </font>is<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>average<font style="letter-spacing:0.05pt;"> </font>sale<font style="letter-spacing:-0.7pt;"> </font>price<font style="letter-spacing:0.15pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>Licensed<font style="letter-spacing:0.25pt;"> </font>Product(s) by<font style="letter-spacing:-0.15pt;"> </font>LICENSEE<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>Sublicensees<font style="letter-spacing:0.1pt;"> </font>when<font style="letter-spacing:-0.1pt;"> </font>sold<font style="letter-spacing:-0.15pt;"> </font>separately<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>finished<font style="letter-spacing:-0.2pt;"> </font>form in<font style="letter-spacing:-0.05pt;"> </font>such country<font style="letter-spacing:0.65pt;"> </font>and B<font style="letter-spacing:0.25pt;"> </font>is the<font style="letter-spacing:0.55pt;"> </font>average<font style="letter-spacing:0.75pt;"> </font>sale<font style="letter-spacing:-0.25pt;"> </font>price<font style="letter-spacing:0.2pt;"> </font>by<font style="letter-spacing:0.6pt;"> </font>LICENSEE or<font style="letter-spacing:0.25pt;"> </font>Sublicensees,<font style="letter-spacing:0.5pt;"> </font>or,<font style="letter-spacing:0.15pt;"> </font>if<font style="letter-spacing:-0.1pt;"> </font>they<font style="letter-spacing:0.3pt;"> </font>have<font style="letter-spacing:0.2pt;"> </font>no<font style="letter-spacing:0.6pt;"> </font>such<font style="letter-spacing:-0.3pt;"> </font>right<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.45pt;"> </font>sale,<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>a Third<font style="letter-spacing:0.4pt;"> </font>Party<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.6pt;"> </font>other product(s)<font style="letter-spacing:1.05pt;"> </font>included<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>Combination<font style="letter-spacing:0.9pt;"> </font>Product<font style="letter-spacing:0.6pt;"> </font>when<font style="letter-spacing:0.7pt;"> </font>sold<font style="letter-spacing:0.6pt;"> </font>separately<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.65pt;"> </font>finished<font style="letter-spacing:1.05pt;"> </font>form<font style="letter-spacing:0.15pt;"> </font>in such<font style="letter-spacing:-0.85pt;"> </font>country,<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.65pt;"> </font>each<font style="letter-spacing:-0.55pt;"> </font>case<font style="letter-spacing:-0.45pt;"> </font>during<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>applicable<font style="letter-spacing:-0.6pt;"> </font>Net<font style="letter-spacing:-0.15pt;"> </font>Sales<font style="letter-spacing:-0.8pt;"> </font>reporting<font style="letter-spacing:-0.45pt;"> </font>period.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:15.11%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</font><font style="letter-spacing:0.95pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:1.85pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">event</font><font style="letter-spacing:1.55pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</font><font style="letter-spacing:1.6pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="letter-spacing:1.25pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</font><font style="letter-spacing:1.35pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensed</font><font style="letter-spacing:1.55pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products</font><font style="letter-spacing:1.65pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:1.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sold</font><font style="letter-spacing:1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">part</font><font style="letter-spacing:1.7pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:1.4pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="letter-spacing:1.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combination</font><font style="letter-spacing:1.5pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product</font><font style="letter-spacing:1.85pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:1.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:1.65pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sold</font><font style="letter-spacing:1.35pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">separately</font><font style="letter-spacing:2.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finished</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">form</font><font style="letter-spacing:-0.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:-0.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</font><font style="letter-spacing:-0.2pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country,</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product(s)</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">included</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:-0.25pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combination</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:-0.7pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sold</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">separately</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finished</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">form</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country,</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Net</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensed</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product,</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purposes</font><font style="letter-spacing:1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determining</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</font><font style="letter-spacing:-1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales,</font><font style="letter-spacing:-0.55pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</font><font style="letter-spacing:-0.5pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined</font><font style="letter-spacing:-0.35pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiplying</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:-0.7pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales</font><font style="letter-spacing:-0.45pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:-0.5pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combination</font><font style="letter-spacing:-0.2pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:-0.45pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</font><font style="letter-spacing:-0.7pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country</font><font style="letter-spacing:-0.3pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:-1.25pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fraction</font><font style="letter-spacing:-1.3pt;"> </font><font style="font-style:italic;letter-spacing:0.2pt;">C/D</font><font style="font-style:italic;letter-spacing:-0.9pt;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where:</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:22.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C<font style="letter-spacing:-0.05pt;"> </font>is<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.65pt;"> </font>average<font style="letter-spacing:1.1pt;"> </font>sale<font style="letter-spacing:0.4pt;"> </font>price,<font style="letter-spacing:1.15pt;"> </font>in<font style="letter-spacing:0.45pt;"> </font>such country,<font style="letter-spacing:1.6pt;"> </font>of<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.6pt;"> </font>Licensed<font style="letter-spacing:0.7pt;"> </font>Product(<font style="letter-spacing:-1.25pt;"> </font>s)<font style="letter-spacing:0.5pt;"> </font>contained<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:-0.9pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>Combination<font style="letter-spacing:0.45pt;"> </font>Product<font style="letter-spacing:1.15pt;"> </font>when sold<font style="letter-spacing:0.3pt;"> </font>separately<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:0.3pt;"> </font>D<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>average<font style="letter-spacing:0.9pt;"> </font>sale<font style="letter-spacing:-0.15pt;"> </font>price,<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font>such<font style="letter-spacing:-0.45pt;"> </font>country,<font style="letter-spacing:1.8pt;"> </font>for<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>Combination<font style="letter-spacing:0.75pt;"> </font>Product,<font style="letter-spacing:1.45pt;"> </font>in<font style="letter-spacing:0.3pt;"> </font>each<font style="letter-spacing:0.25pt;"> </font>case<font style="letter-spacing:0.7pt;"> </font>during<font style="letter-spacing:0.7pt;"> </font>the applicable<font style="letter-spacing:-0.5pt;"> </font>Net<font style="letter-spacing:-0.25pt;"> </font>Sales<font style="letter-spacing:-0.7pt;"> </font>reporting<font style="letter-spacing:-0.45pt;"> </font>period.<font style="letter-spacing:1.55pt;"> </font>Under<font style="letter-spacing:-0.45pt;"> </font>no<font style="letter-spacing:-0.7pt;"> </font>circumstances<font style="letter-spacing:-0.15pt;"> </font>can<font style="letter-spacing:-0.65pt;"> </font><font style="font-style:italic;">C/D</font><font style="font-style:italic;letter-spacing:-0.9pt;"> </font>exceed<font style="letter-spacing:-0.4pt;"> </font>one hundred percent (100%).</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:15.11%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>event<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.2pt;"> </font>one or<font style="letter-spacing:-0.15pt;"> </font>more<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>Licensed<font style="letter-spacing:0.25pt;"> </font>Product(s)<font style="letter-spacing:0.65pt;"> </font>are<font style="letter-spacing:-0.35pt;"> </font>not<font style="letter-spacing:0.5pt;"> </font>sold<font style="letter-spacing:0.2pt;"> </font>separately<font style="letter-spacing:0.2pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font>finished<font style="letter-spacing:0.35pt;"> </font>form<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:0.5pt;"> </font>country,<font style="letter-spacing:0.05pt;"> </font>but all<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>other<font style="letter-spacing:-0.3pt;"> </font>product(s)<font style="letter-spacing:0.5pt;"> </font>included in<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Combination<font style="letter-spacing:0.25pt;"> </font>Product<font style="letter-spacing:0.25pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>such<font style="letter-spacing:-0.15pt;"> </font>country<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:-0.4pt;"> </font>sold<font style="letter-spacing:-0.15pt;"> </font>separately,<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Net<font style="letter-spacing:0.5pt;"> </font>Sales<font style="letter-spacing:-0.2pt;"> </font>of the<font style="letter-spacing:1.95pt;"> </font>Licensed<font style="letter-spacing:2.3pt;"> </font>Product,<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:1.7pt;"> </font>the<font style="letter-spacing:1.6pt;"> </font>purposes<font style="letter-spacing:2.4pt;"> </font>of<font style="letter-spacing:1.5pt;"> </font>determining<font style="letter-spacing:2.2pt;"> </font>payments<font style="letter-spacing:2.3pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:1pt;"> </font>Net<font style="letter-spacing:2.4pt;"> </font>Sales,<font style="letter-spacing:1.85pt;"> </font>shall<font style="letter-spacing:0.9pt;"> </font>be<font style="letter-spacing:1.7pt;"> </font>determined<font style="letter-spacing:1.85pt;"> </font>by multiplying<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.95pt;"> </font>Net<font style="letter-spacing:-0.05pt;"> </font>Sales<font style="letter-spacing:-0.65pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Combination<font style="letter-spacing:-0.25pt;"> </font>Product<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.7pt;"> </font>such<font style="letter-spacing:-0.9pt;"> </font>country<font style="letter-spacing:-0.65pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>fraction<font style="letter-spacing:-0.75pt;"> </font>(D-E)/D,<font style="letter-spacing:-0.45pt;"> </font>where:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:22.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>average<font style="letter-spacing:1.25pt;"> </font>sale<font style="letter-spacing:0.65pt;"> </font>price,<font style="letter-spacing:1.35pt;"> </font>in<font style="letter-spacing:-0.7pt;"> </font>such<font style="letter-spacing:0.25pt;"> </font>country,<font style="letter-spacing:1.45pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:1.2pt;"> </font>Combination<font style="letter-spacing:0.75pt;"> </font>Product,<font style="letter-spacing:1.55pt;"> </font>and<font style="letter-spacing:0.3pt;"> </font>E<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>average<font style="letter-spacing:1.25pt;"> </font>sale<font style="letter-spacing:0.6pt;"> </font>price<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:1.15pt;"> </font>other product(s)<font style="letter-spacing:0.55pt;"> </font>included<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>Combination<font style="letter-spacing:0.2pt;"> </font>Product<font style="letter-spacing:-0.1pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>finished<font style="letter-spacing:-0.05pt;"> </font>form<font style="letter-spacing:-0.6pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>such<font style="letter-spacing:-0.5pt;"> </font>country,<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>each<font style="letter-spacing:-0.15pt;"> </font>case<font style="letter-spacing:-0.35pt;"> </font>during<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>applicable Net<font style="letter-spacing:-0.5pt;"> </font>Sales<font style="letter-spacing:-1.3pt;"> </font>reporting<font style="letter-spacing:-0.7pt;"> </font>period.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:15.11%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the Net Sales of the Licensed Product(s) when included in a Combination Product cannot be determined using the methods above, Net Sales for the purposes of determining payments based on Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by the fraction of F/(F+G) where:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:22.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F<font style="letter-spacing:0.9pt;"> </font>is<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:1pt;"> </font>fair<font style="letter-spacing:0.7pt;"> </font>market<font style="letter-spacing:1pt;"> </font>value<font style="letter-spacing:1.35pt;"> </font>of<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.95pt;"> </font>Licensed<font style="letter-spacing:1.25pt;"> </font>Product(s)<font style="letter-spacing:1.6pt;"> </font>and<font style="letter-spacing:0.65pt;"> </font>G<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:1pt;"> </font>fair<font style="letter-spacing:0.65pt;"> </font>market<font style="letter-spacing:1.1pt;"> </font>value<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:0.8pt;"> </font>all<font style="letter-spacing:0.7pt;"> </font>other<font style="letter-spacing:0.55pt;"> </font>pharmaceutical product(s)<font style="letter-spacing:-0.05pt;"> </font>included<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.95pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Combination<font style="letter-spacing:-0.25pt;"> </font>Product,<font style="letter-spacing:-0.65pt;"> </font>as<font style="letter-spacing:-0.7pt;"> </font>reasonably<font style="letter-spacing:-0.2pt;"> </font>determined<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.7pt;"> </font>good<font style="letter-spacing:-0.6pt;"> </font>faith<font style="letter-spacing:-1.15pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-1pt;"> </font>Parties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.10<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Patent Expenses</font><font style="font-weight:normal;">&#8221; means all fees, costs and expenses (including, without limitation, the professional fees of US and foreign patent counsel) relating to the filing, prosecution and maintenance of the Licensed Patents. For purposes of clarification, included Patent Expenses are any and all fees, costs, and expenses incurred before or after issuance of the Licensed Patents, including, without limitation, fees, costs, and expenses incurred in association with any reissue or reexamination of a Licensed Patent, any interference or opposition proceeding involving one or more Licensed Patents, or any extension or request for extension of the term of one or more Licensed Patents.</font> </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.11<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">SARD&#8221;</font><font style="text-decoration:underline;letter-spacing:2.25pt;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">or</font><font style="text-decoration:underline;letter-spacing:2pt;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">&#8220;SARDs</font><font style="font-weight:normal;">&#8221;</font><font style="letter-spacing:2.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">shall</font><font style="letter-spacing:1.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">mean </font><font style="letter-spacing:0.05pt;font-weight:normal;">selective</font><font style="letter-spacing:2.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">androgen</font><font style="letter-spacing:1.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">receptor</font><font style="letter-spacing:2.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">degrader </font><font style="letter-spacing:0.35pt;font-weight:normal;">whose</font><font style="letter-spacing:2.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">primary pharmacologic</font><font style="letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">effect</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">at</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">any</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">dose</font><font style="letter-spacing:-0.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">observed</font><font style="letter-spacing:-0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-1.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">vivo</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">is</font><font style="letter-spacing:-0.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">the degradation of</font><font style="letter-spacing:-0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">androgen</font><font style="letter-spacing:-0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">receptor. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicense</font><font style="font-weight:normal;">&#8221; means a direct grant of right, license, or option to the Licensed Patents from LICENSEE to a third party and any further grant at any tier. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicense Revenue</font><font style="font-weight:normal;">&#8221;</font><font style="font-weight:normal;"> means all payments received by LICENSEE pursuant to each Sublicense, including, without limitation, up-front fees, milestone payments, and license maintenance fees.</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Notwithstanding the foregoing, </font><font style="font-weight:normal;">the following shall not be considered Sublicense Revenue:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Running royalties received by LICENSEE that are calculated as a percentage of Sublicensee&#8217;s net sales;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Payments received by LICENSEE as reimbursement for actual, otherwise unreimbursed, out-of-pocket research and development expenses incurred after the date of the Sublicense;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Payments made to Third Parties by a Sublicensee on LICENCEE&#8217;S behalf for conducting clinical trials, filing new drug applications, commercially launching a product and/or marketing and selling a product, since these are not payments received by LICENSEE from a Sublicensee;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">consideration paid to Licensee in exchange for securities of Licensee up to the fair market value of such securities; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">In the event the Sublicensee of Licensed Product is granted in conjunction with a license of distinct technology of Licensee that is not Licensed Product covered by the Licensed Patents (&#8220;Other Technology&#8221;), amounts allocable to such Other Technology as reasonably established by Licensee and the Sublicensee and set out in the Sublicense agreement. If no allocation to Other Technology exists in the Sublicense, UTRF and LICENSEE agree to good faith negotiations to determine the excluded amounts. In the event that, after [***] of good faith negotiations, no agreement exists on the amount to be excluded from Sublicense Revenue, the Parties agree that an independent arbitrator shall make the determination of allocation, which shall be final and unappealable.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.14<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicensee</font><font style="font-weight:normal;">&#8221; means any recipient of a Sublicense. </font> </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.15<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Third Party</font><font style="font-weight:normal;">&#8221;</font><font style="letter-spacing:0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">shall mean any person, party or entity other than LICENSEE, its Affiliates,</font><font style="letter-spacing:0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">UTRF,</font><font style="letter-spacing:0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">or</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">UT.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">UT</font><font style="font-weight:normal;">&#8221; means The University of Tennessee, an educational agency of the State of Tennessee.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.17<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">UT Contributo</font><font style="font-weight:normal;">r&#8221; means Duane Miller, Ramesh Narayanan, Dong-Jin Hwang, Thamarai Ponnusamy, Yali He and</font><font style="letter-spacing:0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">any</font><font style="letter-spacing:0.6pt;font-weight:normal;"> </font><font style="font-weight:normal;">other</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">UT</font><font style="letter-spacing:1.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">employee</font><font style="letter-spacing:1.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">who contributes to</font><font style="letter-spacing:1.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:1.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">development of</font><font style="letter-spacing:0.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:1.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">Licensed Patents while under the supervision of Duane Miller or Ramesh Narayanan, either before or after the Amended Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.18<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Valid Claim</font><font style="font-weight:normal;">&#8221; means (a) a claim of an issued patent which (i) has not expired and which has not been held revoked, invalid or unenforceable by decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed with the time allowed for appeal having expired, and (ii) which has not been admitted to be invalid through reissue or disclaimer or otherwise; or (b) a claim of a pending patent application, provided such claim is not pending more than [***] from the earliest date such claim is entitled to claim priority to and has not been canceled, withdrawn, finally determined to be unallowable, or abandoned.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 2</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GRANT</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="font-weight:normal;margin-left:36pt;"></font>Grant of License<font style="font-weight:normal;">: During the Term hereof, and subject to the terms and conditions of this Amended Agreement, UTRF hereby grants to LICENSEE an exclusive, worldwide right and license, with the right to grant Sublicenses, to practice under the Licensed Patents for the purpose of developing, making, having made, using, marketing, selling, having sold, importing, distributing, and offering for sale Licensed Product(s) (collectively, the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">License</font><font style="font-weight:normal;">&#8221;). Subject to the remaining provisions of this Amended Agreement, the Parties hereby agree that the term &#8220;exclusive&#8221; means that, UTRF has not and shall not grant any license to a Third Party or take any action inconsistent with the rights in the Licensed Patents granted to LICENSEE under this Amended Agreement.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;"></font>Limitations on the Rights Granted:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;"></font>Federal Government Rights: <font style="font-weight:normal;">To the extent that any invention included within the Licensed Patents has been or is in the future funded in whole or in part by the United States government, the United States government retains certain rights in such inventions as set forth in 35 U.S.C. &#167;&#167;200-212 and all regulations promulgated thereunder, as amended, and any successor statutes and regulations (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Federal Policy</font><font style="font-weight:normal;">&#8221;). As a condition of the License granted hereby, LICENSEE acknowledges and shall comply with all aspects of Federal Policy applicable to the Licensed Patents, including the obligation that Licensed Products used or sold in the United States be manufactured substantially in the United States. Nothing contained in this Amended Agreement obligates UTRF to take any action that would conflict in any respect with its or UT&#8217;s past, current or future obligations to the United States government under the Federal Policy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;"></font>Reserved Rights: <font style="font-weight:normal;">The License is expressly made subject to UTRF&#8217;s and UT&#8217;s reserved right to practice under the Licensed Patents for its own non-commercial educational, academic research and teaching purposes and to grant such rights to other academic or non-profit institutions for non-commercial purposes. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Third Party Rights:<font style="font-weight:normal;"> The exclusive rights granted in Article 2.1(a) are expressly made subject to any rights in a Licensed Patent held by a third party resulting from co-inventorship by an individual whose contribution to a Licensed Patent is not made in the course of employment by UT; provided that for purposes of entering into this Amended Agreement, UTRF is not aware of any co-inventor holding rights outside of UTRF.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;"></font>Limitation on Assistance:<font style="font-weight:normal;"> UTRF shall have no obligation to provide LICENSEE with technical assistance in the exercise of the License. In the event LICENSEE requires technical assistance with respect to the activities conducted by LICENSEE pursuant to this Amended Agreement, obtaining such technical assistance (whether from the UT Contributors or otherwise) shall be LICENSEE&#8217;s responsibility and at LICENSEE&#8217;s expense.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.3<font style="font-weight:normal;margin-left:36pt;"></font>Applicability: <font style="font-weight:normal;">Nothing in this Amended Agreement shall be construed to confer any rights upon LICENSEE by implication, estoppel, or otherwise except as explicitly set forth herein.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;">ARTICLE 3</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;">SUBLICENSES</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;">Rights and Requirements:</font> <font style="font-weight:normal;">LICENSEE shall have the right to sublicense the rights granted to LICENSEE under this Amended Agreement and to permit further sublicensing by Sublicensees through multiple tiers with respect to the Licensed Patents, </font><font style="text-decoration:underline;font-weight:normal;">provided that</font><font style="font-weight:normal;">: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The Sublicensee shall agree in writing to be bound, to the extent practicable, by all the provisions of this Amended Agreement in the same manner as LICENSEE is bound; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall remain liable to UTRF for the full and timely performance of this Amended Agreement by any Sublicensee. No Sublicense shall relieve LICENSEE of any of its obligations under this Amended Agreement. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">This Amended Agreement is in effect and LICENSEE is not in breach of its obligations under this Amended Agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">All Sublicenses granted by LICENSEE under this Amended Agreement shall conform to this Amended Agreement in the following respects:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall not grant any rights to a third party that are inconsistent with LICENSEE&#8217;s rights and obligations under this Amended Agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ii</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any Sublicense granted by LICENSEE shall include substantially the same definitions and provisions on confidentiality, publicity, reporting, audit requirements, insurance, patent notices, and use of names as are agreed to in this Amended Agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any act or omission of a Sublicensee which would constitute a breach of this Amended Agreement if it were the act or omission of LICENSEE shall be deemed to be an Event of Default of this Amended Agreement by LICENSEE, subject to the same cure provisions in favor of LICENSEE as are otherwise provided herein for breach by LICENSEE (provided that if the Sublicense agreement shall provide to Sublicensee a reasonably longer cure period, that cure period shall control for purposes hereof). Sublicenses shall include such other provisions as are needed to enable LICENSEE to comply with this Amended Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall provide UTRF with a copy of each executed Sublicense Agreement within [***] of its execution.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;">Special Termination Rules:</font> <font style="font-weight:normal;">Upon termination of this Amended Agreement, each Sublicense shall be governed by Article 14 of this Amended Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;">Failure to Conform to this Article:</font> <font style="font-weight:normal;">LICENSEE&#8217;s failure to materially conform any Sublicense to this Article will have the following effects:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The non-conforming Sublicense will be voidable at UTRF&#8217;s sole discretion provided that (i) UTRF has provided written notice to LICENSEE within [***] of receiving a copy of the purportedly non-conforming Sublicense and (ii) within [***] of such notice from UTRF, LICENSEE fails to cure such material non-conformance of the Sublicense. </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4 DILIGENCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;">Diligence</font><font style="font-weight:normal;">: LICENSEE shall use commercially reasonable efforts to acquire funding, staff, equipment, and facilities sufficient to develop and commercialize one or more Licensed Products. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.2<font style="margin-left:36pt;">Milestone</font><font style="font-weight:normal;">: In particular, LICENSEE shall use commercially reasonable efforts meet the following milestone (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Diligence Milestone</font><font style="font-weight:normal;">&#8221;): On or before [***], LICENSEE shall [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that UTRF notifies LICENSEE in writing that UTRF reasonably believes that LICENSEE has failed to use its commercially reasonable efforts to achieve the Diligence Milestone, then LICENSEE shall deliver to UTRF within [***] of receipt of such written notice copies of supporting documentation evidencing that LICENSEE has used commercially reasonable efforts to achieve the Diligence Milestone.&nbsp;&nbsp;If LICENSEE fails to provide such supporting documentation within [***] of UTRF&#8217;s written request for it, or if, after examination of such supporting documentation provided by LICENSEE, UTRF continues to reasonably believe that the LICENSEE has failed to use its commercially reasonable efforts to achieve the Diligence Milestone, then the Parties shall resolve such dispute in accordance with Article 15. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;">Notification:</font>  <font style="font-weight:normal;">LICENSEE will notify UTRF in writing of the achievement of the Diligence Milestone within [***] thereafter, including sufficient information for UTRF to determine whether the Diligence Milestone has been reasonably accomplished. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.55%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;">ARTICLE 5 Royalties and other payments</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;">Fees and Royalties:</font> <font style="font-weight:normal;">For the rights, privileges and license granted hereunder, LICENSEE shall pay to UTRF the following fees and royalties in the manner hereinafter provided until this Amended Agreement expires or is terminated.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#0070C0;"></font>License Issue Fee: <font style="font-weight:normal;">UTRF affirms that the original payment of [***] ($[***]) (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">License Issue Fee</font><font style="font-weight:normal;">&#8221;) under the Original License Agreement was previously received in full.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Annual Maintenance Fee: <font style="font-weight:normal;">LICENSEE shall pay UTRF, in addition to all other amounts payable hereunder, a non-refundable license maintenance fee in the amount of [***] ($[***]) on each anniversary of [***] during the Term of this Amended Agreement (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Annual Maintenance Fee</font><font style="font-weight:normal;">&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Running Royalties: <font style="font-weight:normal;"> On a country-by-country and Licensed Product-by-Licensed Product basis, LICENSEE shall pay to UTRF an amount equal to [***] of Net Sales of Licensed Products (&#8220;Running Royalties&#8221;). Payment of Running Royalties shall be made on a semi-annual basis within [***] of the last day of [***] each year on Net Sales occurring during the immediately preceding [***] calendar quarters. For example, payment of Running Royalties will be due within [***] following the last day of [***] on Net Sales occurring during the last half ([***]) of the immediately preceding calendar year.&nbsp;&nbsp;LICENSEE shall owe no Running Royalties on any Sale that does not take place during the pendency of a Valid Claim of a Licensed Patent in the applicable country. For purposes of determining when a Sale takes place, a Sale shall be deemed to occur upon the earlier of the shipment of a Licensed Product or invoicing.</font></p></td>
<td valign="top" style="width:1.05%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sublicense Royalties</font><font style="font-weight:normal;">: In addition to all other amounts payable hereunder, LICENSEE shall pay to UTRF the following percentages of all Sublicense Revenues received from a Sublicensee pursuant to a </font><font style="font-weight:normal;">Sublicense</font><font style="font-weight:normal;">:</font><font style="font-weight:normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Prior to [***], [***] of Sublicense Revenues; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Following [***], but prior to [***], [***] of Sublicense Revenues; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Following [***], [***] of Sublicense Revenues.</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:15.11%;margin-right:1.05%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of Sublicense Royalties shall be made on a [***] basis within [***] of the last day of [***] each year.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;">Maximum Royalties:</font> <font style="font-weight:normal;">In the event that any royalties payable under this Amended Agreement are higher than the maximum royalties permitted by the law or regulations of a particular country:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The Running Royalties payable for Net Sales in such country shall be equal to the maximum permitted royalty under such law or regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Notice documenting that Running Royalties payable under this Amended Agreement are higher than a country&#8217;s maximum royalties shall be provided to UTRF;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">An authorized representative of LICENSEE shall notify UTRF, in writing, within [***] of discovering that such Running Royalties are approaching or have reached the maximum amount; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall provide UTRF with written documentation regarding the laws or regulations establishing any such maximum.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;">Effect of Taxes on Royalties:</font> <font style="font-weight:normal;">In the event that any taxes are levied by any foreign taxing authority on Running Royalties payable by LICENSEE under this Amended Agreement, and LICENSEE determines in good faith that it must pay such taxes:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall have the right to pay such taxes levied on Running Royalties to the local tax authorities on behalf of UTRF;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall pay the net amount of Running Royalties due after reduction by the amount of such taxes that are actually owed and paid;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall provide UTRF with appropriate documentation and receipts supporting such payment; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall inform UTRF in writing within [***] of being notified that taxes will or have been levied by a taxing authority on Running Royalties.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;">Multiple Licenses. </font><font style="font-weight:normal;">In the event that a Running Royalty is payable to UTRF on the same Net Sales revenue or a Sublicense Royalty is payable to UTRF on the same Sublicense Revenue under this Section 5 and under one or more other UTRF/LICENSEE license agreements, LICENSEE shall only be required to pay UTRF such royalty under one such license agreement, subject to the provisions of Section 6.2 and provided </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">that if the amount due varies from one such license</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">agreeme</font><font style="font-weight:normal;">nt to another, L</font><font style="font-weight:normal;">ICENSEE</font><font style="font-weight:normal;"> shall pay the highest amount.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;">Late Payments:</font> <font style="font-weight:normal;">In the event any payments are not received by UTRF when due, LICENSEE shall pay to UTRF interest on the overdue balance at the lesser of [***] or the maximum rate of interest allowed by law. The payment of such interest shall not foreclose UTRF from exercising any other rights it may have as a consequence of the lateness of any payment.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.6<font style="margin-left:36pt;">Payment Shortage:</font> <font style="font-weight:normal;">If an examination of records provided under Article 6 of this Amended Agreement reveals a payment shortage of greater than [***] of the total amount due under any one royalty payment, LICENSEE shall promptly reimburse UTRF for the reasonable cost of examination, the shortage in payment, and the interest accrued on the shortage under Article 5.5 of this Amended Agreement. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a>5.7<font style="margin-left:36pt;">Manner of Payments:</font><font style="font-weight:normal;"> All payments shall be paid in United States dollars in Memphis<a name="OLE_LINK1"></a><a name="OLE_LINK2"></a>, Tennessee, or at such other place as UTRF may reasonably designate consistent with the laws and regulations controlling in the United States or any foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rate listed in the Wall Street Journal for major New York banks on the last business day of the calendar quarter to which such royalty payments relate. If the transfer of moneys owed to UTRF or the conversion into United States Dollar equivalents in any such instance is not lawful or possible, the payment of such part of the royalties as is necessary shall be made by the deposit thereof, in the currency of the country where the sales were made on which the royalty was based, to the credit and account of UTRF or its nominee in any commercial bank or trust company of its choice located in that country, prompt notice of which shall be given by LICENSEE to UTRF.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8<font style="margin-left:36pt;"></font><font style="color:#000000;">Third Party Licenses</font><font style="color:#000000;font-weight:normal;">:&nbsp;&nbsp;In the event that LICENSEE or a Sublicensee has obtained (as of the Amended Effective Date) or obtains (after the Amended Effective Date) a license under, or other rights to, any patent rights or know-how or other intellectual property from any Third Party(ies) which is required or otherwise used by LICENSEE or a Sublicensee in order to make, have made, use, offer to sell, sell or import Licensed Product(s) (hereinafter &#8220;Additional Licensee Third Party Agreements&#8221;), then [***] of the consideration actually paid under such Additional Licensee Third Party Agreements by LICENSEE or a Sublicensee for sale of such Licensed Product in a country shall be creditable against the royalty payments due to UTRF by LICENSEE or Sublicensee hereunder with respect to the sale of such Licensed Product in such country; provided, however, that in no event shall the royalties owed by LICENSEE or Sublicensee to UTRF for a given two calendar quarter period be reduced by more than [***] (provided, however that if LICENSEE or Sublicensee is not able to fully recover the amounts paid by LICENSEE or Sublicensee under any Additional Licensee Third Party Agreement as a result of the foregoing restriction, then LICENSEE or Sublicensee shall be entitled to carry forward such right of off-set to future [***] periods with respect to such excess amount). If the Additional Licensee Third Party Agreement also covers compounds or products other than Licensed Products, and a particular payment thereunder results directly from the sale of both (i) Licensed Products hereunder and (ii) such other compounds or products, then LICENSEE or Sublicensee shall allocate the amount of such payment between the Licensed Product hereunder and such other compounds or products, respectively (as applicable), using an allocation method reasonably determined by LICENSEE or Sublicensee.&nbsp;&nbsp;Other than as set out above, LICENSEE or Sublicensee shall be responsible for and bear its own costs of negotiation and performance of any Additional Licensee Third Party Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.9<font style="font-weight:normal;margin-left:36pt;"></font>Effect of Receipt or Acceptance:<font style="font-weight:normal;"> Receipt or acceptance by UTRF of any payment or report under this Amended Agreement shall not prevent UTRF from subsequently challenging the validity or accuracy of such payment or report. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.55%;text-indent:-7.55%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 6 REPORTS AND RECORDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;">Books of Account:</font> <font style="font-weight:normal;">LICENSEE shall keep, and shall require each Sublicensee to keep, full, true and accurate books of account containing all particulars reasonably necessary to determine and show the amounts payable to UTRF hereunder. LICENSEE shall ensure that its books are open at all reasonable time for [***] following the end of the calendar year to which they pertain, to the inspection by an independent, certified public accountant selected by UTRF and reasonably acceptable to LICENSEE or Sublicensee, as applicable, upon reasonable notice and no more than [***] for any [***], for the purpose of verifying compliance with this Amended Agreement, and LICENSEE shall require the same of each Sublicensee.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="margin-left:36pt;">Delivery of Reports</font><font style="font-weight:normal;">: LICENSEE shall deliver to UTRF true and accurate reports, giving such particulars of the business conducted by LICENSEE and its Sublicensees under this Amended Agreement as shall be pertinent to a royalty accounting under this Amended Agreement. These</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">reports shall</font><font style="letter-spacing:-1.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">be</font><font style="letter-spacing:-0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">deemed</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">LICENSEE&#8217;s</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">Confidential</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">Information:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Before the first commercial use or sale of a Licensed Product or the granting of the first Sublicense under this Amended Agreement (whichever occurs first), [***]; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">After the first commercial use or sale of Licensed Product or the granting of the first Sublicense under this Amended Agreement, [***] after the end of [***].</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.3<font style="margin-left:36pt;">Content of Reports:</font> <font style="font-weight:normal;">Reports shall include at least the following on a Licensed Product-by-Licensed Product and country-by-country basis:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">A</font> <font style="font-weight:normal;">summary</font><font style="letter-spacing:1.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:0.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">LICENSEE&#8217;s</font><font style="letter-spacing:1.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">activities</font><font style="letter-spacing:1.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">during</font><font style="letter-spacing:1.55pt;font-weight:normal;"> </font><font style="font-weight:normal;">such</font><font style="letter-spacing:0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">quarter</font><font style="letter-spacing:1.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:1.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">develop</font><font style="letter-spacing:1.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">commercialize Licensed</font><font style="letter-spacing:1.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">Products;</font></p></td>
<td valign="top" style="width:1.05%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The number/amount of Licensed Products sold by LICENSEE and each Sublicensee; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Total amounts invoiced and total amounts received for Licensed Products sold by LICENSEE and all Sublicensees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Net Sales of LICENSEE and each Sublicensee; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">A copy of each royalty statement or report submitted to LICENSEE by a Sublicensee, provided that such statement or report has not previously been provided by LICENSEE to UTRF; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Total amount due under this Amended Agreement (including the manner in which Net Sales were calculated pursuant to this Amended Agreement); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The current status of any regulatory activities pertaining to Licensed Products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The name, address, and phone number of each Sublicensee and the Licensed Patents licensed to each Sublicensee as of the last date of the reporting period; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Upon reasonable request by UTRF, any other information that is necessary for the purpose of showing the amounts payable to UTRF hereunder and/or the compliance by LICENSEE </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">with the diligence provisions of Article 4.1 and/or the achievement of Diligence Milestone under Article 4.2.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(j)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If no payment shall be due, LICENSEE shall so report.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.4<font style="margin-left:36pt;">Responsibility for Accuracy:</font><font style="font-weight:normal;"> LICENSEE shall be responsible for the completeness and accuracy of its own records and reports, and for the accuracy of the reports submitted by each Sublicensee. Each report submitted to UTRF by LICENSEE shall be certified as accurate by a duly authorized officer of LICENSEE.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.55%;text-indent:-7.55%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 7 PATENT PROSECUTION</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Rights and Duties:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">During the Term, LICENSEE will be responsible for preparing, applying for, seeking issuance of, and maintaining patent applications and issued patents included in Licensed Patents, and for prosecuting or defending interferences, oppositions, and reexaminations declared with regard to patent applications and issued patents included in Licensed Patents, all for UTRF&#8217;s and Licensee&#8217;s benefit.&nbsp;&nbsp;LICENSEE shall select its own patent counsel for patent maintenance and prosecution, and shall be responsible for the payment of all Patent Expenses. LICENSEE will keep UTRF reasonably informed concerning any substantive actions.&nbsp;&nbsp;LICENSEE shall instruct its chosen firm to copy UTRF on all correspondence with patent offices relating to the Licensed Patents. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">In the event that LICENSEE elects not to file, prosecute or maintain any Licensed Patent, LICENSEE shall so notify UTRF of such decision no later than [***] before any applicable statutory bar date or response date, as the case may be, to permit UTRF (at its own expense) to prosecute and/or maintain the patent application(s) and/or patent(s) that were the subject of such notice. In the event that LICENSEE elects not to file, prosecute or maintain any Licensed Patent, UTRF shall have the right to resume responsibility for preparing, applying for, seeking issuance of, and maintaining patent applications and issued patents for those elected Licensed Patents at its own expense, and such Licensed Patents shall no longer be licensed as part of this Amended Agreement and shall be deleted from Appendix A.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.2<font style="margin-left:36pt;">Ownership:</font> <font style="font-weight:normal;">All Licensed Patents prosecuted or maintained by or on behalf of LICENSEE under Article 7.1 shall be owned by UTRF.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.3<font style="margin-left:36pt;">Patent Numbering:</font> <font style="font-weight:normal;">LICENSEE and all its Sublicensees shall use commercially reasonable efforts to mark all products covered by Licensed Patents with patent numbers in accordance with the statutory requirements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8 INFRINGEMENT</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="margin-left:36pt;">Enforcement:</font> <font style="font-weight:normal;">If either LICENSEE or UTRF becomes aware of any infringement of the Licensed Patents by a third party, the party having the knowledge will give the other party prompt written notice. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LICENSEE shall have the first right during the Term, at its sole cost and expense, to commence any action that LICENSEE deems appropriate, including notifying the infringer to cease and desist all such infringing activity, filing a complaint and/or instituting an action or a lawsuit for any known or suspected third party activity that may infringe the Licensed </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Patents (each an </font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Action</font><font style="font-weight:normal;">&#8221;</font><font style="font-weight:normal;">), and, in furtherance of such right, </font><font style="font-weight:normal;">UTRF</font><font style="font-weight:normal;"> hereby agrees that </font><font style="font-weight:normal;">LICENSEE</font><font style="font-weight:normal;"> may include </font><font style="font-weight:normal;">UTRF</font><font style="font-weight:normal;"> as a party plaintiff in any such suit, without expense to </font><font style="font-weight:normal;">UTRF.</font><font style="font-weight:normal;"> In the event </font><font style="font-weight:normal;">LICENSEE</font><font style="font-weight:normal;"> commences an Action, </font><font style="font-weight:normal;">UTRF</font><font style="font-weight:normal;"> shall retain the right to join such Action as a co-litigant</font><font style="font-weight:normal;"> at its own cost and expense</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Should LICENSEE fail to commence and pursue any particular Action, then UTRF may commence, at its sole cost and expense, such Action as UTRF deems appropriate, provided that:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">UTRF gives LICENSEE a written [***] notice of its intention to initiate such Action; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">LICENSEE fails to initiate said suggested Action within said [***] notice period. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.11%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">LICENSEE shall retain the right to join such Action as a co-litigant at its own cost and expense.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.2<font style="font-weight:normal;margin-left:36pt;"></font>Cooperation: <font style="font-weight:normal;">Upon the request of the party that institutes an Action (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Instituting Party</font><font style="font-weight:normal;">&#8221;), the other party (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Co-Party</font><font style="font-weight:normal;">&#8221;) shall: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Join any such Action as a necessary party; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Use its commercially reasonable efforts to assist and cooperate with the Instituting Party in such Action. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Instituting Party shall reimburse the Co-Party for any reasonable and pre-approved costs related to such assistance and cooperation. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.3<font style="margin-left:36pt;"></font>Recovery of Damages:<font style="font-weight:normal;"> After reimbursement of the parties&#8217; previously unreimbursed out-of-pocket expenses of such Action or any previous Action, including attorney&#8217;s fees and other out of pocket costs associated with the Action, [***] of any remaining recovery of damages resulting from any Action</font><font style="color:#FF0000;font-weight:normal;"> </font><font style="font-weight:normal;">shall be given to the Instituting Party, and [***] to the Co-Party; provided that if the damage award is identified by judgment of the court or in a settlement in such suit as compensating LICENSEE for loss of sales revenue for Licensed Product on account of such Third Party&#8217;s unlicensed or illegal actions, in which event (instead of dividing the remaining balance between the Parties as stated in the preceding sentence), LICENSEE shall pay to UTRF an amount equal to [***] of the equivalent of the lost Net Sales upon which such judgment or settlement award is based, and LICENSEE shall retain the rest. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.4<font style="margin-left:36pt;">Declaratory Judgment Action</font><font style="font-weight:normal;">: In the event that a declaratory judgment action alleging invalidity or noninfringement of any of the Licensed Patents shall be brought against UTRF, UTRF shall promptly notify LICENSEE and LICENSEE may, within [***] of LICENSEE&#8217;s receipt of notice regarding such action and with the written consent of UTRF which shall not be unreasonably withheld, intervene and take over the sole defense of the action against UTRF at LICENSEE&#8217;s own expense, provided that LICENSEE may not enter into a consent judgment acknowledging the invalidity or noninfringement of any of the Licensed Patents or an admission of fault or of wrongdoing or that materially affects the rights of UTRF hereunder without the prior written approval of UTRF, which approval shall not be unreasonably withheld. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.5<font style="margin-left:36pt;">Notice and Settlement:</font> <font style="font-weight:normal;">The Instituting Party shall reasonably notify the Co-Party of the course of any Action and shall not settle any Action without prior approval of the Co-Party (i) during the Term if such settlement contains an admission of the invalidity of any Licensed Patents or (ii) either during or after the </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Term if such settlement contains an admission of fault or wrongdoing or materially affects the rights of the Co-Party hereunder. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.55%;text-indent:-7.55%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9  INDEMNIFICATION; INSURANCE; REPRESENTATIONS; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DISCLAIMER OF WARRANTIES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="font-weight:normal;margin-left:36pt;"></font>Indemnification: <font style="font-weight:normal;">In the event that UTRF, UT, any of their trustees, directors, officers, or employees (each an &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnified Party</font><font style="font-weight:normal;">&#8221;) is, as a result of the manufacture, marketing, use, sale, lease, or import of Licensed Products by LICENSEE or its Sublicensees under this Amended Agreement: (i) charged with infringement of a patent by a third party; or (ii) made a party in any lawsuit arising out of the manufacture, marketing, use, sale, lease, or import of Licensed Products by LICENSEE or its Sublicensees under this Amended Agreement, including, without limitation, actions founded on product liability (collectively, an &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnified Claim</font><font style="font-weight:normal;">&#8221;) LICENSEE shall indemnify, defend and hold the Indemnified Party(ies) harmless for any and all damages, losses, liability, and costs resulting from an Indemnified Claim, except to the extent such damages, losses, liability, or costs result from a breach of this Amended Agreement, gross negligence, willful misconduct or misrepresentation by an Indemnified Party.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:7.55%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Subject to Section 9.1(b), LICENSEE shall defend or settle, at LICENSEE&#8217;s expense, any such Indemnified Claim against an Indemnified Party, provided that LICENSEE shall not enter into any such settlement (i) without the prior approval of UTRF if such settlement contains an admission of the invalidity of any Licensed Patent or materially affects the rights of UTRF hereunder; or (ii) without the prior approval of the Indemnified Party(ies) if such settlement contains an admission of fault or wrongdoing on the part of such Indemnified Party(ies);</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.55%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.55%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;margin-left:36pt;">If a</font><font style="font-weight:normal;">n Indemnified Party intends to claim indemnification under this Section 9.1 it shall promptly notify LICENSEE in writing of such alleged Indemnified Claim. The LICENSEE shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably acceptable to the Indemnified Party; provided, that any Indemnified Party shall have the right to retain its own counsel at its own expense, for any reason, including if representation of any Indemnified Party by the counsel retained by the LICENSEE would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party shall cooperate with LICENSEE and its legal representatives in the investigation of any action, claim or liability covered by this Section 9.1</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2<font style="margin-left:36pt;">Insurance:</font> <font style="font-weight:normal;">During the Term beginning with the date of the first commercial manufacture, sale, or import of a Licensed Product, LICENSEE shall obtain and carry in full force and effect commercial, general liability insurance which shall cover LICENSEE and the Indemnified Parties with respect to events covered by Article 9.1 above. LICENSEE shall provide UTRF with Certificates of Insurance. Such insurance shall:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Be written by a reputable insurance company authorized to do business in the State of Tennessee;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">List UTRF as additional insureds;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Be endorsed to include product liability coverage;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Require [***] written notice to be given to UTRF before any cancellation or material change thereof; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;">Have a limit of not less than $</font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">***</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;"> per occurrence with an aggregate of $</font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">***</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;"> for</font><font style="font-weight:normal;"> property damage,</font><font style="font-weight:normal;"> personal </font><font style="font-weight:normal;">injury</font><font style="font-weight:normal;"> or death</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3<font style="margin-left:36pt;">Representations:</font> <font style="font-weight:normal;">Each party represents that:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">It is authorized to enter into this Amended Agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Entering into this Amended Agreement does not and will not create a conflict with or breach of the terms of any other agreement to which it is a party; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">All rights exercised and obligations undertaken in connection with this Amended Agreement will comply with all applicable foreign, federal, state, and local laws and regulations. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">UTRF represents and warrants that to the best of its actual knowledge as of the Amended Effective Date, it has fully complied and will fully comply with the requirements, to the extent applicable, of 35 U.S.C. &#167; 200 </font><font style="font-style:italic;font-weight:normal;">et seq</font><font style="font-weight:normal;">. and all implementing regulations, to the extent applicable, that are necessary to perfect title to the Licensed Patents.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.4<font style="margin-left:36pt;">Disclaimer of Warranties:</font> <font style="text-transform:uppercase;font-weight:normal;">Except as otherwise expressly set forth in this AMENDED agreement, UTRF, its directors, officers, employees, and affiliates MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, including warranties of merchantability, fitness for a particular purpose, validity of patent rights claims, issued or pending, and the absence of latent or other defects, whether or not discoverable. In no event shall ANY PARTY or their respective trustees, directors, officers, employees OR affiliates be liable for incidental or consequential damages of any kind, including economic damage or injury to property and lost profits, regardless of whether SUCH PARTY shall be advised, shall have other reason to know, or in fact shall know of the possibility of the foregoing. NOTHING IN THIS AMENDED AGREEMENT SHALL BE CONSTRUED AS</font><font style="font-weight:normal;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A representation made or warranty given by UTRF that the practice by LICENSEE of the License granted hereunder shall not infringe the patent rights of any third party;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A representation made or warranty given by UTRF as to the validity or scope of the Licensed Patents;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A representation made or warranty given by UTRF that any patent application included in the Licensed Patents will ultimately issue as a patent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A requirement that UTRF shall be responsible for the expenses of filing or prosecuting any patent application or maintaining any issued patent in force;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">An obligation on the part of UTRF to bring or prosecute actions or suits against third parties for infringement of the Licensed Patents or for unauthorized use of Know-How;</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:uppercase;"></font><font style="text-transform:uppercase;font-weight:normal;">An obligation on the part of UTRF to defend any action or suit brought by any third party;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">g</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A representation made or warranty given by UTRF as to the safety, reliability or efficacy of the Licensed Products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">h</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A representation made or warranty given by UTRF that any Know-How is secret or confidential;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">An obligation on the part of UTRF to take any action to prevent the disclosure of the Licensed Patents by UT OR its employees; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">j</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-transform:none;"></font><font style="font-weight:normal;">A representation made or warranty given by UTRF that any of the Inventors will agree to provide technical assistance or consultation to LICENSEE, or that such technical assistance or consultation, if provided, would be sufficient to enable LICENSEE to successfully exploit the Licensed Patents.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 10 EXPORT CONTROLS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.1 <font style="margin-left:36pt;">Limitations:</font> <font style="font-weight:normal;">LICENSEE hereby agrees that it will not sell, transfer, export or re-export any Licensed Products or Licensed Patents:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">In any form, or any direct products thereof, except in compliance with all applicable laws, including the export laws of any U.S. Government agency and any regulations thereunder; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">To any persons or any entities with regard to which there exist grounds to suspect or believe that they are violating applicable laws, including export laws of any U.S. Government agency. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.2<font style="margin-left:36pt;">Responsibilities:</font> <font style="font-weight:normal;">LICENSEE shall be solely responsible for obtaining all licenses, permits or authorizations required from the U.S. and any other government for any such export or re-export. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.55%;text-indent:-7.55%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 11 NON-USE OF NAMES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.1<font style="margin-left:36pt;">LICENSEE</font><font style="font-weight:normal;"> shall not use the names or trademarks of UTRF, of UT, nor any adaptation thereof, nor the names of any of their employees, directors, trustees, or any UT Contributor in any advertising, promotional or sales literature without prior written consent obtained from UTRF, UT, or said employee, director, trustee, or UT Contributor, in each case, except that LICENSEE may state that it is licensed by UTRF under one or more of the patents and/or patent applications comprising the Licensed Patents.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.2<font style="font-weight:normal;margin-left:36pt;"></font>UTRF<font style="font-weight:normal;"> shall not use the names or trademarks of LICENSEE, nor any adaptation thereof, nor the names of any employee of LICENSEE, in any advertising, promotional, sales or other literature without prior written consent obtained from LICENSEE, or said employee, in each case, except that UTRF may state that it has licensed one or more of the patents and/or applications comprising the Licensed Patents to LICENSEE.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 12 CONFIDENTIALITY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.1<font style="margin-left:36pt;"></font>Disclosure of Agreement: <font style="font-weight:normal;">Nothing herein shall preclude a Party from disclosing the existence of this Amended Agreement and the general scope of the license granted hereunder.  UTRF shall have the right to disclose the financial terms of this Amended Agreement and other information concerning this Amended Agreement to UT Contributors, UT, the State of Tennessee, and to the United States government and any agency, laboratory, and contractor thereof. LICENSEE shall have the right to disclose this Amended Agreement to potential investors and in seeking corporate partnerships or sublicensees, including the economic terms included herein. Except as set forth herein, neither Party shall otherwise disclose the economic terms of this Amended Agreement without the written consent of the other Party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.2<font style="font-weight:normal;margin-left:36pt;"></font>Confidential Information: <font style="font-weight:normal;">Subject to the exceptions set forth herein, all information or material disclosed pursuant to this Amended Agreement and/or related to the Licensed Patents shall be confidential (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential Information</font><font style="font-weight:normal;">&#8221;). The Recipient of Confidential Information (&#8220;Receiving Party&#8221;) agrees to hold in confidence, and not to distribute or disseminate to any person or entity, for any reason and not use for any purpose except for the purposes contemplated by this Amended Agreement, for a period of [***] after the expiration or earlier termination of this Amended Agreement, any Confidential Information received under or relating to this Amended Agreement from the other Party (&#8220;Providing Party&#8221;), except for Confidential Information which:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">was known or used by the Receiving Party prior to the date of disclosure to the Receiving Party as evidenced by written records; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">either before or after the date of disclosure is lawfully disclosed to the Receiving Party by sources other than the Providing Party which are rightfully in possession of the Confidential Information and not subject to any obligation of confidentiality, as evidenced by written records; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">either before or after the date of disclosure to the Receiving Party becomes generally known to the public, through no fault or omission on the part of the Receiving Party; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">is independently developed by or for the Receiving Party without reference to, knowledge of, or reliance upon the Confidential Information as evidenced by written records</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All information concerning Licensed Patents shall be deemed Confidential Information of UTRF.  Disclosures of Confidential Information to LICENSEE, including, without limitation, disclosures that are made to LICENSEE by UT Contributors, shall be deemed, for purposes of this Article, to be disclosures made by UTRF.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either party may disclose Confidential Information disclosed to it by the other party to the extent such disclosure is required (i) by applicable law or (ii) for making applications or submissions to or otherwise dealing with regulatory authorities in connection with the development, manufacture or marketing of Licensed Products or obtaining patent rights, in each case, in accordance with this Amended Agreement; provided, that in the case of (ii) such Confidential Information shall be disclosed only to the extent reasonably necessary to obtain patent rights or authorizations.&nbsp;&nbsp;UTRF shall not disclose any non-public or unpublished information contained in any Licensed Patent except to the extent such disclosure is required (i) by applicable law; (ii) to fulfill obligations to co-owners or research sponsors; or (iii) for making applications or submissions to the extent reasonably necessary to obtain patent rights or regulatory authorizations.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that a public disclosure of information about this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement is</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required, in the reasonable opinion of counsel, by the rules of any</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities exchange or market on which a </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s securities are listed or</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">traded, and to the extent permitted by the notification timing requirements</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of such rules, the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty desiring to make such a disclosure shall use its best</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts to provide copies in a timely manner of the proposed disclosure in</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advance of such disclosure for the non-disclosing </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s prior review. Subject to the foregoing (and </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in particular to</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the extent</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitted by the notification timing requirements of such rules), it is</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">understood that a </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty may not make any disclosure of the financial terms</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other material conditions of this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement without the prior written</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consent of the other </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty following the procedure set forth in this Section.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a party is required, by a written order of a court or administrative body of competent jurisdiction and such order is subject to contempt provisions, to disclose Confidential Information that is subject to the non-disclosure provisions of this Section 12.2, such party shall promptly inform the other party of the disclosure that is being sought in order to provide the other party an opportunity to challenge or limit the disclosure obligations.  Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 12.2, and the party disclosing Confidential Information pursuant to such written order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.3<font style="margin-left:36pt;">Disclosure to Counsel:</font> <font style="font-weight:normal;">The Parties agree that counsel of the parties may receive Confidential Information.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 13 ASSIGNMENT</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:0.43%;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.1<font style="margin-left:36pt;"></font><font style="font-weight:normal;">This Amended Agreement shall be binding upon and shall inure to the benefit of UTRF and its assigns and successors, and shall be binding upon and shall inure to the benefit of LICENSEE and its assigns.&nbsp;&nbsp;Except as provided in this Section 13.1, this Amended Agreement may not be assigned or otherwise transferred, nor may any right or obligations hereunder be assigned or transferred, by either party without the consent of the other party. Notwithstanding the foregoing, no prior written approval from UTRF shall be required for any assignment of this Amended Agreement by LICENSEE to (i) an Affiliate of LICENSEE (or any entity into which LICENSEE shall have been merged or consolidated, provided more than 50% of such merged or consolidated entity is owned by shareholders holding more than 50% of LICENSEE</font> <font style="font-weight:normal;">immediately prior to such merger or consolidation), or (ii) a</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">Third</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Party</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">which acquires</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">all</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">or</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">substantially</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">all</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">LICENSEE&#8217;s</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">assets,</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">or</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">a</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">Controlling interest in</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">business,</font><font style="letter-spacing:0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">which</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">this</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> Amended </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">relates. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.2</font><font style="font-size:12pt;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Failure to Conform to this Article: </font><font style="font-weight:normal;color:#000000;">Any attempt to assign the rights granted to LICENSEE under this Amended Agreement that fails to fulfill any of the terms of this Article in any way shall make said attempt voidable at UTRF&#8217;s sole discretion. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 14 TERM AND TERMINATION</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.1<font style="margin-left:36pt;">Term</font><font style="font-weight:normal;">. This Amended Agreement shall take effect upon the Amended Effective Date, and unless earlier terminated pursuant to the provisions of this Article 14, shall continue in full force and effect until the last Valid Claim for any Licensed Patent in any country covering a Licensed Product shall expire (&#8220;Term&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.2<font style="font-weight:normal;"> </font><font style="font-weight:normal;margin-left:36pt;">After expiration of </font><font style="font-weight:normal;">the last Valid Claim of the Licensed Patents covering a Licensed Product in a country, LICENSEE shall have a perpetual, fully paid, royalty-free license to said Licensed Patents in such </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">country, such license being of no greater scope than that granted hereunder. LICENSEE shall continue to be obligated to pay (</font><font style="font-weight:normal;">i</font><font style="font-weight:normal;">) Running Royalties on account of Licensed Product manufactured or sold in any </font><font style="font-weight:normal;">other </font><font style="font-weight:normal;">country </font><font style="font-weight:normal;">covered by a</font><font style="font-weight:normal;"> Valid Claim</font><font style="font-weight:normal;"> of a</font><font style="font-weight:normal;"> Licensed Patent</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">that has not</font><font style="font-weight:normal;"> expired; and (ii) Sublicense Royalties on Sublicense Revenue generated under any Sublicense that includes a grant of rights </font><font style="font-weight:normal;">under</font><font style="font-weight:normal;"> a </font><font style="font-weight:normal;">Valid Claim of a </font><font style="font-weight:normal;">Licensed Patent</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">covering a Licensed Product </font><font style="font-weight:normal;">in any other country</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">that has not</font><font style="font-weight:normal;"> expired; and (iii) the Annual Maintenance Fee for as long as th</font><font style="font-weight:normal;">is </font><font style="font-weight:normal;">Amended </font><font style="font-weight:normal;">Agreement</font><font style="font-weight:normal;"> shall not have expired.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.3<font style="margin-left:36pt;">Failure to Carry on LICENSEE</font>&#8217;s Business<font style="font-weight:normal;">:</font> <font style="font-weight:normal;">If LICENSEE shall be adjudicated by a court of competent jurisdiction to be insolvent or is dissolved or declared bankrupt or is placed in receivership pursuant to proceedings initiated by LICENSEE declaring bankruptcy or insolvency, this Amended Agreement shall terminate immediately upon written notice from UTRF.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.4<font style="font-weight:normal;margin-left:36pt;"></font>LICENSEE&#8217;s<font style="font-weight:normal;"> </font>Material Breach<font style="font-weight:normal;">:</font> <font style="font-weight:normal;">Upon any material breach or default of this Amended Agreement by LICENSEE, including LICENSEE&#8217;s material failure to make any required payment under this Amended Agreement, LICENSEE shall have [***] after the receiving of written notice of such default by UTRF to correct such default. If such default is not corrected within the said cure period, UTRF shall have the right, at its option, to terminate this Amended Agreement. The failure of UTRF to exercise such right of termination for a material non&#8209;payment of royalties shall not be deemed to be a waiver of any right UTRF might have, nor shall such failure preclude UTRF from exercising or enforcing said right upon any subsequent material breach or default by LICENSEE.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.5<font style="margin-left:36pt;">Notice to Sublicensees. </font><font style="font-weight:normal;">At such time as UTRF shall provide notice to LICENSEE of its material breach hereunder, UTRF agrees to provide similar notice of such breach to any Sublicensee of which it has been properly notified hereunder, and UTRF agrees that a Sublicensee shall have the right to cure the breach to the same extent LICENSEE is provided such right hereunder, provided that any failure on the part of UTRF to provide any such notice to a Sublicensee shall not be deemed to be a default on the part of UTRF under this Amended Agreement.</font><font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.6<font style="font-weight:normal;margin-left:36pt;"></font>LICENSEE&#8217;s Right to Terminate: <font style="font-weight:normal;">LICENSEE shall have the right to terminate this Amended Agreement:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">On [***] written notice in the event that UTRF is in material breach or default of this Amended Agreement and fails to cure such breach or default within [***] after UTRF&#8217;s receipt of such notice; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">At any time on [***] written notice to UTRF, provided that LICENSEE has paid all amounts due UTRF through the effective date of the termination.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.7<font style="font-weight:normal;margin-left:36pt;"></font>Surviving Obligations: <font style="font-weight:normal;">Upon termination of this Amended Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination. In addition, if the Amended Agreement has been terminated for a reason other than breach on the part of LICENSEE, then LICENSEE (and any Sublicensee not then in default) may, after the effective date of such termination, sell all Licensed Products and complete Licensed Products in the process of manufacture at the time of such termination and sell the same, provided that LICENSEE shall pay to UTRF the royalties thereon as required by Article 5 of this Amended Agreement and shall submit the reports required by Article 6 on the sales of Licensed Products.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="margin-left:36pt;">Effect on Sublicensees:</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:normal;">Upon termination of this </font><font style="font-weight:normal;">Amended </font><font style="font-weight:normal;">Agreement for any reason, any Sublicensee not then in default shall have the right to </font><font style="font-weight:normal;">assume the rights of Licensee hereunder, subject to the prior written consent of </font><font style="font-weight:normal;">UTRF</font><font style="font-weight:normal;">, which shall not be unreasonably withheld</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 15 DISPUTE RESOLUTION</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.1 <font style="margin-left:36pt;"></font>Dispute Resolution: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">The parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Amended Agreement or the breach thereof.&nbsp;&nbsp;If the parties do not fully settle, and a party wishes to pursue the matter, each such dispute, controversy or claim that is not an &#8220;Excluded Claim&#8221; shall be finally resolved by binding arbitration in, accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (&#8220;AAA&#8221;), and judgment on the arbitration award may be entered in any court having jurisdiction thereof. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;"></font><font style="color:#010101;font-weight:normal;">The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business: within [***] after initiation of arbitration, each party shall select [***] to act as arbitrator and the [***] party-selected arbitrators shall select a [***] arbitrator within [***] of their appointment. If the arbitrators selected by the parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the AAA. The place of arbitration shall be New York, New York. All proceedings and communications shall be in English</font><font style="color:#2A2828;font-weight:normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Either party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either party also may, without waiving any remedy under this Amended Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a party&#8217;s compensatory damages. Each party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees of arbitration.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Except to the extent necessary to confirm an award or as may be required by law, neither a party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both parties.&nbsp;&nbsp;In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">The parties agree that, in the event of a dispute over the nature or quality of performance under this Amended Agreement, neither party may terminate this Amended Agreement until final resolution of the dispute through arbitration or other judicial determination.&nbsp;&nbsp;The parties further agree that any payments made pursuant to this Amended Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">As used in this Section, the term &#8220;Excluded Claim&#8221; means a dispute, controversy or claim that concerns (a) intellectual property rights, the validity or infringement of a patent, </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.55%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.55%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trademark</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or copyright, or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2<font style="margin-left:36pt;">Non-Waiver:</font><font style="font-weight:normal;"> Nothing in this Article shall be construed to waive the timely performance of any obligations existing under this Amended Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 16 PAYMENTS, NOTICES, AND OTHER COMMUNICATIONS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.1<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Any payment, notice or other communication required or permitted hereunder (hereinafter &#8220;notice&#8221;) shall be in writing and shall be hand-delivered, sent by overnight courier, mailed by certified United States mail, return receipt requested to the address(es) given below or to such other address(es) as the parties may hereafter specify in writing. Notice shall be deemed given and received [***] after being deposited with the U.S. Postal Service certified mail postage prepaid return receipt requested, or if notice is hand-delivered or sent by overnight courier, upon the date of actual delivery. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:15.11%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTRF:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:22.91%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:22.91%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">910 Madison Avenue, Suite 827</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:22.91%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Memphis, Tennessee, 38163 U.S.A. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.66%;text-indent:0.3%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:<font style="margin-left:36pt;">Vice- President</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.66%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.11%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LICENSEE:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:22.91%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:22.91%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12230 El Camino Real, Suite 300</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:22.91%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California 92130</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.66%;text-indent:0.3%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Legal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 17 PUBLICATIONS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.1<font style="margin-left:36pt;"></font>UT Rights to Publish Licensed Patents: <font style="font-weight:normal;">LICENSEE recognizes that under UTRF and UT policy, the results of a UT research project must be publishable and agrees that researchers engaged in such research shall have the right, with regard to the Licensed Patents, to present at symposia, professional meetings and to publish in journals, theses or dissertations, or otherwise of their own choosing (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Publication</font><font style="font-weight:normal;">&#8221;), unless UT, UTRF and LICENSEE agree to more restrictive terms in a sponsored research agreement. UTRF agrees that it shall provide to LICENSEE a copy of proposed Publications, promptly upon receipt and in the manner and form in which received, in order that LICENSEE may review the proposed Publication to identify and protect any Confidential Information of LICENSEE that may be contained therein and to allow for the preparation and filing of a patent application by LICENSEE or Sublicensees.&nbsp;&nbsp;UTRF shall not be deemed in breach or default of this Amended Agreement merely due to a Publication that UTRF does not receive prior to publication.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 18 MISCELLANEOUS PROVISIONS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.1<font style="font-weight:normal;margin-left:36pt;">This </font><font style="font-weight:normal;">Amended Agreement is entered into in the State of Tennessee and shall be construed, governed, interpreted and applied in accordance with the laws of the State of Tennessee without giving effect to any conflict of law provisions thereof.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.2</font><font style="font-weight:normal;margin-left:36pt;">The parties hereto acknowledge that this </font><font style="font-weight:normal;">Amended </font><font style="font-weight:normal;">Agreement sets forth the entire </font><font style="font-weight:normal;">a</font><font style="font-weight:normal;">greement and understanding of the parties hereto as to the subject matter </font><font style="font-weight:normal;">hereof, and</font><font style="font-weight:normal;"> shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the parties hereto.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.3<font style="font-weight:normal;margin-left:36pt;">The provisions of this </font><font style="font-weight:normal;">Amended Agreement are severable, and in the event that any provisions of this Amended Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.4<font style="margin-left:36pt;"></font><font style="font-weight:normal;">The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Amended Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.5<font style="font-weight:normal;margin-left:36pt;">No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this </font><font style="font-weight:normal;">Amended Agreement for failure or delay in fulfilling or performing any obligation (other than a payment obligation) of this Amended Agreement when such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or delaying.&nbsp;&nbsp;For purposes of this Amended Agreement, force majeure is defined as causes beyond the control of the Party, including acts of God; material changes in Law; actions or failures in action by relevant Governmental Authorities; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; shortages of supply; labor disturbances; epidemic; pandemics; and failure of public utilities or common carriers.&nbsp;&nbsp;In such event affected Party, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue.&nbsp;&nbsp;The Party giving such notice shall thereupon be excused from such of its obligations under this Amended Agreement as it is thereby disabled from performing for so long as it is so disabled.&nbsp;&nbsp;To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.6<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">This Amended Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.7<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Each party will execute, acknowledge and deliver such further instruments, and to do all such other ministerial, administrative or similar acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Amended Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.8<font style="font-weight:normal;margin-left:36pt;">The provisions of this </font><font style="font-weight:normal;">Amended Agreement are for the exclusive benefit of the parties, and no other person or entity shall have any right or claim against any party by reason of these provisions or be entitled to enforce any of these provisions against any party.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.9<font style="font-weight:normal;margin-left:36pt;">Except as otherwise specifically provided in this </font><font style="font-weight:normal;">Amended Agreement, each party (and its Affiliates) shall bear its own costs and expenses in connection with entering into this Amended Agreement and the consummation of the transactions and performance of its obligations contemplated hereby.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.10<font style="font-weight:normal;margin-left:36pt;">All rights and licenses granted pursuant to any section of this </font><font style="font-weight:normal;">Amended Agreement, including pursuant to Section 2, are rights and licenses to &#8220;intellectual property&#8221; (as defined in Section 101(35A) of title 11 of the United States Code (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Bankruptcy Code</font><font style="font-weight:normal;">&#8221;)).&nbsp;&nbsp;Each Party shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.55%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have hereunto set their hands and seals and duly executed this </font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended </font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement the day and year set forth below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.55%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.29%;"></td>
<td style="width:43.69%;"></td>
<td style="width:6.66%;"></td>
<td style="width:43.35%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;LICENSEE&#8221;)</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (&#8220;UTRF&#8221;) </p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk97801648"></a>By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer, M.D., Ph.D</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Magid, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Magid, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2022</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2022</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;">APPENDIX A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] = Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>4
<FILENAME>onct-ex1018_739.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex1018_739.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-variant: normal;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;">2019 INCENTIVE AWARD PLAN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This plan document has been updated to reflect the Company&#8217;s name change and the one-for-seven reverse stock split effected by the Company on June 7, 2019 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE I.<br />Purpose </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article&#160;XI.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE II.<br />Eligibility</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE III.<br />Administration and Delegation </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Administration</font>. The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Appointment of Committees</font>. To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries. The Board may abolish any Committee or re-vest in itself any previously delegated authority at any time. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE IV.<font style="font-weight:normal;"><br /></font>Stock Available for Awards</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46667HSNuqu"></a>4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Number of Shares</font>. Subject to adjustment under Article&#160;VIII and the terms of this Article&#160;IV, Awards may be made under the Plan covering up to the Overall Share Limit. <a name="_9kMHG5YVt46667HSNuqu"></a>As of the Effective Date, the Company will cease granting awards under the Prior Plan; however, Prior Plan Awards will remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Share Recycling</font>. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the Participant for such Shares or not issuing any Shares covered by the Award</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or Prior Plan Award</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the unused Shares covered by the Award</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or Prior Plan Award</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as applicable,</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">become or </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">again be available for Award grants under the Plan.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or Prior Plan Award </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or Prior Plan Award </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being exercised or purchased and/or creating the tax obligation) will</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as applicable, become or</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> again be available for Award grants under the Plan.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or Prior Plan Awards </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall not count against the Overall Share Limit.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Incentive Stock Option Limitations</font>. Notwithstanding anything to the contrary herein, no more than 7,142,857 Shares may be issued pursuant to the exercise of Incentive Stock Options. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMIH5YVt46667HSNuqu"></a><a name="_9kMHG5YVt466689LHy0poD"></a><a name="_9kMHG5YVt46668AcQfqvx"></a><a name="_9kMHG5YVt46668BaRjm"></a><a name="_9kMIH5YVt46668AcQfqvx"></a><a name="_9kMIH5YVt46668BaRjm"></a><a name="_9kMHG5YVt46668COHyx02hiBvs"></a><a name="_9kMJI5YVt46668AcQfqvx"></a><a name="_9kMJI5YVt46667HSNuqu"></a><a name="_9kMJI5YVt46668BaRjm"></a>4.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Substitute Awards</font>. In connection with an entity&#8217;s merger or consolidation with the Company or the Company&#8217;s acquisition of an entity&#8217;s property or stock, the Administrator may grant Awards in substitution for any O<a name="_9kMIH5YVt46667HSNuqu"></a>ptions or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. <a name="_9kMHG5YVt466689LHy0poD"></a>Additionally, in the event that a company<a name="_9kMHG5YVt46668AcQfqvx"></a> acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares<a name="_9kMHG5YVt46668BaRjm"></a> available under a pre-existing plan<a name="_9kMIH5YVt46668AcQfqvx"></a> approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares<a name="_9kMIH5YVt46668BaRjm"></a> available for grant pursuant to the terms of such pre-existing plan<a name="_9kMHG5YVt46668COHyx02hiBvs"></a> (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock<a name="_9kMJI5YVt46668AcQfqvx"></a> of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares<a name="_9kMJI5YVt46667HSNuqu"></a> shall not be made after the date awards<a name="_9kMJI5YVt46668BaRjm"></a> or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees or Directors prior to such acquisition or combination.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46668DRHzzzD4l"></a><a name="_9kMIH5YVt46668DRHzzzD4l"></a><a name="_9kR3WTr266457NCrklokjnOAjwFFFB65lt837vA"></a><a name="_9kMJI5YVt46668DRHzzzD4l"></a><a name="_9kMKJ5YVt46668DRHzzzD4l"></a><a name="_9kMLK5YVt46668DRHzzzD4l"></a><a name="_9kMML5YVt46668DRHzzzD4l"></a><a name="_9kMNM5YVt46668DRHzzzD4l"></a><a name="_9kMON5YVt46668DRHzzzD4l"></a><a name="_9kMKJ5YVt46667HSNuqu"></a><a name="_9kMPO5YVt46668DRHzzzD4l"></a>4.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Employee Director Compensation</font>. Notwithstanding any provision to the contrary in the Plan, the <a name="_9kMHG5YVt46668DRHzzzD4l"></a>Administrator may establish compensation for non-employee Directors from time to time, subject to the limitations in the Plan. <a name="_9kMIH5YVt46668DRHzzzD4l"></a>The Administrator will from time to time determine the terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date<a name="_9kR3WTr266457NCrklokjnOAjwFFFB65lt837vA"></a> in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718<a name="_9kMJI5YVt46668DRHzzzD4l"></a>, or any successor thereto) of Awards granted to a non-employee<a name="_9kMKJ5YVt46668DRHzzzD4l"></a> Director as compensation for services as a non-employee Director during any fiscal year of the Company may not exceed $750,000 increased to $1,000,000 in the fiscal year of <a name="_9kMLK5YVt46668DRHzzzD4l"></a>a non-employee Director&#8217;s<a name="_9kMML5YVt46668DRHzzzD4l"></a> initial service as a non-employee Director. <a name="_9kMNM5YVt46668DRHzzzD4l"></a>The Administrator may make exceptions to this limit for individual non-employee<a name="_9kMON5YVt46668DRHzzzD4l"></a> Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the non-employee<a name="_9kMKJ5YVt46667HSNuqu"></a> Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions i<a name="_9kMPO5YVt46668DRHzzzD4l"></a>nvolving non-employee Directors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE V.</font><font style="font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Stock Options and Stock Appreciation Rights</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font>. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exercise Price</font>. The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr5C947G"></a>5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Duration</font>. Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten (10) years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option) (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#8220;lock-up&#8221; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30) days after<a name="_9kR3WTr5C947G"></a> the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten- (10)-year term of the applicable Option or Stock Appreciation Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#8217;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii) the effective date of the Participant&#8217;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such Termination of Service).</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exercise</font>. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as specified in Section&#160;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the number of Shares for which the Award is exercised and (ii) as specified in Section&#160;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for any applicable taxes.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment Upon Exercise</font>. Subject to any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator; </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#8217;s exercise valued at their Fair Market Value on the exercise date; </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration; or</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE VI.<br />Restricted Stock; Restricted Stock Units</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font>. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&#8217;s right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such Shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Restricted Stock</font>.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Dividends</font>. Participants holding Shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hares of Restricted Stock with respect to which they were paid.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Stock Certificates</font>. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of Shares of Restricted Stock, together with a stock power endorsed in blank.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">6.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Restricted Stock Units.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Settlement</font>. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply with Section&#160;409A.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Stockholder Rights</font>. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Dividend Equivalents</font>. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE VII.<br />Other Stock or Cash Based Awards<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMLK5YVt46667HSNuqu"></a>Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic<a name="_9kMLK5YVt46667HSNuqu"></a> or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE VIII.<br />Adjustments for Changes in Common Stock <br />and Certain Other Events</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Equity Restructuring</font>(a)<font style="margin-left:36pt;"></font>. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article&#160;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&#8217;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section&#160;8.1 will be nondiscretionary and final and binding on the affected </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Corporate Transactions</font>. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#8217;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles: </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment; </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>To provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46668Egdts0mnlvK"></a><a name="_9kMML5YVt46667HSNuqu"></a><a name="_9kMIH5YVt46668Egdts0mnlvK"></a>(c)<font style="margin-left:36pt;"></font><a name="_9kMHG5YVt46668Egdts0mnlvK"></a>To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary<a name="_9kMML5YVt46667HSNuqu"></a> thereof, or shall be substituted for by awards<a name="_9kMIH5YVt46668Egdts0mnlvK"></a> covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of Shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator; </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&#160;IV hereof on the maximum number and kind of Shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards; </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>To replace such Award with other rights or property selected by the Administrator; and/or</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMNM5YVt46667HSNuqu"></a><a name="_9kMHG5YVt3DE69HidudgxC99aRD9AR"></a><a name="_9kMJI5YVt46668Egdts0mnlvK"></a><a name="_9kR3WTr24446EOH694082y4"></a><font style="text-decoration:none;">8.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Effect of Non-Assumption in a Change in Control</font><font style="text-decoration:none;">. Notwithstanding the provisions of Section 8.2 above, if a Change in Control occurs and a Participant&#8217;s Awards are not continued, converted, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><a name="_9kMNM5YVt46667HSNuqu"></a>assumed, or replaced with a substantially similar </font><font style="text-decoration:none;">award</font><font style="text-decoration:none;"><a name="_9kMHG5YVt3DE69HidudgxC99aRD9AR"></a> by (a) the Company, or (b) a </font><font style="text-decoration:none;">S</font><font style="text-decoration:none;">uccessor </font><font style="text-decoration:none;">E</font><font style="text-decoration:none;">ntity</font><font style="text-decoration:none;"> (as defined below)</font><font style="text-decoration:none;"><a name="_9kMJI5YVt46668Egdts0mnlvK"></a> or its parent or </font><font style="text-decoration:none;">subsidiary</font><font style="text-decoration:none;"><a name="_9kR3WTr24446EOH694082y4"></a> (an &#8220;</font><font style="font-weight:bold;font-style:italic;text-decoration:none;">Assumption</font><font style="text-decoration:none;">&#8221;), and provided that the Participant has not had a Termination of Service, then, immediately prior to the Change in Control, such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (</font><font style="text-decoration:none;">i</font><font style="text-decoration:none;">) which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and (ii) determined by reference to the number of </font><font style="text-decoration:none;">Shares</font><font style="text-decoration:none;"> subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute &#8220;nonqualified deferred compensation&#8221; that may not be paid upon the Change in Control under Section 409A without the imposition of taxes thereon under Section 409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMKJ5YVt46668AcQfqvx"></a>8.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Administrative Stand Still</font>. In the event of any pending stock dividend, stock split, combination or exchange of Shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stock<a name="_9kMKJ5YVt46668AcQfqvx"></a>holders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty (60) days before or after such transaction.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font>. Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an Equity Restructuring under Section&#160;8.1 above or the Administrator&#8217;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Article&#160;VIII.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE IX.<br />General Provisions Applicable to Awards<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Transferability</font>. Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Documentation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Award may contain terms and conditions in addition to those set forth in the Plan. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Discretion</font>. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46668FSCyrbkvw5M"></a>9.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Status</font>. <a name="_9kMHG5YVt46668FSCyrbkvw5M"></a>The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMON5YVt46667HSNuqu"></a>9.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Withholding</font>. Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#8217;s Awards by the date of the event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant. In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii) below with respect to Awards held by individuals subject to Section 16 of the Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the minimum applicable statutory withholding rates. Subject to any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the Award creating the tax obligation, valued at their Fair Market Value on the date of delivery, (iii) if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. Notwithstanding any other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii) of the immediately preceding sentence shall be limited to the number of Shares which have a Fair Market Value on the date of delivery or retention no greater than the aggregate amount of such liabilities based on the <a name="_9kMON5YVt46667HSNuqu"></a>maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America); provided, however, to the extent such Shares were acquired by Participant from the Company as compensation, the Shares must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#8217;s earnings for financial reporting purposes<font style="letter-spacing:-0.1pt;">; provided, further, that, any such Shares delivered or retained shall be rounded up to the nearest whole Share to the extent rounding up to the nearest whole Share does not result in the liability classification of the applicable Award under </font>generally accepted accounting principles in the United States of America. If any tax withholding obligation will be satisfied under clause (ii) above by the Company&#8217;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#8217;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMLK5YVt46668AcQfqvx"></a><a name="_9kMML5YVt46668AcQfqvx"></a><a name="_9kMNM5YVt46668AcQfqvx"></a>9.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Amendment of Award; Repricing</font>. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Participant&#8217;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Award, or (ii) the change is permitted under Article&#160;VIII or pursuant to Section&#160;10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the approval of the stock<a name="_9kMLK5YVt46668AcQfqvx"></a>holders of the Company, reduce the exercise price per share<a name="_9kMML5YVt46668AcQfqvx"></a> of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share<a name="_9kMNM5YVt46668AcQfqvx"></a> that is less than the exercise price per share of the original Options or Stock Appreciation Rights.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conditions on Delivery of Stock</font>. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&#160;all Award conditions have been met or removed to the Company&#8217;s satisfaction, (ii)&#160;as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Acceleration</font>. The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHzG6ZWu57779ESI000E5m"></a><a name="_9kMKJ5YVt46668Egdts0mnlvK"></a><a name="_9kMH0H6ZWu57779ESI000E5m"></a><a name="_9kR3WTr266458PMrbrwvlWkr"></a><a name="_9kR3WTr266459ca3nkqv0qkz"></a><a name="_9kMHG5YVt46668GQJ8B62A406"></a><a name="_9kMHG5YVt46668HZMnfr7363blEyviiKEAG"></a><a name="_9kMIH5YVt46668HZMnfr7363blEyviiKEAG"></a>9.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Additional Terms of Incentive Stock Options</font>. <a name="_9kMHzG6ZWu57779ESI000E5m"></a>The Administrator may grant Incentive Stock Options only to employees<a name="_9kMKJ5YVt46668Egdts0mnlvK"></a> of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections&#160;<a name="_9kMH0H6ZWu57779ESI000E5m"></a>424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. <a name="_9kR3WTr266458PMrbrwvlWkr"></a>If an Incentive Stock Option is granted to a Greater Than<a name="_9kR3WTr266459ca3nkqv0qkz"></a> 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#8217;s grant date, and the term of the Option will not exceed five (5) years. All Incentive Stock Options will be subject to and construed consistently with Section&#160;422 of the Code. By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i<a name="_9kMHG5YVt46668GQJ8B62A406"></a>) two years from the grant date of the Option or (ii) one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such disposition or other transfer. <a name="_9kMHG5YVt46668HZMnfr7363blEyviiKEAG"></a>Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code. <a name="_9kMIH5YVt46668HZMnfr7363blEyviiKEAG"></a>Any Incentive Stock Option or portion thereof that fails to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code for any reason, including becoming exercisable with respect to Shares having a Fair Market Value exceeding the $100,000 limitation under Treasury Regulation Section&#160;1.422-4, will be a Non-Qualified Stock Option.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE X.</font><font style="font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Miscellaneous</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Right to Employment or Other Status</font>. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMKJ5YVt46668BaRjm"></a><a name="_9kMHG5YVt46668IS4ntvw2EEwzED"></a>10.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Rights as Stockholder; Certificates</font>. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock<a name="_9kMKJ5YVt46668BaRjm"></a> plan<a name="_9kMHG5YVt46668IS4ntvw2EEwzED"></a> administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26645AXFruiujhx"></a><a name="_9kR3WTr1BC47EZFruiuRBzymvwyE"></a>10.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Effective Date and Term of Plan</font>. The Plan was approved by the Board on April 16, 2019.&nbsp;&nbsp;The Plan shall be effective (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;) on the day prior to the date of the closing of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of March 6, 2019 by and among the Company, <a name="_9kR3WTr26645AXFruiujhx"></a>Grizzly Merger Sub, Inc. and Oncternal Therapeutics, Inc. (as amended, <a name="_9kR3WTr1BC47EZFruiuRBzymvwyE"></a>the &#8220;<font style="font-weight:bold;font-style:italic;">Merger Agreement</font>&#8221;), provided that it is approved by a majority of the Company&#8217;s stockholders at a duly held meeting prior to such date and occurring within twelve (12) months following the date the Board approved Plan, and provided further that the effectiveness of the Plan is subject to the consummation of the transactions contemplated by the Merger Agreement.&nbsp;&nbsp;If the Plan is not approved by the Company&#8217;s stockholders within the foregoing time frame, or if the Merger Agreement is terminated prior to the consummation of the transactions contemplated thereby, the Plan will not become effective.  The Plan shall remain in effect until the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) anniversary of the date the Board adopted the Plan, but Awards previously granted may extend beyond that date in accordance with the Plan.&nbsp;&nbsp;The Plan will be submitted for approval of the Company's stockholders within twelve (12) months following the date the Board approved the Plan.  </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Amendment of Plan</font>. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#8217;s consent. No Awards may be granted under the Plan during any suspension period or after the Plan&#8217;s termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMH1I6ZWu57779ESI000E5m"></a>10.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Provisions for Foreign Participants</font>. <a name="_9kMH1I6ZWu57779ESI000E5m"></a>The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Section&#160;409A</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font>. The Company intends that all Awards be structured to comply with, or be exempt from, Section&#160;409A, such that no adverse tax consequences, interest, or penalties under Section&#160;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#8217;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A)&#160;exempt this Plan or any Award from Section&#160;409A, or (B)&#160;comply with Section&#160;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#8217;s grant date. The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section&#160;409A or otherwise. The Company will have no obligation under this Section&#160;10.6 or otherwise to avoid the taxes, penalties or interest under Section&#160;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#8220;nonqualified deferred compensation&#8221; subject to taxes, penalties or interest under Section&#160;409A.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Separation from Service</font>. If an Award constitutes &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&#160;409A, be made only upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&#160;409A), whether such &#8220;separation from service&#8221; occurs upon or after the termination of the Participant&#8217;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a &#8220;separation from service.&#8221;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMH2J6ZWu57779ESI000E5m"></a><a name="_9kMHG5YVt7EB69I"></a><a name="_9kMIH5YVt7EB69I"></a>(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payments to Specified Employees</font>. <a name="_9kMH2J6ZWu57779ESI000E5m"></a>Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&#160;409A and as the Administrator determines) due to his or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section&#160;409A(a)(2)(B)(i<a name="_9kMHG5YVt7EB69I"></a>) of the Code, be delayed for the six- (6)-month period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the specified E<a name="_9kMIH5YVt7EB69I"></a>mployee&#8217;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six- (6)month period or as soon as administratively practicable thereafter (without interest). Any payments of &#8220;nonqualified deferred compensation&#8221; under such Award payable more than six (6) months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46669AMCxugw98"></a><a name="_9kMIH5YVt46669AMCxugw98"></a><a name="_9kMJI5YVt46669AMCxugw98"></a>10.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitations on Liability</font>. <a name="_9kMHG5YVt46669AMCxugw98"></a>Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other E<a name="_9kMIH5YVt46669AMCxugw98"></a>mployee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other Employee or agent of the Company or any Subsidiary. <a name="_9kMJI5YVt46669AMCxugw98"></a>The Company will indemnify and hold harmless each director, officer, other Employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8<font style="margin-left:36pt;"></font>10.9<font style="margin-left:36pt;"></font>Data Privacy</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46669BN4rs"></a><a name="_9kR3WTr244479L2pq"></a><a name="_9kMIH5YVt46669BN4rs"></a>. <a name="_9kMHG5YVt46669BN4rs"></a>As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#8217;s participation in the Plan. <a name="_9kR3WTr244479L2pq"></a>The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#8217;s name, address and telephone number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#8220;<font style="font-weight:bold;font-style:italic;">Data</font>&#8221;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#8217;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. <a name="_9kMIH5YVt46669BN4rs"></a>These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#8217;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section&#160;10.8 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section&#160;10.8. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>. If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Documents</font>. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law</font>. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice-of-law principles requiring the application of a jurisdiction&#8217;s laws other than the State of Delaware.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26645BbV161z0x38"></a>10.13<font style="margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_9kR3WTr26645BbV161z0x38"></a>Claw-back Provisions</font>. All Awards (including, without limitation, any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any Shares underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as and to the extent set forth in such claw-back policy or the Award Agreement.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Titles and Headings</font>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conformity to Securities Laws</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMLK5YVt46668BaRjm"></a><a name="_9kMML5YVt46668BaRjm"></a>10.16<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Relationship to Other Benefits</font>. <a name="_9kMLK5YVt46668BaRjm"></a>No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan<a name="_9kMML5YVt46668BaRjm"></a> of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46669CaGp91lm0tsC"></a>10.17<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Broker-Assisted Sales</font>. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&#160;9.5<a name="_9kMHG5YVt46669CaGp91lm0tsC"></a>: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c) the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#8217;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARTICLE XI.<br />Definitions<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in the Plan, the following words and phrases will have the following meanings:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24446GQ2lrtu0CCuxCB"></a>11.1<font style="margin-left:36pt;"></font><a name="_9kR3WTr24446GQ2lrtu0CCuxCB"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Administrator</font>&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMNM5YVt46668BaRjm"></a>11.2<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Applicable Laws</font>&#8221; <a name="_9kMNM5YVt46668BaRjm"></a>means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24445FQLsos"></a>11.3<font style="margin-left:36pt;"></font><a name="_9kR3WTr24445FQLsos"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Award</font>&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Award Agreement</font>&#8221; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221; means the Board of Directors of the Company.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24447CN1q9u"></a>11.6<font style="margin-left:36pt;"></font><a name="_9kR3WTr24447CN1q9u"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Cause</font>&#8221; means (a) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#8220;cause&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is defined, &#8220;Cause&#8221; as defined in </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such agreement, and (b) if no such a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greement exists, (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the Administrator&#8217;s determination that </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant failed to substantially perform </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant&#8217;s duties (other than a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny such</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> failure resulting from </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant&#8217;s Disability); (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the Administrator&#8217;s determination that </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partic</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ipant&#8217;s immediate supervisor; (iii)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant&#8217;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude; (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant&#8217;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant&#8217;s duties and responsibilities for the Company or any of its Subsidiaries; or (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant&#8217;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24447BM8dkrjmwRN5BGC7"></a>11.7<font style="margin-left:36pt;"></font><a name="_9kR3WTr24447BM8dkrjmwRN5BGC7"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Change in Control</font>&#8221; means and includes each of the following: </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMH3K6ZWu57779ESI000E5m"></a><a name="_9kMON5YVt46668BaRjm"></a>(a)<font style="margin-left:36pt;"></font>A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;<a name="_9kMH3K6ZWu57779ESI000E5m"></a>13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee<a name="_9kMON5YVt46668BaRjm"></a> benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; or</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMJI5YVt7EB69I"></a>(b)<font style="margin-left:36pt;"></font>During any period of two (2) consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stock<a name="_9kMJI5YVt7EB69I"></a>holders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two- (2)-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr1BC47FgbsbevA77YPB78P"></a>(i)<font style="margin-left:36pt;"></font><a name="_9kR3WTr1BC47FgbsbevA77YPB78P"></a>which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<font style="font-weight:bold;font-style:italic;">Successor Entity</font>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt46669DOAfmtloyTP7DIE9"></a>Notwithstanding the foregoing, (x) the transactions contemplated by the Merger Agreement shall not constitute a Change in Control for purposes of this Plan, and (y) if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&#160;409A, to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a), (b) or (c<a name="_9kMHG5YVt46669DOAfmtloyTP7DIE9"></a>) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMIH5YVt46669DOAfmtloyTP7DIE9"></a><a name="_9kMIH5YVt46669DOAfmtloyTP7DIE9"></a>The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMKJ5YVt46669AMCxugw98"></a><a name="_9kMH4L6ZWu57779ESI000E5m"></a><a name="_9kMLK5YVt46669AMCxugw98"></a><a name="_9kMH5M6ZWu57779ESI000E5m"></a><a name="_9kMML5YVt46669AMCxugw98"></a>11.9<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Committee</font><a name="_9kMKJ5YVt46669AMCxugw98"></a>&#8221; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. <a name="_9kMH4L6ZWu57779ESI000E5m"></a>To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#8220;non-employee<a name="_9kMLK5YVt46669AMCxugw98"></a> director<a name="_9kMH5M6ZWu57779ESI000E5m"></a>&#8221; within the meaning of Rule 16b-3; however, a Committee member&#8217;s failure to qualify as a &#8220;non-employee<a name="_9kMML5YVt46669AMCxugw98"></a> director&#8221; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24446AMFwvy0fg9tq"></a>11.10<font style="margin-left:36pt;"></font><a name="_9kR3WTr24446AMFwvy0fg9tq"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Common Stock</font>&#8221; means the common stock of the Company. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr244467JFwynmB"></a>11.11<font style="margin-left:36pt;"></font><a name="_9kR3WTr244467JFwynmB"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221; means Oncternal Therapeutics, Inc., a Delaware corporation, or any successor.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.12<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;font-style:italic;">Consultant</font>&#8221; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (a)&#160;renders bona fide services to the Company; (b)&#160;renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#8217;s securities; and (c)&#160;is a natural person.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.13<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Designated Beneficiary</font>&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the Participant dies or becomes incapacitated. Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr244478KAvseu76"></a>11.14<font style="margin-left:36pt;"></font><a name="_9kR3WTr244478KAvseu76"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Director</font>&#8221; means a Board member.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24446DQAwpZitu3K"></a>11.15<font style="margin-left:36pt;"></font><a name="_9kR3WTr24446DQAwpZitu3K"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Disability</font>&#8221; means a permanent and total disability under Section&#160;22(e)(3) of the Code, as amended.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.16</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Dividend Equivalents</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24446BPFxxxB2j"></a>11.17<font style="margin-left:36pt;"></font><a name="_9kR3WTr24446BPFxxxB2j"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Employee</font>&#8221; means any employee of the Company or its Subsidiaries.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMON5YVt46668AcQfqvx"></a><a name="_9kMHG5YVt46669EP3sBw"></a><a name="_9kMPO5YVt46668AcQfqvx"></a>11.18<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Equity Restructuring</font>&#8221; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or<a name="_9kMON5YVt46668AcQfqvx"></a> kind of Shares (or other Company securities) or the share<a name="_9kMHG5YVt46669EP3sBw"></a> price of Common Stock (or other Company securities) and causes<a name="_9kMPO5YVt46668AcQfqvx"></a> a change in the per share value of the Common Stock underlying outstanding Awards.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.19<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr19A45CS4ewbFr2q0sUrC6"></a>11.20<font style="margin-left:36pt;"></font><a name="_9kR3WTr19A45CS4ewbFr2q0sUrC6"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Fair Market Value</font>&#8221; means, as of any date, the value of a Share determined as follows: (a)&#160;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in <font style="font-style:italic;">The Wall Street Journal</font> or another source the Administrator deems reliable; (b)&#160;if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in <font style="font-style:italic;">The Wall Street Journal </font>or another source the Administrator deems reliable; or (c) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.21<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Good Reason</font>&#8221; means (a) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#8220;good reason&#8221; is defined, &#8220;Good Reason&#8221; as defined in such agreement, and (b) if no such agreement exists, (i) a change in the Participant&#8217;s position with the Company (or its Subsidiary employing the Participant) that materially reduces the Participant&#8217;s authority, duties or responsibilities or the level of management to which he or she reports, (ii) a material diminution in the Participant&#8217;s level of compensation (including base salary, fringe benefits and target bonuses under any corporate performance-based incentive programs) or (iii) a relocation of the Participant&#8217;s place of employment by more than 50 miles, provided that such change, reduction or relocation is effected by the Company (or its Subsidiary employing the Participant) without the Participant&#8217;s consent. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt48867AROtdtyxnYmt"></a><a name="_9kMHG5YVt48867Bec5pmsx2sm1"></a>11.22<font style="margin-left:36pt;"></font><a name="_9kMHG5YVt48867AROtdtyxnYmt"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Greater Than<a name="_9kMHG5YVt48867Bec5pmsx2sm1"></a> 10% Stockholder</font>&#8221; means an individual then owning (within the meaning of Section&#160;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company, its parent or subsidiary corporation, as defined in Section&#160;424(e) and (f) of the Code, respectively.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24446FXKldp5141ZjCwtggIC8E"></a><a name="_9kMHG5YVt46669FcU60w2"></a>11.23<font style="margin-left:36pt;"></font><a name="_9kR3WTr24446FXKldp5141ZjCwtggIC8E"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Incentive Stock Option</font><a name="_9kMHG5YVt46669FcU60w2"></a>&#8221; means an Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.24<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Non-Qualified Stock Option</font>&#8221; means an Option not intended or not qualifying as an Incentive Stock Option.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24447DaS4yu0"></a>11.25<font style="margin-left:36pt;"></font><a name="_9kR3WTr24447DaS4yu0"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Option</font>&#8221; means an option to purchase Shares.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMPO5YVt46667HSNuqu"></a><a name="_9kMHzG6ZWu57778ITOvrv"></a><a name="_9kMH0H6ZWu57778ITOvrv"></a>11.26<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Other Stock or Cash Based Awards</font><a name="_9kMPO5YVt46667HSNuqu"></a>&#8221; means cash awards<a name="_9kMHzG6ZWu57778ITOvrv"></a>, awards<a name="_9kMH0H6ZWu57778ITOvrv"></a> of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.27</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Overall Share Limit</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the sum of (a) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,678,571 </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares; (b) any Shares which are subject to Prior Plan Awards as of the Effective Date which become available for issuance under the Plan pursuant to Article </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IV</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which number added to the Overall Share Limit pursuant to this clause (b) shall not exceed </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278,342</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; and (c)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an annual increase on the first day of each calendar year beginning January 1, 20</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and ending on and including January 1, 202</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, equal to the le</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sser</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the aggregate number of </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding on the final day of the immediately preceding calendar year and (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) such smaller number of Shares as is determined by the Board.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24447AYEn7zjkyrqA"></a>11.28<font style="margin-left:36pt;"></font><a name="_9kR3WTr24447AYEn7zjkyrqA"></a> &#8220;<font style="font-weight:bold;font-style:italic;">Participant</font>&#8221; means a Service Provider who has been granted an Award.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHzG6ZWu57779BdRgrwy"></a><a name="_9kMH0H6ZWu57779BdRgrwy"></a><a name="_9kMH1I6ZWu57779BdRgrwy"></a><a name="_9kMH2J6ZWu57779BdRgrwy"></a><a name="_9kMH3K6ZWu57779BdRgrwy"></a><a name="_9kMH6N6ZWu57779ESI000E5m"></a><a name="_9kR3WTr5DA47H"></a><a name="_9kMIH5YVt466689LHy0poD"></a><a name="_9kMJI5YVt466689LHy0poD"></a><a name="_9kMH4L6ZWu57779BdRgrwy"></a>11.29<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Performance Criteria</font>&#8221; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#8217; equity; total stock<a name="_9kMHzG6ZWu57779BdRgrwy"></a>holder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share<a name="_9kMH0H6ZWu57779BdRgrwy"></a>; adjusted earnings or loss per share<a name="_9kMH1I6ZWu57779BdRgrwy"></a>; price per share<a name="_9kMH2J6ZWu57779BdRgrwy"></a> or dividends per share<a name="_9kMH3K6ZWu57779BdRgrwy"></a> (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service<a name="_9kMH6N6ZWu57779ESI000E5m"></a>; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any i<a name="_9kR3WTr5DA47H"></a>ncremental increase or decrease. <a name="_9kMIH5YVt466689LHy0poD"></a>Such performance goals also may be based solely by reference to the Company&#8217;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies<a name="_9kMJI5YVt466689LHy0poD"></a> or upon comparisons of any of the indicators of performance relative to performance of other companies. The Committee may provide for exclusion of the impact of an event or occurrence which the Committee determines should appropriately be excluded, including (a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b) asset write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g) foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or repurchase of bank loans or debt securities, (j)<a name="_9kMH4L6ZWu57779BdRgrwy"></a> unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l) conversion of some or all of convertible securities to Common Stock, (m) any business interruption event (n) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o) the effect of changes in other laws or regulatory rules affecting reported results.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr244469YPhk"></a><a name="_9kR3WTr26645DWKlROfq2sGKvxxpqny2hdBRABG"></a>11.30<font style="margin-left:36pt;"></font><a name="_9kR3WTr244469YPhk"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Plan</font><a name="_9kR3WTr26645DWKlROfq2sGKvxxpqny2hdBRABG"></a>&#8221; means this Oncternal Therapeutics, Inc. 2019 Incentive Award Plan.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26645EXKl1DDHVQD66NnXyq2IEHEjl36"></a>11.31<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Prior Plan</font><a name="_9kR3WTr26645EXKl1DDHVQD66NnXyq2IEHEjl36"></a>&#8221; means the GTx, Inc. 2013 Equity Incentive Plan, as amended to date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMH1I6ZWu57778ITOvrv"></a>11.32<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;font-style:italic;">Prior Plan Award</font><a name="_9kMH1I6ZWu57778ITOvrv"></a>&#8221; means an award outstanding under the Prior Plan as of the Plan&#8217;s effective date under Section 10.3.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.33<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;font-style:italic;">Restricted Stock</font>&#8221; means Shares awarded to a Participant under Article&#160;VI subject to certain vesting conditions and other restrictions.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.34<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Restricted Stock Unit</font>&#8221; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.35<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Rule 16b-3</font>&#8221; means Rule 16b-3 promulgated under the Exchange Act.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.36<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Section&#160;409A</font>&#8221; means Section&#160;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.37<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.38<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Service Provider</font>&#8221; means an Employee, Consultant or Director.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr244468aOdotv"></a>11.39<font style="margin-left:36pt;"></font><a name="_9kR3WTr244468aOdotv"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Shares</font>&#8221; means shares of Common Stock.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.40<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Stock Appreciation Right</font>&#8221; means a stock appreciation right granted under Article&#160;V.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr24446CebrqykljtI"></a>11.41<font style="margin-left:36pt;"></font><a name="_9kR3WTr24446CebrqykljtI"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Subsidiary</font>&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMIH5YVt46668GQJ8B62A406"></a><a name="_9kMH2J6ZWu57778ITOvrv"></a><a name="_9kMH3K6ZWu57778ITOvrv"></a><a name="_9kMKJ5YVt466689LHy0poD"></a>11.42<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Substitute Awards</font><a name="_9kMIH5YVt46668GQJ8B62A406"></a>&#8221; shall mean Awards granted or Shares issued by the Company in assumption<a name="_9kMH2J6ZWu57778ITOvrv"></a> of, or in substitution or exchange for, awards<a name="_9kMH3K6ZWu57778ITOvrv"></a> previously granted, or the right or obligation to make future awards<a name="_9kMKJ5YVt466689LHy0poD"></a>, in each case by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.43<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Termination of Service</font>&#8221; means the date the Participant ceases to be a Service Provider.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;">*&#160;*&#160;*&#160;*&#160;*</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18.1
<SEQUENCE>5
<FILENAME>onct-ex10181_736.htm
<DESCRIPTION>EX-10.18.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex10181_736.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18.1</p>
<div style="border-top:Solid 0.75pt;padding-top:6pt;border-bottom:Solid 0.75pt;padding-bottom:6pt;border-left:Solid 0.75pt;padding-left:6pt;border-right:Solid 0.75pt;padding-right:6pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;margin-right:6pt;text-indent:0%;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;font-weight:bold;font-size:11pt;font-style:normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;margin-left:6pt;margin-right:6pt;text-indent:0%;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;font-weight:bold;font-size:11pt;font-style:normal;">2019 Incentive Award Plan</p></div>
<p style="margin-top:12pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0.5pt;font-weight:bold;font-size:11pt;font-style:normal;">Stock Option Grant Notice</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) have the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) of Oncternal Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company hereby grants to the participant listed below <font style="letter-spacing:-0.1pt;">(&#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:-0.1pt;">Participant</font><font style="letter-spacing:-0.1pt;">&#8221;) </font>the stock option described in this Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Option</font>&#8221;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached hereto as <font style="font-weight:bold;">Exhibit A</font> (the <font style="letter-spacing:-0.1pt;">&#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:-0.1pt;">Agreement</font><font style="letter-spacing:-0.1pt;">&#8221;)</font>, both of which are incorporated into this Grant Notice by reference.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Participant:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share:</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to the Option:</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Final Expiration Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[To be specified in individual award agreements]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:40%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Type of Option</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;width:60%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:11pt;font-family:'Times New Roman'">&#9744;</font><font style="font-family:Times New Roman;">  Incentive Stock Option</font><font style="font-size:11pt;font-family:'Times New Roman'">&#9744;</font><font style="font-family:Times New Roman;">  Non-Qualified Stock Option</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.&nbsp;&nbsp;Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.&nbsp;&nbsp;Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:32.85pt;">
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name: </p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109067876.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">STOCK OPTION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE I.<font style="text-transform:uppercase;"><br />GENERAL</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">1.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Grant of Option</font><font style="text-decoration:none;">.&nbsp;&nbsp;The </font><font style="text-decoration:none;letter-spacing:0.2pt;">Company </font><font style="text-decoration:none;">has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;</font><font style="font-weight:bold;font-style:italic;text-decoration:none;">Grant Date</font><font style="text-decoration:none;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Incorporation of Terms of Plan</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.&nbsp;&nbsp;In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE II.<font style="text-transform:uppercase;"><br />PERIOD OF EXERCISABILITY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref213842219"></a><a name="_Ref213842229"></a><font style="text-decoration:none;">2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Commencement of Exercisability</font><font style="text-decoration:none;"><a name="_Ref213842219"></a>.&nbsp;&nbsp;The Option will vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;</font><font style="font-weight:bold;font-style:italic;text-decoration:none;">Vesting Schedule</font><font style="text-decoration:none;"><a name="_Ref213842229"></a>&#8221;), except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated.&nbsp;&nbsp;The Option shall not be exercisable with respect to fractional Shares.&nbsp;&nbsp;Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise determines, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref213844326"></a><font style="text-decoration:none;">2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Duration of Exercisability</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Vesting Schedule is cumulative.&nbsp;&nbsp;Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires.&nbsp;&nbsp;The Option will be forfeited immediately upon its expiration.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref213844335"></a><font style="text-decoration:none;">2.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="letter-spacing:-0.1pt;text-decoration:underline;">Expiration of Option</font><font style="text-decoration:none;letter-spacing:-0.1pt;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Subject to Section 5.3 of the Plan, the Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The final expiration date in the Grant Notice; which shall in no event be more than ten (10) years from the Grant Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">If this Option is designated as an Incentive Stock Option and the Participant, at the time the Option was granted, was a Greater Than 10% Stockholder, the expiration of five (5) years from the Grant Date; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">Except as the Administrator may otherwise approve, the expiration of three (3) months from the date of Participant&#8217;s Termination of Service, unless Participant&#8217;s Termination of Service is for Cause or by reason of Participant&#8217;s death or Disability; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">Except as the Administrator may otherwise approve, the expiration of one (1) year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or Disability; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">Except as the Administrator may otherwise approve, the date of Participant&#8217;s Termination of Service for Cause.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109067876.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE III.</font><font style="text-transform:uppercase;"><br />EXERCISE OF OPTION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref214077937"></a><font style="text-decoration:none;">3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Person Eligible to Exercise</font><font style="text-decoration:none;">.&nbsp;&nbsp;During Participant&#8217;s lifetime, only Participant may exercise the Option, unless it has been disposed of, with the consent of the Administrator, pursuant to a domestic relations order.&nbsp;&nbsp;After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 2.3 hereof, be exercised by the Participant&#8217;s Designated Beneficiary or by any person empowered to do so under the deceased Participant&#8217;s will or under the then applicable laws of descent and distribution.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Partial Exercise</font><font style="text-decoration:none;">.&nbsp;&nbsp;Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Tax Withholding.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option.&nbsp;&nbsp;Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares.&nbsp;&nbsp;The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax liability.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE IV.<font style="text-transform:uppercase;"><br />OTHER PROVISIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Adjustments</font><font style="text-decoration:none;">.&nbsp;&nbsp;Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref214078463"></a><font style="text-decoration:none;">4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font><font style="text-decoration:none;">.&nbsp;&nbsp;Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number.&nbsp;&nbsp;Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.&nbsp;&nbsp;By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.&nbsp;&nbsp;Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Titles</font><font style="text-decoration:none;">.&nbsp;&nbsp;Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109067876.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Conformity to Securities Laws</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Participant acknowledges that the Plan, the Grant </font><font style="text-decoration:none;">Notice&nbsp;&nbsp;and</font><font style="text-decoration:none;"> this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such Applicable Laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Successors and Assigns</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.&nbsp;&nbsp;Subject to the restrictions on transfer herein set forth in the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Limitations Applicable to Section 16 Persons</font><font style="text-decoration:none;">.&nbsp;&nbsp;Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule&#160;16b&#8209;3) that are requirements for the application of such exemptive rule.&nbsp;&nbsp;To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Agreement Severable</font><font style="text-decoration:none;">.&nbsp;&nbsp;In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation on Participant&#8217;s Rights</font><font style="text-decoration:none;">.&nbsp;&nbsp;Participation in the Plan confers no rights or interests other than as herein provided.&nbsp;&nbsp;This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.&nbsp;&nbsp;Neither the Plan nor any underlying program, in and of itself, has any assets.&nbsp;&nbsp;Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Not a Contract of Employment</font><font style="text-decoration:none;">.&nbsp;&nbsp;Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Incentive Stock Options</font><font style="text-decoration:none;">.&nbsp;&nbsp;If the Option is designated as an Incentive Stock Option:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which stock options intended to qualify as &#8220;incentive stock options&#8221; under Section&#160;422 of the Code, including the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109067876.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such </font><font style="color:#000000;">stock options</font><font style="color:#000000;"> do not qualify or cease to qualify for treatment as &#8220;incentive stock options&#8221; under Section</font><font style="color:#000000;">&#160;</font><font style="color:#000000;">422 of the Code, such </font><font style="color:#000000;">stock options (including the Option) will </font><font style="color:#000000;">be treated as </font><font style="color:#000000;">n</font><font style="color:#000000;">on-</font><font style="color:#000000;">q</font><font style="color:#000000;">ualified </font><font style="color:#000000;">s</font><font style="color:#000000;">tock </font><font style="color:#000000;">o</font><font style="color:#000000;">ptions.&nbsp;&nbsp;Participant further acknowledges that the rule set forth in the preceding sentence </font><font style="color:#000000;">will</font><font style="color:#000000;"> be applied by taking the Option and other stock options into account in the order in which they were granted, as determined under Section</font><font style="color:#000000;">&#160;</font><font style="color:#000000;">422(d) of the Code.&nbsp;&nbsp;Participant </font><font style="color:#000000;">acknowledges that amendments or modifications made to the Option pursuant to the Plan that would cause the Option to become a Non-Qualified Stock Option will not materially or adversely affect Participant&#8217;s rights under the Option, and that any such amendment or modification shall not require Participant&#8217;s consent.&nbsp;&nbsp;Participant</font><font style="color:#000000;"> </font><font style="color:#000000;">also acknowledges that </font><font style="color:#000000;">if the </font><font style="color:#000000;">Option </font><font style="color:#000000;">is </font><font style="color:#000000;">exercised more than three (3) months after Participant&#8217;s Termination of Service</font><font style="color:#000000;"> as an Employee</font><font style="color:#000000;">, other than by reason of death or disability, </font><font style="color:#000000;">the Option </font><font style="color:#000000;">will be taxed as a Non-Qualified Stock Option.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">Participant will give prompt written notice to the Company of any disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a) within two (2) years from the Grant Date or (b) within one (1) year after the transfer of such Shares to Participant.&nbsp;&nbsp;Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">*&#160;*&#160;*&#160;*&#160;*</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109067876.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18.2
<SEQUENCE>6
<FILENAME>onct-ex10182_1014.htm
<DESCRIPTION>EX-10.18.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex10182_1014.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div style="border-top:Solid 0.75pt;padding-top:6pt;border-bottom:Solid 0.75pt;padding-bottom:6pt;border-left:Solid 0.75pt;padding-left:6pt;border-right:Solid 0.75pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2019 INCENTIVE AWARD PLAN</p></div>
<p style="margin-top:12pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">RESTRICTED STOCK Unit Grant Notice</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (this &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) have the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) of Oncternal Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company hereby grants to the participant listed below (&#8220;<font style="font-weight:bold;font-style:italic;">Participant</font>&#8221;) the Restricted Stock Units described in this Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">RSUs</font>&#8221;), subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement attached hereto as <font style="font-weight:bold;">Exhibit A</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;), both of which are incorporated into this Grant Notice by reference. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.35%;width:471.6pt;;">
<tr>
<td style="width:183.6pt;"></td>
<td style="width:288pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Participant:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">[Insert Participant Name]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">[Insert Grant Date]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Number of RSUs:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">[Insert Number of RSUs]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">[Insert Vesting Commencement Date]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">[Insert Vesting Schedule]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company uses an electronic capitalization table system (such as E*Trade, Shareworks or Carta) and the fields in this Grant Notice are blank or the information is otherwise provided in a different format electronically, the blank fields and other information will be deemed to come from the electronic capitalization system and is considered part of this Grant Notice.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By accepting (whether in writing, electronically or otherwise, including an acceptance through an electronic capitalization table system used by the Company) the RSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has received a copy of the prospectus for the Plan, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:13.96%;"></td>
<td style="width:36.09%;"></td>
<td style="width:14.04%;"></td>
<td style="width:35.91%;"></td>
</tr>
<tr style="height:32.85pt;">
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:24pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p></td>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:24pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name: </p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">exhibit a</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">RESTRICTED STOCK UNIT AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Article I.<br />general</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Award of RSUs</font>.<a name="OLE_LINK5"></a><a name="OLE_LINK6"></a> The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:0.2pt;">Grant Date</font><font style="letter-spacing:0.2pt;">&#8221;)</font>. Each RSU represents the right to receive one Share, as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">1.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Incorporation of Terms of Plan</font><font style="text-decoration:none;">. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">1.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Unsecured Promise</font><font style="text-decoration:none;">. The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Article II.<br />VESTING; forfeiture AND SETTLEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref275243511"></a><a name="_Ref213842219"></a><a name="_Ref213842229"></a><font style="text-decoration:none;">2.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Vesting; Forfeiture</font><font style="text-decoration:none;">.<a name="_Ref213842219"></a> The RSUs will vest according to the vesting schedule in the Grant Notice (the </font><font style="text-decoration:none;letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;font-style:italic;text-decoration:none;">Vesting Schedule</font><font style="text-decoration:none;letter-spacing:0.2pt;">&#8221;</font><font style="text-decoration:none;">), except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. Except as provided in the Grant Notice, in the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.<a name="_Ref213842229"></a> Unless and until the RSUs have vested in accordance with the Vesting Schedule set forth in the Grant Notice, Participant will have no right to any distribution with respect to such RSUs.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref411445960"></a><font style="text-decoration:none;">2.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Settlement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref292204578"></a><a name="_Ref292370224"></a>(a)<font style="margin-left:36pt;"></font>RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than ten (10) days after the applicable vesting date. Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section&#160;409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref275243834"></a>(b)<font style="margin-left:36pt;"></font>All distributions shall be made by the Company in the form of whole shares of Common Stock.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Neither the time nor form of distribution of Shares with respect to the RSUs may be changed, except as may be permitted by the Administrator in accordance with the Plan and Section 409A of the Code and the Treasury Regulations thereunder. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_Ref275244057"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">Article III.</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;"><br /></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">TAXATION AND TAX WITHHOLDING</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Tax Withholding. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the RSUs to Participant or his or her legal representative unless and until Participant or his or her legal representative will have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes required by Applicable Laws to be withheld in connection with the vesting, exercise or settlement of the RSUs, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the RSUs (the &#8220;<font style="font-weight:bold;font-style:italic;">Tax Withholding Obligation</font>&#8221;). Subject to Section 9.5 of the Plan, the Company will have the authority and the right to deduct or withhold, or require Participant to remit to the Company, an amount sufficient to satisfy any Tax Withholding Obligation, including, without limitation, the authority to deduct such amounts from other compensation payable to Participant by the Company. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Unless Participant elects to satisfy the Tax Withholding Obligation by some other means in accordance with Section 9.5 of the Plan, the Company will have the right, but not the obligation, with respect to the Tax Withholding Obligation arising as a result of the vesting, exercise or settlement of the RSUs, to treat Participant&#8217;s failure to provide timely payment in accordance with Section 9.5 of the Plan as Participant&#8217;s election to satisfy the Tax Withholding Obligation by requesting the Company to withhold a net number of vested Shares otherwise issuable pursuant to the RSUs having a then-current fair market value not exceeding the amount necessary to satisfy the Tax Withholding Obligation (provided that if Participant is subject to Section 16 of the Exchange Act, any such action by the Company will require the approval of the Administrator) in accordance with Section 9.5 of the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Participant Responsibility; No Company Liability</font><font style="text-decoration:none;">. Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any Tax Withholding Obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the tax treatment to Participant in connection with the awarding, vesting or settlement of the RSUs or the subsequent sale of Shares. The Company and its Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant&#8217;s tax liability.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Representation</font><font style="text-decoration:none;">. Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_1_119"></a>Article IV.<br />other provisions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.1</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Award Not Transferable; Other Restrictions</font><font style="text-decoration:none;">. Without limiting the generality of any other provision hereof, the Award will be subject to the restrictions on transferability set forth in Section 9.1 of the Plan. Without limiting the generality of any other provision hereof, Participant hereby expressly acknowledges that Section 10.13 (&#8220;</font><font style="font-weight:bold;font-style:italic;text-decoration:none;">Clawback Provisions</font><font style="text-decoration:none;">&#8221;) of the Plan is expressly incorporated into this Agreement and are applicable to the Shares issued pursuant to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.2</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Adjustments</font><font style="text-decoration:none;">. Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref274925246"></a><font style="text-decoration:none;">4.3</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font><font style="text-decoration:none;">.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;">Any notice will be deemed duly given when </font><font style="text-decoration:none;">actually received</font><font style="text-decoration:none;">, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of </font><font style="text-decoration:none;">a </font><font style="text-decoration:none;">facsimile </font><font style="text-decoration:none;">transmission </font><font style="text-decoration:none;">confirmation</font><font style="text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.4</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Titles</font><font style="text-decoration:none;">. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.5</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Conformity to Securities Laws</font><font style="text-decoration:none;">. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule&#160;16b&#8209;3) that are requirements for the application of such exemptive rule. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such Applicable Laws or any such exemptive rule described in the preceding sentence.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.6</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Successors and Assigns</font><font style="text-decoration:none;">. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.7</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font><font style="text-decoration:none;">. The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. This Agreement may be amended by the Company in accordance with Section 9.6 of the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.8</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Agreement Severable</font><font style="text-decoration:none;">. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.9</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation on Participant&#8217;s Rights</font><font style="text-decoration:none;">. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.10</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Rights as a Stockholder</font><font style="text-decoration:none;">. Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). Except as </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">otherwise provided herein, after such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares.</font><font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.11</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Not a Contract of Employment</font><font style="text-decoration:none;">. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.12</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font><font style="text-decoration:none;">. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law</font>. The provisions of the Plan and all Awards made thereunder, including the RSUs, shall be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding choice-of-law principles of the law of any state that would require the application of the laws of a jurisdiction other than such state.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Section 409A</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this </font>Agreement and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;<font style="font-weight:bold;font-style:italic;">Section 409A</font>&#8221;). The Administrator may, in its discretion, adopt such amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate to comply with the requirements of Section 409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the Shares issuable pursuant to the RSUs hereunder shall be distributed to Participant no later than the later of:</font> (A) the fifteenth (15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the third month following Participant&#8217;s first taxable year in which such RSUs are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the third month following first taxable year of the Company in which such RSUs are no longer subject to substantial risk of forfeiture, as determined in accordance with Section 409A and any Treasury Regulations and other guidance issued thereunder.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">*&#160;*&#160;*&#160;*&#160;*</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19.1
<SEQUENCE>7
<FILENAME>onct-ex10191_735.htm
<DESCRIPTION>EX-10.19.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex10191_735.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.19.1</p>
<div style="border-top:Solid 0.75pt;padding-top:6pt;border-bottom:Solid 0.75pt;padding-bottom:6pt;border-left:Solid 0.75pt;padding-left:6pt;border-right:Solid 0.75pt;padding-right:6pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;margin-right:6pt;text-indent:0%;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;font-weight:bold;font-size:11pt;font-style:normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:6pt;margin-right:6pt;text-indent:0%;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;font-weight:bold;font-size:11pt;font-style:normal;">2021 EMPLOYMENT INDUCEMENT Incentive Award Plan</p></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0.5pt;font-weight:bold;font-size:11pt;font-style:normal;">Stock Option Grant Notice</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) have the meanings given to them in the 2021 Employment Inducement Incentive Award Plan (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) of Oncternal Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company hereby grants to the participant listed below <font style="letter-spacing:-0.1pt;">(&#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:-0.1pt;">Participant</font><font style="letter-spacing:-0.1pt;">&#8221;) </font>the stock option described in this Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Option</font>&#8221;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached hereto as <font style="font-weight:bold;">Exhibit A</font> (the <font style="letter-spacing:-0.1pt;">&#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:-0.1pt;">Agreement</font><font style="letter-spacing:-0.1pt;">&#8221;)</font>, both of which are incorporated into this Grant Notice by reference.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:39%;"></td>
<td style="width:61%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Participant:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share:</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to the Option:</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Final Expiration Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[To be specified in individual award agreements]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Type of Option</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:11pt;font-family:'Times New Roman'">&#9746;</font><font style="font-family:Times New Roman;">  Non-Qualified Stock Option</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.&nbsp;&nbsp;Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.&nbsp;&nbsp;Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:12.69%;"></td>
<td style="width:37.31%;"></td>
<td style="width:1.28%;"></td>
<td style="width:12.82%;"></td>
<td style="width:35.9%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name: </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name: </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">STOCK OPTION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE I.<font style="text-transform:uppercase;"><br />GENERAL</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Grant of Option; Employment Inducement Award</font>.&nbsp;&nbsp;The <font style="letter-spacing:0.2pt;">Company </font>has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Date</font>&#8221;). The Option is a Non-Qualified Stock Option.&nbsp;&nbsp;The Option is intended to constitute an &#8220;employment inducement&#8221; award under Nasdaq Stock Market (&#8220;<font style="font-weight:bold;font-style:italic;">Nasdaq</font>&#8221;) Rule 5635(c)(4), and consequently is intended to be exempt from the Nasdaq rules regarding stockholder approval of stock option plans or other equity compensation arrangements.&nbsp;&nbsp;This Agreement and the terms and conditions of the Option shall be interpreted in accordance and consistent with such exemption.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Incorporation of Terms of Plan</font>.&nbsp;&nbsp;The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.&nbsp;&nbsp;In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE II.<font style="text-transform:uppercase;"><br />PERIOD OF EXERCISABILITY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref213842219"></a><a name="_Ref213842229"></a>2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Commencement of Exercisability</font>.<a name="_Ref213842219"></a>&nbsp;&nbsp;The Option will vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Vesting Schedule</font><a name="_Ref213842229"></a>&#8221;), except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated.&nbsp;&nbsp;The Option shall not be exercisable with respect to fractional Shares.&nbsp;&nbsp;Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise determines, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref213844326"></a>2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Duration of Exercisability</font>.&nbsp;&nbsp;The Vesting Schedule is cumulative.&nbsp;&nbsp;Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires.  The Option will be forfeited immediately upon its expiration.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref213844335"></a>2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Expiration of Option</font><font style="letter-spacing:-0.1pt;">.&nbsp;&nbsp;</font>Subject to Section 5.3 of the Plan, the Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The final expiration date in the Grant Notice; which shall in no event be more than ten (10) years from the Grant Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">Except as the Administrator may otherwise approve, the expiration of three (3) months from the date of Participant&#8217;s Termination of Service, unless Participant&#8217;s Termination of Service is for Cause or by reason of Participant&#8217;s death or Disability; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">Except as the Administrator may otherwise approve, the expiration of one (1) year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or Disability; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Except as the Administrator may otherwise approve, the date of Participant&#8217;s Termination of Service for Cause.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\121047186.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;"><font style="text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE III.</font><font style="text-transform:uppercase;"><br />EXERCISE OF OPTION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref214077937"></a>3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Person Eligible to Exercise</font>.&nbsp;&nbsp;During Participant&#8217;s lifetime, only Participant may exercise the Option, unless it has been disposed of, with the consent of the Administrator, pursuant to a domestic relations order.&nbsp;&nbsp;After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 2.3 hereof, be exercised by the Participant&#8217;s Designated Beneficiary or by any person empowered to do so under the deceased Participant&#8217;s will or under the then applicable laws of descent and distribution.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Partial Exercise</font>.&nbsp;&nbsp;Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tax Withholding</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option.&nbsp;&nbsp;Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares.&nbsp;&nbsp;The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax liability.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;">ARTICLE IV.<font style="text-transform:uppercase;"><br />OTHER PROVISIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Adjustments</font>.&nbsp;&nbsp;Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref214078463"></a>4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font>.&nbsp;&nbsp;Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number.&nbsp;&nbsp;Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.&nbsp;&nbsp;By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.&nbsp;&nbsp;Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Titles</font>.&nbsp;&nbsp;Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conformity to Securities Laws</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant acknowledges that the Plan</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Grant </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> this Agreement are intended to conform to the extent necessary with all </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Laws and, to the extent Applicable Laws permit, will </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be deemed amended to the extent necessary to conform to such </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Successors and Assigns</font>.&nbsp;&nbsp;The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.&nbsp;&nbsp;Subject to the restrictions on transfer herein set forth in the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitations Applicable to Section 16 Persons</font>.&nbsp;&nbsp;Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule&#160;16b&#8209;3) that are requirements for the application of such exemptive rule.&nbsp;&nbsp;To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font>.&nbsp;&nbsp;The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Agreement Severable</font>.&nbsp;&nbsp;In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation on Participant&#8217;s Rights</font>.&nbsp;&nbsp;Participation in the Plan confers no rights or interests other than as herein provided.&nbsp;&nbsp;This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.&nbsp;&nbsp;Neither the Plan nor any underlying program, in and of itself, has any assets.&nbsp;&nbsp;Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Not a Contract of Employment</font>.&nbsp;&nbsp;Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font>.&nbsp;&nbsp;The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">*&#160;*&#160;*&#160;*&#160;*</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19.3
<SEQUENCE>8
<FILENAME>onct-ex10193_738.htm
<DESCRIPTION>EX-10.19.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex10193_738.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 10.19.3</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;text-indent:0%;">AMENDMENT NO. 2 TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;">ONCTERNAL THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;">2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS AMENDMENT NO. 2 TO THE ONCTERNAL THERAPEUTICS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is made and adopted by Oncternal Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Plan (as defined below).</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:TimesNewRoman,Bold;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-family:Times New Roman;font-weight:normal;">, the Company has adopted the Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan (the &#8220;</font><font style="font-style:italic;font-family:Times New Roman;">Plan</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:TimesNewRoman,Bold;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-family:Times New Roman;font-weight:normal;">, the Company desires to amend the Plan as set forth below.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:TimesNewRoman,Bold;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-family:Times New Roman;font-weight:normal;">, the Board has approved this Amendment pursuant to resolutions adopted on December 16, 2021, effective immediately.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:TimesNewRoman,Bold;font-variant: small-caps;font-size:11pt;font-style:normal;text-transform:none;">NOW, THEREFORE<font style="font-family:Times New Roman;font-weight:normal;font-variant: normal;">, in consideration of the foregoing, the Company hereby amends the Plan as follows:</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Section 11.28 of the Plan is amended to read as follows:</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.28 &#8220;<font style="font-weight:bold;font-style:italic;">Overall Share Limit</font>&#8221; means 2,800,000 Shares.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. </font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">This Amendment is hereby incorporated in and forms a part of the Plan. All other terms of the </p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plan shall remain unchanged except as specifically modified herein. The Plan, as amended by this Amendment, is hereby ratified and confirmed.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby certify that the foregoing Amendment was duly adopted by the Board on December&#160;16, 2021.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50.22%;">
<tr>
<td style="width:3.85%;"></td>
<td style="width:46.16%;"></td>
<td style="width:0.21%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chase C. Leavitt</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Chase C. Leavitt</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Secretary</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.10
<SEQUENCE>9
<FILENAME>onct-ex2310_945.htm
<DESCRIPTION>EX-23.10
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex2310_945.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-221040, 333-204932, 333-201132, 333-197911, and 333-254985) and Form S-8 (Nos. 333-233288, 333-223742, 333-210220, 333-208744, 333-188377, 333-165507, 333-149661, 333-136527, 333-118882, 333-112576 and 333-254581) of Oncternal Therapeutics, Inc., of our report dated March 10, 2022, relating to the consolidated financial statements, which appears in this annual report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">/s/ BDO USA, LLP</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>onct-ex311_8.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex311_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, James B. Breitmeyer, certify that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Annual Report on Form 10-K of Oncternal Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 10, 2022</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>onct-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard G. Vincent, certify that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Annual Report on Form 10-K of Oncternal Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard G. Vincent</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 10, 2022</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>onct-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James B. Breitmeyer, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>13
<FILENAME>onct-ex322_9.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex322_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Richard G. Vincent, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard G. Vincent</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109979343.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ggtc45pq2o35000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" );!1(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7!ALIH84F&X1)D?* >E;/P U.[N?#&JZ?,[O;V=VRV^XYV*0/E'MW_&NFO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!AZKX2TG5]0CU&:)X=0C78MW;OLE"^F?2GZ?X8TZPO4O<2W-XB
M%$N+E_,=%.,@'MG _*MFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI'_@=%_\52V.B"V\'Q:&'V8L_L^[&=N5QG'XUXO_ ,,S-_T-8_\ !?\ _;*
M/9_^$P\,#_F8](_\#HO_ (JME65T5T8,K#(8'((KXZ^)7PZ_X5Y>V%M_:GV_
M[7$TF[R/*V8(&/O'/6OKG1O^0'I__7M'_P"@B@"[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %4+S0M(U"X6XO=*L;F9/NR36Z.R_0D
M9J_10 BJ%4*H 4#  '2J)T+2#J']H'2K$WN<_:3;IYF?][&:OT4 '48-4+;0
M](LKQKRTTJQ@NG^]-%;HKM]6 S5^B@ HHHH ^<OVE?\ D.:#_P!>TO\ Z$*^
M@-&_Y >G_P#7M'_Z"*^?_P!I7_D.:#_U[2_^A"OH#1O^0'I__7M'_P"@B@"[
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117C?Q<^+TOA>Z;0
M="V-J.P&>=N1!G^$#NV.?;- 'LE%?&,'Q4\;P7:W \17KD-NV2/N0^Q'I7T;
M\+?B5#X\TR6.X1(-4ML>=$IX=3T8?CGCM0!Z#1110 4444 %%%>9_%#5?%?A
MA(-8TO6(8M+DG2&>.2U#?9P<#?G/S<YXXH ],HJC;QW']BHCWPDN##S=^6 "
MV/O;<X]\9KG? ;>)+JSN+_7=4BNH9)72VC2V$9"JQ7>3GJ<=/\: .PHJBNM:
M6][]B74;0W62/)$R[\CJ,9Z^U<9JMUJ=C\7-&@;5ICIMW;32-:GY8T*;>3Z]
M: /0:*JV>I6.H>9]CO(+CRSM?RI VT^^*S].@A7Q#J-S'K3W1E5,V7FAEM\=
MP!TS0!M452N]9TRPF6&\U"UMY&Z++*JG]37$_&6^U'3?AW=:GI6ISV<L+QX:
M!L;PSA>OI@T >AT56MI0NFPS32  1*SNQP.G))J.RU?3=1DDCLK^UN7C^^L,
MJL5^H!H NT45RFE:E<^*=6FOK>Z>WT6PG,48CX-U(OWF)_YYC.,=R#Z4 =71
M5!M:TI()9VU*T$,3;9'\Y=J'&<$YX.*M17,$\"3PS1R0N,K(C JP]01P: ):
M*9YL?_/1?SK-U^;4AHEQ_8:Q2:DX"0;S\B,3C<WL.OX4 :M%>3:M'\4]$L%O
M)_$6D3_O$18(K8[I"Q P,^V3^%=AXFEU70K5?$%K.]Q'9Q9OK+&5FC'+-'Z.
M.2/7@<4 =314%G=P7]E#>6T@D@F0/&ZG@@]*GH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<OVE?^0YH/\
MU[2_^A"OH#1O^0'I_P#U[1_^@BOG_P#:5_Y#F@_]>TO_ *$*^@-&_P"0'I__
M %[1_P#H(H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*6V@G>)Y8D=HFWQL1
MRI]14M% !1110 4444 %1?9H/M)N?*3SRNWS,<X],U+10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M.7[2O_(<T'_KVE_]"%?0&C?\@/3_ /KVC_\ 017S_P#M*_\ (<T'_KVE_P#0
MA7T!HW_(#T__ *]H_P#T$4 7:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !141N;=6*M/&".H+BD^UVW_/Q%_W
MV* )J*8DT4I(CD1R.NU@:?0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHKQ+QA\<=7\)>)[S1I_#<#>0_R2&Y8;U(R#]WT- 'MM%?.O_#2U_\
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M* "F2S1P1-+-(L<:#+,QP *?7CWQ5U6\\2Z;K6BZ5*8],TJW\[4[E>CR9&V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>F17/> /#UYITFMZUJ4/DWFL7KW/DG!,,>3L4X[XQFM_Q-=BR\-ZA*8+F<M
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MXZOH(?&_@*^GD6&W6>:5W<\*/))YK=TO3M5U;5SKK>(-1ATN1UDM=/41;'3
MY8[,[6ZXSGGK7+?$!4F\:>$[-]%U._L+%I/MCQ6,DL81TV 9"X)^G3%3>#]4
MO?"6MWGA2\L]7N](BD!TV^%A,RHK<^4S!>BYZ]NG:@#U&O-]$_Y+EXA_Z\(/
MYM7H[,$1G() &>!D_E7D6FZ[]D^*^LZS-HVO+I]Q;1PQ3#2;@[F4G/ 3..:
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MXWZA?-I.K+8W-BMI'<2:?*L9=3DY)7@8[GB@#J)#XM\U]GB3PVJ;CM5M/D)
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MYH/_ %[2_P#H0KZ T;_D!Z?_ ->T?_H(KY__ &E?^0YH/_7M+_Z$*^@-&_Y
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M 4444 %%%% !1110 4444 ?.7[2O_(<T'_KVE_\ 0A7T!HW_ " ]/_Z]H_\
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MY;:Z= R0S,IZ$(2* /OA65T#HP96&00<@TM4-###0K /][R$SQ[5?H ****
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MT[Q3%;M<F6WO+5]]K>6[;986]CZ>W2H[;P[JQA%OJ?B6ZOK?&'3R(XC(/=D
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M2_\ H0KZ T;_ ) >G_\ 7M'_ .@BOG_]I7_D.:#_ ->TO_H0KZ T;_D!Z?\
M]>T?_H(H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UW6-"[G"CK6/Y\
M]]> 1DJHZ =AZUIW5O\ :8MF[%+;VZ6T>U!R>I]: )1P .M+110 R7_5/_NF
MOFKX.?\ ):=4^MS_ .A&OH&Z\3:!;M-!-KFF13)E6C>[C5E/H03Q7SI\)=2L
M++XOZE=7=[;06[&XVRRRJJ'+'&"3B@#ZBHJC8ZUI6J.R:?J=G=N@RRV\ZR%1
MZG!J]0 4444 ,EACF7;(H84L<:1($084=!3J* *[WD"3>4SX:K'49%4KS3TN
M"74[9/T-<WXC\1OX,\/7VI72DI A\M&Z,Y^Z ?<T >*6#+_PU$YR,?VG,/\
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M110 UXTE #H& .0",\TZBB@ HHHH **** &O&DA4NBL5.1D9P:=110 4444
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M7_T(5] :-_R ]/\ ^O:/_P!!%?/_ .TK_P AS0?^O:7_ -"%?0&C?\@/3_\
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M'7BF?&R1'^*^F,CJP\N+D'/\5?24-Q 8HP)HR2HXW"@">BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_XKM+F2WL]
M1L[!=0N-.F,ZVC,%\T%2AP2"-P#$CW Z=:Z"B@#RK5_B=J5]:SZ3I'@K6)=1
MF1HC'<H(T3(P23R#C-==\/- O/#'@72](U"82W4"'>1T7<Q8+^ ./PKIZ* "
MBBB@ HHHH **** "BBB@ HHHH ^<OVE?^0YH/_7M+_Z$*^@-&_Y >G_]>T?_
M *"*^?\ ]I7_ )#F@_\ 7M+_ .A"OH#1O^0'I_\ U[1_^@B@"[1110 4444
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MG:Q6-G#:P;O*A0(FYBQP/4GDU/0,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!#TX&:S-,UR'4)7M98WM;^+_66
MLV WU7LR^X_'%:E>=^(_'W@234CIM[JC17D#[!>6ZG-NX/\ ?QC@]0<CU!H
MY759/"E_JEU/XI\9ZII^L12-_HJR21"V] B@$,,8.1G.:]1\&W%U=>%;.6[F
MEG?YE2:92KRQAB$=@><LH4G/K64&L1=6[>(]/L+M75?LNK^0K+)Z!L@[6].<
M'G&*[%=NT;<;<<8Z8H 6BBB@ HHHH **** "BBB@ HHHH ^<OVE?^0YH/_7M
M+_Z$*^@-&_Y >G_]>T?_ *"*^?\ ]I7_ )#F@_\ 7M+_ .A"OH#1O^0'I_\
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MXC&>#3=;-_\ 8#_9XS+GG'7'M6BJJJA5  '0 4M '#?V=XEN1^]:4 _WY?\
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M7_#//A/_ )[WO_?RO6Z* .+\%?#/1O M[<W6F27#/<1^6WFMD8R#_2NTHHH
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MUVMEX,T*R VV2R,.C2G<:VXX(H0!%$B ?W5 H^KXNI_$J6] ^JXZK_$J\O\
MA7ZGE8T/QGK?-S)<)$W433;0/^ Y_I6C9_"X];Z_'TA7/\Z]'HJHY;1O>=Y/
MS9<<HP][U+R?FSF;/P'H-IAFM3.X[RL2#^'2N#^+_@WQ/XBAL=)\,:-!_9L>
M99F26*+>_0#!(Z#/YU[%6/K/BK0O#TD4>KZG!9O*"4$A/S 5UPHTZ?P12.ZG
MAZ5+X(I'QIKOA'6_#6L1:5JMH(+R4 I&)5?()P.5)%>F> OAQ\1O"/BVQU:/
M1T\@,$G7[;%AHVX.0&YQUQ[5G?%S7]*UGXE:=?:=?17-JD<0>5"<##<U[_9_
M$/PC=206L&O6DDTA"(BDY8GMTK4V.IHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$\VJ)<M"*@O+?[R99C-+EHI17D8FD^$M#T51]CT^(./^6CC>WYG./PKF_C4
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MPJYI7[/FE:5J]IJ":S>N]M*LH5E3!(.<=*]CHH **** "BBB@ HHHH ****
M"BBH;JZM[*UDN;J9(8(EW/)(V%4>YH FHKR'6/VA?"]A=26]E:7M_L;'G1JJ
MQM],D']*W?"7QC\+^+;Q;*.2:QNW^Y%=@+O/H""10!Z#1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!\Y?M*_\AS0?^O:7_P!"%?0&C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ/\ \12_\+KD_P"@"O\ X%__ &%>E_V!HW_0)L/_  &3_"C^P-&_Z!-A_P"
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MA"I0>FX$Y_(5O>$/@!IFCZ@E_KE[_:<B$,D CVQAO4\G=^E>R44 ( %4*!@
M8 %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ><?%O)3PPK#,)U>+>#T
M]LUO?$@*?AQX@W@$?89>OKM.*?X\\*_\)AX6FTU)O)N5=9[:4]$E7[I-<3J&
ME_$GQAIL7AS6K;3]/L6*K?WT$I9YD'78,8!- ':^$KIK/X<:9=W(=C#8"1Q_
M$=JY/7OQ7R3X[\06WBGQKJ6MV<4L5O=.K(DP&X815YP2.HK[42QMUTT:?Y8-
ML(O)*=BN,8_*OC7XF:58Z)\1=8T[3;=;>S@D01Q*20H,:D]23U)H Y.K>EW7
MV/4[><QQRJKC<DBY5AW!%5* <'(H ]E_LZWQF#,5N23'&%P%!.0*T["YL],8
M21V=K))ZW($@_ &M7X;?#^Q\4?#W3=5N;Z\CN9O-5MK K\LC*.,9Z =ZW9_@
MO&W^IUIU_P!^'=_45Q5L3F\UR.L[>5E^5CJHX25>*6(S&4?)0M;RNF8%S\2]
M0A78VHQ0*O 6)  /RK"N?BF>1)XAN3D?=4O_ $%=5/\ !>_'^JU.WE_WHBO]
M367/\&]> .V.PD&/[_/\J\_ZM6?\1R?S+_U5R^K_ ,S!OUT_,Y&Y^)5JY.^[
MO)N?4\_G5#_A86F][:\_)?\ &NGNOA'K:$[M&CEY_P"69!K._P"%;ZA9Y:;P
MM(P')WJQ'Z&FL-07QPD"X&PLM88B,O61E#X@Z3_%:WOX*O\ \53D^).E1N<Z
M)+*N>-TVTD?A6G_8]M8'$_@VQ;'_ #UBF_H]6(Y/#:?\?'@733_NM,O\W-:1
MA@5O'[[FBX%G'6$(R_[>_P RA'\5M C SX29R.YO6_EBN;\4^/7UF_BFTBT;
M2843#0QREMQ]<UZ!%>?#_.)O $'U2\D_E7 ?$4Z ^JVC^']*&FP-%AX0Y;+9
MZY)KJI+"2=H)7]##$<-5<'!U*E!**ZZ,X^61IIGE<Y9V+$^YIT%Q+;2>9$Q5
MBI7(]",']#7L?@W3?AMIF@PMK]A>ZGJ,J[Y28R$C_P!E0&';UK,^(NF^!+C2
M1?>%K6[L+N$@/ R?NY%/4\L2"*Z57I;*2-7E6-C%R=)V2OMT'_"?XI:1X"TN
M^M=2LKZX>XE#J;=4(  QSN85Z%_PTAX7_P"@3K'_ 'Q%_P#%UX9X>T72=3TJ
MXDO)KJ.[5]L?EX*XQW!Y_6E_X1$;V'VPLN>,1X_K4SQ-*#M)ZFV'R3'XB"J4
MJ=XOK=?YGN7_  TAX7_Z!.L?]\1?_%T?\-(>%_\ H$ZQ_P!\1?\ Q=>,6WA&
M))5=A+, >5*\&MJ6UTFV@VS>'K!,?QNLH/\ Z'BL_KM+I<[%PQCK7ERKU9Z;
M_P -(>%_^@3K'_?$7_Q='_#2'A?_ *!.L?\ ?$7_ ,77C5P/#C-S#:1<]$9O
MZDU9TZUT*[E6.*[TZ)F. )G*\_E2^MW^&#'_ *O\O\3$07SN>@>+_CYHNM>%
MK[3=.TB\^TW">6IO$3RUSU/#'D=N*\A\-IX>:XDE\1PZO-'_  )81J=WU+,,
M?A6[X\\-OHNEZ?<F:QDCG=@GV:4.>!WQTK7\"^%]3\5:(KZ3_9[O ?+DBEN=
MD@QT.-IX-:.K4Y%*,->QRPP&#6)E2JXA**7Q)7OY'*>)XO";HLGARUUVWD!^
M:.^C38!_O!B<_A7HOPY^-NF>%?"D>D:II=U)) QV26:)AU/.6RPY_G57Q3X-
MUKPOHD]_JW]FQ1@85!=;G<GL!M&:Y7X9>%+SQ7J-_;V7DF2&$.1,< @L!Z&B
M-6IRMRAJ@K8'!*O"G2KWC*]VU:W_  Y[!_PTAX7_ .@3K'_?$7_Q='_#2'A?
M_H$ZQ_WQ%_\ %UA3?![7U/-G9/@?PN/\*S)OA+K2XSH8?_<-9_6I+>#.O^PJ
M$O@Q4'^!V'_#2'A?_H$ZQ_WQ%_\ %T?\-(>%_P#H$ZQ_WQ%_\77!'X8:G =\
MGAB9AZ,IQ^AII\*?8AF?PG 0A^;S$D_7#T?7(]8O[A?ZN57\%:#])?\  .__
M .&D/"__ $"=8_[XB_\ BZCN/VD/#IMI1;Z3JHFV'R]Z1[=V.,_/TS7!^7I5
MK\LW@_2#W^=)L_\ HRL;QA+HLF@XLO#MCI\XE4B:W:0DC!ROS,1C_"KABZ<G
MRHQK\/8VA3=65FEKHSB-2U"?5=3N;^Z?=/<2-(Y]R<U5KKM TG2+K0+IKVVN
M)+Z4,+>5)PJ1''!*[3NYSW%2VGAJQCM)8KC=-<.P\N0':%'T[FG+%4HMIO4B
MAD&/KPC4C#W6KWNO\[G:_#7XV6?A+PP-&UJTOKH0N3;O;A3M0_PG<PZ'^==Q
M%^T+X?G(\K0M;?/<11X_]#KP?P7HLVL^*AI5O"DLSA@H?H"#UKW+3/@Q>, ;
M^_AMQW2%-V?QX_E14JU$^6$;A@\!@YT_:8JOR:VLE=FO%\;-(E0DZ/JD9QP)
M!%_1S6+JGQFOV5A8V<%LO:25MQ_+I78Z?\*_#5D,S137C8Y\Z3C\EQ4TOPK\
M$S$F3086SZRR?_%5GR8B?Q22]#J^M9-AOX5*51]Y.R^[_@'ANL?%#4KLLMUK
MDNUNL4#$*?P'%8%EXKT!Y2=3_M0+GK;QHQ/_ 'TPKZ,_X5#X"_Z%NV_[^2?_
M !5'_"H? 7_0MVW_ '\D_P#BJ:P<-YMLF?$>)2Y</&-->2/'=/\ B!\,K$JS
MZ#K=TXZF<1D'\-^*ZFS^/W@G3X_+L_#VI0)_=CAB4?\ H==S_P *A\!?]"W;
M?]_)/_BJ/^%0^ O^A;MO^_DG_P 571&G"'PJQY%?&XG$?QIN7JSD/^&D/"__
M $"=8_[XB_\ BZ/^&D/"_P#T"=8_[XB_^+KK_P#A4/@+_H6[;_OY)_\ %5%<
M?"KX=VEN\]QH%I%"@RSM+( !_P!]59RG#:O\=/ >O6GV75?#6H7D&<A)H8F
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M_)/_ (J@#D/^&D/"_P#T"=8_[XB_^+H_X:0\+_\ 0)UC_OB+_P"+KK_^%0^
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M? 7_ $+=M_W\D_\ BJ/^%0^ O^A;MO\ OY)_\50!R'_#2'A?_H$ZQ_WQ%_\
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M-(>%_P#H$ZQ_WQ%_\777_P#"H? 7_0MVW_?R3_XJC_A4/@+_ *%NV_[^2?\
MQ5 '(?\ #2'A?_H$ZQ_WQ%_\71_PTAX7_P"@3K'_ 'Q%_P#%UU__  J'P%_T
M+=M_W\D_^*H_X5#X"_Z%NV_[^2?_ !5 '(?\-(>%_P#H$ZQ_WQ%_\71_PTAX
M7_Z!.L?]\1?_ !==?_PJ'P%_T+=M_P!_)/\ XJC_ (5#X"_Z%NV_[^2?_%4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'SE^TK_R'-!_Z]I?_0A7T!HW
M_(#T_P#Z]H__ $$5\_\ [2O_ "'-!_Z]I?\ T(5] :-_R ]/_P"O:/\ ]!%
M%VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&I:)I>LB,:
ME86]V(SE!-&&V_3-9_\ PA'A;_H7]._\!U_PK?HH P/^$(\+?]"_IW_@.O\
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ML*F'[1.8ANW=B".U?6-S#]HM9H,[?,1DSZ9&*\)/[-<))/\ PD4G/_3 ?XT
M;G_"&?!;SM_F:;MQC9_:+X^OW\UY'\5=+\*Z;XKT^W\*"V^PO;JTH@G:4;][
M Y))YQCBO0/^&:X?^ABD_P"_ _QIR?LVPI(K_P#"12?*0?\ 4#_&@#TO3OAY
MX02TMI1X?LB_E@Y9,]O>M2+P?X:A!":!I@SUS:H?YBM:"+R;>.+.=BA<^N*D
MH STT'1X]OEZ38IMZ;;9!C]*LQV5I$28[6!,]=L8%3T4 ( %&%  '0"JNJ/?
M1Z5=/IL4<U\(F-O'*VU6?'R@GTS5ND) &2< =Z /%9/"/C[_ (1J_P!?USQC
M>6>KVX:6.")E,(5><$ 8.?\ .:L6/Q7U ?!63Q)<QQOJL<GV16V_*\G9R/H>
M:POB)XXU+X@:N?!'@V)[B!GVW4Z<"3!YY[(#W[U:^(WA*/P;\"K728V$KQ7<
M;W$HZ,Y)R?IV'TH J:BGC/POX%T[Q[_PE-Y<7<IBFNK.=5\K8Y'RA<<'D _I
M7'SZ!XYO?%<WBSP[I5ZGVE_.@N(8PPY SC/OFO3OB'(C_L[VK*P*M;6A4@]>
M4KMOAC;RVOPTT&&;_6+;#/XDD?H: /$?-^./IJW_ 'X3_P")K)UW0/BSXFMH
M[?6;#4[N&)]Z*\*C!QC/ 'K7UC10!S'P[T^[TKX?Z/8WT#07,,)62-Q@J=Q-
M=/110 4444 %(R*XPRAA[C-+10!7>PLY&W26D#-ZM&#59] T:0$/I%@P/7=;
M(<_I6C10!BR^$/#4R@/H&F$#TM4'\A7S=\5=/TK2?C':VZ6MO;:<IMFEC10J
M!<C<2![9KZKKS;QI\'-+\:^(7UB[U&Y@E>-8RD:@C"C'>@#-L;OX,:;J$-_9
MS:5#=0OOCD69LJWKC.*K_%3Q_P"%=:^'>I6.G:W:W%U)LV1(^2V&!J#_ (9O
MT+_H,WO_ 'PM'_#-^A?]!F]_[X6@"_\ L\_\D^F_Z_'_ )"O6ZYGP/X+M? V
MB/I=I<RW$;2F7?( #D]N*Z:@ HHHH **** "BBB@ HHHH **** . \9Z/XUU
M[Q'96.EZB-+\/[<W5S"Z^<3Z 'D>G%<SX%U[7-*^*>H>"[C5WUG3XHV=)I0#
M)$01P6'UYS[5ZMJ4=GJ5I<Z1-=*C7431,B2 2;2O..^<'K7BVB6X^&7QIMO#
M6E,D^FZNBEUD&98SAB/FZXX_4T :-WJFM_$3XFZEX>T_6;C2]'TI/G>TP))'
M]23[Y'X5H_##Q1K/_"4ZYX,UZ\-]/IK,8+I@ 70-MP<=>H-8_P +%,/Q@\:Q
M2?*Y;(4]3\Q-1>"T:;]HOQ,\;@K$LI?!_P!H#'YF@#W.BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<OVE?^0YH
M/_7M+_Z$*^@-&_Y >G_]>T?_ *"*^?\ ]I7_ )#F@_\ 7M+_ .A"OH#1O^0'
MI_\ U[1_^@B@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <!X$^'<_@_Q)X@U674$N5U63>L:Q%3'\
M[-R<G/WJ=XQ^',FN^(+/Q)HFJMI&N6PV^>(PZR+C&"..<''TKO:* .$\$_#H
M^&M7OM=U75'U;7+T8DNFCV!5] ,GK@?D*[NBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\2:==:QX<O].LKH
M6L]U"T2S%<[-PP3^5:M% 'B_AOX0^+/"23KHWB^UMS.09&^P[BV.G):NYM/"
M-_J/A._T3Q?JBZL;ISB:.$1&-<# '7D$$Y]ZZ^B@#QY?@SJ]W;V6CZMXOEN_
M#ME(&CLEM]C%1T7=FO78(([:WC@A4+'$H1%'8 8%244 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ' >+_AM
M+K?B*#Q)HNMSZ1K,0"^8%\Q' &.5R,''%,\+_#.33O%#>*/$6LR:SK.S9%(8
MA&D0]ASR!P/J:]"HH \Z\2_#2[N_%G_"4>&=<;1M4D79<GRO,28<#.,C!P!_
M]:M+P'\/X?!@O;J:^?4=5OWWW-W(@7<<Y( [ GGJ:[.B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G+]I7_D
M.:#_ ->TO_H0KZ T;_D!Z?\ ]>T?_H(KY_\ VE?^0YH/_7M+_P"A"OH#1O\
MD!Z?_P!>T?\ Z"* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4449'K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P" UCZ1KWB70O$FF:%XSL;>Z6=VCT_5[;^)@IX=3T8J#TH ],HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YR_:5_
MY#F@_P#7M+_Z$*^@-&_Y >G_ /7M'_Z"*^?_ -I7_D.:#_U[2_\ H0KZ T;_
M ) >G_\ 7M'_ .@B@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO'!(RV36_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ggtc45pq2o35000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000014.jpg
M_]C_X  02D9)1@ ! @$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$!&4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **\/U;]I#X,:'JFI:+JOC+[)JFCZA>:7J5J?#OBJ<VU_I]S)
M:7EN9K;0YK:;R;B&2/S;>:6"3;OBEDC*L<__ (:D^!/_ $/7_EL>,?\ YGJ
M/H"BOG__ (:D^!/_ $/7_EL>,?\ YGJ/^&I/@3_T/7_EL>,?_F>H ^@**^?_
M /AJ3X$_]#U_Y;'C'_YGJ/\ AJ3X$_\ 0]?^6QXQ_P#F>H ^@**^?_\ AJ3X
M$_\ 0]?^6QXQ_P#F>H_X:D^!/_0]?^6QXQ_^9Z@#Z HKY_\ ^&I/@3_T/7_E
ML>,?_F>H_P"&I/@3_P!#U_Y;'C'_ .9Z@#Z HKY__P"&I/@3_P!#U_Y;'C'_
M .9ZC_AJ3X$_]#U_Y;'C'_YGJ /H"BOG_P#X:D^!/_0]?^6QXQ_^9ZC_ (:D
M^!/_ $/7_EL>,?\ YGJ /H"BOG__ (:D^!/_ $/7_EL>,?\ YGJ/^&I/@3_T
M/7_EL>,?_F>H ^@**^?_ /AJ3X$_]#U_Y;'C'_YGJ/\ AJ3X$_\ 0]?^6QXQ
M_P#F>H ^@**^?_\ AJ3X$_\ 0]?^6QXQ_P#F>H_X:D^!/_0]?^6QXQ_^9Z@#
MZ HKY_\ ^&I/@3_T/7_EL>,?_F>H_P"&I/@3_P!#U_Y;'C'_ .9Z@#Z HKY_
M_P"&I/@3_P!#U_Y;'C'_ .9ZC_AJ3X$_]#U_Y;'C'_YGJ /H"BOG_P#X:D^!
M/_0]?^6QXQ_^9ZC_ (:D^!/_ $/7_EL>,?\ YGJ /H"BOG__ (:D^!/_ $/7
M_EL>,?\ YGJ/^&I/@3_T/7_EL>,?_F>H ^@**^?_ /AJ3X$_]#U_Y;'C'_YG
MJ/\ AJ3X$_\ 0]?^6QXQ_P#F>H ^@**^?_\ AJ3X$_\ 0]?^6QXQ_P#F>H_X
M:D^!/_0]?^6QXQ_^9Z@#Z HKY_\ ^&I/@3_T/7_EL>,?_F>H_P"&I/@3_P!#
MU_Y;'C'_ .9Z@#Z HKY__P"&I/@3_P!#U_Y;'C'_ .9ZC_AJ3X$_]#U_Y;'C
M'_YGJ /H"BOG_P#X:D^!/_0]?^6QXQ_^9ZC_ (:D^!/_ $/7_EL>,?\ YGJ
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M'_YGJ /H"BOG_P#X:D^!/_0]?^6QXQ_^9ZC_ (:D^!/_ $/7_EL>,?\ YGJ
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M'_YGJ /H"BOG_P#X:D^!/_0]?^6QXQ_^9ZC_ (:D^!/_ $/7_EL>,?\ YGJ
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MHH **** "BBB@ HHHH **** /T _87_YJE_W)'_NW44?L+_\U2_[DC_W;J*
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MJL%*DUJM5-K4[J.-PF(2='$T:G-M&,X\_IR-J:?DT1T445YQU!1110 4444
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M-% R>6(R>@&2< $U1MI(KV&*XL9X+ZWF94BGLIXKJ&1V *QB2!G42'/,3$2
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M<XO:4)Q<6NZ"BBBI,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<K)$LWE[R&5@>DO3#D\%'S\Q.<=>1FM71]3N+.1X1$3)=++$7 PPCF4QR%<
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MR>2.V>#C+OM!O]/4M.BE5!+%&R  "2?PP<XSBOS]5:;=E4@WY23[>?FC^?\
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MN$\*VEUK?BI;BWC::PM)-OF$-L+GJPYP>"2#G@$D=!7TC=*D5HP8!$1<Y*X
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MEVR'!R-ZG[JG<2>#ZGH>AP!Z#HH-63W3MUO=Z=O2S\W=>34=6^O9]+;]U?\
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MVW\4W,5O!)<FZM-7M[5-1BU2&2);JUNH9EG^VQ0S,S2*#7X"ZG^W#^TQXD\
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M:TWAP>)I+76KK3&UT6KWW]B?;?LT.G1ZU]@1[W^RWNQ>_98Y)_)\E2]1Z_\
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M_P"I'J5>?T %%%% !1111L!.H)P ,_+D_IC^M7$0')P,Y'7'JOKZG _&JD;
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M=AZ=7#XGAG#T*-.CFM&5/%Y91HX>C"I0RO YA3GSJ%"ER/"Y3A<4G"FZ<:&
MA5]FJ=(^1/ =[=:A8&35YY+6Y>UE@AD*EVC:0&- 4=CA%7@@# !RHS5RWO9/
MM,VG7:1PK8^8D<4,21QL)%&)P8P#*95P0Y)/)!.<@]+X_P# _BSX4>,O$GP^
M\>^';_P?XR\*Z@EAKWAO45C%WI=Q/;0ZA:@26\L]M=VUYIUY::AIM_97%S8Z
MGIUW:7^GW-S9W,,\GW#^TC^R/\./A%\'=.\7^$/%/B_7OB[\*/%'PN\'_M1:
M#J\^A/X;\!Z]\6/AK#\1/#4>A6MEIEMJT.GV=]<V'A.]DUG4;U[S5]3@6VBM
MS%<Q)U5\QP="CA<5*O&=#'5L+0PU2C)585/K=:CA\/6IRIN2=!UL5AJ4ZR<J
M:GBL.G)>U@G[.,SO*\!C\IPE;&>TK9_&M_9ZIP52C.GAJ-.HZL:]).%*G+ZS
MAZ5*=Y1K5L32A3^.Y\ FQ@O="U;5AKEK;ZAI5[:00>'9(Y%N]0LYPWVK4+:?
M)A;[(VT36[8D,?S*6P0+6E:-J.HV#W,5M8FT:1+=+W4YC'9QS*OF%0QW;Y>@
M$01G88VJ:H7][H=U=QM;:)J$DTI!,4-V%+R-C<L<<<$GRLQ)4%E.#UPN:_3[
M]A/]E1OBU<V7B;Q?I;+X0\'^(I]?CTJ\CD>UO]1-@8-/LIV($4X6Y'VNZC#,
M$ALV@<H]RE8YACJ>686OC,352IP?-::ASI.$5&G!1:<W*HERN;3O4M)\J2.7
MBGB?#<-9/BLRQ5>-/V34H4*JI2K2YJ:4*%"E2J1<ZDZL8J$JLE",JO[R?(D=
M)^R9\%-+^'^BS?$'Q/-8WOC/4=/>/1=/CM3;0Z'I%[&?,G@@N$BG6]U2%]@F
M>/<;5FV[5D1J]<\&?VL^N:F(;[2+>&ZUJ9!93VD,EZ(A(H5XY)G!3.XO&T:@
M9&[:.M?5WCGX4W9ANWL]%DNK]6+Q7MD%BE7:"L<8D&P; NU4A.8E 5  H&/+
M-*\-Z6=VF:QHLUMJ^S+&ZA$=V7"@,Z2A0W4$JZN03QGFOP/.LQK9QC:F-KU>
M93_=PA;FA1IQ?[NG%645&+U;C%-RE*35Y,_@[B;B7,^+,YQ&:YG*4Z]5J%&F
MY>YAL+#2CAJ*4(04::E*4N6$54JSG6DN>HSVS1]/30=6T"ZTQHW69I;*X&=Y
ME\Q?M D:0'ADDC8'JI+8517LNM-)<PP2W +(9D C^4!0P 7<6 ]=V<Y^4]!B
MOEOX=DZ9JU[X>U"ZGE2&X%UI,]Q(Q>)" WEDG=GRS\J9Y*L5.<DCZ-35;F:,
MP,MO((6 $FW(VD'YBI)QVSD$]>.P\6BN1N$NKTNE:S2[;:;6[;]^&DTU=+E3
MM=>:M?7KOKWO97>RW-A;21R*(E^SA"IC8#!W!MSLHZ$>HY4].>:X@M#I_GVY
M;!CR(V?DM&<E2#DEC_#N]1SVQTEYJ%]!-*OEB2!U(S&<%&^88.!RI'(QP<'C
MDUQ\\BW,R.ZXFC#,00,[<G@<]R.%]?:O8P]DEZK1:*Z26F_DVM]KV)?GOOMW
MMU\]#*N8FE4!@0""S=\EER>_3H/_ *W%<GJ%K& WRKCOP,9YR..I_$]_2NVO
M[J%H]R$8QR,@8^4=ATP"..#P>_3@;V=I2^P9!QSSCKCG_/7 ]Z]>DM$]E;_@
M]_G_ ) <1J5LB2JZK\H!!Q_"/D/&.Q/7W'& 3446#CZ9R._+=Q^)K;GA+YW
MDY[Y[%/;)S^HK,DC\ML@<8Z#@=3T]N:Z;7NUKI;3372[2MM?_/30 7[H_/\
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M9\1:1<ZA-I-MJNA:OIUQJEO(L-QIL%]I]Q;2ZA!*Q"Q36<<K7$4C$*CQJQ(
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MK;P[XSEBU1T:Y>6TT^>2ZB1%@!'Y+^(OA+KW[/\ \1]3\+BS\;R>$)[Z2Z\
M>+/&W@GQ!X&OO&/AORK::/4(M.\0Z9I<DMU8FZCL]3:TA:W2Z4.A2.>%:^C_
M  ]JEYJUGI5A=ZOKLFC:?J<>O0^'X]=U:W\.3:W' +:WUB^\/07D6CZCJ=I
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M$J+_ ,L\M@!6 K^ES_@H?<VFB?L_R7SV4=PNH^+=)T^6T,"'[9]ITS7D-N2
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M^I'J5>?UZ!\6?^2J?$O_ +*!XR_]2/4J\_H **** "BBF/T'U_H:/Z_K^OO
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M!KZM^'/Q.\/_ !"C0Z8SR:T$S+I;O@VLL9Q-+-MSO@C/*/&2LF5&5)('XZ^
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MDI5O;T<-.CS5ZF(5*GB>5*I5XJ7$4IWC3BO:.@H96ZEE.5.G"L_W:6&7WWX
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M>>:&%DC!D:1U0(1@,<,03D8X(//4"NEF\1CQ+)_9^DR"2#E9+A6P&P2"%P<
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MG6<EB\/G;GB8.FJ4\=E^.J44HT9T'B,-@*U6G>DN2*;3K?4)56;AI71#)DG
M9@-S  YQG)P"3CCGBOU]_97^"7P7M_"%EJ]O!HWCC6+F"%]0NKJ*&ZM]/U!=
MKS:>UC)&I\ZTE0+NOHY&=E-Q:I%!,@/X]Z7J+&ZA6XAQ'&R'AQN^0CEO4+C<
M<$DXQCGCTKX5ZO\ $7P;XWM;CP7J^H6^J'5(H5@L+IVM]4N+B4B"VGL]ZP7L
M$[3_ #6DRM$[R;#M<AQU<3Y7C<WRZ>%P6:3RVI2O6E*,G&EB(*-O95JL&JM*
MFG9RG"3BM>>G55N7L\0.',UXDR66 ROB&MD%6@I8J4E)PPV-IQA9X;%8BG*.
M(P]"+M.=2C*4%>]6A6BH^S_<KQIIUE;:=);6-E;6$$,3+;PV5O%:Q0LJ?*8X
MX%C1-K!3\BJ  %&5.!1=+<65J;AS]I6"$-,K%7<F)26('&2W.WD ]ZT->O3?
M:,K7GDK=/: W2P.S0I=- #-%"6 <PI*SK&S?,R!2<L:\W6_:;0[.6ZN%!B4Q
M#YB9'\IC&B@9R6("C SGT[U_-]&G)R;DVY<WO._.Y2TN[W=[[W3U[G\ UJEY
MS4I*I)WYI\W-S.^LN:[<KN[YF]4TU;2VC=S0)+C[0TIW'/.Y@,D%@54%2,\G
MICOUJ_$I6'=N+*P)5FQG&1CT_IFN;MY_/1B%6$ $?.A#\ X).1D\_KSSUV(+
MY6B%NY421+L7'\8&,8[ C@'.?;/2N^,6MK^=T[Z6].K:W:VW(ALU_7G^GWC9
MQNSD\8&!@#O[>M9$J#<<<=??N:T)YE!//!"]<8['CGT.>/7..E9[MN8X'XD<
M=?\ #Z5K%.]]4ONO_GOIYFA451DGODX]N2*C_C_X%_6IB,$@=B?YU#_'_P "
M_K6B2WM]^Z7;RMV_4":BBBF 4444 %%%% 'Z ?L+_P#-4O\ N2/_ ';J*/V%
M_P#FJ7_<D?\ NW44 ?'_ ,6?^2J?$O\ [*!XR_\ 4CU*O/Z] ^+/_)5/B7_V
M4#QE_P"I'J5>?T %%%% !36. ?R/MD4ZF.N1D#D<GMQ@]?7_ #B@"2/' ..5
M[_A^50WGEK$[2$A>!A1DDY7@ <Y/48Z=:>.P_P!GG]/_ *_^<T]T1AR 0<=<
M9(!!SC@XSG_/-0TF[;[O?JVKK3MV\^FX%BUO94AB5R6&Q?F/WP,9 SP"1G'.
M,]^:MPWIEECCE+^4[JI"N1P3@ X&2,D9YSVZ5E_08 X '8#I3D8HZN,$JP8
M].#G_/\ *FX)IZ:V]/R_03BG:^MO,]<TNUMT\O8BA<CC '&"3UY)//.3_*D\
M06]N]G.) G,;@ @]-IQG(!P<\C'.>*D\/:A8W(A"21DG:6CD*AXW )9-IYSD
MG:5.TC!YQ@=#J5I97$3X53N!+#JN=I/&1D'N.:\I\W,XM/F3U3\]==;Z]_\
MAR9)*.]DOZ_KKU[W^)=-^'VC:CXDU*Y,2)>2-)*Q3:LC$,%4$ #*C@=#GOC.
M:\3_ &C/@K=:SX>NH[.)_,CB+P.HS*DB*Q1D=<,CANCYRO7(%?</]C0VOBL7
M-LI*F#82B,4+.V3DX"9!4L>_ XQS79Z[H%MJ6ERI/$)6>/ 5T)&X@_+@C<<Y
M[8Q[#KYF+PBG6?)9U':3M:T9::.]K.RC=6[[$4L1RPU=HJ\=;6DDDM.ZU?S/
MS=_8F_:&\7>&],N_AUXST<ZI'H%Q+;+YJ&/4+-;?:BW-A-)E&AN@$-S;R#8U
MSNEC>-F?/ZF^ _B'X?\ B)?W&EV,U_:W5C:I?75C-9.DJVS'R_-#AGBD3S3Y
M;&-B5)4E1G(^'HOA_IGA7QG'=)IF)-7N&@9HX4W&39YF]GPH\M$4N[LP"*"6
M)(X^Q/@S-HGA7Q/<WT@@D:]TJYMV"R0Y5[5#=1^8Y8(L4Q0P;RP4.R%_ER:F
MA@<9.2HX52JRJUHTZ44KIU:DXQ4(O73FG:-W9JRO8SJ5:3:G.')&,>:H^67*
ME&-^:7*DEI&[U75OS^</VS?C)J6@SK\,?"%RVCVL-A;W7B"[@?9?7EU=AG2T
M>6-M\44400NF<N[,TJD-$$_(3Q!*9[EY)YY9V"L"\\KRMGG(5I&8JI/.T?+V
MP.@^K?C=K6H^-/&7B?Q7>/(9=6U:\N@&#$+;>9Y5G$ 22%AM(8(XUZHB*A8[
M:^/_ !#!<-=)! "TMU,D,84%B[RL$0* ,EF+#  .X@ #FO\ 0'P]X<P&095A
M<!AJ-&E*A0I+%5HPBIXG$\D7B,36G;FJ2G4YI)S;Y(\L(\L(QBOS#&8VKC*T
MZ]2<W[2<G3IMOEIPYERTX16D4HV6BUE>3O)W?UC^S%X@U7Q-9^)/"EWYMW9^
M&[>VU/3KZ5F9K.WOKC[*VFM(0"86F!EM8V/[O%PJ?*I"_2/B^VG\*WVDV,S.
M#J.DVNK!8V'F&&XFGBC9R,E5/D/L'4J PZ@U@?LQ>")/AI\/]?A\5:5<:=KW
MB?Q$ES<KJ%J89I-,TVQ2'3(D:10?)::XNITVDJ)&=B"6KTC78;+7_%>IZC-<
M?(S6UO;+.6/V:SLK6&W@MHD(!6.((1&J KC'49SP9SB\)+,L95PL:<\(VW3G
M2?/"K44:,95:;AHXSJ.K.\;J349?:;7%*,_:.,KPG!J,E)-2O:\KWL[[+[^B
M3,/0UN=2/EI"[*J-*5')\N%=TC$'+-@< <ECC )YK[7TSP#X;UK]ICQW\*U^
M'&C^+=+^$WP3T[3]"\&:7K'_  A5QX]^(MCX-T+QI<:CJOBW39=.NK6_UW4_
M%D'AMM0UJ6>UTN"SAGFMA#$8U^5KF'2;>(-9R>4ZH@ C5D7<% WAG=I YD(<
M%6ZCY0 !7K'CGXO^&M$^-_CSXAZ+X=\-_&.Q^+_P>T.Q\8> (_'Y\'IID_B?
MP;I/@;Q;X<UW6-%T/Q-K7AW4H8/"D]R+6?3QJ5S;:O;ZA:ZC'%+;S+^=<0PS
M+%U<)'+WBJ3J8#B&&&C0J3H26<2RR/\ 9?-5NX07LO[3<)U.:$*RI2:<U"WK
MY1/#4YUY8E4YPA/*IUO:Q]HG@H9WEKQZC!2IRG)T_9Q=.G4A*I1]O#FBF17/
M@E/$GQ3^)7PM\4? #3_@GXK;]G[Q'JWP\\&VGQEUWXHW"?%#3+75/$>CZS-K
MNFR65M-'K6C6\E@OAVX@O[: Z/\ ;?(GEU PKS.O_ OPYI_[-?P^\5^#;9[O
MXXVVH_#_ ,3_ !$D>]UF:,^!/C%JGC+1_AW&]C-JDFA6B7.HZ;HD/VK3].CO
MPT@:\>-+AMW$>'O'^B_#CQ_X0^(WP[^ /A3X+VG@^2SOE\!Z'\5?$7C<>*KK
M=>Q:C)?^)-7\*:5=Z%%JNC72Z(4ATG4TBC,EY+#>>8UHVGX(_:L\5^'/BO\
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MIQCCZ^5X64^>-2M4PWLZ5665T9J@XUJ+Q.8U:,*^7XBO45>/M'P$\)ZE\9/
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M71((DECC>8%MQ^2(J"I<9P<DC.><=>&TK0[TI))=P2)-=3/),9L"=B=V <9
M"@ *.2,<#!KO=.G2I*,FIU9-6BI7DN7E;O:]K+1\S3MIJU8B$W4J7A'E@D[R
M:TULDHO9W?:^V^IY)J7C.#2FDBO)1;QQ!8U!R5F)+(.0V,Y'(P H]*XG7M1N
M[%+GQ'#'!<$Z?+B!RVQNKQ;2G+%F^7&,L#P>F?5O'_@G3I+"\,D:*##*SL0%
MV\/E@P'R[<;B?4'/:O+HK2)-)M(;J5)_*@CCCCR&#;4V>8^<E\KR3_>R%(KH
MPZG:RA9MKD2CI:VJ;M9):-M]-%K9&DE[R3;;2NTGKTZ)7=];+7JWN[9NFW+7
M$%MJ+.TDEY;0SL#PBF:-9-B(5R@C#>6 >206/)XTQ=2*_F)\AQM8 DAE[!AW
MQ_/D =ZB1I$BQQJ%1%"JH& %48'';\.*=7KJ,=^6-[6T2\OPTT[&D8I)::VL
M_P /\OZN69+IW[!?H2>X..3[#\.N3S2=<'N1SGL<D'U].>3GU/%5ZGW @$?C
MTX)_+\*-(M66^GEK;?UM]^^]U1!42=3]/ZBI:B3J?I_450$M%%% !1110 44
M44 %%%% %:\^U?9+K[#Y7VW[-/\ 8_/SY'VKRG^S^=M^;RO-V>9MYV9QS7Y4
M?!/X*?\ !0#5?''C+4OBK\;];^'GAO5TN8IY--N?"_BZ;5)VN6-O)X1T6]BU
M.R\'6UNJD"\\FPOVMO*MEAN%=IXOT;\=?%WX8_#*XT:S\?\ CKPUX2N_$,_V
M?1;36M4M[2ZU%Q(D4DEO;,QF-K#)+%'<WS(MG;/+$MQ/$9$#>AJRNJNC*Z.H
M9'4AE96 *LK D,K @@@D$$$'%?+YMD>7<0YCE]2KF^:4:V05:M6KE^49U6R^
MG6ECJ,8PCF]'!5(8F<52C*>&BZM!\LZK3G3G*+_3N%.->(_#_AW/L/AN$^&L
M7@^/,-A</A<_XLX.P>>U\-3R3&3J5I\*XK.:%;+J=3ZS5A2S&<<-C4IT<->-
M'$4:52/\]OC7_@F?^T)HUSXS72;WPMXW\*VMY>^(;34#J<L7COQ;:I=-=G3X
M[6?3I8%\275OO\PW5U%8S7S'R9Y1($/ZC_#7]M?]E[7)? WP_P!'^(WV'Q!J
M6CZ/IVF:-XAT[7(+NVO([:*SAT36=<GTU=&CUY)(C!<1S:@AFN5+*Q,T(D^K
M_%.FKK/AGQ%H[ZC+I":KH>JZ=)JL,@BFTV.]L9[9[^*4L@BDM%D,Z2[U\MHP
M^Y=N1_/K^SA^P'X[^,DFB^)/$&K:+I7P7@\3:G=6/B&T:=?%?CG2=*U:6WM[
M[2;41K+IVGZRMNTUIJ=Y=1S"W=+BUMYXY89Q^/8SA[,?"O/\NP_A;PM#.)<:
M8RO7XCAF6.J3C@\/E]>@XXFE7=2%;"T81S*I2G6K_6:*;P]XSK^[7_KC*./>
M'OI0<"<09A])OQ,J\)0\(,LP>#X!K<.9-0P]3-L=G^ Q<:F"QF!^KXC"9KC*
M]3AW#XFA@\!_9N*<(YARU:."Y98/]7/VH_VRO!?[/&E:99:7#I_CSX@^(97B
MT7PG8:S:1K;11JK-J6O3VYNKBPL'+"&VVVSRW4Q81A8XI'7YW_8/^)6A_M _
M$[X]?$+Q_P"$M-'QB35_"5U#.UE!?:;X8\%6&EMI/AO1_#MU=1R3V5U!?V>J
M7NI7*2)-J5U<I=%8A;JB_0_Q"_8(_9I\<^%++PS8> -*\!SZ7>MJ&G>)/!=K
M;Z9XC6YD@>WD&I:M)'->ZY;RHZN\&KW%VIGB@G5EEB5J^$/&6J>,O^">OQ1A
M^'?P#\*:[X^\._$_3/#&KW<?B_26U;4]2\36%S=Z9=VOAWQ#HEC8RRMJ-NT*
M76EW<-ZNE7+K=VT4:WK-+Z?$N+XVR3B_+>)^*,5E:\.\N=*']E95A:^:XVEF
M^-PN)P.&Q#B\)1QF(J1Q.(]G&O"')3IUH.&&C+VLH_.^&^4^#'&GA+Q'X:>&
M.7\2R^D#Q#3Q-5\2\49E@N&,IQ?"N3YKEF=YA@?:PS7&Y1@,+4RW 2KSP%6M
M[;$8C!U/K&93IK#TI_MY16=I%W=7^DZ7?7UA)I5]>Z=97=YIDTBRRZ;=7-M%
M-<6$LJ )))9S.]N\B *[1EE !%:-?NL9*48R5[22DKIQ=FKJ\6DT]=4TFGHT
MF?P]4A*G4G3ER\U.<H2Y91G'FA)Q?+.#E"<;IVE"4HR5G%M-,****9 4444
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MJ;;Z676VG='XZ_LT>#?&OPR\1ZAI$-Y?6MI8W%S)I5U;R/%+'"[G_1E*D%H
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M)[65650&=$(D4C'_ "TA('RGUVXQU-?KY^Q)\9?"6O\ @R+X2ZB@TOQ7HO\
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M3E&K&49IOXHRCR-:6LN716U6][W;^4?B7X*GL[^_,D'EB:622/('ERH[%A)
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MW5:=59]C^=/ZUU/L6Q\?>!KZP2\@N[;3IO* N+"4&-HI&5=RHI W#/RY0L"
M6')K*U7QOX7M[0W=OJ5M*S#*11LTDH(&!B,#N> &X[YZY^3Z*X:>6T:;7+*;
M2;=FT[K31NVNUK]?4EQ3ZM>EO*]KIVO8Z[Q'XPU+7VDB=EALR_R1(N&D1?N>
M<_5CG+$#"Y(XX&.1))ZG/UHHKNC&,4HQ2271#44ME;\_F]W\PHHHJAA1110
M4T+@Y'3'3\J=10 4444 %%%% !1110 4444 ?B-_P5D^#^L2:GX&^.%G%-/X
M=32XOAUXJG2Z$K:1<2ZA>:EX;NQ82*H@LYY+O5()[N!Y=]VUM!<) 9K<W&9^
MR5^V9^TSK/C&/X81^&;/X]6%IX2BDT^'3;K2_"U_X<@TN.PL(-0U3Q!+:FTG
ML/FA@NX;Y7O);JZC>WN4PT;?77_!1;]H/1/A/\*9OAW>^#4\7:K\7M#\2:3I
MQU-57P]H\.GPV:SZI?;X96OKRTGO[26QL;9X)4G6.ZDNH52-9O<OV1/A_P##
M;P?\#_AYJ_@#P-;^#Y_%G@?PEJ6OW$^G+:^(M9OUT>WWW>N7<AEN[EY;B2ZN
MX(VG:TA^V2O9Q1),P/\ /$^%:V)\:LUQG"W&F(R50P&79EQED^$H*I4Q&(G2
ME0P5/_:*%3 U55P\H8B7MX8AX:>(E54)5)PC#_02EXGX3+?H;\+95XG^#V7\
M8NMGG$'#OA#Q7FF,]CA\'@*.)HXS-L1.6 QM#/<)+"XVGB,OI_4*^ _M"C@*
M.&E5I4*56I7^!/VRKW]O/QYIWAO1;+X:ZIX,\&ZU;:AINJ>'_A3XR/BO5-6O
MKXBTCM?%]]IUCIKPV<MNY^R:?:/=Z4S/)+=WLETMNEO^E_[.'A;QGX'^!7PM
M\'?$!-.B\5^&/"&E:'J4&EI"EI:Q:;%]ETVS_P!'5;>2YL]+CLK6]F@7RI[R
M&>92PDW'VRBOU7)N#HY3Q'FW$E7/L]S;%9K@\-@OJV9XG#SP>#HX=PD_JF'P
MV&PM&E*I.FIOV=.$8N53W92J2D?RWQ?XO5.*O#SA7PYPW W!'"N6<,9OF&<_
MVAPWE^/HYKFV+QT:M."S/'YEF.98S$PP]&M.FGB,37JU%##IU(0P].F%0R6U
MO++#/+!#)/;%S;S21(\L!D4I(89&4O$70E'*%2RDJV0<5-17V+2>Z3U3UUU3
MNGZII-=FKGY FUJFT[-73MHTTUIT:;375-IZ,****8@HHHH **** "BBB@ H
MHHH **** "BBB@ !(Y!P?44YG=SEW9SQRS%CP,#DD]!P/0<#BFT4 :NDZQ=Z
M/<K/;-N3/[VW<GRIE/!##^%N!AUPRD#D@8/M5AX_\.3V1^TM):SB)WD@EC9S
MN"[66.6-"LA;/R ;&(R" >!X!17/5PU*M)2FFI+[479M+H]T_5JZ6B=B7%/N
MGW5OU3.N\4:U8:G<YL820BB,7,B;&* 8(C0_,N[H68 A2RA>=U<C116T(1A%
M1BK)= A!05E?>[;W;[O[EM9=D8>NZ#::Y:R03J%=D*K* ,CA@N3U^0L2C#E<
MNI#Q22Q2?,'B?]GW5]>O[6VBGL;;3S>PO/J!2*22"W\Y1(XA$T4US)'"&D2(
M1Q++(/+:6'?YJ_7=%?9Y!QWQ%PY25#+\12E2AS/#PQ5+VZPLI.[E0?/!Q7-[
MZIS=2BI7E[.\I\WEXS)<!C:OMJM.4:CM[25*7)[51M95%9IM62YH\L[63E9*
MWU5I?CSX:Z'X?T72H-4NI='TS3;315MY]-9KR.WT_3X+5'NK<RK$UNT*[#*)
MG#R+*&C5=K-^<'C.XT'7_%>L)H-I)%HT6H2K97,NY?M$"$JMP(&R\32#YFCW
M$HVY69B&-=GXYUJ>WA32;(XGNU_?L 3B%MP$8/"X/WY5.[*F*-XWBG?'#:9I
M$BQB5MJ(/F>65MB[FP22S<L2><#).,D9SGZ_P\R2KE. QN:U:M55,Z=.5*E.
M:?[JC.LUBJB2C^\KSJS]FFOX:4W?VL;>-FF+I5,=3PM/WOJ=U4F^72<E#]U"
MR3M3C!<[=_?;CHXN]NS\-+$J3$6XB(&96FC**#DDO@[\C/3;GG&,D5JW<MKY
M"V, #PJ29'95 F<X7!3D!$'$8.2/F8X)JO>-#;6JO%=13+N*2;,AE88/*MM(
M4C[K#@X(."*Y!M;A$NS>#AL$ @D8..@__7UZ]_J<0JE1WE)M1?9IWTM=-N[M
M;R[:VMZN"DY<MKMV6J_[=[6=^ZZ==;E:98UOI"H"('(55&% &!C ' '?..H]
M:Z&WOHD$:.B.$Y#9PQ7/W2PZJ#D\\C\,5Y]J&KQ6MRRNX =F>-R?E8-SC) '
M!."#SCG'%8M]XSL[.,!6,LAX5(\$EO3CCK@>G)]:\3'X:5:*2C*3<7:U[ZI*
M]TUW>[LK['Z%D\IWI\J;NXK>_P#+>[M:ZM;7UT/H"WUS3XY(3]@@(#*26>5R
MQZ9Y< '.-H(Z@8Z\;.HW&A:O#-IEUIMIJ%G?VD]IJ%G)&MQ;W=G=QM%<65S:
MW"R0S02Q,RRQL!U&"& 8?*%EXSOY9=SV<_EYR&PV%&3C!'?I@]QZ5Z]X5\;:
M=:7$5Q>VKW_F)-%-"\C1X\U-JR(5^=G1SYA&<.4&?E+"ORCB'AV5559>S=1I
M23C&5_.VK25TFM6E?U37[7D.+J8)4:U.57VU)<U/V59QESI*46IJ:Y91=VG>
M-G9I]5OR>$?"-KX0OOAYX7LF\)>&;G2-4T6U@\-L=-N-'AU:*=;F\TR8&22&
M_6:XEN?M,SR223G,C$/7/>"/ .C?#?P7I'@?P_>7^H6^D)<[]5U+[/\ VQJE
MU>WT]_<7=]-:Q(KR-<7#".,EQ%$J*68H2;VL>(+))5CTYD+,&#LK'#L>6!],
M8Y ')Z#M4%AJDDLBLC'<""S9)7/4\>G8CT/-?EE?A1J:ER2237NM6O9JSM:R
MO?KT^5OVK <8X]X"<*F/KNEB,3''UXXB?/5KXR,)TUB:]:5ZLYN-2HFY3:E*
M;G*\K./#Z'\$[_2OB3XE\5?VUH]A\//$.A63W/@73-%2RN&\66L45JVNR3P1
MQV8F>)9C-=0D7%Y]I$%S;XMUG;E/C/\  _7OBRW@S2?!7B&#0K?0-;N?MVEZ
MA)<+926%W%%'+XBMYK:"9I/$>D627=KI]M<1F"5+Z412PS<R?2$6J^:<"2/*
M8,I9 \?.?E9<D-GYCV'?CBM/P9>V[ZCJD!E@\V0DVR+A&,*&-VPA<\RLQ=HQ
MO/\ HPD0@(QK6CPQ&=.=+$0FZ=3E4ES/1.4>;=-62M>-W%Q]UK5HPS'Q>XAR
M"NN*\-7H5,RX?P-L%!8:C*F_9T'A:52K1C%>UQ#C63EC9/ZS32]M[2+IIKP?
MQY\'OV<4\">(/!^D:5H=KK?P\\*:SJL$?AJ\LI?']I]BTV>62YUB:WD74-7>
MYN#&=375 T<C.8S]C5P%^%C\5I?B7\5? T=GGX0Z7::7X,\,7.L^#[^[2WL;
M6WGE8WLT^DPVQ%Q/)>2:=:0W230Z5:&..XN7"RRM]S^-_P!DK2]6U;QWXP\'
M^,?$?ASQAXIBU273O+OC;:59W>N&)->MKV>TA;4KO3-:LEN=/>%Y&:PCNC/"
M)Y(@K?,L&B?#/P#\-_%/A?7U\/CXW_"?6;W5- CMGD@M([6UU+2=3CAM[YTC
MT[Q/86<3WFIW&DZTLNL0J^HP0VEN462O+S/"8^-6$:N$P654%#VDI4I+V>-C
M@*ZGAJ'MJ4H8A8J6&51QI02]J])62Y8_=^%7%/ V*RO&5\!Q5QGXJ\0XG%T<
M!0PN9X/$_P!H\"XKC_*HX+BC/5E&8PQF05.%J/$M3+*6+S3%>VIY7%2JTZ==
MRC/'?35W^S1J?P]U+_A+O@+XEN]%\637C6E[:>+KFVU?09/#=]*MWJ>G1+-I
M%S>),VHP6UW'<2RSW"KYRB4L$#?='@GQ3?>$-5M=3\N*[#0K;ZK9KN2"]@?8
MTZ1[BYC994$UK(XD,,J1NP?:0?SN\'?MHVATSPO%\0?!NNV&JZ].THUC2=-D
MMO#U]X?DO1I]EXCTF'4KIM0O(9KL7%O+9P"5U^QRW$<K"1+=/7_C;\7O$OPV
MU71+'0['0[J+4M/N+J=M6MK^>1)(;D0JL1L]3L%5"IRP=)&+<A@.*WSKB[@_
M@_AW,N(<95Q%/)L/+ 4\=A<+0JUIX:KF-6%*@U@;PE3J5JE>#K2B[^ZI/6+O
M_,?'W _CAQ'Q%PUPMQ[E^$Q?$%5<0T<CXIQM;+ZN)XBP&1.CAL90J\28:=6>
M:9?D[P?L\LIXI*IA5BZRBN7$)1_5R/XQ>"9[ W$6HM:S;%+6E[93K=+($&57
M[-%<0R;6RJR+*/,QN*H,*/GCQC\0M2UZZD2PO;RWTXJRE"1"\P?A@PC9BD>W
M*%-[&0%C(Q#"-/R\_P"&J/B#_P! ?P;_ ."_6_\ YH:/^&J/B#_T!_!O_@OU
MO_YH:_+:/TE/""@[QQ6>R=[ISR:L[7MVFKVUWOIWT;\7_B6CQ-<N9X3)F^G-
MG%%I;;+V=KZ:-W:[W29]]?UY/U/4_C17P+_PU1\0?^@/X-_\%^M__-#1_P -
M4?$'_H#^#?\ P7ZW_P#-#79_Q-'X4?\ 07GG_AEK?_+/ZL_*]?\ $M?B?_T"
MY-_X=Z/_ ,K/OJOE/XY_%SQCX!\6Z=H_AZ?3X[*Y\.VFIRK=V$=U(;J;4]7M
M7*R,ZD(8K. !,8#!FS\QKS'_ (:H^(/_ $!_!O\ X+];_P#FAKR'Q_X_UGXC
M:S;:WK=MIEK=VNF0Z5''I4-U!;M;P75[=H[I=WM](9C)?2JS+*J%%C C#!F?
M\W\5OI&\.9UPC6P/ 6=\09;Q#+'8&I2Q5+"XC+9QPM.<GBH?6HU+I3BTG#[=
MK'Z'X8?1_P"(,GXJI8WCC)\BS'(8X+&4ZF&JXFAF,'BJD(K#3^K2IV;A)2:G
M]GYGZL=>" 1W!&0?8@\$>QK\6OC#X5N?"?Q%\3:5<1-'$NI326CLK*);.1MU
MK+NPH+26QAF<J"H,N0 "!7ZZ>.-=NM!T83605;J^FN-/@N&57-I,^E:E=072
MQ.525HY[2(>6YVE78E7VB-_S:^)C^(/'6FVOBSQC/'9WUMI[V-O:SI#;W]S;
MZ6S1MJ(CABB M[Z5I98A+$C"42[6:(H%_P!(_#S#8VB\5COW/U#$KZM).H_;
M/$491E"<*:BX\L54G&3E*+?->-U%GQ/@-''9=C,PS&J\.LGS.%/ 3@ZLOK<L
M;0G*IAJM*C"G-3IQC+%4ZG/4I-<\9JZ5I>#Z9"#:D'!R[E5R#N 4*0 >O S^
MOM2S64P=5B0OYAPJ@$L&[#(R"!G.>@QR1C-7O#MA*[VY:)F#NF5;@;&(+%CR
M$7!))XXS[U?U>YND,J6L\GEK*ZJT7R_NU;Y0-@! QTQW ]:_39R?,[;.6C\[
MK3TW_*^C/ZOYW%\L>5W]Z[NE&[22=K^?7I9;.W&:U$UO/ CX^T0;(Y2I#?..
M2N[/S$+A6 /48Z5W&FWK'2DMU"_O2LDI;YF^08C"]D/5F(P6! )QQ7G=U'/=
M7,,7S,S29RQ)+D^_4^^3DXYXKT*PL;B.V4^4^U0 SD$*. #EC@=,#CH..F,F
MJ@E9.2?JWHF[ZZ)-JSOI;S8DTVE/ENG'=V7,DFNNU]8IW::2Z7&7-\L40A"[
MG#,RKT&6 4NS#G    '-8Z233;S<7,JK_#'"!&A/X?3N23R2>@K7-K%'-//<
MD"*.(29P'?Y"%,<2EB&;D,3_  J"3P,5F#4([F18EMB(\XSYA,A'&#P @.,'
M !&>.:7-&UN5N22O+31WV2:L^W=;FEHM-0C=VCS3T?*W9M13TNVVG;6V_2SX
M[@Q[8P,J@P QRQ7M@]R._!%37%Q&L3#.21^7?G/?M[<GM4MUILT8;[.DLQ1%
M?Y8G<@.@8950<$9P><'E@=N!7,R>;O*2[U<'#(X*LIZ?,I (/U'3IQ2MU2;U
M;ZI]&EJG=^:T?<B,$[.[Y79]=7HUOM;;7=Z=T:=M?S*^$)X) QS@$=.^0>>Y
M'M@XKVGX.V6KWWQ"\,/X<$]GJMOJEM=FZM6:(P10N9I96="KI'&J-+-$&*20
MPR HP!4^3:1I4]U/#;6\+W%S<R)'#$BL[/(S8 "J&8@'&< ]"3Z5^HOP0^$]
MM\/="COM0@5O%&JPH]](X!>PA<!UL(^6"2_=-V48@R*L(++"9)?GN)LXP^4Y
M=4E44:F(Q,*E##T&DU5G*%I2FKN]&E&5ZC>C;C3T=1'Y[XE\8Y?PCP]BJE94
MZ^/S.AB,#EN ERR6)JU*7)4K5Z;OS83"PJ*>(YDU-RIT+J=>+7NSN\C,\CL[
ML2S.[%F8DY))))))IM%%?@A_! 4444 %%%% !3=HZXP1C]#3J* "BBB@ HHH
MH **** /T _87_YJE_W)'_NW44?L+_\ -4O^Y(_]VZB@#X_^+/\ R53XE_\
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MMGIN)+G$T@&U+9,!=PX#2N" %'=1R2 #Z5T-[?W-X"+B1=F%"QA0%55&T*,
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M*4Y_S7QYXX5\MQN+R3A3#495,'4K83%YKCJ<JD8XJE-TJL<#A5*,9JC4@_\
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MG3Y'[6<I1BH)6]]2?PM;]^9)[FN(Q.%AE^+_ +5K0PV#5":Q%?$58T84:?\
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MSE&'N\R:PI8F6.K1H^VC3<E>S;YI123E&"LHN7*^:SV5Y=+/;C4J@!QN.6;
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M53XE_P#90/&7_J1ZE7G]>@?%G_DJGQ+_ .R@>,O_ %(]2KS^@ HHHH ****
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M=5J=6C5JX>I95*%25.=M5S0:5TU9N,E9Q;:NFM'<UW): JI."K+D@XS@\X.
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MN1%!-;ZF(HXW"KD/;R36RC:'D1F"'^R'_A4WPK_Z)I\/_P#PC?#G_P K:/\
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MI\/_ /PC?#G_ ,K:/^%3?"O_ *)I\/\ _P (WPY_\K: /P_HK]P/^%3?"O\
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MGP__ /"-\.?_ "MH _#^BOW _P"%3?"O_HFGP_\ _"-\.?\ RMH_X5-\*_\
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ggtc45pq2o35000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000017.jpg
M_]C_X  02D9)1@ ! @$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $&! ,# 2(  A$! Q$!_\0
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M^VO_ ,%K/^"E'["7@CPU\4_C-_P1(_L[X6:_<_![PC-XS_X>2_ 2[_L_XO\
MQ5T/3);CX9_\([X5^%7B_P 17?\ PC7C.XUCP7_PF:Z=#X8UG^Q?^$C2YT[2
MM1M0OH'Q5_X+0?MA? 7PS\!/AS\:O^"3'BOPE^WS^UE\9_&OPW_9G_8WT/\
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M]FCPIX9N/%GP\\;_ !GB^$;>'-%^)_B_QC\5]6O_ (C^%KS0]?\ $GBO3Y?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF88O$NE6>M?!3Q=JD*6^GVWVGPU>7QN-:U2U6[]V^(WB?5?^"<7[>'_!(O\
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MF#1])_8)_P"#H#1O!/Q.A^+OPRNO@Y^QUXM\"?$31/V7M+_8F\%_$/1/$_\
MPG5[I_Q"\'_LJ^'=+T'PS\*?#_B;3/L4NA)I&A:6GB;08-,\4RVL$FLM!%_I
MJT5YE?!T:F XNP%%U:4>*LFQN4.K5E&O/"K'X#AS#3Q%:/)2IXCZKB\AKXO!
MT\)'*VZ>;XC"YC5S%X'*\1@_;6-FY9#.K3IRGD68Y=F%.5).BZKRS/\ %YK3
MIQDW4J4UB<!C*F6XN5:IBXJK%8W 4\!1Q&89?COYFO\ @FM_P2,^)OBK5?\
M@GS^W?\ MP_MU>,_VQM4_9X_9L\ ZE^QW\&XO@3\-?@+\.O@#9?$;X6>'4\G
M6AX'U'6KSXLZ_P"&=#FTO3=)\7ZRGA[6KR_T#2-9UI]1:QLK&UW/^"/\,WB+
M_@K9_P '"WQ)\/D3_#B^_:0_9N^&]C?VE]=7VE3_ !'^&/PW\::5\3+*"61!
M:?VIIFJ7ME%K5K [S:7<7$&GS*MO%9O+_2002" 2I((##&5)'4;@RY'4;E(S
MU!'%?%W["_["?P=_X)_?"KQ?\+/A#K7Q!\8M\1_C%\1OCU\3/B+\5]8\/Z]\
M1_B)\4OBCJD.H>)O$WBG5/"OA7P5X?EF6WL],T;3H=+\,Z7#;Z5I5F+A+O4'
MOM0O/8EC.?-LTQE.DL+@,1DW$6%PF#4O;RCC^(N+.&\_KU:M=QA4Q5>5+*<=
M/,,TQ;EC<9BIX*51U[U)8;Q*>"=+),#ETZJQ.*I9GPU4Q>*</8<V X>R?/*%
M&&$HIU*6 P\,PQ. CA\LPKAA,-A*^/IX>G!5)2E]I4445PG>%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?B/
M_P %_OVK?VE/V/OV#--^)'[)_P 5+'X+?%[Q5^T?\!OA-9?$C4/!/A#XA6_A
MS0OB'XGN=+UNZ;PQXX\,^,- O4,,40N&?P_?7\=I]I&E^1?O!/'^W%?BI_P7
MI_9(_:$_;1_8F\(_"+]FCX?_ /"R?B'I?[4_[//Q'OO#W_"5^"/!WD>#/ WB
MFZU+Q3K/]K>/O$GA70Y?[+LI$F_LZ'4I-5O=WEZ=8W<H,8YZU%XC$9-AY5*]
M&A7XGX2H8^MAZDJ,Z655>*,HIYO5J5EI2PU/+)8N>,JU/W%/"*M/$?N(U"G6
MEA\)G&(I4Z5;$T.'>):V!I5::K*KF5+A_,JF64X47K5KSS".&CAJ4/WM3$.E
M"C^]<#\V?B[_ ,%=?VMXO^"-@^+VG^-;;X1?\%"?V;/VQ/@[^Q5^V)%%X,^'
MVMO8?$S1_C!H?@7XB:E;>$_%/A+5_"%KH?Q=\'7MEXPT74-'\-6=C8)X@NH/
M"4]DNE12P_J)^V5_P6V_9F_8^^.OB+]FBQ^"?[9'[77QR^'_ ((L?B3\8/A_
M^Q7\ 9OC;J7P0\"ZM90:GI/B;XLWU]XI\&:-X9TZ_P!,N[+4P8=2U*>PT[4=
M+O=7ATZVU33I;K\P?^"XO_!)O]LGXX_&ZS^*G[ G@?1_'OA/]K+Q#^SQI?[;
M_P .+[QGX%\ PZ+XC_9@^)&@>+OA%^TAI=SXX\5>&;37M6@\$'Q-\,/%VD:*
M-1\02Z-;^'KNPT;6KF2>73/0OB?^SO\ \%6?V$?^"F/[?'[6W[#O['7PS_;K
M^&/_  42\&?"9Y(]3_:)^''[/WBO]GCXD?"/P5'X*TJ^\4P_$L0?\)QX0N)[
M_5M;ET#P7)+=Z]9K8PWFM^%]0TN*+5F\7B:V6O$U:-.CF.(S/BK%3PM'"KEK
M9GEW"W!^'RK+:4(SA3RGAWB/.L)G^;Y=5]I'+LNCB:F3U,7@<PQ.)QN&S>&6
M'QF*AAYRQ.$PV3<+T\#+$8J2C]5QO%G$M3-\57G*4J^/SKA[(L3E^6XRDX2S
M3-E@\+G-+#XO!K"8+%_KU)^W7\-_VA?^":OQ3_;K_8_\=1>(/#$_[-_QM^)/
MPP\3WNAF&]T7QA\/?"'B]OL'B+PMK]L_V;6?"OC#P]-8:QHFJVEQ93W%@X7^
MT-*NH+FZ_GI_X)-_'[_@H+^WU\,_@IX^UO\ X.2?V?X_C?\ %SX;?%'5-4_8
M;TO]D']@GQ%\:_ .O6^C>.O#F@:MJ.G^'O%OACXC7_\ P@=_;>'_ (N7=A=?
M#C0[/5M)T^/1-9CBT'4;G4Y/U._81_X)K?&7]CW_ ((D^,OV%_$6J^'?''[1
M/C7X(_M//KEOX<U*&W\'K\5/CSI_CK4M.\'Z%KFKPZ3$=+T>Z\1:1X>N->U/
M[+97.H6^H:LLEKI,UND'YU_\$2_V8_VS_P!B\?LI?!GXR_\ !OM^S_\ "OQ5
MX&TWQ/X.^*/_  4TTO\ :4_8?UGXUVVE:\_BS5+CQ+J/AGP!X8U[XQ>(?M]I
MJ.F> ;O1K#XGZK<W&DF.:YNO[+@DT^'M6'PO^L6?8:-2H\-/!<+4\M;Q55X2
MEC:BXN6;4L-CZOU?*:N'P^-EDU''YA55#$5\%3P&+I*C0G-1RJ5\1'*,HQ%*
MU1TL=Q1+&5*F"I4L5BL!0K\+K)\5BLL@\1FM#$XS+89MB<%EL/;4,/C*V-P>
M)4Z].FGR7PXM/^"ZGCK_ (*A?'[_ ()PR?\ !<S^SH_@1^SE\.?VA'^,/_#L
MO]CV[_X2U/'FM:'I3>#O^%?*UFV@_P!F+K!F_P"$A'CG6#>_9_+&BV9E\R*'
MP1_P41_X*%?M2?\ !2C]K;]GC2/^"FO[-/[ OCO]F/\ :4@^$/P2_P""?OQT
M_9N\$:A;?M=^ ]#U41V7BVY^.7C26P^(UMK?Q3T?9J]AHOP:_M[5_P"RM1TK
M6_#_ (:T_P /W%IKFK?KG\&_V2/VA/"G_!=[]L/]LS7_ (?_ &#]FSXI_L3_
M  :^$?@/XD?\)7X(NO[=^(?A3Q)X7O\ 7_#_ /PA]EXDN?'NE_8+33KR7^UM
M9\+:=H=UY/EV6I7,LD2/^5'_  52_8V_X*>?\%/[?7_V9/'G_!)[]D;PSXNL
M?BA;0_"#_@J[I/[4W@DS?"SX3Z5\3X-?TRYTCX4MX>M_VD5UG4O %G!HGBKP
M^VL7GA2]\2W=]KVG^&[9H-'32^3 8FO!\*SJX?ZU7G5XF6,PTX4,*H27B%7P
M>78W%XC$PCEK^J\*Y=@%@\LSKDP&899CL9F=!QQU=XO$ZXN%.2XDA[:>%HTJ
MF0QP&)IT\3BV\/7X+RW%9IAZ6'P:EF%6E5XAQ&,E7S'*_:YIEF882&745]4E
MBL"?U/?M%^,=>^'7[/GQV^(/A:XBL_$_@7X-_$_QCX<N[BV@O8+77O#'@G7-
M;TBXFL[E)+:[B@U"QMY9+:XC>"=%:*5&C=E/\M?_  0W_:X_;$_;+C_9>^-O
MQ_\ ^"^_P ^)WBCQS:?$/6_B%_P3!M/V=_V(_#?QOU.S\-+XZT6UTN?Q1X"\
M1^&OC+HYL;/2-+^*<MYIOPOTZ0Z' MI=QOHEQ/JTO],_Q<^&?C#5/V0?B=\'
M-'U&_P#B'X_U']F[QI\,]+U;5+BPTS4_'/C"[^&&I>%K'4=1NM1OH=,T^_\
M$VM217-Y<7^I16%I<7LDEU?);QO<#\K/^"&W_!+3P)^QK^P_^S!/^T!^QK\
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M=$L=::[^'.C^)=3^(NA:+9:C:W.IW=S>^%H-,_LY);;2-1U"[^S13?&W@O\
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MXD\0:?;ZOJ>E>'9M9T_3H_$VJZ9X?;4KZ#\?/V.?BC_P7).G_L_?LB_M,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRW=6":C<?%S0M6\*:A?QB'P_!+ /%GAV]M(-5T.:?[+F\OM.U^TT;A_V._\
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MS3Y>;WK6;OROI2]K;UY;JW62:6S#V<M=M//^\H?FU\MS][Z*_!K]E#_@H/\
MM$^,O&7[+EI\9-1T#4M"^*/[2_[7/[%WC[16^'+_  O^(&A?$'X4>'[GXG_!
M?QWX\^'MSJWB74OA=X[UGPAX2\1^'O'GPP7Q7XFT.&U\7^"O%NFWUG_I=J?W
MEJZ=2-1-QOI9.^CUC&2V;Z22]4UT%*+B[/K_ )M=;=@HHHK0D**** "BBB@
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M^*_AMJ/Q:^+?QBT+3OA1I-NWC?2]1=_A/_PF/A/PIH_A/Q;XF\&6NBWWB_\
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M*W.N:E96D%YJUP"21-?S7$@))#9)IW7;TU\K:]']WX!RO=O6]WI_AVU_N_\
M /\ .-^'GB'3O$?_  3H_8D_X)$Z?<:PW_!0KX>_\%K[9O'GP*NM#UJ#Q_X$
M\->&O&'Q#\0Z_P#%35%-E]DM_!6EZ3XHTW4+KQ.+Q;-K==7O;>26PTG4+R+^
M[3]O'XR?MK_!;X<^#]?_ &'?V2/#_P"V#\0M5\;QZ/XM\#>(OC#X:^#-MX9\
M%MH.LWLGBR#7O$[+9ZI.FN6FD:/_ &3;DW)CU1[P*8K64CZ^C\%>#8O%-QXX
MB\)>&8O&MU8QZ9=>,(]!TI/%-SIL*A(M/N/$"V@U::QB156.TDNVMT50JQ@
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MP_\ !/P3&LDZK!XM3<MU"[/=Z+S_ ,MW\D3S).6[=]DK]$C^J3XX?M&? /\
M9G\(7'C[]H3XR_#/X+>#;9)6/B#XE^,]!\'V%R\*;WM=.;6KZTDU6_88$.G:
M9'=W\[LL<%M)(RJ?YB?VN?\ @[ ^ F@^(++X<_\ !-GX!?$S]OWXA66K7,GB
M[4=*\+^.?!WP]T_PI96MU'/?^'+BW\+:W\0/$6HMJYL8EED\":5X:&FFZNXO
M$%U,UK;R=W\#_P#@UB_9XUGQC;_&;_@I/^TS^T-_P46^--Q)!>ZM)\0O&_BC
MPK\/7N3,;NXLVMX?$>M_$K5K!+DI'#!-\1M,T>:TB\F3PW%#)]GC_HS^!'[-
M'[/?[+_@^#P#^SK\%?AE\%/"$"1JVA_#;P;H7A.VO'B&%NM6ETFRMKK6M0;)
M:;4M7N+W4+ARTD]S([%B_=7=_@O\^^NGH'O/M'\7_D=Q\,O%.H>.?AO\/O&V
MKZ-+X<U7QAX(\*>*=3\/3_:!-H.H>(-!L-6O=&F%Y;VEWYNEW-W+8R?:K2VN
M-\!\^WAEW1K^ 'B+P3\ ?C)_P7?_ &A?"/[<?A[X;>.=$\%_L:_"*^_8]\"_
M'JS\/Z[\.[CPWK6H7,WQI\3>$O"?CA+GPEJGBZ#Q;%?6-WJ4%C<:[;Z/9:FR
MN++2'EL?Z-J^7_VEOV*_V4OVQ-,T+2?VF_@/\/?C';^%YIY_#5UXLT@OK6@&
M[,37L.C>(M/FL/$&F6=^T%NVHV%GJ<-CJ#6]NU[;SF"$I)<7:][ZJUUNM4[K
M;MY:-GX,:W\??@%\!_A!\&/V=_\ @DC\8+7X%?"3]I[_ (*5_$/]G;XB_M":
MO8:OX[\ _ GQBNAGQ-XYT'X 6'Q7:7X?R6WC!H-&T_X77/AO^U_AD9;C5+_3
M//U^_O-4MO&OBM_P4*_;O^#7PF_X* _ K0?VF--^*7Q!_8W_ &N_V*/AI\+O
MVP;KX;^ VG\<^%OVDM76Y\4_#CQYX6T331X!UG7_ (:/:'P[XIN]"@TS6;I+
MVZ@N9=(OTM9X_P"E#6OV+OV3?$7P M?V5M9_9X^$U[^SK80P1Z=\(#X-TB#P
M7ID]M<S7T&J:7IMM;PG3=?CO[BYU%?$=C+;Z_P#VC=76H'4C>7,\\G-:!_P3
M_P#V+O"OP1L_V;_#G[-_PPT;X(67B_1_'Z_#S3]$-OI%WXXT#4+34](\6ZO<
M)<?VKKGB&QO-/L&CU;6=0O[UX+*TLY9I+.VAMT"^9=5?6[;LV]4]7OLFK;:W
M/YP/VY_'G[7^F_"7_@M7^QK\5/VO?%WQ=\.?!;]G+]GWXZ^$OB%J'PV^&/@W
MQ@VF_$^:]'Q&^$5W;>#=!TC1QX"\436T5I;&.!M<T+25%A9ZE<?:=0-Y])>"
MO$O[;WB3]L;]BW]@_P"'/[>7B?PE\-4_X)H^#?VE/B'\0K/X0_!;Q!XK\<W^
MA?&B30H=)TL/X?\ [&\.37'A_4_"_@:YU#3OM=K_ ,(YX=NKF33KC7=6O-2;
M][?$_P"RI^SGXTU[XQ>)_%OP=\$^(]=_:"\":3\,?C3J&L:6+Y_B-X"T*TNK
M+1O#/B2*>1[>ZT_3+:]N([,QPPW$!:.1)Q+! \7,?!C]B+]D_P#9XUKP=XC^
M"OP,\$?#S7_A_P##76/@]X.UG0[:^.IZ%\,_$'C:\^(^M>#K6]OKZ[N)-)U+
MQUJ%]XGN5NGGN'U2ZFE$X5RE <RMLKV?1;N,5?RU3?S[G\V6H_\ !1+]NB/X
M&WW_  4IM_VK_#<%O9_MSS?L[6__  33F^&OP[;3[OX=Q?%X?#%?AL/$<8;X
MLR?'DZ,Q^(<WB$:C% -+BGFAT!=)$=B_Z@?\$H%5?VH/^"S 7'_*0C53P,<M
M\//#KL/J'=B?5BQZDD_=K?\ !/3]B%_VAE_:N;]E_P"#Q_:&74_[>'Q/_P"$
M2LAK1\2CD>+6LQC1'\9"3$Z^,7TMO$ZW06[&K"Z591[M\/?@E\)_A/KWQ-\3
M_#GP)H/A#Q!\9?&4OQ"^*.JZ/!)#=>-O&DUG#82^(]::2619M1DM((H6>)88
MR%+&/>[LP2Y)K:WR2ZQLM.UGKN[ZG\P'CC]HOXN_"#]E7_@X,_;L^&_BIO"G
M[2G@_P#;[B^ OACQHVDZ-K-YX>^&/[/NO_ _X;_#SPY%IGB&TUG238Q>&_'W
MC"1[:2T>U:^\1:AJ\,,.I7+W%>J:S^T#^WO\(?VHOVJ/V0_$'[4_QM^/>H:M
M_P $Y_!?[9/@7Q=\(OV;O@WX@^-GPY^)NH_'+PU\.=;\*_ [X26MIH'AOQAX
M;N])O]2N;;PYXWUK5;W3=*A2Z.L7>J6%_?ZQ^LFF_P#!._X<7'Q3_;;'C^P\
M)?$K]F+]M[4/A3\1O'?P$\3:'<M:Z3\;/ MI;Z1XL\3P7MM>16^H:'X]MO#'
MP]\37MI/%%J5AXT\.WM]%<R66H)!;_7-E\ ?@SIWQF/[0UC\.O#=M\;#\,K?
MX,GXDQ6L@\3?\*MM=<A\2V_@@71F,8T.+7K>#5%MQ"'-U%&[2D*% /FCVOIO
MI?:-E=KHT[][[-'X _L#_$/]OCXH?'\>!/C)\8_^"L-IX.\1_#?XFZ:NK_M(
M?\$\?V<?V>?AOX=UZ[\)WUMH'B4?$KP5XC\0:O8^*= U.:#5/">ERZ5=Z9K.
MMVUK8ZG&UE+,IUO^"5'[/<?PG_;!_P""Y7[/'@WXK_%BXU"TUG]E'0+;XY>-
MO$EOXZ^-$OC#QS^S[X[UK6?BEJWB+6].;3M8\8+XP\2ZGXKLH[O2?[$M;O[/
MI\>F#2X%MC_217E?@SX(?";X>?$#XK?%3P3X#T#PW\1/CE>^%=1^+GB[3+9X
MM8\?7W@C1Y] \)7/B"=I76XDT#1KJXT_3_+CB6*">4$,SEB!S?%I:Z2225KI
MIZI)+H^F[V/PR_X)5_LT^ _AQ^TO_P %J?V8[[5_&WQ4\#S?$/\ 9Z\)^,-?
M^,/B23QWX[^(Z?$7]F^ZU/XA:OX[\1WEM;?VUJ7C#5_%/B*_U$?8[>RA74WL
M;2UALH885^J/^"$_CGQ3XW_X)@?L[1>+-6E\07?P\N?BI\&M%\0S,SMK/@SX
M/?%OQO\ #KP-.KGAX['PCX=T;1HF3Y&CTQ2.2:^ZO%/P TC0=#_:7\3_ +/6
MD^"_A?\ M!_M$^')SK7Q3OM*O[^'4OB'H_@FZ\&?#OQ?XQLK*]MKO68/!EM)
M:&'3[&XTZ2YM+5[5;B"2=KE7?LB?LV^$?V/_ -F?X*_LS^!KF74/#WP>\":3
MX376KFWCM+OQ+K,8DO\ Q3XMOK6%Y(;74/%WBB^UGQ-?V\,CPP7FJSQ1.T:*
M2!*5T^_N_A&S?;5V/HVBBB@@**** "BBB@ HHHH **** "BBB@ HHHH ****
M "OY)_VCO^&!?CM\;_C)\7OVM/A)_P %'OVT/AW\/OB_X\L-6\1>,]8B\#_L
M=_L^_#GP;\3[KX/:_J_PM\-^#OB-\.D\3:+X&^(:7?@[5=!N;;Q'\</%)TR^
M\:OX1U#2;K1M1U3^MBOQA_X*J>/?B#\"_"'P$^%/[+WP _93U7Q?^UG^U-;0
MZKXU_:7\,PVG[/?@SXGZ/HLOQ$T7X@_$&/18]/6^^*'B77?!NF_\(3X@U&6\
MU>]\3:#;)9V^K:^=(B0*B]?-^=K:W>VO3O\ >2ZE_P $'/\ @GUH>I0^,?V=
MO#'Q7_8^^*^FP_\ %/\ Q9_9J^-WQ-\'^*M(N8F$UK++IVO>(_%'A/6K1)T0
MW>F:SX>N[34+8SV=RI@NIP_Z\^$])U30/"OAG0M;\1WWC#6M%\/Z-I.K^+=4
MM;"QU/Q3JFG:=;6=_P"(]1LM*@M=+L[[6[N&74[NUTVVMK"WN+J2&S@AMTCC
M7\N/V)]3_P""N-W\8[N+]M[QK_P3^\0?!D>"];>TL?V9)_B7)\1AXU%_HPT.
MXG7Q:HTO_A&DT\ZTNIE3]K%V^FB$;/.-?K/0$F[ZOF\[W_%A7X,?\%YOV\?V
ML_V2/@7X%^&?[$OP5^-7C_XY?M#:GK6@7GQ=^%7P4\9?&6V_9R^'.D'2+;Q5
M\0%T3PYI=YINH?$:[37H;;X;:%KE[8Z?-<V.MZW=/+_8EM9WW[ST4UH]K^1#
MU6CMYG\)7CK]G?PU\4/^"/NH^#_V%/V1?V_[CXE_L@?MO?L^_MI_'VY_:W^"
M6I?#S]HK]LOQH@\5Q?%'XB>&=-N]>\0WGCS6K/3;M[]]!TZYFO-#T33++3+1
M-?UV]GO=7[_XD?LX_'7_ (*T?$G_ (+=?M:? _X%?&OX?_#7XT_L)_"+]FK]
MFS3?CKX!U'X0^-OC5\2?AUJOP[^+'B?3] \*^*9(+N"SM]>^&"^"K;6;Z6'1
M[K4?$6FI'?JT6K1:9_;M11S/U]?E_DB>1=_7IJM$_P _5G\4/[/O@GXP?\%,
M?VOOV"IO#_[.O[0_P)\'_L(_\$KOC%^S=^T!XQ^/OPJ\2_"K1;#]H7XL? CQ
M#^SZ?ASX0N?$$%O/XPETF_U-/%3WFE6[1CP];SSWL%C/Y5M-\X_LQ?"O]I'X
MY^"/^")?_!+_ %K]E+]H_P"&?Q?_ .";O[;7B'XX_M9^._&WPOUOP_\ !GPA
M\._AE\3?%?CCP[JOASXIW:_\(OXO;XAZ7XDCL/"_]B75Q'JNJP*-/>\L+NUO
MI/[[**?-I:VVJ\GW_'9^6^MWR[:[;Z;_  V]/A7XGYF_\%)-/_X*L7NA_"5_
M^"7&N_LPZ1K\.M^*E^,D/[2MMKLUE=Z)+8Z*?!TOA2;1=.U)HI;2^BU]-;BE
MCCFFCN]+>V<K!<J?PS_X-'U\;IX%_P""GB?$A]$E\>+^W%JB^.)?#@8:')XW
M&CZ@/%SZ*"D>-$;61.VD QQL+,H&1<!1_7]7\E__  :M_P#'O_P5K_[2(>.?
M_0-7H7PR^7Y@_BCYW_+H?UH4445)04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7P_^WI^WE\.?^">?PALOCC\6OA;\?_B-
M\/7\0V'A[Q!J?P&^'-K\0YO S:M/;Z=HVL^-XKOQ'X;BT/0=8U^^TOPQINH?
M:+IKGQ#J^F:>(%^T^:GW!7X\?\%]/^43?[4W_7[^SW_ZU%\%*:U:]4)Z)OLF
M?J/\*?'Y^*GPW\$_$<^"/B!\-CXT\.Z=XA/@'XK>'4\(_$GPB=1@68Z%XV\,
MI?:FFA^(K#=Y.I::NH7BVTZL@N) -Q] HHI#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /Q%_X."=1AT__@GAJ"^(/B;_ ,*I^&%_\?\
M]GFP^-WB/2]&MM:^($GPB?XCZ9<>*HOA%!>6LUK!\4M'GMM*\8^%Y9KK2?M*
M^%[_ $N'5K2XU&$2?FW_ ,$OOB5_P3GUW]M#X*Z+\ _^"PW_  4@_:B^)UQ:
M^.D\+? 3X^^(OBQ>_"OQC%;?#/Q;-JL?B>R\3_"KPWHC-X;T&'4?$^C+=:W:
MF/7-#TR2V-Q<1Q6T_P"OG_!9G]H7XH?LY?L@:1XA^%?BGPQ\+]3^(7[0'P/^
M#/B;X^>-/"6E^.?"O[-_@?XE>+1H_B+XXZYX8URTOM&U*T\)HEK8(NHVLT45
MUKEO- AO4M:^7M>_:_L],_X*L?L+_#?]FC]IOX$_M$_"?X__  R\?^"OC3\"
MOA%HWPU\2R?#/5/A_P""_%?CG3_VEX/'?@6XUJ^\*R^,+FZM_"U[X=U75;'3
M+OP]HCVME:ZU>3VM[HH:1OR-:_:>C[*-[^Z_S7RT;_H#HHHH,PHHHH ****
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M++4KE[?Q%+#'IC6Z]5^8FFU*RO:+;\DEJS^XVOQC_;S^.'[2/C_]M?\ 9?\
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M\*^?YL****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%X;'[?\ :A:FYMQ<&+RC/$'\Q0EZ_P# /Y O!NC_ +4OQ,_X-*/@%\-OV5O
M_P 4OBM\<OC#H&C>!;>T^&TE[=^.+'PW>?M7>*-9\9ZZNH_;[2YL;*/PUH5]
MHUWJ4UVMI8P:M']L,>G+.\7ROX0^+_@C_@GG\"O^"L_@GP%^S]^U_P#L-?\
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M^'_(W?\ !:/_ +3$?M1?^B_#E?T=4WO\H_DB8?"OG^;"BBBD4%%%% !1110
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M:5=?LQ14WW\_\[_H5;\+?@%%%%(84444 %%%% !1110 4444 %%%% !1110
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M@I8>%_ =W-H%MXBUF3P-XCT6]\0:_JECI]_+I%A]G@M[I;)EU&4WB37LV?\
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MM5UV\C\H_P#@WP_Y&[_@M'_VF(_:B_\ 1?AROZ.J_F'_ .#9OQ5XI\<^'_\
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M7K5U<0ZWX;DMOAWHUC=>(/$%QH>G>(&M;C4-4U'1VM%>7P[:VFIRSJ;6*/\
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MP_)XC^"OCGP):M._C3P+XVLHK'4'@TWQ)I):TDO?)B2!%=9;VPAE>]@_"_\
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MIJ"_HS111_7W"22T04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRRZC/;6D;6FD07FGZF<KW^[SW_R];VTU#FVTWM\MM?Q7_ /[QZ_DO_X-6_\
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M  3)T3]M#3/V?_"'[/G_  2#\(_%CP_\*O%OPH\>ZMXP\3_M.:[XMT6T\%^
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MX**_\%$_V'?C?_P3U_X)=3^$/B';Z1\6? W[//Q:_:?^ NF>(-;^)?B#5)_
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MGPWNWU_\1(SNE?ZCE/!F6=I8+@CA9U%MJJV+RO%5KJV[J-ZN[M9+^>_]J_\
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M&?[07PL\4:EH/[->F>%M#7Q'?^"_CS\&];\8ZCH>CZ7H<?\ 8/A#2]4TV_\
M$5QIEH\%I8Z;9+)&8=.M&EBTVVG2RL(S#&BUXS\7?AY\4=$^(7[3.E^&?AOX
MD\;V/[36F_#"+POX@T8Z?'H/AG4?"E@NDZW;^,-0N;Q)='@:$7%W97+V<MLY
M%E TZK=7,NG_ *945MQ!X8Y5GWU^7]I9GEU3'5:$O:81X2K+#TH<.9OPIBJ5
M+ZYAL3SO&9/GF81J5J_M:M/&2HXN,FZ<H5,\E\0<RR;ZFOJ& QT,'3K1Y,3]
M9IQK5)9]E?$F&J3^JXC#\GU3-,GP3A2H^SISPL:N&E%*HI0^+_#VA-IG[57@
M#PU8&:Z'PU_9<M=(\0:HD9>V;[5XDMM+T?3KBZ8*WVJ].EW6KQ6S*KF"V-PR
MH&3=]H5S^F>%/#NCZWXC\2:9I%I9Z]XNETR;Q+JT:,;W6&T6P73-)6[F=F8Q
M:=8J8+2"/9!"))I$C$L\[R=!7U'#>1/(J6:QE.G*699UC<R4*+FZ5##NGA\!
ME]"#J*,W..68#!2Q3MR_7)8GV<IT^2<OGL^SA9Q5RZ48SC' Y3A, YU5!5*U
M=2K8S&U9*#<5"6/QF*6'5^986-#G49\T8E%%%?1GA!1110 4444 %%%% !11
M10 4444 %%%% !7Y#?\ !77X.>)_$/@C]GK]IGX8_'3X _ ?XU?L=?&<_%#X
M9:S^U)XAT_PM\"?&=QXA\,:IX7\0_#[Q?KNH75HND7WB#2Y%ET#5;63[;:W5
MC/%:SZ3+=+X@T?\ 7FOYYO\ @OIIFA:Q)_P3TT]/V>M9_;!^(DO[4GB"7P/^
MR=)&$\ ?&S3(/A1XGD\<V?C74VNHDT2[\):/]D\4>%]4FLM;L(;BQU2/7-%O
M/#<NM-"%1W7S[=M=]-?,P?\ @GKK7Q+_ &M?V_8_VNOVIOVF/V -;^*WPU_9
M[\6?"3X+?LU_L5?&CP]\6-3TWPGXB\3:!K'CCXD_$#5K7Q-XDU2ZABNDM]+T
MVQM=2U#3+5M9BN)H-#NH$.O?T;U^ /\ P3.\*/HO[1M]>-_P0K\/?\$YP?AM
MXFA_X:!TKQK\,_$%Q>%]4\.'_A7IL/"7A+0]3$/B/8=2:X^V-:QGP^BS0.TD
M3Q_O]0$M_*RMJGI;R;_S"BBB@D^,?V]/@C^TO\>_V>]3\(?LB?M)WW[+'Q\T
MCQ1X8\9^"?B*-(M]<\,ZO-X<NY9KWP#\0=,>ROKZ;P+XMM+B2VU>71XCJ=G=
M6^FWH@U2RM[W1=3_ !ST+_@BU^TE^U;XR_;D^/\ _P %,_C%\#V^//[6O[(*
M?L6>"=!_91\-^,O^%6_!CX=V>M:1XRM?&:R_$R6T\2>+?%;^/_#'ASQ,-+O&
M@L[2*'6-.36I;75K&W\/_P!+5%.[7]>G^0FDW=_=T^[8_FQ_8_\ ^"0/[8$_
M[0WP2^,/_!1WXQ_L^?$CPU^Q]^QSXK_8F_9P\*?L\Z'X[TJ^\6^#/&7A6]^'
M/B#XH?%[4_&]O:Q6/C34OAMJ5]X<N]'\+VUSH]S>SV^JQOIKZ?/'KGCW[,W_
M  0L_;)\">./V&_@9\?OVBO@'X]_8"_X)J?M ^,_VA_V<+7PEX2\:V'[1OQ.
M\0ZKXDU;Q=X!T#XPKJBCX?Z)IW@3Q'JEU?/=^%KO49-1L;N[T9[>X6:RU+1?
MZKZ*.9^6UMEY[?>_O%RK3?3S]/\ )?H?G/\ \%"?^"8'[.G_  4MTCX6:-^T
M'K_QHT&V^$.J>*=6\*R_!WXEW?P[N+B?QA:Z'::O%KS0:;J<.K0+'X>TYM/\
MR"*XT]_M?V:=$O;E)/P<_P"#23P;I'P_\$_\%0/!6@RZE-HW@W]N75O!ND2Z
MO>G4-2DTCPMI.I:3IDNHWGE0B\U*2UA1K^]\J(W<^93%'D*/Z[]1U"PTC3[[
M5=5O;73M,TRSN=0U'4+Z>*ULK"PLH7N;R]O+F9DAM[6UMXI)[B>5TBABC>21
ME121_(=_P:?^/_ OB:7_ (*NZ=X;\9>&=?O]3_;CU_Q_IUEI&M6%_=7_ (%\
M2-K\'A[QE:06\SRW'AG79K.[BTG6HE:POI+6=()G:-A33]V2[6_%@U[T7WO?
M[C^OVBCIUKYW^)/[5OP$^%7VB#Q-\0M'N=7MB$?P]X<D_P"$DUQ9F)58+BST
MG[1'ILC%6PVK3Z?" K%I5 )KR,XSW)>'\'/,,]S;+<FP,+\V+S/&X? X>Z5^
M55<34IPE-K:$6YR=DDVTCT\LR?-<[Q,<%D^6X_-,7*W+ALOPE?&5K-VYG3H0
MJ2C%/><DHQ5VVDFSZ(KYR_:P_:H^$7[%?P(\:?M(?'>\\4:7\*/AZ-(D\7ZQ
MX2\%>)_'NHZ+9ZUK-CH5MJEUH7A+3=5U9-(MM0U&T&IZHUJ+'2[9VN[Z>"W1
MI!^5'QT_X+?_  8\$75[H^B>+/A%\.&@9H)-9^,'Q T./6;9CN^8>!=$U)M2
M%P(P)((8KO5YI69$.GN=R5_-E_P5V_X+$_"K]H#]C/\ :"^%'A+]J'QS\8OB
M'XYT"T\,?V#X8^%OBCP]\$].T"]\2Z.WB!]0UO7+WX<RMJ0TN":V\.WMEX"\
M26DVJO;I<7LUK-)./@\%XH8;B#&87#<%\,\3<582OBJ%*OQ#3R^62<,87#3K
M0AB<5#.,]^I?VE]6I2E6C1R?"YA+$<G)3DG)2/L\5X>8G)L+B<1Q7GV0\.8B
MCAZU6CDL\8LWX@Q%:%*4Z&'EE>3K%_4/;U%&G*KFF(P*H<W/4BU%Q/[7_P!E
M'_@H/^R9^V?\#=&_:+^!_P 5=,NOA7K^M^(_#VF:QXW@G^'6H3ZGX4U)M*UJ
M-M#\9KH^JQ107J%(IY;58KA"LD+,C GU'4_VJ_V<=):1+GXR^!)WB.V2/2=:
MBUZ1&P#M,>AKJ+YY' 4GVK_/1_X(U?"7_@JK\>_V&?!'PX_8I_9O^$7A?X;P
M^-_B@UY^UO\ %_Q+?P6]W?:IXGD:_P!/\/:!?^)+G37/AR[\RPGNM&^&'C&Y
M:6&3SYH)X@D?]#7P _X-Y/C??/::Y^VQ_P %*/CWX]NFF6XOOA[^SS<0?##P
MP"%4O93^-M2TZYUO5+*24N';3O"/A&\6$(L-Q$Y+COS&IXK5<=C*>4X/P]P6
M6PQ-:&!Q69YEQ'F..KX6-1JA6Q. P>59;A\/7J4[3J8>GF6(A3FW".(J)*;X
M\#2\-Z>#PM3,\9QKB\?/#T9XO#9?@<BP6%I8F4(NM2H8S$9ACZM6E"HY1IUJ
MF!H3G%*<J$&W!?M=XW_X*(?LW>$M,U&[TG6/$OCS4K.%WM]#\+^&;^RN-0F
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MO[57[5/Q/^']T[W,GPK^$WA+5O@QX(O9)I@[6(TZ^T6/P%8V@@7[,MY)\/\
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M%M+^*_@?0/&]CX?U/4;6.RO[_2+;7K*]BL;J\M(HK>XFMU1Y8HHU<D(N/6O
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M&T>26'4GD;]K=4_X+L?\%E?% U";P)_P2I^!/PWM;ES'HS?%S]IA/$$^E L
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M&K&^\4>(; >+Y3K6DKKWB;3'USQQ'KOB=+>:O]69(XXE"1(D:#HB*J*/HJ@
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M.<G5;EI\#2?"7]N[5H(QJ?[2W@[1)D/S1^'_  EH]Q&ZG</FN)_ FESY ((
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"#7KQ-\+M/\/Q?&G4?^"JFH6][J^@6VE_\)=J5E??M$_$"U^(D.MWUJO\
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M6.6&5"5DC=6'!K[M_;GU/]@C]LW3OC%_P2G_ &B?CA%HGBSQS\%-.^._Q/\
M GA'Q')X9\8>$O@U\.?B!X5\7KXVUGQK=Z#K'@SP986VO:!HEU?6/B:Z@U.[
M\,S3:DFF?V-=)J8Z[]BW_@I/_P $]_VO]4U7X+_L@?M/>!_C+XH^$7AFQAU7
MPQIX\1Z;XB3PQH;6GAQ?$.GQ>*_#_AUO%^AV]U]@M-0\3>%4U?1(;N_T_P ^
M]A_M.P%P]+;>N_E;[]?O] UO\2MHNE[JU_O_  N?G8__  71_:'C1Y'_ ."%
MO_!6=$C1I'=_@I:*B(BEG9F-SA55022>@!KS'X.?\'''C#]H/P%IOQ0^"/\
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M_;V_Z0!_\% /_!OH?_S'4?\ #ZO]O;_I '_P4 _\&^A__,=7]&5%*Z[+\?\
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M% /_  ;Z'_\ ,=1_P^K_ &]O^D ?_!0#_P &^A__ #'5_1E12NNR_'_,+/\
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M/^;KT2\ON>_X'\YO_#ZO]O;_ *0!_P#!0#_P;Z'_ /,=1_P^K_;V_P"D ?\
MP4 _\&^A_P#S'5_1E11==E^/^86?\S^Y?Y>O]+7^<W_A]7^WM_T@#_X* ?\
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M)IEKHNC:1H]E)+-9:3IEAIEI-/*)IY;6PM(K6WDFF55665XHD:25542.2X4
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M_%_Q%J<UI NC:/H6D6E[I\QO9I?LO_@V.^-7@WXH?\$B/V<?!/AFU\66^L?
MRU\4_#WQI-XB\):WX=TF\U[4?&_BGQM!-X0U?4[:&P\7Z*FD>)=/AGUK0YKJ
MQM]5COM+G>.\LYXE_>WQ-X<T;QAX;\0>$?$5G_:'A_Q3HFK>'-=L#/<6POM&
MUNPN-,U.S-S:2P7=O]ILKJ>'S[6>&XBW^9#+'(JNOF/[._[/7PA_92^"_@/]
MGOX">$4\"?"+X9Z=>Z3X*\)IJ^NZ\NC6&HZQJ6OWL/\ ;'B;4]9UV^-QJ^KZ
MA>-+J.IW<JM<F-'6%(HTJZM:SZ=?6[V\_P NVLV?->_?]++?^OGI[37X8?\
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M &-HGCB+P]?Z=<>)_!C7.IF_U+PG?W)TC5KVQTU]1@N(K00O]1T$9!!Z'@T
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M'^+-GI&BV]GH4<NL_P!M7&E7EUHEI;:=?SZ*UX8DOYK]5_;>O.OA+\(OA?\
M ;X<^%/A%\&/ 7A;X8_#+P-IB:/X2\#^#-'M-"\.Z%IZRRW$D5EI]E''$)KJ
M[GN+[4+R7S+S4M1N;K4;^XN;ZZN+B3T6D]WT!;*_8****!G^<)\*/'G[2_[-
MW[(W_!6[]I(?M/\ P1TB;]G'_@J'\0=4^,'[ 7QJ^!/PD^(FG?M1>)?%'Q:\
M":;J%W\6M:\>VU]\0V74I)8Y/A*G@Z*RCT35/A_XHUG3KP:G?3ZMHG^BAX#U
MR3Q/X&\&>)9M$N/#,OB'PIX=UR7PY=H([KP_)JVCV=^^B7,8CB$=QI37!L)D
M$4862!E$: ;1\9?$?_@EO_P3T^+W[0^F?M7_ !,_9'^#?C/]H+2M1T?68OB/
MK/AQIKZ_UOP\MLNA:YXAT6.ZB\,>*M<T=;*Q73=:\3:)JVJ62V&GK;W<8L;0
M0_?%-M.W?KIY)?I^),4UN[_\.];=/EH%%%%(H**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /P C_X+Q^$-'_8L_X*&_M4?$#]GO5/!OCG_@GS^TQX
MG_9>\3_ EOB5%J&I?$/QM8>*?"7@SPA>:3XM?P'I[Z);^,O$'B2]A6R?PGK5
MSI%KX>U&Z\S4U95CAMO^"]?@O7OV%_V"_P!KOP5^SUJOBCQU^W?^U'X:_9/\
M+_L_)\3K+3]6\#>/]3\9>,?!OB.[U?QA+X(F.JZ=X9NO"EM=ML\(Z6+N'Q+H
MBW<^DK*TI_"K]J?]G+XL7O\ P<4ZU^PCH/AZ\E_9G_;=_:K_ &.?^"B7Q)*Z
M5*^FW&B?LW_#WXF^(_B#I%_>I:M9'2_&OC73O&BZD;N5-VJVGAZ$1374J3/=
M_9;_ &<_BM8_\'$-K^P9K7AJ\A_9D_8T_:\_:X_X*4^ ;@V=VNF16'[1/PR^
M&FM?#G0K29;6+3O[-\">-=1\*C1FCG:X74K_ ,36\P<VP5KLO312]59:;Z7=
M_,S3EU[\MU;>_P#D?VZWOQZ^!FF_$ZS^"6H_&?X3V'QFU&TCO]/^$=[\1?!]
MK\3KZQE@^U17MGX!GUB/Q5=6DML1<1W$&DO"\'[U7,?S4>.?CU\#/AAXH\+>
M"/B5\9_A/\//&GCIUB\$^$/'/Q%\'^$O%'C&1IVM5C\+:!K^L:?JOB%VN5:W
M5-)M+MC.K0@&0%1_FTZA\/)M9U+]I7X!_M*?%?X.?!C_ (*'^+O^"D.K^(M*
MUA_V&OV@OC;_ ,%-&\8R_$+2-=^&GQ'^"'QH\*_$?0-"G^!FHVFG73:99Z)I
M5QI-IHDU[=VMK?ZCK7@N\E^C?^"AOAK2='_;O_X*[^%?V\?''[-O@KQ;\9M.
M^%>F?L]^*/VA_P!C;XU_M'_&CQC\)9O QT#PS?\ [ ?B;P3\0/"GAGP!XL\.
M:_<Z.NM:3%*\C>+8%.J2C2?#WC.TB7+Y]NE]^7MOOT_4.?2]NJZ_UV_KK_:?
MXL_X* :=X3_X*:^ _P#@G->?#5R?&G[(WB3]JV?XTS^-+:RTW0[+PYX\UCP5
M/X0N/!TOA]WG#II$FKS>)'\56<%K%,MN=)E$4ER/I[6_VH?V9_#/P_M_BQXC
M_:)^!?A_X67>JRZ#:_$O6_BWX TKX?W.N0220SZ-;^,K_P 06_AV;589H98I
M=.CU)KR.2*1'A5D8#^%G_@H1^Q]^W3\=/VH/V0_V=?@'\:/%E[\;+3_@W[M]
M)^(WB_Q=X-\8?#WQO^T-X-\*^-O&FH:W\%]=TS4AJ'B3P+\2/C EGX:\,>)]
M,\1:[9:G#=W&L:;XJU58-1U"WN_3?VQ/%_[&7QY_9=_X(Z?M _!?Q7X-_8+T
MOX8>#OC-\/?!?P\_:+_9.'QX_8!^'7Q-@TC1- ^*OP<_:,'B32/$)^'_ ,2?
M^$FT:Z?P3\0O$W@;Q/XD\?6.K1>/3)8ZH_\ PDUD.*TL]TNE[:7UMKKZ=^P^
M9W=UV>NF]M-;+2_7NC^ZGPAXS\'_ !"\-:1XS\ ^*_#?CCP?K]M]MT'Q7X0U
MW2_$OAK6[/S'A^UZ1KNBW5[I>I6WFQ21>?9W4T7F1NF_<C =)7\^7_!N)\1K
M[Q[^QO\ %VTB_9V^"?P2\)^$_P!J/XGZ)X2\<_LS:/\ $;PO^SG^TG MKH']
MK?&[X-^$_B>PU[0O"&MZC"VGV46C6ND^#9(K"&'P_P"'_#<MIJ>@:;_0;4M6
MT*3ND^Z"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YE_\%5?^"@V
MK?\ !-+X > _VBU^$]I\5?!&H?'SX8?"KXH"?Q=-X1F^'_@CXA7.IV%S\1;:
M:/P]X@BUA]$U.UTW3QHEP-+CO9M8M\ZI;"-MWZ:5^77_  6J_9WF_:D_X)7_
M +;?PBT_26UOQ#/\$/$7CSP?IL-LUU>WGC+X22VGQ4\,66FPQI),^H:EJ_@Z
MVTNU2!'FE>^,"*YEV,U:ZOM?7T$[V=M_O/E?]HC_ (+E>#_@-_P5R^ ?_!,0
M?"%/$WA_XJCX7:!XV^/B>-WL;7X=_$?XUV7BJ^^&/@O_ (16/PO?V6K3>(;?
M3?"ES#/<^*]'GN+/Q//<65G<)H\OVGZ7_9G_ ."G&@_'?]H+_@I-X#\6^%O!
M_P 'O@#_ ,$\_B3X7^%.J_M"^+_B78V.B>,/%<VEZQ<_$/\ MNVUG2-#T+P-
MIW@'5-)33+BZNO%&J+>G4["60V4CF"OY)_@]^SO^T?\ M*_\$=OVW_\ @J=X
M]\%ZI!^V:/VK?V;/VF/A39W7AK64\0GPM_P3ST3P;X!T1M/L[RW775CF\/:E
M\55$%I&RWEQHMG*L4I6'RZOCC]F_]ISQ7_P0>^%7[36I>!M>2X_:;_X*U:Q^
MWY^W'X2'PP\0?$ZZ@^$&N>.?%_AB+6O''P?MY]%\0?$SX:>%]3\.^&?&6L^
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MD<:*JHJA5   J2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** &JJHH5%5%'15 51SG@  #GG@=:%1$W;55=[%VVJ!N<@ LV ,L0 "
MQR2 .>*** '4W8F_S-J[PI0/M&\(2&*[L9VD@$KG!(!QD444 .HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ggtc45pq2o35000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )-! P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD8'')(':@#F?#T\L6D:$D<C*LM]=*X!X8>9*<&NVKB_"EZJ^'M$W6H)N;NY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKH:YSP+&D/A&UCC4*B37"JHZ "=\"NCH **** "BBB@ HHHH **** "BBB@
MJAK9M5T6[-ZK-;",^8$ZD>U7ZI:Q:+?:1=6K2K"LL94R-T7WI/84MF7!]T8]
M*6D'  I:8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.G2WDDEZ+M"JI<LL.5
MQF/ P??G-7JRM%N)KB75!+(SB*]>-,_PJ%7C]:3W+BO=9JU@Z]_R&?#W_7ZW
M_HIZWJP=>_Y#/A[_ *_6_P#13UK2^+[_ ,C-F]11168PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK O/&OAVQULZ-/J<0U
M(1M(;=068*JECG Z[03CK0!OT55TW4K/5].@U"PG6>UN%WQ2+T85:H ****
M"BBB@#GO!/\ R*L'_7>Y_P#1\E=#7/>"?^15@_Z[W/\ Z/DKH: "BBB@ HHH
MH **** "BBB@ HHHH *S/$,$MUX?OH($+RO$0JKU)K3K,\13RVWAZ^FAD:.1
M(B59>H-*6S)G\+-)?NCZ4M(OW1]*6F4%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5C:"K+-J^Y2,W[D9'4;5K9JE8/>L]X+Q0JK<$08'6/ P?SS2>Y<7[K+M8.
MO?\ (9\/?]?K?^BGK>K!U[_D,^'O^OUO_13UK2^+[_R,V;U%%%9C"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-R,]%[4 9G@G_D58/^N]S_Z/DKH:YSP)()?"%K(%90\MPP#K@C,S]1V-='0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCY*Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[W/_ */DKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 9FL26D<FF"[A:0O>HL!4_<DVMAC[8
MS^=:=87B3_7Z%_V%(_\ T!ZW:2W-)+W8A1113,PHHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,[5;Y;*33E:!9?M%XL(+?P$JQW#WX_6M&L+Q)_K]"_["D?_H#UNTEN
M7))13"BBBF0%%%% !1110 4444 %%%% %34M3LM'LFO-1N8[:V0@-)(< $G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9>LWT]E+I:PE0+B^2"3(S\I5B<?D*U*PO$G^OT+_L*1_^
M@/6[26YI)+EB%%%%,S"BBB@ HHHH **** "BBB@ KR%[:^\3^)?%#ZGXNOM'
MDTR[,&G6]K=K%&JA0RNZ_P >>,@^XKUZO$+SP@/&WB7Q)>Z98:%91Z=?26[_
M &NS,LEU, &=W.X8!)XQ0!Z+\//$4WB3P5I=]?2PG498<SHC#/#%0Q Z9 !_
M&NJKA?AAIWAZ?PS8^)=)T*VTRZO[<K,(0>S88#)Z;ER/PKNJ "FQR)*NZ-U=
M<XRIR*P?&T\T'A*\,,KPL^R-I$.&16<*Q![<$\U5TB"+3/'&H:=8KY=FUC%,
MT"_=C?<R@CT)'7UVT =.98Q*L1D42,,A2>2/I3ZXKQN(;&YTS4)-(>: 7L)G
MOX90)+;Y@JX7J5)(!QV/2NIU*_.G6ZRBSNKK+;=EL@9A[X)'% &5X)_Y%6#_
M *[W/_H^2NAKG/ DGF^$+638Z;Y;AMKC##,S\$>M='0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUWN?_1\E=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 45E:UK#:2+-(K*6\GNY_)BBC=5YVLQ)+$#&%-5?[:UO\ Z%:Z_P#
MN'_XJ@#?HK _MK6_^A6NO_ N'_XJC^VM;_Z%:Z_\"X?_ (J@#?HK _MK6_\
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MLE]");>6[8(1#Y8*B3.<XD &,?WN:N^,3,?".J06]I<W4]Q;201Q6Z;F+,I
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M4C_] >MVL[5;$7LFG,9UB^SWBS@,/OX5AM'OS^E:-);ER:<4@HHHID!1110
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MI]PK:T^G#3(X2)Q&)2@?=O.2 -QRH'6NXT6VN[+3([:[6R5HAL1+*-DC5!T
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M26WA.Z'B^/6[B6QC$+2$&T@:.2<,, 2G=AL#VZ@4 =;1110 5A>-/^1)UO\
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M-&P'(' (/3YC6;XJL+_5]6L3=P:M!IDEHX5=/57>&XW@@MP=IV]#V.17H=%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%+U&A 'WY-K87\L_E6G26YI)^[$****9F%%%% !1110 4444 %%%% !1110
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M/2+D2%H94E>Z:[$T4SI(DK*%9E8'*Y  P.*K?\)>/^A>\0?^ )_QH_X2\?\
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M5G$(H(@0J@YZG))/<DDDGWK+\:?\B3K?_7E+_P"@FH/^$O'_ $+WB#_P!/\
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M=&X] .<?4^M:]% &+?\ A;3=1O\ [7.)MS;/.C24K'/L.5\Q1PV/?TK:HHH
MX2.W\1^'[W3=$M-1T]H+R:Y9&DM6W(,M)@_/S][':MO[)XL_Z"NE_P#@$_\
M\76W):P2W$,\D2M+!GRG(Y3(P<?45+0!S_V3Q9_T%=+_ / )_P#XNC[)XL_Z
M"NE_^ 3_ /Q==!10!S_V3Q9_T%=+_P# )_\ XNC[)XL_Z"NE_P#@$_\ \770
M44 <_P#9/%G_ $%=+_\  )__ (NC[)XL_P"@KI?_ (!/_P#%UT%% '/_ &3Q
M9_T%=+_\ G_^+K/UNY\5Z/I4E]_:.ER['C7;]D<9W.J_W_\ :KL*BN;:"\@:
M"XB66)B"489!(((_4"@#$^R>+/\ H*Z7_P" 3_\ Q='V3Q9_T%=+_P# )_\
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M_P#P"?\ ^+KH** .0TFX\5ZI#<2#4=+3R;J6WQ]D<YV,5S]_OBK_ -D\6?\
M05TO_P  G_\ BZVX+:&U5U@B6-7=I&"CJS')/U)J6@#G_LGBS_H*Z7_X!/\
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MLGBS_H*Z7_X!/_\ %UT%% '/_9/%G_05TO\ \ G_ /BZ/LGBS_H*Z7_X!/\
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MTY)S6M/!%=6\D$\:R12*5=&'# ]13U4(@51A5& !V% "T444 %%%% !1110
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M#=A3Q\W0<< ]J[@Y*D X..#Z5S-MX.4:#JFD7VI3W4.H2M*SA%C:-F()QCW
M/- %3P%?+J$5W-!<WGV=1&K6E^Y,\$NWY\@\@'@CL>2.M=E6/I.A?V=>SW]Q
M>27E[-$D#2LBI\B9VC"\9RQ.??TK8H **** "BBB@ I#DJ0#@XX-+2'.#CKV
MH Y7[%?67C73A9W]U/!)#*VHI,^Y ./+8#^%LY''85-HYN(_&?B"WDO;B>'9
M!+''*V5BW!LA?0<5:T_1M1L[KS9M9>X1G+R*8%4N>P)]!Z#TIUEH<]IXDO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTS4K36--M]0L9?-M;A-\;[2-P^AYH RO^$<O_P#H;-;_ .^;;_XS1_PCE_\
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M_P"$<O\ _H;-;_[YMO\ XS7045('/_\ ".7_ /T-FM_]\VW_ ,9H_P"$<O\
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M_P#H;-;_ .^;;_XS1_PCE_\ ]#9K?_?-M_\ &:Z"BI Y_P#X1R__ .ALUO\
M[YMO_C-'_".7_P#T-FM_]\VW_P 9KH** .?_ .$<O_\ H;-;_P"^;;_XS1_P
MCE__ -#9K?\ WS;?_&:Z"B@#G_\ A'+_ /Z&S6_^^;;_ .,T?\(Y?_\ 0V:W
M_P!\VW_QFN@HH Y__A'+_P#Z&S6_^^;;_P",T?\ ".7_ /T-FM_]\VW_ ,9H
MMO$_G^-;CPXVGS1-#:BY%P[#$@W;> /YUT%5*#CN!S__  CE_P#]#9K?_?-M
M_P#&:/\ A'+_ /Z&S6_^^;;_ .,UT%%2!S__  CE_P#]#9K?_?-M_P#&:/\
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M_P#0V:W_ -\VW_QFN@HH Y__ (1R_P#^ALUO_OFV_P#C-'_".7__ $-FM_\
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MFTE6^CUV>YGN-G6U9<+\_<'@8KU*DJLJGQ=-#.G/FOH%%%%,T"BBB@ HHHH
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M46KVM].8\^4Z;%P2/WA.UG./NXKK:Q7\,6,VHP7EQ)=3FWF,\,4LQ:..0_Q
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M .@5J_\ X!M1_P );;_] K5__ -JZ"B@#G_^$MM_^@5J_P#X!M1_PEMO_P!
MK5__  #:N@HH Y__ (2VW_Z!6K_^ ;4?\);;_P#0*U?_ , VKH** .?_ .$M
MM_\ H%:O_P" ;4?\);;_ /0*U?\ \ VKH** .?\ ^$MM_P#H%:O_ . ;4?\
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M_P#H%:O_ . ;4?\ "6V__0*U?_P#:N@HH Y__A+;?_H%:O\ ^ ;4?\);;_\
M0*U?_P  VKH** .?_P"$MM_^@5J__@&U'_"6V_\ T"M7_P# -JZ"B@#G_P#A
M+;?_ *!6K_\ @&U'_"6V_P#T"M7_ / -JZ"B@#G_ /A+;?\ Z!6K_P#@&U'_
M  EMO_T"M7_\ VKH** .?_X2VW_Z!6K_ /@&U'_"6V__ $"M7_\  -JZ"B@#
MG_\ A+;?_H%:O_X!M1_PEMO_ - K5_\ P#:N@HH Y_\ X2VW_P"@5J__ (!M
M1_PEMO\ ] K5_P#P#:N@HH Y_P#X2VW_ .@5J_\ X!M1_P );;_] K5__ -J
MZ"B@#G_^$MM_^@5J_P#X!M1_PEMO_P! K5__  #:N@HH Y__ (2VW_Z!6K_^
M ;4?\);;_P#0*U?_ , VKH** .?_ .$MM_\ H%:O_P" ;4?\);;_ /0*U?\
M\ VKH** .?\ ^$MM_P#H%:O_ . ;4?\ "6V__0*U?_P#:N@HH Y__A+;?_H%
M:O\ ^ ;4?\);;_\ 0*U?_P  VKH** .?_P"$MM_^@5J__@&U'_"6V_\ T"M7
M_P# -JZ"B@#G_P#A+;?_ *!6K_\ @&U'_"6V_P#T"M7_ / -JZ"B@#G_ /A+
M;?\ Z!6K_P#@&U'_  EMO_T"M7_\ VKH** .?_X2VW_Z!6K_ /@&U'_"6V__
M $"M7_\  -JZ"B@#G_\ A+;?_H%:O_X!M1_PEMO_ - K5_\ P#:N@HH Y_\
MX2VW_P"@5J__ (!M1_PEMO\ ] K5_P#P#:N@HH Y_P#X2VW_ .@5J_\ X!M1
M_P );;_] K5__ -JZ"B@#G_^$MM_^@5J_P#X!M1_PEMO_P! K5__  #:N@HH
M Y__ (2VW_Z!6K_^ ;4?\);;_P#0*U?_ , VKH** .?_ .$MM_\ H%:O_P"
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M* .?_P"$MM_^@5J__@&U'_"6V_\ T"M7_P# -JZ"B@#G_P#A+;?_ *!6K_\
M@&U'_"6V_P#T"M7_ / -JZ"B@#G_ /A+;?\ Z!6K_P#@&U'_  EMO_T"M7_\
M VKH** .?_X2VW_Z!6K_ /@&U'_"6V__ $"M7_\  -JZ"B@#G_\ A+;?_H%:
MO_X!M1_PEMO_ - K5_\ P#:N@HH Y_\ X2VW_P"@5J__ (!M1_PEMO\ ] O5
M_P#P#:N@HH P/!L<T7AJ/SX)8'>YN91'*NU@KSR,N1VX(-;]%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ggtc45pq2o35000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *Q ZT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY^5V7@''!(YKB-)TU]:\=VTNC:V\\KVCL#J-OY\MN!\K072G!/7Y6//!'(H
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M^L" ^1?+$ZX9\=)%  *GK@8X->BZ)IDFD:5%:37MQ>S+EI+B=LL[$Y)]AD\
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M5P@R< 9X]Z\B\1:VVKZDVIQZZ]OIMU%%/HT\QS8.Z#+V]PA&%<L,@GD<>F*
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MO[HRW]K*_EM!(S$BX@;^!ESR!UQ7<:#X>M?#\$ZP2W-Q-<2>9/<7,ADDE8
M9/L !^%?(G_";^*]^_\ X275]WK]LD_QH_X3?Q7OW_\ "2ZON]?MDF?YU])+
M)Z\4VVM/7_(X_:(^SID,L$D8;:64J#C.,BO,XOAQ/IKZ?I/F3:CHV?,6<S>7
M<:=< 9,L3==K'JO:L7XRBZ\+>'M-OM&U75K6YGNO+D<:A,<KL8XY;U KQ<>-
M_%8?>/$NK[CW^V2?XUAALOJXF'/!JWF-S2=C[ T31;70=/\ LEJ97#2-+++,
M^YY9&.69CW)-&O:6-;\/ZAI1E,0O+=X#(!G:&!!/ZU\H>'O%WB:[\3Z7;S>(
M]7:*>\ACE'VV0;E9P".OH:]S\4:;_9_B6QM[74M7BBFM99) NI3<L&4 _>]S
M7'F4'E\7*KK97T_I&E"#K34(]2:#P!<1ZM#I]S+=2V%I$3INK0W/EW=JO1K=
MS_&ASP:[O2M+M-%TNWTVQB\JUMTV1KG/'^.>:\N6R=22NJ:P">I&I3__ !5-
MAMI8]<TB%=4U?R[F[$<JG49CN7:QQ][VKP:&?8:O5C2BG=Z=/\SNJ9;5IP<V
MUI_78]%\5>'8O%.A2:3<3O##+)&TC1_>(5PV >V<=:Y"S^']Q?7]W;>('N',
M40MX]6M;CRI-0MC_ ,LKA1U9<8)[@_6O-/BWJNK^%O&@L-&US5K:V:V1R@OY
M3\Q)R>6K@E\;^*T!"^)=7&>N+R3_ !KZVAE=:M352+5G_78\QS2=C[.ABC@A
MCAB4)'&H1%'0 < 5A>+?"T?BRQM;26\GM4@N!<![<X?< 0N#V()!_"O#?@]J
MNK^(_&,EAJNMZM/:_97?R_MTJC<".>&K'^(/B'7M!\=:KIFFZ_J\%G#( D8O
MI#@;1ZFLE@*CKNA=77W#YE:Y[+I7@)]0N;J7Q)%(EVLJ)/-9SF.'543#))+&
M.C9QGW'I7HM?%P\;^*U4J/$NKA3U'VR3_&O5?@I=:AXIN=7AUG6-6N8X8T,:
MF_E7!).>C"KQ&6U</3]I-JW]>0E--V/5/%?A!_$=W97L&ISV%Y8*[6LD0^[(
M<8)]5XP1W!K,\-^"(3+#J>J64EC>QW)GEL;>Y)M'G&0)U3L2"3CWKY[\0>+?
M$MCXBU6QMO$6KI;0W<L<:?;9#A0Q '7TK-_X3?Q7LV?\)+J^WT^V2?XUI3RB
MO."FFM?7_('41]HUQ?B;P;>ZAK4GB'2]0,6IQ6RP06\@S!*H+%TD'=6R![8S
M7$_!W[5XH\+:I/K&JZK<R0W&V,G4)5VC8#CAO6O%QXW\5F,*?$NKE?3[9)_C
M6-' 5*M25.+5XC<DE<^HO"O@RPTQK34_LMU:3QQMY6GR7)EALF?[XC'0 X_*
MNPKXN/C?Q64"GQ+JY4=OMDG^->U>$%N=6^"MWK5[JNJRZA%%=,DW]H2C!3=M
MX#8XP*6*P%3#14IM:]@C)2.I\1^";U]5U/Q!IDXNKJ[58Y],N,?9[J (%,3>
MC=2&[$XK9\->#]/T&1;V'[89FMQ#''=7!E^S1YW&)/0 _P JX5+.22"/?JFL
M'Y0>=2F]/]ZG&Q=P VJ:P0.F=2G_ /BJ^2_UDPG\LON7^9ZO]E5NZ_KY'KM>
M:ZK\/[FVGO9[;.K6.JWC2ZEIL[[%(9\K)$?X'3CZ@>M8VL1W$7P3.NIJFK#4
MDAW+/_:$V<^9CINQTKQ%O&_BM\;O$NKG'3-Y)_C7UF$P53%1<H-:=SRI2479
MGUOX?\,67AT7+P375S<7)7S;B[F,DC!1A%R>P!./K6RP)4@'!(ZU\7/XW\5L
M,MXEU<D=,WDG^->T_$C[5H_PSTK6+#5=5BOY?(WRB_E.=R9/!;'6G7P%2C.,
M)-7D"DFKFP/AM<:<]EI>^75-%FE\R1FE\J?3[C)/GPL.BGH5']37>Z%H5IX?
ML7M;5YI#)*TTTT[[Y)9&ZLQ[FOD(^-_%;,&/B75R1T/VR3_&K>F>,?%%SK5C
M'-XDU=E>XC1O]-DY!8 ]ZZ)Y17A%R;6GK_D+VB/KW4+4WVFW5H)/+\^)H]^,
M[=P(SC\:\ZMOAS<6-[8:1)-<7>D6Z>99:BD_EW>G2@?,H;JT;GH.W3I7,?&V
M:^\+'1Y-&U?5K9YS()"+^4YQC'5O<UY'_P )OXKW[_\ A)=7W>OVR3_&LL-E
MU7$0YX-6_KR!S2=C["T;1[30=*ATZQ5E@BS@NVYF).22>Y))-0^(]$C\1Z!=
MZ1+*T45RH1V4<[<@G%?,?@;Q-XAU;QWH]E?>(-6EMY[@)(IO9!N&#QG->O>(
M;!K3QBUK!J6KQP_84EVKJ,WWB[@G[WH!7GYG_P )T7*MK;MYZ>1M0INO-0CU
M+EOX N)M4DL]4ENG@MX/+LM8M[CR[AX"<&VFQ]_ Z-Z>]>@65G!I]C!9VL8C
MMX(Q'&@_A4# %>4BR</O&J:QN/?^TI__ (JI-+LW;Q;I=LVIZNT5P)O,4ZC,
M=V%!'\7K7C8;/,/B*JI03N_3_,[*N75:4'.35D=WXL\,1>+--M[">ZFMHH[E
M9R\!PY*AL8/8Y(.?:N9T_P  OJ-U=GQ$DHN%98I;JTG\N/58ARIFC'\0P ?6
MO)?BEKFM^'/B%?:?I6NZM;VJ1Q,J"^E."R GDMZUQB^-_%:L2OB75P3U(O)/
M\:^KHY76K4U4BU9_UV/-<TG8^T0,# Z"N:\6^$?^$I?3W&HW%C)8.\T,EOPP
ME(PK9]!SQWS7CWP4U#5/$WB/4K?5]9U6XBCM!(BF^E7#;P,\-7)>-/$WB'1O
M&^M6%AXAU>&V@NGCC07LAPH[<FLHX"I*NZ":NA\RM<]UT/P.MS.;_6[5[6^6
MZ$MQ#:7!%K>R(<I<&/L2><>HKOJ^+E\;^*TSM\2ZN,]<7DG^->O_  2EO?$]
MEKC:QJVJW)@>(1YOY5V@AL]&]A58G+JN'ASS:M_7D"FF['H?BCP?=:SK,&N:
M=JCV6I65L8[7C,98MDB0?Q*PX(_&H/"_@FRM6LM5N+&>PNHBTJZ8+DR6UM,P
M*L\:]!D9_ UQFE0SSZ<LCZMK!9F<'&I3#.'8#^+T%7!8NJE1JFL!3U']I3__
M !5?)U.(<+3FX.,KIVV7^9Z<,LK2BI)K7^NQZ[7#>)_!5[>:Q>>(M+NU:_:V
M2W%C.,V]S$N[?%(.^[=P>Q%97A^P-SX:\0RS:CJSO:S2K"3J,WR@1*P_B]2:
M^?!XW\5A-@\2ZOM]/MDG^-?28##RQT.>EHK)Z^9Y]5>SDXOH?4WA3P;I^B&'
M4(XKR.X^S^5';7-R9A9HQW-&A],_RKJZ^+O^$W\5[-G_  DNK[?3[9)_C7MF
MB+<WGP3CUF?5-5;4".9OM\H_Y:[>F['2M<9@JF$ASU&OD3!\SLC?U[P)>0WV
MJZQIY&J+J<P.H:1<D+%<P[54!3_#(N"0WO@UT_AWPE8>'9)I[>6\N)Y8TB\R
M[G,KI&N=L8)[#)K@?L3F,*=4UC;Z?VE/_P#%5%=6DJ64Q&JZQ\D;,O\ Q,IN
M" ?]JODUQ'A6[<LON7^9ZCRJMW7]?(]BKS.X^'<]BPMHR^K:3?W1EOK:63RW
MMI68D7$#?PE<\@=1TYJ#5[)HO V@W::EJHGN9H%E?^T)LL&4D_Q55:Q=AM.J
M:P0.@_M*?_XJNW'9M1P<U"HFVU?2W^9SX?!5*\7*+6AZ/H/A^U\/V\Z02W%Q
M-<2>;/<7,ADDE;  )/L !^%:4\9FMY(@VTNA4-CID=:\:U>&>#2+F:/5M8#Q
MIE"=2F.#_P!]5'\9WO/#7A_1KC2=6U6WEGG*2,+^5LC9GNWK73EF,AF+M136
MMM?Z9&)P\\.TIF_'\.)].EL-)#S7^B[O,CG\[R[G3;C&3)$W78W=>Q]J[W1-
M%M=!TX6=J97!=I9))GW/)(QRS,>Y)KX_;QOXK?&[Q+JYQTS>2?XUK>&?%?B3
M4_%FCV=YXBU>6">\BCD4WLG*E@".M>]4RFO3@YMJRUZ_Y'(JB9]5:_I7]N:!
M?:69C"+N(Q&0#)4'K7$6_@"XCU:*PN9;J2QM8C_9NKP7'EW=LIX,#G^-?0UQ
M7QNN]1\,:EHJ:/K&JVRSQ2M(!?2MD@KCJWN:\K;QOXK9@S>)=7)'0F\D_P :
MSP^6U<13]I!JW]>0.:3L?8VF:;:Z/IEOIUE'Y=M;H(XUSG %9_BKPY%XJT,Z
M5<3R0PO-%)(T9PQ".&P#V)QUKYS^&_B#7M?^(>DZ?J>OZM/:S-)O0WT@SB-B
M.0?4"M3XOZOK'AOQPMGI6N:M;P?98WVB^E/S$G)Y;VJ'@*BKJA=7_ ?,K7/3
M;/P#-?WUW#X@,[/'&(!J=K/Y3:E;'_EG.@ZLN,$]Z]#ABCMX(X8D"1QJ$11T
M  P!7QB?&_BLOO/B75]P[_;)/\:[[X0:MJ_B;QP]IJ^N:M<P+:/(%-]*/F!4
M \-[FM*^65J--U)-67]=A*:;L>Y>+?"L?BRTLK:6]GM%M;D7*R6YVN'",JD'
MM@L#^%<[I?@,ZC/<S>(X'CNO.5;E[2<I;ZH$P4EDC'1NF1ZBO&?B+XBU[1/'
M^J6.G:_JT-O"X$:"]D.T;1W)KE_^$W\5A]X\2ZON]?MDG^-52RJM5@IQ:L_Z
M[ YI.Q]HUROBWP?+XCO;'4+759]/OM/20VDD0R%D;;@M_>7Y<%>X)KRSX)W>
MH^*-2U<:QK&K7/D1(8\W\HP23GHU>>^(/%OB6P\3ZI;VWB+5XXHKJ1$ O9.%
M#' ZUC# 5)UI44U=#YE:Y]!^&?!$.^WU74[&33[Z.Y:XDT^WN2UH;@97ST3M
MD9(';/K7>5\7#QOXK5BR^)=7!/4B\D_QKV/X1/>>(/">M7^J:MJL]S!(RQN;
M^4;1LSV;UJL3E]7#0YYM6\@4TV=UXF\&WE_K,GB'2K_RM4CMQ#%!*,P3)DEH
MY!W5LXSVZU+X5\&6&EFTU/[-=VLZ1-Y6GRW)EBLB^"ZQCH <#\!7RZOC?Q6F
M=OB75QGKB\DY_6A?&_BM,[?$NKC/7%Y)_C6\<FKM7NOQ_P B?:(^T:X#Q'X)
MO6U+4M>TN5;NYNE6.XTRY_U%W %P8SZ-W#=C7*^&_M5U\#;_ %^;5=5;4TMK
MEUG^WRY#+NVG&['&*\77QOXK52%\2ZN >H%Y)_C7-A\!4KN48M>Z4Y)'U9X9
M\'Z?H,@O(?MAG:!842ZN#+]FC^]Y2GT!KI:^+AXW\5JI4>)=7 /4"\D_QKW:
M.VE_X4]I6K_VGJPOKE;,RRC4)LMOE16XW8Y!(J,;A)X./-4MUV\AP?.[(T=3
M^']S:S74MN3J]CJEVTFI:=.VP?,^5EA/\#H,?7%=CH'AJS\/+<&":ZN9[DJ9
M;BZE,DCA1A02>P' KSO["X4H-4U@*>W]I3__ !55=2MY[?1[V2+5M85H[>1U
M_P")E-P0I(_B]:^6CQ'A9-)1E]R_S/3>5UDKW7]?(]F()4@'!QUKS"'X;3Z8
M-/TCS)=2T5G$AD,OESZ=< 9\Z%NH5CU7L32Z_IYM- \.O!J.K(UW)&)B-1F^
M<&(L?XO451^POLV?VIK&WT_M*?\ ^*KKQV;4,'45.HFVU?2W^9CA\%4KQYH-
M'I6AZ%:>'[!K6U:5S)*TTTTS[Y)9&^\S'N3@?E5C5+(ZEI%[8B3R_M,#P[\9
MV[E(SC\:\AU6&XMM-+Q:MK (= /^)E,1RP!_BJG\;)K[PM!HZZ-J^JVPF:02
M 7\K;L 8ZM77EF*AF/\ !TUMK_P+F6)P\L.[3.JM_AY/::A9:7++<W.E6T9>
MPU*.?R[O3GP-T8;JT;=AVZ>E=[H^D6FA:5!IUBC+;P@XW-N8DDDDGN222?K7
MQX?&_BME"GQ+JY4=!]LD_P :Z#P1XE\0ZSXVT;3;_P 0:O-:3W*I)&;V09'I
MP:]RKE-:G!S;5EZ_Y'*IINQ]-^)M#3Q)X>N](DF:&.Y 5W49. P) _*N,M_A
M]/<ZI-9ZO)=/#;P>59ZQ;7/ESRV[<&WGQ]_ _B]/>JOB*P:#Q8;&/4M66W2S
M60(-1F^\6(S][TJJUD[XW:IK!QTSJ4__ ,57RF+SK#X6JZ4T[KM;_,]&CE]6
MM!3BU8]7M+2"PLX;2VC$<$"".-!_"H& *Q_%?AB'Q7I\%E/=36\<4ZS[X#M?
M*YQ@]B#@_A7":=9/<>*M+M)M3U=X)A+O1M2FYPN1_%7G'Q3UW7-"\?WNGZ=K
MVK0VL21E(_MTAP2H)ZGUKULLFLRBI4=+WW\O2YRXBE*A+DD>MZ;X"?4;J[;Q
M''*MRKI'-=6D_EQZK&O*--&/XA@ ^OTKT0   #@#I7Q>WC?Q6S MXEU<D=";
MR3_&O3O@O>ZEXLUS4XM;UG5KI+>W1X@;^5=I+'T:O3Q&6UJ%-U)-6_KR,%--
MV/7O%GA(>*&L)!J-Q8S6+M-!+ <,LA&%;Z#T[UC:#X'6XF_M#6[5[2^2Z\VX
M@M+@BTO)4P4N/+[$]<>HKP;QCXI\1Z=XVUJSM?$.K1P6U[+%$OVV0[5#$ =:
MQ3XW\5E]Y\2ZON'?[9)_C5T\IKU(*::L_7_('429]HUR'B?P==:OK46NZ=JC
MVFI6=MY5JN,QL2Q+"0?Q*PP".W6N!^"AN_%=AJUSK6K:M=36\Z)$QOYAM!4D
M]&IVBQW-YI-K=SZOK#3R*2S_ -I3#/)']ZO!S/%PR[^-=ZVT_I'5AL/+$.T#
MM_"W@JRLVL]5FLKBQNH]\BZ:+DR6]K*P*NT:]!D9_ UVE>1?8GW[_P"U-8W>
MO]I3_P#Q57?#]@;GPWXDOIM2U9[BTGN$A<ZC-E0L2L/XN>2>M<V!S:CC9N%-
M--*^MO\ ,TQ&"J4(J4VC3\2>"KZ75M2\0Z7<+<7=Q&D4NFW _P!'NH N&B;W
M/4-V/M6KX9\&Z=H4L=_"MX)_L_DQ0W-P91:1DAC&GH,X_(5P6GVTTMA:SOJN
ML&62%&=O[2FY)4$_Q586R=6+#5-8!/4_VE/_ /%5QOB/"IVY9?<O\S=976:O
M=?U\CUVBN%\$Z+%J'AF"]NK[59+AY9E9SJ,W(65U'\7H!73Z=H5IID[S6\MZ
MS/\ >$UY+*OY,Q%>[&2E%274\YJSL:=%%%4(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "N>M/\ D?=4_P"O&W_]"DKH:YZT_P"1]U3_ *\;?_T*2@!G
MC_\ Y$75?^N0_P#0A7(+]U?H*Z_Q_P#\B+JO_7(?^A"N07[J_05\CQ/\5/Y_
MH>WE&T_D,N/^/:;_ '&_E5+XB?\ )OFF_P#7&R_]EJ[<?\>TW^XW\JI?$3_D
MWS3?^N-E_P"RUT<(_P 27K']2,X^S\_T/G.BBBOV"K_#EZ,^>6Y]%?M"_P#(
MG:-_U^C_ -%M7SK7T5^T+_R)VC?]?H_]%M7SK7FY+_N[]?T1=3<UO"W_ ".&
MB?\ 80M__1BU],^-?^1NTO\ Z\IO_0TKYF\+?\CAHG_80M__ $8M?3/C7_D;
MM+_Z\IO_ $-*^>XP_@S_ ,/ZG9EW\>/J9M1)_P C'X?_ .O\?^@-4M1)_P C
M'X?_ .O\?^@-7YAE?^^T_5'TN,_@3]#SCX]_\E$7_KSC_F:\NKU'X]_\E$7_
M *\X_P"9KRZOW?+/]UC_ %U/C)_$>I? +_DH4G_7F_\ ,5@_%G_DI^M_]=5_
M]!%;WP"_Y*%)_P!>;_S%8/Q9_P"2GZW_ -=5_P#017)#_D9R]/T13^ XNO</
MV<_^0AKO_7*/^9KP^O</V<_^0AKO_7*/^9K?-_\ =7ZH5/XCR?Q9_P CCK?_
M %_S?^AFL>MCQ9_R..M_]?\ -_Z&:QZ[,+_ AZ+\B7N?1'[/O_(G:W_U]?\
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M$*]3$?P9^C_(A;GM?[1O^K\/_P"]-_):\&KWG]HW_5^'_P#>F_DM>#5PY/\
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M5>]6M;_Y)SX9_P"OBU_]!-5>]?0\2_[Q#_#^K/,RG^%+U,[7?^0%>_\ 7/\
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M,_U6@_[TO\A7N\%[K_%^B././C7H>"UU7PT_Y*5X?_Z_%KE:ZKX:?\E*\/\
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MZFOU&C_#CZ(^0J?&PHHHK0@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M*K3 ?[M#T"7Q,]N_9S_Y">N_]<8_YFO*?%G_ ".&L_\ 7Y+_ .A&O5OV<_\
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ME=#7/6G_ "/NJ?\ 7C;_ /H4E #/'_\ R(NJ_P#7(?\ H0KD%^ZOT%=?X_\
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M+X!?\E"D_P"O-_YBL'XL_P#)3];_ .NJ_P#H(K>^ 7_)0I/^O-_YBL'XL_\
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MM>#5[S^T;_J_#_\ O3?R6O!JX<G_ -V^;*J;G5?#3_DI.@_]?0_D:]^\5?\
M(^M_V#8__1CUX#\-/^2DZ#_U]#^1KW[Q5_R/K?\ 8-C_ /1CU\MQG_!GZ+\S
MT,K_ (\?G^14I^D_\COHGTG_ /0!3*?I/_([Z)])_P#T 5^=9-_OU/U_1GOX
M_P#W>1Y%\;O^2IZC_P!<8/\ T6*\\KT/XW?\E3U'_KC!_P"BQ7GE?NN7?[K
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M_D!7O_7/^HJK^T)_R*WA_P#Z^3_Z+KV.#?B_[>1R9Q\:]#Y]K=\%?\CUH/\
MV$(/_0Q6%6[X*_Y'K0?^PA!_Z&*_4L7_ +O/T?Y'A1W1ZA^T=_R%O#__ %PG
M_P#0DKQ*O;?VCO\ D+>'_P#KA/\ ^A)7B5<F4?[JO5E5/B.X^#__ "571/\
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M '>/S_,?I'_([Z+_ +L__H%>/_&K_DJ.I?\ 7.+_ - %>P:1_P COHO^[/\
M^@5X_P#&K_DJ.I?]<XO_ $ 5]UP5_#A_V\>+FW\=_(\_KV?]G7_D8=:_Z]8_
M_0C7C%>S_LZ_\C#K7_7K'_Z$:^SS;_=9?+\SS(?$>=>/O^2A^(O^PC/_ .AF
MN=KHO'W_ "4/Q%_V$9__ $,USM=.#_W>'HOR%+<^@_V<O^0-KW_7S'_Z :F\
M.?\ (NV7^X?_ $(U#^SE_P @;7O^OF/_ - -3>'/^1=LO]P_^A&OR_C/?_M]
M_J>WD_QOT-2KWAC_ )$SQ=_U]77_ *(2J-7O#'_(F>+O^OJZ_P#1"5XO#/\
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MPLV?$1D/AGPB9556\V+A3D?ZEJIU?\3_ /(N^$O^NL7_ *):J%>_Q+_O4?\
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M:^F?&O\ R-VE_P#7E-_Z&E?/<8?P9_X?U.S+OX\?4S:B3_D8_#__ %_C_P!
M:I:B3_D8_#__ %_C_P! :OS#*_\ ?:?JCZ7&?P)^AYQ\>_\ DHB_]><?\S7E
MU>H_'O\ Y*(O_7G'_,UY=7[OEG^ZQ_KJ?&3^(]2^ 7_)0I/^O-_YBL'XL_\
M)3];_P"NJ_\ H(K>^ 7_ "4*3_KS?^8K!^+/_)3];_ZZK_Z"*Y(?\C.7I^B*
M?P'%U[A^SG_R$-=_ZY1_S->'U[A^SG_R$-=_ZY1_S-;YO_NK]4*G\1Y/XL_Y
M''6_^O\ F_\ 0S6/6QXL_P"1QUO_ *_YO_0S6/79A?X$/1?D2]SZ(_9]_P"1
M.UO_ *^O_:8KYV7[H^E?1/[/O_(G:W_U]?\ M,5\[+]T?2O,P'^^5OZZER^%
M"U]&?#__ )-XU#_KC>_S:OG.OHSX?_\ )O&H?]<;W^;49W_"CZ_H.EN7H?\
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MO'W_ "4/Q%_V$9__ $,USM=.#_W>'HOR%+<^@_V<O^0-KW_7S'_Z :F\.?\
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M@_\ 0Q6%6YX,94\<:"S$!1?PDD_[XK]2Q?\ N\_1_D>%'='J/[1W_(6\/_\
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MU'_#^K/-RG^"_7]$9VN?\@IO^ND?_H8K-_:,_P!5H/\ O2_R%:.O,%TB1F.
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MZZ:VO;:[:5;>99#$VU]O\)K]1H_PX^B/D*GQLGHHHK0@**** "BBB@ HHHH
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M5_\ 017)#_D9R]/T13^ XNO;_P!G0 ZAKH(S^ZC_ )FO$*]P_9S_ .0AKO\
MURC_ )FM\W_W5^J%3^(\F\5_\CCK?_7_ #?^AFLBMCQ9_P CCK?_ %_S?^AF
ML>NS"_P(>B_(E[GT/^S\ ?!VM@@'_2N__7,5\[K]T?2OHG]GW_D3M;_Z^O\
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M^=9-_OU/U_1GOX__ '>1Y#\;>/BGJ./^>,'_ *+%>>UZ'\;O^2IZC_UQ@_\
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MZ5#>?\>%S_UR?^1K\+C\2/MGL:&M_P#).?#/_7Q:_P#H)JMWJUK?_).?#/\
MU\6O_H)JKWKZ'B7_ 'B'^']6>9E/\*7J9VN_\@&]_P"N?]157]H3_D5O#_\
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M\ -3^'/^1=LO]P_^A&H?V<O^0-KW_7S'_P"@&IO#G_(NV7^X?_0C7Y?QGO\
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M^O\ F_\ 0S6/79A?X$/1?D2]SZ(_9]_Y$[6_^OK_ -IBOG9?NCZ5]$_L^_\
M(G:W_P!?7_M,5\[+]T?2O,P'^^5OZZER^%"U]&?#_P#Y-XU#_KC>_P VKYSK
MZ,^'_P#R;QJ'_7&]_FU&=_PH^OZ#I;EZ'_41_P"X/Y4^F0_ZB/\ W!_*GU^"
MO<^X6Q2US_DW)_\ K@/_ $;7S?7TAKG_ ";D_P#UP'_HVOF^OW;(/X4OE^1\
M16^(1ONGZ5]$_%S_ )(SHO\ VZ_^@5\[-]T_2OHGXN?\D9T7_MU_] K3,O\
M>*/K^J)ALSYWJ]HG_(?TW_KZB_\ 0A5&KVB?\A_3?^OJ+_T(5ZF(_@S]'^1"
MW/:_VC?]7X?_ -Z;^2UX-7O/[1O^K\/_ .]-_):\&KAR?_=OFRJFYU7PT_Y*
M3H/_ %]#^1KW[Q5_R/K?]@V/_P!&/7@/PT_Y*3H/_7T/Y&O?O%7_ "/K?]@V
M/_T8]?+<9_P9^B_,]#*_X\?G^14I^D_\COHGTG_] %,I^D_\COHGTG_] %?G
M63?[]3]?T9[^/_W>1Y%\;O\ DJ>H_P#7&#_T6*\\KT/XW?\ )4]1_P"N,'_H
ML5YY7[KEW^ZP/CY_$>Q?L[?\C9JW_7B/_0Q7"_$?_DI'B'_K]>NZ_9V_Y&S5
MO^O$?^ABN%^(_P#R4CQ#_P!?KUQ4/^1G/T_R*?P(Y>O?/V<_^0?XC_ZZ0?\
MH+UX'7OG[.?_ "#_ !'_ -=(/_07K;./]V^:%3W-'1/^03%_OR?^C&K0K/T3
M_D$Q?[\G_HQJT*_!L7_O%3U?YGVU#^%'T1?\,?\ (J^*_P#KXF_]$I7RG7U9
MX8_Y%7Q7_P!?$W_HE*^4Z_8N%O\ =U_AC^1\CC?XLO5A7T=X:_Y-WB^G_M<5
M\XU]'>&O^3=XOI_[7%=G$'\!?/\ (RH?&7AT'TJ&\_X\+G_KD_\ (U,.@^E0
MWG_'A<_]<G_D:_"X_$C[9[&CK?\ R3GPS_U\6O\ Z":J]ZM:W_R3GPS_ -?%
MK_Z":J]Z^AXE_P!XA_A_5GF93_"EZF=KO_("O?\ KG_455_:$_Y%;P__ -?)
M_P#1=6M=_P"0%>_]<_ZBJO[0G_(K>'_^OD_^BZ]C@WXO^WD<F<?&O0^?:W?!
M7_(]:#_V$(/_ $,5A5N^"O\ D>M!_P"PA!_Z&*_4L7_N\_1_D>%'='J'[1W_
M "%O#_\ UPG_ /0DKQ*O;?VCO^0MX?\ ^N$__H25XE7)E'^ZKU953XCN/@__
M ,E5T3_>E_\ 13UL_'O_ )**O_7E'_-JQO@__P E5T3_ 'I?_13UL_'O_DHJ
M_P#7E'_-JPE_R-(^GZ,?V#RZO4O@%_R423_KQD_]"6O+:]2^ 7_)1)/^O&3_
M -"6NO,_]UE\OS)A\1A?%K_DI^M?]=%_]!%<57:_%K_DI^M?]=%_]!%<56F
M_P!VAZ!+XF>W?LY_\A/7?^N,?\S7E/BS_D<-9_Z_)?\ T(UZM^SG_P A/7?^
MN,?\S7E/BS_D<-9_Z_)?_0C7!AO^1C4_KL4_@1CU]!? G_D0O$/_ %U;_P!%
MU\^U]!? G_D0O$/_ %U;_P!%UIG/^[KU_P PI[GS[1117IT_@7H0SZ(\)_\
M)M>I?]>=W_[-7SO7T1X3_P"3:]2_Z\[O_P!FKYWKR,I_B5?7_,N>R"OIR/\
MY(+H7^Y8?^CXZ^8Z^G(_^2"Z%_N6'_H^.N;B/^"O27Y&F&^->J%[U2UG_D!:
MC_UZR_\ H!J[WJEK/_("U'_KUE_] -?B%+XX^I]G/X6;GB?_ )%WPE_UUB_]
M$M5"K_B?_D7?"7_76+_T2U4*]_B7_>H_X?U9YN4_P7Z_HC.US_D%-_UTC_\
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MII7A_P "Z[9?:]+M-/O+<G&^%MPSZ'GBL'XVP16OPGF@@C6.&*:W1$48"J&
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M_([Z)])__0!3*?I/_([Z)])__0!7YUDW^_4_7]&>_C_]WD>1?&[_ )*GJ/\
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M_KY/_HNO8X-^+_MY')G'QKT/GVMWP5_R/6@_]A"#_P!#%85;O@K_ )'K0?\
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M_P#7>Y_]'R5U-?J-'^''T1\A4^-A1116A 4444 %%%% !1110 4444 %%%%
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M]$?L^_\ (G:W_P!?7_M,5\[+]T?2OHG]GW_D3M;_ .OK_P!IBOG9?NCZ5YF
M_P!\K?UU+E\*%KZ,^'__ ";QJ'_7&]_FU?.=?1GP_P#^3>-0_P"N-[_-J,[_
M (4?7]!TMR]#_J(_]P?RI],A_P!1'_N#^5/K\%>Y]PMBEKG_ ";D_P#UP'_H
MVOF^OI#7/^3<G_ZX#_T;7S?7[MD'\*7R_(^(K?$(WW3]*^B?BY_R1G1?^W7_
M - KYV;[I^E?1/Q<_P"2,Z+_ -NO_H%:9E_O%'U_5$PV9\[U>T3_ )#^F_\
M7U%_Z$*HU>T3_D/Z;_U]1?\ H0KU,1_!GZ/\B%N>U_M&_P"K\/\ ^]-_):\&
MKWG]HW_5^'_]Z;^2UX-7#D_^[?-E5-SJOAI_R4G0?^OH?R->_>*O^1];_L&Q
M_P#HQZ\!^&G_ "4G0?\ KZ'\C7OWBK_D?6_[!L?_ *,>OEN,_P"#/T7YGH97
M_'C\_P BI3])_P"1WT3Z3_\ H IE/TG_ )'?1/I/_P"@"OSK)O\ ?J?K^C/?
MQ_\ N\CR+XW?\E3U'_KC!_Z+%>>5Z'\;O^2IZC_UQ@_]%BO/*_=<N_W6!\?/
MXCV+]G;_ )&S5O\ KQ'_ *&*X7XC_P#)2/$/_7Z]=U^SM_R-FK?]>(_]#%<+
M\1_^2D>(?^OUZXJ'_(SGZ?Y%/X$<O7OG[.?_ "#_ !'_ -=(/_07KP.O?/V<
M_P#D'^(_^ND'_H+UMG'^[?-"I[FCHG_()B_WY/\ T8U:%9^B?\@F+_?D_P#1
MC5H5^#8O_>*GJ_S/MJ'\*/HB_P"&/^15\5_]?$W_ *)2OE.OJSPQ_P BKXK_
M .OB;_T2E?*=?L7"W^[K_#'\CY'&_P 67JPKZ.\-?\F[Q?3_ -KBOG&OH[PU
M_P F[Q?3_P!KBNSB#^ OG^1E0^,O#H/I4-Y_QX7/_7)_Y&IAT'TJ&\_X\+G_
M *Y/_(U^%Q^)'VSV-'6_^2<^&?\ KXM?_0357O5K6_\ DG/AG_KXM?\ T$U5
M[U]#Q+_O$/\ #^K/,RG^%+U,[7?^0%>_]<_ZBJO[0G_(K>'_ /KY/_HNK6N_
M\@*]_P"N?]157]H3_D5O#_\ U\G_ -%U['!OQ?\ ;R.3./C7H?/M;O@K_D>M
M!_["$'_H8K"K=\%?\CUH/_80@_\ 0Q7ZEB_]WGZ/\CPH[H]0_:._Y"WA_P#Z
MX3_^A)7B5>V_M'?\A;P__P!<)_\ T)*\2KDRC_=5ZLJI\1W'P?\ ^2JZ)_O2
M_P#HIZV?CW_R45?^O*/^;5C?!_\ Y*KHG^]+_P"BGK9^/?\ R45?^O*/^;5A
M+_D:1]/T8_L'EU>I? +_ )*))_UXR?\ H2UY;7J7P"_Y*))_UXR?^A+77F?^
MZR^7YDP^(POBU_R4_6O^NB_^@BN*KM?BU_R4_6O^NB_^@BN*K3 ?[M#T"7Q,
M]N_9S_Y">N_]<8_YFO*?%G_(X:S_ -?DO_H1KU;]G/\ Y">N_P#7&/\ F:\I
M\6?\CAK/_7Y+_P"A&N##?\C&I_78I_ C'KZ"^!/_ "(7B'_KJW_HNOGVOH+X
M$_\ (A>(?^NK?^BZTSG_ '=>O^84]SY]HHHKTZ?P+T(9]$>$_P#DVO4O^O.[
M_P#9J^=Z^B/"?_)M>I?]>=W_ .S5\[UY&4_Q*OK_ )ESV05].1_\D%T+_<L/
M_1\=?,=?3D?_ "070O\ <L/_ $?'7-Q'_!7I+\C3#?&O5"]ZI:S_ ,@+4?\
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M1GB1W/??%'_(]R?]>"?^AFJM6O%'_(]R?]>"?^AFJM?A6>_[]/Y?DCZ[+O\
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MO./^9KRZOW?+/]UC_74^,G\1ZE\ O^2A2?\ 7F_\Q6#\6?\ DI^M_P#75?\
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MG_'A<_\ 7)_Y&IAT'TJ&\_X\+G_KD_\ (U^%Q^)'VSV-'6_^2<^&?^OBU_\
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M_P"ND?\ Z&*S?VC/]5H/^]+_ "%>[P7NO\7Z(X\X^->AX+75?#3_ )*5X?\
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M_P"@&IO#G_(NV7^X?_0C7Y?QGO\ ]OO]3V\G^-^AJ5>\,?\ (F>+O^OJZ_\
M1"51J]X8_P"1,\7?]?5U_P"B$KQ>&?\ >9_X?U1V9M_"CZ_H8^F?\@BQ_P"O
M>/\ ]!%6JJZ9_P @BQ_Z]X__ $$5:KYZI\;/3A\*.I^'G_(EVO\ UWN?_1\E
M=37+?#S_ )$NU_Z[W/\ Z/DKJ:_4:/\ #CZ(^0J?&PHHHK0@**** "BBB@ H
MKC=?@O\ Q1XC;PY!?7FG:;:VZW%]/:,$EE9R1'$K9RJD*Y; [ 9YJA+\+K#0
MXGO_  =/>Z5JD2ET5;IY(KDCD1RJ[$%2?IC.: /0:*SM U4:WH%CJ8C:/[3$
M'*-U4]QW[YK1H **** *&M:JFB:3/J,EK=W2PXS#9PF65LD#Y5'7KGZ9KA[W
MX@:?KMLU@D]QH65<W8U0"TG$6T[?+#'DLW&1T ;H<9]'J"YM(+J)TEC5MRE<
ME02 : /$- O[>]\!?#G15EM[FVGU$1WUN"'Z%W57';D X/6NZ\,%;'XH>*](
MM(XX+$0VUT(8T"@2.I#,/3.!6I;^!-,M?"-GX=@GNXXK)EDM[I'"SHZL6#9
MQD9/48Q6EHF@1:*;N7[5<WEW>2^;<7-RP+N0, 84   #   H 9?:S?6MV\,.
M@7UU&N,31-&%;CME@:Q=*U.[N/'&I/)H]Y;DV=NNV1DR!NDYX8\?X5V=<]:?
M\C[JG_7C;_\ H4E &S-<213(B6LLJMU=2,+]<FB6XDCN$C6UED5NLBD87Z\Y
MJQ10!7DN)$NEB%K*Z-UE!&T?KFAKB1;I81:RLAZR@C:/US5BB@"N;B078A^R
MRE/^>N1M_GFC[1)]K\G[++L_Y[9&W^>:L44 5UN)#=F$VLH0?\M21M/ZYI$G
MD:[:,VDBJ.DQ*X/ZYJS10!6BG=KAXC:21HN<2'&UOR.:X/Q?,\OC'3U>WDC"
MV<P#,1AOG3I@UZ+7G_C7_D;M+_Z\IO\ T-*\[-O]RJ>AU8+_ 'B)FU$G_(Q^
M'_\ K_'_ * U2U$G_(Q^'_\ K_'_ * U?$97_OM/U1]#C/X$_0\S^.DKR_$$
M,\+Q$6D8VOC)Y//%>9UZC\>_^2B+_P!><?\ ,UY=7[OEG^ZQ^?YGQD_B/4?@
M*2OC^4@%B+*0@#OR*Y[XINTGQ*UIVC:,F5?E;&1\H]*Z+X!?\E"D_P"O-_YB
ML'XL_P#)3];_ .NJ_P#H(KDA_P C.7I^B*?P'%U[;^SNY2\U]E1G(ACPJ]3R
M:\2KW#]G/_D(:[_URC_F:WS;_=7ZH5/XCR7Q2Q;Q=K+%2I-],2IZCYS636QX
ML_Y''6_^O^;_ -#-8]=F%_@0]%^1+W/H3X"2-%X*UQTB>5A=?<3&3\@]:^>E
M^Z/I7T3^S[_R)VM_]?7_ +3%?.R_='TKS,!_OE;^NI<OA0M?1'@21H_V>+W;
M$\FZ*\!VX^49;GFOG>OHSX?_ /)O&H?]<;W^;49W_"CZ_H.EN7H?]1'_ +@_
ME3Z9#_J(_P#<'\J?7X*]S[A;&?X@D9?V=MHB=PT'+#&%_>]Z^<J^D-<_Y-R?
M_K@/_1M?-]?NV0?PI?+\CXBM\0C?=/TKZ&^+KL/@_H:")BI6V)?C ^3I7SRW
MW3]*^B?BY_R1G1?^W7_T"M,R_P!XH^OZHF&S/G>KVB?\A_3?^OJ+_P!"%4:O
M:)_R']-_Z^HO_0A7J8C^#/T?Y$+<]H_:,=B=!3RV"@RD/V/W>*\)KWG]HW_5
M^'_]Z;^2UX-7#D_^[?-E5-SJOAI_R4G0?^OH?R->^>)W9O'\H,;*%TZ, G^+
M]X_(KP/X:?\ )2=!_P"OH?R->_>*O^1];_L&Q_\ HQZ^6XS_ (,_1?F>AE?\
M>/S_ "*E/TG_ )'?0_I<?^@"F4_2?^1WT3Z3_P#H K\ZR;_?J?K^C/?Q_P#N
M\CQ_XU,7^*6I$HR8CA&#W_=CFO/Z]#^-W_)4]1_ZXP?^BQ7GE?NN7?[K ^/G
M\1[%^SM_R-FK?]>(_P#0Q7!_$-B_Q%\0,R%";U_E/45WG[.W_(V:M_UXC_T,
M5POQ'_Y*1XA_Z_7KBH?\C.?I_D4_@1R]>]_LZ$C3O$A )(>#@=_E>O!*]\_9
MS_Y!_B/_ *Z0?^@O6V<?[M\T*GN:&A$G1X205):3@]OG:M&L_1/^03%_OR?^
MC&K0K\&Q?^\5/5_F?;4/X4?1%[PVQ7PEXL(0L1<38 [_ +E*^5*^K/#'_(J^
M*_\ KXF_]$I7RG7[%PM_NZ_PQ_(^1QO\67JPKZ,\-L1^SM#\I/;_ ,CCFOG.
MOH[PU_R;O%]/_:XKLX@_@+Y_D94/C+PZ#Z5#>?\ 'A<_]<G_ )&IAT'TJ&\_
MX\+G_KD_\C7X7'XD?;/8OZTQ/PX\+DJ1FXMN/3Y6JOWJUK?_ "3GPS_U\6O_
M *":J]Z^AXE_WB'^']6>9E/\*7J9VO<:#?'&?W1XJI^T&2?"OA[*D9N">>W[
MNK>N_P#("O?^N?\ 455_:$_Y%;P__P!?)_\ 1=>QP;\7_;R.3./C7H?/M;G@
MTE?&^A$*6(OX< =_G%8=;O@K_D>M!_["$'_H8K]2Q?\ N\_1_D>%'='J'[1O
M_(6\/\?\L)__ $)*\2KVW]H[_D+>'_\ KA/_ .A)7B5<F4?[JO5E5/B.V^$)
M*_%30R%+?/(,#_KD];7Q[_Y*,./^7*+^;5C_  ?_ .2JZ)_O2_\ HIZV?CW_
M ,E%7_KRC_FU82_Y&D?3]&/[!Y=7J/P#8CXC, I.;*0$CMRM>75ZE\ O^2B2
M?]>,G_H2UUYG_NLOE^9,/B,+XM?\E.UKC_EHO_H(KBJ[7XM?\E/UK_KHO_H(
MKBJTP'^[0] E\3/;/V=&(U?7%VD@P1_-V')KROQ7_P C?K/_ %^2_P#H1KU;
M]G/_ )">N_\ 7&/^9KRGQ9_R.&L_]?DO_H1K@PW_ ",:G]=BG\",>OH#X$,?
M^$'\0KL;;YC'=V_U?2OG^OH+X$_\B%XA_P"NK?\ HNM,Y_W=>O\ F%/<^?:*
M**].G\"]"&?0WA%V;]F_55,;*%L[O#'&&^]TKYYKZ(\)_P#)M>I?]>=W_P"S
M5\[UY&4_Q*OK_F7/9!7TS;NS_ ;1-T;)M%@!G'S#SX^17S-7TY'_ ,D%T+_<
ML/\ T?'7-Q'_  5Z2_(TPWQKU0O>J6L?\@+4?^O67_T U=[U2UG_ ) 6H_\
M7K+_ .@&OQ"E\<?4^SG\+-GQ$[2>&?"3-&T9\V+Y6QG_ %+>E4ZO^)_^1=\)
M?]=8O_1+50KW^)?]ZC_A_5GFY3_!?K^B,W7B1I$A +$21\#O\XK+_:(8O;:
MS(R$M+E6ZC@5JZY_R"F_ZZ1_^ABLW]HS_5:#_O2_R%>[P7NO\7Z(X\X^->AX
M+73_  Y=H_B+H+K&TA%VN%7&3^=<Q75?#3_DI7A__K\6OTW&_P"[S]&>)'<]
M\\3$GQRQ(()T]#@]OG-5JM>*/^1[D_Z\$_\ 0S56OPK/?]^G\OR1]=EW^[Q^
M?YB:?(T7C/162)Y3B8;5QG[O7FO(_C5_R5'4O^N<7_H KV#2/^1WT7_=G_\
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MCOHGTG_] %?G63?[]3]?T9[^/_W>1Y%\;O\ DJ>H_P#7&#_T6*\\KT/XW?\
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M*]W@O=?XOT1QYQ\:]#P6NJ^&G_)2O#__ %^+7*UU7PT_Y*5X?_Z_%K]-QO\
MN\_1GB1W/??%'_(]R?\ 7@G_ *&:JU:\4?\ (]R?]>"?^AFJM?A6>_[]/Y?D
MCZ[+O]WC\_S'Z1_R.^B_[L__ *!7C_QJ_P"2HZE_USB_] %>P:1_R.^B_P"[
M/_Z!7C_QJ_Y*CJ7_ %SB_P#0!7W7!7\.'_;QXN;?QW\CS^O9_P!G7_D8=:_Z
M]8__ $(UXQ7L_P"SK_R,.M?]>L?_ *$:^SS;_=9?+\SS(?$>=>/O^2A^(O\
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M[/O_ ")VM_\ 7U_[3%?.R_='TKS,!_OE;^NI<OA0M?1GP_\ ^3>-0_ZXWO\
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M_0!7YUDW^_4_7]&>_C_]WD>1?&[_ )*GJ/\ UQ@_]%BO/*]#^-W_ "5/4?\
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M7%5I@/\ =H>@2^)GMW[.?_(3UW_KC'_,UY3XL_Y'#6?^OR7_ -"->K?LY_\
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M&:YVNB\??\E#\1?]A&?_ -#-<[73@_\ =X>B_(4MSZ#_ &<O^0-KW_7S'_Z
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M8/\ !8?^CXZYN(_X*])?D:8;XUZH7O5+6?\ D!:C_P!>LO\ Z :N]ZI:S_R
MM1_Z]9?_ $ U^(4OCCZGV<_A9N>)_P#D7?"7_76+_P!$M5"K_B8@^'/"6/\
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M^C7V>;?[K+Y?F>9#XCSKQ]_R4/Q%_P!A&?\ ]#-<[71>/O\ DH?B+_L(S_\
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MI_R/NJ?]>-O_ .A24 ;4MG;3RI++ CR)]UF'(HDL[::=9I(4:5/NN1R*GHH
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M_P!#-8]=F%_@0]%^1+W/H3X!PQ3^"M;CF170W7*L./N"OGI?NCZ5]$_L^_\
M(G:W_P!?7_M,5\[+]T?2O,P'^^5OZZER^%"U]$> X8IOV>+[S8U?;%>,N1T.
M6YKYWKZ,^'__ ";QJ'_7&]_FU&=_PH^OZ#I;EZ'_ %$?^X/Y4^F0_P"HC_W!
M_*GU^"O<^X6QGZ_#')^SMO=%9T@RI(Y7][VKYRKZ0US_ )-R?_K@/_1M?-]?
MNV0?PI?+\CXBM\0C?=/TKZ&^+D49^#VARE%,@%L V.0-E?/+?=/TKZ)^+G_)
M&=%_[=?_ $"M,R_WBCZ_JB8;,^=ZO:)_R']-_P"OJ+_T(51J]HG_ "']-_Z^
MHO\ T(5ZF(_@S]'^1"W/:/VC(T!T&0* [&4%NY VUX37O/[1O^K\/_[TW\EK
MP:N')_\ =OFRJFYU7PT_Y*3H/_7T/Y&O?/$\:)X^D95 +Z=&6([GS'KP/X:?
M\E)T'_KZ'\C7OWBK_D?6_P"P;'_Z,>OEN,_X,_1?F>AE?\>/S_(J4_2?^1WT
M/Z3_ /H IE/TG_D=]$^D_P#Z *_.LF_WZGZ_HSW\?_N\CR#XUQI'\4M2"*%!
MBA)QZF,5Y]7H?QN_Y*GJ/_7&#_T6*\\K]UR[_=8'Q\_B/8OV=O\ D;-6_P"O
M$?\ H8K@_B(BQ_$7Q B*%47KX KO/V=O^1LU;_KQ'_H8KA?B/_R4CQ#_ -?K
MUQ4/^1G/T_R*?P(Y>O>_V= &T[Q(",@O "/^ O7@E>^?LY_\@_Q'_P!=(/\
MT%ZVSC_=OFA4]S0T(!='A51@!I  .W[QJT:S]$_Y!,7^_)_Z,:M"OP;%_P"\
M5/5_F?;4/X4?1%[PTBOX3\6*R@J;B;(/?]RE?*E?5GAC_D5?%?\ U\3?^B4K
MY3K]BX6_W=?X8_D?(XW^++U85]&^&U4_L[PY Z9_'SQ7SE7T=X:_Y-WB^G_M
M<5V<0?P%\_R,J'QEX=!]*AO/^/"Y_P"N3_R-3#H/I4-Y_P >%S_UR?\ D:_"
MX_$C[9[%_6E4?#CPP H %Q;8]OE:J_>K6M_\DY\,_P#7Q:_^@FJO>OH>)?\
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M&,5WU !1110 4444 %%%% !7/6G_ "/NJ?\ 7C;_ /H4E=#7/6G_ "/NJ?\
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MSX?_ /)O&H?]<;W^;5\YU]&?#_\ Y-XU#_KC>_S:C._X4?7]!TMR]#_J(_\
M<'\J?3(?]1'_ +@_E3Z_!7N?<+8I:Y_R;D__ %P'_HVOF^OI#7/^3<G_ .N
M_P#1M?-]?NV0?PI?+\CXBM\0C?=/TKZ)^+G_ "1G1?\ MU_] KYV;[I^E?1/
MQ<_Y(SHO_;K_ .@5IF7^\4?7]43#9GSO5[1/^0_IO_7U%_Z$*HU>T3_D/Z;_
M -?47_H0KU,1_!GZ/\B%N>U_M&_ZOP__ +TW\EKP:O>?VC?]7X?_ -Z;^2UX
M-7#D_P#NWS953<ZKX:?\E)T'_KZ'\C7OWBK_ )'UO^P;'_Z,>O ?AI_R4G0?
M^OH?R->_>*O^1];_ +!L?_HQZ^6XS_@S]%^9Z&5_QX_/\BI3])_Y'?1/I/\
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MUXR?^A+7EM>I? +_ )*))_UXR?\ H2UUYG_NLOE^9,/B,+XM?\E/UK_KHO\
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M7J8C^#/T?Y$+<]K_ &C?]7X?_P!Z;^2UX-7O/[1O^K\/_P"]-_):\&KAR?\
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M$E>)5R91_NJ]654^([CX/_\ )5=$_P!Z7_T4];/Q[_Y**O\ UY1_S:L;X/\
M_)5=$_WI?_13UL_'O_DHJ_\ 7E'_ #:L)?\ (TCZ?HQ_8/+J]2^ 7_)1)/\
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M )!3?]=(_P#T,5F_M&?ZK0?]Z7^0KW>"]U_B_1''G'QKT/!:ZKX:?\E*\/\
M_7XM<K75?#3_ )*5X?\ ^OQ:_3<;_N\_1GB1W/??%'_(]R?]>"?^AFJM6O%'
M_(]R?]>"?^AFJM?A6>_[]/Y?DCZ[+O\ =X_/\Q^D?\COHO\ NS_^@5X_\:O^
M2HZE_P!<XO\ T 5[!I'_ ".^B_[L_P#Z!7C_ ,:O^2HZE_USB_\ 0!7W7!7\
M.'_;QXN;?QW\CS^O9_V=?^1AUK_KUC_]"->,5[/^SK_R,.M?]>L?_H1K[/-O
M]UE\OS/,A\1YUX^_Y*'XB_[",_\ Z&:YVNB\??\ )0_$7_81G_\ 0S7.UTX/
M_=X>B_(4MSZ#_9R_Y VO?]?,?_H!J;PY_P B[9?[A_\ 0C4/[.7_ "!M>_Z^
M8_\ T U-X<_Y%VR_W#_Z$:_+^,]_^WW^I[>3_&_0U*O>&/\ D3/%W_7U=?\
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M66(6_="AW?GF@"Q15<K=_:PPEB^S]TV'=^>?Z4;;O[7N\V+[/_<V'=^>?Z4
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M/I^C']@\OKU+X!?\E$D_Z\9/_0EKRVO4?@'N_P"%C-M( ^Q2;LCJ,K77F?\
MNLOE^9,/B,/XM?\ )3]:_P"NB_\ H(KBJ[7XM9_X6=K6?^>B_P#H(KBJTP'^
M[0] E\3/;OV<_P#D)Z[_ -<8_P"9KRGQ9_R.&L_]?DO_ *$:]4_9TW_VOKA!
M&WR(\C'/4UY7XK_Y&_6?^OR7_P!"-<&&_P"1C4_KL4_@1CU]!? G_D0O$/\
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MA8V]YJ,5S)'/.(%%O%O;<03TSTX[5UX3&3PK;BKW)E'F/CO^QM5_Z!E[_P"
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MGJ/_ %Q@_P#18KSROW7+O]U@?'S^(]B_9V_Y&S5O^O$?^ABN%^(__)2/$/\
MU^O7=?L[?\C9JW_7B/\ T,5POQ'_ .2D>(?^OUZXJ'_(SGZ?Y%/X$<O7OG[.
M?_(/\1_]=(/_ $%Z\#KWS]G/_D'^(_\ KI!_Z"];9Q_NWS0J>YHZ)_R"8O\
M?D_]&-6A6?HG_()B_P!^3_T8U:%?@V+_ -XJ>K_,^VH?PH^B+_AC_D5?%?\
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MJ6BB@ HHHH **** "BBB@ KGK3_D?=4_Z\;?_P!"DKH:YZT_Y'W5/^O&W_\
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M]7M$_P"0_IO_ %]1?^A"J-7M$_Y#^F_]?47_ *$*]3$?P9^C_(A;GM?[1O\
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M>J6L_P#("U'_ *]9?_0#5WO5+6?^0%J/_7K+_P"@&OQ"E\<?4^SG\+-SQ/\
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M^1WT7_=G_P#0*\?^-7_)4=2_ZYQ?^@"ONN"OX</^WCQ<V_COY'G]>S_LZ_\
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M#'ALJ93G''.WO7A->\_M&_ZOP_\ [TW\EKP:N')_]V^;*J;G5?#3_DI.@_\
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M?^0%J/\ UZR_^@&OQ"E\<?4^SG\+-GQ%()?#/A%PK >;%PPP?]2U4ZO^)_\
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M\+G_ *Y/_(U^%Q^)'VSV-'6_^2<^&?\ KXM?_0357O5K6_\ DG/AG_KXM?\
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M"7Q,]N_9S_Y">N_]<8_YFO*?%G_(X:S_ -?DO_H1KU;]G/\ Y">N_P#7&/\
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M_P"B6JA5_P 3_P#(N^$O^NL7_HEJH5[_ !+_ +U'_#^K/-RG^"_7]$9VN?\
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M#^%'T1?\,?\ (J^*_P#KXF_]$I7RG7U9X8_Y%7Q7_P!?$W_HE*^4Z_8N%O\
M=U_AC^1\CC?XLO5A7T=X:_Y-WB^G_M<5\XU]'>&O^3=XOI_[7%=G$'\!?/\
M(RH?&7AT'TJ&\_X\+G_KD_\ (U,.@^E0WG_'A<_]<G_D:_"X_$C[9[&CK?\
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MMG+))$XRCC(R/0@]Q0!T=<]:?\C[JG_7C;_^A25T-<_:?\C[JG_7C;_^A24
M=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+6?^0%J/_7K+_P"@&OQ"E\<?4^SG\+-SQ/\ \B[X2_ZZQ?\ HEJH5?\ $_\
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M&<_SKC?"/A6V\.>)[%)]8@;61I\WVJUAB($V^7?O!_NJ25 (KT>AMO<#CY_
MO@RV18I[2"$D9&^X96/YM4-EX.\"ZQ:-]AM[>YB4E&:*X8G(.""<U;\;>!M/
M\86L+S11#4+0[K:61=RY_N..Z'N/RK,^%_A^Q\-:;=:<W]GKKB2%KZ.TEWE
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M[K.#$[#<#[\\?C7KX/,UAZ2I\M_F9RA=W/$?@_\ \E5T/_>E_P#13UL_'O\
MY**O_7E'_-J][TGP3X4TR[AU+2M&L89U&8IX5YP1C(/N#7@?Q\8#XC*"0/\
M0HNI]VJ\/BE7Q\:EK:?HP<;1L>7UZE\ O^2B2?\ 7C)_Z$M>5[U_O+^=>J?
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MU5K\*SW_ 'Z?R_)'UV7?[O'Y_F/TC_D=]%_W9_\ T"O'_C5_R5'4O^N<7_H
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MHH *" >HHHH ,#.<=>M%%% #3&C2+(44NN=K$<C/7!H"('+A5#L,%L<FG44
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M,_U6@_[TO\A7N\%[K_%^B././C7H>"UU7PT_Y*5X?_Z_%KE:ZKX:?\E*\/\
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M^:^ASYAB(XB2<.Q\F5U7PT_Y*5X?_P"OQ:]+_P"&<G_Z&-?_  &_^RK6\,_
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MY'W5/^O&W_\ 0I* .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .*\1>!1XC\33W5VZ?V==:4UC* ?WL;>8'#)D$=L5
M?\-^&Y]%U_7[U_LZV]\\'V>.'.0L<>W+# &X^U=-10 5Y;K.HV5CXPUU+#2'
MU'69[NPA%M=.H@,FPLDPXRNT @GU Q7J5<UXB\!^'O%-W%>:G9L;N(!4GAE:
M-\ Y RIYYH H_#4QG0M1_<RPWO\ :EP;Y))1(!.2"VU@ "N"N/RKLZH:-HNG
M^'],CT[3+9;>VC)(4$DDGDDD\DGU-7Z .;LO!]K;V.M6-Q,UQ:ZG>2780KM,
M)?!X/J",@]JM^%= 3POX:LM&CN&N$M5*B5EP6RQ/(_&MFB@ [5XUJ_Q$U#6[
M*6TB;1+)8+6XEU&WU%BP<I(4$.,@@D#/XC%>RU\Z:_K%KJ^K>;J=QHVBZSI\
M4\MR)-.5Y+J=9"(XBK9R"H!R,DYXH ]Y\/2Q3^'--FAM1:1/;1LEN!CRP5'R
M_A6B0""",@]0:I:+<SWFAV%S<P"">6W1Y(@,;&*@D4NKPSW&C7T%M*(IY('2
M-R<;6*D _G0!A:MIVEV'A4Z;I^C0ZA;22;%LHYE0OE\MAB>QR<5U"#$:C;MP
M!QZ5\W1^%+Z&:UA/A\6ES,L4&GYU-3]FG0@S7&-W\6,\=:^DDR$4,<G')]:
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MY1U%3!5#;@H!/?% 5020H!/4@4 0PWEO<2/'%*KNGW@.U$-Y;W+.L,JNR?>
M[5,$522% )ZX% 15SM4#/7 H A@O+>YW^3,K[/O8[407EO<J[0S*X3[Q':I@
MBKG:H&>N!0$5<[5 SUP* (8;VVN(WDAF5T3[Q':B*]MIX6EBF5HT^\PZ"I@B
MJ,!0 >N!0$4# 4 'L!0!#'>VTL#3QS*T2_>8=!0E[;26S7"3*85ZN.@J8(H7
M 4 'MBC8H7:%&WTQ0!"M[;-;&Y$RF$=7[4?;;8VWVGSE\D?Q]JFV+MV[1M],
M4;%V[=HV^F.* (3>VPMOM)F7R3_'VH:]MDMA<M,HA/1^U3;%V[=HV^F.*-B[
M=NT;?3% $+WMM';K</,HB;HYZ&B2]MHH%GDF58G^ZQZ&IBBE=I48],4%%(P5
M! [8H AEO;:"))99E6-_NL>]$UY;6\:/-,J*_P!TGO4Q12 "H('0$4%%8 %0
M0.F10!#/>VULJ--,J!_ND]Z)[RWMB@FF5-_W<]ZF**V-R@XZ9%!16QN4''3(
MH AFO+>V=$FE5&?[H/>B:\M[>5(Y951W^Z#WJ8HK$%E!QTR*"BL<E02.A(H
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M_,5]TUMCL']5FHWO<49<QS3>&-'1MKZGJJMZ'6K@'_T94O\ PAVG?\_FM?\
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MJQ.2=AS@KSY9]>-/X>^+]5\9:EK]Y(+==%M;HVUB8D)\[!.7WD\\ '&!]X4
M;O\ PAVG_P#/YK7_ (-[G_XY6=JFF>&-$$1U77M0LA*2(_/URX3?C&<9DYQD
M?G78UP7CO_D9O#__ %[WG\X:Y\57]A1E5M>RN:T:?M*BAW(OMO@'_H<)O_"@
MG_\ CE;\7A32IX8YH=0UB2*10Z.NL7)# \@@^9TKBKS_ (\;G_KD_P#(UZ!X
M3_Y$W0_^P?;_ /HM:XLKS/Z\I/EY>6W6^]_)&^,PGU9I7O<HMX9T96*MJFJA
MEZ@ZU<9'_D2I$\):7*@>._UAU/0KK%R1_P"C*\Y^,^E:<GB#P9*FGVJR76K
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M.;>,:=J.B7&GZ.;:VTV^BPSPF4$R!P3D X&* /4:*** "BBB@ HHHH ****
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M\\5WL7S!O)++CI@\?D*ZO_A&;G_H8]7_ ._J_P"%'_",W/\ T,>K_P#?U?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ggtc45pq2o35000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -"!SX# 2(  A$! Q$!_\0
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MK7EE% 'J?_"UK'_H&7'_ 'VM'_"UK'_H&7'_ 'VM>644 >I_\+6L?^@9<?\
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MC_A:UC_T#+C_ +[6O+** /4_^%K6/_0,N/\ OM:/^%K6/_0,N/\ OM:\LHH
M]3_X6M8_] RX_P"^UH_X6M8_] RX_P"^UKRRB@#U/_A:UC_T#+C_ +[6C_A:
MUC_T#+C_ +[6O+** /4_^%K6/_0,N/\ OM:/^%K6/_0,N/\ OM:\LHH ]3_X
M6M8_] RX_P"^UH_X6M8_] RX_P"^UKRRB@#U/_A:UC_T#+C_ +[6C_A:UC_T
M#+C_ +[6O+** /4_^%K6/_0,N/\ OM:/^%K6/_0,N/\ OM:\LHH ]3_X6M8_
M] RX_P"^UH_X6M8_] RX_P"^UKRRB@#U/_A:UC_T#+C_ +[6C_A:UC_T#+C_
M +[6O+** /4_^%K6/_0,N/\ OM:/^%K6/_0,N/\ OM:\LHH ]3_X6M8_] RX
M_P"^UH_X6M8_] RX_P"^UKRRB@#U/_A:UC_T#+C_ +[6C_A:UC_T#+C_ +[6
MO+** /4_^%K6/_0,N/\ OM:/^%K6/_0,N/\ OM:\LHH ]3_X6M8_] RX_P"^
MUH_X6M8_] RX_P"^UKRRB@#U/_A:UC_T#+C_ +[6C_A:UC_T#+C_ +[6O+**
M /4_^%K6/_0,N/\ OM:VM>\:6^@K9&6TEE^U1>8NU@-HXX_6O$J[KXC?ZK0O
M^O3_ .)H V?^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^U
MH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^
M%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_
M[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^U
MH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^
M%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_
M[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^U
MH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^
M%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_
M[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^U
MH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^
M%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_
M[[6O+** /4_^%K6/_0,N/^^UH_X6M8_] RX_[[6O+** /4_^%K6/_0,N/^^U
MK4T#QY:Z_JJ6$5E-$S*S;F8$<#->,5UGPY_Y'&#_ *Y2?^@T =;=_$ZRM+V>
MV;3IV:&1HR0XYP<5#_PM:Q_Z!EQ_WVM>=:U_R'=0_P"OF3_T(U1H ]3_ .%K
M6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\
MT#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K
M6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\
MT#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K
M6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\
MT#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K
M6/\ T#+C_OM:/^%K6/\ T#+C_OM:\LHH ]3_ .%K6/\ T#+C_OM:/^%K6/\
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M[6O+** /4_\ A:UC_P! RX_[[6C_ (6M8_\ 0,N/^^UKRRB@#U/_ (6M8_\
M0,N/^^UH_P"%K6/_ $#+C_OM:\LHH ]3_P"%K6/_ $#+C_OM:/\ A:UC_P!
MRX_[[6O+** /4_\ A:UC_P! RX_[[6C_ (6M8_\ 0,N/^^UKRRB@#U/_ (6M
M8_\ 0,N/^^UH_P"%K6/_ $#+C_OM:\LHH ]3_P"%K6/_ $#+C_OM:/\ A:UC
M_P! RX_[[6O+** /4_\ A:UC_P! RX_[[6C_ (6M8_\ 0,N/^^UKRRB@#U/_
M (6M8_\ 0,N/^^UH_P"%K6/_ $#+C_OM:\LHH ]3_P"%K6/_ $#+C_OM:/\
MA:UC_P! RX_[[6O+** /4_\ A:UC_P! RX_[[6C_ (6M8_\ 0,N/^^UKRRB@
M#U[2_B/::IJEM8I83HT[A S.,#-/UCXAVFCZM<:?)832/"0"ZN #D _UKS?P
ME_R-NE_]?"U/XX_Y'/4O]]?_ $$4 =G_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'
M_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\
MH&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'
M_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\
MH&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'
M_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\
MH&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'
M_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\
MH&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'
M_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\
MH&7'_?:TZ/XIV4DBH--N!N('WUKRJI;?_CZA_P!\?SH ]F\1^-[;PYJ2V4UG
M+,S1"3<C #DD8_2L?_A:UC_T#+C_ +[6L'XH?\C3#_UZ)_Z$U<50!ZG_ ,+6
ML?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\
MH&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6
ML?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\
MH&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6
ML?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\
MH&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6
ML?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\
MH&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6
ML?\ H&7'_?:T?\+6L?\ H&7'_?:UY910!ZG_ ,+6L?\ H&7'_?:T?\+6L?\
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M_P!?"U/XX_Y'/4O]]?\ T$5!X2_Y&W2_^OA:G\<?\CGJ7^^O_H(H Y^BBB@
MHHHH **** "BBB@!T:AY44]"P!KU'7-)\$^'I;6*^TN<_: <21RN0N,9)^?W
M[ UYA!_Q\1_[P_G7L'C*#PW+<6$FOW<\)16,4<8)$@XR#A2?3N* .<U'PM;:
M#XPT.>R<M9W-RA57.2I# ]>XY%/\;>'-6UKQ5))IUB\R+ @9\JJYYXRQ )J*
M^\4P^(O&6AQVD;I:6UPH3?P6)(R<=AQQ5KQMX@U2Q\7VMM:WDD,$:QMY:' 8
MD\[O7Z&@#@9],OK;4/L$UK*MWN"B+;EB3TQZYK6;P-XE6 S'2WV@9P)$+?\
M?.<_ABNO\865Q=_$#1H[&58+IX@5F(SMVECG'? !XK8TPV%IXF^QOXEU*\U+
M!WVTCDQ$XR> NT>O!H \BLM-O=1O/LEI;22W'=%'(QUSZ?C5O5/#.L:+ LVH
M630Q,VT.'5AG_@).*Z^SU^Q\/^.]=2\5HX;F0KYT8R8SG/3K@Y[>U1>)M,O#
MX<DOK#Q#-J>D,ZLZ3OO9#G ^8^YY'% '+:9X8UG683-86#RQ XWEE13]"Q&?
MPJGJ.EWVDW/V>_MI()<9 8<$>H/0CZ5ZYK3Z1IVDZ9:W>LWVEPB/$7V(E=^
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M26/G>;C;D ?=QST]:YVB@#H= \4?V'IFHV7V/S_MB[=_F[=G!'3!SUKGJ**
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M_I'Y?D>=_LXSNV_TKDZ* +NKZA_:NKW5_P"5Y7GR%]F[=M_'BJ5%% !1110
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M1110 4444 %%%% !7T#X=_Y%C2?^O.'_ - %?/U?0/AW_D6-)_Z\X?\ T 4
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M_3?^^A_\11_PM>S_ .A/TW_OH?\ Q%>9T4?5:/8/:S[GIG_"U[/_ *$_3?\
MOH?_ !%'_"U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/\ Z$_3?^^A_P#$
M4?\ "U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/_H3]-_[Z'_Q%'_"U[/_
M *$_3?\ OH?_ !%>9T4?5:/8/:S[GIG_  M>S_Z$_3?^^A_\11_PM>S_ .A/
MTW_OH?\ Q%>9T4?5:/8/:S[GIG_"U[/_ *$_3?\ OH?_ !%'_"U[/_H3]-_[
MZ'_Q%>9T4?5:/8/:S[GIG_"U[/\ Z$_3?^^A_P#$4?\ "U[/_H3]-_[Z'_Q%
M>9T4?5:/8/:S[GIG_"U[/_H3]-_[Z'_Q%'_"U[/_ *$_3?\ OH?_ !%>9T4?
M5:/8/:S[GIG_  M>S_Z$_3?^^A_\11_PM>S_ .A/TW_OH?\ Q%>9T4?5:/8/
M:S[GIG_"U[/_ *$_3?\ OH?_ !%'_"U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GI
MG_"U[/\ Z$_3?^^A_P#$4?\ "U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[
M/_H3]-_[Z'_Q%=!XH^(D.F1Z,TOAZTN_MFGQ7:B5A^ZW_P  ^4\#'7CZ5XG7
M9^/_ /4^%?\ L VW]:B6&I*25BE5G9ZFS_PM>S_Z$_3?^^A_\11_PM>S_P"A
M/TW_ +Z'_P 17F=%7]5H]B?:S[GIG_"U[/\ Z$_3?^^A_P#$4?\ "U[/_H3]
M-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/_H3]-_[Z'_Q%'_"U[/_ *$_3?\ OH?_
M !%>9T4?5:/8/:S[GIG_  M>S_Z$_3?^^A_\11_PM>S_ .A/TW_OH?\ Q%>9
MT4?5:/8/:S[GIG_"U[/_ *$_3?\ OH?_ !%'_"U[/_H3]-_[Z'_Q%>9T4?5:
M/8/:S[GIG_"U[/\ Z$_3?^^A_P#$4?\ "U[/_H3]-_[Z'_Q%>9T4?5:/8/:S
M[GIG_"U[/_H3]-_[Z'_Q%'_"U[/_ *$_3?\ OH?_ !%>9T4?5:/8/:S[GIG_
M  M>S_Z$_3?^^A_\11_PM>S_ .A/TW_OH?\ Q%>9T4?5:/8/:S[GIG_"U[/_
M *$_3?\ OH?_ !%'_"U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/\ Z$_3
M?^^A_P#$4?\ "U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/_H3]-_[Z'_Q
M%'_"U[/_ *$_3?\ OH?_ !%>9T4?5:/8/:S[GIG_  M>S_Z$_3?^^A_\11_P
MM>S_ .A/TW_OH?\ Q%>9T4?5:/8/:S[GIG_"U[/_ *$_3?\ OH?_ !%'_"U[
M/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/\ Z$_3?^^A_P#$4?\ "U[/_H3]
M-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/_H3]-_[Z'_Q%'_"U[/_ *$_3?\ OH?_
M !%>9T4?5:/8/:S[GIG_  M>S_Z$_3?^^A_\11_PM>S_ .A/TW_OH?\ Q%>9
MT4?5:/8/:S[GIG_"U[/_ *$_3?\ OH?_ !%'_"U[/_H3]-_[Z'_Q%>9T4?5:
M/8/:S[GIG_"U[/\ Z$_3?^^A_P#$4?\ "U[/_H3]-_[Z'_Q%>9T4?5:/8/:S
M[GIG_"U[/_H3]-_[Z'_Q%'_"U[/_ *$_3?\ OH?_ !%>9T4?5:/8/:S[GIG_
M  M>S_Z$_3?^^A_\11_PM>S_ .A/TW_OH?\ Q%>9T4?5:/8/:S[GIG_"U[/_
M *$_3?\ OH?_ !%'_"U[/_H3]-_[Z'_Q%>9T4?5:/8/:S[GIG_"U[/\ Z$_3
M?^^A_P#$5H:%\4[>XUVQM8O"]E;M<3I!YL3@,NY@N?N>_2O(ZUO"_P#R-NC?
M]?T'_HQ:4L-246[#56=]SZ2:STUW9WTNS9F.23"I)/Y4GV'2_P#H$V7_ 'Y7
M_"N>NOB!X7LKN:UN-3V302-'(OV>4[6!P1D+CJ*B_P"%D^$O^@M_Y+2__$UY
M?LJG\K^XZ^>/<Z;[#I?_ $";+_ORO^%'V'2_^@39?]^5_P *YG_A9/A+_H+?
M^2TO_P 31_PLGPE_T%O_ "6E_P#B:/8U/Y7]P<\>YTWV'2_^@39?]^5_PH^P
MZ7_T";+_ +\K_A7,_P#"R?"7_06_\EI?_B:/^%D^$O\ H+?^2TO_ ,31[&I_
M*_N#GCW.F^PZ7_T";+_ORO\ A1]ATO\ Z!-E_P!^5_PKF?\ A9/A+_H+?^2T
MO_Q-'_"R?"7_ $%O_):7_P")H]C4_E?W!SQ[G3?8=+_Z!-E_WY7_  H^PZ7_
M - FR_[\K_A7,_\ "R?"7_06_P#):7_XFC_A9/A+_H+?^2TO_P 31[&I_*_N
M#GCW.F^PZ7_T";+_ +\K_A1]ATO_ *!-E_WY7_"N9_X63X2_Z"W_ )+2_P#Q
M-'_"R?"7_06_\EI?_B:/8U/Y7]P<\>YTWV'2_P#H$V7_ 'Y7_"C[#I?_ $";
M+_ORO^%<S_PLGPE_T%O_ "6E_P#B:/\ A9/A+_H+?^2TO_Q-'L:G\K^X.>/<
MZ;[#I?\ T";+_ORO^%'V'2_^@39?]^5_PKF?^%D^$O\ H+?^2TO_ ,31_P +
M)\)?]!;_ ,EI?_B:/8U/Y7]P<\>YTWV'2_\ H$V7_?E?\*/L.E_] FR_[\K_
M (5S/_"R?"7_ $%O_):7_P")H_X63X2_Z"W_ )+2_P#Q-'L:G\K^X.>/<Z;[
M#I?_ $";+_ORO^%'V'2_^@39?]^5_P *YG_A9/A+_H+?^2TO_P 31_PLGPE_
MT%O_ "6E_P#B:/8U/Y7]P<\>YTWV'2_^@39?]^5_PH^PZ7_T";+_ +\K_A7,
M_P#"R?"7_06_\EI?_B:/^%D^$O\ H+?^2TO_ ,31[&I_*_N#GCW.F^PZ7_T"
M;+_ORO\ A1]ATO\ Z!-E_P!^5_PKF?\ A9/A+_H+?^2TO_Q-'_"R?"7_ $%O
M_):7_P")H]C4_E?W!SQ[G3?8=+_Z!-E_WY7_  J6"&RM9/,M]/MHGQC='&JG
M'U KE/\ A9/A+_H+?^2TO_Q-'_"R?"7_ $%O_):7_P")H]C4_E?W!SQ[G3M9
M:8S%FTNS+$Y),*\_I2?8=+_Z!-E_WY7_  KF?^%D^$O^@M_Y+2__ !-'_"R?
M"7_06_\ ):7_ .)H]C4_E?W!SQ[G3?8=+_Z!-E_WY7_"C[#I?_0)LO\ ORO^
M%<S_ ,+)\)?]!;_R6E_^)H_X63X2_P"@M_Y+2_\ Q-'L:G\K^X.>/<Z;[#I?
M_0)LO^_*_P"%'V'2_P#H$V7_ 'Y7_"N9_P"%D^$O^@M_Y+2__$T?\+)\)?\
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M^)H]C4_E?W!SQ[G3?8=+_P"@39?]^5_PH^PZ7_T";+_ORO\ A7,_\+)\)?\
M06_\EI?_ (FC_A9/A+_H+?\ DM+_ /$T>QJ?RO[@YX]SIOL.E_\ 0)LO^_*_
MX4?8=+_Z!-E_WY7_  KF?^%D^$O^@M_Y+2__ !-'_"R?"7_06_\ ):7_ .)H
M]C4_E?W!SQ[G3?8=+_Z!-E_WY7_"C[#I?_0)LO\ ORO^%<S_ ,+)\)?]!;_R
M6E_^)H_X63X2_P"@M_Y+2_\ Q-'L:G\K^X.>/<Z;[#I?_0)LO^_*_P"%'V'2
M_P#H$V7_ 'Y7_"N9_P"%D^$O^@M_Y+2__$T?\+)\)?\ 06_\EI?_ (FCV-3^
M5_<'/'N=-]ATO_H$V7_?E?\ "C[#I?\ T";+_ORO^%<S_P +)\)?]!;_ ,EI
M?_B:/^%D^$O^@M_Y+2__ !-'L:G\K^X.>/<Z;[#I?_0)LO\ ORO^%'V'2_\
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MS_PLGPE_T%O_ "6E_P#B:/\ A9/A+_H+?^2TO_Q-'L:G\K^X.>/<Z;[#I?\
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M_06_\EI?_B:/^%D^$O\ H+?^2TO_ ,31[&I_*_N#GCW.F^PZ7_T";+_ORO\
MA1]ATO\ Z!-E_P!^5_PKF?\ A9/A+_H+?^2TO_Q-'_"R?"7_ $%O_):7_P")
MH]C4_E?W!SQ[G3?8=+_Z!-E_WY7_  I18Z8#D:59@C_IBO\ A7,?\+)\)?\
M06_\EI?_ (FC_A9/A+_H+?\ DM+_ /$T>QJ?RO[@YX]SJ[B*RNI/,N+"WF<#
M :2,,<>F2*B^PZ7_ - FR_[\K_A572-;T[7;0W.F72W$0;:2 00?0@@$5?J&
MFG9E*S(OL.E_] FR_P"_*_X4?8=+_P"@39?]^5_PJ6BD,B^PZ7_T";+_ +\K
M_A1]ATO_ *!-E_WY7_"I:* (OL.E_P#0)LO^_*_X4?8=+_Z!-E_WY7_"I:*
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M1RL_^P>G_HR2O-Z](^-?_(Y6?_8/3_T9)7F]>WA_X43AJ?&PHHHK8S"BBB@
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MU9-:WBC_ )&W6?\ K^G_ /1C5DT0^%!+<****H04444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!R[#RX5Z_+G!R?4?Q4>T7XV#E9R5%>F^)K+P/X3U>&WET2YOI)HHW>$73QI
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MXVYX!//M4>V]ZZU5KE<FEO,\SHKM-%\%V\_BG6+34KATTW1A))<R1CYG52<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK4T#0+[Q'J:65DF2>9)#]V-?4TFTE=C2;=D&
M@:!?>(]32RLDR3S)(?NQKZFOH'P[X=L?#6F+9V:Y)YEE8?-(WJ?Z#M1X=\.V
M/AK3%L[-<D\RRL/FD;U/]!VK7KR,1B'4=EL=M*ER*[W"BBBN8U"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KUO\
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M9?\ XJC_ (5MX2_Z!/\ Y,R__%57UZGV8OJ\CY^HKZ!_X5MX2_Z!/_DS+_\
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M+_\ %4?\*V\)?] G_P F9?\ XJCZ]3[,/J\CY^HKZ!_X5MX2_P"@3_Y,R_\
MQ5'_  K;PE_T"?\ R9E_^*H^O4^S#ZO(^?J*^@?^%;>$O^@3_P"3,O\ \51_
MPK;PE_T"?_)F7_XJCZ]3[,/J\CY^HKZ!_P"%;>$O^@3_ .3,O_Q5'_"MO"7_
M $"?_)F7_P"*H^O4^S#ZO(^?J*^@?^%;>$O^@3_Y,R__ !5'_"MO"7_0)_\
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MR_\ Q5'_  K;PE_T"?\ R9E_^*H^O4^S#ZO(^?J*^@?^%;>$O^@3_P"3,O\
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M +!Z?^C)*\WKTCXU_P#(Y6?_ &#T_P#1DE>;U[>'_A1."I\;"BBBMC,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .S^'/_'_ *Y_V!;G_P!EKC*[/X<_\?\ KG_8%N?_ &6N,K./QR^1;^%!
M1116A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>H>)=*T"^T[PQ)JOB3^RYET6V58O
ML,DVY<'YLJ<#G(Q[5Y?79^/_ /4^%?\ L VW]:QJ)N4;.VY<79,9_P ([X-_
MZ'O_ ,I$W^-'_".^#?\ H>__ "D3?XUQ]%5R2_F?X?Y"YEV_,[#_ (1WP;_T
M/?\ Y2)O\:/^$=\&_P#0]_\ E(F_QKCZ*.27\S_#_(.9=OS.P_X1WP;_ -#W
M_P"4B;_&C_A'?!O_ $/?_E(F_P :X^BCDE_,_P /\@YEV_,[#_A'?!O_ $/?
M_E(F_P :/^$=\&_]#W_Y2)O\:X^BCDE_,_P_R#F7;\SL/^$=\&_]#W_Y2)O\
M:/\ A'?!O_0]_P#E(F_QKCZ*.27\S_#_ "#F7;\SL/\ A'?!O_0]_P#E(F_Q
MH_X1WP;_ -#W_P"4B;_&N/HHY)?S/\/\@YEV_,[#_A'?!O\ T/?_ )2)O\:/
M^$=\&_\ 0]_^4B;_ !KCZ*.27\S_  _R#F7;\SL/^$=\&_\ 0]_^4B;_ !H_
MX1WP;_T/?_E(F_QKCZ*.27\S_#_(.9=OS.P_X1WP;_T/?_E(F_QH_P"$=\&_
M]#W_ .4B;_&N/HHY)?S/\/\ (.9=OS.P_P"$=\&_]#W_ .4B;_&C_A'?!O\
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M /H.Z9_X%Q_XT?\ "4>'_P#H.Z9_X%Q_XT<DNP<R-:BLG_A*/#__ $'=,_\
M N/_ !H_X2CP_P#]!W3/_ N/_&CDEV#F1K45D_\ "4>'_P#H.Z9_X%Q_XT?\
M)1X?_P"@[IG_ (%Q_P"-')+L',C6HK)_X2CP_P#]!W3/_ N/_&C_ (2CP_\
M]!W3/_ N/_&CDEV#F1K45D_\)1X?_P"@[IG_ (%Q_P"-'_"4>'_^@[IG_@7'
M_C1R2[!S(UJ*R?\ A*/#_P#T'=,_\"X_\:/^$H\/_P#0=TS_ ,"X_P#&CDEV
M#F1K45D_\)1X?_Z#NF?^!<?^-'_"4>'_ /H.Z9_X%Q_XT<DNP<R-:BLG_A*/
M#_\ T'=,_P# N/\ QH_X2CP__P!!W3/_  +C_P :.278.9&M163_ ,)1X?\
M^@[IG_@7'_C1_P )1X?_ .@[IG_@7'_C1R2[!S(UJ*R?^$H\/_\ 0=TS_P "
MX_\ &C_A*/#_ /T'=,_\"X_\:.278.9&M163_P )1X?_ .@[IG_@7'_C1_PE
M'A__ *#NF?\ @7'_ (T<DNP<R-:BLG_A*/#_ /T'=,_\"X_\:T+6\MKZ 3VE
MS#<0DD"2%PZG'N*3BUN@NF34444AA1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z/PAXON_"NH;TW2V4I
M'GV^>O\ M#T8?K7.45,HJ2LQIM.Z/J'3-3M-7T^*^L9A+!*,JP[>Q]"/2K=?
M.WA#Q?=^%=0WINELI2//M\]?]H>C#]:]^TS4[35]/BOK&82P2C*L.WL?0CTK
MR*]!TGY'=3J*:\RW1117.:!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:-;)'/!"%=@6;$A.3C_>K6F^*7AFXE-W/X.@EO3SYCK&Q)_WRN:XV^\7M?\
MCBV\1O8I&()8G%O&_&U,8&<>W7'X4X4VVVXM.W<)2\SL/C>[_P!JZ3'N;8('
M8+GC.X<_H*P?A*0/']KD]89<?]\FJ?COQDGC&^M+B.R:U6WB*8:3?NR<^@K%
MT'6;CP]KEKJEJJM+;L3M;HP(((/U!-7"G+V'(][$RDO:<QTWQ:1E^(%V6! >
M*(K[C:!_,&N@TOP=X:\/^"(/$OB2">^>>-)%AC8@*'QM  (R<'DDXJOXD^*M
MCKN@W-F-#*74\1C$LDBMY8/4@XR?TJOX?^*$-GX=CT/7-(74;6)!&AR/F0=
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M_P"_L?\ \11_PI_P_P#\_FI_]_8__B*/KE(/83/$Z*]L_P"%/^'_ /G\U/\
M[^Q__$4?\*?\/_\ /YJ?_?V/_P"(H^N4@]A,\3HKVS_A3_A__G\U/_O['_\
M$4?\*?\ #_\ S^:G_P!_8_\ XBCZY2#V$SQ.BO;/^%/^'_\ G\U/_O['_P#$
M4?\ "G_#_P#S^:G_ -_8_P#XBCZY2#V$SQ.BO;/^%/\ A_\ Y_-3_P"_L?\
M\11_PI_P_P#\_FI_]_8__B*/KE(/83/$Z*]L_P"%/^'_ /G\U/\ [^Q__$4?
M\*?\/_\ /YJ?_?V/_P"(H^N4@]A,\3HKVS_A3_A__G\U/_O['_\ $4?\*?\
M#_\ S^:G_P!_8_\ XBCZY2#V$SQ.BO;/^%/^'_\ G\U/_O['_P#$4?\ "G_#
M_P#S^:G_ -_8_P#XBCZY2#V$SQ.BO;/^%/\ A_\ Y_-3_P"_L?\ \11_PI_P
M_P#\_FI_]_8__B*/KE(/83/$Z*]L_P"%/^'_ /G\U/\ [^Q__$4?\*?\/_\
M/YJ?_?V/_P"(H^N4@]A,\3HKVS_A3_A__G\U/_O['_\ $4?\*?\ #_\ S^:G
M_P!_8_\ XBCZY2#V$SQ.BO;/^%/^'_\ G\U/_O['_P#$4?\ "G_#_P#S^:G_
M -_8_P#XBCZY2#V$SQ.BO;/^%/\ A_\ Y_-3_P"_L?\ \11_PI_P_P#\_FI_
M]_8__B*/KE(/83/$Z*]L_P"%/^'_ /G\U/\ [^Q__$4?\*?\/_\ /YJ?_?V/
M_P"(H^N4@]A,\3HKVS_A3_A__G\U/_O['_\ $4?\*?\ #_\ S^:G_P!_8_\
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M_G\U/_O['_\ $4?\*?\ #_\ S^:G_P!_8_\ XBCZY2#V$SQ.BO;/^%/^'_\
MG\U/_O['_P#$4?\ "G_#_P#S^:G_ -_8_P#XBCZY2#V$SQ.BO;/^%/\ A_\
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MSK225D%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M];_ZA?Q_G5&KUO\ ZA?Q_G0!X;\:_P#D<K/_ +!Z?^C)*\WKTCXU_P#(Y6?_
M &#T_P#1DE>;U[>'_A1."I\;"BBBMC,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .S^'/_'_ *Y_V!;G_P!E
MKC*[/X<_\?\ KG_8%N?_ &6N,K./QR^1;^%!1116A 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %=GX__P!3X5_[ -M_6N,KU#Q+XRU_P[IWABUTJ_\ L\,FBVTC+Y,;
MY;!&<LI/0"L:E^:-O,N-K.YY?178?\+1\9?]!G_R5A_^(H_X6CXR_P"@S_Y*
MP_\ Q%5>IV7W_P# %:/?^OO./HKL/^%H^,O^@S_Y*P__ !%'_"T?&7_09_\
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MT?&7_09_\E8?_B*+U.R^_P#X 6CW_K[SCZ*[#_A:/C+_ *#/_DK#_P#$4?\
M"T?&7_09_P#)6'_XBB]3LOO_ . %H]_Z^\X^BNP_X6CXR_Z#/_DK#_\ $4?\
M+1\9?]!G_P E8?\ XBB]3LOO_P" %H]_Z^\X^BNP_P"%H^,O^@S_ .2L/_Q%
M'_"T?&7_ $&?_)6'_P"(HO4[+[_^ %H]_P"OO./HKL/^%H^,O^@S_P"2L/\
M\11_PM'QE_T&?_)6'_XBB]3LOO\ ^ %H]_Z^\X^BNP_X6CXR_P"@S_Y*P_\
MQ%'_  M'QE_T&?\ R5A_^(HO4[+[_P#@!:/?^OO./HKL/^%H^,O^@S_Y*P__
M !%'_"T?&7_09_\ )6'_ .(HO4[+[_\ @!:/?^OO./HKL/\ A:/C+_H,_P#D
MK#_\11_PM'QE_P!!G_R5A_\ B*+U.R^__@!:/?\ K[SCZ*[#_A:/C+_H,_\
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MDKS>O;P_\*)P5/C84445L9A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!V?PY_P"/_7/^P+<_^RUQE=G\.?\
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ML_X7!X?_ .?/4_\ OU'_ /%T?\+@\/\ _/GJ?_?J/_XNO$Z*/J=(/;S/;/\
MA<'A_P#Y\]3_ ._4?_Q='_"X/#__ #YZG_WZC_\ BZ\3HH^IT@]O,]L_X7!X
M?_Y\]3_[]1__ !='_"X/#_\ SYZG_P!^H_\ XNO$Z*/J=(/;S/;/^%P>'_\
MGSU/_OU'_P#%T?\ "X/#_P#SYZG_ -^H_P#XNO$Z*/J=(/;S/;/^%P>'_P#G
MSU/_ +]1_P#Q='_"X/#_ /SYZG_WZC_^+KQ.BCZG2#V\SVS_ (7!X?\ ^?/4
M_P#OU'_\71_PN#P__P ^>I_]^H__ (NO$Z*/J=(/;S/;/^%P>'_^?/4_^_4?
M_P 71_PN#P__ ,^>I_\ ?J/_ .+KQ.BCZG2#V\SVS_A<'A__ )\]3_[]1_\
MQ='_  N#P_\ \^>I_P#?J/\ ^+KQ.BCZG2#V\SVS_A<'A_\ Y\]3_P"_4?\
M\71_PN#P_P#\^>I_]^H__BZ\3HH^IT@]O,]L_P"%P>'_ /GSU/\ []1__%T?
M\+@\/_\ /GJ?_?J/_P"+KQ.BCZG2#V\SVS_A<'A__GSU/_OU'_\ %T?\+@\/
M_P#/GJ?_ 'ZC_P#BZ\3HH^IT@]O,]L_X7!X?_P"?/4_^_4?_ ,71_P +@\/_
M //GJ?\ WZC_ /BZ\3HH^IT@]O,]L_X7!X?_ .?/4_\ OU'_ /%T?\+@\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HHHH **** "NS\?\ ^I\*_P#8!MOZUQE=GX__ -3X5_[
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M /(VZ-_U_0?^C%K)K6\+_P#(VZ-_U_0?^C%J9_"QQW0>*/\ D;=9_P"OZ?\
M]&-636MXH_Y&W6?^OZ?_ -&-631#X4$MPHHHJA!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K'PETG6(/.U!
MY6ATN886%A_KF_O#TQZ]^GTQ_ /@%]:=-4U2,KIRG,<9X,Y'_LOOWKVI$6-%
M1%"HH 55&  .PK@Q>(5O9Q.FC3?Q,=1117FG4%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5ZW_U"_C_ #JC5ZW_ -0OX_SH \-^-?\ R.5G
M_P!@]/\ T9)7F]>D?&O_ )'*S_[!Z?\ HR2O-Z]O#_PHG!4^-A1116QF%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '9_#G_C_P!<_P"P+<_^RUQE=G\.?^/_ %S_ + MS_[+7&5G'XY?(M_"
M@HHHK0@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6_P#J
M%_'^=4:O6_\ J%_'^= 'AOQK_P"1RL_^P>G_ *,DKS>O>/'_ (;\.:QKT%QK
M'B)--N%ME18691N7<Q#<^Y(_"N5_X07P-_T.T7_?<?\ C7K4*J5-*S^YG#47
MO/5?>>8T5Z=_P@O@;_H=HO\ ON/_ !H_X07P-_T.T7_?<?\ C6WMEV?W,CE\
MU]YYC17IW_""^!O^AVB_[[C_ ,:/^$%\#?\ 0[1?]]Q_XT>V79_<PY?-?>>8
MT5Z=_P (+X&_Z':+_ON/_&C_ (07P-_T.T7_ 'W'_C1[9=G]S#E\U]YYC17I
MW_""^!O^AVB_[[C_ ,:/^$%\#?\ 0[1?]]Q_XT>V79_<PY?-?>>8T5Z=_P (
M+X&_Z':+_ON/_&C_ (07P-_T.T7_ 'W'_C1[9=G]S#E\U]YYC17IW_""^!O^
MAVB_[[C_ ,:/^$%\#?\ 0[1?]]Q_XT>V79_<PY?-?>>8T5Z=_P (+X&_Z':+
M_ON/_&C_ (07P-_T.T7_ 'W'_C1[9=G]S#E\U]YYC17IW_""^!O^AVB_[[C_
M ,:/^$%\#?\ 0[1?]]Q_XT>V79_<PY?-?>>8T5Z=_P (+X&_Z':+_ON/_&C_
M (07P-_T.T7_ 'W'_C1[9=G]S#E\U]YYC17IW_""^!O^AVB_[[C_ ,:/^$%\
M#?\ 0[1?]]Q_XT>V79_<PY?-?>>8T5Z=_P (+X&_Z':+_ON/_&C_ (07P-_T
M.T7_ 'W'_C1[9=G]S#E\U]YYC17IW_""^!O^AVB_[[C_ ,:/^$%\#?\ 0[1?
M]]Q_XT>V79_<PY?-?>>8T5Z=_P (+X&_Z':+_ON/_&C_ (07P-_T.T7_ 'W'
M_C1[9=G]S#E\U]YYC17IW_""^!O^AVB_[[C_ ,:/^$%\#?\ 0[1?]]Q_XT>V
M79_<PY?-?>8GPY_X_P#7/^P+<_\ LM<97MGA;PIX5T^YU%M/\41WC2V$L4JA
MD/EQG&Y^/3BL'_A!? W_ $.T7_?<?^-9QJKG;L^G1E->ZM5]YYC17IW_  @O
M@;_H=HO^^X_\:/\ A!? W_0[1?\ ?<?^-:>V79_<R>7S7WGF-%>G?\(+X&_Z
M':+_ +[C_P :/^$%\#?]#M%_WW'_ (T>V79_<PY?-?>>8T5Z=_P@O@;_ *':
M+_ON/_&C_A!? W_0[1?]]Q_XT>V79_<PY?-?>>8T5Z=_P@O@;_H=HO\ ON/_
M !H_X07P-_T.T7_?<?\ C1[9=G]S#E\U]YYC17IW_""^!O\ H=HO^^X_\:/^
M$%\#?]#M%_WW'_C1[9=G]S#E\U]YYC17IW_""^!O^AVB_P"^X_\ &C_A!? W
M_0[1?]]Q_P"-'MEV?W,.7S7WGF-%>G?\(+X&_P"AVB_[[C_QH_X07P-_T.T7
M_?<?^-'MEV?W,.7S7WGF-%>G?\(+X&_Z':+_ +[C_P :/^$%\#?]#M%_WW'_
M (T>V79_<PY?-?>>8T5Z=_P@O@;_ *':+_ON/_&C_A!? W_0[1?]]Q_XT>V7
M9_<PY?-?>>8T5Z=_P@O@;_H=HO\ ON/_ !H_X07P-_T.T7_?<?\ C1[9=G]S
M#E\U]YYC17IW_""^!O\ H=HO^^X_\:/^$%\#?]#M%_WW'_C1[9=G]S#E\U]Y
MYC17IW_""^!O^AVB_P"^X_\ &C_A!? W_0[1?]]Q_P"-'MEV?W,.7S7WGF-%
M>G?\(+X&_P"AVB_[[C_QH_X07P-_T.T7_?<?^-'MEV?W,.7S7WGF-%>G?\(+
MX&_Z':+_ +[C_P :/^$%\#?]#M%_WW'_ (T>V79_<PY?-?>>8T5Z=_P@O@;_
M *':+_ON/_&C_A!? W_0[1?]]Q_XT>V79_<PY?-?>>8T5Z=_P@O@;_H=HO\
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M7HJQY,/_ #UH\F'_ )ZT 5Z*L>3#_P ]:/)A_P">M %>BK'DP_\ /6CR8?\
MGK0!7HJQY,/_ #UH\F'_ )ZT 5Z*L>3#_P ]:/)A_P">M %>BK'DP_\ /6CR
M8?\ GK0!7HJQY,/_ #UH\F'_ )ZT 5Z*L>3#_P ]:/)A_P">M %>BK'DP_\
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M#YFT/X<OD<;1116YB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?U!K@JZ,+A:3I1DU=[W,,1B*JJRBG9;'J?A3XE^(]7\4Z=I]W+;F">4(X6$
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M/_PK'P0DVN7T]S)*P\JS7!$;$$[%/7W)SCT'K->&P^*G@]QIMY<6LL3<PDX
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M/_R-FL_]?T__ *,:LJBG\"] J?&PHHHJR HHHH **** "BBB@ HHHH ****
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MM#TXE@+R[\N(W+9SRS EL=!P!@>U)\3+11;:!J4CV<M]=6["YN+,@QSLNW#
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M>@5/C844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%:F@:!?>(M32RLDR3S)(?NQKZFIE)17-+8<8N3LCTWX9^,+S4\Z-?
M)+.\,>Z.Y SA1V<_R/>O2:R?#OAVQ\-:8MG9KDGF65A\TC>I_H.U:U?+8F<)
MU'*FK(^DH0G"FHS=V%%%%8&P4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#1C5E5J^)_^1LUG_K^G_\ 1C5E4Z?P+T%4^-A1115D!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !116IH&@7WB+4TLK),D\R2'[L:^I
MJ9245S2V'&+D[(- T"^\1:FEE9)DGF20_=C7U-?0'AWP[8^&M,6SLUR3S+*P
M^:1O4_T':CP[X=L?#6F+9V:Y)YEE8?-(WJ?Z#M6M7SN,QCKOEC\)[V%PJHKF
M?Q!1117"=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_A3'_4?_P#)/_[.C_A3'_4?_P#)/_[.O5:*/[0Q/\WX+_(/J-#^7\6>5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "KUO\ ZA?Q_G5&KUO_ *A?Q_G0!X=\:?\
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M'_"VK;_H4M/_ .^Q_P#$4>VK_P#/O\4'LJ/_ #\_!GF5%>F_\+:MO^A2T_\
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M'_Q%'MJ__/O\4'LJ/_/S\&>945Z;_P +:MO^A2T__OL?_$4?\+:MO^A2T_\
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MA-\-?^ 0H_X6!;?]";X:_P# (4>TJ_R?B@Y*?\WX,XJBNU_X6!;?]";X:_\
M (4?\+ MO^A-\-?^ 0H]I5_D_%!R4_YOP9Q5%=K_ ,+ MO\ H3?#7_@$*/\
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MNU_X6!;?]";X:_\  (4?\+ MO^A-\-?^ 0H]I5_D_%!R4_YOP9Q5%=K_ ,+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_HQ:53X'Z#I_&CTO5/BU_9NK7EC_8GF?9IWAW_:\;MK$9QLXZ54_P"%S_\
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M7/\ ]0#_ ,G/_L*/^%S_ /4 _P#)S_["O*J*/[/PW\OXO_,/KU?^;\$>J_\
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M-36VH7MFCI:WEQ K_?6*5E#?7!YJM6=*@X5)SO\ %8TJ5N>G&%MCVV7_ )(
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M:5_O6_\ Z+->+3W$]U*9;B:2:0]7D8L3^)J6;4+VXMTMYKRXE@3[D;RL57Z
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M5H7OA+Q#IULUQ=Z/>10J,M(8B0H]21T_&NYSBG9O4XU"35TC&HI0"2  23T
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M->I \CD+G" IRO3.?KZUR=KXRFB@\0K<6B2RZS&$9D;RUBQGHN#D<],CI3-
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MG\C:?\./S"BBBMS$**** "BBB@ KVKX7V3:'X$U+7_(:6XN SQ(BEF=8P0H
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M3+$\JQ_9OM+R9)R<G/'&/>N?#QC+D]Y)I]M?1FU>4ES^ZVFN^AV-C_R0!O\
MKUE_]&M2?#BVMO#OP[OO$K0B2XD264D]2D>0%'H"0?S]J6Q_Y( W_7K+_P"C
M6H^&M[8^(/ -SX8FG$=PB2Q%<C<8WR=RCO@L?R'K1._LZG;GU] A;VD._+IZ
MG''XL:_<6][;7J6MQ!=0O%L$>SR]P(R".N,]\UP=>EO\'[RPMKZ\U35;1+6W
MA>1##DLQ .,[@ O;N?ZUYI7J8=T'?V)Y]=5E;VH4445TG.%%%% !1110 5V7
MC_\ U/A7_L VW]:XVNR\?_ZGPK_V ;;^M85/XD/F;0_AR^1QM%%%;F(4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHKP&[ZL]M*P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPHKT_P#X4S=_]!VQ_P"^31_PIF[_ .@[8_\ ?)H^NT/YOS#ZI6_E/,**]/\
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MX4S=_P#0=L?^^31]=H?S?F'U2M_*>845Z?\ \*9N_P#H.V/_ 'R:/^%,W?\
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MX4S=_P#0=L?^^31]=H?S?F'U2M_*>845Z?\ \*9N_P#H.V/_ 'R:/^%,W?\
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M_P#4+^/\ZA^RG^^M6(EV1A<YQ0(\O^)7_(QV_P#UZ+_Z&]<;79?$K_D8[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %='XL_U>A?\ 8*A_K7.5T?BS_5Z%_P!@J'^M93_B1^9I
M'X)?(YRBBBM3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M_P#4+^/\ZHU>M_\
M4+^/\Z /,?B5_P C';_]>B_^AO7&UV7Q*_Y&.W_Z]%_]#>N-KZ#"_P &)X>(
M_BR"BBBMS$].\.ZGHLO@J'3;[4(82R/'(C2!6 +'U]C45K;^!]$G6[%ZMQ*G
MS)N<R8/; 48S]:\VHKD^J*[M)I,Z?K.BO%:'2>+?%)\07"10(T=G"245NKG^
M\?Z"ND\,:UI%_P"%_P"Q=2N(X&53&1(^P,I)(()XS_A7F]%7+#0<%!:6)C7D
MIN;UN>I:->>%/#UXUG9WBN\BEI+J20$#'1=PP/RK#T?7K'3_ !WJ5S-*OV6Y
M9T69>0,L"#]#C^5<314K"QUNV[HIXF6EE:QZ->V?AF#6VUZ;6EF_>"9;>)U<
MEATZ'.,_2LWXA:E9:C<6!L[J*<(C[C&V<9(Q7%T4X8?EDI.3=A2KWBXI6N>@
M>*]6T^[\&65M;WD,LZF+=&K9884YR*\_HHK2E25*/*C.I4=1W9U_@";3K/4+
MF\OKN&!DC"1"1@,YZD?EC\:I:QXKU.XUBZDM-1N([8R$1*CD#:.!Q[XS7.T4
MO81=1S>MQ^VER*"T/0_!7BOBZ@UG4/1XI+A_P(R?P_6J.AZY8^'/%.H0B97T
MVX?Y98_F"\Y4_0 D'%<514/"P;EV92Q$DH]T>E7FC^#;B^?4Y=5CV2,7>%+A
M<,>IX'S?@/6N9T/5[#2_&;WB QZ>\DBK@'Y4).WCKZ5S=%..'M%QE)N^@2K7
M:E%)'H/B^U\.7L-UJ\.J1O>LBA8HIU8,1@#Y>O2D?5M//PS%D+R'[5Y(7R=W
MS9WYZ5Y_126&7*HMWL[C>(]YM+='>^$?$FG#1GT/5G$<1#*CM]TJV<@GL<D\
MU=T^P\)^'+O^TAJZ7#HI,2^:KE<C' 7DGM7FM%*6%3;:DTGN$<0TE=)VV.J;
MQ#'JGCNTU*8B&VCE54W\;4![_B2?QI_Q O[34-6MI+.XCG18-I:-L@'<>*Y*
MBM%0BI*2Z*Q+K2<7%]=3T!-6T\?#,V1O(?M7DE?)W?-G?Z5Y_113I4E3O;J[
MDU*CG:_16"BBBM3,Z/P=_P ?6J?]@V;^E<Y71^#O^/K5/^P;-_2N<K*'\27R
M-)?!'YA1116IF%%%% !1110 5/:6=Q?7*6]K"\LS]$4<U!7IGP_LX+'0;G5Y
M!\[ELG'1%]/QS^0K&O5]E#F-:-/VD^4PHOAQK4D6YY;.-L?<:0D_H"*R-7\+
MZKHD8ENX 82<>;&VY0??T_&GW_BS6;Z]:X%_/ I;*1Q2%54>F!U_&O0/"NHM
MXF\-3P:CB5U)AD./O@C@_7_"N>=2O22G.S74WA3HU7RPNF>9Z1I%WK=]]DLP
MIDVER7.  ._ZBK.M>&M1T%8WO$0QR'"O&V1GT-;GP_B-OXMNH6ZQP2(?P=17
M:7D=OXFTW4],8JLT,ICS_=8<HW^?>BKBI0JV^R%+#QG3OU/*]%T&\UZ>6*S,
M0:-=S&1L#K5"Y@>UNIK>3'F1.4;!XR#@UW/PXADM]8U."52LD:!&4]B&P:S]
M(TR/5/B%=13*&ABN9I74]" QP/IDBM/;M3DGLE<S]C>$6MVRGI7@K6-6MQ<1
MQQP0MRK3L5W?0 $T:IX)UC2K<SR)#-$/O-"^=OU! -=)X\\37EC=QZ;83-!\
M@>61.&.>@![5R2^*M8^PW%G+=O/#.FQO..XCW!ZU-.6(FE/2SZ%5(T8-PUOW
M-7_A7.M_W[3_ +^'_"C_ (5SK?\ ?M/^_A_PJ/PUKVK7/B.PAGU&YDB>7#(T
MA((K:^(.JZAI^I6B6=Y- K0DL(W(!.:ASQ"J*G=:EJ%%TW.ST.'U33;C2-0E
MLKG;YL>,[#D<@$?SJG4MQ<SW<[3W,KRRO]YW.2>U15W1O;7<XW:^ATUCX%U?
M4+&&[B-LL<RAU#R$'!_"DO\ P-J^G6,UY,UL8X5W,$D)./RKKYO[5_X0'2_[
M'\W[5LBSY77;M.?Z5Q>K7OB>*V:#5)+Q(9?E(D7"M[9KBIU:M26C6_S.NI3I
MPCL]BCI&A:AKDK)8P[@F-[L<*N?4UN3_  YUJ*$NDEI,P'W$D()^F0!6+I>J
M:M:PS6>F22KYY#,(5RYQZ$<C\*[SP)'KB&ZDU0W0MBHV"Z)SN]1NYQBJQ%2K
M3O)-6[$T(4YVBT[GF,L;PRO%*A21&*LK#!!'45H:-H=[KMR\%FJY1=S,YPH%
M3^*KB"]\47TUJ0\3. I7D,0 "1^(-=K:!?!OAZSMR!_:6H3(&]1DC/\ WR#C
MZFKJ5I1@K+WF33I)S=]D<1K?AN^T 0&\,1$V[;Y;9Z8SV]ZR*]%^)_\ J]+^
MLO\ [+7G55AJCJ4E*6Y->"A4<4%%%%;F(4444 %%%% !71^+/]7H7_8*A_K7
M.5T?BS_5Z%_V"H?ZUE/^)'YFD?@E\CG***[[Q+XDU71[FPM[*Y$<)LXW*&-6
M!//J,]J<YR4E&*O<(033;>QP-%==XJT^*YO-&F@@CMKK48E,L8&U0YQSCMU_
M2J%[X1O=.@FDN[NQB:,,5B:;#R@=2BXY_2IC7@TF]+CE2DFTM;&!16Y9>%KV
MZL$O9KBSL;>0XC>\F\O?].#5;5M!OM&FB2X5'689BDB;<LGT/XBK56#?*GJ2
MZ<DKM&91702>$+Z)2LEWIZW03=]C-P/.Z9QCIG'O5[2/#-I>>%[R[EN[$7!V
M&*1YV @YY#CH">W!J'7@E>Y2HS;M8Y&BM2'0Y[C4YK*"YM)!"N][@3 1!>.=
MQ^H%6+OPO=6]A+>07EC>PPX\TVDV\H/4C XJ_:P3M<GV<K7L8=%==I'AFTO/
M"]Y=RW=B+@[#%(\[ 0<\AQT!/;@UA1Z+=7&KG3;-H;N7^_ ^4(QDG<<<"IC6
M@VUV&Z4DD^YG45O3>$[Q+>:6WO-/O6A7=)%:S[W4=SC%8-7&<9?"R91E'<**
M[2YF'@[1[!;.&+^U;R/S9+ET#-&IZ!<_YXK%U#Q'<ZO8M!J,,,]P&!CN@@1U
M'<' Y'M6<:DI:I:%R@HZ-ZF+171)X.NVD6%]1TN*Z;C[,]T/,SZ8 //XUG6V
MBWESK8T@JL-T7*$2G@$#/49]*I58.]F2Z<UNC.HKI4\$:FY\HW%BEU@LMJT^
M)6'J%Q_.L:STJ]O]1^P6\!:X!(93QMQUR>V*:JP=[/8'3FMT4Z*V[_PQ=V-I
M)=)=65W'"0)OLLV\Q9X^88'>BS\,7=S91WD]S96,$O\ JFO)O+\SZ#!I>UA:
M]P]G.]K&)16G=Z#>V6J06$P0/<%1%(&RCAC@$'TJY>^$;W3H)I+N[L8FC#%8
MFFP\H'4HN.?TH]K#37</9SUTV,"BBBM" HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "KVB_\A[3O^OJ/_T(51J]HO\ R'M._P"OJ/\ ]"%3/X65
M#XD&M?\ (>U'_KZD_P#0C5&KVM?\A[4?^OJ3_P!"-4:(?"@G\3"BBBJ)"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *D@GEMITG@D:.5#E64\@U
M'11N!ZGX;\21:U!Y4NV.]0?.G9A_>'^%;]>(P3RVTZ3P2-'*ARK*>0:]>T2[
MNK[28;B\@\F9AR/[P_O8[9]*\7&894GS1V9ZV%Q#J+EENC0HHHKB.P**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MKUO_ *A?Q_G5&KUO_J%_'^= 'F/Q*_Y&.W_Z]%_]#>N-KLOB5_R,=O\ ]>B_
M^AO7&U]!A?X,3P\1_%D%%%%;F(45I:%I+ZWJ\-BK^6'R6?&=J@9)_P ^M;_B
M+P-_8FDM?0WC3A& =3'MP#QGKZX_.LI5H1FH-ZLTC2G*+FEHCCJ*4#+ #N<5
MZ"_PVM8$5I]9\O/&6B !/XM14K0IVYGN%.E.I?E//:*[;4_AW<6]FUSI]XMV
MJKNV;-I(]L$@UQ-.G5A45X,4Z<H.TD%%;?AC0%\0ZC+:M<& 1Q&3<$W9Y QU
M]ZIZUIPTG6+FP$IE$+ !RN,Y /3\::J1<^3J'))1Y^A0HHHJR HKN?#WAW2[
M[P;=W]S;%[I!*5?S&&-JY' .*X:LX55-M+H:3IN*3?4**NZ1;VMWJ]K;WLWD
MV\CX=\@8'U/2MCQ+I&E:=K%G;Z=<>;'*!YB^8'V\XZCVH=1*?()4VX\QS5%=
MKX[T'3=&AL6T^W\DRLX?]XS9QC'4GUKBJ*515(\Z"I3=.7*PHKJO"6BZ)JMM
M=/JEWY4D; *OFJF%Q][GK6-8Z1/JNJO8Z?MD(+%69L J.]'M8W:?0?LY63[F
M=15K4=/N-+OY;*Z55FBQN"G(Y (Y^A%5:M--71#33LPHHHIB"BBB@ HHHH Z
M/P=_Q]:I_P!@V;^E<Y71^#O^/K5/^P;-_2N<K*'\27R-)?!'YA1116IF%%%%
M !1110 5ZMX0 OO +6D9&_;-">>[$G_V85Y36]X:\3W'AV=P$$UK*1YD1.#]
M0?6N?%4I5*=H[K4WP]10G>6S,-T:-V1U*LIP0>H->G?#FV:UT*YNYALCEERI
M;CY5'7Z9S^55Y?$G@S4)C=75@?/SDF2W&6^N#@_C69XA\<I>V#:=I5NUO;,N
MQG8!25_N@#H/Z>E8574KQ]GRM=S:FJ=&7/S7["^ 9OM/C"\G/_+2&1_S=33X
M];_L7XC7S2-BVGF\N;G@=,-^!_3-8OA#6;70M8>ZNQ(8VA:/]VN3DD'U]JH:
MY>Q:EK=W>0AA%+(64,,'%6Z/-5DFM&K$*KRTU9ZIGL$&DK:^([C48E 6Z@ D
MQ_?!'/XC^7O7$^%YQ#\1]00D?OGG09_W]W_LM6M!^(%I;:3#;:DEP9X1L#HH
M8.HZ=^M<3-J4@UR74K5FB<W#31D]1EB1FL*-"I[\9]K&U6M#W91[W.A^(MI)
M#XA6Y*GRIXEVMVR."/Y?G7(@%LX!.!DXKT:#QYI&I62P:W8$M_$!&'C)]1DY
M'^>:HZIXIT&'2+FQT73MCW"%&D\L( #^IK:C4JPBJ;AJON,JL*<I.:D<_P"$
M_P#D:M._Z[#^1K?^)G_(5LO^N!_]"-<OH=[%IVMVEY.&,44FYMHR<5J^,M>M
M->O[>:S64)'%M;S% YSGUJY0D\1&5M+$1DO8./6Y'X:;PVL=Q_;R.S97RL;\
M8YS]T_3K4OB-_"K6$8T.-UN?-&\DR8V8.?O'UQ7,T5K[+W^?F?I?0CVGN\ME
M^IOVGC/6[*TBM8+E!%$H5 8E. /PKT'1+W_A*?"<IU*)!NWQ2$#"G'(8>G^(
MKGHM;\%WL,;7VFF*=4 ;$74@>JGG\:BUGQQ:?V4=,T.U:")D*&0J%V@]0H'K
MZ^]<56#J-*$+.^YU4YJFFY3NK;'*:1J]SHM\+NTV>8%*X=<C!KO_  QXKD\2
MW4NF:G9V[AHRP*J=I QP0<US'AK6M&L[&:QUBP\^.23S%D"!BO 'U'3MZUT,
M'BKPIHD<CZ592&9U_A3!/L68Y J\2N=M<COT9-!\J3Y].J&P^&K"S^(L,,:_
MZ.(/M:1$Y"L#@#Z9YK3U?PE=ZMX@CU*3446.)E\N'RR=J@YQG/4G->;ZOK%S
MK&J27TIV.W"JI^XO85!:7LD%[!,\DA2.168!NH!S3^KU7:7-K:W<7MZ:O'ET
MN>H>.]$?5-+6Z6=8_L,<DI4KG?P#C/;[M>2UUWC/Q-9Z]'9I8^>HB+[]Z[0<
MXQT/L:Y&M,'"<*5I$8J<95+Q"BBBNHY@HHHH **** "NC\6?ZO0O^P5#_6N<
MKH_%G^KT+_L%0_UK*?\ $C\S2/P2^1SE=]XEUYM*NM/C33=.G;['&ZRW$&]U
M//0Y]JX&K5]J-WJ4D<EW+YC1QB-3M PHZ#@45*7/)-[*XX5.6+2W9>M]2N]5
M\465W>2F25KB,9Q@ ;A@ =A4OC%W?Q9?[F9MK@#)S@8'%8L,TEO/'-$VV2-@
MZG&<$<BI+R[GO[N2ZN7\R:0Y=L 9/T'%"IVFFMDK"<[P:>]SI_'$<CG2[F-2
M;%K-%B9?N@]Q]<8I]XD]OX#TF"57%XUV7MXR/GV\]!UZD?F*P].\2:QI4'D6
M5\\<6<A"JL!] P./PJK=ZG?7UX+NYNI)+A2"KDX*XY&,=/PK.-*:2B[61HZL
M;N2W9U,']G^,M0:WN[.6RU<H=T\1RCE1_&IZ?YYJMH\;?\(5XBC7#,K1$[?0
M-R?TK.F\6Z[<6S6\FHN8V&UMJ*K$?[P&?UJGINKW^CS-+87+0LXPV "#]0<B
ME[&?+;TLK]@]K"]_6_S+_AS1K?4GO9KQIA!9P^<T<0^>3V&:Z#19K"YT/76L
M-'DLXQ:,K2M.T@<X/'(P#WKDUUW4TU5]32\=;Q_O2 #YAZ$8QC@<8[58G\5Z
MY<I(DM^S))&8G7RU"E3UX Q^/6BI2J3?W=7_ $PA4A%??T_JQH:(I?P/X@51
MD@Q,0/0-DU-X%\O?JT3PF69[,[(@Q5I!W4'J,\5SVFZO?Z/,TMA<M"SC#8 (
M/U!R*;)JM]+J9U%KEQ>$Y\U?E.<8[>U5*E)\RZ/_ ('^0HU(KE?8Z'3?$&FZ
M=?&2P\,RK<A64@7CL<=\J5KDR<L2!C)Z5M3^+]>N86BDU%]K##;$5"1]0 :Q
M*NG!Q;;7XM_F34GS62_)+\CL?%L$FJ:9I>MVRF2#[,(I2O/EL/7\21^%<W::
M5=WD8G2%EMO,5&F884%B /KR>U/TW6]2T@L;"[>$-]Y>"I]\'(S2ZEKNIZOM
M%]>22JIR%X50?7 P,^]3"$X+E5K#G*$GS/<Z1[31]&\0PZ3'I%U?7:.G[]IR
MAW'!RJJ.@_I5E@!\7!@?QC_T57-_\)=KWV80?VE)L VYVKNQ_O8S^M53K>H'
M5_[5-Q_IN<^;L7TQTQCI[5FJ$W>_9K=_TC1UH*UNZ>QH6$CGQ[$Y=BQO^23D
MGY\5T-@I?Q!XMA@ ^U212"(#J>3G'XD5PL=[<17RWJ28N%D\T/M'WLYSCIUJ
M3^U+T:DVHK<.MVSES*GRG)Z]./PJYT7+;L1"JH_>%O:7SQ73P1RB.)/]((X"
MKGHWX]O:NT\376EQ1Z9/<:,U[!):((IENFC4#^[@#&:Y74?$FKZK (+V]>2(
M'.P*J@_7:!G\:33_ !'J^EP>1:7KI#_<95=1] P./PHG3G-J3W7F_P PC.$;
MI=?)?D:\NL)J5]X?@ATQ[."WG41%I3)N!9>A('3%4?&+N_BR_P!S,VUP!DYP
M,#BJ-UK6HWM[%>7-V\L\1#1LV,*0<\#I^E5[R[GO[N2ZN7\R:0Y=L 9/T'%.
M%+EDGY?J*=3FBT04445N8A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %7M%_P"0]IW_ %]1_P#H0JC5[1?^0]IW_7U'_P"A"IG\+*A\2#6O^0]J
M/_7U)_Z$:HU>UK_D/:C_ -?4G_H1JC1#X4$_B844451(4444 %%%% !1110
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MW8]6$>3EA=>?S/+GA>WO&@E&V2.38P]"#@UZKX[TN]U72[:*Q@::1)]S $#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV;^E<Y71^#O^/K5/^P;-_2N<K*'\27R-)?!'YA1116IF%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !71^+/]7H7_ &"H?ZUSE='XL_U>A?\ 8*A_K64_XD?F:1^"7R.<
MHHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O:+_R'
MM._Z^H__ $(51J]HO_(>T[_KZC_]"%3/X65#XD>R4445\T?0!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H#R_F?_ (NCR/"'_0'E_,__ !=9E%'(_P"9_>',NR^XT_(\(?\ 0'E_,_\
MQ='D>$/^@/+^9_\ BZS**.1_S/[PYEV7W&GY'A#_ * \OYG_ .+H\CPA_P!
M>7\S_P#%UF44<C_F?WAS+LON-/R/"'_0'E_,_P#Q='D>$/\ H#R_F?\ XNLR
MBCD?\S^\.9=E]QI^1X0_Z \OYG_XNCR/"'_0'E_,_P#Q=9E%'(_YG]X<R[+[
MC3\CPA_T!Y?S/_Q='D>$/^@/+^9_^+K,HHY'_,_O#F79?<:?D>$/^@/+^9_^
M+H\CPA_T!Y?S/_Q=9E%'(_YG]X<R[+[C3\CPA_T!Y?S/_P 71Y'A#_H#R_F?
M_BZS**.1_P S^\.9=E]QI^1X0_Z \OYG_P"+H\CPA_T!Y?S/_P 76911R/\
MF?WAS+LON-/R/"'_ $!Y?S/_ ,71Y'A#_H#R_F?_ (NLRBCD?\S^\.9=E]QT
M6E1>'5EN?L6G21,;=Q(23\R<9'WC5#R/"'_0'E_,_P#Q=+H?^NN_^O63^E9=
M2H>\]7]Y3DN5:+[C3\CPA_T!Y?S/_P 71Y'A#_H#R_F?_BZS**KD?\S^\GF7
M9?<:?D>$/^@/+^9_^+H\CPA_T!Y?S/\ \76911R/^9_>',NR^XT_(\(?] >7
M\S_\71Y'A#_H#R_F?_BZS**.1_S/[PYEV7W&GY'A#_H#R_F?_BZ/(\(?] >7
M\S_\76911R/^9_>',NR^XT_(\(?] >7\S_\ %T>1X0_Z \OYG_XNLRBCD?\
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M_P"@/+^9_P#BZ/(\(?\ 0'E_,_\ Q=9E%'(_YG]X<R[+[C3\CPA_T!Y?S/\
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M_0FK"K=\5_\ (4B_ZXC_ -":L*O4H_PT>=5^-A1116IF%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM36ON:=_UYQ_UK+K4UK[FG?]><?]:B7Q(M?"S+HHHJR HHHH **** "BBB@
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MZ>__ "'_ /7H_P"$<_Z>_P#R'_\ 7H^L4^X>PJ=C"HK=_P"$<_Z>_P#R'_\
M7H_X1S_I[_\ (?\ ]>CZQ3[A["IV,*BMW_A'/^GO_P A_P#UZ/\ A'/^GO\
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M<_Z>_P#R'_\ 7H^L4^X>PJ=C"HK=_P"$<_Z>_P#R'_\ 7H_X1S_I[_\ (?\
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M["IV,*BMW_A'/^GO_P A_P#UZ/\ A'/^GO\ \A__ %Z/K%/N'L*G8PJ*W?\
MA'/^GO\ \A__ %Z/^$<_Z>__ "'_ /7H^L4^X>PJ=C"HK=_X1S_I[_\ (?\
M]>C_ (1S_I[_ /(?_P!>CZQ3[A["IV,*BMW_ (1S_I[_ /(?_P!>C_A'/^GO
M_P A_P#UZ/K%/N'L*G8PJ*W?^$<_Z>__ "'_ /7H_P"$<_Z>_P#R'_\ 7H^L
M4^X>PJ=C"HK=_P"$<_Z>_P#R'_\ 7H_X1S_I[_\ (?\ ]>CZQ3[A["IV,*BM
MW_A'/^GO_P A_P#UZ/\ A'/^GO\ \A__ %Z/K%/N'L*G8PJ*W?\ A'/^GO\
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MW/\ W];_ !HM5[H+T^S+G_".:G_SQ7_OL4?\(YJ?_/%?^^Q5/^TK[_G]N?\
MOZW^-']I7W_/[<_]_6_QHM5[H+T^S+G_  CFI_\ /%?^^Q1_PCFI_P#/%?\
MOL53_M*^_P"?VY_[^M_C1_:5]_S^W/\ W];_ !HM5[H+T^S+G_".:G_SQ7_O
ML4?\(YJ?_/%?^^Q5/^TK[_G]N?\ OZW^-']I7W_/[<_]_6_QHM5[H+T^S+G_
M  CFI_\ /%?^^Q1_PCFI_P#/%?\ OL53_M*^_P"?VY_[^M_C1_:5]_S^W/\
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M_/%?^^Q5/^TK[_G]N?\ OZW^-']I7W_/[<_]_6_QHM5[H+T^S+G_  CFI_\
M/%?^^Q1_PCFI_P#/%?\ OL53_M*^_P"?VY_[^M_C1_:5]_S^W/\ W];_ !HM
M5[H+T^S+G_".:G_SQ7_OL4?\(YJ?_/%?^^Q5/^TK[_G]N?\ OZW^-']I7W_/
M[<_]_6_QHM5[H+T^S+G_  CFI_\ /%?^^Q4EMH&HPW4,KQ*%1PS'>.@-9_\
M:5]_S^W/_?UO\:FM-0O7O8%:[N&5I%!!D)!&?K2DJEGJBDZ=^IU5%%%>8=X4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(1DYS5:MB#_D5KK_ *[K_2L>JBV[BDK6"BBBK("BBB@ HHHH **** "BBB@
MHHHH *GLO^/^W_ZZK_,5!4]E_P ?]O\ ]=5_F*F7PLJ.Z-.XURYAN98ECA*H
MY49!['ZU'_PD%W_SSA_[Y/\ C5"]_P"/^X_ZZM_,U!6<:,++0MU9WW-;_A(+
MO_GG#_WR?\:/^$@N_P#GG#_WR?\ &LFBG[&GV%[6?<UO^$@N_P#GG#_WR?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'X4$MV%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 7-/U"2QER,M&WWD_K]:ZJ&:.XB66)MRMT-<35S3]0DL9
M<C+1M]Y/Z_6N>O0Y]5N;TJO+H]CKJ*CAFCN(EEB;<K=#4E><U8[@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6_P#J%_'^=4:O6_\
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M)/8>M-3N["<;*Y1HK6TT?:],O;,\E%\^/V(ZUDTU*[:[ U9)A1115$A1110
M4444 %%%% !1110 4444 %3V7_'_ &__ %U7^8J"I[+_ (_[?_KJO\Q4R^%E
M1W07O_'_ ''_ %U;^9J"I[W_ (_[C_KJW\S4%$?A02W844451(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)##)<
M2K%$NYFZ"B&&2XE6*)=S-T%=5I^GQV,6!\TC?>?_ #VK&K55->9K3IN;\A=/
MLEL;?8"69N6/O5NBBO-DW)W9WI)*R"BBBD,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.1GYNN:?M??Y4A>S]WF;.=HHHK8R"BBB@ HHHH U-#_UUW_UZR?TK+K4T/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M_P#4+^/\ZHU>M_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-30_]==_]>LG]*RZU-#_ -==_P#7K)_2LNHC\3+?PH****L@**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "M36ON:=_UYQ_UK+K4UK[FG?]><?]:B7Q(M?"S+HHHJR HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I[+_C_M_P#KJO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8=P]G/L-T/\ UUW_ ->LG]*RZZ32]%OK62X:6-0'@=%PX/)QBJ/_  CFI_\
M/%?^^Q4JI#F>I;A+E6ADT5K?\(YJ?_/%?^^Q1_PCFI_\\5_[[%5[6'<CV<^Q
MDT5K?\(YJ?\ SQ7_ +[%'_".:G_SQ7_OL4>UAW#V<^QDT5K?\(YJ?_/%?^^Q
M1_PCFI_\\5_[[%'M8=P]G/L9-%:W_".:G_SQ7_OL4?\ ".:G_P \5_[[%'M8
M=P]G/L9-%:W_  CFI_\ /%?^^Q1_PCFI_P#/%?\ OL4>UAW#V<^QDT5K?\(Y
MJ?\ SQ7_ +[%'_".:G_SQ7_OL4>UAW#V<^QDT5K?\(YJ?_/%?^^Q1_PCFI_\
M\5_[[%'M8=P]G/L9-%:W_".:G_SQ7_OL4?\ ".:G_P \5_[[%'M8=P]G/L9-
M%:W_  CFI_\ /%?^^Q1_PCFI_P#/%?\ OL4>UAW#V<^QDT5K?\(YJ?\ SQ7_
M +[%'_".:G_SQ7_OL4>UAW#V<^QDT5K?\(YJ?_/%?^^Q1_PCFI_\\5_[[%'M
M8=P]G/L9-%:W_".:G_SQ7_OL4?\ ".:G_P \5_[[%'M8=P]G/L9-%:W_  CF
MI_\ /%?^^Q1_PCFI_P#/%?\ OL4>UAW#V<^QDT5K?\(YJ?\ SQ7_ +[%'_".
M:G_SQ7_OL4>UAW#V<^QDT5K?\(YJ?_/%?^^Q1_PCFI_\\5_[[%'M8=P]G/L9
M-%:W_".:G_SQ7_OL4?\ ".:G_P \5_[[%'M8=P]G/L9-%:W_  CFI_\ /%?^
M^Q1_PCFI_P#/%?\ OL4>UAW#V<^QDUJ:U]S3O^O./^M._P"$<U/_ )XK_P!]
MBKVI:+?7*V8BC4^5;)&WS@88=:F52',M2U"7*]#FZ*UO^$<U/_GBO_?8H_X1
MS4_^>*_]]BJ]K#N1[.?8R:*UO^$<U/\ YXK_ -]BC_A'-3_YXK_WV*/:P[A[
M.?8R:*UO^$<U/_GBO_?8H_X1S4_^>*_]]BCVL.X>SGV,FBM;_A'-3_YXK_WV
M*/\ A'-3_P">*_\ ?8H]K#N'LY]C)HK6_P"$<U/_ )XK_P!]BC_A'-3_ .>*
M_P#?8H]K#N'LY]C)HK6_X1S4_P#GBO\ WV*/^$<U/_GBO_?8H]K#N'LY]C)H
MK6_X1S4_^>*_]]BC_A'-3_YXK_WV*/:P[A[.?8R:*UO^$<U/_GBO_?8H_P"$
M<U/_ )XK_P!]BCVL.X>SGV,FBM;_ (1S4_\ GBO_ 'V*/^$<U/\ YXK_ -]B
MCVL.X>SGV,FBM;_A'-3_ .>*_P#?8H_X1S4_^>*_]]BCVL.X>SGV,FBM;_A'
M-3_YXK_WV*/^$<U/_GBO_?8H]K#N'LY]C)HK6_X1S4_^>*_]]BC_ (1S4_\
MGBO_ 'V*/:P[A[.?8R:*UO\ A'-3_P">*_\ ?8H_X1S4_P#GBO\ WV*/:P[A
M[.?8R:*UO^$<U/\ YXK_ -]BC_A'-3_YXK_WV*/:P[A[.?8R:*UO^$<U/_GB
MO_?8H_X1S4_^>*_]]BCVL.X>SGV,FBM;_A'-3_YXK_WV*/\ A'-3_P">*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ggtc45pq2o35000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (^!#(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **H6VM:?>:K=Z9;W >\M%5IXP#\@;..>G8T_4M4M=
M*MUFNF?YVV(D:%WD;T55!+'Z"@"Y15:QOK;4K*.[LY1+!(/E8>QP01V(/!%)
M+J-G#<202W$:210^>X8XVQY(W'VX- %JBD5E=0RD%2,@CN*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **:[I%&SR,J(HRS,< "G4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LR8V?\
MPD=J'\S[;]GD\O'W=F1G/OG%:=9DUTB^(K6U-NA=[>1Q,?O* 1P/8Y_2DRX;
MLTZ***9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K#N?^1TL/^O.7_T):W*SIIK4:_;0
MM!FZ:!V27^ZH(R/QXI,NF[-^C-&BBBF0%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]X8;4Y;>4Q"[@2! X &,[V7)'J*M1DX)*V[Z^A%FGH>ORSPP1>;+*D<?]YV
M'YU7_M;3?^@A:_\ ?Y?\:RI=5OYXO*F\(:A)&?X7EM2/R\VN?L+F5O$FKHW@
M^YD15AVPYMOW65.>LF.>O!H=.?2WWK_,;;Z'>QSQ31>;%*CQG^-6!'YU7_M;
M3?\ H(6G_?Y?\:RHM5OX8A%%X0U!(QT19;4#\O-J/3IK"\U1].N?#9L;A8?/
M GCA8,N<<%&;OZTG3G:^GW@V^AOP7=M=;OL]Q%+MZ^6X;'Y4R34K&&1HY;VW
M1UZJTJ@C\,TZ"SMK7=]GMXHMW7RT"Y_*F2:;832-)+96[NW5FB!)J-;#]ZPQ
MM8TQ1EM1M /4SK_C6=IGBK3KZ:_CDO;*/[/=&"/_ $A3Y@"J=W7_ &B/PK0;
M1=+<8;3K0CT,*_X5EZ9X0TVSN+^6;3[&0SW9GBQ ,HI51CIZJ?SHUL'O6-;^
MU=.)P-0M>?\ ILO^-2W-[:6:JUU=0P*QPIED"@_3-1?V1IH.1I]KD?\ 3%?\
M*?=Z?97\:I>6D-PB'*K+&& /MFC42YNIE:)XIL-4TN&ZFN[.":0MF+[0I(PQ
M'K[9K:CN(9H?.BFC>+GYU8$<>]8&@>$--TK3(8)["QEN8RV91".<L2.2,]#B
MMZ*W@AA\F*&-(N?D50!SUXH5^H+FZF/K?BG3]*TBZNX;NSGFA3<L/VA06_6M
M6VO[.]+"UNX)ROWA%(&Q]<5BZ_X1TW5=)NK>"PLHKF5-J3&$?*<^H&:U[/2[
M#3BYLK*WM]_WO*C"Y^N*%<%S=19-2L(I&CDO;9'4X*M*H(_#-+'J-C-(L<5[
M;N[=%6523^&:;)IEA+(TDEE;N['+,T0)-+%IMC#(LD5G;HZ]&6, BC4/>N/G
MO;6V8+<7,,3$9 DD"D_G47]K:;_T$+7_ +_+_C4L]E:73!KBVAE8# ,B!B/S
MJ'^R--_Z!]K_ -^5_P *-0?-T+,D\,,7FRRHD?\ ?9@!^=5_[6TW_H(6G_?Y
M?\:L2P0S1>5+$CQ_W&4$?E5;^R--_P"@?:_]^5_PH=^@/FZ%F*>&:+S8I4DC
M_OHP(_.J_P#:VG?]!"U_[_+_ (U8B@A@B\J&)(X_[BJ /RJM_9&F_P#0/M?^
M_*_X4:@^;H3P7EM=%A;W$,VWKY;AL?E3)-1L89#'+>6\;KU5I5!'X9IUO9VM
MJ6-O;Q0[OO>6@7/Y4R73;&>1I);.WDD;JS1@DT:V'[UA8M1L9I!'%>6\CGHJ
M2J2?PS3Y[RUM2!<7,,1;H)'"Y_.HXM-L8)!)%9V\;CHRQ@$4^>SM;HJ;BVBE
M*]#(@;'YT:V%[UB+^UM-_P"@A:_]_E_QJQ+/#!'YDTJ1Q_WG8 ?F:K?V1IO_
M $#[7_ORO^%698(;B+RIHDDC/\+J"/RHU!<W4K_VMIO_ $$+3_O\O^-6(KB"
M:+S8IHY(QU=&!'YU6_LC3?\ H'VO_?E?\*L16\$$7E0PQQQG^!5 'Y4*_4%S
M=2#^UM-_Z"%I_P!_E_QJ6"\M;HD6]S#*5Y(C<-C\JA_LC3?^@?:_]^5_PJ:"
MRM;4L;>VAB+<$QH%S^5"N"YNHR34K&*1HY+VV1UX*M*H(_#-$>I6,LBQQWML
M[L<!5E4D_K1)IEA-(TDME;N[<EFB!)HCTRPAD62*RMT=3D,L0!%'O![P^>\M
M;4J+BYAB+<@2.%S^=1?VMIO_ $$+3_O\O^-2SV5K=%3<6T,I7@&1 V/SJ'^R
M--_Z!]K_ -^5_P *'<'S="S)/%%#YLDJ)&!G>S #\ZK_ -K:;_T$+3_O\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^+H_X2F3_H7-=_\  =/_ (NCV4PN=!17/_\ "4R?]"YKO_@.G_Q='_"4R?\
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MO/CGV%SYD9^4Y<G^N*TZ4=D3'X4%%%%,H**** "BBB@ HHHH **** "BBB@
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M&23G/X5M?"U8;2'6]+:T^SZC878AO-EP\T;G;E64N<@$'I0!Z#1110 4444
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M9?\ ?X4?\)7X?_Z#-E_W^%'LY]F%T;%%8_\ PE?A_P#Z#-E_W^%'_"5^'_\
MH,V7_?X4>SGV871L45C_ /"5^'_^@S9?]_A1_P )7X?_ .@S9?\ ?X4>SGV8
M71L45C_\)7X?_P"@S9?]_A3)/%_AR&,O)K=BJCJ3,*/9S[,+HVZ*XVQ^(WA^
M?5=0@FUK3U@B=%MV\T#?E>?UK6F\8^&X$WRZW8JN<9,PH]G/LQ71N45QVC?$
M30;W[4MUK.GQNEY+%"!*!NC!PI_$5L_\)7X?_P"@S9?]_A1[.?9A=&Q16/\
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M(L$KG&00>H.!^5=?13).*\"?#/1O EK.MLSWES<8\VXG49('0 =A78?9;?\
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MY\R/[IRY/]<?A6E2CLB8_"@HHHIE!1110 4444 %%%% !1110 4444 %%%%
M'CWQ0TS5(O$DMU9RVZIK.GII8DENEB-O^]#,P!.2&7CBNA^&&FG2F\16MMA-
M+CU#R[.#S-QC"J ^1D[<L,XKE_BYHMZVM2:G_95SJ,4UK!#;/ GF&UD2<.YV
M]1N7N/3%=A\/+"\6Y\1:W<V4UC#K%_\ :+>VG7;(J!=NYAV+=<4 =Q1110 4
M444 %<ZG_)1I_P#L$Q_^C7KHJYU/^2C3_P#8)C_]&O0!T5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'J^@OJNC7&FBT+Q6PG-O(KE@2I]0<9%8/AGPMJG_  DFEZ[8Z!)IMM+K4UP
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M@<.P_I6G69H#6CZ+ U@CI;$OL5^H^=L_KFM.E'9$Q^%!1113*"BBB@ HHHH
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MVM?.CT\6V[G8S[]O\LUJ446)YM]"G?G40J?V<MLS9._SRP'X8I]B;XP'[>L
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MPJG J]X8\0:'K\%Q)HBE8XG"RYMFAY(XX(&: -ZBBB@ HHHH *YU/^2C3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -&O715SJ?\ )1I_^P3'_P"C7H Z*BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTK3J8_"B8?"@HHHJB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BN.L_$VI2OI^IS)#_96I79M8H50B2(98)(6S@[BHR,#&X<FNBU--3EA$>F7
M$%M(<DS31&0#VV@C.?K0!?KG4_Y*-/\ ]@F/_P!&O5GPIJUUK?AVWOKVW6"Y
M9GCD5"=I*.5W+GG!VY&?6JZ?\E%G_P"P3'_Z->@#H:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6=I'1O/WJJ;4VD_)\I/S8[<5SZ>#?$4NBVTES;(VI32?V;>#S%P+ @(6'/\
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ML/\ ^!L5']K^(/\ H6'_ / V*M^B@# _M?Q!_P!"P_\ X&Q4?VOX@_Z%A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7/>,/\ CPT[_L*6G_HU:Z&N>\8?\>&G?]A2T_\ 1JT
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MA;Q#_P!BVW_H4E '8:=_R"[3_KBG_H(JS5;3O^07:?\ 7%/_ $$59H ****
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M6KI=-CE:5;,HAP2Q8KOQNVY)X_"NBHHH YZ^_P"1\T?_ *\[G^:5T-<]??\
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MD(RH7;DYXZF@#M*PO%EK=W.EVYLK9KF6"]MYS$K!2RI(&;!/&<"F?\(C:?\
M01U?_P #Y/\ &C_A$;3_ *".K_\ @?)_C0 ?V]JO_0KW_P#W^A_^*H_M[5?^
MA7O_ /O]#_\ %4?\(C:?]!'5_P#P/D_QH_X1&T_Z".K_ /@?)_C0 ?V]JO\
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M]O:K_P!"O?\ _?Z'_P"*H_X1&T_Z".K_ /@?)_C1_P (C:?]!'5__ ^3_&@
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M'V-+')=0_$N!)+>QEM)[*06TMMD20!2I82#H0V1CZ4 =E1110 4444 %%%%
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MB@ HHHH **** "BBB@"I-IEA<7D=Y-9P27,7W)60%E_&K=%% !1110 4444
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MCO5^B@"*VMH+.VCM[:)8H8QM1%& H]!4M%% !1110 4444 %-DC66-HW7<C
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M=9\^VAXS)'YB'<.>F ?RKVO189+?0=.@F0I+':QHZGJ"% (H O4444 %%%%
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M_P!^W_\ B:/^$\\,_P#053_OV_\ \371T4 <Y_PGGAG_ *"J?]^W_P#B:/\
MA//#/_053_OV_P#\371T4 <Y_P )YX9_Z"J?]^W_ /B:/^$\\,_]!5/^_;__
M !-='10!SG_">>&?^@JG_?M__B:/^$\\,_\ 053_ +]O_P#$UT=% '.?\)YX
M9_Z"J?\ ?M__ (FC_A//#/\ T%4_[]O_ /$UT=% '.?\)YX9_P"@JG_?M_\
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M_P!!5/\ OV__ ,371T4 <Y_PGGAG_H*I_P!^W_\ B:/^$\\,_P#053_OV_\
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M\\,_]!5/^_;_ /Q-='10!SG_  GGAG_H*I_W[?\ ^)H_X3SPS_T%4_[]O_\
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MET,N6P((V;:&)]23P.^#74 Y4'U%:3K*<5#K$B,DY-(6BBBLRPHHHH ****
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M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
MC1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G
M_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<
M_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_
M .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8
M_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^
M- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V
M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
MC1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G
M_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<
M_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_
M .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8
M_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^
M- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V
M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
MC1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G
M_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<
M_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_
M .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8
M_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^
M- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V
M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
MC1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G
M_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<
M_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_
M .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8
M_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^
M- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V
M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
MC1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G
M_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<
M_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_
M .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8
M_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^
M- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V
M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
MC1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G
M_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<
M_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^- '045S_ /PA]C_S^:G_
M .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V/_/YJ?\ X&O_ (T?\(?8
M_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\ C1_PA]C_ ,_FI_\ @:_^
M- '045S_ /PA]C_S^:G_ .!K_P"-'_"'V/\ S^:G_P"!K_XT =!17/\ _"'V
M/_/YJ?\ X&O_ (T?\(?8_P#/YJ?_ (&O_C0!T%%<_P#\(?8_\_FI_P#@:_\
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ggtc45pq2o35000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0G![<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_%_B.2U
MF&F6Q*W#X(85CW5SJ7AF?3YIKEIDN<%AZ5#XI3R_B!#<2 ^4$ SVJ[X^F1H=
M,1,,9!\N* .\L[Q+RS6Y0?*1FN'U?Q!+J7B2#2+>8P^8<=>M=/X9B,.@PQR'
M![YKG=<\&2OXAM]8T]E62+GYFH SY=0U#PAK4<5Y<-/#.X5!Z5Z5&V^-6_O
M&O%]1GU/Q1XFBLG +VDH9B!Q7LJ*RVR*/O! /TH IZ[_ ,@6Z_W#6;X+_P"0
M"G^\:R-?B\3FUNRI3[/@_7%:G@;>/#D?F??W<T =-1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >6_&:SMH_#\-PD2K,9,%@.M>>?#7_ )'NRKTK
MXT_\BO!_UUKS7X:_\CU8UZ-'_=W\SBJ_QD?2M%%%><=H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7?^0+=?[AK-\%_P#(
M!3_>-:6N_P#(%NO]PUF^"_\ D I_O&@#HZ*** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!G:[_R!;K_ '#6;X+_ .0"
MG^\:TM=_Y MU_N&LWP7_ ,@%/]XT ='1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "'I7F?Q=\*R^(=',T/+0(< =37
MIAJO,H92"H(]#0!\6Z-8WMEJ30SV\B 9^\N*ZW2=)N-7U2.QC4H9#PQ' KWC
M5_"FFZC(7DB5&S_"*BT_PS8V5RDT2_.G3BNRGB>2'+U.>I0YYW.&7X,:FY_X
M_DJ3_A2>I?\ 01CKV"W!Z\U>7I4?6ZO<KZO3/$?^%):E_P!!&.C_ (4EJ7_0
M1CKW"BCZW5[B^KTSP_\ X4EJ7_01CKF]:\!W^B2,CR>9M[BOI2LV]T2TOR3,
MN2:7UJKW#ZO3/#/#_P +[_Q#IWVU+I8!G 5JU?\ A26I?]!&.O9=/T^#3;?R
M(!A,YJW3^MU>X?5Z9X?_ ,*2U+_H(QT?\*2U+_H(QU[A11];J]P^KTSP_P#X
M4EJ7_01CK.U#X5:CIT@0W2R9[BOH&JUQ917+;I!DBE]:J]P^KTSQ6'X+ZE-"
MDO\ :"+N&<'M3_\ A26I?]!&.O;D01H$'0<"G4_K=7N'U>F>'_\ "DM2_P"@
MC'1_PI+4O^@C'7N%%'UNKW#ZO3/#)O@OJ4,32?;T;'852TWX4:CJ4LJ"[6/R
M^Y[U[\Z"1"IZ&H;>SBMF9HQ@MUI?6JO</J],\7_X4EJ7_01CH_X4EJ7_ $$8
MZ]PHI_6ZO</J],\/_P"%):E_T$8Z/^%):E_T$8Z]PHH^MU>X?5Z9X?\ \*2U
M+_H(QT?\*2U+_H(QU[A11];J]P^KTSP__A26I?\ 01CH_P"%):E_T$8Z]PHH
M^MU>X?5Z9X?_ ,*2U+_H(QT?\*2U+_H(QU[A11];J]P^KTSY[N_A;J-I?"U-
MR&)&=PK33X*:DR*W]H1C(SBO9Y;"&:;S6'S594;5 ':E]:J]P^KTSQ#_ (4E
MJ7_01CH_X4EJ7_01CKW"BG];J]P^KTSP_P#X4EJ7_01CH_X4EJ7_ $$8Z]PH
MH^MU>X?5Z9X?_P *2U+_ *",='_"DM2_Z",=>X44?6ZO</J],\/_ .%):E_T
M$8Z/^%):E_T$8Z]PHH^MU>X?5Z9X?_PI+4O^@C'1_P *2U+_ *",=>X44?6Z
MO</J],\/_P"%):E_T$8Z/^%):E_T$8Z]PHH^MU>X?5Z9X?\ \*2U+_H(QT?\
M*2U+_H(QU[A11];J]P^KTSP__A26I?\ 01CH_P"%):E_T$8Z]PHH^MU>X?5Z
M9X?_ ,*2U+_H(QUE7?PNU&TNE@-R&).,BOH6JLMA#-*)'&6!S2^M5>X_J],\
M9'P3U(@'^T8^11_PI+4O^@C'7N X&**?UNKW%]7IGA__  I+4O\ H(QT?\*2
MU+_H(QU[A11];J]P^KTSP_\ X4EJ7_01CH_X4EJ7_01CKW"BCZW5[A]7IGA_
M_"DM2_Z",='_  I+4O\ H(QU[A11];J]P^KTSY['PNU$WZVGV@98XW5J?\*2
MU+_H(QU[-]@A\\38^85:I?6JO</J],\/_P"%):E_T$8Z/^%):E_T$8Z]PHI_
M6ZO</J],\/\ ^%):E_T$8Z/^%):E_P!!&.O<**/K=7N'U>F>'_\ "DM2_P"@
MC'1_PI+4O^@C'7N%%'UNKW#ZO3/#_P#A26I?]!&.C_A26I?]!&.O<**/K=7N
M'U>F>'_\*2U+_H(QT?\ "DM2_P"@C'7N%%'UNKW#ZO3/#_\ A26I?]!&.L_5
M/A3J.E>5F[67S&QQVKZ JO<V<5WM\P9VG(H^M5>X?5Z9XI#\%]2FB#_;T7(S
M@T__ (4EJ7_01CKVY$$:A1T%.H^M5>X?5Z9\Y^*OAU=^$],6_GNUF0MMVCM6
M9X&B-SXPLXU."QKUCXS?\BE'_P!=:\L^'?\ R/%A^%=E.I*=%R9SS@HU4D?2
MT,?E1*F<X'6I***\H[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /./C-_R*4?_76O+/AW_P CQ8?A7J?Q
MF_Y%*/\ ZZUY9\._^1XL/PKTJ'\!_,XJO\9'TU1117FG:%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y9XI!3XA0R2?
MZK8/I5_Q_)&(-,7C+CY*Z7Q%X=CU>(O'A+@='K"M/"EW?7=N^H3^9':GY0U
M'1^%T=-"A$GWJY+QZ++5[^+28Y=E_*,1LO#5TNHV-_\ :%%E.8H01\HK(\1^
M#IK_ %.UUBUF\NXMU_$F@#E?"<VI^$]7:PUJ(M"3MCDDY)->OD[H@R]QD5Q=
MMX;N]3N(Y]1E,AC(8;J[91M15]!B@#@_$)U[[/=;+<^1@\^U:_@7=_PC<6\8
M;/-:VN$C1;K']PUF^#/^0"G^\: .BHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%&*6B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SC
MXS?\BE'_ -=:\L^'?_(\6'X5ZG\9O^12C_ZZUY9\._\ D>+#\*]*A_ ?S.*K
M_&1]-4445YIVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 8 [4444 9VN_\ (%NO]PUF^"_^0"G^\:TM
M=_Y MU_N&LWP7_R 4_WC0!T=%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQ\9O^12C_
M .NM>6?#O_D>+#\*]3^,W_(I1_\ 76O+?AT"WCFP ]17I4/X#^9Q5?XR/IFB
MBBO-.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#.UW_D"W7^X:S?!?_(!3_>-:6N_\@6Z_W#6;
MX+_Y *?[QH Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N^-&H0)X<CMRPW^9GK7B
M^G:A<:?<QWMB^R=/NM7HOQWT2^ELEO(59H]^2!7C6GZQ:06^R9F#@8/%=V&J
MQY7"1RUZ;OSQ/?-%^,=K;V*1ZJDDMP!\S+6E_P +IT+_ )]YZ\CT;PMJ_B.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH SM=_Y MU_N&LWP7_R 4_WC6EKO_(%NO\ <-9O@O\ Y *?[QH Z.BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH K7VGVNI6Y@NX5EC/9A7"2?"+0'OO/-K%L)R5
MQ7HE% %'2](LM'M5M[*!8D QA15ZBB@ KSKXRG_BD%'_ $UKT6O.OC+_ ,B@
MG_76M:'\1&=7X&>4_#S_ )'C3_J*^FZ^9/AY_P CQI_U%?3=;XWXT987X6%%
M%%<9TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2 ,DX
M%-66-SA'5B/0T /HHJ.2>*+_ %DBI_O'% $E%0K=VSG"SQD^S"IJ ,[7?^0+
M=?[AK-\%_P#(!3_>-:6N_P#(%NO]PUF^"_\ D I_O&@#HZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O.OC+_P B@G_76O1:\Z^,O_(H)_UUK6A_$1G5
M^!GE/P\_Y'C3_J*^FZ^9/AY_R/&G_45]-UOC?C1EA?A84445QG2%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKR2PT]IXUR00,4:1>2WMMYLB@4 :-%%% !1110 4444 %%%% !1110 4444
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MH^L4.WX![&KW/'O^$\\2_P#05?\ .C_A//$O_05?\Z]A_P"%0^&O[DOYT?\
M"H?#7]R7\Z/K%#M^ >QJ]SQ[_A//$O\ T%7_ #H_X3SQ+_T%7_.O8?\ A4/A
MK^Y+^='_  J'PU_<E_.CZQ0[?@'L:O<\>_X3SQ+_ -!5_P Z/^$\\2_]!5_S
MKV'_ (5#X:_N2_G1_P *A\-?W)?SH^L4.WX![&KW/'O^$\\2_P#05?\ .C_A
M//$O_05?\Z]A_P"%0^&O[DOYT?\ "H?#7]R7\Z/K%#M^ >QJ]SQ[_A//$O\
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MK RDN>_-'_"H?#7]R7\Z/K%#M^ >QJ]SQ[_A//$O_05?\Z/^$\\2_P#05?\
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M/AK^Y+^='_"H?#7]R7\Z/K%#M^ >QJ]SQ[_A//$O_05?\Z/^$\\2_P#05?\
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M&-/^#>?^$OFRQ/[L\9IU8PJ4N>*"G*<)\C/?:***\T[0HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!XY\<.NF_C6+\&_\ D;YO^N9K:^.'73?QK%^#?_(WS?\
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MMXB\2V;VFM75A9K"9&*,[*DR,-K!=P 8ANH/\)JG_P *X\2?]%#U7\I/_CM
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MKJZPO#,FC7]O/K&C8"7K S)M"%'4;2I7'#>OKUZ8K=H **** "BBB@ HHHH
M**** "BBB@#.UW_D"W7^X:S?!?\ R 4_WC6EKO\ R!;K_<-9O@O_ ) *?[QH
M Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-\%_\@%/]XUI:[_R!;K_ '#6;X+_ .0"G^\: .CHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^XKLK:YAO+:.YMI4EAE4,DB'(8'N*X+P-F;Q_P"-IW)WI<QQCTQEQ_[**T_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_R!;K_<-9O@O_D I_O&@#HZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7]DEPG1A4.M:A_9^G2RJ?W@'RB@"\)HRY0."PZBGUY7\/=9U/5?%VI?;')A
MRB^E>J4 9VN_\@6Z_P!PUF^"_P#D I_O&M'7&0Z-=#>H^0]ZS_!?_(!3_>-
M'14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CGQPZZ;^-8O
MP;_Y&^;_ *YFMKXX==-_&L7X-_\ (WS?]<S7HQ_W8XI?QSWVBBBO..T****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!%@G%;/@4,OAN(,<MGDT =-1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >.?'#KIOXUB_!O_ )&^;_KF:VOCAUTW\:Q?@W_R-\W_ %S->C'_
M '8XI?QSWVBBBO..T**** "BBB@ HHHH **** .#UW0CXU\93:=?74D6E:7!
M&S01/AII)-QR?0 *!^''4UH'X9^#RFPZ*F.G$TF?SW9IOB:RNO[8AO/#^JVE
MKKQAVFSG=<7<0R>5ZY!S@_R[<U-<_%G4W6T%E::<#A'G0QX /\62S'_OD9%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^8"F<XR><^YKN* "BBB@ HHHH **** "BBB@ HHHH SM=_Y MU_N&LWP7_R
M4_WC6EKO_(%NO]PUF^"_^0"G^\: .CHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /'/CAUTW\:Q?@W_R-\W_ %S-;7QPZZ;^-8OP;_Y&^;_K
MF:]&/^['%+^.>^T445YQVA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9VN_\@6Z_P!PUF^"_P#D I_O&M+7?^0+=?[AK-\%
M_P#(!3_>- '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C
MGQPZZ;^-8OP;_P"1OF_ZYFMKXX==-_&L7X-_\C?-_P!<S7HQ_P!V.*7\<]]H
MHHKSCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0D*,D@#WJ*&
MZBG9E1P2IYYKB?&>OS+>C1[<E9'P=R]:R]3CN_#$NFSI<22B;!D!/2@#U"HY
M9XX$+R.J@>IJOIUZ+^Q2Y48W"N6\2>&[[Q)>*BW4MK%C!*F@#L8IXIT#1NK
M^AJ2O%O"T6K>&_&%SIYN9;N%6V@L<XKVA3E%)[B@#/UW_D"W7^X:S?!?_(!3
M_>-7]=EB_L>Z!< [#5#P7_R 4Q_>- '1T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]PUF^"_^0"G^\:TM=_Y MU_N&LWP7_R 4_WC0!T=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!QWBW UC320#\_>NM149%.Q>GI7)>+O^0OIW^]771?ZI?I0 OEI
M_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI
M_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI
M_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI
M_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI
M_<7\J/+3^XOY4ZB@!OEI_<7\JXW7@H\8Z?A0..PKM*XO7_\ D<M/^E '9K]T
M4M(OW12T >.?'#KIOXUB_!O_ )&^;_KF:VOCAUTW\:Q?@W_R-\W_ %S->C'_
M '8XI?QSWVBBBO..T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW=,]LUQ?A/7]8U+QCX@TW4IX7BL2JQ)#'M49)YSU/&.I[4 =M1110 5Q>O\
M_(Y:?]*[2N+U_P#Y'+3_ *4 =FOW12TB_=%+0!XY\<.NF_C6+\&_^1OF_P"N
M9K:^.'73?QK%^#?_ "-\W_7,UZ,?]V.*7\<]]HHHKSCM"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH X3QGK\\=V-)M&*3/@[A65J+:EX:FTV8W#
M.LV#(!3/%@-OX]ANY ?*"@9J]X\N%>'2DCPQE VXH [O3KQ;^S2X48#"L'Q\
MET/"UW+9SF*5%R"*O^&T-KHD,<I 8=B:K^-B/^$1OCG^"@##^&M[>7.E*MY,
M99 O+&N]KS[X9$&PZC[M=^X)4@=<4 9^N.AT:Z!<#Y#WK.\%_P#(!3_>-8_B
M'3=<>VNG0KY.">O:M7P*K+X<C#_>W'- '34444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML'^ UG>"_P#D I_O&M'7?^0+=?[AK-\%_P#(!3_>- '1T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <=XN_Y"^G?[U==%_JE^E<CXN_Y"^G?[U==%_JE^E #Z*** "BBB@ /(
MQ5&'3(H9S*O4G-7J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KB]?_P"1RT_Z5VE<7K__ ".6G_2@#LU^Z*6D7[HI: /'/CAU
MTW\:Q?@W_P C?-_US-;7QPZZ;^-8OP;_ .1OF_ZYFO1C_NQQ2_CGOM%%%><=
MH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M=KO_ "!;K_<-9O@O_D I_O&M+7?^0+=?[AK-\%_\@%/]XT ='1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]_SYS?E1_P )-??\^<WY4 =K17%?\)-??\^<WY4?\)-??\^<WY4 =K17%?\
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M?E1_PDU]_P ^<WY4 =K17%?\)-??\^<WY4?\)-??\^<WY4 =K17%?\)-??\
M/G-^5'_"37W_ #YS?E0!VM%<5_PDU]_SYS?E1_PDU]_SYS?E0!VM%<4/$M\3
MC['-^55!XYG-\;(6<OFKR>* /0**XK_A)KW_ )\YORH_X2:^_P"?.;\J .UH
MKBO^$FOO^?.;\J/^$FOO^?.;\J .UHKBO^$FOO\ GSF_*C_A)K[_ )\YORH
M[6BN*_X2:^_Y\YORH_X2:^_Y\YORH [6BN*_X2:^_P"?.;\J/^$FOO\ GSF_
M*@#M:*XK_A)K[_GSF_*C_A)K[_GSF_*@#M:*XK_A)K[_ )\YORH_X2:^_P"?
M.;\J .UHKBO^$FOO^?.;\J/^$FOO^?.;\J .UHKBO^$FO?\ GSF_*J]UXRN;
M&(RRV<NT>U '>T5PT/BR[N(%F2SEVN,CBI/^$FOO^?.;\J .UHKBO^$FOO\
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M[8\2?] \5%_PD][_ ,^<O_?-'_"3WO\ SYR_]\T 2_VQXD_Z!XH_MCQ)_P!
M\5%_PD][_P ^<O\ WS1_PD][_P ^<O\ WS0!+_;'B3_H'BC^V/$G_0/%1?\
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M/[B_E1L3^ZOY4ZB@#AY<#QS)^[&,>E=JJ(4'R+T]*A-C ;DW!0>8>^*LC@4
M-\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44
M-\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44
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MDMX[O2[R2:ZP"T9;@&@#U6BL_1);B;28'NEVS%?F%:% !1110 4444 %%%%
M!1110 4444 %%%% !3'FBB_UDJ)_O,!3B<#->?>*=!U;79I@IDCA491D.,T
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M:SVMS(9V;)3=QF@#TGK16;HCW;Z:AO$VR^E:5 !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% '-^-&"Z(Y+!>#6-\*F1M"N=K!OWW:M[Q3I$^LZ?\
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M>-J>] #OA\5/AE-K C<>E=57/>$M%FT+2Q:/C .:Z&@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !12,0JECG &>!DUSK>._#D>JIIDU])!>NZHL,]K-
M&<GIG<H SGJ: .CHHIKNL:,[L%11EF8X 'J: '45SFG>._#NKW'D:==SW4@Q
MD0V4[;<G&2=G ]SQ71T %%%% !1110 45'<3Q6MO)/.X2*-=S,>PK%T3Q?I7
MB'4[VRTYII&LPIDD:/8ISD8&><@@YR!0!O4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &NX1&<@D*,G:I)_ #DUPBZQ_P 7)?4?[*UG^SSI@M?M']F3X\P2
M%_N[-V,'&<=1Z<UWM% 'GWQ+\,7FM#2-4TA91J-O<)&#&I#!6((;U&UL'MC)
M)Z5U$0M/"?AZUM([>ZFCMXO+1+6U>5G(&3PH."3GDD#)ZULT4 >3?"LWFB3:
MK%JND:I:F[DC:)FL)F4GYL@D+QC(Y.!6E?:'J7A/QY)XFTFQEU#3[Y6%[;0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ggtc45pq2o35000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .S"N # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@C(I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M01S+<O$!""%P ".I//-=Q7DW[//_ "3F7_K^D_DM>LT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M22.12K(P.""#R"#VK[[KX@\=_P#)0_$W_85NO_1K4 ?;]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OGO]I;_ (^?#_\ N3?S6OH2OGO]I;_CY\/_ .Y-
M_-: .K_9Y_Y)S+_U_2?R6O6:\F_9Y_Y)S+_U_2?R6O6: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKC/B=XX_P"$$\)/J$,:2WT\@@M4?[N\@G<WL "??@=Z .SHKYI\#7'CZX^)
MGA[4O%$NL+:WL\BH+HM'&Y\ISA8^ !WX %>_Z]X?AUZWC1[R^LIX23#<V5RT
M3QD]^#AAQT8$4 :]%>8^ O'6I2>+M3\"^)Y8IM6L&;[/>HFS[4@P?F7H&VD-
MQVSZ9/IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$'CO\
MY*'XF_["MU_Z-:OM^OB#QW_R4/Q-_P!A6Z_]&M0!]OT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\]_M+?\?/A_\ W)OY
MK7T)7SW^TM_Q\^'_ /<F_FM '5_L\_\ ).9?^OZ3^2UZS7DW[//_ "3F7_K^
MD_DM>LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6XM+B*XA;[LD3AU/T(XJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[.>"Y0S,X#%HRA&]BW9NG'T[][0 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?/?[2W_ !\^'_\ <F_FM?0E?/?[2W_'SX?_ -R;^:T =7^SS_R3F7_K
M^D_DM>LUY-^SS_R3F7_K^D_DM>LT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_$75/#FE^#+T^*(
M_.TZ<>3Y"C+RN>0$_P!H8R#D8QG/%=57D/[0&B7&I^&M)NU=EL[2] NV R(T
M?"^81Z \?\"H Y'2OVBYM+TZ.QFT*34?(RD=S+>".1XP?EW@1D;L8!(ZGG J
M[_PTU_U*/_E2_P#M5>JZ?\./!5C8Q6\/AK2IHU4 23VJ3.WN68$FK7_"">#_
M /H5-#_\%T/_ ,30!YQX"^*%Q\1/B3;H=,33[>STZX81B;S6=F>+DMM'0#IC
MN:]GKDK;P;H>C^-;'5=)LM/TZ0V<\$L%NJQ&8%HR"$48.W!R?]H=>,=;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q!X[_Y*'XF_P"PK=?^
MC6K[?KX@\=_\E#\3?]A6Z_\ 1K4 ?;]%%% !5.;2--N9FFGT^TEE;[SR0JQ/
MU)%7** ,_P#L+2 <C2K'_P !T_PJ^JA5"J % P !TI:* /D;XP> KKPEXJN+
MZ&$G2+^5I8)5'RHQY,9]"#G'J/QQYS7WMJ&G66K6,MEJ%K%=6LHP\4J!E/X&
MO,;W]GKP7=W3312ZK9HW2&"X4H/IO1C^M 'RW##+<3QP01M)+(P5$09+$] !
MZU]??"/P3)X*\&I#>*!J5X_VBY YV'&%3/L/U)JYX3^&'A;P;(MQIMB9;P#
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M?[0?_(.\,_\ 81_I7JVMZS9^'M$O-6U!V2UM8S)(5&2?0 >I. /K7E/[0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45#<7=O:1F
M2XF2)!W8XJ&TU6POR1:W<4Q'4*U %RBBHY[B&VB,L\BQH.K,<"@"2BJEIJEC
M?Y^R744V.NQLU;H **AN+JWM(S)<3)$@[L<4RSU&SOU+6ES', <'8V: +-%%
M% !7SW^TM_Q\^'_]R;^:U]"5\]_M+?\ 'SX?_P!R;^:T =7^SS_R3F7_ *_I
M/Y+7K->3?L\_\DYE_P"OZ3^2UZS0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>_%[Q5K/A#PQ#?Z;
M86%Y;2S&WO([V)I%VLIQPK#@X(.<]17H597B30K;Q+X>O-(NMOEW"  LFX*P
M(*G'?! .* /FG3/C]XLTJPCLH;+2'AB^6(2Q2L43L@/F9( X&<G Y)JY_P -
M'>,/^@;H?_?B;_X[7TY'%'#&L<4:QHO 51@#\*?0!X/\+_B+KGC[XF1G5EM8
MH[739_*BM495RSQ9)RQ)/ [U[Q7+Q+IE_P#$:62+RDU/2[/9+M +2QSE2N2.
MFTQ'@Y^\#QGGJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M(/'?_)0_$W_85NO_ $:U?;]?$'CO_DH?B;_L*W7_ *-:@#[?HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N'\1?#NWU[XB:!XJ:5$_LT?OHL',I
M4EHB#T&&.3[5W%% !6=KNB6/B/0[O2-2C,EI=)L< X(YR"/<$ CW K1HH \,
ML?A'X_\ "]Z\'A7QI%!I;2;MDQ<%0<9/E[60M[Y&<#IV]*\.^&+KPMH]U)'<
M?VQKUV5DNKN^F:/SV' 7<%<HB@G: #C\:ZFB@#R3P7X%\:^%_&FL:_<#P_<I
MJ\CR7$4=W,AC+2%\H3$<XR>#UXY%2_$3P1XS\9>(-(OK'^PK.'1YGEM3-=2N
M\I+*0S@1 #A%^4$XYY->K44 <7XQTOQ7XD\%3:/;6NBP75[$8[IY+V5DB&[^
M#$66R/7;@_WJ7X;Z%XC\+>&K?0M;73)8;16$-Q9W#LS MNVLC1J.,GD'TX[U
MV=% 'C7B'X.:S:>+I?$G@/7(M+N;AV::"8LJJ6Y;:5#94GG85P.QZ =;X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]+EN(8 #--'&#TWL!G\Z )*^>_VEO^/GP_\ [DW\UKWO^T;'_G\M_P#OZO\
MC7@'[2,\,]QX?,,T<F$FSL8''*^E '7_ +//_).9?^OZ3^2UZS7DW[//_).9
M?^OZ3^2UZS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KSKXSV&HZKX-M-.TD.;VYU*&.((^W)(;J>P[UZ+5/4)M.M
MHXKC4I;:&.*0-')<.JA7P0,$]\$_K0!\WCX%_$,C/]JV0]OMTG_Q-!^!?Q#
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M^*H Z"BJ.FZSI6M1O)I6IV=]'&=KM:SK*%/H2I.#5Z@ HHHH **** "BBB@
MHK&USQ;H'AM4_M?5;:U=V"I$S;I&)('"+ECU'(''>MF@ HHHH **** "BBB@
M HHHH **** "BL1_%VA1^*X_##:@@UF2/S%M=C$D;2WWL;0< G&<XK;H **@
MN[RUT^V>YO;F&VMT&7EFD"*H]R>!5/0_$&E>)+.2\T>\2[MHYF@:5%(7>O4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC /S<9QTSQG&: .LHKRA?ASHR?#0R>*H(8]>-J\MQJ=W=;I8I\$@^;N_A..
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M.,ULUXA;P7=C^TO9V4^K7]_"EF\D7VN7=Y>Z([@H   )7/ %=/\ $;Q-??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OGO]I;_CY\/_[DW\UKZ$KY[_:6_P"/GP__ +DW\UH ZO\ 9Y_Y)S+_
M -?TG\EKUFO)OV>?^2<R_P#7])_):]9H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O"?VD?^/#2/\ >?\ I7NU>$_M(_\ 'AI'^\_]* .B_9__ .2<?]O<G]*]
M4KRO]G__ ))Q_P!O<G]*]4H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:GIUOJ
M^E7>G72[K>ZA:&0?[+#!_G5NB@#PCPW^SQH]SHR2Z[?ZK'?^9(CI 4C4;790
M0&1B00 0<\@UK_\ #./@_P#Z"6N?]_X?_C5>P55U+4K/2--N-0U"X2WM+="\
MLKGA1_GMWH \I_X9Q\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJN2U
M_P#:!U[4M2:T\):6D<&2(WEB,T\GOM!P/I@_6DTWXN?$_39!-JWAN:]M <N)
M-/DA;'LRC _$&@#N_"7PJM? 7Q!M[[2KB\N;&XL)XI?M #&)PT97YE4#D9X(
M'W>_;U.N8\$^.]'\=Z2UYICLDL1"W%M+@20L>F?4'!P1P<'N"!T] !1110 4
M444 %%%% 'C7C:TE\,_&[P]XUO5/]AM']EFN!TMW9)$&_P!%^<'/UKUR:_LH
M=/:_FNH$LEC\QKAI!Y83&=V[ICWJ:6*.>)HIHTDC<89'4$$>X-8T'@WPQ;2(
M\/A[2XRC;DVVB (WJ!C /N* .!^#/ATVUWXH\0QVY@TK5[PG38GCV;K<.Y5]
MIZ*0X ^A[8JEX"TUOAK\4-8\.7>8]+UE1/ID['Y&*EL1YZ;P&((ZG:/45[/5
M74--L=5M&M=1L[>[MVZQ3QAU/X&@#S?XS7,^M:79^"-'47.L:I.CO"I_U4"'
M)D?^ZNX+R?0^E;FH?#NSN/A2?!<#*HCM0L4I&!YP._>?J^2?J:ZC3=%TO1UD
M73=.M;02G=)Y$2H7/JQ'4_6KU 'F_P &=3E_X1%O#>I(T&L:'*]M<6\I&\(2
M61L?W<' /0[?I7/ZWI7_  LSXRV7V;$N@>'0HNKA>4DG#;S$I_B_@! Z -[5
MZKJ?AW1=9D634])LKR1%*J\\"NP4]1DC.#Z5>MK6WLK=+>U@B@@C&$CB0*JC
MT ' H EHHHH *^(/'?\ R4/Q-_V%;K_T:U?;]?$'CO\ Y*'XF_["MU_Z-:@#
M[?HHHH **** "FR+OC9,XW C-.HH ^9V_9O\3%V(U?2,$\?-)_\ $4G_  S?
MXG_Z"^D?]]2?_$5],T4 ?,W_  S?XG_Z"^D?]]2?_$5Z;\(_AOJ?P^&L?VC>
M6EP;[R=GV<L=NS?G.X#^^/RKTRB@ HHHH **** "BBH;J&2XM9(8KF6V=QA9
MH0I=/<;E9<_4&@#P_7O^3I]%_P"N*_\ HJ2O=J\WN_@UI=[XD_X2&X\2>(VU
M8.)!<B>%64@8& (@ ,<8 Q6PW@6Z92I\;^*L$8XN8 ?S\F@#7.LVEMXCM/#E
MG"C3&W>YF2,A1;P@@*2,?Q,0 ..C'M7E6F_\G7:Q_P!>B_\ I/%7H?AKP#8^
M%[G5;RVU+4[O4-3"B:]O94EE7:"!M.P#OT((X'85DQ?"6R@\52>)X_$WB(:S
M(27N?-@.[(VX*F';C&!C&!@8' H P/VCO^2>:?\ ]A6/_P!%2UZ5>:Q8^'_"
MYU;4IA#:6MNKR.?H  /4DD #N2*P?&'PXL_' CBU?7-9%I$XDCM8'A2-6"[=
MW^J))ZGDG&XXP#BH=8^%UEKWAJRT#4O$.NSV5F^^/,L(=L*%4,PB^8* <9Y^
M8Y)XP <3X!TF\^)OC*;X@^(8\:;;2&/2K-N5!4\'W"^O=\G@#%>PW6K06EQ-
M"Z2LT-JUTY5>-@.,9SU.#@>U<_8^!)M,T^WL;+Q?XAAM;>-8HHU-KA5 P!_J
M*N:%X/@T35=0U.35=3U.ZOXTBE;4)$<!4S@*%10!\QXZ4 </\/+AOBK!?>(?
M$<OGVL-VUO;:,K$6T0 #;I%Z2L0V/F!'!XYP,GP1)8Q?M%^+6M'MDLX=.908
MBHC0*8 1QP,$$'TP:ZRV^"OA6SUFXO[:34X(+@YDT^&[*6[>Q"@,1G)P6QSZ
M<5=D^$WA27Q=_P )$;243;54VBN!;,0  2F/0#Y<[>.E '(_M!,&TSPPRD%3
MJ.00>#\M>H>*59_".M*H)8V$X  Y)\MJY[QC\,=/\<W$;ZQK6L^1$2T-K!)"
MD49( .!Y9)/'5B3R<5U&EZ;)IVG+9SZC=ZEM&/.O=AD*XQ@E%4'ZD$G/)- '
MGGP FBD^&,<:2(SQW<H=0P)4D@C([<<USWAK4[/4/VG]<N;.99X)K+RTD3E2
M5CA!P>XRIY'7MQ75Q_!#PA%JUQ>1_P!HI;7#;I-.2ZVVS>Q  8C.3@MCGTXK
M5?X6^%9O%DOB.YL6GNG$82%VQ!$$C6,!4  QM4<-D<GVP <5\8&$7Q-^'$TA
M"1+J"DNQPHQ-"3S[5W'Q&\:'P;X3OK^T6&XU"(1JD+O]SS"55V YVY5L=,[2
M,]:M>,/ >B>-K*UMM32:-K1BUO/;.$DBR!G:<$8X'&.PI(O .AKX2N/#<R7-
MU9W07[1)<7#/-*R[<,7]1M7 & ,<"@#G_#VAZ9=^"K?Q5XCODUC4)[$W3WU\
MX,5N'3YEC0_)&HZ' !)!SZ#$_9TECB^'MZ))%0OJ\BKN.-Q\F+@>IX-=5X<^
M%/AWPV5$3W]]'&YDB@OKGS(HB?[L8 3/)Y()YZTWPQ\*- \(?:I-)N+]+N;(
MCNI721[?/!\L%-@..,E2<<9Q0!RGPS_Y+3\0/^NQ_P#1AH^._P#R$?!/_81/
M\XZZ;0?A/8^&]<N-8TWQ'X@6\NF)N6DF@<3Y;<=X:+G)[]>3@BI?%GPNL/&E
M[%<:OKVME8&9K>&&2%$AR?X<19[#DDGCK0!T?BK_ )$_6_\ KPG_ /1;5Y_^
MSU_R35_^O^7_ -!2NVU'PM-JGAYM'N?$FL>7(&2:X3[.LLJ$8VDB+ 'N #ZD
MU1\&_#VS\#02VVDZQJK6<KM(]M<-"R;R -V1&&SA1WQQT- '$W/_ "=-9_\
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M*-(\;:TFJ:IJFK)+$@CACMI(D6)1SQF,MUR<DGD^F!76:582:1I_V>XU6\U
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M7H%>)?#"V\2>.?&0\?\ B0&*UMHFBTV%5*IEA@E >=H!/)ZD]>*]MH ****
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M.1@<]*T:* "BBB@ JAJFDVVLVXM;TR/:$_O;<-M28>CXY*\<KG!Y!!'%7Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O"?VD?^/#2/\ >?\ I7NU>$_M(_\
M'AI'^\_]* .B_9__ .2<?]O<G]*]4KRO]G__ ))Q_P!O<G]*]4H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4F-O^^@?:@#K54*H50 H&  .!2TV.1)8UDC=71AE64Y!'L:=0 4444 %%%%
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MAQ/"GB,ZM$GF/!Y5N $X^;=YVW;R.<XYKN48O&K,C(2 2K8ROL<9'Y5Q2?\
M)<Y_^Q:C_P#2EZYSX[>.KOPQH%KI.ESO!?ZD6WS)UCA48;!ZAB2 #Z!NAP:
M.KU#XDZ#:ZG)I5@+S6M2C($EKI4!G9.<'<W"+@]<L,8YIZ^/]/@>,:SIVJZ'
M'(<+/J5L$A#9P TBED4G_:(JQX$\)6O@OPI::3 J&8+ON90H!EE/WB?Y#V K
M>NK6WOK2:TNX8Y[>9"DD4BY5U/4$>E '/3^/=$B\'WWBB%Y;O3;.1HV:W"LS
ME7V$KD@$9Y!R,CFL9?BK$VF_VB/!GB_['Y1F\XZ>@79C.[_6=,<Y]*FT'P"F
MF^%+WPQ(=NG+JJW%N2=YD@$D<NQN>^UD.>W//?H_%7_(GZW_ ->$_P#Z+:@#
MC](^,6GZ_;/<:1X6\47L,;['>"SB8*V <'$OH16UX5^(%CXLU:]TR'2M7T^[
MLXUDECU&W6)@"<#@,3^8KA?V;O\ D3-5_P"P@?\ T6E>J_V-"/$JZVA"3&T:
MUE 7_6#<K*2?]G#?]]=NX!I445%<W$5I:S7,S%8H4,CD*6(4#)X')_"@#C?&
M_P 4_#_@*^M;+4X[V>YN(C*([2-6*)G +;F7J0V,9^Z>G&8?!GQ:T7QUK+Z9
MI.G:JDD<1FDEN(XU1%! Y(D)R20, '\@:\Q\/_%[P_;^(M7G\5>'IQ=ZA>[F
MN'C20P1 !8XRA ("*.<9)))QSBO=M!GT/4-/CU/0OL;VLX^6:V0*&P>AP,\'
ML>E $/B;Q;HWA"QCNM8N_)65_+AC12\DK>BJ.3_+D>M<MX;^-7A+Q)J\>E(U
M[87DTGE1)?0A/,?H%!5F )/ SCGCKBNT71;+^W'UEXS+?&(0QR2'/DIW"#^'
M).21R>,\ 8\J^-'A>'Q/XA\-:?I<2CQ!<2G?+&OS16HQF1R#PJL>,]3D#GB@
M#V6BBN.\7:A<:I?Q>#-)N/*O;Z(R7TZYW6MGG:S*<$;VY5?3D]J +7ASQYHW
MBK6]7TO2FFE?2V599RH\J0DD?(0<D J>< >F1S73UX5\"K6&Q\;>.+.V39!!
M.L4:9)VJLDH R>3P.]>ZT %9^JZW8:.L(NY3YUPVRWMXU+RSMZ(@Y..YZ <D
M@<U8OKV#3=/N;ZZ?9;VT332M_=5023^0K@/A>TOBC[=X\U%6-SJ$KP6*,<BU
MM4; 1?<L#N(ZD4 >BHQ>-69&0D E6QE?8XR/RK&UWQ=HGAR2&#4+S%W<<6]G
M"C2SS'H L:@L<GC.,9[U0^(GC&/P/X0N-6,8DN&806T9. TK9QGV !;_ (#B
MN4^'MKHWAJV36_%>O6)\6:N@FF>^NT66-'PRQJ">!R"0!UXZ 4 >@:+K,VL)
M(\FB:GIT:XV-?+&AD^BJ[,/^! =:BU_Q3IOATVT-R9I[V[8I:65K'YD\[#D[
M5]!W8D =S6RK!E#*05(R"#P:\7^'-XOC'XS^*_$<N9([!!:6>3D(A8J".."0
MC'_@;=: /1M)\9V.I:R=&N+2^TO5/+\U+34(U1I4!(+(59E;&.Q_K71UY1\>
MX9+;PKI>OVC&._TK44>&4<%0P.1GKRP3\J[>S\7:6/"6F:]JM_:6$5[:1W'[
MZ4(,L@8J,GDC.,#)H Z"BN;O/'_A;3]"M=:N]8AAL+M=]N[JVZ0>H3&X]/2K
M>E^*] UK1I-7T_5K673XAF6<OL6+ R=^[&W@YYQ0!LT5R^C_ !&\(:_JITS3
M-=MY[S.%BPR[^"?E+ !N >A-:^KZ]I.@6RW&KZE:V,3'"M/*$W'T /4^PH T
M:*Y?5OB+X3T/3K"_U'68H(+^))[8>6[/)&PRK;%4L 1W('IUK7T;7=+\0V"W
MVD7T-Y;DXWQ-G!]".H/L: .1NOBK90^/-/\ "<6CZB+JZFV--=1^0BH0<.H(
MW.#CT'U[5W]>+^.XU'[0W@F0#YV@52?8/)C^9KTGQ+XTT'P@D+Z[>26D<QQ'
M)]EED0GTW(I /L3F@#5U"_33;4W,D-Q+&K /Y$9D9 3][:.2!WP"?:GV=Y;:
MA9Q7=G<1W%M,N^.6)@RL/4$53T37M/\ $-G]KTUKA[?.!)-:RPAO=?,5=P]Q
MD5Y^^HGX?_%N'2P"-!\4GS8T/W8+W.&V^S$KD>KCH!R >IT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534]2M-'TRX
MU&_E\FTMD,DLFTMM4=3@ D_@*MUC>+-'F\0>$]4TBWDCCFN[=HD>3.U2?7%
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M\/\ ^Y-_-: .K_9Y_P"2<R_]?TG\EKUFO)OV>?\ DG,O_7])_):]9H ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"JHP !@ 4 >4_#+X5:UX,N([O4/$\[* =VFVK'[.20?O;NO7/"@^_->KT44
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MUGPC\/7$=[XC\7WEM);-KUX\]I#)PRP%V<,1_M;NXZ*#WK/TBP7X;_&+4GO
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MT >QV=R+RQM[I5*K-&L@4]LC-3U'!"EO;QP1C"1H$4>P&!4E !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\Z>)OCYXIT;Q5J^EVUAHS06=[-;QM)#*6*HY4$XD S@>
M@KZ+KCKWX5^"=1O[B^N] AEN;B5I99#+("SL<D\-W)H \1_X:.\8?] W0_\
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M[70Q'XKN8KC4-WWXR,8_ "@"#P+>>)I=/EM?%-LB7MNVU94'$J]F_&NLHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^>_VEO^/GP__N3?S6OH2OGO]I;_
M (^?#_\ N3?S6@#J_P!GG_DG,O\ U_2?R6O6:\F_9Y_Y)S+_ -?TG\EKUF@
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MZMDE*CT!8'%:5% &'!X,\*VMQ%<6_AG1H9XG#QR1V$2LC Y!!"Y!![UN444
M%-=$EC:.15=&!5E89!!Z@BG44 95GX7\/Z?=?:K+0M,MKC.[S8;2-'SZY SW
M/YUJT44 9NI>'M%UF19-4T?3[YU&U6NK9)2!SP"P/J?S-6+'3;'2X!!I]E;6
MD(Z1V\2QK^0&*M44 %%%% %&RT;2M-N+BXL-,L[6>Y.Z>2"!4:4Y)RQ RQR3
MU]:O444 (RAE*L 5(P01P:\]\,V!^&^L7FBRJX\-ZA<^=IUTS96VE? ,#_W0
M2!L/0YQG<:]#IKHDL;1R*KHP*LK#((/4$4 .K*_X1?P^;\WQT+3/MA()N/LD
M?F$C&#NQGL/RK31$BC6.-51% 5548  Z "G4 %0W5I;7UN]O=V\5Q ^-T4J!
MU;!R,@\=0#4U% %33]+T_2;?[/IMC:V<&<^7;0K&OY* *@U+P]HFM21R:KH^
MGW[QC:C75LDI4>@+ XK2HH QH/"7AJV@N(+?P]I,4-PH2>..RC595!R P Y&
M>>:BC\$>$XI%DC\+Z*DB$,K+I\0*D="#MZUO44 8MWX/\,W]U)=7GAS2+BXE
M.Z26:QC=W/J25R:XCXRZ;8:5\'=1M=.LK:SMQ-"PBMXEC0$RKDX4 5ZC7/>(
M? ^@>*GSK5M<W2#&(C?3I$".^Q7"Y]\9H S/"/AW0-6\"^&+N^T;3;RX72K4
M":>UCD8$1*.I!/&/TKLU4*H50 H&  .!61H'AC2O#%M]FTF.YAM\!5ADO)ID
M09)^57<A>2>F,UL4 <__ ,()X/\ ^A4T/_P70_\ Q-6+CPGX<NX;>&Y\/Z5/
M%;)L@26SC98E]%!'RCV%;%% &/;Z3X=\+P7-_:Z;IFE1+&6GGAMXX1L'/S$
M<#WKFM'T.7Q)XY/C;4X)X(+6'[-H]K.NU@A!W3NIY5F+$ '! QD9QCN98(I]
MGFQ))L<.F]0=K#H1Z'WJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y
ME_:0_P"1XTO_ +!J_P#HR2O7?@O_ ,DET/\ W9?_ $:]>1?M(?\ (\:7_P!@
MU?\ T9)7KOP7_P"22Z'_ +LO_HUZ .]HHHH **** "BBB@ HHHH *R?$VOV_
MA?PW?:U=(7AM(]Y13@L20 ![DD"M:N#^,_/PDU[_ '8?_1R4 <7_ ,-*:/\
M]"_??]_DKP>[U>.X\7S:T(F$<E\;H1D\@%]V/K6110!]'C]I31P /^$?OO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7-^/O\ D1M5_P"N0_\ 0A725S?C
M[_D1M5_ZY#_T(5=+XUZDS^%GAMG_ ,><?TJ>H+/_ (\X_I4]<-?^++U?YGP&
M(_C2]7^84445D8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !45U_QZ2_[M2U%=?\ 'I+_ +M:4OXD?5&E'^)'U1[+\,O^1%LO]^3_ -"-
M=?7(?#+_ )$6R_WY/_0C77UZ-?\ B2]3] I_"@HHHK(L**** "BBB@ HHHH
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MT.N6FDL2;FYAEG4 CA4* D_4N,?0U?KP'X6^%_%7AOXL;O%*3&:YTR8Q3R7
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M.<>E=/\ &'PY::QX U"X:W4W5HGFPL  <Y ZUF_ +_DG$7_7>3_T*NP\??\
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MSX#$?QI>K_,****R,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J*Z_X])?\ =J6HKK_CTE_W:TI?Q(^J-*/\2/JCV7X9?\B+9?[\G_H1
MKKZY#X9?\B+9?[\G_H1KKZ]&O_$EZGZ!3^%!1116184444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5#=VUO>6<UM=1K);RH5D5N
MA4]:FKS?XPSZI>:/I?A;1G\N[U^[^S.Y) $(4L_/ITSZC(P<T 9GB;]H#PUH
MMW)::7;3ZQ+'P98G"0D^@<Y)^H7'H36;H_[2.C75P(]7T2ZL$8X$L,PG ]R,
M*?R!KI?#/P2\'Z#:1B\LEU:\V_O)[L94GOMCSM ^N3[FNED\ >#I8RC>%=%
M/]VQC4_F!F@#0TV\TCQ!!::WIT\-Y&$98+B-L@!L;A['Y1D'D8K3KS33= MO
MAU\0=/M-&,D>A^(!+')9LY98+B--ZNN3G#*&7'T]L>ET %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5\0>._\ DH?B;_L*W7_HUJ^WZ^(/'?\
MR4/Q-_V%;K_T:U 'V_1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\+^(+NY/B35/](F_X^Y?XS_?-?=%?".O_P#(
MQZG_ -?<O_H1H H/))*<R.SD<98YIZW$Z*%2:15'0!B!45% 'M'[/&H^5XHU
M;[5=E8C9 XDDX)WC]>M>^W'B?3XLB,R3'_97 _6OFOX'V-Q?^)=0CMTW,+3)
MR0,#<*^@K?PE,V#<7*)[(-W^%>=B:V+]IR48Z=_ZT/)Q=?&^U=/#PT[_ -:#
M;CQ9<OQ!!'&/5CN/]*S)=4U&\;:UQ*V?X4XS^ KJK?PUIT."R/,WJ[?T&*TX
M;>&W7;#$D8]$4"N?ZEBZO\6I;T_I(YO[/QU?^/5LNR_I(X6#0]2N>1;,H/>3
MY?Y\UJ6_A%S@W%TH]HUS^I_PKJJ*WIY50C\5V=%+)<-#XKR]?^ 95OX<TV#!
M,1E8=Y&S^G2M*.&*%=L4:1KZ*H I]%=U.C3I_!%(]&E0I4OX<4@KA_C#$TWP
MHUY$4L1'&V!Z"5"?Y5W%>8_'76=8TCP"RZ7&?)NY?L]Y,$W>7$RG(]MW3/;Z
MD5H;'R=15B6QO(;2&[EM9X[:<D13-&0DF.NT]#CVJO0 5]>?!!"GPFT?*XW-
M,1GO^]>OF7P;X.U/QKKD>G:=$VS(,\Y7Y(4[L?Z#O7VAH^EVVB:-9Z79KMM[
M6)8DSU( QD^YH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8>L>+M$T"\BMM5OHK1I?N-*P53^-;E9
M.M^&M'\10"+5+&&X5?NEU!(^AH K7%IX:\9VT;2?9-3A7YD*ON'Z&JO_  KC
MPC_T [;]?\:Y74/@G81@OX<U?4-)FSE=L[% ?]WCBJGV#XL^%S&EG>6NNVJ_
M>5D5'/XDT =K_P *X\(?] .V_7_&MO2]'T_1;7[+IULEO#G.Q.E>:0_&2XTV
MY%KXF\-7NGL.&E3,B_H*]$\/^(],\3Z8NH:5,9;=N 60J1^!H U:*** "BBB
M@ KPGPY_R<1?_P#7,_R->[5RMGX"TFR\82^)HO-^W2 ALO\ +^5 '1W@F:SF
M%NP68J=A/8UY'\/OBK)+K&HZ)XPN5M+V.7$#3#8,<\'/?IBO8ZY'Q3\-?#7B
M^43:E9D7 _Y;0-L8_4CK0!E?$+XD:%H?AJZ2WOX+J^F0I%!$X8Y/<XZ"L7X3
M^"KFW^&.H6]\"C:UND\MUP4!&W!%;6B?!CPEHU\M[]FFNIU/'VB3>H_ UZ$J
MJBA5 "@8 ':@#P?X0^++/PI>ZEX2UV46#0SL;=I_D!&3U)]>,5O?%_QWI'_"
M(W.A:?=1WM]J(\E8[=@Y7D'G%=9XK^&OAKQC,D^IVC"X08$L+;&/U(ZU1\-_
M"'PKX:U$:A!;RSW2_=:X?>!^![T 7OAEH,_ASP%IMA=(%N0A>0#U))'Z&M7Q
M#X2T/Q7'!'K=@EVMNQ:(,Q&TGKT(]*VJ* .'_P"%/^ _^A>@_P"_C_XUXS\=
MO".@^%9M%71-.2S$ZRF78S'=@KCJ3ZFOIZOGO]I;_CY\/_[DW\UH ZO]GG_D
MG,O_ %_2?R6O6:\F_9Y_Y)S+_P!?TG\EKUF@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *YOQ]_R(VJ_P#7(?\ H0KI*YOQ
M]_R(VJ_]<A_Z$*NE\:]29_"SPVS_ ././Z5/4%G_ ,><?TJ>N&O_ !9>K_,^
M Q'\:7J_S"BBBLC$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *BNO^/27_=J6HKK_ (])?]VM*7\2/JC2C_$CZH]E^&7_ "(ME_OR?^A&
MNOKD/AE_R(ME_OR?^A&NOKT:_P#$EZGZ!3^%!1116184444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5P_Q'2[L(='\565J]U)H-
MV9YX(_O-;NA27;[@$'\#7<44 <AI7Q1\%:O:)<1>(["WW#)CO)E@=?8AR/TI
MFJ_%;P1I$#22^(K.X(Z)9OY[,?0;,C\\"N?\4_ ?PMX@NGN[%IM(N7.6%L T
M3'UV'I_P$@>U8&E_LV:7!<J^J>(+F\B!SY<%N(,^Q)9OTQ0!)X4\2W_Q4^*E
MGK,-G+:^'] CE:$/U>61=HW8XW$'.!G 7KSS[;69HVD:3X;T^WTC2[>&T@4$
MQPJ>6QC+'/+'D9)S6G0 4444 %%%% !1110!%=74%E:RW5U-'!;PH7DED8*J
M*.I)/05YMI_C?Q#\0=2FA\&0Q:?HEN^R76KV$NTA](HN 3_O=CS@X!Y'XW^(
MKO7/$^F_#_3)MBRR1&\(/!=R-@;_ &5&'/U![5Z=I&M^"?"FD6.B6NO:3;PP
M)Y48-U&-Q'WB3G&XG)/N: -G1M*O--20WNN7VJ2R8RURD2*I_P!E8T7'XYKD
M;CQC?>)O'L_A+PS<K;06"%]3U,()&0@X\J(,"N[/!+ XPW''/9:SJB:;X;U#
M5D972UM)+D%3D,%0M^/2O'?V;X6EL_$FJ32&2>XN(D=F.22 S$Y]R_Z4 =?X
MJ\1:I\.+FPU*]O9]5\.W,PM[KSXT\^T8C*NI10&7@Y##.<8/.!W,^IV5MI4F
MJ2W,:V,<)G:?.5\O&=WTQ7&_&>U2Z^$^MAL QK%*IQG!653_ "R/QKR/4?%5
MTW[,VG6GF,TDE]_9SMG!\M"T@'Y!%^E 'JOA'6M;^(L5SK:WMQHVAB9H;&"V
M2,S3A>#)([JV!G@*N.0<DXYETGQC>Z3X_?P3XDG2>>:(3Z9?B,1FX0Y^211\
MH<%6&5 !QT' .A\+;1++X8>'8D  :S67CU<ES^K&O,?VB97TO7?".L6I"W<3
M3,C8Z&-HV7]6- 'OM%16TZW5K#<)]V5%<?0C-9$_C/PK:W$MO<>)=&AGB<I)
M')?Q*R,#@@@MD$'M0!N5\0>._P#DH?B;_L*W7_HUJ^O_ /A._!__ $->A_\
M@QA_^*KX\\:3PW7CKQ#<6\L<T$NIW+QR1L&5U,K$$$<$$=Z /N.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC:K_ -<A_P"A"NDKF_'W_(C:K_UR'_H0JZ7QKU)G\+/#;/\ X\X_I4]06?\
MQYQ_2IZX:_\ %EZO\SX#$?QI>K_,****R,0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J*Z_X])?]VI:BNO\ CTE_W:TI?Q(^J-*/\2/J
MCV7X9?\ (BV7^_)_Z$:Z^N0^&7_(BV7^_)_Z$:Z^O1K_ ,27J?H%/X4%%%%9
M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFMIAKVN*!^Y-M&6/^T&./T+5]'4 %%%% !1110 4444 %%%% !1110 4444
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MUWM% '!?\*9\!?\ 0"3_ +_/_C1_PIGP%_T D_[_ #_XUWM% '!?\*9\!?\
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M *-:OM^OB#QW_P E#\3?]A6Z_P#1K4 ?;]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16%+XV\)P
M2O%+XGT6.1&*NCW\0*D=01NX-,_X3OP?_P!#7H?_ (,8?_BJ .@HKG_^$[\'
M_P#0UZ'_ .#&'_XJM'3-;TG6DD?2M4LK]8R [6MPDH4GIG:3B@"_1110 445
M'//%;0M+,X1%ZDTFTE=B;25V/)"@DD #DDUR^L>(RVZWL6P.C3#O]/\ &J.K
MZ[+J!,468[;T[M]?\*M:/X=:?;<7JE8NJQ]"WU]!7CUL74Q,O8X;YL\#$8ZK
MBY^PPFW5_P!;(I:3HLVIOYC92W!^9SU/L*[2UM8;.!88$"(/U]S4JJJ($10J
M@8  X%+7;A,'##K35]ST<%E]/"QTUEU84445V'>%%%5KO4K'3_+^VWMO;>:V
MV/SI53>?09/)H LUB^*?%>D^#M';5-8G,< ;8BHNYY&/15'<\'VK:KD/B)X"
MM_B!H46GRWCV<T$OFPS*F\ XP05R,@@^HH \'\:_';7O$/F6FBAM(T\\;HVS
M/(/=_P"'Z+^9K@9?"GB$: ?$,NE78TUG -TZ'!)[\\D'^]TSQFOICP9\$/#?
MA=DNKX?VQJ"\B2X0"-#_ +,?(S[DGVQ7I4D4<L3121J\;+M9&&00>Q'I0!\!
MU)!!-=3QP6\3RS2,%2-%)9B>@ '4UZ;\=O#ND>'?&=I%H]C%9Q7-F)Y8XLA2
MY=QD#HO ' P*]:^"'A?1+?P)IFNQZ;!_:MRLGF73 L_$CJ,9^[P .,9H O\
MP>\!R^"?"[M?*%U2_99;A0?]6H'RI]1DD^Y/I7HM%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%13W$%K&9+B:.*,=6D8*/S-
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MK=2>BC^@KL=*T:#3$W??G(^:0C]!Z"O'<JV82M'W8'@.6(S2?+'W::_'_/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7CGQ#^#.GZOKFFZOI%IY*S7T,>J6]O\H>
M)G >51T# $D]L<]0<^QT4 >5?\,]^"?[VI_^!(_^)H_X9[\$_P![4_\ P)'_
M ,37JM% '(^$?AIX9\%7$EUI-H_VN1=C7$\A=]OH.P_ 5UU%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?$'CO_ )*'XF_["MU_Z-:OM^OB
M#QW_ ,E#\3?]A6Z_]&M0!]OT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?+/[0W_ "4B+_L'Q?\
MH3UW#_M)Z.LC*- OR < F5*\@^)GC.W\=^*$U:VM);6-;9(?+E8$Y!8YX^M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIG_?+_\ Q5 'TW17S)_PT=XG_P"@9IG_ 'R__P 51_PT=XG_ .@9IG_?+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M >=_ ?PGXE3Q0OB*6*XM=):%P[RY7[5N'  /+#/.[IQ7TC110 4444 %%%%
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M%MH.C6NF6B[8;= JC^=:%%% !7SW^TM_Q\^'_P#<F_FM?0E?/?[2W_'SX?\
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M?^)+U/T"G\*"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>^'/B,/!>OW1NH+V,3:5?R "1@<CRI,  G*D \'@9R30!Z+1110 5\0>._\
MDH?B;_L*W7_HUJ^WZ^(/'?\ R4/Q-_V%;K_T:U 'V_1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)9$AB
M:21@J*,DGM3B0 23@#J:XS7M9-]*;>!O]'0]?[Y]?I7+B\5'#PYGOT1QX[&0
MPM/F>_1'QO,<S2'_ &C3*O:U=K?ZU>W21I&DLS,J(H 49X&![51KIBVU=G5%
MMQ385U_@OXA:GX%L]432883<WXC43RC=Y07=R%Z$_-WXXZ&N0KU/X*^ -&\;
M:CJ4VLF9X=/\HK;HVU9=^[[Q'.!MZ#'7K3*.=T&S\:^/O%D5[8S7UUJ*2JS7
M[.=MOSP2W10.P'X"OLU00@#'+ <GUJMI^FV6DV4=EIUI#:VT8PD4*!5'X"K5
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ^N0^&7_ "(ME_OR?^A&NOKT:_\ $EZGZ!3^%!1116184444 %%%% !1110
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MWG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'PR_Y$6R_P!^3_T(UU]>C7_B2]3] I_"@HHHK(L**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KY[_ &EO^/GP_P#[DW\UKZ$KY[_:6_X^
M?#_^Y-_-: .K_9Y_Y)S+_P!?TG\EKUFO)OV>?^2<R_\ 7])_):]9H **** "
MBBB@ HHHH **** "N3^)W_),O$7_ %Y/765R?Q._Y)EXB_Z\GH ^1_"O_(<3
M_<;^5=W7">%?^0XG^XW\J[NOM^'?]T?J_P!#FJ_$%%%%>Z9A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "-]UOH:XSP5_R4'1/^PA%_P"A
MBNS;[K?0UQG@K_DH.B?]A"+_ -#%?+<3?\N_G^AM1ZGV[1117RAN%%%% !11
M10 4444 %%%% !7-^/O^1&U7_KD/_0A725S?C[_D1M5_ZY#_ -"%72^->I,_
MA9X;9_\ 'G']*GJ"S_X\X_I4]<-?^++U?YGP&(_C2]7^84445D8A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !45U_QZ2_[M2U%=?\>DO^
M[6E+^)'U1I1_B1]4>R_#+_D1;+_?D_\ 0C77UR'PR_Y$6R_WY/\ T(UU]>C7
M_B2]3] I_"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOP#>7<UU<:#OFF<R2-]LG&6)R3@/CK47_"DOAY_T+W_D[<?_ !RO0** //\
M_A27P\_Z%[_R=N/_ (Y71^&O!N@>#X;B+0;#[(EPP:4>=))N(Z??8XZ]JW:*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \[^*OQ'N_A[!
MI<EI8079O&E#"5RNW;MZ8_WJ\T_X:4UC_H7['_O\]>T^+_ >B>.([1-:CG=;
M0N8O*E*?>QG/K]T5YGX\^#7A'P_X'U;5;"&[%U;0[XR]P6&=P'(_&@#"_P"&
ME-8_Z%^Q_P"_SU<TC]H?5M2UJPL7T*R1;FXCA+"5\J&8#/ZUP/PB\)Z7XR\8
MRZ9JZ2M;+9O,!$^P[@R <_\  C7O%E\#/!=A?V]Y!!>B:WE65";DD;E.1V]1
M0!Z3VHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGO]I;_CY\/_ .Y-_-:^
MA*^>_P!I;_CY\/\ ^Y-_-: .K_9Y_P"2<R_]?TG\EKUFO)OV>?\ DG,O_7])
M_):]9H **** "BBB@ HHHH **** "N3^)W_),O$7_7D]=97)_$[_ ))EXB_Z
M\GH ^1_"O_(<3_<;^5=W7">%?^0XG^XW\J[NOM^'?]T?J_T.:K\04445[IF%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW6^AKC/!7_)
M0=$_["$7_H8KLV^ZWT-<9X*_Y*#HG_80B_\ 0Q7RW$W_ "[^?Z&U'J?;M%%%
M?*&X4444 %%%% !1110 4444 %<WX^_Y$;5?^N0_]"%=)7-^/O\ D1M5_P"N
M0_\ 0A5TOC7J3/X6>&V?_'G']*GJ"S_X\X_I4]<-?^++U?YGP&(_C2]7^844
M45D8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45U_P >
MDO\ NU+45U_QZ2_[M:4OXD?5&E'^)'U1[+\,O^1%LO\ ?D_]"-=?7(?#+_D1
M;+_?D_\ 0C77UZ-?^)+U/T"G\*"BBBLBPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ JAK.C6'B#2+G2M3MUGL[A=LB'\P0>Q!
MP0>Q%7ZXCXO:A>:7\+=9O-/NY[2ZC\G9-!(4=<S1@X8<C@D?C0!P6O\ @#XI
M:==64FA>(UU:VTUVDL/M/EB>(E2N#O!#?*<9+8[X%<YJ'P]^,7C240^(+C9"
MI! N;R,19]=D61GWVUWA^/\ X/L8[:VD;4KV01HLL\$ V!L#=]YE)YST!KT3
MPYXGT?Q7I8U#1KU+F#.UL<,C>C*>0?K0!SOPX^&FG_#ZPE*2F[U.Y %Q=,N!
M@?P(.RYY]3WZ #N:\C\:^/?$%S\2;'P%X3N(+*Y<K]JOI(A*R$KO(56!& @R
M<]2<<8R>BM==USPKK&GZ1XMN[>_M-0?R+/5X8?(/G8R(Y4R0"W.TKP<=* .Z
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB#QW_P E#\3?]A6Z
M_P#1K5]OU\0>._\ DH?B;_L*W7_HUJ /M^BBB@ HHHH **** "BBB@ HHHH
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M"BBBM#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#I?_ $..OJ6OC3X5^*8_"7CZQOK@A;2;-M<,?X4<CYOP(4GV!K[*!! (Z&D
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5\]_M+?\ 'SX?_P!R;^:U]"5\
M]_M+?\?/A_\ W)OYK0!U?[//_).9?^OZ3^2UZS7DW[//_).9?^OZ3^2UZS0
M4444 %%%% !1110 4444 %<G\3O^29>(O^O)ZZRN3^)W_),O$7_7D] 'R/X5
M_P"0XG^XW\J[NN$\*_\ (<3_ '&_E7=U]OP[_NC]7^AS5?B"BBBO=,PHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR'_H0JZ7QKU)G\+/#;/_ (\X_I4]06?_ !YQ_2IZX:_\67J_S/@,1_&EZO\
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M2Y1KZ^3RHT1LLO.<_3B@"+X"_P#(@C_KJ?YFM[XA_$6U^'MM8S7.GS7@NW9
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M*** "N;\??\ (C:K_P!<A_Z$*Z2N;\??\B-JO_7(?^A"KI?&O4F?PL\-L_\
MCSC^E3U!9_\ 'G']*GKAK_Q9>K_,^ Q'\:7J_P PHHHK(Q"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HKK_CTE_W:EJ*Z_X])?\ =K2E
M_$CZHTH_Q(^J/9?AE_R(ME_OR?\ H1KKZY#X9?\ (BV7^_)_Z$:Z^O1K_P 2
M7J?H%/X4%%%%9%C)HDGA>*10R."I!KY^\"L? WQIU'P](Y6TN<E<]R1E?YU]
M"5X1\==)GTK6-(\7V2[?L\@$Q'4MD8_E0![I)(L43R.<*BEB?85X-X)(\<?&
MK4]>.9+&SS]G;' ((Q7:^,_&0@^$)UF&0?:+RV01C/\ $V,C]:9\$O#JZ-X$
M@O&3$^H'SW)'([4 6_'_ ,3;7P?-#IMK;-?:M<<1P1G[I/3-<@WB;XTQ1_;)
M/#]H;<'<T01=X7_OJN-N=?U6V^-U[J5GI#:O>1@HEN%+$#&,@"N]/Q/\?$$'
MX>7?/_3)Z .O^'OQ"L_'&GR8C-O?VYVSP-U!]17EOQ9U&#2?B]I=_<DB&")6
M;'TJW\+=+\2_\+2O=9U#0;G2K.ZB<O&8RJ!N,8S4/Q/M8+WXT:-;W,8DA94W
M(>AP* -2[^(/Q)UW=J'A/PVJZ2!\K7"!F;WZBNB^&GQ0/C">;2M3M?LNK6X^
M91P'QUP.V*](CC2*-8XT"HHP% X%>!V,0LOVF9T@^53$20!ZJ,T >_TR;S#"
MXA($F#M+#C-/HH \I^'OQ%UC6O&>K>'M?%NLT#$6PBCVD@$YSSSP!7J%W<QV
M=I+<RL%CC4LQ->"_$N"3P5\6-(\368\J.\81L%Z=@W\Z[?XO^*(M-^'<OD2C
MS-27RH2#R<\YH J?#'QYX@\::QJTMX+5-)LW*+LC(;/..<^U9VI?$_Q5K_B&
M\TGP+I"3FR8K--. 5X.,]176_##PO_8'@&UL[A )[A"\Q'?=G'Z&O./[-\8_
M"CQ1J6H:9IG]JZ3?2&1UC4G8,YYQT- '8^%/&'C2/78M(\8:$(FN/]5<V^ G
MX\FO3JX3P?\ %7P]XON19QF2TOQQY%P I+>B\\UW= !1110!Y#^T P7PK9,3
M@"X!/YBMWPY\2O!\.@:?;OKENLJQ*I4@Y!_*NLUWPWI/B6S6UU>R2ZA4[@KY
MX-<]+\(_ DD;(/#MLA88#*6R/UH ZZSO[34(%FM+B.:-AD%&S5BOFI;:[^$O
MQ8M;"PO)Y=+O9$38YZAB!R/;-?2C#<A&<9&,T 1M=6Z9WSQ+CKEP,5\\?$":
M+QY\6=,T[08_/>V=3+<)]T[<$\^V*[+5O@39:O?W%U-XEU5?.?<8QMVBN&FA
MU_X%Z]!(KQW^D7;[1O'(&><XZ'F@#Z1C3RXU3).T8R:\B^+WB6ZO+NR\$Z+*
M?MFH.%N&3.8T)Q@_@:[W4_%UG8^")/$ZAC;BW\Y%;J<]!7DWPNU?0'U2_P#&
M/B;7M/35KQRL22S /$G3!!Z=J ,WXN^'+7PIX8\)Z3:@!8YR9"/XGP,FO?-!
M_P"0#8_]<5KPGXZ^)-$UN/0O[+U6TO#%<$R"&0-M'')KV/PEXCT75=,MK33]
M4M;J>*$%XXI Q7ZB@#I*X'XK^,-3\&>'K>^TOR/->;8WG)N&VN^KR+]H3_D3
M+3WN* *US\5/$OB15MO FC?;98E'GW4BCRR<<X!(JGI?Q@\2:%XCCT?QUI:6
M[RD /$FT+GH>IS7I?P^LK6Q\$:7':P)$ABR0HZG-<#^T+91/X;L+_P"436\W
MRGN<XH ]CCD26-9$8,C#(([BL'Q'XTT'PK;>=JE_'$3]U =S,?3 KA]:OO%1
M^#>D7/AH2M?O"OFF(9<+@Y(]ZX7X=6O@6_U-Y/%EW<2:]O&^+4\(F_MMYY/U
MH Z>3X@>-/'L[6W@W2&LM/)\N2]N0"1_M#I5_P"(;:CX3^"RV&H:D]W>O_H\
MMSDYD+9/>O5[>*"*!$MT18@H"A!QBO,?C];R7'P[S&,^7<H[?0 T :7P7TQ=
M-^'%D/+"R2LTCMCDY/%7OBKIL6H_#G5UDB$DD4.^+U#9'-'PJN([KX>:;)&<
MJ%*_B*O?$!E3P#K3,0%%N<D_44 <C\!;][KP"+9F!%K(5  Z9)->IUY%^SY;
MR1>#;J5A\DT^4/KC->NT >$?M 7<EWJ6AZ"CMB=A(4SP>2,U[3HUK'9Z+96\
M:*BQP(,*/85X=\<U-OX\\.7T@_<(H4GWW&O=[%@^GVS#HT2D?D* /&OVB=/B
M_L?2=22(>?'<;6D_V<?XUZ#I]\VH_#-;MV#-)8MDCV!%<9^T*RCP=9*2 S7.
M%'KP*[CP18X^'^F6=T@8&WVNIZ$'- 'D_P &_&/A_P /66JV^JZG%:S-<,P5
MP>1N->SZ1XIT/75+:;J4%QCL&P?UK$_X5/X&+,S^';5V9BQ)+=_QKS'XK?#:
MQ\*6,?B;PN9+"2W<;H8V^51_>&><T ?0-%<M\.M?F\2^!].U.?)FD4JY/<@X
MKJ: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?XH^#YO%GAR
M%[&-9-2TV<7=K$^-LQ'6,YX^8?J!VKN*\O\ CMX8EU_P*MW:H7NM-G655'\2
M-\K#]0W_  &@#T'1=7MM=TF#4+7<$D&&C<8>)QPR..S*001ZBK]?+L?[.?C%
MXU9K[18R1RC3R9'Y1D?K3_\ AG'QA_T$M#_[_P W_P :H ^A+K4+#_A,M-T]
MD234#:7$JL)3NB0&,'*]/F)')_NG'>MNO!OA=\.]<\!?$V-=6^S21W6G3^5-
M;.60E7CR#D @\CM_6O>: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^(/'?\ R4/Q-_V%;K_T:U?;]?$'CO\ Y*'XF_["MU_Z-:@#[?HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HKS[XRZ_JGAOP&=0T>[:UNOM4:>8J@G:<Y'(([5\\_\+@\??\ 0QS_ /?J
M/_XF@#['HKXX_P"%P>/O^ACG_P"_4?\ \31_PN#Q]_T,<_\ WZC_ /B: /L>
MBJ6CS27.B6$\S;Y9+>-W8]R5!)J[0 445S/Q!M=:O/ >K6_AYG74WB BV-M8
MC<-P4]B5W ?6@#*\:?%CPUX,$D$UQ]MU)>EG;,"RG_;;HGX\^QKPV\^.GCC4
M]?AFT^2*WB\P+%I\, D$F3PI)!9B>G!'MBJOA3X+>+/$MUNO;272+0-^\GO8
MRKGUVQG#$_7 ]Z^A?!OPR\-^"HU>QM?/O\8:]N &D/KM[*/8?CF@#KH'>2WC
M>6/RY&0%DSG:<<BI*R[[7[*RRH?SI1_!&<X^I[5S-]K][>Y0/Y,1_@C[_4]:
MX<1F%&CI>[[(\W%9IA\/I>[[(ZB_UNRL,JTGF2C_ )9IR?Q]*^5?C3?MJ/Q#
MFN"@3-O$ H.> *^@['P]>WF&9?(B/\3CD_05X)\<M*.D_$%8QN*2V44B,Q&6
M&64GVY4U&%K8FM4YYJT3/!5\7B*O/4CRPMI_6_Z'FE%%%>B>L=?\+?\ DI_A
M[_K['\C7VA7QG\)H)+CXI^'TB7<PN"Y&<<*C,?T!K[,H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **KW=_9V";[
MR[@MU]99 @_6N;O_ (D>&+'(%\URX_AMXRWZG _6MZ6&K5OX<6_1";2W.LHK
MRR_^,2#*Z?I+'T>XDQ_XZ/\ &N-\1_%OQ)'I\TZ74-KQA%@B RQZ<MD_K7>L
MEQ2@YU$HI:ZO_*Y'M([(Y;X]ZY;:O\13!:MN&G6RVLC Y!D#,S#\-V/J#7HW
MP=^(.@V/PXMM.U"[$%U8221F/:69PS%U8 #I\V/^ FOFR>:6YGDGGD:261BS
MNYR6)ZDFM7PQ=+;Z[;1RSK!!.XBED?[J G[Q]AUK@PRI2JQ59VCUL6[VT/I[
M4/C!IT65T_3KBX/9I6$:_ID_RKEM0^*GB*[RML;>S4]/*CW-^;9_0"NFT_X/
MV*!6U#4YY^^V!!&/S.<_I74Z?X&\-Z=@Q:5#(X_BGS(?_'LC\J][ZQE&'_AP
M<WY_\'_(RM4>YX@USXB\2RE#)J.H'/W%WN!^ X%;.G_#'Q+>X,EO%:(>]Q(,
M_DN3^=>[(B1($C140<!5& *=6=3B&JERT(**^_\ R&J2ZL\PT_X.VZX;4=4E
MD]4MT"_J<_RKJM/\ >&=/P4TR.9Q_%<$R9_ \?I72T5YM;,\76^.H_EI^1:A
M%=!D4,5O&(X8DC0=%10 /P%/HHK@;ON4%4M6NK"RTFYNM4,8L8D+S&1-RA1W
M(P<U=K%\7Z1<:_X1U72;5XDN+NW:*-I20H)]2 3C\* .1_X6'\*?^?[2O_ %
MO_B*^9;Z[L9/'EQ>1,AL&U)I58+\OE^9G./3':O0_P#AG'QA_P!!+0_^_P#-
M_P#&J/\ AG'QA_T$M#_[_P W_P :H ]7'Q"^%.!_IVE?^ +?_$5W&B7NF:CH
M]O=Z,T3:?*"T+1)L4C)S@8&.<]J^</\ AG'QA_T$M#_[_P W_P :KW[P+H-U
MX8\%Z9HU[)#)<6L91VA)*$[B>"0#W]* .AHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *X'Q9\)= \3WIU$"2RU _\MX&*_H*[ZB@#RK2?@9H
MUM>I=:O?76J-&<QB:0X!_.O4HHHX(EBB14C0855& !3Z* .!\7_"?0_%5^-1
M!DLM0[SP,5S^ K.\/?!/1-+U*+4=2N;C5+F%MT1G<E1]02<UZ?10 @ 4
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MMO:0)#"OW408 JG=^'=&O]2CU&[TVVFO(ON3N@++]#0!ICI7@<9'_#3LW/\
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M(86)WPDG^Z5;![J.>G/JU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?$'CO_ )*'XF_["MU_Z-:OM^OB#QW_ ,E#\3?]A6Z_]&M0!]OT444
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M*@,"ORH#@D@]>U4? /B_0?"R7XUOPK::Z;@H8C<)&?)V[LXW*W7(Z>E>Q?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGO]I;_ (^?#_\
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M-+U?YA11161B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM<O[.3S+6ZU">:%]I&Y&D8J<'D9!'6@#[GHHHH **** "BBB@ HHHH ****
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M(K2:2*,R2)&S(@_B(' K*T3Q9H?B*)7TS48)BPR(]X#_ )=:VJ /%IK/XO\
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MR.@JG9_&#P5?72V\6J@.QP"Z[1^9KM;6[MKV!9[6XBGB;H\;A@?Q% $U%%%
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M?B!;6.DV][;V5O83RRBY(4R.6C"_*K$<#=R?[W;OZE0 4444 %%%% !1110
MA( ))  Y)->=3P)\4M:A;B3P;ILQ;.?EU.X4XX]8D.1GHQSU'-<7\3OBM<W&
MI2>'](TR\GTN*39?S)OB:Z /S1(P&50]"PY/.,#DP6WQ[U&RM8K6U\!^3;PH
M$CBCF9510,  "/@4 >U^*;&34O"&M:?#_K;FPGA3 SRT;*/YUY+^S7*A\/ZY
M"&_>+=1L1Z I@?R/Y5U/PR\5:_XXNM2UK4[7^S[" +:VMHN[!<_,[L3]XXV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\0>._^2A^)O^PK=?\
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MN?K7JE<;XM^&/AOQKJD6HZQ%<M<10"!3%,4&T,S#CZL: /*O^&E[S_H6(/\
MP,/_ ,11_P -+WG_ $+$'_@8?_B*@^+WPN\->#/!T.IZ1%<K<O>)"3+,7&TJ
MY/'U45D?!;X?Z%XXBUEM:CG<VAA$7E2E/O;\Y]?NB@#O_ WQRN?&'C*PT&30
M8K5;KS,S+<EBNV-GZ;1_=Q^->S5P?AWX0>%/"^NVVLZ;#=K>6V[RS).67YE*
MG(^C&NRO]1LM+MC<7UU%;Q#^*1L9^GJ?:G&+D[)78%JHY[B&U@::XECBB099
MY&"J/J37FNN_%R"+=#H=KYS=/M$X(7\%ZG\<?2O/KB^\0>+[]4D>YOYB<K$@
MRJ?11P/K7MX7(J]1<]9\D?/?_@?,S=5+8].UWXK:98[H=*B-],./,/RQ#\>I
M_#\Z\VU7Q-K_ (IN!!//+*'/R6MNI"_@HZ_CDUUV@_"2XFVS:W<B!.OV> AG
M_%N@_#->E:1H&EZ%#Y>G6<<.1AG R[?5CR:Z_K>79?IAX\\^_P#P?\D3RSEN
M>4:%\*M4O]LVJ2+80GG9]Z4_AT'X_E7INA^$=%\/J#96:F8#F>7YI#^/;\,5
MN45Y.+S3$XK2<K+LM%_P?F7&"B%%%%><6?+VM? SQK?:[J%W#!9&*>YDD0FY
M .UF)'\ZH_\ "@O'7_/O8_\ @4/\*^KZ* /E#_A07CK_ )]['_P*'^%>O_!C
MP-K7@C3]5AUF.%'N94>/RI0_ !!S^=>H44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:* *UIIUC8%S9V=O;[SE_)B5-Q]\#FJ\^@:-<RM+/I-C+(W5WMT8G\2*T:*
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MNK*UO8_+N[:&=/[LJ!A^M06NBZ592^;::99P2#^.*!5/Y@5>HH *K7>G6-^
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M%=?\>DO^[6E+^)'U1I1_B1]4>R_#+_D1;+_?D_\ 0C77UR'PR_Y$6R_WY/\
MT(UU]>C7_B2]3] I_"@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH *0D
M*"20 .I-+5+5XII](NHK<$S/&0@!QS0 _P#M.P_Y_;?_ +^BD_M.P_Y_;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML2T5%]IM_P#GXB_[[%'VFW_Y^(O^^Q1[2'<+$M%1?:;?_GXB_P"^Q1]IM_\
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M3,"5C4L0.IP,U3_M[1_^@M8_^!"?XU!>:YI#6-PJZK8DF)@ +A/3ZT(#AO\
MA>>@?] K6?\ P'7_ .*I/^%Y^'_^@5K/_@.O_P 57'>%="L-7T^::[C=W67:
M"'(XQ6[_ ,(;HW_/O+_W\->?C,ZR_"5Y4*G->.CLE_F;4<'B*U-5(VL_,U/^
M%Y^'_P#H%:S_ . Z_P#Q5'_"\_#_ /T"M9_\!U_^*K+_ .$-T;_GWE_[^&C_
M (0W1O\ GWE_[^&N;_63+/[_ -R_S-?[.Q7E][_R-3_A>?A__H%:S_X#K_\
M%4?\+S\/_P#0*UG_ ,!U_P#BJR_^$-T;_GWE_P"_AH_X0W1O^?>7_OX:/]9,
ML_O_ '+_ ##^SL5Y?>_\C4_X7GX?_P"@5K/_ (#K_P#%4?\ "\_#_P#T"M9_
M\!U_^*K+_P"$-T;_ )]Y?^_AH_X0W1O^?>7_ +^&C_63+/[_ -R_S#^SL5Y?
M>_\ (U/^%Y^'_P#H%:S_ . Z_P#Q5'_"\_#_ /T"M9_\!U_^*K+_ .$-T;_G
MWE_[^&C_ (0W1O\ GWE_[^&C_63+/[_W+_,/[.Q7E][_ ,C4_P"%Y^'_ /H%
M:S_X#K_\57GOQ8\=V7C?1K>TTS3M122.0,3-$%&/P)KKO^$-T;_GWE_[^&C_
M (0W1O\ GWE_[^&C_63+/[_W+_,/[.Q7E][_ ,CF?A7\0K#P5X8;3M2TW4GF
M,K/F&(%<'ZD5W7_"\_#_ /T"M9_\!U_^*K+_ .$-T;_GWE_[^&C_ (0W1O\
MGWE_[^&C_63+/[_W+_,/[.Q7E][_ ,C4_P"%Y^'_ /H%:S_X#K_\51_PO/P_
M_P! K6?_  '7_P"*K+_X0W1O^?>7_OX:/^$-T;_GWE_[^&C_ %DRS^_]R_S#
M^SL5Y?>_\C4_X7GX?_Z!6L_^ Z__ !5'_"\_#_\ T"M9_P# =?\ XJLO_A#=
M&_Y]Y?\ OX:/^$-T;_GWE_[^&C_63+/[_P!R_P P_L[%>7WO_(U/^%Y^'_\
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MISP>N,T <SXM\)-\3O'EUI%]JLMII&APPL;>WQOEEE#'?SP  , D'OCO2?\
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M@V_AGP[9Z1:C$5NF.O4GD_J36M0!\9?\*H\=_P#0M7O_ ([_ (T?\*H\=_\
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M_P"-'_"J/'?_ $+5[_X[_C7V;10!\9?\*H\=_P#0M7O_ ([_ (T?\*H\=_\
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M?Y@]E#L<#HMCXU\16)O=(T-KNV#E#)&HQN'4<GWK1_X1/XD_]"M-_P!\K_\
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M?XU](446I_\ /N/_ ("O\@M+^9_>SYO^Q?$;_H ZU_WVG^-'V+XC?] '6O\
MOM/\:^D**+4_^?<?_ 5_D%I?S/[V?-_V+XC?] '6O^^T_P :/L7Q&_Z .M?]
M]I_C7TA11:G_ ,^X_P#@*_R"TOYG][/F_P"Q?$;_ * .M?\ ?:?XT?8OB-_T
M =:_[[3_ !KZ0HHM3_Y]Q_\  5_D%I?S/[V?*FO>#?'.M6Y5O"^I&9G#-)(4
M.?UKG?\ A5'CO_H6KW_QW_&OLVBG*3EN$8I'QE_PJCQW_P!"U>_^._XT?\*H
M\=_]"U>_^._XU]FT5(SXR_X51X[_ .A:O?\ QW_&C_A5'CO_ *%J]_\ '?\
M&OLVB@#XR_X51X[_ .A:O?\ QW_&C_A5'CO_ *%J]_\ '?\ &OLVB@#XR_X5
M1X[_ .A:O?\ QW_&C_A5'CO_ *%J]_\ '?\ &OLVB@#XR_X51X[_ .A:O?\
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M/MWKA[3X9^-KVY%O%X8U-')QF: Q+_WTV!^M?9]S<0VEK-<W$BQ00H9))&.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &NB2*5=0RGJ",BFQ010*5BC2-3R0JXJ2B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\^^*/PYN/B
M%;:=%!J,=F;1W8F2,ONW #L1Z5Z#10!C>$]$?PWX4TW1I)UG>SA$1E5<!L=\
M5LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7G'Q1^&5Q\0I=->#4XK/[('!#Q%]
MV['H?:O1Z* ..^&W@N;P)X9?29[U+MFN&F\Q$*@ @#&#]*[&BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Y'XC^#9O'7A?\ LB&\2T?STE\QT+#Y<\8'UKKJ* .4
M^'?A"7P1X3CT::[2Z=9GD\U$*CYCTP:ZNBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ JMJ-FNH:9=V3L52XA>%B.P8$?UJS10!
MX1I?QEN/ =O#X5\6>'9TN],C6W$MHPVR(HPC!6QP0!R#@^@Z5;N?VD]"2%C:
M:%J,LN/E65TC4GZ@M_*O6=9\.:+XAA6'6-+M;U%^[YT88K]#U'X5F:3\//"&
MB72W6G^'[**X0Y24IO9#ZJ6SC\* *7PWBU:?2+[7=;M5L[[6KLW?V55QY,81
M(T![YVH"?KT!S79T44 9U[H.F:AJECJ=S9QO?6+%K>XZ.F05(R.H()X/'?J*
MT:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(/'?\ R4/Q
M-_V%;K_T:U?;]?$'CO\ Y*'XF_["MU_Z-:@#[?HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O+OB;\8;3P5(=+TV&.]UDC+*Y_=VX(XW8Y)_P!D
M8]<^O;>,K^XTOP3KE_:2^5<V]C-+%)@':P0D'GCK7Q#=W<]_>37=U*TMQ.YD
MED8Y+,3DD_C0!WD_QO\ B!+<-*NMK$"<K&EI#M7VY4D_CFO0_ /Q^>[OHM,\
M6QPQB4A4U"(;5![>8O0 _P!X8QZ=Q\]44 ??P((!!R#T(KE_'/B6;0_#&I3:
M5B;58X&,,87=M;U(]ASCOBO,?A1XLUJ_\"-:W-Z\BVUR;>)R!N6)8TVIGT&3
M[\UWFG:'=ZB1(1Y4)_Y:..OT'>O,KXZ?M?8T8W:/'Q.95%6]AAX<TEO_ %^I
M\N22^*_'FI@R/J.KW1.!DLX3/8?PJ/R%>E^%_P!G;5;T)<>(]033XCR;>WQ)
M*?8G[J_^/5]"Z=I%GIB8@C&\_>D(^8U>KOASM7GIY?\ !/3I^T:O/3RW_$H:
M-H]EH&D6VEZ=#Y5K;($1<Y)QW)[D^M7Z*BGN8+6(RW$T<,8ZO(X4#\36B5]$
M:[$M%<IJ/Q&\,Z?D?;OM+C^&V4OG\?N_K7)ZC\8G.5TS2E'I)<OG_P =7_&O
M0HY5C*WPP?ST_,ASBNIZO5:\U"RT^/S+V[@MT]99 H_6O!=0\?\ B;4B5;4G
M@0]$M@(_U'/ZU33P[K^H0S7TEE<^2B&26YN?D4*!DL6;' %>G#A_D7-B:JBO
MZZNQ/M>R-WXU?$W3G\,G0-#O/.N+UL7$B*0$B'4 \?>.!QD8!'>O -&U>[T'
M6;35;%]ES:RB5">A(['U!Z$>E-U2];4-1EG/W2<(/11TJG7@UE351JE\/2YH
MKVU/>G^)WB36+5)X]1\B*5<A8$5<>V>OZU46Q\1^(&#B#4K_ "<AW#N/S/%2
M_L\:_8_;[SP[>V]N;B3-Q9S/&N\D#YTR>>GS >S5]%U[L,\IT8)4:*3[_P##
M+]3/V;>[/"K+X7>);K!EAM[13WFF!_1<UT=E\'$&&O\ 5V/JD$6/_'B?Z5ZE
M17-5S[&3V:CZ+_.XU2BCD++X9^&+/!>TEN6'\4\I/Z# _2NBLM(TW3O^/*PM
MK?WBB53^8%7:*\ZKBJ]7^)-OYEJ*6P4445SC"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"RJ,
MLP'U-(KJWW6!^AH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(SJ@RS!1ZDX
MI%=7&48,/4'- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \;:[/X:\(:CK%M
M )I+6/>$)P.H']:YKX;_ !4L/&UN+:XVVVJ(/FA)X;Z'O76>*M/75?"VI6+#
M*S0$'^?]*^=-$\"7>I^";3Q'X7D:/6=.D9940X,F&)_D* /J.BO-OAQ\3[?Q
M)9O8:NRVFL6@(F20XW8ZG]*[+0?$^D>)HKB32+Q;E()/+D90>&H UZ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***S?$&MVOAOP_?:S>D_9[2(R,%
MZL>RC/<G 'N: -*BO,/A[:7'CW2Y/%OB@M<B]D=++3RY^SVT*L1PG0N2#\QR
M< =*C3Q%<> _BC;^%KVYFGT#6$5]/>=R[6LI)7R][')4D< YQN7WH ]3HHHH
M *^(/'?_ "4/Q-_V%;K_ -&M7V_7Q!X[_P"2A^)O^PK=?^C6H ^WZ*** "BB
MB@ HKY]\5?'OQ!H7BS5=)MM+TQX;.ZD@1I!(68*<9.& [5C/^TAXJ(^32M&'
MUCE/_M2@#Z;HKYD7]I#Q3CYM)T<GV24?^SUVOPP^,&L^-_%ATB_T^P@A^SO*
M'MPX;(QZL1CDT >S445F:_XATOPQI,FIZQ=K;6J$+N()+,>B@#DGV% &G17B
M>L?M(:+;[DTC1KR\8<![AUA7ZC&XG\A7%7'[1/BZ6^26&TTR&W5N8!$S;QZ%
MBV?RQ0!]0U1UC6+#0-)N-4U.X6WL[==TDC G'.!P.222  .YK'A\9V\]E!.M
MG.KR1JY1R!M)&<?A]*YSQG,OC+PS=Z)/&+>*XVD2*2S(RL&![9Y%<4\QPT7;
MF/.J9KA(.SG]USF]8_:0T6WW)H^C7EXPX#W#K"OU&-Q/Y"N$U#]H/QE=7 >T
M73[*)3D1QP;]P]&+$_IBK=A\&K&-MVH:K/.,_=@C$?ZG=78:3\.M!LRK6FB+
M<2#^.53,<^O.0/P%93S2BM(7DS&IG6'3M33D_)'6ZSKPUOX*7VH7JQ6MU>Z+
M)(T!;HS1GH#S@]1]:^0*^I/%VEW<7@W6GEC6)5LI20[JI^Z>V<U\MUT86M4K
M1<IQY>QU8+$U,1%RJ0Y>P4445U':?2G[.^F6MQX*OKJ:/S'74W50WW1^ZB.<
M?C7M+ND2%W9411RS' %?*GPZ\7:SHGA6YL--N5@BDO&E9A&"V2B#J<X^Z*W!
M'XB\32YVZAJ+9ZG=(%_'H*]K!Y"ZE-5Y248RU\_GM^9A>$)/E6KW/;M1\=^&
MM-R)=4BE<?P6_P"\/YKQ^9KD]1^,-NN5TW2Y)/1[APO_ (Z,_P ZYW3OA5XA
MN\-<BWLD/7S9-S?DN?U(KK-.^$.E08:_OKBZ8?PH!&O]3^M=?L,HPWQS<WY?
M\#_,=ZCV.)U'XE>);_*K=I:1G^&V0+^IR?UK+@TCQ'XBE$R6M_>LW_+:3<1_
MWVW'ZU[MIWA30=*P;/2K9&'1V3>P_P"!-DULTGGE&BK86BEYO_@?YA[-OXF>
M+:=\)-:N<-?7%M9J>HSYCC\!Q^M=9IWPFT*UPUY+<WK=PS>6A_!>?UKO:*X*
MV=8RK]JR\M/^#^):IQ1G:?H&D:4!]ATZV@8?QK&-W_?76N<^*&D>(M?\'R:1
MX<6'SKJ0)<-)+LQ$.2 ?<@#Z9]:[2BO,G.4W>3NRSY0_X4%XZ_Y]['_P*'^%
M'_"@O'7_ #[V/_@4/\*^KZ*D#Y>T7X,_$30=:L]5LHK%;BUE65/]*&#@]#['
MH1Z&OI]"QC4NH5R!N4'.#]:=10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116;K]I>W^
MA7EKIUR+:[EB*Q2D9VGUH TJIZMJ=MHVE7.HWD@CM[="[L>@%>+>!/B%J?A/
M77\(^-BZMYA$%U)SR3W/<'/X5Z3\1[&;6/AQK-K9 2R36_[L*<[N0: /-]+L
M/%GQ<GFU6XU:;2- +D6\4 ^9@.,C/TKG_$0U_P"%GBFQM=%\1RZH]P?FLY""
MY';<!T!J[X3^*L>B_#:R\.Z1:R7'B1&-O%#L. 68_,3TXSTKNOA_\,VTJZ;Q
M%XCE^W:]<_.QDY$)/8?2@#OM'O+F\TJTEOX5MKV6(/) #]PU?KQ/0K_49/VA
MM7@CO)9[8(0T9<E8UR. .@KVR@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JMJ-_;Z7I\][=
MR"."%"S,33=3U.ST?3YK^_G2"VA4L[L?\Y-<9\1XIO%OPMNO[!8W!N5C>-4X
M,B[@<>W% '"B#Q5\9[N>Y2[ETGPNC;(E'#S?[6.]8<>NZS\%/%JZ/<7XU#2)
M,,8BV64'OCL>:](T[7)/AQ\';&36+40WEM!Y4<&X$R/R0.*RO G@*;Q)::CX
MB\8Q+-=:LO[J)UY@3D#!^A% 'J.BZU8Z_I<.HZ=.LMO*,@@\@^A]#6A7S'X0
MG\6^#O&.I67ANVDU#2(+Y[:2!F&&"GL3]T^]?2]M)++;1R3P^3*RY:/=G:?3
M- $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4453U:9[?2+R:+[Z0L5^N* ./\5?%71?#FH?V7"DVH
MZD/O6]JN\I[''0UD^'_C7I>H:Q'I.KV5QI=W*VU/.7"^P.?6L?X"VMAJ>GZM
MK%TL=SJKW9$DLB@LHQGC-)\>[;1K6PTN^:../4DN%,9C #,H(SG'6@#VF0;H
MF7U4BO'_ (13QZ!?^+=*NI1%;VEUYH,AP(UP2?PYI++X[:/:16MO=Z?>QQ!0
MK7#HP&?7D5@Z]\/-5\9>-Y-6T/4<^']9Q+/+$^W:H !4C/.: .7\8HWQ+\:W
MDW@[2CY5NA$MTF1YN._'&#CCUKT/X'>*=*CTUO"\MF+#5H#^\5L@S'IDY_B]
MJ]*\+>%-+\(Z0FGZ9"$4<NY^\Y]2:6#PGHMMXBDUV*QC74)$V-( /7.<>OO0
M!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y%^T3>RVWP]M;:,X6
MZOT23W4*[8_,*?PKUVO)/VA]/FNOAY!=1#*V=_')+[*RLF?^^F4?C0!V/PTA
M2#X9^'$08!L8W_%AN/ZDUY5^TH3;W?A6ZB8I,OVG#J>1M,1'ZFO5?AK,DWPT
M\./&<@6$2'ZJ,']0:\I_:0#WFI^%=/MT+W#>?L0=6+F)0/S% 'O-C.;K3[:X
M(P98E<CTR :XZ_\ B_X$TS4;FPO-=\NZM96AF3[).=KJ2&&0F#@@]*[*T@%K
M906P.1%&L8/K@8KYZ\2_ /Q5K/BK5]4M]0T98+V]FN(UDFE#!7<L <1D9P?4
MT >E_P#"[?AY_P!##_Y)7'_QNOECQ9?6^I^,M<O[.3S+6ZU">:%]I&Y&D8J<
M'D9!'6O2/^&<?&'_ $$M#_[_ ,W_ ,:KRO5M-FT;6;[2[AHVGLKB2WD:,DJ6
M1BI(R <9'H* /K/_ (7;\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&Z\@_X
M9Q\8?]!+0_\ O_-_\:H_X9Q\8?\ 02T/_O\ S?\ QJ@#U_\ X7;\//\ H8?_
M "2N/_C='_"[?AY_T,/_ ))7'_QNO(/^&<?&'_02T/\ [_S?_&J/^&<?&'_0
M2T/_ +_S?_&J /._&>H6NK>-M;U&RE\VUN;V66&3:5W*6)!P<$<>M8=7M:TJ
M?0M;O=*NGC>>SG:"1HB2I93@X) ./PJC0 5T_@'Q;=>#/%5OJ=K;QW!8&%XW
M!Y5L9Q@]:YBNB\%>%=4\8>(5TW2+F"VNUC:999I&0 +CNH)SSZ4GL*2;3L?1
MLWQ$O)/N$1CT51_4&N*\>7J^+]%6ROK\P&.431/))E0P!'(X[$U2;X%?$1UV
MMXDT]@>H-]<'_P!IU5;]GCQJS9;5]&)/4FYF_P#C=<E+!^_S5:CT[:_F_P!#
MPX9;B^=3G7>GS..@\-^'+4@ZAKWG'NELG'TS@Y_2MZPU+P9I#K)9V,3S(<B2
M6)W.?4;LX/T%:7_#.WC3_H*Z+_X$3?\ QJC_ (9V\:?]!71?_ B;_P"-5ZT:
M>7_\O5.7S27X([)8&=3^)4;_  7X6))/B2C?ZN=5^L9/]*JR>/Y'_P"8D5_W
M8C_A4W_#.OC,]=5T7_P(F_\ C5-/[.7C$]=3T/\ [_S?_&JZZ57**/\ #PB?
MKK^=Q0RO#PVBOS_,HGQJ=Q;^V;E3[,X_E4$OBRUE&)=5D?C'SLYK5_X9Q\8?
M]!+0_P#O_-_\:H_X9Q\8?]!+0_\ O_-_\:KMCGT::M2HJ/\ 7DD=4</&*LM#
MF=0UW3)M.N(H[M2[QLJC:W)(^E<,1C^('Z5ZO??L^^*-.T^YOKK5="2WMHFF
ME?SIOE5023_JO05Y/WKS<?F$\;)2FDK=C:,.4*<H#, 6"CU.<?I3:*\\H]K^
M$7B;P!X;\.W">);JU_M)KQGC+V<LV(]B =$('(;WKU-?C7\.D4*NOA5'  LK
M@ ?^0Z\$\(_!W7O&F@QZQI>HZ0L#.T;1S2R!T93T8",CI@]>A%;O_#./C#_H
M):'_ -_YO_C54YRDDF]@/7_^%V_#S_H8?_)*X_\ C='_  NWX>?]##_Y)7'_
M ,;KR#_AG'QA_P!!+0_^_P#-_P#&J/\ AG'QA_T$M#_[_P W_P :J0/7_P#A
M=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z\@_X9Q\8?]!+0_P#O_-_\
M:H_X9Q\8?]!+0_\ O_-_\:H ]?\ ^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;KR#_ (9Q\8?]!+0_^_\ -_\ &J/^&<?&'_02T/\ [_S?_&J /7_^
M%V_#S_H8?_)*X_\ C='_  NWX>?]##_Y)7'_ ,;KR#_AG'QA_P!!+0_^_P#-
M_P#&J/\ AG'QA_T$M#_[_P W_P :H ]?_P"%V_#S_H8?_)*X_P#C='_"[?AY
M_P!##_Y)7'_QNO%-6^ 7BK1]&OM4N-0T9H+.WDN)%CFE+%44L0,Q@9P/45P?
MA;PY>>+?$=IH=A)!'=76_8\[$(-J,YR0">BGM0!]3_\ "[?AY_T,/_DE<?\
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M "2N/_C=>0?\,X^,/^@EH?\ W_F_^-4?\,X^,/\ H):'_P!_YO\ XU0!Z_\
M\+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=>0?\ #./C#_H):'_W_F_^
M-4?\,X^,/^@EH?\ W_F_^-4 >O\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_
M\DKC_P"-UY!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-4 >O_\
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MX^,/^@EH?_?^;_XU0!Z__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
MXW7D'_#./C#_ *"6A_\ ?^;_ .-4?\,X^,/^@EH?_?\ F_\ C5 'K_\ PNWX
M>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C=>0?\,X^,/^@EH?\ W_F_^-4?
M\,X^,/\ H):'_P!_YO\ XU0!Z_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\
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M /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C=>0?\,X^,/^@EH?_?\
MF_\ C5'_  SCXP_Z"6A_]_YO_C5 'K__  NWX>?]##_Y)7'_ ,;H_P"%V_#S
M_H8?_)*X_P#C=>0?\,X^,/\ H):'_P!_YO\ XU1_PSCXP_Z"6A_]_P";_P"-
M4 >O_P#"[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_^-UY!_PSCXP_Z"6A
M_P#?^;_XU1_PSCXP_P"@EH?_ '_F_P#C5 'K_P#PNWX>?]##_P"25Q_\;H_X
M7;\//^AA_P#)*X_^-U\R>-?!.I> ]8ATS5)[2:::W%PK6KLRA2S+@[E4YRI[
M5T?A;X*^(_%WARUURPO=*CM;G?L2XED#C:Y0Y C(ZJ>] 'O'_"[?AY_T,/\
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MK_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C=>0?\,X^,/^@EH?\
MW_F_^-4?\,X^,/\ H):'_P!_YO\ XU0!Z_\ \+M^'G_0P_\ DE<?_&Z/^%V_
M#S_H8?\ R2N/_C=>0?\ #./C#_H):'_W_F_^-4?\,X^,/^@EH?\ W_F_^-4
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MN_!! (Z&O@[5],FT76K[2KEHWGLYWMY&C)*ED8J2,@'&1Z"OO"/_ %2?[HH
M=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%(2%!). .I-9^FZ]I>L2SQZ??07+0-MD$;AL&@#1JEJFKZ?HMFUY
MJ=W%:VZ]9)&P!5FXF6WMI9G^[&A8_@*\(\,:2/C-XFU/7M<N)7T>SE\BWL@Q
M48Z\XH [+Q)IW@SXL:;):V&IVDVHQ+F"X@/SH?3Z'O7(^"_'VH>!=5;P;XY)
MCBC^6WNWSMV]!S_=XKT?P]\,_#7A;6&U+2;5X92NT#S&8#\S6;XZT;POX]FD
M\-SW42:U#'YL$BX+1GI@^OTH Y#Q7\*+^PUL>*_ EP$E9O-^S+T/?"^QIJ>+
MOC!J:G35\,QVLCC8URT;#9G^(G-)\,M?\3^$O$A\$>(;*XGMU)%O.J%@GT..
M5.>O:O=* .%^'7P_'@^VGO+^<7FM7AW7-R3G\ ?2NZHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JAK.LV.@Z7-J&H3K#;Q+EF8U<DECB7=(ZHO3+'%<9XR^'T?C75=.FOM1E_L
MRV8-)8J,++[[A0!Y1XBNO$'Q6TS4M8<26/AG3HGDMXQD&=P#ACZUZ5\$[K[7
M\-+-]Y<I(Z'/;&.*Z3Q)810^!=5L;.&.-!8R)&BC 'R$"N)^ $A'P\:W9<&*
M[ER<^XH B^/6CZAJ'A>SO+&)YUL[@221*,@+@_,:Q(/CK]OT6'2-%T.\DUMH
MA#&,#8&QC/!S77>)_B8D'B2S\-^'K--6U"64+<(#F-$Z')&:[BSTJQML31V%
MM#.P!8I&,@]\&@#FOAKX5N/#7AYWU%B^IW\IN;HMU5FQE?PKM*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHKEOB%JVKZ)X-OK[1;<2W,:$Y[H/4#N: .=^)?Q/3POMTC1U%WKDY")$
MO/EYZ9]^>*Z_PRVKWOA>V/B&&*.^EBQ+''G@$=#GOZUY9\$?#FE:E#/XLO[H
M7^LLY#B3G[/U_4_I6QXK^--OI6JR:9H&ER:Q=PG$HCSM4_4 T =OX9\&Z-X3
M2X72K<1^>^YS5/6_A]I'B'Q/9:UJ?F7'V12%MGYC)[''J,5Q7ASXZV]WJRZ?
MXETI]'DE8+$S$D<]VR!@>]=9\0?&&I>&-(MKS1]*?4S*P),8+ +QSP#U% &S
MKOA/1M=TB2PO;&)HBA"D*,I[BO+O@7+<Z?J.O:"TQEMK>?\ =G.0OL*6Y^,>
MMZS8K8Z'X8O%U*X&PL\;;8B>^<5V/PN\#/X,T&3[8P?4KU_-N2#G!] : .[H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:UI%IKVBWFDWR;
MK:[B:*0#J >X]P>1[BK]% 'F/@%K_P"'FE3^%_$-K=O;6DSOI]_:6<DT4\3'
M=@B,,5?<6.TXZ\9QDEIX4O?&'Q-C\9:U92V>F::BQ:79W Q+*RDL)77^#YF)
M .&X7.,<^G44 %%%% !7Q!X[_P"2A^)O^PK=?^C6K[?KQ#7?V>/[;\0ZGJW_
M  E/D_;KN6Y\K^S]VS>Y;;GS!G&<9P* /;Z*** "BBB@#XU^(&AZO-\0_$,L
M6E7SQOJ$S*RVSD,-YP0<<BN:;0=809?2;Y1ZFV<?TK[OHH ^$1X?UI@"ND7Y
M!Z$6S_X5ZA\!M)U.S^(OFW6G7D,?V.7+R0,JCIW(KZ>HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \=?\D]\2_]@JZ_
M]%-7R]\$_P#DKVA?]M__ $1)7UAKNF?VUX>U+2O.\G[;:2VWF[=VS>A7=C(S
MC.<9%>7^"?@7_P (=XOL=>_X2/[7]E\S]Q]A\O=NC9/O>8<8W9Z=J /8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \@_:-_Y)Y8_]A6/_ -%2USW[,OWO%'TM?_:U>H_$?P-_
MPL#P[!I/]H_8/*NEN?-\CS<X5UVXW+_?SG/:L[X9?#+_ (5R=4/]K_VA]O\
M*_Y=O*V;-_\ MMG._P!NE 'H%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,/[1_\ R4#3_P#L
M%Q_^C9:]=^"/_)(M$^L__H^2J/Q'^$'_  L'Q!;ZK_;OV#R;5;;ROLGFYP[M
MG.]?[^,8[5UW@CPQ_P (;X0LM!^V?;/LID_?^5Y>[<[/]W)QC=CKVH Z&BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>ZU*Y'[^ZE^\>^![9H [ PQ&99C&IE4%0^.0#VS3Z** "BBB@ HHHH ****
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M9/S)*YZ[FY(_"@#I(;6WMR3#!'&3U*J!FIJ** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$^#Q5XSNM$T_39KBPC7#7@QL4X.<^QKL-)\.Z3HDMS+IUC#;O<.7D9%P6)H
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M-CHVF:82;*PMK=CU:.(*?S%7J** "BBB@ HHHH **** "BBB@ HHHH ****
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M=@0",$9!KYZ_9YG:U\6>)=,0GR#&' )Z%'*C]&_2@#Z%HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDL4<\312HKQN,,K#((I]%
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M%% !5;4+^WTO3[B^NG"001F1V/8 9JS7EWQ\NYK;X<2)"S(9;F-693CCG(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\\:R12*>&4C((_"@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)@<#/(/3('^SBO1** /%OB#XST3XB>%)O#7A:WNM8U>XECV(EHZ"V(8$LS.
M%X#+G/<]J]1\*:,_A[PGI6D22"22TMDB=QT+ <X]LYQ6Q10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M0NM$TF^O8KV[TNRN+N$8CGFMT=T^C$9%7Z** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ggtc45pq2o35000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *P! T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***#Q0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114,5W;
M3NR0W$,C+U"."1^5 [,FHJ..>&8L(I8W*G#!6!Q4E M@HHHH **** "BBB@
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MFE!R,CH:S8YY-3E_=@I9HW+'K(?;VK2H **** "BBB@ HHHH **** "BBB@
MHHHH **** "B@G R:Y_4_&&FZ?(8D9KF8<%(N<?C6=6M3I+FJ.Q=.E.H[05S
MH**XW_A,K]_FCT:4QGN<U8L_'-E+((KR&6U?.,N.*YXYAAV[<UO6Z-W@ZR5[
M'544R*6.:-9(G5T89#*<@T^NQ.YRA1110 4444 %%%% !1110 4444 %%%%
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MSRA]%1PNTD0=EV[N0#V%24 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH6S74 X2=.I'O5)7V%>PW7Y/M5^81\JQ\97KFJ<$C6^U9U)R>'521^/I5/\
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M_H8Y?R;_ !H_X1/Q!_T,<OY-_C7;44>WG_2#ZI3\_O9Q/_")^(/^ACE_)O\
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M)/#)/<3 LD:' P.Y/;\JRM"^*&FZO=K;36LEI(W"EGW _H*=XVC\'R:C;_\
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M^,+:ZO)IH+:6$01NY*Q@[\[1VZ"N]KRSX66LMCXO\8VLUR]S)%) IF<?,_\
MK.3[UZG2K)*>GE^046W#7S_,****R-0HHHH **** "BBB@ HHHH **** (YH
MVEB**Y3/5AUJ+[(D-A);P+@%& ]R15FB@#@%;!(/8TT6T+,6==[$YR:O:W;?
M9=28J,))\P_K5".56Z'I6QF68PD9^55]OE'%&[]:BWTFZ@![DLC+G&1C-1QS
M[@$<8D48(]?>@OQ41._!Z$'(- $K'BH2,="12EJB=Z!#6"[LDEF]34,CXI&W
M!6<GC/%59),U2$$CYJ#=S2,U,S5"+"MDC/.*],\/VOV31H%(PSC>WX__ %L5
MYG96DU]>1P0']XYXSTKN='UB]M;U-*U>,)(1B&4<!L=JSJ:K0N)T]%%%8F@5
MRGQ'U&[TKP/?WEC.\%PFW;(AP1R*ZNN+^*__ "3K4O\ @'_H0JZ>LT14^!G&
M26OC'1?!MMXLM_%-U=*;:.YEMKEBX"L <#/UKU'PSK']O^&K#5-NTW$6YAZ$
M'!_45XQJ-_XID\)>'M(U=K2QT"]AAB6YMT9G,>T;=^3C.,=,5VOC?4I/!O@W
M1])T69X1<2I;+<HNYE3J6 [D_P!:Z*D.:RZM_@<].?+=]$OQ/2**\E\,ZA?6
M'BR.QL[W6K_2KFW<ROJ$39BD R"&('!-9/A+1]6U[P'<:U+XJU:*XMS(T"BX
M^0;>?FSRV?K6?L;;LT]M?9'N%%>,:_XFU?5/ACX;U!+R6UOIM2CADEB8KO\
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MK4\+>$8O#<E[<O>RWU]>LK3W,JA2V.G ^M='10ZDFFFP5.*V04445!84444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4J-5U$[JS0LRP,<)./LYJ<9*Z84445L><%%%% !1110 4444 %%%% !1110
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M@#<C!E/H?_U9J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4084# I)CYNIN>T2!1]3S3ZYV[R;.M+EBE\PHHHH **** "BBB@!&8*I9B
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M@ HHHH **** "BBB@ HHHH **** "BBB@#FO%>OW6FR66FZ9&LFI7SE8MW1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5'-!#<Q^7/%'+&3G;(H8?D:DHH 0 *    . !44]G;76W[1;0S;>GF(&Q^=3
M44 0365K<1K'/;0RQKT5XPP'X&D%C:+Y6+6 >428\1CY">N/2K%% %8Z?9&%
MH39VYB9MS(8EVD^I&.M310Q01B.&-(XQT5%  _ 4^B@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT?\ "0ZU_P!!6]_[_M_C1]3EW#^TX?RL]PHKP_\ X2'6O^@K>_\ ?]O\:/\
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M3Z5XUJO_ "%KO_KJW\Z]PM/^/.'_ '!_*N[%-J,3R<O2<YW(?[*T[_H'VO\
MWY7_  H_LK3O^@?:_P#?E?\ "KE%<7,^YZG)'L4_[*T[_H'VO_?E?\*/[*T[
M_H'VO_?E?\*N44<S[AR1[%/^RM._Z!]K_P!^5_PH_LK3O^@?:_\ ?E?\*N44
M<S[AR1[%/^RM._Z!]K_WY7_"C^RM._Z!]K_WY7_"KE%',^X<D>Q3_LK3O^@?
M:_\ ?E?\*/[*T[_H'VO_ 'Y7_"KE%',^X<D>Q3_LK3O^@?:_]^5_PH_LK3O^
M@?:_]^5_PJY11S/N')'L4_[*T[_H'VO_ 'Y7_"C^RM._Z!]K_P!^5_PJY11S
M/N')'L4_[*T[_H'VO_?E?\*/[*T[_H'VO_?E?\*N44<S[AR1[%/^RM._Z!]K
M_P!^5_PH_LK3O^@?:_\ ?E?\*N44<S[AR1[%/^RM._Z!]K_WY7_"C^RM._Z!
M]K_WY7_"KE%',^X<D>Q3_LK3O^@?:_\ ?E?\*/[*T[_H'VO_ 'Y7_"KE%',^
MX<D>Q3_LK3O^@?:_]^5_PH_LK3O^@?:_]^5_PJY11S/N')'L4_[*T[_H'VO_
M 'Y7_"C^RM._Z!]K_P!^5_PJY11S/N')'L4_[*T[_H'VO_?E?\*/[*T[_H'V
MO_?E?\*N44<S[AR1[%/^RM._Z!]K_P!^5_PH_LK3O^@?:_\ ?E?\*N44<S[A
MR1[%/^RM._Z!]K_WY7_"C^RM._Z!]K_WY7_"KE%',^X<D>Q3_LK3O^@?:_\
M?E?\*/[*T[_H'VO_ 'Y7_"KE%',^X<D>Q3_LK3O^@?:_]^5_PH_LK3O^@?:_
M]^5_PJY11S/N')'L4_[*T[_H'VO_ 'Y7_"C^RM._Z!]K_P!^5_PJY11S/N')
M'L4_[*T[_H'VO_?E?\*/[*T[_H'VO_?E?\*N44<S[AR1[%/^RM._Z!]K_P!^
M5_PH_LK3O^@?:_\ ?E?\*N44<S[AR1[%/^RM._Z!]K_WY7_"C^RM._Z!]K_W
MY7_"KE%',^X<D>Q3_LK3O^@?:_\ ?E?\*/[*T[_H'VO_ 'Y7_"KE%',^X<D>
MQX[XTAB@\3W,<,:1H N%10 /E'85Z+X._P"16LO]W^M>>^.?^1KN?]U/_017
MH7@[_D5K+_=_K797_@Q/,PO^]3^?YF[1117$>J%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7'?$+_CPL?\ KO78UQWQ"_X\+'_K
MO6M#^(CGQ?\ !D==#_J(_P#='\J?3(?]1'_NC^5/K(W6P4444#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **AGNH;<?O'
M^8]%')/X54>XNK@XC'V>/U;ES^'0?K42FEH:1IREKT+<]S' /F.6/11R350F
M2=Q)-P!]R,=O<^])'"D9+ $L>K,<DU+@^E0VY;FJ48["4444 %(12T4 ,Q4*
M>;:.7M_FC)RT1/'U'I5FDV^QJ6BE+HR>WO(;D84X<=4;@BK%94MNDF"00PZ.
MIP13DNKFVP)%-Q'_ 'EX<?4=#^E6JC7Q$2I)_ :=%0P74-RN8G!(ZCH1]14U
M:)IJZ,&FG9A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% 'A.J_\
M(6N_^NK?SKW"T_X\X?\ <'\J\/U7_D+7?_75OYU[A:?\></^X/Y5VXOX8GE9
M=\<_Z[DU%%%<1ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 >0>.?^1KN?\ =3_T$5Z%X._Y%:R_W?ZUY[XY_P"1KN?]U/\
MT$5Z%X._Y%:R_P!W^M=M;^#$\K"_[U/Y_F;M%%%<1ZH4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<=\0O\ CPL?^N]=C7'?$+_C
MPL?^N]:T/XB.?%_P9'70_P"HC_W1_*GTR'_41_[H_E3ZR-UL%%%% PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDLJPQEW/ _6ANPT
MFW9"R2)%&7D8*HZDFJ#W,]QQ$#%'_>8?,?H.U(5:>02S=N43LOO]:DK%R<O0
MWC%1\V11P1Q9(&6/5CR34M%%)*VQ3;>X4N3244Q"Y-'%)10 4O%)10 N?3BD
MR:** #-(12T4 02VR.P;E7'1UX(IR7LUMQ<CS(_^>BCD?45+32*FUM45=-6E
MJ7D=)$#HP96&00<@TZLA=]FYE@&8R<O$.A]Q[UJ12I-$LD9RK#(K6$^;1[F%
M2GRZK8?1115F84444 %%%% !1110 4444 %%%% !1110!X3JO_(6N_\ KJW\
MZ]PM/^/.'_<'\J\/U7_D+7?_ %U;^=>X6G_'G#_N#^5=N+^&)Y67?'/^NY-1
M117$>J%%%% !1110 444=!DT %%9-_XGT/3#B]U2UA(ZAI!_2J4'CWPK</LB
MUVS9O3?5<DGK8GGBNIT=%16]U;W48DMYHY4/=&!J6I*"BBJ][?6NG6CW5Y.D
M,"<M(YP!0!8HI%974,I!5AD$=Q2T %%%127$$1Q)-&A_VF H EHJJ=3L <&^
MM@?^NJ_XU-'/#-_JI4?_ '6!HLPN24444 %%,EFB@3?-(D:=-SL /UJO_:FG
M_P#/]:_]_E_QHLPN6Z*J?VII_P#S_6O_ '^7_&C^U-/_ .?ZU_[_ "_XT[,5
MT6Z*J?VII_\ S_6O_?Y?\:LI(DJ!XW5T89#*<@TK#N.HHHH **** "BBB@ H
MHHH **AFN[:V($]Q%$3R [A<_G3XIHITWPR)(AZ,C C]* 'T56DU"RBD,<EW
M;HZ]5:0 C]:L A@"""#T(H 6BBB@ HHHH **** /(/'/_(UW/^ZG_H(KT+P=
M_P BM9?[O]:\]\<_\C7<_P"ZG_H(KT+P=_R*UE_N_P!:[:W\&)Y6%_WJ?S_,
MW:***XCU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X[XA?\>%C_P!=Z[&N.^(7_'A8_P#7>M:'\1'/B_X,CKH?]1'_ +H_E3Z9
M#_J(_P#='\J?61NM@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %9TK_:+QA_RSAX'NW?\O\ &KTT@BA>0G 4$UG6B%+9-WWV&YOJ
M>3^IK*H]4C>DK)R)J***104444 %%%% !1110 4444 %%%% !1110 4444 -
M/6H[5_LM[Y/_ "RGR5]G'4?B.?PJ5JKW0_<%Q]Z,AQ^'/\LU#TU70N.ONOJ:
M]%-1MZ*WJ,TZNDXPHHHH **** "BBB@ HHHH **** "BBB@#PG5?^0M=_P#7
M5OYU[A:?\></^X/Y5X?JO_(6N_\ KJW\Z]PM/^/.'_<'\J[<7\,3RLN^.?\
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M>(I-'G?$%^O[O)X$B\C\QD?E15IRE17-N@IU(QK/EV9]!U\P?%G_ )*9J_\
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M7Q[_ .0UH_\ U[O_ .A5V_P;_P"2=VO_ %UE_P#0S7$?'O\ Y#6C_P#7N_\
MZ%7;_!O_ ))W:_\ 767_ -#-1/\ W>)</]XD>+_$S_DHVM?]=A_Z M?3.C?\
M@6R_ZXK_ "KYF^)G_)1M:_Z[#_T!:^F=&_Y ME_UQ7^5&(_AP##_ ,29>HHH
MKC.P**** "BBB@#R#QS_ ,C7<_[J?^@BO0O!W_(K67^[_6O/?'/_ "-=S_NI
M_P"@BO0O!W_(K67^[_6NVM_!B>5A?]ZG\_S-VBBBN(]4**** "BBB@ HHHH
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M1C&'O+4XQOA7X1*D#3%&1UW5\_:[I]SX0\8S01Y22TG$D+>V<J:^M*\\\?\
MPQ'C+4K>_M[V.SF2,QR%HBV\=NA'3G\ZJA7M*TWH37H7C>"U.N\-:U%X@\/6
M>IPD8FC!89^ZW<5\Z_%G_DIFK_\ ;+_T4E>X^ ?"-]X.TV>PN-22\A9]\86,
MKL]>YKE_&'PAN?$_BF\UB/5X;=;C9B-H2Q7:BKUS[4Z,X4ZC=] K1G.FE;4Z
MSX:_\DZT3_KA_P"S&N3^,WA'^T-+77K2/-Q:C$X ^]'Z_A7?^%]&;P_X:L=)
M>83-;1[#(JX#<D]/QK3GACN()(94#QR*592,@@UBJG+4YD:NGS4^5GS]\(/&
M?]C:L=%O),65XW[LL>$D_P#KU] O;PRMNDAC=O5E!KQFY^!$YOY9K/6XH(3(
M6B0PDE!G(&<]J];T:UO;+2;>VO[E+FXB0*TR)MW8Z'&:TQ#A)\T&1AU.*Y9H
ML_8[;_GVA_[X%2JBHH5%"J.@ P*6BN8Z#PWX^?\ (2T3_KC+_-:VO@-_R+6J
M?]?@_P#0!6W\0_AY/XWN;&:+48[3[*CJ0\1;=N(/J/2KWP^\%R^"M+N[.6]2
MZ,\WFADC*X^4#'4^E=;J1]AR7U.54Y>WYK:'7$ @@C(/4&HOL=M_S[0_]\"I
MJ*Y#J(EM;=&#+!$K#H0@!%>+?';19?M6G:TB$Q%#;RL/X2#E?SRWY5[=534M
M-M-7T^:QOH5FMYEVNC#_ #S6E*IR34C.K3YX.)Y5\)/'FG1Z/'H.I7"6\\+'
MR7D;"NI[9]:]+U#Q+HNEVYGO-3MHD [R#)^@[UY%KGP,NUN'DT2^C>$G*Q3\
M%?;-9MC\#_$4TP6\N;2WCSRROO./IQ71*%&;YN:QSQG6@N7EN>C?%"R'B+X<
M27-CB98BEW&1W4 @G\F->2_#*Y\,#59K+Q+:6LD<X'DS7 X1O0GMFOH/P_HB
M:%X>MM(,[W4<*%-\H!+ ]OIS7FOBKX)Q7MW)=Z%<K;[SN-O(,J#['M2I5(J+
MIMZ=QU:<G)5$M>QV?_"%^!_(\[^Q],\HC._ Q_.GZ!HO@S^T'NM"L].-U:'#
M2VV"8RP(QD>V:\=3X)>*3+M=K)4S][SL_IBO4/AOX$N_!45]]IOHY_M>PE$3
M&TKGO^-*HHJ+M.Y4')R5X6.$^/?_ "&M'_Z]W_\ 0J[?X-_\D[M?^NLO_H9I
M/B%\.9_&U]97$6HQV@MXF0J\1;=DY]16]X)\-2>$_#<.E27*W+1N[>8J;0<L
M3T_&E*I%T5&^H1A)5G*VA\]?$S_DHVM?]=A_Z M?3.C?\@6R_P"N*_RKS/Q3
M\';KQ%XFOM63688%N7#"-H"Q7@#KGVKU.RMS:6,%N6W&) FX#K@45ZD90BD]
M@HTY1G)M;D]%%%<QTA1110 4444 >0>.?^1KN?\ =3_T$5Z%X._Y%:R_W?ZU
MY[XY_P"1KN?]U/\ T$5Z%X._Y%:R_P!W^M=M;^#$\K"_[U/Y_F;M%%%<1ZH4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (RAU*L 5
M(P0>]>(Z_IITK6KBU(^56RGNIZ5[?7$>/=$>]:TNX$S)O$38]">*Z<+4Y9V?
M4X<?1YZ=UNAGPYTKRK2?4I%^:4^7'_NCJ?S_ )5W55=.LTT_3K>TC "Q(%X[
MGN?SJU656?/-R.BA2]E340HHHK,V"BBB@ HHHH **** "BBB@ HHHH ****
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M?]=R:BBBN(]4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /(/'/\ R-=S_NI_Z"*]"\'?\BM9?[O]:\]\<_\ (UW/^ZG_ *"*
M]"\'?\BM9?[O]:[:W\&)Y6%_WJ?S_,W:***XCU0HHHH **** "BBB@ HHHH
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M#=0#@YY%!(498@#U-+UZ4 %%%% !12$A1DD >II>HR* "BBB@ HHHH ****
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M_P"1KN?]U/\ T$5Z%X._Y%:R_P!W^M=M;^#$\K"_[U/Y_F;M%%%<1ZH4444
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MS*X4445)04444 %%%% !1110 4444 %%%% !1110 52U0_Z&$[M(@'_?0/\
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M(OE)('&?6O+/A!_R4K3O]R;_ -%M71!P=*7*834U5CS'=?'S_D%:+_UWD_\
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M;&46F?[1E_N^4O\ ,T46A/\ :,J]O)4_J:2^)#?PLT:***Z#D"BBB@ HHHH
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M^KGD_ET_"NFHHKEE)R=V=,4HJR"BBBD,**** "BBB@ HHHH **** /(/'/\
MR-=S_NI_Z"*]"\'?\BM9?[O]:\]\<_\ (UW/^ZG_ *"*]"\'?\BM9?[O]:[:
MW\&)Y6%_WJ?S_,W:***XCU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M73"38J3U+,?_ !XU">AJ?33NT^$^JYIP^,53^'\_\RW1116YS!1110 4444
M%%%% !1110 4444 >$ZK_P A:[_ZZM_.M1/&WB"-%1;X!5& /)3_  KTJ3PK
MH<TC22:=$SL<L23R?SIG_"(Z!_T#(OS;_&NYXFFU:2N>2L#7BVXRM?U/.?\
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MZ-_PB.@?] R+\V_QH_X1'0/^@9%^;?XT>WH_R_@@^J8K_GY^+/.?^$X\0_\
M/^/^_*?X4?\ "<>(?^?\?]^4_P *]&_X1'0/^@9%^;?XT?\ "(Z!_P! R+\V
M_P :/;T?Y?P0?5,5_P _/Q9YS_PG'B'_ )_Q_P!^4_PH_P"$X\0_\_X_[\I_
MA7HW_"(Z!_T#(OS;_&C_ (1'0/\ H&1?FW^-'MZ/\OX(/JF*_P"?GXL\Y_X3
MCQ#_ ,_X_P"_*?X4?\)QXA_Y_P ?]^4_PKT;_A$= _Z!D7YM_C1_PB.@?] R
M+\V_QH]O1_E_!!]4Q7_/S\6><_\ "<>(?^?\?]^4_P */^$X\0_\_P"/^_*?
MX5Z-_P (CH'_ $#(OS;_ !H_X1'0/^@9%^;?XT>WH_R_@@^J8K_GY^+/.?\
MA./$/_/^/^_*?X4?\)QXA_Y_Q_WY3_"O1O\ A$= _P"@9%^;?XT?\(CH'_0,
MB_-O\:/;T?Y?P0?5,5_S\_%GD-_?W.IW;75W)YDSXRVT#./85ZYX._Y%:R_W
M?ZT[_A$= _Z!D7YM_C6K:VL%E;I;VT8CB3A5':HK5XSBHQ1MA<+.E4<YN]R:
MBBBN4[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y*;QS;+XNAT*&
M)9-TABED+E3&P]L<CWS4RDH[FM*C.K?D5[*[]#K:Y^[\9:/9:D]A-,XG25(F
M 7@,QXK7EO(;<2&:15"G@=SQZ5R-_IVA77B&+59;/S)!A^AR6&2"1]<424VO
M='1=%-^VO;R[G;]1D45FVM\L\$,,,P:;&&+ C'X5C:KXWM=)\40:1/&%A= S
MW#,>"3@ *!S3E)05Y$TJ4ZKY8*[.KHI 0RAAT(R*6F9A117*^+?&MOX8V1"(
M3W3 -Y3,4RN<<'!!//2IE)15Y&M&C.M-0IJ[9U59&L>)-.T*:"*^D96G5V3:
M,\*,G^=7%OXF926"QM$) QX')KG?$MOHOB""(741D>%R$8@KC/4#ZX%.2E;W
M=Q4G34U[6_+Y;G2:??V^IV$-[:L6AE7<I(P:LUB:?>V-I8"VM%6/8,1Q,"H_
M.JWB?Q/_ ,(O:VC/$MQ+/)M.Z0(%'<_2B3Y8WD$*;JU.2FM]CI**K:??V^J6
M$-[:/O@E&4;!&><=ZLTT[ZD--.S"BBB@04444 %%%% !1110 4444 %%%% !
M534EW6+#./G0_DXJW534AFPE'T/ZBIG\++I?''U(:;(VR)V]%)I1]T?2HKK/
MD[1U9@H_.L&]#IBKNQ?L4\NRA7_9S^?-4\^9?7#CIN"C\!S6F %4*.@&!659
M_/'YG_/1B_YFKFK6B9TW?FD71T%(YPM.J-SS5,E;C:***DL***;DT@'44T&G
M4P"BBB@ I#TI:* &4V,[-1@/]\,A_+/]*=4,YVF)_P"[*I)]L\_I4/34M*^G
M<NZBA>PEQU R*KJP90PZ$9K0D7?&R_W@165:G-L@_N_+^1Q_2KG\1G2UA\R4
M_=/TJQIR[=.MQG.8P?S%5V^Z?I5C31C2[0>D*?R%$/B'4^#YEJBBBMCF"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#Z4Z@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAKFJXJM22E9,^HP&$HSI*4H]OR.@7Q7?L<+;P$GL%;_&I/\ A)=4_P"?*/\
M[]M_C5#PV =?M 1D;C_(UZ5Y:?W%_*E&4FKW,,;4HX:IR*FGH>7:]XSUFPMH
MWBTR.4LV"/+?C]:Y_P#X63XA_P"@&G_?J3_&O;VBC(YC0_513?(A_P">4?\
MWR*B4I)[G/#,:*5O8K[V>)?\+)\0_P#0#3_OU)_C5=_BOJT;E'TVU5@<$$,"
M/UKW7R(?^>4?_?(KYE\:@#QKK    NY, ?[QK-U)I;GIY;5H8RHX.DE97W9T
MG_"V=3_Z!]I_X]_C5WP]XQN_%/C?08+FVAA6WN&E4QYY/ELO.3[UYA76?#7_
M )'_ $O_ 'V_]!-53JS<TKGH8[ X>.&J24=4G^1]*T445Z9\&%%%% !1110
M4444 %%%% !1110 4444 %%%% !534K^/3=/FNY?NQKG'J?2K=<CX\E8VEG:
M+TFFPPKGQ55TJ,IK=&V'IJI5465_#ND2:W<OKFKCS-[?N(F^Z!]/3TKM0
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MUR==;\-?^1]TO_KH?_0312^->I]+CO\ =:O^%_D?2E%%%>N?FX4444 %%%%
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M*VT)Q A]>WY=:[:C"7J3G7Z2M;T77YBQ-H1C1ZK?U84445WG(%%%% !1110
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M=55CN(R%.16R"&4,I!!&01WI:'%26HX5)TW>#LPHHHID!1110 4444 %%%%
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MWA"ZO;D7.NWIG(.1$IXKL**CZC!N]23EZO0KZW)+W$H^@R*&.")8HD"(HP%
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %,FFCMX7FF<)&BEF9CP
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MD\">(8_$5IIT:"S+1R6;L<G/0AJI^&/%FH75GH7A_P .0V\TD5NKW]S.K-'
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M'_HJ.L[+G.II?5D_-_DC=HHHK0Y0HHHH **** "BBB@ HHHH **** "BBB@
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M<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8R^>M@=I^2(LL@(RQ+#CBO0:PC)2;\CJJT7246W?F5PHHHJC$**** "BBB@
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MP4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'C<Q+-CVR34+639U5/<H1IO>]RY1115G*%%%% !1110 4444 %%%% !1110
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M84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ggtc45pq2o35000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4R#M(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRJGX<^(/A;Q;=O:Z)J\=U<(A=HC$\;;1C) =1D<CI0!TM%%% !1110 4444
M%%%% !1110 44R65((7EE8+&BEF8]@.2:XA?C)\/VNOLX\11;]Q7)MY@F?\
M>V;<>^<4 =U12*P90RD%2,@@\&EH **** "BBB@ HKA/BIX^G\ >'K>\L[2*
MYN[J?R8UF)"*-I)8XY."!QD=>M>-_P##1WC#_H&Z'_WXF_\ CM 'T_17F?PK
M^*__  G\EW87MG'::E;)YP$3$I)'G!(SR""0#UZBO3* "BBO)OBI\89?!&I1
M:/I%G;76HF,2RO<,Q2$$\*57!)(YZC''7- 'K-%?,'_#1WC#_H&Z'_WXF_\
MCM>^> _%!\9>#+#7&@6"6<,LL2DD*ZL5./8XR/K0!T=%<!\6/']YX T"UNM/
MM(+BZNI_*0W&2B #)) ()].H]?:O'_\ AH[QA_T#=#_[\3?_ !V@#Z?HKYA7
M]H_Q=N&[3-$*YY AE!(_[^5T6B_M)Q/(D>N:"8U+ --9S;L#']QAZ_[7?VY
M/?**R/#GBC1_%>FB_P!&O8[F'@.!PT9QG:R]0:S_ (@^(;_PKX)U#6M,M([F
MYM@A"2@E0"X!8@$$@ YX(H Z>BOFBP_:0\1K?P'4-*TJ2SWCSEMXY$D*]]I9
MR,_45]*12I/"DL3!HW4,K#N#R#0 ^BBN3^(WC,>!?",NKK D]RTJP6\3G"L[
M9/..<!0QX].W6@#K**^>?"7QX\5:]XNTG29]+TEH;RZ2&3R(I%=5)P6!,A'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBO&/BG\8]8\%^*4T;2=/L9 D"RRRW:N^XMT"A67&
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M@^'_ (>2^:W6ZNYY/*M[<OMW'&2Q.#P!_,#C.:\1_P"&CO&'_0-T/_OQ-_\
M': /I^BO-/A'\3+WX@6^I1:G:6UO>611@UL&".C[NS$D$%?7G(]*[3Q3K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*RG((/0@U\J^._@AJG@[19-7MM1CU.SA(\_; 8Y(P?XMN6!4=SGC\\6O@?\
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M&^HQ+)-#8Z>&7<!=W'/Y(&P?KZ<UC>,_A7XE\#6<=[J26T]F[[#<6DA=48]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1A@#T([=ZY;XV_\ )(==_P"W?_T?'0!\F:5I=UK.HQV%DJM<2ABBLV-Q52V
M?4XP/?%:'@_Q-=>$/%-EK5K\S0/B2//$D9&&4_4'CT.#VK5^%/\ R5'P]_U]
M?^RFK?Q<\'?\(?XYN8[>+9IM[FYM-JX503\R#@ ;6R !T4KZT ?76GW]MJFG
M6U_9R"2VN8EEB<=U89%> _M+_P#(0\.?]<I_YI6A^SQXS\ZRN/"-Y)\]OFXL
M>.J$YD3\&.X?[Q]*S_VE_P#D(>'/^N4_\TH /V:/^0AXC_ZY0?S>O8_$O@+P
MQXON(+C7=+6[F@0I&_G21D*3G'R,,\^OOZUXY^S1_P A#Q'_ -<H/YO7T/0!
MY_\ \*2^'G_0O?\ D[<?_'*\O^,OAOP#X*TJWL-(T5$UN\.]6-W,_D1 \O@N
M1DD;1D8^]Z5[]K^MV?AO0;S6-0?9;6L>]CW)Z!1[DD >YKXI\4>(KSQ7XDO=
M:OL":Y?(0'(C4<*H]@ !0 >%_#MYXK\266BV.!-<O@N1D1J.68^P )K[=TO3
MH-(TBRTRVW_9[.!+>+><MM10HR?7 KS/X'> O^$9\.G6[^';JNIH" RX:&#@
MJOJ"3\Q_X#Z5ZO0!!>7<.GV-Q>W+B.WMXFEE<GA549)_(5\/^(M7N?%7BN_U
M1D=IKZY+I&!D@$X1!CK@8'X5]-_'7Q =%^'%Q:Q.5N-3E6U7'9/O/^&U2O\
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M\D6*)!PJY.%1!V'/'YGDDUZ[%^S1>FP5YO$]NEX5RT26A:,-Z!RP)'OM'TH
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MQ./Q)Y_PH ^GK#4K#5;476G7MM>6Y)42V\JR(2.HRI(JU7SQ^S3-<_;_ !!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3V-]:ZE8PWME/'/;3H'CEC.58'N* +%%%% 'B/[2G_(MZ)_U]O\ ^@5Y_P#
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MI[[6R/H5% 'LE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^SC:>\NY1'&N?O,QZD^G<D_6OM7P;X5L_!OABUT:S)<1 M+*W620\LQ_D/8
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M7=P/D;.=W/T%>@_\--?]2C_Y4O\ [57-? _PKX5\7W6KV/B#3Q=74*1S6_\
MI$D9V9(?A&&<$IZ]:]D_X4E\//\ H7O_ "=N/_CE 'RAKNI)K/B#4=4CM_LR
MWES)<"'?N\O>Q;;G SC/H*^M_A+*U]\)="\\.0;=XB'X)5791^& ,>V*K_\
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MM8@T"6:RF@6XC:&:-W=& *D(&+$D$<8S[5R<'DQ7B?;(9GA5_P![%&XC<CN
MQ5MI^H/TK[9\"?\ )//#/_8*M?\ T4M?/OQ_\)C1O%T6MVT16UU52TF!PLZX
MW?3((/N=U 'MOPNA\)CP=#=>$K;R;6<_OO,YF\P=5D)Y)&?I@\<&NUKY;^ /
MBQM&\8OHEQ*%L]57:H8\+.O*D?4;E]R5]*^I* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^!U[!J7A[1=9D635-'T^^=1M5KJV24@<\ L#ZG\S2Z9H&C:*TC:5I%A8-*
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M/<6D<CX'3YB,\5IHB11K'&JHB@*JJ,  = !0 ZBBB@#Q']I3_D6]$_Z^W_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMG_"">#_ /H5-#_\%T/_ ,35V7P[H<^FQ:;-HVG26$)S':O:H8D[\(1@?@*
M/D;X4^'SXC^(^DVK(6MX)?M4^.R1_-S[%MJ_\"K[,K-TWP]HFBR22:5H^GV#
MR#:[6MLD18>A*@9K2H *^;?VCO#_ -E\0:;K\2 )>PF"8C_GI'T)^JL!_P
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MK.DVP9KB:#?"BD NZ,'5>>.2H'XUTD$$-M D%O$D4,8VI'&H55'H .E24 ?
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MRPTX$6-C;6P(P1!$J?R%6J (K:V@L[6&UMHDBMX46.*-!A44#  '8 "I:**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*I9B
MH&22>!0 M%8D7C'PO/=+:P^)-'DN&;8L27T1<MZ !LYK;H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F"J68
M@*!DDG@4 +16)%XQ\+SW2VL/B31Y+AFV+$E]$7+>@ ;.:VZ "BBB@ HHK)\0
M^)='\*:8-1UN]6TM3((@Y1FRQR0 %!). 3T[&@#6HKFO#?C_ ,+^+KJ6UT/5
MDNYXD,CQ^5)&P4$#.'49&2/SKI: "BBB@ HHHH **** "BBB@ HHHH ****
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ME4.Y.  Q0+R>G/- ':T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWI7LE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF.[5_+:![V,2!\XVE2<YSVIWB#Q1HGA:S6[UO48;.)B0F\DLY'7:HRS=>P-
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M8W.I7[_-.Z\QQ# 2)?10!SZG)/MM44 ,EBCFB>*5%>-P596&0P/4$5\K^&M
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M/;NSM^^HSG:>GI0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML(@O8!*98PX?;NE=ARI(/##H:K_"#_DE&@?]<7_]&-7;T ?"/B#_ )&35/\
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M+>0$_)<1,-KKD95QSVSC@]<&OJCX3:+;Z)\,]%C@C"M=6ZWDS8&7>0!LG'7
M*@>RBIOB=HVGZS\.]<%_;),;2RFNH&/6.5(V96![=/Q&10!\7U]_U\ 5]_T
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MF_QKM/VA?^2:I_U_Q?\ H+T >'_![_DK&@?]=7_]%O7UQK?_ " -1_Z]9?\
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MU&#4-/N)+>[MWWQ2QG!4_P"'8CH1Q7WK7PWXRMX[3QSX@MH5"Q0ZE<1HH&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&>AZ5VW[0W_)28O^P?%_Z$]=A^S1_P @SQ%_UV@_D] &Q\#/ _B'P:NO'7K
M6ANS;B$><DA;9YF[[C''WAUKSWXMV7BSQ1\5K_1K2WOKZ& 0_9K>)6\I%:,'
M=Z#DOEC[C.!7U#7.>*?'7AWP;%&VMZBD,D@S' BEY''/(4<XX/)P.V: /GJS
M_9Z\:W4(DFDTJS8@'RY[EBP]OD5AQ]:XSQCX&UOP-?Q6NL0Q@3AFAGA;='*
M<'!P#D9'! /(]:]HO_VE=,C;_B7>'+NX7/6XN%A./^ AZ\W^)?Q2_P"%B6VG
M0_V-_9_V-W;/VKS=^X ?W%QTH ])_9Y\8W>HVE]X9O[AIOL4:S6>_DK%G:RY
MZX!*8],XZ "O5?&'B:V\(>%;_6[D!_L\?[N+./,D/"+^)(R>PR>U?/'[.TA3
MXCW*@#$FFRJ<_P"_&?Z5V?[2M]Y>@Z%I_P#SWNI)^_\ RS4+_P"U* /"M=U_
M6?&6OM>ZA++=7EPX6.) 2%R<!(U[#H !R?<UWMM^SWXTN+!;EY-+MY&3=]GE
MN&\P<9Q\J%<]NM4O@5I<&I_$^T>=0PLH9+E5/0L %7\BV?J!7UM0!\P?";0?
M$?A7XRVFF7]E<VNZ&;[0ISLDB"-A@1PR[]O/(S[UG?$SX;>*[+Q#XB\12V(D
MTAKN2Y%T+B/A'?(&TMNXW!>G;TKZPKB/B_\ \DHU_P#ZXI_Z,6@#X]M+6:^O
M8+.V3?//(L4:9 W,QP!D\#D]Z](T;X,>/K;7=/GGT(1PQ7,;R.;R [5# DX#
MD]/2N)\)?\CGH7_80M__ $8M?<] !1110!C>+;B^M/!VM7.F,5OH;&:2 JNX
MAPA(P.Y]!ZU\F:'\/?&OC>5KZWL+F9)?F:]O9-BOQP=S<MVZ9[5]F5YMXE^.
M'@_P]-);0W$NJ74;;62R4% ?=R0I_P" Y_G0!Y'-^SOXSBM6E2YTB9P,B&.X
M<.?;YD"_K7FEO<ZGX;UQ9H'FL=3L9B,CY7B=3@@C\P0?<&O=)OVF8A*PA\*.
M\8/RL^H!21[@1G'YFO$/$FL_\)#XEU+6/(^S_;;AYO*W[]FXYQG S^0H ^SO
M!NOKXH\':5K0QNNH T@'02#Y7 ]@P85\^_M'?\E#T_\ [!4?_HV6O6_@;(7^
M$NDJ0,1O.HQ_UV<_UKR3]H[_ )*'I_\ V"H__1LM '"6_B[6CX1B\'Z>9$M9
MKEI)$@R9+EGP AQR1Q]T=2><\58U+X8^--)T5M7OM!N(K)%WN^]&9%]60,64
M#OD<=Z]$_9OT;3[W5M:U2YMDEN[!8%MG;GR_,\S<0/7Y0,_7U-?1CHDL;1R*
MKHP*LK#((/4$4 ?#'AKQ'J/A77;?5M+G:*>(_, ?ED3NC#N#_P#7Z@5]P:??
M0:GIMK?VS%K>ZA2:(GNK $?H:^%-4MEL]7O;5/N0SO&OT#$?TK[)^&<GF_#/
MPZV,8L8UZ^@Q_2@#YT^.W_)5]0_ZXP?^BUKT_P#9N_Y$S5?^P@?_ $6E>8?'
M;_DJ^H?]<8/_ $6M>G_LW?\ (F:K_P!A _\ HM* (/VE/^1;T3_K[?\ ] KP
M[P_XQU3PQI6K6>E2>1)J:1QR7"G#HB[LA?0G=U[=N>1[C^TI_P BWHG_ %]O
M_P"@5YA\%M&T_7/B1:6^I6R7,$43SB)^5+KC;D=QGG'2@#+C^&GC:[T<ZTF@
M7<EHZ^;O)7>P(W;@F=Y!'.<<US>FZE>:1J,&H:?<26]W;OOBEC."I_P[$=".
M*^]:^(_'UK%9?$+Q#;P+MB34)MJ^@+DX_6@#7\1^*O%?Q8U^.VBMYI@!F#3;
M3)2/ Y8CN>3ECZXX%8OB3P/XD\(K$VN:5+:1RG:DFY70G&<;E)&<=L]CZ5]%
M_ +2;&T^'4.HPVZ+>7LTGGS8^9@KE5&?0 =/4GUJ_P#'*WCF^$NK2.H+0/!)
M&2.A\Y%S^3'\Z /%_@7XMNM$\<6^CO,QTW5"8GB9OE67&4<#U) 7W#=\"OJM
M]_EMY>W?@[=W3/;-?$7@3_DH?AG_ +"MK_Z-6OM^@#XRLO"OCGXA:O-="RO;
MV=G(ENKH[$0[CD;FP!@Y^5>G.!74C]G;QD;;S3=:.'VY\HW$F[/I]S&?QQ7M
M/BOXO>$O"5Q+9W-X]Y?Q</:V:;V4YQAF)"@CN"<CTZ5P%Q^TQ;K+BV\*RR1X
M^]+?!#GZ!&_G0!X7J>FZGX8UZ:QO$DL]1LI1G:V&1A@JRD?@01[&OKGX4^*Y
MO&'@&SO[N3S+Z%FMKI\ ;G7H>.Y4J3[DU\L^._%G_":^*[C7/L7V+SD1?)\W
MS,;5"_>P/3TKW?\ 9OD)\#:G%@;5U)F'KS%'_A0!B?M-?\RM_P!O?_M&N?\
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MZB@"MJ]DNI:+?V#J&6YMY(2IZ$,I&/UKX,K[_KX(OE5-0N550JB5@ !@ 9-
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MBBB@ KP#]IK_ )E?_M[_ /:->_UX!^TU_P RO_V]_P#M&@#G_P!G'_DH=_\
M]@J3_P!&Q5]/U\P?LX_\E#O_ /L%2?\ HV*OI^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@U#3/$-B+J3[,)K8&=X\;6PP^1ADX8'\#7NWQ6\"GQSX3:WM0@U2T;SK0NV
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MO6+_ -!% 'B_[2__ "#/#O\ UVG_ ))7'_L\_P#)29?^P?+_ .A)78?M+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O"-7^)OQ/\ #WB>ZBO?"B36"S,L:1VLA5DS\I65<@DC
MO@_0=![O10!Y38_%O7M7MPFG?#K6GO6' D.R%3[R%0,?@*O>$O .IR^)V\9^
M-9X+G72NVVMH/]39KSP/4C)]<9)R2<UZ110 5Y)\2OAUJDWB*T\;^#U3^V[1
MU>:V/ N-O1AR,G'RD9^8>XY];HH \X_X6PS::$B\'^(FUPKM_L\V3@!_>3&
MF?XL9QVK/^'GPXU.#Q+=>-_&#1/KETS/%;)RMMN&"2>1G'R@#.!W)Z>KT4 (
M0&4JP!!&"#WKQ%O"6M_"GQY-XA\.:;/JOAN]!6ZL;4;IH 3G"K_%M/*GTRIQ
M]X^WT4 >6>(/'VK^)-,DT?P5X>U=[^[3RWO+RU-O%:J>&.YOX@.GY\XQ6Y\,
MOAY;^ -">%I$N-3NB'N[A1@''1%S_",GZDD\=!V]% !1110 4444 ?('QM_Y
M*]KG_;O_ .B(Z[_]F7_F:/\ MT_]K5P'QM_Y*]KG_;O_ .B(Z[_]F7_F:/\
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M[_KT7^9KP_\ :._Y*'I__8*C_P#1LM '0?LR_P#,T_\ ;I_[6KW^O /V9?\
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M_P"96_[>_P#VC7/_ +./_)0]0_[!4G_HV*N@_::_YE;_ +>__:-<_P#LX_\
M)0]0_P"P5)_Z-BH ^GZ\Y\6?!7PGXG::YAMSI=_(<F>T&%)XY,?W?7I@DG)-
M9'QWU_Q#X;L-"U#0KRZM EQ)YTD0RA.T;0X(*D?>P&XX]JX[2OVD]4@MMFJ^
M'[6\F  $EO<&#/N05?GZ8^E 'G?C_P  :C\/]8CL[R:.YM[A2]M<QC'F*#@Y
M4_=8<9'(Y')KUW]G'Q%<W.GZIX?GD=X;3;/; \B,,3O7VYP<>I;\?(O'_C_4
M?B!J\-Y>0QVT%NA2"WC.0@/)))ZDG'IT'%>\? GP/?>&- N]4U2)X+S4RA2W
M?@QQ*"5+#LQ+'CL .AR* /5Y9!#"\K E44L<=>*^!9)&EE>1SEW8LQ]2:^V_
M'NJ#1O .NWY=$:.RD"%SQO8;5'_?1 QWKXJL+*74=1M;&#;YUS,D,>XX&YB
M,^V30!]I_#VW:U^'7AR)E"L-.@8C&,$H#S[\UTE16\"6MK#;Q9\N) BY/. ,
M"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'R!\;?^2O:Y_V[_P#HB.N__9E_YFC_ +=/_:U<!\;?^2O:Y_V[_P#HB.N_
M_9E_YFC_ +=/_:U 'T!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,\**[SX1> IO OAB5+]8QJE[)YESL8,% R$3..< D]^6.* /0:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O /VFO^97_P"WO_VC7O\ 7@'[37_,
MK_\ ;W_[1H Y_P#9Q_Y*'?\ _8*D_P#1L5?3]?,'[./_ "4._P#^P5)_Z-BK
MZ?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /D#XV_\E>US_MW_ /1$==_^S+_S-'_;I_[6K@/C;_R5
M[7/^W?\ ]$1UW_[,O_,T?]NG_M:@#Z HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 44A( ))  Y)-5#JNG!]AU"U#YQM\Y<Y_.@"Y12*RNH96#*>A!R#2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M('QM_P"2O:Y_V[_^B(Z[_P#9E_YFC_MT_P#:U<!\;?\ DKVN?]N__HB.N_\
MV9?^9H_[=/\ VM0!] 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN(Z8P :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7@'[37_ #*__;W_ .T:]_KP#]IK_F5_^WO_ -HT <_^SC_R4.__ .P5)_Z-
MBKZ?KY@_9Q_Y*'?_ /8*D_\ 1L5?3] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !112$A5+,0 !DD]J (+Z_M-,L9KV^N([>UA7=)+*V
MU5'UKPSQ%\;==UZ\ETWX>Z/<SA.&O/LS2R'T*Q@$*/=L_05U;Z'/\5M7_M'5
MGEB\'6LA%A9*Q4Z@P)!G<CD(>=O<CGC//H]AI]GI=FEI86L-K;1C"Q0H%4?@
M* /ENZ^'GQ:\6/YVJ6]],KG=_IMZBJ/HA;C\!0/@!XX*@F+3QD=#==/TKZMH
MH ^4H/A;\5/#$GGZ3#<Q$'):POU7./5=P)SZ8KK-"^,?BSPK<QV7Q T2[-LQ
MV"[-L8I1[XP%<?3!Z]:^@:BN;6WO;=[>Z@BG@D&'CE0,K#T(/!H KZ3J^GZ[
MID.HZ7=QW5I,,I+&<CZ'T([@\BKM>;S^%W^'6H2Z_P"%UD_L61]^JZ."64)W
MFA'4,O4KW P,8 KT6&:*Y@CGA=9(I%#HZG(92,@B@!]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\@?&W_DKVN?]N__ *(C
MKO\ ]F7_ )FC_MT_]K5P'QM_Y*]KG_;O_P"B(Z[_ /9E_P"9H_[=/_:U 'T!
M1110 4444 %%%% !1110 4444 %%<]K?CKPMX=D:+5=<L[>93AH=^^1?JBY8
M?E6?I_Q6\"ZG,(;;Q):!ST\\-"/S< 4 =C134=)(UDC971AE64Y!'J*=0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A(52S$  9)/:
MDCD26-9(W5T895E.01[&@!U%%% !14:3PRR21QRQN\9PZJP)7ZCM4E !1110
M 444Q)8Y'=$D1F0X=0V2I]_2@!]%%% !1110 4444 %%(2%&20!G'-+0 444
M4 %%%% !1110 4444 %%%)D;@N1DC(% "T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%><^(IO&'@W7[K7[!)-=\/7+J]UIJC]]:84 O%ZCC
M)'J>@Y:NN\-^*-(\6Z4FHZ/=K/">'7H\;?W67J#_ )'% &Q7SGXOUSQ]\3M8
MO+/PA:7H\/VLK0H\#B%+@C@LTA(# \X7/ QD9KZ*==Z,I)&X8R#R*\-\(?%;
M3? 5B?!?BBPN+2ZTAW@$]O'NCE7<2&(X()!SD9!Z]Z //3\#?B# !-%ID1D0
M@J([R(,#[$L!Q]:]#^%_BOQ;X>\46_@SQK!> 7:M]AGNCN96 W%1)D[U(XZG
M!P.G3JV^.O@$(2-4G8_W1:2Y_P#0:P(O'5M\4O'WA_3="T^=;'2;O^T;F]G4
M*V$4A0 ,X!+ <\GC@8H ]GHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O /VFO^97_[>_\ VC7O]> ?M-?\RO\ ]O?_ +1H
M Y_]G'_DH=__ -@J3_T;%7T_7S!^SC_R4.__ .P5)_Z-BKZ?H **** "BBB@
M HHHH **** "L37/&/AWPWQK&L6EH^,^4\F9,>NP9;'X5YA\9/BU-X?D?PWX
M?EVZBR_Z5=+UMP?X5_VR._;/KT^;IYYKJ=Y[B5Y9I&+.[L69B>I)- 'V/9?%
MKP)?W @@\26JN3C,RO$O_?3J!^M=C#-%<0I-!(DL3C<KHP96'J".M? ==GX"
M^)&L^!=00V\KW&FLW[^QD<[&'<K_ '6]Q^.1Q0!]F45GZ)K-CXAT:UU73IA+
M:W*;T;N/4'T(.01ZBM"@ HHHH **** "BBB@ HHHH *Y[Q9XTT;P59P76M2R
MQQ3R&.,QQ%\D#/;I70UPOQ?\/?\ "1?#;4XD3=<6B_;(?ER<IRV/<KN'XT =
M-X>\0:=XHT6#5]*F,MI-N"LRE2""000>0<BM2O!?V;O$&^VU;P[*_P T;"\@
M4GG!PKX]@0G_ 'T:]ZH *XVT^*/A:^\6GPS;7<TFI"=X,"!MA=,[ANQT&T\]
M.*V?%FMKX<\):KK#%=UI;.\88\,^,(/Q8@?C7@W[.^@R:AXHU+Q'<AG6TC\J
M-WY)EDZG/J%!S_OT ?25%%1S3PVT?F3RQQ)_>=@H_6@"2BHH+F"Z3?;SQRKZ
MQN&'Z5+0!YO\8_'&K^!]"T^ZT?[.)KBY,;F:/?A0I/ S72> =<N_$O@;2M8O
MQ&+JYB+2>4NU<AB.!D^E>;?M)_\ (L:+_P!?C?\ H!KM_A#_ ,DJT#_KBW_H
M;4 =M14$=[:33-#%=0R2+U19 2/PJ>@#"\8>*K/P9X<GUJ^BFEBB95$<(&YF
M8X Y('_ZJSO /Q!T[X@:?=7-C;7%LUK((Y8YL9Y&000>1U_*MKQ!X?TWQ1HT
MVDZM!YUI*064,5((.001R#D54\*>#-$\%V,UIHMLT4<TGF2,\A=F.,#D^U &
M_114<T\-O'YD\J1(/XG8*/S- $E%1P7$-S'YD$T<J=-T;!A^8J2@#Q/X<?%3
MQ%XJ^(MQHFHBS^Q!)F411%67:>.<U[97RY\$_P#DLES_ -<KG_T(5]1T %%%
M5EU&R>;R4O+=I<XV"52WY9H LT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %17%O%=VTMM.@>&5"DB'HRD8(_*I:0D*I9B  ,DGM0 D<:0Q)%
M$BI&BA551@*!T %.IL<B2QK)&ZNC#*LIR"/4&G4 %0W-W;6<)FNKB*"(=7E<
M*!^)K%\:^(I/"_A6ZU*WMS<W8*PVL &?,F=@J#Z9.3["O&9?@CXV\73_ -I^
M*O$D$=U)\WEG=,8@?X<#"KSV4XH ]YM-8TS4'*66HVERPZK#.KG]#5VOG6;]
MF[5[8";3_$ULURAW1[X'BPPZ'<"Q'UQ7H/POUKQ)%<ZAX0\7 OJNF1I+#<E]
MYN(&R 2W\6"/O=3GGD'(!Z34%G9V^GV<5I:0K#;PJ$CC085%'0 =A4]% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?('Q
MM_Y*]KG_ &[_ /HB.N__ &9?^9H_[=/_ &M7 ?&W_DKVN?\ ;O\ ^B(Z[_\
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M"K]Z1CT1?<G_ !Z5KUX3X]U(^,?C?X?\'!BVGV$ZRW$?:20+YC9]<( /;+4
M>C^%]+U#5D@\1^)QF_E'FVM@"?)L$/W0%_BEQ]YSR"2!@=>OHKSSQ1\:/"'A
MIWMUO&U*\0X,-D X4^[_ '1],D^U 'H=%</XF^*6B^')!:I;WFIZB$$DEI81
M^8T*D9!D/1>H]^>F*=X$^)^A^/FG@L5GMKV!=[VUP!N*<#<I!.1D@'N/3D4
M=M17/^(O&.G>&)H(KZ#4)6F4LIM;1Y@ /7:.*Q/^%LZ!_P ^6N?^"N7_  H
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M:W5O>VL5U:SQSV\JAXY8V#*ZGH01P14M !1110 4444 %%%% !1110 4444
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M9U4Q  D#('WJ\K_X1?Q!_P! +4__  $D_P *I:OX8U\:/>,VB:DJK"S$FTD
M  SZ5%3*\#&#:EK;N3/+\(HMI_B>67]]<:GJ-S?7<ADN+F5I97/5F8Y)JO11
M7RQ\\%%%% 'M7P0^(MKX;L=2T?5#</;EUGMA$@;:3P_4CK\OZUZS_P +;\-_
M\\[_ /[\K_\ %5\S^!-)U'4M2N6L+"ZNA'#A_(A9]N2,9P..AKO?^$7\0?\
M0"U/_P !)/\ "O?R_ 86M04ZKL_4]G!8/#U:7-4>OJ>M_P#"V_#?_/.__P"_
M*_\ Q5'_  MOPW_SSO\ _ORO_P 57DG_  B_B#_H!:G_ . DG^%'_"+^(/\
MH!:G_P" DG^%=O\ 9. _F_%'5_9V#[_B>]^'/%>G>*([A]/6<" J'\U O7.,
M8)]*W*\X^$NF7^FVVJ"^L;FU+O&4$\3)NP&SC(YKT>OG<;2A2KRA3V7^1XF+
MIPIUI0AL@HHHKE.<**** "D95=&1U#*PP01P12T4 ?)VALWPT^/'V-B4M(KT
MVS<]8)?N$Y] R-^%?6-?.G[1_ATPZKI?B*)3LN(S:SXZ!URRGZD$C_@%>S?#
M_P 0?\)/X$TC56?=-) $G/\ TU7Y7_4$_C0!YY^T9K_V/PMI^B1OB2_G,L@'
M>./L?JS*?^ UU?P;\/\ _"/_  UTU73;<7H-[-QU+XV_^.!17COCLM\0OCY!
MH<;;[6"9+'Y3T1,M,?J#YGY"OIU$6.-8T4*B@!5 P !0!QOQ.\=)X#\+->Q(
MDNH7#>3:1/T+8R6/LHY^N!QG->/^%?AAXB^*,"^)?%>NW,=O/G[.&7?(XSR5
M4X5$],#GT P3#^T=?RS>-=-L"?W%M8B11_M.[;C^2+^5>B6'QN^'VFZ=:V-O
M<W:0VT2Q1J+1@ J@ #\A0!YYXO\ A5KOPR@'B;PQK=Q)!;L#,4!CEB&1@G'#
MIGKGUY!&<>R?"_QR/'?A-+V94CU"W?R+M%Z;@,A@/1AS]<CM7*^(/C5X$U?P
MYJ>F_:;IC=VLL(#6K8RRD#]37*_LTSR#5/$%N#^[:&%R/<%@/YF@#<_:3_Y%
MC1?^OQO_ $ UYYX?O?&WQ!T/3_!?AX&TTRPA*W4PD*1OEB<RN!G'. @SG!.#
MCCT/]I/_ )%C1?\ K\;_ - -=?\ !BQM;/X6Z0]O D;W"O+,RCF1]Y&2>YP
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MC452.Z/)O^%:^+O^@3_Y,Q?_ !5'_"M?%W_0)_\ )F+_ .*KZ"HKU?[>Q/\
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MGRQOA92<'!SEFKZ.K%USQ%!H]WIM@NR;4-1N4A@MM^&*9S(_T5 Q^H [UM4
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M(_''YUU'PETUM*^%VA02+AW@,YR.?WC%Q^C"@#M:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^BR 1@C(-?&WC'P5K?A[Q?K&FV&F7[64DI$1A@=DDA+!T&0,'&%_%?:@#O\
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M]%]AC/3GI7T3X;TEM!\,:7I#2B9K*UC@:0# 8JH!('IQ0!\X?!/_ )+)<_\
M7*Y_]"%>W?%RQDU#X5:_!%]Y8%F/&>(W5S^BFO'_ (.Z+JME\7KJ:ZTV\@B6
M.X!DE@95!+#')&*^D9X(KFWDMYT#Q2H4=#T92,$?E0!\]? ;PWX9\2Z)JT>K
MZ5:7MY;W*L&F7)6-EX'TRK5ZY_PJ_P #_P#0L:?_ -^Z\.U#P_XM^"GB^;6=
M%@>\T1\@R;2T;1$YV2XY5AV;C]2*ZN+]I73#; S>';M9\<HEPK+GZD _I0!Z
M5;_#?P9:W,=Q#X;T])8F#HWE9P1R#74UXQX2^*WBWQQXKT^'3_#(M-$+G[5<
M$-+A0#_RT(51SVQFO9Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5'-!%<1^7/$DJ'JKJ"/R-244 0065K:Y^SVT,.>OEQA<_E4]%% !11
M10 4444 %%%% !44]M;W2!+B"*91R!(@8?K4M% #(H8H(Q'#&D:#HJ* !^ I
M]%% !1110 55.F6!E\TV-L9,YW^4N?SQ5JB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O(OBK\6=6\!>([33;"PLKB.:
MT$[-/OR"79<<$<?**]=KQ[XM?"C7?'GB6SU+2[O3H88;-8&6ZD=6+!W;(VHP
MQAAWH XG_AI'Q)_T!M*_*3_XJC_AI'Q)_P! ;2ORD_\ BJK_ /#./C#_ *"6
MA_\ ?^;_ .-5Y=K6DSZ#K=[I-T\;SV<S0R-$25+*<'!(!Q^% 'K/_#2/B3_H
M#:5^4G_Q5'_#2/B3_H#:5^4G_P 57,^$/@[XA\::"FL:=>:7%;N[(%N)9%?*
MG!X5"/UK>_X9Q\8?]!+0_P#O_-_\:H ^D]*NWO\ 2+.\D55>>%)&5>@) /%7
M*IZ3:26&CV5G*5,D$"1L5/!( !Q5R@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#
MJ5895A@CUI:AN[J*RLY[N<L(8(VD<JA<A0,G"J"2<=@": /")?''B;X,N?#N
MIZ(-4T6)V&FWGFF(M$22%+[6!(Z8P",>F#4S_M+V00E/#%P6QP&NP ?QVFO;
M\6>J6"EEANK2= R[E#I(I&0>>""*Q4\!>#XYQ,GA?1UD!R"+*/@^PQQ0!YMX
M:\2>)_BWXBTRXETH:7X7TVY6]=@Q8SS1DE%WG&[#8. ,#'/85[73418T5$4*
MBC 51@ 4Z@ JO]AM1J'V\6\8N_+\HS!1O*9SM)],BK%% !137=8T9W8*B@EF
M8X  [FH+"_MM4T^"^LY/-MKA!)%)M*[U/0@'G!H LT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!\;?^2O:Y_V[_\ HB.N
M_P#V9?\ F:/^W3_VM7 ?&W_DKVN?]N__ *(CKO\ ]F7_ )FC_MT_]K4 ?0%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %34],LM8TV?3]0MTN+2=-DD3CAA_C[]J\6U;P
MU\1/AFSS^#-0FU;P^OS+83+YSP#TV=2/="#ZCN?=** /GBR_:3U" B+5?#,$
MDBG;(8+AHL'O\K*WOQFMA/VE-&* OH%^&[@2H1^=>I:WX+\->(R6U?1;.ZD(
MQYK1XDQ_OC#?K7)R_ CP%(^Y-.N8A_=2[DQ^I)H Y"Z_:7M%!%GX8FD/8S78
M3] IK*@^+WQ'\;W9L/"FBP0$\&2&(R&/W:1_D4?4"O4-/^#/@+3I%E70DGD7
MO<S/(#_P$G;^E=M9V5KI]JEM96T-M;H,)%#&$11[ <"@#@/ OPQ;1=0_X2+Q
M-?OK'B20?Z^5BZ6_J$SWYQGC X '.?1J** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KP#]IK_ )E?_M[_ /:->_UX!^TU_P R
MO_V]_P#M&@#G_P!G'_DH=_\ ]@J3_P!&Q5]/U\P?LX_\E#O_ /L%2?\ HV*O
MI^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OBCXC_P#)2/$?_80F_P#0S7VO7Q1\1_\ DI'B/_L(3?\ H9H
M^B/@'_R3"W_Z^9?_ $*O3Z\P^ ?_ "3"W_Z^9?\ T*O3Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /-+O5[CX57K1WT$MQX,N),V\\*%GTQF/,3#O%G
ME2.1G;SQ7>:3K>EZ]:"ZTG4+:]@/\<$@;'L<=#[&K5S;07MK+:W4,<]O*I22
M*10RNIZ@@]17B/BKX"S07K:KX&U)["?)86LDK)M]HY!R/H<_6@#W.BOE*YUC
MXR^$\PW4NNHJ#)DEB%TG_?PAAV]:SS\:/B-YAB.O,),[=OV&#.?3'E]: /KV
MJ.JZSINAV37FJ7UO9VZ]9)G"CZ#/4^PKY>M=9^,?BK$-I-KTBN/]9%']G3_O
MX H'YUVWACX"7E]>+J?CK5)+J0\FTCF9V;V>4\_@OYT =,FNW/Q:U(Z?I*7%
MMX.MW_T^]=2C:@1_RP3N$/\ $>I'!QG!]21%C1410JJ,*H& !Z5#965KIME#
M9V5O';VT*[8XHE"JH] !4] !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?('QM_Y*]KG_;O_P"B(Z[_ /9E_P"9H_[=/_:U
M<!\;?^2O:Y_V[_\ HB.N_P#V9?\ F:/^W3_VM0!] 4444 %%%% !1110 444
M4 %%</\ %S5]0T/X<W]_I=U):W2/$%ECQN +@&OFC_A:GCG_ *&:^_[Z'^%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@^,]?
ME\+^$-1UJ&!)Y+2,.L;D@-E@.<?6MZN>\<Z%=>)O!>IZ-920QW%U&%1IB0@(
M8'D@$]O2@#Q'_AI36/\ H7['_O\ /1_PTIK'_0OV/_?YZS_^&<?&'_02T/\
M[_S?_&JY7QO\+];\ VEK<ZK=:?,ER[(@M9'8@@9YW(OK0!W7_#2FL?\ 0OV/
M_?YZ/^&E-8_Z%^Q_[_/7D_A?PW>>+?$-MHMA)!'<W&[8T[$(-JECD@$]!Z5Z
M1_PSCXP_Z"6A_P#?^;_XU0!ZK\*?B9>?$.355N]/@M/L0B*^4Y;=OWYSG_=_
M6O2J\M^$'PVUCX?R:PVJW-A,+T0B/[+([8V;\YW*O]X>M>I4 %%%% !1110
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M/4(,L?P% &U17FK?'?P$LNP:C<LN?OBTDQ^HS^E=?X=\7Z!XLMVFT35(+L(
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MV\]QI6J6MW#;G$SQR B/C//IQ7)WOQL\!V-\UJVL-,5.&D@@=XQ_P(#GZC-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\4?$?\ Y*1XC_["$W_H9K[7KXH^(_\ R4CQ'_V$
M)O\ T,T ?1'P#_Y)A;_]?,O_ *%7I]>8? /_ ))A;_\ 7S+_ .A5Z?0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/.U%4@#'Y>@ KRGXAZ3J&@?$_0-)NM0GOK.!H&L9;@[I1$TOW&;OA@PSZ8H
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M6/H^_A@?^!\GW% 'TU1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6D>H:?<V4Q817$31.5/.&!!Q^=?,GQ6_Y+W![S6?_LM?4?:@#Q+_ (9LT/\
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MM0 5YCXP\2W_ (L\>VNIZEIATZX/DQ^00PX#<'Y@#SF@#[*KY<O_ /DYU?\
ML+Q?R6OJ,=*^7+__ ).=7_L+Q?R6@#ZCKY<^"?\ R62Y_P"N5S_Z$*^HZ^7/
M@G_R62Y_ZY7/_H0H ^HZ^<_VE?\ D-Z#_P!>TG_H0KZ,KYS_ &E?^0WH/_7M
M)_Z$* /9K#1[/Q!\.-/TK4$9[2YTZ!)%5BI(V*>"/<5\X?&;P9HW@K7]/M-&
MBECAGM?-<22%SNW$=_85]/>%O^11T7_KQ@_] %> _M)?\C9H_P#UXG_T-J .
M^TWX%^![G2[2>6TNS)+"CL1=,.2H)KTBYTR-] FTJU/V>-K5K:(K_P LQMVC
M'TI=%_Y 6G_]>T?_ *"*ND@ DD #J30!Y/X7^ /AG2(5DUHOK%YU.\F.%?H@
M.3^).?059\:?!GPMJ7AV\;2=+BL-2AA9[>2 E0S 9"L.A!Z9QD51\4_M!>']
M&NI+31[276)8SAI4D$<.?9L$M^ P>QKGYOCGXKN()-G@:012*<-B4\$=<[:
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M=\_3= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7Q1\1_P#DI'B/_L(3?^AFOM>OBCXC_P#)2/$?_80F_P#0S0!]$? /_DF%
MO_U\R_\ H5>GUYA\ _\ DF%O_P!?,O\ Z%7I] !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH ^0/C;_ ,E>US_MW_\ 1$==_P#LR_\
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M(.AW5X]7N'[-?_(PZX?^G1/_ $.DTFK,J$Y0ES0=GY'MO_"">%_^@):_D?\
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M337\ORVZQD+D ]6DX(V@8[D]J &_M+?\@GP__P!=YO\ T%:]GT7_ ) 6G_\
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M"\LB0EL<R2/O;\0N/^^Z /?J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %> ?M-?\ ,K_]O?\ [1KW^O /VFO^97_[>_\ VC0!S_[./_)0[_\
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MX0G'H1ZUZM\'K*:P^%&@PSKM=XGF _V9)&=?_'6%>7^#/@%JESJJ:EXSFC2
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M8)"CZGCTKZ-LK.VTZQ@LK.%8;:!!'%&@P%4#  H GHHHH ^7?C?_ ,EAM?\
MKC;_ /H1KZA7[H^E>*_$KX6>(O%?Q"MM:TTV?V-8XE8RRE64J>>,&O:AP *
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(RAE*L 5(P01P:6B@#S#1M.?X5^)+NW.X^#]6F\V&;J-.G/&
MU_2-N &/3"@^I].!# $$$'D$4DD:2QM'(BNC##*PR"/0BH+"PM=,LH[.RA$-
MM$"(XU)P@SG ] .PZ <#B@"S1110 4444 %%%% !1110 4444 <-X]U"]U6W
MD\'^'B'U:_39<S#[EE;MPSN>Q89"CJ>3VKHO#'AVQ\*>'K31M/4B"W3!9OO2
M,>68^Y/-7-/TRRTJ PV-LD*,Q=]HY=CU9B>68]R<FK= !1110 4444 %%%%
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M+YLI?.W.,>GWC74T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH)@+VP+[HYD.#E>V2IRK#VSQD5]A5\M_M$O$WQ'MA'C<NFQ"3'][?(>?P*T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5A2.AD2/ _\ '@*\(_9TM#/X^O[M^1!I[\GKN9T'\@U>T?%W_DE7B#_K@O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD]2?<UWXO,</A:?L*"3?X?/N=F)QM'#P]C22?Y?\$^0/&_PSU_P1<$W4!N;
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MH=A)/):VOE;'G8%SNB1SD@ =6/:O5_V9?^9H_P"W3_VM7 ?&W_DKVN?]N_\
MZ(CKO_V9?^9H_P"W3_VM0!] 4444 %%%% !1110 4444 %%%% !115;3]1L]
M5LUN["YCN;=F95EB;*DJ2IY]B"* +-%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %1S_P#'O)_N'^525'/_ ,>\G^X?Y4 ? TG^L;ZFOL_X
M7?\ ),O#_P#UYI7QA)_K&^IK[/\ A=_R3+P__P!>:4 ==1110 4444 %%%%
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MU\K7GP<\17?C;6]'T6T5K6QF!6::4(HC?YH^3RQV]< \@U9_X9_\<?W-/_\
M G_ZU 'U!_;.E_\ 02L_^_Z_XUES>+M,_P"$FTS0[2\M;FZN_,:1(I0S1(J%
MMQQTR<#GKSZ5\Y_\,_\ CC^YI_\ X$__ %JW_AM\/_$7@CXKZ2=9M%2&XAG$
M4T4@=&(C.1D=#]<9[=#0!]'4444 %%%% !1110 5\U?';XAWM[K5QX1L6>"P
MM"HNBIYN'P&P?]E<].Y^@KZ5KB=;^$W@WQ#K%QJNHZ8\EY<$&5TN)$#$ #.
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MU9CR3]:UZ "BBB@ KP#]IK_F5_\ M[_]HU[_ %X!^TU_S*__ &]_^T: .?\
MV<?^2AW_ /V"I/\ T;%7T_7S!^SC_P E#O\ _L%2?^C8J^GZ "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 %%%% $-W:PWUE/9W"LT,\;12!7*DJPP<$$$<'J#FN%_X4E\//\
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M54CL: .GHK@_^%P^#_\ GYO_ /P73_\ Q%'_  N'P?\ \_-__P""Z?\ ^(H
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M)C[2R>7< ?\ /13M8_CC(]B*ZF@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "HY_\ CWD_W#_*I*CG_P"/>3_</\J
M/@:3_6-]37V?\+O^29>'_P#KS2OC"3_6-]37V?\ "[_DF7A__KS2@#KJ***
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJLDDUK7K\KF2"WBA5O0.S$_^BQ^5?1E %:_TZRU6RDL]0M8;JVD&'BF0,I_
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M^A_.@#UJ6*.>)XI8UDC<;61UR&![$=Z^2_B'I'_"M?BO'<:0/*A5X[^TC5B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KQK]H[_D2=-_Z_P ?^@-7LM>-?M'?
M\B3IO_7^/_0&H \>^#O_ "5C0?\ KI)_Z*>OL:OCGX._\E8T'_KI)_Z*>OL:
M@ HHHH **** "J6IZM8Z-9-=ZA<I!"O=CR3Z =2?85S?BSXA:=X<#VT&V[U$
M<>4I^6,_[1_IU^E>*ZUKNHZ_>FZU&X:5OX5Z*@]%':O7P.4U,1:<_=C^+]#T
ML)ELZWO3TC^9U/BWXDWVN;[/3M]G8'@\_O)1[D=![#]:XNTL[F_NDMK2!YIY
M#A409)K>\+^"=4\3RAHD\BR!^>YD'R_11_$:]M\.^%M+\,VOE6,.96&))WY=
M_J?3V'%>Q7QF&R^'LJ*O+M_FSTZN*H8*/LZ:N_ZW.1\)?"Z"R\N]UT)<7 Y6
MV!S&G^]_>/Z?6O2  JA5   P .U+17S&(Q57$3YZCN>!7Q%2O+FFPHHJGJ6J
MV&D6IN=0NHK>$?Q.V,^P'4GV%<S:2NS.,)3DHQ5VRY7RG^T!_P E+?\ Z](O
MY&O3_$?Q?=]]OX?@V#I]JG7)_P" K_C^5?/WC.^NM2\0R75[<23SNBEGD;)-
M80Q,)SY(ZGJXC)<5AL+]9KKE5TK==?R.>HHHKH/("BBB@#[;^'W_ "3GPW_V
M#+?_ -%K725S?P^_Y)SX;_[!EO\ ^BUKI* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***Y[QY<SV?@#7[FUFD@GBL)GCEB<JR,%."".0: -+1](M="TQ-/L5
M9;:-W:-#CY0SE]H]@6P/;%7Z^6;/PQ\;KZSBNH+KQ!Y4JAT\S6?+;!&1E6E!
M'XBI_P#A#?CG_P _6N?^#Y?_ (]0!]/UB: ^FZE)=:]IYDW7N(9E< ;6A9T(
M('<'(/)Z#%?-.MZ)\8-&T_[3J]_K<5FTBQ-(^LAD4L< N1*0JYQ\S8 [FO5?
M@CX=\7^%+;4=,U_3OL^GR%9[9_M,4F'Z, $8G!&T^G'O0!ZY1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!\;?^2O
M:Y_V[_\ HB.N_P#V9?\ F:/^W3_VM7 ?&W_DKVN?]N__ *(CKO\ ]F7_ )FC
M_MT_]K4 ?0%%%% !1110!C>+;.XU#P?K-E:1F6XGLI8XD! +,4( Y]Z^9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5'/_ ,>\G^X?Y5)4<_\ Q[R?[A_E0!\#2?ZQOJ:^S_A=
M_P DR\/_ /7FE?&$G^L;ZFOL_P"%W_),O#__ %YI0!UU%%% !1110 4444 %
M%%% !7#?&+_DD^O?]<X__1J5W-<-\8O^23Z]_P!<X_\ T:E 'R)I?_(7LO\
MKNG_ *$*^\D_U:_05\&Z7_R%[+_KNG_H0K[R3_5K]!0 ZBBB@ HHHH ****
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MT: .?_9Q_P"2AW__ &"I/_1L5?3]?,'[./\ R4.__P"P5)_Z-BKZ?H ****
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M \]^%?@35/ ]MJ<>ISV<K73QLGV9V;&T-G.Y1ZUZ%117B8O%5,56E6J_$_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "L+QI?7.F>"M:OK.4Q7,%G))%(
M"58*<'FMVL_7=*37=!OM*EE:*.\@:%G49*AAC(H ^2/^%P>/O^ACG_[]1_\
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M"U3PY;W^NZW%);WE^JI%;R@B14SN+.#R"3C@\C'/6@#V*BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D#XV_\ )7M<
M_P"W?_T1'7?_ +,O_,T?]NG_ +6K@/C;_P E>US_ +=__1$==_\ LR_\S1_V
MZ?\ M:@#Z HHHH **** "BBB@ HHHH R/%%KJU]X8U"TT.:"#4IXC'#+.S*J
M9X)RH)! SCCKBOG?_AG'Q@3DZEH?_?\ F_\ C5?3]% 'S!_PSCXP_P"@EH?_
M '_F_P#C5'_#./C#_H):'_W_ )O_ (U7T_10!\P?\,X^,/\ H):'_P!_YO\
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M<#J>PKIO"7A?5?"VGVFF-KXOM/ME*)'+9A9 N#A0X;H#CJ#P,5U-% !1110
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M %%%% !1110 5X!^TU_S*_\ V]_^T:]_KP#]IK_F5_\ M[_]HT <_P#LX_\
M)0[_ /[!4G_HV*OI^OF#]G'_ )*'?_\ 8*D_]&Q5]/T %%%% !1110 4444
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ML)X=L4U_R#JJQA;@P-N1F'?.!R1@GMG.*U:** "BBB@ HHHH **** "BBB@
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MHU:^I]2>+?BHS^99>'B57HUX1R?]P'I]3_\ 7KS!FEN9RS,\LTC9))+,Q/\
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M+!!!%K'D'_=%:=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \8_:&TO4-3T;14T^QN;MDN)"PMX6D*C:.N!Q7S_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#A-:^&.B:_\0%U_4["*Z@:R\J2)W('G*PV
MN0,;OD)')Q\HXJ]_PJ_P/_T+&G_]^ZZVB@#DO^%7^!_^A8T__OW1_P *O\#_
M /0L:?\ ]^Z;XZ^(VB^ K)7OV:>]E7,%G$?G<=,G^ZON?PS7ANH?M$^++BX9
MK*STVS@S\J&-I& ]V)P?P H ]T_X5?X'_P"A8T__ +]U4MOAIHFB^,M*U[0K
M".R:$2QW*1L0CHR$ [3W!QTQP3GM7E6@?M'ZG%.J>(=(M[B G!ELLQR*/7:Q
M(8_BM>\^'_$6E^*-(BU32+I;BUDXR!@JPZJP/((]* -2BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\ _::_P"97_[>_P#V
MC7O]> ?M-?\ ,K_]O?\ [1H Y_\ 9Q_Y*'?_ /8*D_\ 1L5?3]?,'[./_)0[
M_P#[!4G_ *-BKZ?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L2[\'>'+[6EUFZT6RFU)65A<O
M$"^Y<;3GN1@8^@K;HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#0S7+T4 ?6'P#_ .286_\ U\R_^A5Z?7P!10!]_P!%9?AO_D6-+_Z](O\
MT$5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !2$!E*L 01@@]Z6B@#R;0_@5X6AN-
M4.L::]TK7KM:?Z2Z*("%*C",#D$LO/IGIBMG_A27P\_Z%[_R=N/_ (Y7H%%
M'G__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE0^/?C%H?@FX?3XX
MVU'5E W6T3;5BSTWO@X/L 3]*\KE_:0\3FYW0Z1I"09^XZ2LV/\ >W@?I0!Z
MU_PI+X>?]"__ .3MQ_\ '*N>"/ UMX(U77(M-CD73+LPRP"23<58!@R^N!P>
M?7OBN-\*_M"Z-JEQ'::_8OI4CG:+A7\R'/\ M< K^1'J17LD<B2Q+)&ZO&X#
M*RG(8'H0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?('QM_Y*]KG_ &[_ /HB.N__ &9?^9H_[=/_ &M7 ?&W
M_DKVN?\ ;O\ ^B(Z[_\ 9E_YFC_MT_\ :U 'T!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"I/_ $;%7T_7S!^SC_R4._\ ^P5)_P"C8J^GZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUW_[,O\ S-'_ &Z?^UJ /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#9/ -?*;??;ZTE %K365-4M'=@JK,A+$X &X5]J)XZ\(;%_XJO0^G_01B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUW_[,O\ S-'_ &Z?^UJX#XV_\E>US_MW_P#1$==_^S+_ ,S1_P!NG_M:@#Z
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHKE?B1K=]X<^'^K:MILJQ7ENJ&-V0,!F15/!XZ$U\Y?\+U\??]!2#_P$C_\
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M7PO9Y$4\]VP[00G^;8%9RJPC\3.NA@,57_A4V_D_S.VJAK?_ " -1_Z]9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ])T/Q+HOB2V^T:-J=M>Q@9;RG^9?]Y>J_B!0!JT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7@'[37_,K_ /;W_P"T:]_K
MP#]IK_F5_P#M[_\ :- '/_LX_P#)0[__ +!4G_HV*OI^OF#]G'_DH=__ -@J
M3_T;%7T_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH \D^-'P^U[QQ<:0^C1P.MJD@D\V4)]XKC'Y&O*_\ A07CK_GWL?\
MP*'^%?5]% 'PEK^A7OAK6[G2-15%N[<@2!&W#D ]?H:WO"7PT\1^-=.FOM'B
MMWAAE\ES+,$.[ /3Z$5:^,?_ "5;7/\ KHG_ *+6O7_V;_\ D2M4_P"PB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!B>+_#J>+?"M]H<ERULMVJ@RJFXKAPW3(S]VO(_
M^&:+/_H9Y_\ P#'_ ,77N]% 'R3\4/A=#\/+739HM5DO?MCNI#PA-NT ^ISU
MKF_ 7A5/&?BZUT.2[:U6=78RJF\C:I;ID>E>R?M+?\@SP]_UVF_DE>>? S_D
MJ^F_]<YO_1;4 >A?\,T6?_0SS_\ @&/_ (NN\^''PUA^':ZBL6IO??;3&3OA
M";-F[W.<[OTKNZ* "BBB@ HHHH **** "BBB@#Y2^/\ _P E.D_Z](OY&NL_
M9F_UGB?Z6O\ [5KD_C__ ,E.D_Z](OY&NL_9F_UGB?Z6O_M6@#Z!HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^*/B1_R4GQ'_P!A";_T(UR]=1\1R#\2
M?$1!S_Q,)O\ T(UR] !1110 5]57?QGMTC"V&D2R<8#3RA/T&?YU\JU[UI_P
MS\4WRJWV!;="/O7$BK^@R?TKDQ4ZL;*EU/HL@PV7U?:2QS22M:[MWOU5RY??
M%GQ+=9$#6MFO;RHMQ_-LUS5]XFUS4L_;-6O)5/5#*0O_ 'R.*[^Q^"]RV#J&
MKQ1^JV\1?]3C^5=+8_";PS:X,ZW5X1U\V7 _)<5Q^PQ-3XG^)]%_:V1X/^#%
M-^4=?O=OS/!JT+'0=7U/!LM,NYU/1HX6*_GTKZ.L?#6AZ;C['I-G$P_C$0+?
M]]'FM6M(Y=_-(Y*_&2VHTOO?Z+_,\"L?A5XHO,&6""T4]YYA_)<FMJ7X."WT
MF[N+[5]S1P._EP18'"D_>)_I7L=5=2@>ZTJ\MX\>9+ Z+D\9*D"NB&"I1\SQ
M\1Q/F%5-)J*\E_G<^"VX8CWI*]';X&>/RQ(TB+K_ ,_D7_Q59VM_";QCX>T>
MXU74M-CBL[< R.+F-B 2 . V>I%=9\\<313XHGGFCAC&7D8*HSU)X%>A#X&^
M/R 1I$7/_3Y%_P#%4 4?A#_R5+0_^NK?^@-7V17S=\.OA)XRT#QYI>J:EIT4
M-G;NS2.+F-L#:1T!)ZFOI&@ HHHH *P?%OB:#PQHSW3X:X?*6\1_C;_ =3_]
M>M:^OK?3;&:\NY!'!"I9V/I_C7SMXJ\27'B;69+R7*PK\L$6>$3_ ![FO3RS
M /%5+R^%;_Y'?@,&\1.\OA6_^1E7=W<:A>2W5S(TL\SEG8]237MGPY\'?V%I
M_P#:%['C4+E>A',2?W?J>_Y=JY3X8^#OM]RNN7\?^BPM_HZ,/]8X_B^@_G]*
M]EKOSC'K_=J6RW_R.S,\8OX%/;K_ )!7@_[2_P#R#_#O_76?^25[Q7@_[2__
M "#_  [_ -=9_P"25\Z>(>:_!?\ Y*WH7^]-_P"B7K["KX]^"_\ R5O0O]Z;
M_P!$O7V%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M/VFO^97_ .WO_P!HU[_7@'[37_,K_P#;W_[1H Y_]G'_ )*'?_\ 8*D_]&Q5
M]/U\P?LX_P#)0[__ +!4G_HV*OI^@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV;:"23RQ)/)/4U>H **** "BBB@ KE=7^&WA#7=4FU+4]$BN+R;'F2M(X+8
M Z,!T KJJ* .$F^$'@)89&'AR $*2/WLG_Q5?'C<,1[U]]3_ /'O)_N'^5?
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M27R7IE^Q7=MAEB4$^8K#:>HXP7_.JA"4Y*,5=LJ,7)\L=SZOHKDK?XE^%9\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'R!\;?^2O:Y_P!N_P#Z(CKO_P!F7_F:/^W3_P!K5P'QM_Y*]KG_ &[_
M /HB.N__ &9?^9H_[=/_ &M0!] 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,Z5^<G_Q-,S/%Z*]H_X9N\2?]!G2OSD_^)H_X9N\2?\ 09TK\Y/_ (F@"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /"?VEO^09X>_P"NTW\DKSSX&?\ )5]-_P"N<W_H
MMJ]#_:6_Y!GA[_KM-_)*\\^!G_)5]-_ZYS?^BVH ^N:*** "BBB@ HHHH **
M** "BO/_ (F?$T?#K^S?^)1_:!O?,_Y>?*V;=O\ LMG.[VZ5P'_#37_4H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBBMSR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%5H14IG/4445PG(%=1X9\0WL2+HTMW,;!V+I"7.Q7]<=.:Y>K.G,$U.U9E+
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MRZ3XD>(52YF51?2  2$ <URIO;M@0;J<@\$&0\T 0G[Q^M?<_A;_ )%+1_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-WAO'_(9U7\X_P#XFM_P=\&-&\&>(HM:LM2OYYHT9 DVS:0PP>B@UZ0.@I:
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M\S5W2O#>L:VP&G:?-,I./,VX0?\  CQ^M>WZ1\._#FD;7%G]KF'_ "TNCO\
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M-LI'$CC^+Z _K]*]IKV<WS!-?5Z+TZV_(]/,L8FO8TMNO^04445\\>*%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK@/C;_R5[7/^W?\ ]$1UW_[,O_,T?]NG_M:@#Z HHHH **** "BBB@ HHHH
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M.T/_ )&#3?\ KZB_]#%?6/QK_P"21:[](/\ T?'7R=H?_(P:;_U]1?\ H8H
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M@$?@IKE?AH^O?$WXF_\ "9:Q\MCI0*PH@Q&KD';&OKC<6)Z],]10!]"T444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&W@GN;.-YY8XP'E8C.6/4_C7:URWPU_Y)KX=_P"O"+_T$5U- !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/S./88Q^)]*^A:@L[.WT^SAM+2%(;>% D<:# 4#H!4] !1110 4444 %%%%
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MXKW?Q"^)FBV9TR/3[2V2>78)C*SOY9 ); X )XQWH ]RHHHH **** "BBB@
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MD?\ D<=*_P"P>/\ T8]>+U[1^TC_ ,CCI7_8/'_HQZ\7H **** "OL?X0?\
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M5OQ"<?[WO7T[7FWQ)^&<OB>\M/$.@7*6/B.Q96CD;A)@IRH/!PP/0].QXP0
M>DU\Q_&-)_%_QGM/#^GYDFCAALP!DA68EV;\ X)/HOM7JO\ PEWQ"?319IX!
M=-9*[#.]Y']E4_W\YR1WVYS[T[X>?#-O#-_=>(==O!J/B.]):68#Y(MQRP7C
MDGN<#C@ #.0"7XE>"TU?X5RZ+I\69--ACDLT R?W2XVCW*;@/K7(?LW:LLOA
MW6-(9SYEO=+<*"?X74+Q^*?K7M]>1:K\/=<\(^.6\8>!(H;E+C<+W2))!&)
MQRVQCP 2 <=B.,@[0 >N,P52S$!0,DD\"OESX;Z:_CCXVW6N;&>QM[R747=@
M<#+DQ#GH<D$#T4^E>I:_J'C_ ,::<^B:5X;?P_!<KY=WJ%_<H2J'AE15R3D=
M_KTZUU?@7P1IW@30%TVQ)EE=M]Q<N &F?U]@.@';W.20#IZ*** "BBB@#Y ^
M-O\ R5[7/^W?_P!$1UW_ .S+_P S1_VZ?^UJX#XV_P#)7M<_[=__ $1'7?\
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MN3?RJ>H+W_CQN/\ KDW\J /@E_\ 6-]37V/\(O\ DEF@_P#7 _\ H1KXX?\
MUC?4U]C_  B_Y)9H/_7 _P#H1H [:BBB@ HHHH **** "BBB@ K@OC1_R237
MO]V'_P!'1UWM<%\:/^22:]_NP_\ HZ.@#Y!M_P#CYB_WQ_.OOB+_ %2?[HKX
M'M_^/F+_ 'Q_.OOB+_5)_NB@!]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_B*/^&E[/_H6)_\ P,'_ ,10![O17A'_  TO9_\ 0L3_ /@8/_B*/^&E[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;(Q2)W"EBH)"
MCJ?:G44 ?'_A3P9K_P 7/$>I:@]W'$/,\V[NY@6 9\X55[].!D  =>E>@#]F
M4XY\7<_]@W_[;7=^'=&7X>>,M1MN!H6OSB:TD P+:XYS"WH&!^4_[.WJ1GT6
M@#P#_AF7_J;O_*;_ /;:O^$/A/<_#WXE:+>_VHFH6MPD\1;R?*9'\HD#&YL@
M@'G/:O<*R;W7[6TU_3=&W1O=7QD.P2 ,B(A8MM],@#MUH UJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP#]IK_F5_^WO_
M -HU[_7@'[37_,K_ /;W_P"T: .?_9Q_Y*'?_P#8*D_]&Q5]/U\P?LX_\E#O
M_P#L%2?^C8J^GZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *"0!DG %%>5_$OQQM$N@:9+\Q^6[F4]/\ IF#_
M #_+UKIPF%GB:BIP_P"&-\/AYUZBA$Q?B+XW.M7#:5ITG_$NB;]XZG_7L/\
MV4=O7KZ5S/AGPY=^)M62RM@5C'S33$<1KZ_7T%4M*TN[UG4H;"RC,D\IP!V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBY /)RR@5XGX*O[;2_&VBW][*(K6WO(Y)9""=JA@2<#FL*B@#[%_X7'\/_\
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MVDXZ<?2OA6OH+]F?_5>)/]ZW_P#:E 'OM%%% !1110 4444 %%%% 'RE\?\
M_DITG_7I%_(UUG[,W^L\3_2U_P#:M<G\?_\ DITG_7I%_(UUG[,W^L\3_2U_
M]JT ?0-%%% !1110 4444 %%%% !1110 4444 %%%% '*:M\2O!^AZG-IVI:
MW%;WD) DB:-R5R,]EQT-9\OQ?\!-"ZCQ' 25('[J3_XFOGOXP6ES)\5-;=+>
M9E,B8*H2#^[6N'^P7G_/I/\ ]^S0!"Y!=B.A-?4/@#XG^#-(\!:-I]_KL,%U
M!;*DL9CD)4CMPN*^9/L%Y_SZ3_\ ?LT?8+S_ )])_P#OV: /L*'XM^!+B>.&
M+Q# TDC!%7RI.23@#[M=KU&:^%M%L;L:]IQ-K. +F/)\L_WA7W0OW!]* %HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E";X4^*
MO%_B#7=3TVU@6S;4[E4EGF";R)6!P.O!XS3O^&?_ !Q_<T__ ,"?_K5]36EG
M;V$'D6L*Q1;WDVJ.-SL68_BS$_C4] 'R?+\ O',4+R""QD*J6")<C<V.PR ,
M_C6[\(? /BG3O$FE^)K5[-K#<T-W'Y^)$4C#HRXR&4XX/<"OI.O&[KQ#'X8_
M:)73;&4&SUN"(7\ /"7)#!&QV; 3/J&)]* /9**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP#]IK_F5_\ M[_]HU[_ %X!
M^TU_S*__ &]_^T: .?\ V<?^2AW_ /V"I/\ T;%7T_7S!^SC_P E#O\ _L%2
M?^C8J^GZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.*65@H +,H).!P* -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\;M7;T %%%% !1110 445\F?$/QUXKL?B%KEK:>(M2M[>&[=(XHKAE55'0
MT ?5\_\ Q[R?[A_E7P*WWV^M=(?B'XS((/BC5R#U'VM_\:YJ@#[6^&O_ "37
MP[_UX1?^@BNIKX@M/'/BNPM(K2T\1:G!;PJ$CBCN7544= !G@5<M?B)XS-Y
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MUW_[,O\ S-'_ &Z?^UJX#XV_\E>US_MW_P#1$==_^S+_ ,S1_P!NG_M:@#Z
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MLHY\I,I&/ZG]/I7I"J%4*H 4#  ' I:Z:6"IPU>K/"QW$^,Q-XT_<CY;_?\
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MHMU LH4GJ1N!Q6;_ ,()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$U
MKV.GV6EVB6FGV=O:6R$E8;>)8T7)R<* !UJS10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?/WQ*\*-XT^/.EZ+YC102:?&]Q*F,I&K2%L9[GH.O)%>
MP>&O!'AWP@A&B:9';R,FQYB2TCC.>6))Z\XZ5P6KZG8:3^T;;76I7UM96_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BJUYJ-CIZAKV]M[93T,TJH#^9JE_PE'A__ *#NF?\
M@7'_ (T :U%9)\4^'@,G7M+_ / R/_&JGA_Q;8>)=7U:WTNY@NK2P\I/M$+;
ME=V#%@&Z$ !>1[T =#1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YX^*_A&_\;?&6
MWTC39K:*X.DI+NN694PKOGE5)SSZ5C_\,X^,/^@EH?\ W_F_^-5Z-?74-O\
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MX_(/^NB_SJ&IK3_C\@_ZZ+_.@#[X7[B_2EI%^XOTI: "BBB@ HHHH S/$?\
MR+&K?]>4W_H!KX4/4U]]S0QW,$D$R!XI%*.IZ,",$5R7_"J_ W_0LV/_ 'R?
M\: /C"BOL_\ X57X%_Z%FQ_[Y/\ C1_PJOP+_P!"S8_]\G_&@#XPKV+]G'_D
M?-0_[!K_ /HR.O;?^%5^!?\ H6;'_OD_XUIZ)X+\.>'+M[O1](MK.X=/+:2(
M')7(..OJ!0!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'V;\/M#O/#?@32M(OP@NK:,K($;< 2Q/!_&K^H>)]#TK(O=4M8F'5-^Y_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#S#Q[\(9?&OBN#7H/$;Z9-!"D<82U+LK(S,&#"1<')_#%=?X:TG
MQ%I2&+6_$D6LQA,(W]GB"0'/4L'(/''3/O7044 %%%% !1110 4444 %%%%
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M/^?N?_OX: /K#X&?\DJT[WDF_P#0S7H]<1\('>3X5Z&[LS,8WR6.2?WC5V]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX6V,R'!NB/XB?[GH/Q/;'D]%% !76>!?B!J_@75DN+.5I+)V'VFS=ODE7O\
M1O1OYC(KDZ* /O#1=8L]?T:TU73Y?,M;J,21MW'J#[@Y!'J#5^ODOX>^./$.
MDZ-<:58ZB\-K')YBKL5L%NN"02!\O0>I]:Z.;QEXDG^_K=Z,_P!R4I_Z#BO7
MPN3U<1355223]3TL/EE2M!5%)69](U%+<P6XS--''_ON!_.OF.;5M2N<^?J%
MW+GKOF9OYFJ?4Y-=L>'G]JI^'_!.J.2OK/\ #_@GTQ-XFT&W_P!;K.GJ?0W*
M9_+-9\WQ \*P??UB(_[B._\ (&OG>I8K:>X_U,$DG^XA/\JV6045\4W^!JLG
MI+XI/\#W.;XJ>&(ON37,W^Y 1_Z%BLZ;XQ:,O^IT^_?_ 'PB_P#LQKRV'PSK
MT_\ JM%U!AZ_9GQ^>*T8?A]XJG^YH\H_WW1/YD4_[,RZ'Q2^^2']0P4/BE][
M.QF^,XZ0:'^+W/\ 0+_6L^;XQZPW^HTZQ3_?WM_(BLZ'X5>)Y/OPVT7^_.#_
M "S6A#\'=9;_ %VHV*?[A=OYJ*/9Y33[?>V')EL.WWMF?-\5?$\GW);6+_<@
M!_GFL^;XA>*I_OZQ*/\ <C1/Y 5V$7P8[S:Y^"6O]2U:,/P=T=?]=J-\_P#N
M;%_FIH^MY5#X8I_]N_YH/K.7PV2^[_@'ETOB?7Y_]9K6H,/3[2X'Y9KSOQI-
M/<:M#)/+)*?( #.Q)^\>.:^I8?A5X8B^_%=2_P"_.1_+%<9\6_A182^$O[0\
M.6+1WE@QD>)79S+$?O?>)Y&,_3-<6/S#"UJ#ITHM/T1RXS&X>K2<*:L_1'S3
M11T.#17@GCA116_X-\+7GC'Q/::1:*V)&#32A<B*,'YF/T'YG [T ?0WPW^&
MVBW'@K1]0U..>XGN+=92C2%4 /(P%P>F.]>E6&AZ5I0'V'3K:W(_BCC 8_4]
M35FSM(;"R@L[= D$$:Q1J.RJ, ?D*GK:>)K37+*3:]365>I-6E)V"BBBL3(*
M*** "ODCXI^'-<O/B9KEQ:Z-J,\+S@I)%:NRL-HZ$#!KZWHH ^&/^$3\2?\
M0OZK_P" 4G^%'_")^)/^A?U7_P  I/\ "ON>B@#X8_X1/Q)_T+^J_P#@%)_A
M6CX?\+>(8_$FER2:#JB(MY$S,UG(  '&23BOM:B@ '2BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[NXT'9!!=Q22-]L@.U5<$G ?/05]744 ':BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!\;?\
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M*G36ZMHOU9G5Q.!A!P@MUT1\:45W7Q-^'5[X&UV0I'))H\[DVMQC@ \[&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'0IH&2'0'MY"/ED2^9L'Z,I% &+116S:ZCH<%NJ3Z"]Q(!\TC7K+D_10 *
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M6?\ SZ0?]^Q1]@L_^?2#_OV* ,+X>?\ )./#?_8-@_\ 0!72TBJJ*%50J@8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]>F_$KQ[O,V@:3+\HREW.AZ^J*?3U/X>M>;:/I%YKNIPZ?8Q&2:0_@H[L3V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&1OM$W##!^\: /2J*** "BBB@ HHHH ***QM8\5Z'H0(U#488Y!_RR4[I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO>P=0LR!MIZ9!Z@^XK0HKQCRSS:;X$^ Y9A(NG7$2@Y\M+I]I_,D_K72^'O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!TES_P!\DFCZEP_B?A<4_*5OPO\ H'-51[=9_&SP7=8\VZNK3/\ SWMF./\
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M^0UKW_7O%_Z$U<M\<?$>F^)/'L<VE7"7-O:V4=N9HSE';<[G:>X&\#Z@U>^
MWBG2_#GB?4(M6NHK2"\M@$FE;"AU;.">V03^50!]3T5S/_"Q/!O_ $,VF?\
M@0M:%KXIT"]M#=VVM:?);ABID%PNT$=1G/N/SIJ+D[(#6HKGKGQYX2M"1+XC
MTS(X(2Y5R/P4FLB?XO>"(3M35VG?^[#;2L3^.W'ZUU1P.*DKQIR:]&+F3=CN
M**\YN/C+H*1L;6RU"9\?+O18U/U).1^5<9K/Q6\0:EN2S,>GPGM"-SX]V/\
M0"O,K8FG1?*W=^6I[F#X>Q^*UY>5=Y:?AO\ @>VZCJVGZ3!YVH7D%M'V,K@9
M^@ZG\*X+6?C!I=KNCTJUEO9!TD?]W'_B?R%>-7%S/=S--<SR32M]YY'+,?Q-
M5)KJ"W'[V15/IW_*N2.)Q&(G[/#P;;Z)79]-0X8P6%C[3&3O;N^6/]?,Z_6?
MB'XCUG<CWQMH3_RRM?W8_/[Q_$UR_+')R2:R)M: X@CS_M/_ (52&JWZR^9'
M=2Q-C&8G*?RKZ'!<%YIB_?Q#5->>K^Y?JT36XGRK+X^SPD>;_"K+[_\ AST?
M2? GB#5U$J61MK<]9[H^4F/7GDCZ UU^G^ O".ED2>(?$]E(XZQ"Z2%/H23N
M/Z5X%/<SW+;IYI)6]9'+']:BKZ&AP!0AK4JM_+_@GS.,XOQV(TI^XO+?[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[YE33
M[EW8*JQ,2Q. !@U8KB_BN\__  KO4+:VE\J2]DAL_,_NK+*B-]?E)'XT ?/7
M@_XKZ]X5\-1^'M!TZWDG>X>4RR(TK-N X5!CICWKMM ^/&OZ;J4,'C/1A'93
M-C[1';O%)'_M;3PX'H,'Z]*]I\,^%-'\):7'8:19QPHJ@/)M'F2G^\[=2?\
M(J_JFEV6LZ;/I^HVT=Q:SJ5DC<9!']#[]J )5NH)+);R*19+=H_-5T.0RXR"
M#]*^<O@U&OC?XI:UXAUJ%+J186F595#JCNP"XS_=4$#CTZ8KU'P0_P!G^$4\
M$EP9HK!+VV29N2T<<DBJ>/\ 9 _*O-_V:8R=6\029&%@A7'U9O\ "@#N/&@C
M^&>JV7B[1X!!I=Q<"VUFQA7;&ZMTF51P'&",]\CW->H1R)-$DL;!XW4,K*<@
M@]#7G?QT_P"23:I_UT@_]&K6S\+[M[WX8^'II"2PLUCR3GA,H/T6@#K:***
M"BBB@ HHHH **** "BBB@ HHHH **** ,_7-8M?#^A7NKWI(M[2%I7 ZM@<
M>Y. /<UX;\);>X^(WQ!U3QKX@'G_ &+:MK$W*1NV=H4>B*#QZL&Z\UTG[1.J
MO9^ K6PC;!OKQ5D'JB M_P"A;*?^SO9BW^'=Q<$?-<ZA(V<=@J*/U!_.@#T/
MQ1X=L_%7AR\T>^16CN(R$<C)C?'RN/<'FO'_ (%^-;R'4+GP)K4C&:W+_8C(
MV2I3[\/OC!8>@#=L5[Q7R3KEP?#/[0<]W"S1B+65F?CJLC!G'T(=A^- 'UM1
M110!XQ\</'?B3PAJ&D1:#J/V1)XI&E'D1R;B",??4X_"O)_^%V_$/_H8?_)*
MW_\ C==K^TK_ ,A;0?\ KA)_Z$*\*H T-;UO4?$>L3ZMJUQ]HOI]OF2[%3=M
M4*.%  X ' K0\,^-O$7@[[5_8.H?8_M6SSOW,<F[;G;]]3C&X]/6N?HH ]$A
M^,WQ(N)1'#KK.YZ*MC;G_P!IUZ)9?%;Q(OA:VM+IDDU<[O/O61!U)P%50%R!
MCG'X=Z^?[&\EL+M)XCRIY'9AW%>Q^%_"^J>+5CETZ BU8 M<2_*B_CW/L,U[
M654<))2J5WK'OM_P3U<NI8:2<ZKU7?8S+JZN+VY>XNIY)IG.6DD8L3^)KK_#
M/PVU;7-EQ=@V%D>=\B_.X_V5_J?UKTGPS\/-(\/[)Y%%[?#GSI5X4_[*]!]>
M377UTXO.[+DPR^?^2_KT-\3FVG)07S_R1C:#X6TGPW!LT^V D(P\[_-(_P!3
M_08%;-%%?/SJ2J2YIN[/%G.4WS2=V%%%%02<;XB^*7A/PKK#Z5JU]+#=HJNR
M+;NXP1D<@8K)_P"%Z^ ?^@I/_P" DG_Q->5?&KPMXAU7XDW5UIV@ZI>6[01
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7HGP=T#QAX0\9*+K32--OD\JY"W$9VXR5? ;G!X^C&O#/,?^^WYUU/PU=O\
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MHH ^\H]9TN:58HM2LY)&.%59U))]AFKM?%/PV_Y*1X?_ .OU/YU]K4 %%%%
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MU.$<+47-0JM?<U^%CE6\;^,U^]XHUX?74)O_ (JF_P#"=^,/^AKUS_P8S?\
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M5X-DN+/15CU2Z<0VA-W,VT]6;!?! 'L>2* /GNM\>.O%X  \5:X .@&H2_\
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MT+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY0!\P?\)WXP_Z&O7/_!C-_P#%4?\
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M\51_PG?C#_H:]<_\&,W_ ,57T_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\
MR=N/_CE 'S!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %5]/_P#"
MDOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 ?,'_  G?C#_H:]<_\&,W
M_P 51_PG?C#_ *&O7/\ P8S?_%5]/_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^
MA>_\G;C_ ..4 ?,'_"=^,/\ H:]<_P#!C-_\51_PG?C#_H:]<_\ !C-_\57T
M_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'S!_PG?C#_H:]<_\
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M#S_H7O\ R=N/_CE 'S!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\
M%5]/_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 ?,'_  G?C#_H
M:]<_\&,W_P 51_PG?C#_ *&O7/\ P8S?_%5]/_\ "DOAY_T+W_D[<?\ QRC_
M (4E\//^A>_\G;C_ ..4 ?,'_"=^,/\ H:]<_P#!C-_\51_PG?C#_H:]<_\
M!C-_\57T_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'S!_PG?C#
M_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,57T_\ \*2^'G_0O?\ D[<?_'*/
M^%)?#S_H7O\ R=N/_CE 'S!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C
M-_\ %5]/_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 ?,'_  G?
MC#_H:]<_\&,W_P 51_PG?C#_ *&O7/\ P8S?_%5]/_\ "DOAY_T+W_D[<?\
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MS!_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,57T_\ \*2^'G_0O?\
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M-H6.2+>Y;'Y-G'X4 >?>.?V@GU&QET[PK:S6BR@I)>W&!(%Z'8H)VG_:)S[
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M_HKX HH ^_Z*^ ** /O^BO@"B@#Z#_:)\7E([/PI:R<OBYN]I[<A$/ZL0?\
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M_P"/>3_</\J^!6^^WUI** /M;X:_\DU\._\ 7A%_Z"*ZFO@"B@#[_HKX HH
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M6?F:IW"BBBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^(?'G_)0_$O_85NO_1K5]O5\0^//^2A^)?^PK=?^C6H
M ]]_9P_Y)]J'_85D_P#145>PUX]^SA_R3[4/^PK)_P"BHJ]AH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /B+Q]_P E%\2_]A2Y_P#1C5]-_!#_ ))'HO\ O3_^
MCY*^9/'W_)1?$O\ V%+G_P!&-7TW\$/^21Z+_O3_ /H^2@#T*BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KX$N/^/F7_ 'S_ #K[[KX$N/\ CYE_WS_.@#[7^'W_
M "3GPW_V#+?_ -%BNDKF_A]_R3GPW_V#+?\ ]%BNDH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHILCB*)Y&SA%+''M0!\Z:Y\0S\/OB[XRN8K 7EQ=^1'&&
MDVHN(U))XR?I^M-TG]I'6%OU_MG1;&6S)P?L>^.11Z_,S!OIQ]:ZCX=_"[2M
M=L%\8^*HO[2U'5G:\6&1CY42N21D?Q$@YYX'  XR?09_AWX,N+8P/X6T@(1C
M,=HB-_WTH!_6@#7T;6;#Q!I%MJNF7"SV=PNZ-Q^1!'8@Y!'8BO OB7?3>,?C
M?I?A">24Z5;7$$4D"L0K%@'D;COM;;GMCZUZ3\.-(7PKKWBKPM;2N^GVDT%W
M:!VW%%F1LK^!C/\ /J37E@#W'[5/4%A?]_18?\!0!ZIXK\'6^A:3+XA\&VD&
ME:QID9F"6L82*[C49:*5%P'! .#U!Q@BNJ\+>(K3Q7X:L=;LLB*ZCW%#U1@<
M,I^A!%:D\:2V\D<G^K=2K?0CFO&OV;K]YO">K6+,Q6WO1(N3T#H.!^*$_C0!
M[31110 4444 %%%% !1110 4444 %%%% !7G?QQMC<?"?5652QA>&3 _ZZJ#
M^A->B5F>(M'C\0>&]2TB1MJWEN\(;^Z2.#^!P?PH \I_9MNE?PAJ]IN^:*_\
MTKZ!HU'_ +(?RKVFODKX:>+Y?A=XVO;+7+>6.UF/V:]0#+0LI.U\?Q 9/3J&
MR,\ _0ES\5? ]MIYO&\264B!<A(GWR'VV#YL_A0!Y/\ M+7:/JGAZR#?/%!-
M*5] [*!_Z ?RKVCP'9O8?#_P_;2+LD33X=Z^C% 2/S-?-LLMY\:OB]&8X)([
M)BH*D\P6B'DDCH3D_P# GQ7UDB+&BHBA548  X H @OK"SU.SDL[^T@N[63&
M^&>,2(V"",J>#@@'\*\6^/7AK0='\!VMSI>B:;8SMJ,:&6UM$B8J8Y"1E0#C
M(''M7N->1?M&?\DZL_\ L*1_^BY: /EVBBB@ HHHH ]0^&WA74?$NB7CZ3$D
MCVTH$RNX4DL#C&>,8'M6_>>"_$EB?W^C79QU,2>8!^*YK;_9I(_LKQ ,\^?#
M_P"@M7NM>OA\YK48*G9-(].AFE6E%0LFD?*LD4D,A26-HW'56&"*97U1/;6]
MTFRX@BF3^[(@8?K6%>>!/#%]GS='MT)[P@Q?^@D5Z-/B"F_XD&O37_([89S#
M[<6O3^D?.+Q1R#YT5OJ*(X;>(C;:VQ]F@1OYBO;[SX0Z'-DVMU>6S'H-P=1^
M!&?UKG[SX-Z@F39:K;3>@FC:/^6ZNFGF. GL^5_-?BO\SI_M'"5M)N_JK_YH
MX:TU+38,"X\+Z+<KW+0LK?F&Q^E<3\09+*YUB"ZT_2H-,MVA">1"Y8%@3EN1
MQU%>GWGPV\4VF2-/$ZC^*"56_3.?TKR?QS:7EAKB6M[;S6\J0@^7*A4\D\X-
M<>9JA+#N5.HY;:<S:^YMG)CX8-T'.DH\WE_DCF:***^:/!"M'1M1;3K]'W'R
M7.V0>WK^%9U%:4JLJ4U.&Z+IU)4Y*<=T>GK*IVLNUUZ]>#5F[OUO$5)--TH*
MJA0?[/A+8]W92Q_$UT'A+X7:[K'AS3;T2VEO;SVR2(9')8J5!!P ?YUV-G\%
MHA@WNLNWJL, 7]23_*N/'XW,,=4?-I'HEHO^"?HD,?DU*E%U6I/?;FU^ZQX[
M';01',4$49/]Q O\JEKWRS^%'A>VQYL-S=$?\]IR/_0=M;]GX4\/V&/LVC62
M,.C&$,WYG)K@6 J2UDS.?%F"I+EHTV_N2_KY'S9:V%[?-MM+2>X;.,11ES^E
M;UG\/?%5[@II$T:GO,RQX_!B#7T8JA5"J  .@ I:VCET?M,\VMQC7?\ "II>
MK;_R/$;/X.:Y+@W5[96ZGJ 6=A^& /UKYRG3R[B5,YVN1G\:^^Z^#;RSNA?7
M -M,#YC?P'UKKI4(4K\IX&89KB<P<?;M:;65MRE14WV2Y_Y]Y?\ O@T?9+G_
M )]Y?^^#6QYI#72_#ZUM[WXA:#;74$4]O+>1K)%*@97!/0@\$5@?9+G_ )]Y
M?^^#75?#6UN!\2O#Q,$H OHR24/'- 'U?_P@G@__ *%30_\ P70__$T?\()X
M/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__
M  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q
M-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_
M /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__
M *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!X5\<_!-K#H6EOX:\,0
M1R_:6$QTVQ4-C;QNV+G''>O#?^$3\2?]"_JO_@%)_A7W/10!\,?\(GXD_P"A
M?U7_ , I/\*/^$3\2?\ 0OZK_P" 4G^%?<]% 'PQ_P (GXD_Z%_5?_ *3_"O
M?O@EX(T^7P5=/XC\+VKW9OW\LZC8*9/+V1XQO7.W.[VSFO::* .?_P"$$\'_
M /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X
M+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC
M_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH*
M* .?_P"$$\'_ /0J:'_X+H?_ (FL3QEX+\*VO@;Q!<6_AG1H9XM-N'CDCL(E
M9&$;$$$+D$'O7=U@>.?^2?>)/^P5=?\ HIJ /A^OL+P5X,\+77@3P]<7'AK1
MIIY=-MWDEDL(F9V,:DDDKDDGO7Q[7V]X#_Y)YX:_[!5K_P"BEH 7_A!/!_\
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M[>ZTZ0]?/BW+GZIG]0*5'+\57INK1@Y):::_AN#G%.S.I_X03P?_ -"IH?\
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M5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\
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M_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\
MA!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T
M*FA_^"Z'_P")KH*R/$^O6_ACPU?ZQ<D;+6(L%/\ &W15_$D"@"M_P@G@_P#Z
M%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UYO\"_']UX@.IZ/JUT\UZLK
M7<+2')*,?F4>P8Y_X%[5[10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H
M5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\
M\%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__
M !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%
M% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__
M ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@
M_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5
M-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P7
M0_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$
MT?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P (
M)X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\
MZ%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_
M /!=#_\ $UT%% '#^+?!?A6V\&:[/!X9T:*:+3[AXY([")61A&Q!!"Y!![U\
M<5]Q^,_^1%\0_P#8,N?_ $4U?#E 'WW!_P >\7^X/Y5)4<'_ ![Q?[@_E4E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"0>#R.015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^(M0P>HBF,8/X+BL*YO+J\??=7,T[?WI7+']:[Z?!M5_Q*J7HK_Y$O$+HC[
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M=WBHV-X_AC;'8KDD>X/:@#VNBJ>E:E;:QI-KJ-H^^WN8EEC;V(S5R@ HHHH
M**** "BBB@ HHHH P_&?_(B^(?\ L&7/_HIJ^'*^_P"B@".#_CWB_P!P?RJ2
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J.>>*VMY)YY%CAB4N[L<!5 R23Z8J2N$^,ES<6_PMU=;7/FS^5;C
M![/(JD?B"1^- ')ZI^T=X?M;MXM.TF]OHE.!,S"(-[@')Q]0*H_\-+6'_0M7
M/_@4O_Q-=OX=^#_@_1-+AM[C1[;4+H(/.N+I/,+MCD@'A1Z "L#PIX-\+VGC
M7Q+X8U/0=.GD24:CI[3VZ,6MI.JKQG:C@K^- &'-^TGI\L$D;>%II%=2I1[I
M=K9'0_*>#]*O? +Q9?:S_;>E3)ML+5UGLX\EOLZ.S?N@3_",#'I@_AVNN?"G
MPAJVB7=C!H=A93S1D17,%NJ/$_56!'/7&1W&153X2:UIVH^';BPATVSTW5=-
MF-OJ5O:Q*BF09'F84=&VG\01VH ]!HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#Y ^-O\ R5[7/^W?_P!$1UW_ .S+
M_P S1_VZ?^UJX#XV_P#)7M<_[=__ $1'7?\ [,O_ #-'_;I_[6H ^@**** "
MBBB@ HHHH **** ,/4_!OAK6KUKW4]#L+NY8!3+- K,0.G)JG_PKCP5_T*^E
M?^ R_P"%=110!R__  KCP5_T*^E?^ R_X4?\*X\%?]"OI7_@,O\ A7444 <O
M_P *X\%?]"OI7_@,O^%=1110 4444 %%%% !1110!\]ZK^SOJVH:Q>WJ:[9(
MMQ.\H4Q/D!F)Q^M5/^&:]8_Z&"Q_[\O7T?10!\X?\,UZQ_T,%C_WY>C_ (9K
MUC_H8+'_ +\O7T?10!X?X)^!>I^%?&.G:W/K-I/':.S-&D; ME2O&?K7N%%%
M !1110 4444 %9>K^'-%UZ/9JNEVMWQ@-+&"R_1NH_ UJ454)RA+F@[/R!JY
MY/K7P%T"\W/I-Y=:=(>B-^^C'X'#?^/&O.=:^"WB[2MSVUO#J4(_BM7^;'^Z
MV#GZ9KZ>HKW<+Q+F%#1RYE_>U_'?\3*5&#/B6\L;O3[AK>]M9[:9>L<T91A^
M!J]H_B?7- <-I6JW5J <[(Y#L/U4\'\17V%?Z;8ZI;^1J%E;W<)_@GC#C\C7
M :W\$?"FI[GLDN-,F/.8'W)GW5L_H17T%#BO"5X\F+IV_P#)E_7WF3H26L6<
M#HGQ[URTVQZO86VH1CK)'^YD_3*_H*]&T3XS>$-7VI/=2Z=,>-EVF%_[[&5Q
M]2*\QUOX$^)+#<^F7%MJ<8Z*#Y4A_!N/_'J\\U30M6T2;RM4TZZM&S@>=$5#
M?0]#^%;/*LES'7#R2?\ ==O_ "5_Y(7/4AN?9EK>6U];K<6=S#<0M]V2%PZG
M\1Q7FGQS\8?\([X+;3+:3;?:MF$8ZK%_&?Q!"_\  CZ5\\Z?JNH:1/Y^G7UQ
M:2C^."4H3]<=:S_$GB;5O%.HI>:O>O=2Q1B&-V4#" D@< =R3^-?,9SDG]FJ
M,O:*2ELK69M3J<_0]=_9X\8?9[^Z\*74G[NYS<6F3T<#YU_%1G_@)]:^BJ^"
M]+U*YT?5;74K.3R[FUE66-O0@Y_*OM?PKXKTSQ;HEKJ%A<PL\L0>6!9 7A;N
MK#J,'BO"2;V-3=HHHI %%%% !1110 4444 %%%% !1110 44R26.&)I976.-
M!EG8X"CU)KRKQ=\>O#FA>9;:,#K-Z.,Q-M@4^[_Q?\!!'N* /6**Y[P+K]SX
MH\%Z;K5Y'%'<72%G2$$*,,1QDD]O6NAH **P/%WC#2?!6C-J6K3$*3MBA3!D
MF;^ZH_KT%<I9>(/BAK=A'J^G>']!L[*5?,BL[Z>4W,B'IRN%4D?WL4 >E45Q
M7@GXBV?BVXNM,N;232]=LB5N=/G;)&."5/\ $ ?;(_(GM: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHKCO'WQ'TCP#8(]V#<W\P)@LXV 9_=C_"N>^#[ T =C17S/-^TCXD:ZW0:
M/I*6^?N.)&?_ +Z# ?I7I?P^^,VE>-+M=,N[<Z;JK#*1L^Z.;V1N.>^"/IF@
M#TVBBN6\;^/-)\"Z8ES?EYKF8[;:TBQYDQ_H/4_S/% '4T5YNFM?%:>R758_
M#V@1VY7>--DN)?M97TW?<!^M;?@?Q_IGC>TF\B.2SU&V.VZL9S^\B/3\1GO^
M8% '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !17%^.OB-8^#/(LX[6;4]8NAFWL+?EV']YL D
M#CT)/IUKRS4OCCX_T>X274_"$%C9NV%6ZM)XV;V#L0,_\!H ^AZ*X?X>?$W2
M_B!:RK#$UIJ,"AI[1VW8!_B5OXA^ ([CD9[B@ HKC?''Q%TSP4L%LT3WVKW9
M M;" _.Y)P"Q_A!/'J>P.#6//KOQ4LK ZO/X<T&>U5/,?3K>>7[6HZD;N4)'
MH ?;- 'I5%<UX+\;Z3XXTG[;IKLDD9VW%M)_K(6]"/3T/>NEH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBFR!FB<(=KE2%/H: /)/&OQZTGPUJDVEZ78-JMU Y2>
M3S?+B1AU ."6(/!X ]ZX_P#X:5U3_H7;/_P(;_"JGP<^&>E^);W6KCQ/!)-)
MITXMS9F4KB3G<7VG)P1@<XZYS7M0^%W@=5 'AG3^!CF//]: /(/^&E=4_P"A
M=L__  (;_"M+P1\4M6^('Q0T>VNK6WM+.VCGD6&')+.8R,LQ]!G&,=3UKT[_
M (5?X'_Z%C3_ /OW56W^&VAZ-XPTK7="TZ*R: 2QW*Q,0K(R$ [>F0V.F.IS
M0!V]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5X!^TU_P RO_V]_P#M&O?Z\ _::_YE?_M[_P#:- '/_LX_\E#O_P#L%2?^
MC8J^GZ^8/V<?^2AW_P#V"I/_ $;%7T_0 4444 %%%% !1110 5\T?M(_\CEI
M/_8/_P#:CU]+U6N=.L;UP]U96\[*,!I8E8@>G(H ^":*^[_["T?_ *!-C_X#
MI_A1_86C_P#0)L?_  '3_"@#X0HK[O\ ["T?_H$V/_@.G^%']A:/_P! FQ_\
M!T_PH C\,\>%='_Z\H?_ $ 5J4BJJ(J(H55&  , "EH **** "BBB@ HHHH
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MXDB8@E278]N.A%=;0 4444 %%%% !7!>(/A!X5\3:W<:OJ:7LEW<$%RMR0.
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M ))?='_Y(/83[GRN222222>I-)7U@/A3X'4 #0(>/660_P#LU+_PJKP1_P!
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MFOMRQO8-1L+>]MI!)!<1K)&XZ,I&0:\LLL4444 %%%% !1110 4444 %%%%
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M &6NRH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_Y*'?\ _8*D_P#1L5?3] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9'B+Q-H_A73&U#6;
MV.VA'"@\M(?[JKU8_2@#7HKQWPK\=5\5>.+30K?03#:W4CK'<27.7 "E@2H7
M&3CIGC/4U[%0 445POQ#^*&D^ ((XI8VO-3F7=%9QMMPO]YV_A7(QT)/IU(
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MBTU*T;=;W42RQGV89Y]ZC_L+1_\ H$V/_@.G^%78HHX(EBAC2.-1A41< #V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIVJQ=_!;0=.^(NG^'KO4M06PU*S>2SG#)O:>,Y>,_+C&TY_2@#N?^&A/!/\
M=U/_ ,!A_P#%5@^#OBM8W_Q8?3-(BNDT+5LD17 &8[G!)= "=JMCD>ISQS5W
M_AF[PS_T&-6_[ZC_ /B*I_"SX>:#H7C2^M]2DN)/$VCN6C1V ADA8?)/&N,G
M@X().T^^, 'N5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5X!^TU_S*_P#V]_\ M&O?Z\ _::_YE?\ [>__ &C0!S_[./\
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M^^*B6H8@I;0P@D<#.3_[-0![)\(_ ]EX6\(6=V]LAU6]B6:XF91O7<,A >P
MQQZY-:WQ#\%V/C3PO=6LMNC7\<3/9S[?G20#(&?0G@CW]<5U4*"."-%&%50
M*?0!\7>#?B-K_@-;N'26MVBN6!>.X0NH89&1@C!]?H*ZK_AH;QK_ ,\M*_\
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M'^&/^A<TC_P!C_\ B:/^$/\ #'_0N:1_X Q__$UM44 8O_"'^&/^A<TC_P
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MAIMLIZ$H[L/Q+ ?I6-9?!KQM=X+Z;%:J?XI[A!^BDG]*Z*R_9]UF3'V[6;&
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MCQ-&G7]CB4G3GH[]'T?EZ^9G53:NMT?8/A#XD:!XP18[:?[-?X^:SG(#_P#
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MQ^%=70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQG_/?!]#6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '+7'Q(\&VES+;7'B.PCFA<QR(TG*L#@@_C4?\ PM#P/_T,^G_]_*\C
M\;_!Z^U_XM7<>ES6UI:W]N=0,DV<!MP60  <G<0W8?/UJ/\ X9JU3_H8K/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:SHVG^(-*GTS5+5+FT
MG7:\;C\B#U!'8CD5\\^+OV>M7LIY+CPO.FH6I.5MIG"3)[9.%;Z\?2OI6B@#
MXGE\'>-M*D:(Z#K<.3SY5O(5/XJ,&I[#X;^.==N,Q^']2W-C,MW&80??=)C-
M?:-% 'B_P]^ ]KH=S#JOB:6&^O8VW16L>3#&1T+$@%S[8 'O7M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R
M!\;?^2O:Y_V[_P#HB.N__9E_YFC_ +=/_:U<!\;?^2O:Y_V[_P#HB.N__9E_
MYFC_ +=/_:U 'T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*C7BVULU;8PJ47)W1\N45]<CX;>#58$>';+(.>4)_K4W_" >$/\ H6],_P#
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M!ZBJ']A:/_T"K'_P'3_"@#X0HK[O_L+1_P#H$V/_ (#I_A1_86C_ /0)L?\
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M1110 4444 %%%% !56]TVQU*+RK^RMKJ/^[/$KC\B*M44XR<7=.P'":O\)O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G/
MA _:?C)X_GE.9($L8(O]E#&20/Q4&O1J\FU/4X_!'QV6[O7\K3/$UFD33,<*
MD\>%7/H,!1_P.O6: "BBB@ KRWXAW L_BQ\.)X_]:]Q<Q-@\[6$:_P#LS5ZE
M7@KZTOC[]HS3$T]A-IFAH_[Q>5)0$LX]BY50>AP".M 'O5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X!^TU_S*_\ V]_^
MT:]_KP#]IK_F5_\ M[_]HT <_P#LX_\ )0[_ /[!4G_HV*OI^OF#]G'_ )*'
M?_\ 8*D_]&Q5]/T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<E\2_$=[X4\!:C
MJ^G>7]LB\M8C(NY5+.JDX[\$_CBO!K'XM_%35(FET^.2[C5MK/;Z8) #Z$A3
MS0!]345\P2?&'XHZ,//U.P"Q9'_'YIK1K^8V_P Z[SP3\?=+URZCT_Q!;+I=
MU(=J7"OF!CZ'/*?CD>XH ]CHHZC(HH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/D#XV_\ )7M<_P"W?_T1'7?_ +,O_,T?]NG_ +6K@/C;_P E>US_ +=__1$=
M=_\ LR_\S1_VZ?\ M:@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D#XV_\E>U
MS_MW_P#1$==_^S+_ ,S1_P!NG_M:N ^-O_)7M<_[=_\ T1'7?_LR_P#,T?\
M;I_[6H ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\ _::_YE?_
M +>__:->_P!> ?M-?\RO_P!O?_M&@#G_ -G'_DH=_P#]@J3_ -&Q5]/U\P?L
MX_\ )0[_ /[!4G_HV*OI^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !7@'[37_,K_\ ;W_[1KW^O /VFO\ F5_^WO\ ]HT
M<_\ LX_\E#O_ /L%2?\ HV*OI^OF#]G'_DH=_P#]@J3_ -&Q5]/T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <_XU\+IXQ\)7VAO<&V^T!2LP7=L96# XR,CC'XU
MXS_PS/=?]#3#_P" 1_\ BZ^AJ* / ;7]FA1*#>>*"T8/*PV6"?Q+G'Y&O2_!
M_P +O#'@J07&GVCSWV,?:[IM\@_W> %_  ^M=G10 5R?C[P%IWC_ $5;*\<P
M7,#%[:Z10S1,1SQW4X&1D9P/2NLHH ^>K+X/_$W0M]CHOBV"WL&)QY5Y-&!G
MJ=H4[3]/SKI8_@-8_P#"*7]G/JC7&O7Q5I-3GB+[,.&(52<\XP23D_I7L%%
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MP!6Y10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%<EJOQ*\+Z& =5N;^Q4MM5KC2KI%8^Q,>#T[4 =;17G_\ PNWX>?\ 0P_^
M25Q_\;IT?QI^'LCA%\0J"?[UI.H_,IB@#OJ*Y[2_'GA/69%BL/$.G32O]V+S
MPKGZ*V"?RKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KC?BO:PW?POUY)D#!+?S%SV92"#^8KLJY/XG?\DS\0_]>;T >'?L
M[6=K=^,-2-S;0S&.RW(9(PVT[UY&>AKZ9>"*2'RGB1H\8V,H(Q]*^;/V;O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'10!\^_";X4ZO-XA7Q=XM@DB9)#/!;W'^MEF)SYC@\K@G(!YSSP!S]!444
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M_6_&_ASP[J]GI6K:B+:]O-I@C,,C;LMM'S*I Y]2* .@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIM%M=;TV&\B4DIO!#)GKM88*_@: .+M?CCX4O[* 6"W]WJLX 33(;5C*7/\
M#G&W\0>E>&^)]3O;#XW)JWB&UCLYX+^UNKB"%S((T'EL!G^([<9QWSBOISP[
MX&\,^%&9]$TB"UD88,N6>0CTWL2V/;-,UWP#X6\2ZG#J.L:/#=7<*[5D9F7(
M[!@" P_W@: )?#'BVR\71W%WI4-PVFQD)%>2QF-;AN=VQ6PV%X&2.I([&M^H
MX((;6"."WB2*&-0J1QJ%50.@ '05)0!\Q_'#0;GPIX^M?%&E,UNMZPG66/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6YOY;^9"0Z6,6\*1_M$A3^!-5-(^/?@C5+E8)9KW3B[!5:\@ 4D^I1F 'N<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5U-KU
M=*O&TU8WOQ YMEE^X9=IVAO;.,UX/I/BOXX_VO+:/HC7+,Q&;RP$<,?TD7:"
M!_O'\:^@J* .+\">"[GP^]]K.MW:W_B/4V#7=RH^5 .D:?[(^@Z#T%=I110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(;&0C:TMU ZD$]"ID*KQ@]<CI^(!Z5X*\$:7X$TF;3M*DNI8YIC,[W+AF+8
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MP[.O'WL5Y9\$I/'CWNK_ /"5+K'V,HK1'4PX;S"?X-XSC'IP./6@#V2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM>@?\()X/\ ^A4T/_P70_\
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MY_WXA_\ CM>@?\()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-
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MZSHUCJENLBP7MO'<1K( &"NH8 X)&<'U-7*C@@AM;>*WMXHX8(D"1QQJ%5%
MP  .  .U24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?#]KD0#Q'%O)QDV\P7_OK9C]:Z[3=5T[6+476F7UM>0'I);RAU_,4 7****
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M3Q' 7SC,<,LB?]]*I7]:ZC1]<TO7[%;W2;^"\MV_CA?.#Z$=0?8\T :%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;O[(U?[1C[FR+;G_ 'M^?TJ;P'\2/%/C[QLCV^C_ &+PQ%&_FMMWY;'RYD(
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M)MP6)QG .['MR16AX'^*3^/?$UQ:Z;H-U#H\$!=KZ?KYF5PA RH)!/&XGC-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;0+&';U.T#)INIZ)I.M+&NJZ797ZQ$F,75NDH0GKC<#CI5^B@!%4*H50 H&
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M5UR#]13Z* ,2/P9X6BN!<1^&M'28'<)%L8@P/KG;G-;*(D4:QQJJ(H"JJC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ggtc45pq2o35000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )> ZT# 2(  A$! Q$!_\0
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MM=%_Y^]6_P# YZT]GA_YW_X#_P $+L[&BN._X5KHO_/WJW_@<]'_  K71?\
MG[U;_P #GH]GA_YW_P" _P#!"[.QHKCO^%:Z+_S]ZM_X'/1_PK71?^?O5O\
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M!M)V@@'L?IFNL\>_#K2?B!96\5_)-;W%LQ,-Q#C<H.,J0>H.!^57/!?@S3/
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M^1#4X[_A9WAC_GO=_P#@'+_\31_PL[PQ_P ][O\ \ Y?_B:[&BCGPW\C_P#
ME_\ (AJ<QIOC_P /ZMJ<&G6MQ.;F<D1J]NZ X!)Y(QT%=/7'>)O^1_\ !?\
MUTN__10KL:6(A3BH2III25]7?JUV78%<****YAA1110 4444 %%%(2 "2< =
M30 M%1I/%*$,<J.)%WH58'<OJ/4<CGWI3+& Y,B (<.2P^7C//IP1^= #Z**
M* "BBB@ HI"ZAPA8!B"0N>2!U_F/SH5U8L%8$J<, >AZX/YB@!:*1'61%=&#
M*PRK*<@CUI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBJ-[K.G:;<V]O>7212W!Q&K9YY R?09(&3@9('
M4T 7J*KWM[;:=:/=7<RPPI@%F]2< #U))  '))Q26&H6FJ6BW5E.LT+$KN&1
MA@2&!!Y!!!!!Y!% &1#_ ,E#O/\ L%0?^C9JZ"N?A_Y*'>?]@J#_ -&S5T%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-FKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y^'_DH=Y_V"H/\ T;-705S\/_)0[S_L%0?^C9JZ
M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ..\3_\
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M3Z-8W!U R1$_VA"(+GYR-Z $8]N&/2K]% #8XUBB2-!A4 4#V%.HHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445E^([:6\
M\/WEO#'-*SIAHH)/+DE3(W(K9&"RY .1UZCK0!J45YIX$-_=>(K:2V\.:CH>
MDV&E+93_ &^/RGNIEV!,+SN"*A ?)X;%>ET %%%% !1110!S\/\ R4.\_P"P
M5!_Z-FKH*Y^'_DH=Y_V"H/\ T;-704 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117)^*/B#I/A+48
MK*_M[V262(2@P(A&"2.[#G@T =916;H.MVOB+1H-4LA(L$V<+( &!!(((!/I
MZURVK?%C0-'U:YTZ:WU"66W<QN\,:%=PZX)<'CIT[4 =W134<21JXSA@",TZ
M@ HHK.UW6;;P]HUQJEVDKP0!2RQ %CE@O&2!U/K0!HT5S@\:Z:W@P^*1!=_8
M1_RSV+YGW]G3=CK[]*T= UNV\1:-!JEHDJ03;MJS !AABIS@D=1ZT :5%%%
M!1110 457O[R/3M.N;V96:*WB:5P@R2%!)Q[\5Y__P +K\-_\^6J_P#?J/\
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M_P BEK/_ %XS?^@&O(/A[J_@K3]"GB\21637AN2R&>Q,S;-JXY"'C.>*]?\
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M+_>VP!L#W.,"NIT7Q6?$'PIUJSNGSJ%C9/')GJZ;3M;^A]Q[U7D_Y.(3Z?\
MMM69\2]#N/"^NRZOIH*66JQR13@#@.P^93['[P]P?2@#J/A=J%OI7PUNK^[8
MK!;SRR.0,G "]/>J.FZ[\0O&R37^B2V6EV$;E(Q(H/F$=LLK$D<<X JMX5TZ
M?5?@EJUG:JS3/-(R*O5BNQL#ZXQ6E\,/%^B6OA%--OK^WLKFT=]RSN$WJ6+
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MIR".6X:%IEC&,EG96)^J]: ._P!8\:Z;HGB*QT2Y@NWN;W9Y;QHI0;F*C)+
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MY4@<=.>.G?T"B@#@/!7P]N="U:76M:U 7VINI52&9@N>"Q9N6)''3BN_HHH
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M-FKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!4'_ *-FKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N.UKX7^$_$FLW.JZWIIO+J8J WGRQ[550H7", >A.<=Z[&L?Q5=W-AX8O[F
MSO+:RGCC&VYN<>7%R 6.>#@9P#U.!0!E:!\-?"_A76%U/0M/-G/Y31.?/DDW
MJV#CYV..0*ZVO//"%U>R^(T2X^)VG>)D\AS]BM;>"-E.5^<^4QR!TYXYKT.@
M HHHH **** .?A_Y*'>?]@J#_P!&S5T%<_#_ ,E#O/\ L%0?^C9JZ"@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N5\='Q!%I4=QH=]I]NJ2QB=+RWDD#@NH&"AR/<8.0>HKJJQ/%\<
M,OA'4XIS=A)(2@%F?WS,>%5/]HD@#ZT 9V@Z?XR77%N_$>IZ3);) \:06$4B
M[G8J=S;CV"G&/[QKK*\R\ :)>V6O&YU2Q\0V$_DN((]1U9;V*5"5R1M^XXXX
M(Z$]<''IM !44MK;SRQ2S01220DM$[H"4)[J>WX5+10 Q88DEDE2)%DDQO<*
M 6QTR>^*(H8H(_+AC2-,EMJ* ,DDD\=R23^-/HH Y^'_ )*'>?\ 8*@_]&S5
MT%<_#_R4.\_[!4'_ *-FKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/FR]G4$]:ZVN?A_Y*'>?]@J#_P!&S5T% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8
M'C5G7PAJ&R22-BJ+NC<JP!=0<$<C@T ;]%<__P (7HF/N7W_ (,KG_XY1_PA
M>B?W+[_P97/_ ,<H Z"BN?\ ^$+T3^Y??^#*Y_\ CE'_  A>B?W+[_P97/\
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M>NG264C)Y0A&<8(7?NR[G)8\N?;'2T4 <\WA**2.W:75]3DOK:0/%?EXQ,H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2AWG_8*@_P#1LU=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-0UK2WM[>ZCN&2WTN2-VV'.-QN& _(T =/1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '/P_\ )0[S_L%0?^C9JZ"N?A_Y*'>?]@J#_P!&S5T%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<?K^JZE]MUIM/NFA71+!+L1 +MNI6WML?()"[8P,J1]\GL*["N9USPW=:C=
M:A]EN(HK?5K-;*^W[MRH-_S1XXW%9&7G_9/.,$ M>(-2GATRR2SE,$^H7,-M
M'+M!,8<Y9@#D;@@;&>,XZ]*70+Z=EU6SO9S*VEW9MS<2;09$,4<JLV !D+*
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M_7H_X2K_ *@.N?\ @'_]>@#H**Y__A*O^H#KG_@'_P#7H_X2K_J ZY_X!_\
MUZ .@HKG_P#A*O\ J ZY_P" ?_UZ@M/&L%[;^?;Z+K<D99DW"S[JQ4]^Q!%
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M_7H_X2K_ *@.N?\ @'_]>@#H**Y__A*O^H#KG_@'_P#7H_X2K_J ZY_X!_\
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MK_J ZY_X!_\ UZ .@HKG_P#A*O\ J ZY_P" ?_UZ/^$J_P"H#KG_ (!__7H
MZ"BN?_X2K_J ZY_X!_\ UZ@G\:P6TMM%+HNMJ]S(8H@;/[[!6? Y_NHQ_"@#
MIZ*Y_P#X2K_J ZY_X!__ %Z/^$J_Z@.N?^ ?_P!>@#H**Y__ (2K_J ZY_X!
M_P#UZ/\ A*O^H#KG_@'_ /7H Z"BN?\ ^$J_Z@.N?^ ?_P!>C_A*O^H#KG_@
M'_\ 7H Z"BN?_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZ .@HKF%\:P/
M?2V:Z+K9N(HTE=/L?(5RP4]>Y1ORJ?\ X2K_ *@.N?\ @'_]>@#H**Y__A*O
M^H#KG_@'_P#7H_X2K_J ZY_X!_\ UZ .@HKG_P#A*O\ J ZY_P" ?_UZ/^$J
M_P"H#KG_ (!__7H Z"BN?_X2K_J ZY_X!_\ UZ/^$J_Z@.N?^ ?_ ->@#H**
MY_\ X2K_ *@.N?\ @'_]>H+7QK!>PF:WT76Y(P[QEA9_Q*Q5AU[$$?A0!T]%
M<_\ \)5_U =<_P# /_Z]'_"5?]0'7/\ P#_^O0!T%%<__P )5_U =<_\ _\
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M *R_$)8Z/<0Q:S'I$\J%8[MPI\L^H#$ UJ5%-;P7&WSH8Y-AW+O4':?49[T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN\@NU9BRE]OE(0R[3A7.X@_P\=: .P_X0CP[_P! _P#\C2?_ !5'_"$>'?\
MH'_^1I/_ (JMNVG2ZM8;B/.R5 ZY]",U+0!S_P#PA'AW_H'_ /D:3_XJC_A"
M/#O_ $#_ /R-)_\ %5T%% '/_P#"$>'?^@?_ .1I/_BJ/^$(\._] _\ \C2?
M_%5T%% '/_\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\ R-)_\5705RGCKQ)J
M7A+1Y-;A@M9["V,0EA;=YTI>0(0F. 0&!YSGGI0!;_X0CP[_ - __P C2?\
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ML>H /0UV= '/_P#"$>'?^@?_ .1I/_BJ/^$(\._] _\ \C2?_%5T%% '/_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <M8>,?MGQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *&IZ3!JGV5I'DBFM)UG@FB(#QL,@
MXR",%2RD$=&/?!J_110 4444 %%%% !1110 4444 %%%% !1110!66QB74I+
M_<[3/$L6"?E502>![D\_059HHH **** *$VDP7.LVNIS/(\EJC+!&2-B%N&<
M#&=Q'&2>!G&,G-^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ggtc45pq2o35000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )+ ^H# 2(  A$! Q$!_\0
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M$;?KQ46L^'K#5H9WFM5EN&B9$)=ASCCH:Y^S^'^EQ:PDLNF1?9?L"1MB5O\
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M8?;TY(Q5;^Q-._Y]A_WT?\:-0U-"BHYH(KB$PRINC/49JG_8FG?\^P_[Z/\
MC1J#OT-"JUI=B[:Y 0KY$QB.3UP <_K22:;:2V0LWA!MP<A,GZUE:1X9L=/G
MN)?LB(WVDR0D.QPN!COZ@TQF_1110 4444 %':BCM0 4444 %%%% !1110 4
M444 %%%% !67HW^LU/\ Z_7_ /05K4K+T;_6:G_U^O\ ^@K0!J4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "CM11VH **** "BBB@ HHHH *S]=^TGP]J8L]WVK[)+Y
M.WKOV';CWSBM"B@#S;1-IU3X="P/R#19C/L_YY^7#C=_P/'XULZ^DVBZ[>>(
MYD@N=-ETP6DL#OAU969E"C!W;]^W YR%Z]NC@TC3K5IVM[*"(S@B4H@&X')(
M^F23CW-":1IR/;.MG#NM4"097/E =-OI0!E^%;+4M*\":19SHKZA!9QHZ22$
M , /E)P>G3\*L>'S,R:B;B-$E^VON5'W <+WP/Y5LUEZ-_K-3_Z_7_\ 05H
MU**** "BBB@ HHHH **** "BBB@ HHHH I:Q_P @2_\ ^O:3_P!!-6+;_CTA
M_P!Q?Y57UC_D"7__ %[2?^@FK%M_QZ0_[B_RJOL@2T445(!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1VHH[4 %%%% !1110 4444 %%%% !1110 5EZ-_K-3_Z_7_\ 05K4K+T;
M_6:G_P!?K_\ H*T :E%%% !1110 4444 %%%% !1110 4444 4M8_P"0)?\
M_7M)_P"@FK%M_P >D/\ N+_*N8\?>,M%\):%)_:MPRR7<;Q00QKN>0[<<#T&
M1DGUJWX.\7:/XPT5;O1[@R+#B.6-UVO&V.A']>E5]D#H:***D HHHH ****
M"BBB@ HHHH ***@^UH=0-GAO,$0ESCC!)'Y\4 3T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445!)=I%>P6I#;YE=E(' VXSG\Q0!/1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1VHH[4
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M;?\ /:]_\#)?_BJ/[$MO^>U[_P"!DO\ \56E11SR[A8S?[$MO^>U[_X&2_\
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MV_Y[7O\ X&2__%5I44<\NX6,W^Q+;_GM>_\ @9+_ /%4?V);?\]KW_P,E_\
MBJTJ*.>7<+&;_8EM_P ]KW_P,E_^*H_L2V_Y[7O_ (&2_P#Q5:5%'/+N%C-_
ML2V_Y[7O_@9+_P#%4?V);?\ /:]_\#)?_BJTJ*.>7<+&;_8EM_SVO?\ P,E_
M^*H_L2V_Y[7O_@9+_P#%5I44<\NX6,>WMQ9^(%ABFN&C>U9F269G&0Z@'YB<
M=36Q6:__ ",T/_7F_P#Z&E:5.;O9@%%%%0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1VHH[4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH S7_Y&:'_ *\W_P#0TK2K-?\ Y&:'_KS?_P!#2M*J
MET ****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *.U%':@ HHHH *H:VCRZ#J,<:L
MSM:RJJJ,DDJ< 5?HH ^;- U[Q/HMYX4E/@W7WAT6TFMYHEB<"<OG!QMQQGO7
MO'A37KCQ'HBZA=:1=:5(9&3[-=##@#OT'!K-\2?$OPIX3U$:?J^I>5=[ YB2
M)W*@],[0<9K7\.>)=+\5Z2-3TB=IK0NT8=D*'(Z\'F@#6HHHH 8L,2[]L2#S
M#E\*/F^OK0L4:HB+&@5/N +PO;CTI]% !67HW^LU/_K]?_T%:U*R]&_UFI_]
M?K_^@K0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% &:_\ R,T/_7F__H:5I5FO_P C-#_U
MYO\ ^AI6E52Z %%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BCM0 4444 %%%
M% 'C?C;1_$UA\0KS7],LO#;6UW;1VZOJLB#>5') 8C![<=@*]"\%1ZS'X<0:
M[::=:WAD9O+T\ 1%#T(QW->6_$BRL8OB)<WOBOPYK&LZ5-9QIIQL2VR)AG>I
MP1R3SU_ ]N]^$]CJ&G?#^T@U""XMOWLKV]O<',D4)8E%;WQ0!V]%%% !1110
M 5EZ-_K-3_Z_7_\ 05K4K+T;_6:G_P!?K_\ H*T :E%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIO UM-:ZGJ&H))+(6DU'_7HV<%&Y/0CUKA/B)!X=B\=7FN7-SJ9?2A9S7MA
MBF*[EW'R%R6SG&<\'@''-=O\*#:2>!H[FUGFE:YNIYKCSHO+=9F<[U*Y.,'W
MH [>JNIWJZ;I5Y?NI=;:!YBHZD*I./TJU4-U;17MG/:SKNAGC:.1?56&"/R-
M '':-KNIQZEX9CO[CSQKUA)<.FP 02JJ/A<?P[6(P<_=!]:N>(O$4MOK*Z1:
MO-"L5J;Z]NH8#,\46[:H5<'YF(;D@X"G@DBC2_"EU9W6ES75W%<'1[)[2PPA
M&=P4;Y/?:BC ]6/<8LRZ+J8U==9MKBT2^FL5M+N-T8Q':2RNO?@LW!Z@]L4
M:MG?6;Z1;WL=\DUF\2NET[C#J1PQ/ YJKH,T4XU*2&1)(VO7PR,"#PO<5-HN
MC6VB:!9:/#F2"UA6)2XSNQW-1Z(JHVI*BA5%Z^ !@?=6@#5HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444UP61E5MI(
MP#Z4 <K/XO\ #L/CF+39=:LDO! T)B,HR)"RD*>P;VZUUE?&M[\-?&B^*)M,
M;1;V>Y><XN0A,;Y/W_,Z8/7)-?6-EI6J06%M#-KDSRQQ*CMY,9R0 ">5JW9I
M:B-FBLW[!J'_ $&9_P#OQ'_\31]@U#_H,S_]^(__ (FERKO^8S2HJAHT\USI
M44EQ)YDN75GV@;L,1G ^E7Z35G8 HHHI %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .OU_P#T%: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 5EZ-_K-3_Z_7_\ 05K4K+T;_6:G_P!?K_\ H*T :E%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &9H'_(&B_ZZ2_^C&K3K,T#_D#1?]=)?_1C5IU4
M_B8(****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "CM11VH **** "BBB@#Q3QKX?UW_ (67?ZO9
M^!;+7K.>UBA5[R5-N\#E@&(P?X>G:O1/ ,5Y#X85+[P]:Z#-YS_Z%;8V ?WN
M.,FO+?B<^BGXC7">.)M:CT@6<9TL67^K+<^9G_:S_P#7[5Z%\)6U!OA]9F_-
MTP\R3[*;O_6FWW'R]WX?IB@#MZ**I:Q>MIFB7]^J!VM;:28*>^U2<?I0!=HK
M@=%U&^L]5\(I-=S7)US3I9;L2.2OFJB2!U'\/WF7 XQCTJY\0=:DM/#>J6]C
M?BTNXK1IWE60!T'\(7W;!^@!]J .RK+T;_6:G_U^O_Z"M6S>00V"W4D@,(4$
MNN6S],9S6?X>N(KI-1FA8M&UZ^"5([+V- &S1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!F:!_P @:+_KI+_Z,:M.LS0/^0-%_P!=)?\ T8U:=5/XF""BBBI
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ME_\ 1C5IUF:!_P @:+_KI+_Z,:M.JG\3!!1114@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=J*.U
M !1110 4444 >,^/HHM6\<75AHW@&SU_4[:".2_NKJ0H%##Y%'S#G _^MQ7;
M?#.[TR\\&0R:9I"Z0JS21SV2G(BF5L.,]^17G7Q8N/#D'C7,-]XCMM<-LHO/
M[%4$&+^'?DCG'IVQ7I'PU70%\"V'_"-RS2Z>=Q+S_P"M:0D[]_\ M9_#TXH
MZVBBB@ HHHH *R]&_P!9J?\ U^O_ .@K6I67HW^LU/\ Z_7_ /05H U****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,S0/^0-%_P!=)?\ T8U:=9F@?\@:+_KI
M+_Z,:M.JG\3!!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4=J*.U !1110 4444 >0>-;?Q-H
M7CV[U[2O$/AO28;^WB@ U&4(\FSO@@YY)Y],5;^''AWQWH-S;QWFHZ+-X?E>
M6XD%I\S2-)E@5;:!C<1WZ5B^/]/6U^(]YJ6K^#KKQ187-G%%:K;NQ-LRYW J
MO3).<GUX[UW7PKTC4-$\"6UKJ-L]I(TTLL=J[[FMXV<E4)]0/YT =I3))$AB
M>61@D:*69B> !U-/JEK-DVI:'J%@C!7N;:2%6/0%E(S^M &;I/BJVU2ZLX3;
MS6XO[=KJR>3'[^,$9.!T.&4X/8^QP_Q%X@E\/VCW8TF[O;:",S7,D!0>5&.I
MPQ!8@9.!V'TKF-'M;JZU+PC+):3VZZ#IDJ7N^(@+*8TC$:_WC\K'C/ 'J*U_
M%C0:[H,EC:W6I6]Y+;_:;0VT<B%F_@#97'WL95L>] '5(XDC5USM8 C(Q6;H
MW^LU/_K]?_T%:G@AO)='@BNK@QWIA032P </@;BN01C.>U5/#\30IJ,;S/,P
MO7R\F,GA?0 4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9H'_ "!HO^ND
MO_HQJTZS- _Y \7_ %TE_P#1C5IU4_B8(****D HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CM11VH
M **** "BBJ6L-*NB7[0;O.%M(4V]=VTXQ[YH \JUNS\4S?%/4=7\%ZGX<>9[
M1+66&6X#2X7!)=!D@@\9],5Z-X4'B,:(H\4M:-J?F-DVGW-G\/XU\UZ/<)H?
M_",WUAX/UZ+6=/NQ+J%T(G(NHR3N4#W''0=Z^E/"GB/_ (2G1%U+^S;O3\R,
MGD7:;7&.^/0T ;E%%% !1110 5EZ-_K-3_Z_7_\ 05K4K+T;_6:G_P!?K_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4=J*.U !1110 4444 %%%% !11
M10 4444 %9>C?ZS4_P#K]?\ ]!6M2LO1O]9J?_7Z_P#Z"M &I1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_:3S8R=I>-P[ '<"#T(S4_@TM!XHUZQ1KZVM(TA:&POYFDD'WPTREB<(V ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR* /2:*\TUS6->T"35])BUI[J2.UM+JWNYH4\R R7'E,K!0%8$#(R >HKH=
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MGS2V<;2:<2;1CUARNTX_#BH_[6F_Z ^H_P#?,?\ \71_:TW_ $!]1_[YC_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDJLD)MX<R$^1$3DI'_=&0/R'H*+OPU87L<(G:X:2*!K8S"8B22)L;D=AR0<
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MK3HH S/LFL?]!6W_ / /_P"SH^R:Q_T%;?\ \ __ +.M.B@#,^R:Q_T%;?\
M\ __ +.JER=:@O;* :G;$7$C*2;3IA"W]_VK>IC11NZ.R*6C)*$CE3C''X4
M9_V36/\ H*V__@'_ /9T?9-8_P"@K;_^ ?\ ]G6G10!F?9-8_P"@K;_^ ?\
M]G1]DUC_ *"MO_X!_P#V=:=% &9]DUC_ *"MO_X!_P#V='V36/\ H*V__@'_
M /9UIT4 9GV36/\ H*V__@'_ /9T?9-8_P"@K;_^ ?\ ]G6G10!F?9-8_P"@
MK;_^ ?\ ]G1]DUC_ *"MO_X!_P#V=:=% &9]DUC_ *"MO_X!_P#V='V36/\
MH*V__@'_ /9UIT4 9GV36/\ H*V__@'_ /9U3N3K4%_96PU*V(N&<$FTZ;5S
M_?K?IC11O(DC(I=,[&(Y7/!Q0!G_ &36/^@K;_\ @'_]G1]DUC_H*V__ (!_
M_9UIT4 9GV36/^@K;_\ @'_]G1]DUC_H*V__ (!__9UIT4 9GV36/^@K;_\
M@'_]G1]DUC_H*V__ (!__9UIT4 9GV36/^@K;_\ @'_]G1]DUC_H*V__ (!_
M_9UIT4 9GV36/^@K;_\ @'_]G1]DUC_H*V__ (!__9UIT4 9GV36/^@K;_\
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M /LZ/LFL?]!6W_\  /\ ^SK3HH S/LFL?]!6W_\  /\ ^SH^R:Q_T%;?_P
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MS;YB[CL<KV++M)'J:W*J:;%?0V2KJ-S%<7.26>&+RTQG@ 9)X'J:MT %%%%
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M%;.MZ=K5]>6[V%[8Q6T7S&&YMFDW29X8X=>!V'KSV%0:YH&I:SHVG6CW]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %':BCM0!F:E<WD=Y8VMF\,;7!?<\J%\!5SP 11Y&M_\_UE_P" K?\
MQ=-O_P#D/:3_ -MO_0:IIXTT9_&LGA(2O_:B0^<5V_)C .,^N#G'I0!>\C6_
M^?ZR_P# 5O\ XNCR-;_Y_K+_ ,!6_P#BZ;HGB32?$4<[Z7>1W @E:&0#@AE.
M#QUQGOT-<]IOQ2T#4M5M[!(=2A^TW+6D-S-:E89)EZH'Y&: .C\C6_\ G^LO
M_ 5O_BZ/(UO_ )_K+_P%;_XNG6VM6DUL\\K?9429H<W#JNY@<<<D<]N_M5/3
M/%5CJ6I:M9<P-IMREJ[S,H61V4,-O/O0!:\C6_\ G^LO_ 5O_BZ/(UO_ )_K
M+_P%;_XNM"*:*=6:&5) K%248'!'4?6L35O&&D:)X@TO1+R5UO-2.( JY4<X
M&X]LG@5482D[15P+?D:W_P _UE_X"M_\71Y&M_\ /]9?^ K?_%UH+-$\KQ+(
MAD3!= PRN>F1VI]2!F>1K?\ S_67_@*W_P 71Y&M_P#/]9?^ K?_ !=:=<_K
MOC'3= OH+"6*\N[^9#(EK8V[32; <;B!T&>.:J,)3=HJX%WR-;_Y_K+_ ,!6
M_P#BZ/(UO_G^LO\ P%;_ .+K21MZ*V",C.",$4M2!F>1K?\ S_67_@*W_P 7
M1Y&M_P#/]9?^ K?_ !=:=% &9Y&M_P#/]9?^ K?_ !='D:W_ ,_UE_X"M_\
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M3HH S/(UO_G^LO\ P%;_ .+H\C6_^?ZR_P# 5O\ XNM.B@#,\C6_^?ZR_P#
M5O\ XNCR-;_Y_K+_ ,!6_P#BZTZ* ,SR-;_Y_K+_ ,!6_P#BZ/(UO_G^LO\
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M=%2!F>1K?_/]9?\ @*W_ ,71Y&M_\_UE_P" K?\ Q=:=% &9Y&M_\_UE_P"
MK?\ Q='D:W_S_67_ ("M_P#%UIT4 9GD:W_S_67_ ("M_P#%T>1K?_/]9?\
M@*W_ ,76G10!F>1K?_/]9?\ @*W_ ,71Y&M_\_UE_P" K?\ Q=:=% &9Y&M_
M\_UE_P" K?\ Q='D:W_S_67_ ("M_P#%UIT4 9GD:W_S_67_ ("M_P#%T>1K
M?_/]9?\ @*W_ ,76G7,6'CO2K_7XM&-MJ-K=3AS;F[M&B2?9][83UQ51A*2;
MBM@N:GD:W_S_ %E_X"M_\71Y&M_\_P!9?^ K?_%UIT5(&9Y&M_\ /]9?^ K?
M_%T>1K?_ #_67_@*W_Q=:=% &9Y&M_\ /]9?^ K?_%T>1K?_ #_67_@*W_Q=
M:=% &9Y&M_\ /]9?^ K?_%T>1K?_ #_67_@*W_Q=:=% &9Y&M_\ /]9?^ K?
M_%T>1K?_ #_67_@*W_Q=:=% &9Y&M_\ /]9?^ K?_%T>1K?_ #_67_@*W_Q=
M:=% &9Y&M_\ /]9?^ K?_%T>1K?_ #_67_@*W_Q=:9.!D]!6%X<\7:1XK:^_
MLB9YH[.4122%"JL2,_+GDBJ49-.26B M>1K?_/\ 67_@*W_Q='D:W_S_ %E_
MX"M_\76G14@9GD:W_P _UE_X"M_\71Y&M_\ /]9?^ K?_%UIT4 9GD:W_P _
MUE_X"M_\71Y&M_\ /]9?^ K?_%UIT4 9GD:W_P _UE_X"M_\71Y&M_\ /]9?
M^ K?_%UIT4 9GD:W_P _UE_X"M_\71Y&M_\ /]9?^ K?_%UIT4 9GD:W_P _
MUE_X"M_\71Y&M_\ /]9?^ K?_%UIT4 9GD:W_P _UE_X"M_\71Y&M_\ /]9?
M^ K?_%UH331V\$D\SA(HU+N[=% &2:YOPYX]T7Q1?-9V/VJ.;R?M$0N8&B\Z
M+.-Z9^\N:N-.4DY):(+FIY&M_P#/]9?^ K?_ !='D:W_ ,_UE_X"M_\ %UIT
M5 &9Y&M_\_UE_P" K?\ Q='D:W_S_67_ ("M_P#%UIT4 9GD:W_S_67_ ("M
M_P#%T>1K?_/]9?\ @*W_ ,76G10!F>1K?_/]9?\ @*W_ ,71Y&M_\_UE_P"
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MCB7AWSHRJS4%=GJXZ=<TM(IW*".XS2U)J%%%% !1110 4444 %%%% !1110
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M$U]IG]JW.I68L+>Z$D\OF%)''S 'T/7%4L3*"]DEO_7Z&4II343JQ_R-3_\
M7DO_ *&:U.U98_Y&I_\ KR7_ -#-:G:I-3*O_P#D/:3_ -MO_0:U:R]4AO#?
M6%U:0)/Y!?>C2[.&7&0<&C[9K'_0(B_\"Q_\30!J45E_;-8_Z!$7_@6/_B:/
MMFL?] B+_P "Q_\ $T :E%9?VS6/^@1%_P"!8_\ B:/MFL?] B+_ ,"Q_P#$
MT :E9%YX6T'4+\WUYI-I<71QF62,,3CIUI_VS6/^@1%_X%C_ .)H^V:Q_P!
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MT?;-8_Z!$7_@6/\ XF@#4HK+^V:Q_P! B+_P+'_Q-'VS6/\ H$1?^!8_^)H
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M_$T?;-8_Z!$7_@6/_B: -2BLO[9K'_0(B_\  L?_ !-'VS6/^@1%_P"!8_\
MB: -2BLO[9K'_0(B_P# L?\ Q-'VS6/^@1%_X%C_ .)H U**R_MFL?\ 0(B_
M\"Q_\31]LUC_ *!$7_@6/_B: -2BLO[9K'_0(B_\"Q_\31]LUC_H$1?^!8_^
M)H U*QK?PEX?M+];ZWTBUCNE<NLJIA@QZG]:E^V:Q_T"(O\ P+'_ ,31]LUC
M_H$1?^!8_P#B:32>XG%/<U**R_MFL?\ 0(B_\"Q_\31]LUC_ *!$7_@6/_B:
M8S4HK+^V:Q_T"(O_  +'_P 31]LUC_H$1?\ @6/_ (F@#4HK+^V:Q_T"(O\
MP+'_ ,31]LUC_H$1?^!8_P#B: -2BLO[9K'_ $"(O_ L?_$T?;-8_P"@1%_X
M%C_XF@#4HK+^V:Q_T"(O_ L?_$T?;-8_Z!$7_@6/_B: -2BLO[9K'_0(B_\
M L?_ !-'VS6/^@1%_P"!8_\ B: -0\C!K)T[PQH>D71NM/TNVMIRI4R1I@X/
M44[[9K'_ $"(O_ L?_$T?;-8_P"@1%_X%C_XFDTF)I/5FI167]LUC_H$1?\
M@6/_ (FC[9K'_0(B_P# L?\ Q-,9J45E_;-8_P"@1%_X%C_XFC[9K'_0(B_\
M"Q_\30!J45E_;-8_Z!$7_@6/_B:/MFL?] B+_P "Q_\ $T :E%9?VS6/^@1%
M_P"!8_\ B:/MFL?] B+_ ,"Q_P#$T :E%9?VS6/^@1%_X%C_ .)H^V:Q_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ggtc45pq2o35000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" * !!<# 2(  A$! Q$!_\0
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MG_VC=?\ 0&OO^^X/_CE']HW7_0&OO^^X/_CE &A16?\ VC=?] :^_P"^X/\
MXY1_:-U_T!K[_ON#_P".4 :%%9_]HW7_ $!K[_ON#_XY1_:-U_T!K[_ON#_X
MY0!H45G_ -HW7_0&OO\ ON#_ ..4?VC=?] :^_[[@_\ CE &A16?_:-U_P!
M:^_[[@_^.4?VC=?] :^_[[@_^.4 :%%9_P#:-U_T!K[_ +[@_P#CE']HW7_0
M&OO^^X/_ (Y0!H45G_VC=?\ 0&OO^^X/_CE']HW7_0&OO^^X/_CE &A16?\
MVC=?] :^_P"^X/\ XY4<^KSV]O)/)HU_LC0NV'@Z 9/_ "TH U**S8]4N9(U
MD&BWX# $ M!GG_MI3O[1NO\ H#7W_?<'_P <H T**S_[1NO^@-??]]P?_'*/
M[1NO^@-??]]P?_'* -"BL_\ M&Z_Z U]_P!]P?\ QRC^T;K_ * U]_WW!_\
M'* -"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_ +1NO^@-??\
M?<'_ ,<H_M&Z_P"@-??]]P?_ !R@#0HK/_M&Z_Z U]_WW!_\<H_M&Z_Z U]_
MWW!_\<H T**S_P"T;K_H#7W_ 'W!_P#'*/[1NO\ H#7W_?<'_P <H T**S_[
M1NO^@-??]]P?_'*/[1NO^@-??]]P?_'* -"BL_\ M&Z_Z U]_P!]P?\ QRC^
MT;K_ * U]_WW!_\ '* -"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0
MHK/_ +1NO^@-??\ ?<'_ ,<H_M&Z_P"@-??]]P?_ !R@#0HK/_M&Z_Z U]_W
MW!_\<H_M&Z_Z U]_WW!_\<H T**S_P"T;K_H#7W_ 'W!_P#'*/[1NO\ H#7W
M_?<'_P <H T**S_[1NO^@-??]]P?_'*/[1NO^@-??]]P?_'* -"BL_\ M&Z_
MZ U]_P!]P?\ QRC^T;K_ * U]_WW!_\ '* -"BL_^T;K_H#7W_?<'_QRC^T;
MK_H#7W_?<'_QR@#0HK/_ +1NO^@-??\ ?<'_ ,<H_M&Z_P"@-??]]P?_ !R@
M#0HK/_M&Z_Z U]_WW!_\<H_M&Z_Z U]_WW!_\<H T**S_P"T;K_H#7W_ 'W!
M_P#'*/[1NO\ H#7W_?<'_P <H T**S_[1NO^@-??]]P?_'*/[1NO^@-??]]P
M?_'* -"BL_\ M&Z_Z U]_P!]P?\ QRC^T;K_ * U]_WW!_\ '* -"BL_^T;K
M_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_ +1NO^@-??\ ?<'_ ,<H_M&Z
M_P"@-??]]P?_ !R@#0HK/_M&Z_Z U]_WW!_\<H_M&Z_Z U]_WW!_\<H T**S
M_P"T;K_H#7W_ 'W!_P#'*/[1NO\ H#7W_?<'_P <H T**S_[1NO^@-??]]P?
M_'*/[1NO^@-??]]P?_'* -"BL_\ M&Z_Z U]_P!]P?\ QRC^T;K_ * U]_WW
M!_\ '* -"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_ +1NO^@-
M??\ ?<'_ ,<H_M&Z_P"@-??]]P?_ !R@#0HK/_M&Z_Z U]_WW!_\<H_M&Z_Z
M U]_WW!_\<H T**S_P"T;K_H#7W_ 'W!_P#'*/[1NO\ H#7W_?<'_P <H T*
M*S_[1NO^@-??]]P?_'*/[1NO^@-??]]P?_'* -"BL_\ M&Z_Z U]_P!]P?\
MQRC^T;K_ * U]_WW!_\ '* -"BL_^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_Q
MR@#0HK/_ +1NO^@-??\ ?<'_ ,<H_M&Z_P"@-??]]P?_ !R@#0HK/_M&Z_Z
MU]_WW!_\<H_M&Z_Z U]_WW!_\<H T**S_P"T;K_H#7W_ 'W!_P#'*/[1NO\
MH#7W_?<'_P <H T**S_[1NO^@-??]]P?_'*/[1NO^@-??]]P?_'* -"BL_\
MM&Z_Z U]_P!]P?\ QRC^T;K_ * U]_WW!_\ '* -"BL_^T;K_H#7W_?<'_QR
MC^T;K_H#7W_?<'_QR@#0HK/_ +1NO^@-??\ ?<'_ ,<H_M&Z_P"@-??]]P?_
M !R@#0HK/_M&Z_Z U]_WW!_\<H_M&Z_Z U]_WW!_\<H T**S_P"T;K_H#7W_
M 'W!_P#'*/[1NO\ H#7W_?<'_P <H T**S_[1NO^@-??]]P?_'*/[1NO^@-?
M?]]P?_'* -"BL_\ M&Z_Z U]_P!]P?\ QRC^T;K_ * U]_WW!_\ '* -"BL_
M^T;K_H#7W_?<'_QRC^T;K_H#7W_?<'_QR@#0HK/_ +1NO^@-??\ ?<'_ ,<H
M_M&Z_P"@-??]]P?_ !R@#0HK/_M&Z_Z U]_WW!_\<H_M&Z_Z U]_WW!_\<H
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MH]B^X>U1UM%<E]LNO^?F;_OLT?;+K_GYF_[[-'L7W#VJ.MHKDOMEU_S\S?\
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M[%]P]JCK:*Y+[9=?\_,W_?9H^V77_/S-_P!]FCV+[A[5'6T5R7VRZ_Y^9O\
MOLT?;+K_ )^9O^^S1[%]P]JCK:*Y+[9=?\_,W_?9H^V77_/S-_WV:/8ON'M4
M=;17)?;+K_GYF_[[-'VRZ_Y^9O\ OLT>Q?</:HZVBN2^V77_ #\S?]]FC[9=
M?\_,W_?9H]B^X>U1UM%<E]LNO^?F;_OLT?;+K_GYF_[[-'L7W#VJ.MHKDOME
MU_S\S?\ ?9H^V77_ #\S?]]FCV+[A[5'6T5R7VRZ_P"?F;_OLUSFK:MJUIJ$
M@TJYN9Y9%#746YG$"]!(!G[V!]P?>QD=#D=%H%51ZA17$:==N-/A-MJ%Q/$R
M[A*TQ8OGDDGW-6OMEU_S\S?]]FCV+[A[5'5+(CE@CJQ4X8 ]*?7'"619/,#L
M'SG=GFM_3[J[="UR@$0&?-;Y>*4Z?*KCC4OH:5%>=^$OB%<^*OB'J6F06Z)H
MD-EY]G,4(>XQ($,@/]PG=CCL#7HE9&A@>-?^15N?^ND'_HY*WAT%8/C7_D5;
MG_KI!_Z.2MX=!0 M%%% !1110 4444 <GX;_ .1W\:?]?=K_ .DL==1*T  \
MXQCTWD?UKE_#?_([^-/^ONU_])8ZUM;AEE$'EQN^-V=JDXZ545=V%)V5R[OL
M?[UO^:T;['^];_FM<W]CNO\ GVF_[X-'V.Z_Y]IO^^#6WLUW,N=]CI-]C_>M
M_P UHWV/]ZW_ #6N;^QW7_/M-_WP:/L=U_S[3?\ ?!H]FNX<[['2;['^];_F
MM-4Z>@PIM5'H-HKG?L=U_P ^TW_?!H^QW7_/M-_WP:/9KN'.^QT7G:?OV>;:
M[L9V[ESBG;['^];_ )K7SC+X(\;-\0VNELKS<;OS1>[3L"9]?3;QM_"O:OL=
MU_S[3?\ ?!KOQV7TL-R<E53YE?3I^(E4;Z'2;['^];_FM&^Q_O6_YK7-_8[K
M_GVF_P"^#1]CNO\ GVF_[X-<'LUW'SOL=)OL?[UO^:T;['^];_FM<W]CNO\
MGVF_[X-'V.Z_Y]IO^^#1[-=PYWV.DWV/]ZW_ #6C?8_WK?\ -:YO['=?\^TW
M_?!H^QW7_/M-_P!\&CV:[ASOL=)OL?[UO^:T;['^];_FM<W]CNO^?:;_ +X-
M'V.Z_P"?:;_O@T>S7<.=]CI-]C_>M_S6C?8_WK?\UKF_L=U_S[3?]\&C['=?
M\^TW_?!H]FNX<[['2;['^];_ )K33-IX8*9+8$]!N7FN=^QW7_/M-_WP:\R\
M1^%/%%UXJDG@L+N17<&&95.$';G^''_UZY\1)THIQ7,8UL1*FKJ-SW'?8_WK
M?\UHWV/]ZW_-:YB.RO%B0/!*SA0&(C/)I_V.Z_Y]IO\ O@UO[-=S;VC['2;[
M'^];_FM5=2-I)I=VD9@9VA<* 1DG:<5B_8[K_GVF_P"^#4-U!=06DTHMY04C
M9LE#C@9H]FNX<[['2Q?8/)BWFVW*HZ[>#BI=]C_>M_S6N92TNFC5OL\O(!^X
M:=]CNO\ GVF_[X-'LUW#G?8Z3?8_WK?\UHWV/]ZW_-:YO['=?\^TW_?!H^QW
M7_/M-_WP:?LUW#G?8Z3?8_WK?\UHWV/]ZW_-:YO['=?\^TW_ 'P:/L=U_P ^
MTW_?!H]FNX<[['2;['^];_FM&^Q_O6_YK7-_8[K_ )]IO^^#1]CNO^?:;_O@
MT>S7<.=]CI-]C_>M_P UHWV/]ZW_ #6N;^QW7_/M-_WP:/L=U_S[3?\ ?!H]
MFNX<[['2;['^];_FM&^Q_O6_YK7-_8[K_GVF_P"^#1]CNO\ GVF_[X-'LUW#
MG?8Z3?8_WK?\UHWV/]ZW_-:YO['=?\^TW_?!H^QW7_/M-_WP:/9KN'.^QTF^
MQ_O6_P":T;['^];_ )K7-_8[K_GVF_[X-'V.Z_Y]IO\ O@T>S7<.=]CI-]C_
M 'K?\UHWV/\ >M_S6N;^QW7_ #[3?]\&C['=?\^TW_?!H]FNX<[['2;['^];
M_FM&^Q_O6_YK7-_8[K_GVF_[X-'V.Z_Y]IO^^#1[-=PYWV.DWV/]ZW_-:-]C
M_>M_S6N;^QW7_/M-_P!\&C['=?\ /M-_WP:/9KN'.^QTF^Q_O6_YK1OL?[UO
M^:US?V.Z_P"?:;_O@T?8[K_GVF_[X-'LUW#G?8Z3?8_WK?\ -:-]C_>M_P U
MKF_L=U_S[3?]\&C['=?\^TW_ 'P:/9KN'.^QTF^Q_O6_YK1OL?[UO^:US?V.
MZ_Y]IO\ O@T?8[K_ )]IO^^#1[-=PYWV.DWV/]ZW_-:-]C_>M_S6N;^QW7_/
MM-_WP:/L=U_S[3?]\&CV:[ASOL=)OL?[UO\ FM&^Q_O6_P":US?V.Z_Y]IO^
M^#1]CNO^?:;_ +X-'LUW#G?8Z3?8_P!ZW_-:-]C_ 'K?\UKF_L=U_P ^TW_?
M!H^QW7_/M-_WP:/9KN'.^QTF^Q_O6_YK1OL?[UO^:US?V.Z_Y]IO^^#1]CNO
M^?:;_O@T>S7<.=]CI-]C_>M_S6C?8_WK?\UKF_L=U_S[3?\ ?!H^QW7_ #[3
M?]\&CV:[ASOL=)OL?[UO^:T;['^];_FM<W]CNO\ GVF_[X-'V.Z_Y]IO^^#1
M[-=PYWV.DWV/]ZW_ #6C?8_WK?\ -:YO['=?\^TW_?!H^QW7_/M-_P!\&CV:
M[ASOL=)OL?[UO^:T;['^];_FM<W]CNO^?:;_ +X-'V.Z_P"?:;_O@T>S7<.=
M]CI-]C_>M_S6C?8_WK?\UKF_L=U_S[3?]\&C['=?\^TW_?!H]FNX<[['2;['
M^];_ )K1OL?[UO\ FM<W]CNO^?:;_O@T?8[K_GVF_P"^#1[-=PYWV.DWV/\
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MW^%']K6/_/?_ ,<;_"LC^QKS^ZO_ 'U1_8UY_=7_ +ZHY*?<.>?8U_[6L?\
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M&]/I3_[6L?\ GO\ ^.-_A6-'I%X\:MM3D _>IW]C7G]U?^^J.2GW#FGV-?\
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M]PYY]C7_ +6L?^>__CC?X4?VM8_\]_\ QQO\*R/[&O/[J_\ ?5']C7G]U?\
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M#(PRK*<@CU%.KF_ &@7?ACP-I6CWTWFW5O$?,(;(4EBVT'T&<?A724 %%%%
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MV^O_ #[G_OK_ .M1_;Z_\^Y_[Z_^M2?V /\ GY_\<_\ KT?V /\ GY_\<_\
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MY_\ '/\ Z]:_NCF_>"_V^O\ S[G_ +Z_^M1_;Z_\^Y_[Z_\ K4G]@#_GY_\
M'/\ Z]']@#_GY_\ '/\ Z]'[H/W@O]OK_P ^Y_[Z_P#K4?V^O_/N?^^O_K4G
M]@#_ )^?_'/_ *]']@#_ )^?_'/_ *]'[H/W@O\ ;Z_\^Y_[Z_\ K4?V^O\
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MN@_>"_V^O_/N?^^O_K4?V^O_ #[G_OK_ .M2?V /^?G_ ,<_^O1_8 _Y^?\
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M?V^O_/N?^^O_ *U)_8 _Y^?_ !S_ .O1_8 _Y^?_ !S_ .O1^Z#]X+_;Z_\
M/N?^^O\ ZU']OK_S[G_OK_ZU)_8 _P"?G_QS_P"O1_8 _P"?G_QS_P"O1^Z#
M]X+_ &^O_/N?^^O_ *U']OK_ ,^Y_P"^O_K4G]@#_GY_\<_^O1_8 _Y^?_'/
M_KT?N@_>"_V^O_/N?^^O_K4?V^O_ #[G_OK_ .M2?V /^?G_ ,<_^O1_8 _Y
M^?\ QS_Z]'[H/W@O]OK_ ,^Y_P"^O_K4?V^O_/N?^^O_ *U)_8 _Y^?_ !S_
M .O1_8 _Y^?_ !S_ .O1^Z#]X+_;Z_\ /N?^^O\ ZU']OK_S[G_OK_ZU)_8
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M63_OK_ZU'-3[!RS[E#^W;K_GG#^1_P :/[=NO^></Y'_ !J__8EIZR?]]?\
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M7_UJ/[$M/63_ +Z_^M1S4^P<L^Y0_MVZ_P"></Y'_&C^W;K_ )YP_D?\:O\
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M^QVO_/M#_P!\"O0]K'L<OLY=SF?MMU_S\2_]]FC[;=?\_$O_ 'V:Z;[':_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Y/^%'M)?RAR+N<QM/H?RHVGT/Y5T_\ :ME_SW'_ 'R?\*/[5LO^>X_[Y/\
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M4]PUP'8AB'0*NT8YY^E=;0 4444 %%%% !1110 4444 %%%% !1110 4444
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MX@ABLYY(HY/,2-F7<HQD#C/-#E4[!RP[F?'I%]Y2Y@[#^)?\:=_9-]_SP_\
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M1]--K?ZQ<:M,9"_VBX15;!Q\N%[#'ZT :M%%% !1110 4444 %%%% !1110
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M#]V)_85Q_P ](OS/^%']A7'_ #TB_,_X4O\ ;T__ #RC_6C^WI_^>4?ZT?O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK[_GO_XXO^%:<M3N<_-#L:G]A6O_ #TF_,?X57O?#-M>6DEN+FYAWX!>,KN
MSSC(X..,]JI_VM??\]__ !Q?\*/[6OO^>_\ XXO^%3*E*47&6J8U.,7="VO@
M;2K&>&:S>X@,:[&",,2)S@-QS@G(/7KSR<WI_#MK/;R0^?<Q[U*[T90RY[CC
MK5#^UK[_ )[_ /CB_P"%']K7W_/?_P <7_"IIX=TX<D-$4ZRE+G>Y4T;X:Z1
MH=Z;JTO-1+,I1EDD0JP]\(*W_P"PK7_GI-^8_P *R_[6OO\ GO\ ^.+_ (4?
MVM??\]__ !Q?\*=.@Z:Y8:(TQ.,GB9^TK/FEW-3^PK7_ )Z3?F/\*/["M?\
MGI-^8_PK+_M:^_Y[_P#CB_X4?VM??\]__'%_PJ^6IW,.:'8U/["M?^>DWYC_
M  JM?Z#"=.NA$9FD\I]J@CDX.!TJI_:U]_SW_P#'%_PJ*XUJ_BM99%G&Y$+#
M*+V'THY:G<.:'8UHM"MO)3<\P.T9&1_A3_["M?\ GI-^8_PK)35[YD4F?J,_
M<7_"G?VM??\ /?\ \<7_  HY:G<.:'8U/["M?^>DWYC_  H_L*U_YZ3?F/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>-?\
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MN8+S0_B'-;RK+$790ZG()$*@_J#6AK&F6/\ Q1=O]EB\E+D1JFWC:86)'T)
MSZXYKL/[.L?)FA^Q6_E3C$R>4NV08QAACG@ <]A3WM+:0PE[>)C VZ(L@/EG
M&,KZ'!(XH Y.4[/'6OHO"R:/&[@#[S N 3[XXKGX1IZ?!:U6R\I;EC%Y?E_?
M^U[P1[[L_I[5Z8;.V-Q).;:$S2)Y;R;!N9/[I/4CD\57CT;2H;J*ZBTRS2XA
M0)'*L"AT4#  .,@8XP.U '+6\>I3^/->C2ZL(9C! (UN[1IF>';SMQ(GR[\Y
MZ\U5ET>"U3P=IDMU%J,$=_-B15PAPLA"@9/"GC&3TKM;[2=.U01C4-/M;OR\
M[/M$*R;<]<9!QT%2FSM3]GS;0G[/_J/W8_=<8^7^[QQQVH YWQ!;7-OJS:[I
MEW9&ZL[,I<VEV?E: MNR&'*$[6Y((..>E;>C74=]HEC=PV_V:.:!'2'&/+!
MPO'I2WND:9J4D<E]IUI=/']QIX%<K],CBKM '">'H)(? .M3:?'B^EDO65D'
MS,X=PO\ (8INDZ5-?^'O#<_]L:7#9VTD$T'DV11RW0Q[S*1ELLI^7).>*[B"
MV@M8_+MX8X8]Q;;&@49)R3@=R>:K1:-I4%\U]#IMG'>,26N$@42$GJ2P&>:
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M((DBAC4*D:*%50.@ '04 <C?:;;:QXVU73KM-T%QH\:-ZC]X^"/<'!'N*R]
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M\-_\COXT_P"ONU_])8ZW-3L9;WRO+9!LSG<3WQ_A51LWJ*5[:"?VW:?]-/\
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M&%4\V$X[Y/\ A4G]A77_ #TA_,_X5M1M*G%U-)65UYF=1M3:AJNAH?VW:?\
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MTZ,KYH,'F@98 $K@\ XY[5!9G:?KOACXB:9J&FQ_Z7"H$=W:7$31NH;E258
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M1110 4444 %%%% !1110 4444 8'C7_D5;G_ *Z0?^CDK>'05@^-?^15N?\
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M^^?_ *]'[H/W@G]OC_GV_P#'_P#ZU']OC_GV_P#'_P#ZU+_8"_\ /P?^^?\
MZ]']@+_S\'_OG_Z]'[H/W@G]OC_GV_\ '_\ ZU']OC_GV_\ '_\ ZU+_ & O
M_/P?^^?_ *]']@+_ ,_!_P"^?_KT?N@_>"?V^/\ GV_\?_\ K4?V^/\ GV_\
M?_\ K4O]@+_S\'_OG_Z]']@+_P _!_[Y_P#KT?N@_>"?V^/^?;_Q_P#^M1_;
MX_Y]O_'_ /ZU+_8"_P#/P?\ OG_Z]']@+_S\'_OG_P"O1^Z#]X)_;X_Y]O\
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MD'3^'_6;N_3'?-=AX3?Q%?\ B'5]6U[P[_8GFVEK;0Q?;8[GS/+>=F;*=/\
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M2\4:Q/;[;"]M[5+>7>#O*)AN,Y&#ZUV= !1110 4444 %%%% !1110 4444
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M^/.6,XZ;P/ZU479W%)75CEOMEU_S\S?]]FC[9=?\_,W_ 'V:Z3R;+_GG;_\
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M_/S-_P!]FND\FR_YYV__ 'RM'DV7_/.W_P"^5K7VB['%[-]SF_MEU_S\S?\
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M]A<D>YS_ -CNO^?:;_O@T?8[K_GVF_[X-=!_:UC_ ,]__'&_PH_M:Q_Y[_\
MCC?X4>TGV#DCW.?^QW7_ #[3?]\&C['=?\^TW_?!KH/[6L?^>_\ XXW^%5KG
MQ+I%FLC3W@41*'?Y&)52<;B .!UR>@P2:/:2[ J:>S,C['=?\^TW_?!H^QW7
M_/M-_P!\&ME_$6E1W$$!NLRSY,:JC'( R3P.!TY/&2!W%3_VM8_\]_\ QQO\
M*/:3[!R1[G/_ &.Z_P"?:;_O@T?8[K_GVF_[X-=!_:UC_P ]_P#QQO\ "C^U
MK'_GO_XXW^%'M)]@Y(]SG_L=U_S[3?\ ?!H^QW7_ #[3?]\&N@_M:Q_Y[_\
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M]IO^^#4-K\6/ U[=0VMOX@A>::18XT\J0%F)P!ROJ:[.I]L^P_9(Y+['=?\
M/M-_WP:/L=U_S[3?]\&NJEEC@ADFF=8XHU+N[' 4#DDGTKG?!GC6P\<6%[>Z
M;#,EO;736RM+@>9@ [@.P(/?FCVS[![)&AHD,L23>9&Z9(QN4C/6KU]/):Z?
M<W$4#W$D43.L*?>D(!(4>YZ5/164GS.YI%65CYTT34-0A^*_AO5=7T#7%UN]
MDN3=^;;[0P9=J"($_P"KC7J3SU-?1=5Y;"SFO8+V6UA>ZMPPAF9 7C#<,%/4
M9[U8I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPQXTA\3S:PEA#*LA,?DFY4#RSP 3[<$_0]:]&_MZ/_G@W_?5']O1_P#/!O\
MOJL:E.=1IOIJ=F$Q:PRFHI/G5G==/(Y+2/"&J:)=82);F*Y'[Q]RJ8",D*@S
M_JNH"CE2>X)QN_V1>_\ /'_Q\?XUH?V]'_SP;_OJC^WH_P#G@W_?5:IU%T.2
MT'U,_P#LB]_YX_\ CX_QH_LB]_YX_P#CX_QK0_MZ/_G@W_?5']O1_P#/!O\
MOJGS5.PK0[F?_9%[_P \?_'Q_C1_9%[_ ,\?_'Q_C6A_;T?_ #P;_OJC^WH_
M^>#?]]4<U3L%H=S/_LB]_P">/_CX_P :/[(O?^>/_CX_QK0_MZ/_ )X-_P!]
M4?V]'_SP;_OJCFJ=@M#N9_\ 9%[_ ,\?_'Q_C1_9%[_SQ_\ 'Q_C6A_;T?\
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M4A.R7Y08U&.4  PW>O5:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@# \:_\BK<_P#72#_T<E;PZ"L'QK_R*MS_
M -=(/_1R5O#H* %HHHH **** //_ !I97&N>(4TW1_#'AS4-2M[1)[B_UZ 2
M1QQ,[K'$FT%RQ9)&[* O<MQ<\"0MIUQJ6D7WAW1M)U:!(9IY=&B5+>ZB<R>6
MPX#@J4D4AAU&1PW&?\28-(:XM+CRO$YUJ--AD\+*?M:V[$G$I' B++P&Y+*=
MO1ZL?#3["MOJ*V^C>)[6[+QO=7_B.';<7A(8+\^3N"*N,<  CN22 :'AO_D=
M_&G_ %]VO_I+'6_J%A]N$?[W9LS_  YSG%8'AO\ Y'?QI_U]VO\ Z2QUN:G?
M2V0B\M4._.=P/;%5&]]"96MJ5?[ _P"GG_R'_P#7H_L#_IY_\A__ %ZA_MVZ
M_P"></Y'_&C^W;K_ )YP_D?\:VM5,[TR;^P/^GG_ ,A__7H_L#_IY_\ (?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS1? 6DZ!YZV,MX(IB&:)Y0RAN[#C@GC/T%,_M"[_ .?A_P Z/[0N_P#GX?\
M.G[%\W/U(^M25+V-_=WMTN;']AVO]Z7_ +Z'^%']AVO]Z7_OH?X5C_VA=_\
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M=>UF!-.O; V(M;6 B1KB&,E2_EJ!C>S=3SP,5ZAX5744\*Z8FJI"EZMNHD6
M-M'' ^;G.,9]\UKT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!@>-?^15N?\ KI!_Z.2MX=!6#XU_Y%6Y
M_P"ND'_HY*WAT% "T444 %%%% 'F_@#Q3X3TCPNFGWFJ6.F:O;RO'JT5_=HD
MTEZ#B:1F9CYFY@2'!(Q@<8P-#P3=Z7J?BCQ5J'A\9TB26&-Y8W_<SWJAS/(B
MY[JT +@ .5S\W4U_&/B?X8V&N?9?%8TJ?4XXE!$^GFY>-#DJI8(VWJ3M)_BS
MCGGL-#OM+U'0[*ZT22"33'B46Q@7:@0<!0O&W&,;<#&,8&* ,/PW_P COXT_
MZ^[7_P!)8ZZF2&*7'F1H^.FY0<5RWAO_ )'?QI_U]VO_ *2QUJ:\&*P8!/+=
M/PJHJ[L*3LKFC]CM?^?:'_O@4?8[7_GVA_[X%<IM?^ZWY4;7_NM^5;>R?<R]
MHNQU?V.U_P"?:'_O@4?8[7_GVA_[X%<IM?\ NM^5&U_[K?E1[)]P]HNQU$VF
M6%S"T,]C;2Q-]Y)(E8'\"*AMM"T>R=GM=*L8&88+16Z*2/P%<[M?^ZWY4;7_
M +K?E4^P3=[EK$347!;/I<ZO[):YQ]GA_P"^!1]DM<X^SP_]\"O(_B%>2VNE
M01VD<QU.5R+9X@=R#'SGC^'& <^OJ!5OP?>-J-I)<7:2C5V %T)%(P,G;L'9
M.N/?.><U"LZCIWU-Y4)QPZQ%O=;M_7XGJ/V.U_Y]H?\ O@4?8[7_ )]H?^^!
M7*;7_NM^5&U_[K?E6OLGW.7VB['5_8[7_GVA_P"^!37T^REC:.2TMW1AAE:,
M$$>A&*Y;:_\ =;\J-K_W6_*CV;[A[1=CI;71M+L8O*L]-L[>/.=D,"H,^N *
MF^QVO_/M#_WP*Y3:_P#=;\J-K_W6_*FZ<F[N0>T78ZO[':_\^T/_ 'P*/L=K
M_P ^T/\ WP*Y3:_]UORHVO\ W6_*E[)]P]HNQU?V.U_Y]H?^^!4<2:?.6$<4
M#%3@C8,C\*YC:_\ =;\J6/S/,7RMWF9XV]:/9/N+VGD=5]CM?^?:'_O@4?8[
M7_GVA_[X%0Z>+[9_I17&.,_>_&KM8NZ=KFRLUL0?8[7_ )]H?^^!7+Z=XA\-
MZ]XOO=$L)//N+& 23-"!Y.=V"-P/+#(SV_E77.BR(R,,JPP1ZBO,_#>F6.C_
M !KU:PTVTAM;6+1(0D42A0/WG\_>ES-!9'HPL[87"7 @C$L:&-'"\JI() ],
MD#/T%5[ZRC%CJ3V\ $]S"P<H.9&"D#/J<8'Y>E7ZKWTS6VGW,Z8WQQ,ZYZ9
M)I#)801!&",$* 1^%4Y=&T^?6K?6)+8-J%O$T,4VXY5&ZC&<<_2KD3%XD8]6
M4$T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX8UB\\*VA5Y([(!?MTHP1N8G_5@]AU(^F #U32[^/5=)L]1A5ECNH$G17&"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MONU_])8ZZ*\L8KW9YC.-F<;2._\ ^JJC:^HI7MH97]O3_P#/*/\ 6C^WI_\
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M2Y?W:U.K"0INK_M$FHZ[=^A<T_Q5=WZ/<BUC2T?'V<MG=(/[Y'8'C ZXY/7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@@L9!6JME8PZ5XNTSS$T[2[;48EC2.',$">1;2,K1K@>2S,QD'R@J\A)&2P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M##@ ?-O;^+"])5.VTV&TU"^NX6D!O622:,D%?,50F\<9!*J@(SCY!@ EB;E
M!1110!@>-?\ D5;G_KI!_P"CDK>'05@^-?\ D5;G_KI!_P"CDK>'04 +1110
M 4444 %%%% 'GMMXDTWPYXZ\6+JANXOM%Q;/"T=E-*K@6T8)!1".O%:A^)OA
M02B(WEYYC*6"_P!F762!C)QY?3D?G775CSV-P_C&QOUCS;1:?<0N^1P[20E1
MCKR$;\J ,O\ X63X8_Y^;[_P5W7_ ,;H_P"%D^&/^?F^_P#!7=?_ !NNLHH
MY/\ X63X8_Y^;[_P5W7_ ,;H_P"%D^&/^?F^_P#!7=?_ !NNLHH Y/\ X63X
M8_Y^;[_P5W7_ ,;H_P"%D^&/^?F^_P#!7=?_ !NNLHH Y/\ X63X8_Y^;[_P
M5W7_ ,;H_P"%D^&/^?F^_P#!7=?_ !NNLHH Y/\ X63X8_Y^;[_P5W7_ ,;H
M_P"%D^&/^?F^_P#!7=?_ !NNLHH Y/\ X63X8_Y^;[_P5W7_ ,;H_P"%D^&/
M^?F^_P#!7=?_ !NNLHH Y/\ X63X8_Y^;[_P5W7_ ,;H_P"%D^&/^?F^_P#!
M7=?_ !NNLHH Y/\ X63X8_Y^;[_P5W7_ ,;H_P"%D^&/^?F^_P#!7=?_ !NN
MLHH Y/\ X63X8_Y^;[_P5W7_ ,;H_P"%D^&/^?F^_P#!7=?_ !NNLHH Y/\
MX63X8_Y^;[_P5W7_ ,;ILGQ-\*0QM)+>7B(HRS-IET !_P!^ZZZL?Q58W&I>
M%=3LK2/S+B>W9(TR!DD>IXH R_\ A9/AC_GYOO\ P5W7_P ;H_X63X8_Y^;[
M_P %=U_\;KK** .3_P"%D^&/^?F^_P#!7=?_ !NJVH_$3PW/IEU#'<7S220N
MJC^R[KDD$#_EG7:T4 <A%\1_#*PQJ;F^!"@'_B5W7_QNG_\ "R?#'_/S??\
M@KNO_C==910!R?\ PLGPQ_S\WW_@KNO_ (W1_P +)\,?\_-]_P""NZ_^-UUE
M% ')_P#"R?#'_/S??^"NZ_\ C='_  LGPQ_S\WW_ (*[K_XW7644 <G_ ,+)
M\,?\_-]_X*[K_P"-T?\ "R?#'_/S??\ @KNO_C==910!R?\ PLGPQ_S\WW_@
MKNO_ (W1_P +)\,?\_-]_P""NZ_^-UUE% ')_P#"R?#'_/S??^"NZ_\ C='_
M  LGPQ_S\WW_ (*[K_XW7644 <G_ ,+)\,?\_-]_X*[K_P"-T?\ "R?#'_/S
M??\ @KNO_C==910!R?\ PLGPQ_S\WW_@KNO_ (W1_P +)\,?\_-]_P""NZ_^
M-UUE% '(I\3?"DF[9>7C;6VMMTRZ.#Z?ZOK3O^%D^&/^?F^_\%=U_P#&ZU-
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MC-%$F0-S,A &3P.36C"I2"-6ZA0#0!RW_"R?#'_/S??^"NZ_^-T?\+)\,?\
M/S??^"NZ_P#C==910!R?_"R?#'_/S??^"NZ_^-T?\+)\,?\ /S??^"NZ_P#C
M==910!R?_"R?#'_/S??^"NZ_^-T?\+)\,?\ /S??^"NZ_P#C==910!R?_"R?
M#'_/S??^"NZ_^-T?\+)\,?\ /S??^"NZ_P#C==910!R?_"R?#'_/S??^"NZ_
M^-T?\+)\,?\ /S??^"NZ_P#C==910!R?_"R?#'_/S??^"NZ_^-T?\+)\,?\
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MOHLEA8R7TMS--"(T_LVY7)$JGJ8P.@KT =!2T4 %%%% !1110 4444 %<O\
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M/45Y_KJSQV?C;2/L5])=ZWO^P>39RR1R;[.*%=TJJ4C_ 'B,#O9< 9. 0:]
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MK4;355TN#;YJP:7<SK?$J&V[XXV7RAG#+G+D%2 @(D3Q!9^'6\0-<Z]X7_M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMY;5Y9]0N)'>&1</&S,Y+)W"DX4Y88))K0F\.:1<>&AX=GL8Y=)%NML+9R6
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MR6X\K?$S-@R,QY//7T]*Z!?!/AT:?J=C)I_VB'5,?;6NII)Y)]H 7=([%_E
M&WGY3R,'FK%UX7TF]\C[3#/)Y42P'-W*//C'1)L-^^7EN)-P^9O[S9 /*/"N
MNZQK'ASX<Z+=:K?>7K4U^]]=)<.+F1;=V9$$N=RJ> <8; P"!G);:+?Z=XP^
M()T6]U6XNM*NM,U&.)KV1I+M%C=VMF?#,ZE"R*#GD)DG!SZ>G@GP['X<M= C
MT[9IMI*)[9%FD#PR!RX=)-V]6W$\AL\D=.*R[CPQ#X0T?6[GP;H]W)K6J(P,
MBW0E8S;7*2N;B3! 9N<9)W=#0!'X0U&?Q7XHU7Q1;:A._AY8DL=,B7S8XY\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ggtc45pq2o35000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ". A8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#@O&WC74?"_BC2((;>*72FADN-1)4F2.)71"Z\_P[P3[ U9\/\
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M!<B/SCY?FB/R]V/7;QUQ2W'@/2)_#NF:*LE[!;Z9*LUK)#<%98W7.#N_X$:
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M^GN)5O%AN%B6>SCNG2WE6)0J!D!P0 !Q0 [PMX@N=4\0ZW93R%X(TM;RTW(
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M5WFHS6X\8Z06EBD8++$(@P+1N0"&Q[@$9KD_''AK58;^[U/2KBVD2<;WMI9
MCJV.2I/!Z9Q433:T/*S.G7JT[4'9IK9VT.BUCQO%HU_;::+22]NVCW3&-PJH
M0!QSU/M6SI6NVNJZ;)>J'@2(D2K, "F!DY]L=Z\J&D:]=Q0Z^+%UA@A$KB0Y
M>3.=VT#.X\YS5<>+HKFUU#3HYT7[5%F09VD[0?E ]^_L*GG:>IR_VGB*=:]:
M%H-.VFNAZ%<>*=&\1);:?IVJH8[N39+("4.P=5!('+=*CN=7L_!^OP:7:Z!.
M+>^&XS6REM\F#@ =\ <\UYWI,UK;6)MKJ,HP_>IO&T[3\RL/:NKUGXAZ,?$5
MA)NDN+&Q+,TL(&&F(QQDC( )Y'K50J+6YTX/,O:N?M8V:=E\R>]O+F:VUBPC
MT;4B+^=9HY7MR/+SMW9_W=N1BMA]7M_$]]<>'7TZZDT^2#$MV,IM<<[3QD$'
M%=%INI6FK:?#?V4PEMYEW(X_SUKD(_''A[0]4U"UNKWS)IKPN9(D+K@@#DCL
MN,?A6T;OI=GI1M#63O<N:=KJ:%JESH>N:O',8HQ/;74[*'>,\%7QQN!]N00:
MT];\6:1H%A!=W=QN2X_U A&XR?3V]Z\+UB83>(GU-&$CSW3;]O.Y3GD?0 5/
MJ6K+>V]E:,JM!;*RQ '^\<FO0C@5*"G?U.)XUQDX6]#U$_$2"XT?4+FWLY8;
MB"(O"MQC;(>PR._M7 6GC/Q =4BOKS4I=RG/D@8C8=P%Z$?K56[TS4-UG8Z:
MK:E)<P+*T,'+0DCI)V7V)KK? ?AMA/J>D^)M,C:X"1S)&S+(JH2><CHQ(Z5I
M_LM#WDN9/H]T9?[567*WRM=4=)X2\=P^)[N6S-E)!/&NX,#N1@.O/;\:Z^N9
M\)Z;:6<^JS6-M';VKW'DQ1H.,1\$_BQ;\JZ:O,J<O,^561Z=/FY?>=V%%%%9
MEA1110 5SOB2[@ADBAFC$JR12*T9.,@X']*Z*N+\?>)K#0K5+>>U\^ZNHW$3
M;0?*[;CGZ]O2HJ4*M>/LZ+M)_,TI3C":E-719T[Q&MMIL%O<?/<K\BDG 8#I
MSZU<T;Q"NIW4EI+ 89U!*D'*N!_(UR.GZ6M[+:W%M"YM;4";#$GA1D Y[DXK
M1T&]MH)IKR0[Y=NU$'<GDGVKQL-C:K<>=^[=J]K:+J>E5PM-QERK73[WT.RN
MYDC@D5IUA9E(5CU!QUQ7,^#8)();VWD99(X J*Z_=8G)/7UX-94=Y<W&IW4M
MT50NY*9/\/;'M70Z!JEDUP^FQQ^5/@R'G/F>I^M.GC%7QBB]$KVWU_0\>2DI
M\LE:Q9\0V]Y+;126<7FM$Q+1@X)&.WO6='IMUJ]BL$Z211,FT[P5P#UX]:ZF
ML#QC->P^'G-BLID:5%<Q9W*F>3Q_GFNZK@J=2I[1M^?G8QKQBHNH^ARK:>=-
M>7[*A:.#+(QQG:/8]:['PSJ(U;1(KTPK'(Q9&VKC)4XS7&6%K_:<T=M+<+!O
MXWN<G/H/>MRSLT\.ZG#;65Q(;;(6<2'(8GJ?8THU'0BG4=[NQXV5R7/*K%6B
M]-[Z^G0VM4OK9)[>U\Y5NO-1U4G&!GDY^F:U&(52QS@#/ KS"TNIM7\9EV19
M \Y*(QX(7IGV&,UI>/=2UJ"*V@M;IK$NKES"P/F >AZULJRLY,]"EC+J=22T
MO9?\$TM.\82W=]=0R6:B)&S&RO@[??WK?L-5M=1+K _[R/[R-U'O69H4=A#X
M?LDN19B9H5DD 8'<<<MZ\XJM9/;2^+4DL+810I XFD48##C&1TZU$9SC)*4D
M[]"Z=2I&4>>:=^G4ZFBLS^WK!B?),]P!U:"!W7\P,'\*NVEW!>P+/;R;XR2,
MXP01U!!Y!]J[7"25VCM4D]BS1114C"BBB@ HHHH **** "BBB@ HHHH ****
M "O*OBEI\J:M:7ZH3%+%Y98#HP)./R/Z5ZK2,JN,,H8>A&:SJT_:1Y29QYE8
M^;/P-'X&OH_[/!_SQC_[Y%'V>#_GC'_WR*Y?J?\ >,?8>9\X?@:/P-?1_P!G
M@_YXQ_\ ?(H^SP?\\8_^^11]3_O![#S/G>RM);Z]@M8$9Y)7"* /6O6/!LTF
MCZG?>%KN0LT#>;:,W\<9ZX_G^==DL,2-N6-%/J% KE?&VGSJEIK]A&&O--?S
M& ZO'W'X?U-7&@Z2YD[_ .12I\FIUM<9"HN?BQ=,P#"VL5 S_"3C_$UU&EZC
M!JVF6]_;D^5,FX ]1ZC\#7,Z=\GQ2UA3U>SC(_#;6U1I\OJ7+6QT&O6$.IZ%
M>6LZAE>)B..A R"/QK+\$7SW'@JSFF8LT2,A)]%) _0"NCD3S(G0]&4BO*[?
M49]+^'FK:?&3'=VUX;>3U57/4?7D5-27)/F\F*3L[C/#6M:I,;V#1;83:I?W
M#37%Q+_JX4S\OX]?_KUU%KX#BN9S=^(KR35+H]B2L:^P H^&K6G_  C 2%56
MX25A<<8;.>,_A78U-&FG!.6HH132;*]I86EA$(K.VB@0=HT JQ1172E8U"BB
MFNZQHSNP55&6)Z 4 .I&)"DCJ!Q7%IXYO[LR7&G>&[N\T]7*K,C<OCN!BMNX
MUZ>UF*/HFI2)@%9((U<-D9['(].:B,XRV(YXV.5TK3AK%]IZP2""2TA-[-=H
MH,CSR,P )/4  Y'T%=";[^Q[C=K%G%^\8[;RW0L&^J\LI^F16+X;L=2TG6M0
MOAIUR-)F&(DE($R98L<KW&6/X5U"3)>ZI%<HDBPV\3Y>1"HRV.F?8&J1E27N
M^93GUB(Z*X\-I'=7 &(8D4[ ??ICOUIUAX<M)[:.YUG3;";47;S96\E6".>P
M)&<"O+7U7Q+XN\2-/X=U2+1;2Y+1VH1.9MF<-)CN<'\*Z_P3XC\5:Q8W5G=P
MZ<=1TV7[/=&1V!9NQ^48Z4^;2Q7M5:S5RA\1O";:]K4*Z8I6_6S,LBAL>9&K
M ;![G)Q57P]#H^FV7FV]C-?:_(#%!8/ P\@GCY\C QU9ORKI(->T_3_$\LFL
M:E$^HS(MNL=NC&*! <X+'J2>2:[;CJ._>I23=R%AXNI[9K4YK3O#TF@^ Y-(
MLW+W(MI/F!QF5@2<>@R>*XB^L;;Q8MAI27ECI<,%G"]E))!EYVP1(N[('RL,
M%>N>:]=KE/$7A;PPT%QJ&K1M%:[O-G1966-V]2H[GVY-;4YJ)K.%S@M'T#3[
M'P\-;6Y:75+;45A@PV8I660+\BXR0RD]:[W5/ /AJZM)O]!2TW'>\UN K@#D
M@$YQGIQ5'PUI'A74Y%U/PXSP>02FP _)GNJOG;]14'Q"UB_T;2([>6<&"<MO
MF3Y690.5/;G/:J=3G>C)4.1:HM_#B[T=/#D-K8W%NLDDDD@@#Y= 6)53GDD#
M')JG>S>)_#%QK>K&WTJ>*ZNP(?,F<2NN L8Z8 'I]>:\QT:;7O#UE:>(DT61
MM(\T2"?(!V \=>@.< ]Z[9-3@\61VVJZ_9WEYI!G5%\EO*MK9F.T9&0\I!."
MW09X%:RA%2NG=$N5URQT?0Y%=?U"Y\031ZGJ\VCI;2/<RVD,QC"$Y.$ZEBQ/
M'7J:]B\%:K/J&@VT5X9&NXH(V=Y$96<$<$@\@\'.?KWKEO'</A[PJVD/_9K6
ML-U<I#<75N@^6-3NPQZD\9!] :]!TR&R2T66Q=98I_WGG!]_F9[[N]37J*:3
M4;!1A*#:;NR[117 >(M7UBVO?$J6;DP06]NP?S]IMR0<E5P<Y^HK&$'-V1M*
M7*KG?T5PL_B+4[6[O+>R6W)6:[<M<%WXB5#@<\9R>.@I1XSU"74+D0P6S6]M
M;M,\7.]L1!Q@YY)9L8V\ 9J_82)]I$[FO'/C1#.FIZ7=+$S0M"\6[MN#9Q^5
M>B^%]8O-7M9I+M+?"LOEO"ZD,"H/(#-C!XZ\^U0^.K>WN?"5ZES&'7Y=I/5&
MW !A[C-.E66%J>TGLM_0N*Y[)=3FH/&<NG>'8[VW:*:W6/*JZXY'&..^>*Y#
MP?K-WJ'CF'^T9=\%Y*P:! %1202N /0U9T[X=S:D%A'B-8+%Y Y@>/YB?4<X
MKI-=^&TMO_9UYX6DCAO+(*"LS8\T@Y#;O[V?PQ6>64\#[*47/VBDWRMKX5;2
M]^IT8F=1332Y7UMU,?XA:S=6>M+#8E;=H9 B@H#\J@$<'L2:FL_$.IWD-EK)
MEB:_CW1NPB 4_P"SCZ5.W@;Q%XJ\13:CXE^SV$10*B6TGF'@< ?CR2:X^X.K
M^');S2);:03[\PR!<QMVW9Z8Q@_A48K!T5@^6E)>U4N:^U[MZ>?*G?Y$0KN5
M:+K)N*TL>[Z3?'4M*M[QHC$TJY*'L>GY51USQ-9:"R1SB1YI%W*B#J,XZ_6N
M!T33-7A(71=:U!YW0;Q*X:,GUVGA1]*LVMKJ'B[5_-OY($O;*$(BH"%D^8Y8
M^A&?IS65.O1DTE*_RM=^1..P^)ITI3I1U6MM'9$.KSSZ_J5LMCIHM)I)5R#)
MN+<]2JCY<=SFNCTVWU&]UBZ@O(DCDMWS*X;*G=R"O<@BH-+OKS1/$5MI%U!A
M+D[5P <<$Y!';BNAUB$)=V=U%.UK/)(+=IE(^Z02 000>1QZ9IU:-*NDJBM8
M\;+Z7M8.=1>]?56L<P?"O]D7\MV;IGD:9I( #_JU!R,^]=%?:K9^9 T]A]I
M'#[02F1S@&J&K^%+J[E6>/4+FXDX5A-,4P/5=N /IBFW#2Z7I5Q;W\,\EU&O
M[J[CA+I*!TSM'RGL0?K6'L*L9R]D].W^7](Z%2G3<N1618O-$36KN/4;*Z2.
M(Q",H8^003^76J6I6U_HNE7)B0&)T*RON!# C'/>I[+6WFLDM=+B,3[2TEW>
MILC3U('5C[=/4US,FJ:/J,T?]LZU-(C-M+ON,9(/(&T;::H*3C.*?.^VMO7M
M\[&514[J<5[S[/0[2'4YTT#1WMTB1[I(TWS9"1_)G) ^F .*72K/6+/7KPW$
MMO+ITZ"4/&FP^=P" ,GC SFLSQY+93^#V@AN%:24H;6&!MQGYP  .H_PKHM%
MBN8-$L8KPYN4@19?]X#FO3E94^9=6]#NCK.W8T:***YC8**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *;(BRQM&XRK@JP]0:=10!PFA7O_
M  B&L3>'=2F"V+DRV-PYP,$\J3_GGZU+I\R7WQ1O;BS=98(;)8Y9%.5W9'&?
M\]*ZK4M)L-7M_(O[6.>,<@,.1]#U%,TK1M/T6W,&GVR0HQRV.2Q]R>36"IR3
M2Z(SY7MT+]>4ZY:FZU/QFL0/[N*&7CIE2"?TS7;^,M7GT;PY+<6C;;EW6*)L
M9P6/7\LTOAKP]_8UK<274YNKV\;S+F5AU/I].3147/+D"2YG8\^TOQG;:-KE
M]>0VLMQ#>QQ%D7Y"L@7YOKSFNBB^)33,%C\/7SY_NG/]*G\1QQIXY\-):QJ+
MC<Y=0H \OO\ UKMJBG"=VE+;R%%2U5SE].\=Z9>WD=G<0W5C<2'"+<Q[03Z9
MKJ*P/&6GVE_X9O#=!5,,9EBD[HP&1@^_2I_"UW->>%=.N;ILRM "[$]<=S^%
M:Q<E+ED6F[V9C>*YKZ]\1:5H-K>RV<=RKR320G#$#H/T-)_PKRVE7%WK&J3Y
MZ@SX!J![ZWUOXE:<VG/Y\=C!()Y4&54G/&:[FIC&,VV]=24E)MLJZ;I]OI6G
M0V-JI$,*[5R<G\:S?&#SQ>%-0GMKJ6VEAC\T21'#?*<D?CC%;E8OB_\ Y%#5
MO^O9_P"5;6TLC1:"^%]8_MO0;>[<J9L;9=O3<._XC!_&MAE#J5894C!%<-H;
M#PYXB%@2$L[Z-'BR>A(X_7*_]\UW512DY1L]UHRYJSTV/#-3TGQ#X)DDLK'2
MKR]MHYS)IMY:C>5#'.QP!D$'O_C6_P"$]-UO0]%U*_U0/%JVMSHJHY&\<'+'
M'0\G]*]4K U(F?Q3I=NO1%:5^.W;]13DM#&%**ES(Y^?1(9O NI6K*L=Q!<-
MOG5?F)1@<_E5*W\97'@C5[+0O$S!M/N8_P#0]27[N!CANX'(^GN*ZZ"W\^/7
MK)ERLDC8'^\@KD_%&G6NO^!M!O\ 481)#;21K<^JQN/*<CW!(;\*F,5=,V;=
MK'I*LKJ&4AE(R"#P17GGC>Z?5/$FEZ*F3:Q7,+7('1F9N%/X9_.JG@CQ!/X6
M.J>$_$4^Z31XS-:W!/,UOU&/<#&/R[59TZWEFN-&O[M-EQJFIM=[&ZJBQL5%
M:D$%]#?^'O%VJZQIBHUM&T;75OTQ&RC+#VR.<=.OK73:YIUAX\\&S0H,^=&3
M"<X:.0#@'TYX-6ML+>+;NU<9^TV"LP]0&*_UKB_!=S/X<OTTZZFWVTTCP;B?
MNLC;0#[CY1]&'I7,I.E*_1LU<5.-NIP6J^)_$NJ:+'X,N=/N(K@&.W^SQ6Q!
M.PC'/IP.>E>M>'?!D]K\-V\.ZC.%N+A',K1\B)V.1CUP<5V>!G..?6H[JYBL
M[62XF;;'&NYC7;*I=;6.>,+,\Y\9PWG]B0+XI-G=P1./)L[0,&N9 ,!G8\JO
M/('KUK$&K^.O G]EVL&AZ?=Z;.LKQZ;9EO,C5?G;#'.3@YQS73_9)=>TG4O$
M=\2<VTHLH>T:@'GZ\5;UN8HW@O5!G:+N.)B/26(K_/%9>TE+1[%\BCZE_P )
M>.M%\96S-I\S1W4?$UI.-LL9]QW'N*Z(PQ-NW1H=XPV5'S?6O+M:\&65[\84
MNEGGL;R>Q%W;3V[;09(VVN&'?(92?I76^5XML&^2:TU&/T<;&'\JUA#FZI$3
MGR]&SH)A:P123S+$B*"SNP' /7-8&F6_AN\UDWMC,)+I7:41^8V%<C:6"GOC
MBHWTC6]<<)K%Q';68.3;VYY?ZFK>J>&+:X@CDT]5M+V#!AE08Z=CZUJHPC[K
MEJ^VQDY3EJHZ+ON;<,$-NI6"&.)2<D(H )]>*AOH;:XLY8;P(;=QAPYP,5B6
M/B5T^TV>KHEI>VT>XL6&V3T(K$L/#G]M^'I=1GEN)+Z82-$&D^4GG:<5$Z-H
MR=3;[[E1K7DE#_*P7HL?L[+ITDI0=&?&"/;O73>%Q.OART%RTC28;F0_,1N.
M/TKGM+N4TJUQ>V,;R1C+,YP5_/BMS2KZ;Q!9_;[:]^SP,Y5(XXU8C']XGO\
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MHC/;3(!L XR2/SSFETP!=4U;M^^4G_O@5SHCN-2UO4M-L7Q9S7 FN+A3QC:
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MT?U_*K).RHHHH HWNC:=J,J2W=I'+(G 9AS_ /7J25HK"QD=8PL,$98(@Q@
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M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *3%+10 W;5:?3K:YF666(,ZC&?7ZU;HJ9PC-6DKH:;6Q6
MAL8H'=@7=G&TF1BV%].>U3A .@ P,"G44XQ459"&[:-M.HI@-VT;:=10 W;1
CMIU% #=M&VG44 -VT8IU% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ggtc45pq2o35000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000016.jpg
M_]C_X  02D9)1@ ! @$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $&!+(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBOQY_;
M8_:8_P""N/PJ^-]QX4_8T_X)^?#K]I#X+)X6\/ZA;?$GQ+\8_"W@G59?$UXM
MV=?T5]$UCQUX=NT@TMH[58;C^SO*G$S.ES+RL7RUHO[;'_!P==ZQI-KJ_P#P
M2.^#>FZ5<ZE80:GJ _:.\"2FQTZ:ZBCO;L1Q?%*>1FM[9I90J03OE!B"4XC8
M*Y6U>\?_  **?Y_GV/Z*Z***"3B?B7\0?#?PE^''Q ^*GC&6]@\(_#/P3XJ^
M('BJ?3-.N]7U*'PYX-T*_P#$>N2Z?I-A'-?:I?1Z9IMT]IIUE%+=WMP([:WC
M>:5%/\\?_!.3_@L3^T9^WE_P5=^,O[/VM?!'7OV?OV3]'_8\C^/'P1\'_%CP
M5)X>^.GC.UN?B)\.O#OAWXL^*)7U&8:%H/C?2?$OB"[T/PC#;7,,6CQZ%J(U
M:[F>:YO?Z42 P*L RD$$$ @@]00>"#W!K^;CX0Z/K$?_  =,?M6ZY)H^KQZ'
M<_\ !+KP'8V^MOI=\FC3WT7Q,^$$DEE#JS6XT^6\6/+FV2Y:<K',1&1!-Y;5
MK/R5_P 4OU)E>\==+I6_K\C]7_\ @I=^VA8?\$]_V'/VA/VN[KP_;>+K_P"$
MGA&TG\*^%+V\>PL?$?CGQ5X@T?P5X(TK4;J$BZBT>7Q3XBTJ?77LLWZ:'!J,
MED/M*15^,'['G_!3/_@I!\-?VT_V&_V:O^"D4'[.OB[P?_P4O_9ZNOC%\#/%
M'P+\*>*/!NJ_!OQ]IWA:Y\=W7PL\91:WJ6H6GB.&/09-+T>_NK=;F6V\0:SH
MSV>O7MC!J7VOK?\ @K?\0+/_ (*L?\$^O^"KW[&_[-'PP^-U_P#'']C7Q;\-
M+77='\1^!HM&TWXH>)/ OQ(C\<7]E\&[FRUG6+[Q]#<>'?AOXJ%A;KIFE:IJ
M6IS^';*PT^>36;5J_.C]GWXZ0?\ !6#_ (*<_P#!%+6?@!X$^)MMX._X)O\
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M3;.V!BTJVU,Z#?"^U^_W6FF01%DM]0OI;+3;SX"_X(-?M^_M-?\ !0_]G?\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I%Z#Z#^5+2+T'T'\J %HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E5U9'4,K JRL RLK#!5@
M<@@@D$$$$'!I$1(T6.-51$541$4*B(H"JJJH 55  50    !@4ZB@#\!?^#B
M7Q*WAO\ 9/\ V>D#HJ>(_P!L7P3X8D#E1YBZE\%_CS)'&FYU'F--:1>6 '8L
M $0M@C[:_P""2?B"TU_]@/X%?9KIKJ;1XO'.B7Y=-C075I\1/%4\=N1W$=A=
MV+(W5D=2<MDG\P_^#I#4M4TK]C#]DZ[T2&"XU67_ (*+?L^Z98PW(D:%YM=\
M"_&?0L,(F20$)J3M&RM\L@1F5U!1M_\ X(5_&V3PWJ7QO_9-\8ZB;/6-$UQO
M&GA'2)H) /MEA)<^'/B) MPFF1>2]F^G>%V>+4M01G8RBPM%>._:M*2G*GBH
MWDX1EAZT8_93:K4JK2WT4:'/:]N:+T3;/G,VKX3"<1\*XF<:%*MF& XAR&K7
MM-5)RHXC)LURNC6FDZ:E5G6S:&$4^5U/9UX1E*4:<'_1[134=) 2CJX!P2C!
M@#UP2"1G':G5F?1A7G%S\8OA'9>+[#X>WGQ3^'%IX^U6_N=+TOP/<^./#,'B
M_4M3L[6"_O-.L/#4NJ)K5Y?VEC=6UY<VEO927$%K<07$L:0RQNWH]?RB^,_@
MWXC_ &@_'O\ P5V^!GPE_8\U#Q=\;OBM_P %#/AY;>!/VTH3\++#PM\$-8\!
M_!C]D/Q9;^)?%GC/4O%6G_%SP7J_P'M%U#Q]X*TSP;X7UV;QMK/B2/1= ,5W
MJ7B&6V:\W;_AU_P_R$W;97W?7I;MWOOT_ _J/\7>._ _@"QMM3\=^,O"G@K3
M;R[%A::AXN\1:1X;L;J^:&6X6SMKO6;RRMY[LP03SBWBD:8PPRR!-D;L#PCX
M\\#>/[*YU+P'XS\*>-M.LKHV-YJ'A'Q%H_B2RM+T0QW!L[FZT:\O8(+H030S
M&WED2;R98Y-FR16/RU^V[^R1-^V%\.O"O@.'Q1\,?"K>&_&<'BTWWQ3_ &9?
M@[^U'HMP(=$UC1S:Z?X,^-&GZCX?T#4V.JB5?$VF1)K$5K%<Z6DGV+4KM6C_
M &(?V1IOV._A]XN\#S>*/ACXL;Q/XQ?Q8+SX5_LQ?!O]EO2+=6T32M(^RZAX
M/^"^GZ;H/B'4\Z893XEU6)]7:UEM]+,GV+3[550:WVT[Z?YW[]#SOP9_P4K^
M%GB[QW\+]!NOA%^T'X*^&?QV^+OB_P"!'P+_ &@O'/@C0-"^%?Q2^*/@ZU\8
M7LF@Z7IG_"8W/Q9\,Z=XLMO 'C&7X=^*/'WPR\)^&_&Z:%.^CZF\=_H;ZM]M
MZ#\5?A?XJ\7>)/ 'ACXD> ?$GCOP:"?%_@K0?&'A[6/%WA4":.W)\2>&]/U&
MXUG0P+B6* G5+*U FDCB^^ZJ?PL^&,O[7?[27[6]K\6OVOOV./VLO -[X.\4
M?$KPQ^QSX>LKO]G&^_9B_92L-=T7Q%X+TG]ICXC7NC_M"7OQ#^+/[0?B?PI?
MW,$NMKX"N-"^$7A_Q1J?@[X=^&Y-3O\ Q-XWUCY\_80_8#^/O@CQ?^QAX ^*
M7PJ_:1\$^,_V8K7QK:_&3XT67_#%OPV^%FKW.N_"?QS\/_%^M>"OC3\(?!-Q
M^U1^T)8_'7Q#XGM_&SZ'X[U/PKXATOQ"-,^(?Q/\2Q_$3P-HT&JNR[].G?\
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M%KXAO_AKX2TKX@:+XD^/VK7_ (>USXM+\0M$L7L-9MO#'VG1_P!LZ0U>VO\
M7]>B_5E%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5\'/'GQ(LM GF>V@\0ZWX;T"\O/#WAZ:YC_>6T.NZ\NFZ3+<1YD@2\:5 60
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MQ=X\NK_X9>*]"L+7PAX=U?4K75O$-Q?:Y<6^CVD6E6ETT^ISQ6: S.%KS_\
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M/H/S/^%*!@ >@Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPKRIP<J=2#G)0:3C>,E&:3N[7N?%^+/A%Q7X(\:9[POP[C<VQV09%G6<0RC
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MA?X&_P""2_\ P1D_:-_9!_:2UG]K?XM_%;X>_!>R\7:?KXOOV)?V7)_B+=?
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M!\*>.O!WB?7/#<GE>(M%\/>)]$UK5M!E\PQ>5K6G:;?7-YI<GFJT6R^A@;S
M4QN!% 'R1_P4_P#^4;?[??\ V9K^TM_ZIWQA7R?_ ,&]?_*&7]@G_LE.N_\
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M5:<5&5W2FYR35*-*\_Z$**165U#(RLIZ,I#*>W!&0>?2EKC/O@HHHH ****
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M'Q#X1BO]+MH[7PE-H?\ 15\8?V"/VEOVR_A+_P %(/V9/VV/V@O!/B_]G?\
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M+XQN]+T-O"=AXE\5W%QI5Y:+87_ABRL+#4[N]N(M,M]3NIPBK;QBOS&_8/\
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M_P '-[.O[.G[ FQW0G_@J7^RJ#L=T+ V/Q$&UMA&X=]IR-P#8W*"/3?VB/\
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M;'[9KUE'IE]_PC&F%HWZ;+J[=.]O.^NWFA7DTMUMI;797OV^YJ]TW:Q]:?\
M!1;_ (+/_&K]EGX_?LM?LH>#/ G[+7[/'Q:^/G[/MO\ 'KQG\3?V_OB[XC\,
M_L]?"_4+C4;S13\&(_&GP<TW6[+Q9XYM=:T?6+&]\1V>OV7@^!&T2[BN;BUU
M;SK;P7_@H_\ MC>+_BE_P0@^,WQW_;Z_8H^$OBZ+3?B_\-?#$_PO^%W[68\5
M?!3XUZ!;_%SP;8>%/B_\._C-\ /%%YXJT3P[<:I=M?67A;5]4BUOSM#9-9$N
MG:FD*^F?M%?\$H/VUK'X%_L3_ KX=2?L4_M[?!']G7]G;0_@K\4O@!^W;\.V
MTB7Q'X[TG3YH'^-GPC^.WA[PKXS^*W@+4)@-)T*U\'P^(M,TS2/#OAS38VN]
M<O+V273/D;3?^#>+]JC1_P#@D=^VK^QQH?C;X ^%OC/^UW^T]X%^/?ASX4^&
MO%7Q2?\ 9H_9^\+^$O''AG7$^'_A#Q9XJT7Q/\0M:NET+1YK*;7-2T%[B_33
M_#>F7UU>OIUQKUX*VFRUU[[][Z?=;L[W0/FUTOIM9=H^5GUM;JWV5OT9_:._
MX*??M16?[4/PU_X)R?\ !-+]F+X;?&?]HS2OV;?"GQ_^,'B;XY>/-=\*_!;X
M)?#O5++1K7PWH-[<Z2UOXH\3^(=2&JZ%&D\>HVQMUU_P\RVVLO<:])X>\%_X
MB!?B3IO_  3T_;[^.WC3]EW0O /[;/\ P3>^*7@/X2?M"?LY:WXUOK_P!/JO
MCCXHZ7\/M+\6>&/&>DV<^I3^'M4A'BN;3[0Q7I34_#BI'K.IZ)JNG:U<^P?M
M%?\ !.;]OCX0?MS^%O\ @H]_P3?\9_LZZU\5O%?[,_A/]F?]I'X#_M-S>-],
M^'?CC2O!]MHJZ%XR\)>+? UC/K=EJEC+X<\-1M872:3Y::!YZ7]];Z_J>D0_
M*6I_\$'/VL?$O_!.O_@I?X-^(7QA^#?CG_@HA_P4^^*GPS^+/Q;\36;>)?#'
MP#\'+\/?BMIGC_1_A_X9U%?#.I>*YM+T:TO/&*VVJR^&(5EFO]$T1=/%IHSZ
M]J8N73;IWONKWZ6WM_PX+FNUKUW2M;E5K=-]U?>^ECW/P=_P6(_;X\'?M8?\
M$_O!'[6W[$OPD^$/[-?_  4NG_L;X"ZEX)^+NL^.OC7\.M:N=!\.ZQHP^,$%
MQI6D^%$OM37Q=X7N-0\+Z-I=I)H&GZKJ"CQ-K6K^&M0TNZ_6?_@I[^U#XA_8
MS_8&_:?_ &CO!EM#>>/_  '\.9;#X9V]Q##=6I^*?C[6=)^''PQFO;2=XXKR
MPM/'GB[P]>:A9NZ_:K&WN( 09 :^-?VO/^"<GQU^/'Q@_P""+_CWP=K_ ,-[
M31O^">WQ0L/&7QNBU_6M>M-0US2K7PI\--%D3X>0V?AO4(=9O6O/!NJ%(=<N
M?#D7DW%E*UP&::*/ZJ_X*S?LV^,_VMO^"=7[57P+^&T7VGXG:_\ #R'Q9\,+
M'9&S:M\2OA1XFT'XL^ =!C,K)%%)XB\6>"-)T%9Y'6.W.I>?(P2-C1H^7IKJ
MM;;^?EYE*]GWZ;;\J_6__#'QUX[^(_QJ_P""8WAS_@F5_P $_/V2O@SX#^/O
MQ0_:3M?C7X-UKQ?\7?B-XB\#VTGQ4\!?#NU^+WQ,^/WQ%\1Z/X9\9:MKZ^,/
M&6L^-_B/\3C#8S>(M9N+F;3_  V3J>I6BP]G\$_V\_VVO$UY^W7^S?\ $KX"
M?LTS_MP?L86WP#\2:9:^$?C7XR\'_LN_&/P+^T-!?ZIX7UNW\>^-_ NJ>./A
MWJ>@:5X:\7VVN:1K7AO6UNM=L=)M-/O?L6J-?6O6Z-X<U3_@H#\5O^"0'_!1
MCX0ZSX5A^$/PH\*?M&>/OB)HFM7VHVWC*VO_ (_?L^K\,;;PCI6F6VE7-F?$
MW@#XAPZMX<^(6E:W?Z)<:#>Z-J5FJ7.HVDMDN[IO_!.VR\<?MG?\%'/BE^T7
MX5^%GQ8_9E_;2^%G[&7@32_A?K\5YK]S?W?[.-GX_N/$'_">>'M1TBWT6.P/
MB+7_  WJOA>2QU;5)IIM-DN+N'3I;: 3FG7>VN^]_ET]/O#7ILG9+I:R_7KK
MZ/8YCX4_M5?\%1?$WQ-^'_AWXC_LC?L,^%OA_KGC'P[I/C;Q+X-_;]O_ !OX
MMT#PK?ZK:VVO:QX8\&M\ =%3Q5KVG:9)<W>E>'GUC2DUB]AAL'U*Q6<W47\\
M-OXJ^$G[9FF?MZ_M2_M'_P#!/S]K_P#;7U/1?VEOVF_!/C#]JGX9ZUX2\-7?
M_!/WX'_!?Q#K?A;X1^'?V0?#_C7XD>'-;\4_$;X:>"_#^D_&KQS+\(/#$SWW
MBOQ6L_C#6/$6I>=X8M_Z@_ '_!(3_@F#\*_'/A#XE_#G]A?]F_P9X_\  'B7
M1?&/@KQ=H'PXT>PUSPQXI\.:A;ZKH6O:/>QQ^99ZGI.I6MM?6-U'B2WNH(ID
M(=%(^*H?V+_^"CW[,.G_ +7?[/?[%\W[*'BK]G3]K'XL_&#XO^!OB/\ &[QG
M\1O"GQ._92\0?M&2/>?%K25^'7A/X;>*_#/QR\,^'_$-_J_BKX66LWC/X>ZA
M!->_V!XNNM2TVVAN6$U?[NZZKKT[W\OD)INU_/L]=+:62[]':_3=;OQ@_9._
M9B_:1^"/[./[8WQJU7]H;_@IS^SK\*/V._ 6F_"?]GBR\*:?\1I?CSXJ\<S>
M$I(OVJ]8^&^F/X&MO'_QV\1>$)[&SU"V\2KI_AOP;ITOBC7=.T70M;-U/#\S
M_P#!/SX0K^V%_P $A/VH/@M;>,M<\/:UX?\ VBOVEM2_9=^&WB#7_$>H_'?_
M ()T>(_AYXZ'Q _95^"_CW5O%0'BW0_BQ^SQXKTWPUXD2RN+R\M[#PSJVG>#
M['5]7\,1A[G[2TO]D']N#]B6Q_97TC]@WQ]\/OCC\&/@=^R?X3_97\=_LM?M
M)>.->^#_ (3\2ZUX'G@OM!_::\#_ !#\"_#CXJ7WA[XIZQ,VH:+XY\+ZMX9U
M#PGJGAJ>TBT>33-3T^"Z'->"_!GC?_@F1^R;_P %#_VW_P!J'Q-X,\6_M*_M
M%>+O$?[0'C3P7\'[76Y/AS8?$:Y\%^'_ (0_L^?L[_"%->M;/Q3XUUC6-5L?
M!G@FT\1:MI>E:SXX\:>)PPT6QA%LLB7KJMO6_P#3^0[:K3HU)]'HNO\ GY]C
M[R_X)W?M.W/[9W[#G[+?[4&I6EKI_B#XQ?!WPEXF\8Z=8(T6GZ=X^AL_[&^(
M.GZ=&_[R/3K'QMI>OVNGI)F1;.*!9"7#&OLVOA3_ ()C_LT:[^QW_P $_P#]
MDO\ 9M\6&+_A-/A?\&?"^G^/DMYDN;:'XAZY%-XK^(%M:W*?)<VEKXSU[7+:
MUN4PMQ;Q13*JAPH^ZZ7H-;*^]E<****!A1110 4444 %%%% !1110 4444 ?
M@5_P6Y^#M_XZ\3?L6?%'PE^W;^S'^P+\3?@;XQ^*OBGP!\3OCQ=:!I/BK6-2
MU?1O!VCWNG?#[5M=N%MKC1;739+J'Q_X;NK#4])UR+6/#1U*#991Q7'%?\$[
MOBQ^UGXK_:@\&:%\5/\ @M-^P]^VAX)DT+QC)J?P%^"NE?"*+XC>)YK;PQJ,
MFG:MIESX/TFPUN.#PUJ"VVO:L\,K0OIUE=17$)CE+Q_0'_!8CXH?\$__ (:V
M/P D_;K_ &.?B7^UM!K%W\3$^&47PZ^%,?Q,?P)+8P^!6\7OJTDWBWPG'HB^
M)4NO#0LH_.O&U0Z#=.L40TQG;\FO^"?&J?LO?%/_ (*R?L[?$7_@G)_P3L^+
M'[.7PF\*?!CX\:'^U#X]^+_PD/A#PY8_VSHE@WPPO_AY++X@\7V?A7QU'KR7
MOAG6+C2]8TZ_\7^$_&-UIUQH]QI^@W6HV@:J[AMTE9N,;6OT;UWO\WINK?V'
MT444&1_,-_P="^-/%%W\ /V'?V8;#6M5T7X>_M?_ +>OP9^$'QICT?4KW2+C
MQ+\-FFN+F]\(7E_830SQZ7J6KW6DZM=1@MYD^@69(*1NC^4_\$_O G@3]A/_
M (.,_P!L;]AC]F;P[-\-_P!ESXH_L4?#_P"/#_!W2=6UB]\%^%_BCX7G^&>B
MIXET/3]6O=0ET^?4].\0>)4OY#<R///K0A+BRM-+M+#]>O\ @KQ_P3?O/^"E
M/[-_A/P!X*^(EA\(OCI\$_C!X,_: ^ /Q*U?2)=<T'0?B1X(74+>VL/$^F6Y
M-U/X;UJPU2Z@NY;2*ZN-.U*WTC5QI^K1:=-I&H?*7['/_!,O]N+P)\=/VT/^
M"@O[5?Q_^ WB'_@H7^T1^SZ?@%\&+WX-^"_$$?P%^!6DZ%X>T]/"^KRV'C2P
M;Q!XF>\\9^&?!>OZ]IEQI<EO#;Z3K,/VG7%\0_9=*J_NM7[Z?./RZ,AI\VW5
M._DEJO+7[SX8_P"#G'XNZ[?_ !M_X)2_L;:A\/?BC\9_@O\ M _'?Q7XN^+O
M[/OPGUT^&_$G[1TW@#4?ASH_P_\ A!)J[:CH]O;:-K.M>,]2&LS:CJEMIVE1
MW-IXG=X+_P .Z=>VOT+_ ,$)$_99^'G[1G[?7P.^&_[,_P"T!_P3]_:4T;4?
MA;XQ^.7["GQ$^+>@_%;X(^#M&U3P^A\(_$OX":CX=T^/3C!XBM=3A;Q?=)J-
MX"NK^&;6QN;K0(=#M-$]:_:C_P""6?[;7[5G[-'[#7CCQW^U9\*X?^"JO["?
MQ1UWXN^!OVB;+X=I:? _QMJ^K^,)+^3P?XF\%Z3X<TBXT_P[>^$=$^'NGZEJ
M&F^$Y#-JGA?4?,\/7-KXBNY8?8?^";?_  3I_:0^"?[3/[4?_!0#]NSXN_"K
MXH?MB?M3>'? 'P]U+1_@%X;UWPW\%_AI\,_AWI>D6.F:%X=;Q5%!XFUS5=7?
M0= ?4[W5+:$68T*,QW6K3ZG>7:%URV_SUU3OVVZO7H%GS7MO9ZI:*UGKJT]=
MM.OR_!K_ (../V]OB9\4]?\ AG^QKK?[#O[1WPS\!?"7_@H?\ -8T']KCQAH
M>K6OP+^*4^B:?XFLX-*\&:O-X4L]*O+W6H_%-Y>:<EMXGOI3;^&M7)@D,4WV
M7^XZOYF?^#IPG_ABO]D9<G!_X*6?LP$C)P2- ^*^"1T)&3@]LG'4U_3-0[65
ME;5_-V6I2ZZWU_1!7\QG_!/;PCK7P9_X+K?\%"OAC'=S_P!@^*_!WCWXFR6A
M:2&WE3QC\0/AC\0_#CM;17UU;SRZ18_$34--MKVZW79AGNI%CL6OKFUK^G.O
MY9/COJ/Q4_9/_P"#@+X:?%*.SC'@/]KQOA_\,[:_U.>YTG1=3\/ZGH/@#X=^
M+M/\^&\"ZGJ/A;6]+T'Q):PW$:6;ZLVA120.T7FGY7B5QH5,@QTHS<<+GF%A
M4G!-^SHXNG6P\I22^S*I.C%ONTEK*S_H3P&IU\VP?C)PC0KX2-7B+PBS_$8+
M"XJ<8/'9GPWF649Y0I8>4FKXBG@<-F=>$=E&G.M*T:+DOZFZ***^H/Y\"ORA
M_P""@'_!,/PC^U[J^K?%_0?$VO>&OC3I/P[B\+>$K"UO-#TKP9KNKZ7=ZM>:
M3>>,+N7PUJ^NL735?[+NKJQNXW33+#3X8H@;<E_U>HJZ=2=*2G3ERR77RNG9
M^6B/.S7*<!G6#J8',:$<1AYM2Y6W%PJ14E"K"2:<:E/F;A+5)[IJZ/Y<?V9O
MVU/C[_P3M^*NE?LM?M?6UW?_  BT:YA\%>&=>L=.^Q^&/"T=]XIL=5\1>.-&
MU^+P(GB3X@Z3H=IKU]+>:?#)+-B:*UM?+ECM(6_H'^ _[5_[/O[3;>)T^!GQ
M&L_'S>#%T9_$PM-$\4:.=*7Q VJKHS2_\))H>C><+]M$U41?9?/V&RE\WR\Q
M[]WXM_LY? SX\S:%/\8_A=X2^(TWAF/4(= D\4:<-0.DQ:J]F^I)9[G41+>O
MI]DT_!WFUAS]P5^#?[9/_!),?!;X<_%[XZ_LU?$/Q=IU_8ZIXB^(>O> 8[_2
M?"WA70OA]ID/B3Q3J=CI<D,]K/J$7A>T6#3=#TR:26\N;+>B?:;L[9NN^&Q,
MES-T*TN5-I7I2FY)-N*U3:NV[Q5][GPRH\6\'4*D<'&CQ+P_A76JTL/7K5*6
M<X/!4\/S4\/3KR<H5:=&HN6G!4<5-T:?+"-",HQI_P!)U%?FS_P2Z_:F3]I+
M]FCPHGBGQIX>\0?%[P;:W>F>.-!TI4M]3T'1K7Q!K>A>"KG6;-%"K-J^AZ'%
M<K>;G:^=99Y&\YI /TFKDJ0E3G*G+XH-I_+JO)[KNM3[O*\QP^;9?@\RPKO0
MQN'I8BFG*,I052*DZ53DE**JTI-TZL+MPJ1E%V::"BBBH.\**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM=7?@KA?.,+B/;9;QCG-.G*BJ<Z6:4Z.=)SY^9U*?UB5&G2;BHP7+2<TE/\
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M^&'_  3[_9,^#?QH\'?'OX<_"G3O#OQ#^'/[/OA;]F#X=W<5_J5UI?@;X/\
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MO?:A/)]IF>Z02T?X:VZKOW3T?_ $V[JVS:UWOKMV_4_L3_X*?_\ *-O]OO\
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MMH[[^NVJ5K;W[WVTZCOJNUM+:WVUO;;7H_4^I_\ @Z<_Y,L_9&_[25_LP_\
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M@?\ P4A_Z1K>*_\ R^?_ )G:/JE7O2_\'T?_ ),/]=LD_P"?>=?^(]G?E_U
M>?X/L?N'17X>?\/ _P#@I#_TC6\5_P#E\_\ S.T?\/ _^"D/_2-;Q7_Y?/\
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M^<K[/O\ U]X<R?7R^_7^ONW/V&HKX'_X)U_\%%O@5_P4O^"&L_&OX':9X_\
M"B^#?'^N_"KXD_#GXJ^'8?"WQ#^'/Q%\-V6E:CJWAGQ)I5IJ.KV!E2PUK3;N
MWNM/U.[A=;B2TNA9ZK9:EIUEYO\ '?XQ^/\ XF_\%&?V9OV(/ACXRU[P-X9^
M'WPQUS]N/]JC7/#%XVFZQXC\ Z#XK3X7? ;X'KJL23-9Z'\3OBC<^(_&'Q M
M(UMKS6/!7PEG\,+=1Z7XKU(.K/L%]+][?B?J!17XC>+/^"Z/P+T#2OC9XU\.
M_LM?MM_$GX0?LN_%CXJ_"']J+XU^!?A#X4O?AS\#==^#_C;4_!WB_4M8O-4^
M)&DZSXUTJPLK"W\?:G_PK31O&%_X9\ :QI&L>+;+0M2N7T6'ZQ^-_P#P46\$
M?!G7?"NEZ3^S/^W-^T%H7C7P!X:^)'AWXB_LP?LI?$3XV_#2]\/^+!>3:/;G
MQAX:B%C!KC6-K#J=UHLRI>6FFZGI-U,BK?1 .S^__@?YH+I[/M^.Q^A%%?@K
M^VA_P4Y^)VK_ +)NG:Q^SO\ #+]H_P#9"^(GQ9_:V_9D_8]L?BQ^U]^S;K_P
MLD^$EA^T5XTB\/ZU\;_#W@[XB+'I/C.T\$Z1#>6=G/JLB>';#Q;JNAG64NX$
M-A=XL/Q?^*?_  33_;X_9]_9;^('[7'QE_:_^"O[5G[.'[4/Q2FL?VB[KX>Z
M]\9?@]\1OV5?!VC?$74?%.A>-? O@WP#Y_PT^*WA ^*M*3P;XAT&^M]"\5>&
M#>^&=:MK%M5TDEOU_#5_@+F7RTU[7M;1ZZW_ *Z?T"45_*5>_&;]NSP'_P $
MV?!G_!<?Q#^U_P#%?6_&VH6'P^_::\>?L6C3OAQ_PR1-^RQ\0_'^@6DWP6\*
M^'8_ T/CW0_&OA7X-^(K37=.^,$OCK4/$FJ>.M*N9-7L9M,U5[:U_6S7OC?X
MX^!'_!3;X0_#GQ%XTU[Q3^SO_P %$?A!XNF^%.CZ]>M>67P?_:8_9L\.Z=XG
MUO0O",DJ1?V1X0^.OP0U:[\2S>'9)KI+;Q_\)M9U?2HX9?&6L("W]:]+7_/\
M&._KT_';\=/^!J?J31112&%%%% !1110!^!?_!0V+]M"^_:&\;7GP#_X+'?L
MZ_L4_#GP%\*_!GBOQC\&/B-X-^$>O^(?!>G7VLQ>&I?B3XGU/QEI-]JVD>&?
M%7B/6M!T72[[4+FWTMM4NK+3K7%U=Q+/^>?AKXB?MRR>(M CN/\ @YP_8.U^
MWDUK2TGT*U\+?LT?:=9A>^@672[;[+I27)GOXRUK"MN\<S22J(Y(W(=?VI_X
M*7>#/V#?@9\!?VF?VT_VGOV;_#'Q<FG^%7A'X;>/[46$DWB?XJZ%'\1_!EU\
M,OAA+=/=);V]A<?%2S\#7J7X@+:5+IMOJTJ7B:8MK)_-MING^!OV>-1\"?&_
M]N;_ (-T_A3^S[^R7X@\8^#]+OOB[X3\:/XJ\9?!U/%^O:?I_A7Q%X\\'G7;
MK5#;VE]?6%MJ5GK>@^ [J2^FCL((?[;N++P[?!K'5;+LO=IZV2NE=7;U;Z].
MK/[H**:CK(BR(P9'571@<AE8!E8'N"""#Z&G4&05Y1X-^ WP-^'/B_Q1\0/A
M]\&?A3X$\>^-VD?QGXV\'?#OPCX8\7>+6FG2YE;Q-XDT31[+6=>,MS%'<R'5
M+VZ\RX19VS* ]>KT4 <IH'@/P/X3U7Q/KWA;P9X4\-:YXVU&+5_&>LZ!X=TC
M1M5\7:M LR0:GXGU'3K.VO-?U&%+B=(KW59KNYC6:94E D<,+X$\#IXRE^(J
M>#?"B?$&;1%\-3>.E\.Z0OC*7PXMPEVN@2^)Q9C6Y-$6[C2Z72FOC8BX1)A!
MYBAAU=% 'PO_ ,%/_P#E&W^WW_V9K^TM_P"J=\85\G_\&]?_ "AE_8)_[)3K
MO_JS?'5?6'_!3_\ Y1M_M]_]F:_M+?\ JG?&%?)__!O7_P H9?V"?^R4Z[_Z
MLWQU5?8_[>_075>C_.)^S%%%%2,**** "BBB@ HHHH \3U+]FG]G+6-0OM7U
M?X ?!/5=5U2\N=1U/4]2^%7@2^U#4=0O9WN;R^OKVZT&6YN[R[N99+BYN;B6
M2>>>1Y97>1V8TO\ AE?]F'_HW'X#?^&@^'O_ ,SU>\T5@\+AF[O#T&WJVZ-.
M]^_P^2/7CQ!GT8QC'.\WC&*48QCF6,48Q2LHQ2K))))))*R6B/Y8+OXC?LZ?
ML??\%[?BCK_C;5?A_P# ;X5V?[.FE:3:R6VCVOAGPO#K>N>!_AS>16EOIWA[
M3%MHKS4I(;VZ=EM4\^2.9Y)#*RA_V1_X>Q_\$Y?^CM_A7_X%:U_\IZ[WXR_\
M$[_V+?V@_'VJ?%'XR_ #PCX]\?:U;:9::IXEU6]\307M[;Z-I]OI6F1RQ:9K
MMC9_Z)IUI;6D;I;*[101B1G*@UY;_P .@_\ @FU_T:=X _\ !GXU_P#FIKYC
M#9?Q%EU3'PP']AO"XK,<7CJ2Q+QRJPCB9IQIRC1A&FN2,4K1ND]%)K5?O^>\
M:>!_&^"X/Q/&4?%VEQ!P_P #\,\)8^ID4.$*F7XNMD6#=&KC*53-<95QM1XB
MO5K3]I6=.4X*FY4J<W-&K_P]C_X)R_\ 1V_PK_\  K6O_E/1_P /8_\ @G+_
M -';_"O_ ,"M:_\ E/65_P .@_\ @FU_T:=X _\ !GXU_P#FIH_X=!_\$VO^
MC3O '_@S\:__ #4UU?\ &7=N&_\ P+,__D?7^GI\];Z,_P#S\\=?_!7 '_R[
MU_IZ:O\ P]C_ ."<O_1V_P *_P#P*UK_ .4]'_#V/_@G+_T=O\*__ K6O_E/
M65_PZ#_X)M?]&G> /_!GXU_^:FC_ (=!_P#!-K_HT[P!_P"#/QK_ /-31_QE
MW;AO_P "S/\ ^1]?Z>A;Z,__ #\\=?\ P5P!_P#+O7^GIJ_\/8_^"<O_ $=O
M\*__  *UK_Y3T?\ #V/_ ()R_P#1V_PK_P# K6O_ )3UE?\ #H/_ ()M?]&G
M> /_  9^-?\ YJ:/^'0?_!-K_HT[P!_X,_&O_P U-'_&7=N&_P#P+,__ )'U
M_IZ%OHS_ //SQU_\%< ?_+O7^GIZ%X$_X*4?L*?$[QCX;^'W@']IGX<>*/&?
MC#5[/0?#/A[3;G56O]8UC49EM['3[03:7#";BZG=(HA)+&K2,J[LL ?N&OY1
M/VROV;?V9/V.O^"HW_!,O_A3O@/PA\%O"FL>,+;Q!XSO(]8O[32)9-*\;Z7;
MP:CJFH>)=8N[>RBL[5Y4\WS[:((Y\PL=I']*/_#2?[.O_1??@K_X=/P-_P#+
MVKRC-,57JYEALT> HXG+\73P_P#LLZD:52,\-0Q',OK$O:.SK<M^6*NK6ZOE
M\2_#SA_)\!P%GWA[3XQS/).-.&\9G;CQ#A<%7S'!5L)G^:Y)+#U/[#H?4X1G
M_9KKQC[6M-QJ1;G%MPC[517D^D?'OX%^(-3L=$T'XT?";6]9U2YBLM,TC2/B
M-X/U+4]1O)V"06EC866L37=W<S.0D4%O%)+(Q"HA) KUBO>A4IU$W3G":3LW
M"49).U[-Q;L[-/T/QW$X/&8*488S"XG"3G'GA#$T*M"4X7<>:,:L(.4>9-<R
M35TU>Z"BBBK.8**_GK_X*"?\%3_VY_@A_P %(_A1_P $Z_V)OV3_ (-_M#^.
M?BA^S>/CU977Q+^*%]\.+B+^S_$?Q'TWQ%IHO;BXT[P]#9Z?I'@>VOK22XOS
M>7MW?7%LL2B*$R>S?"3]KC_@K1X:^%_[67Q8_;C_ &'O@!\"/"_P._9F^)WQ
M@^&=UX ^/=G\1Y?'7Q#\ ^'M1\26W@SQ#8Z+JFLWFBZ!?:=IEU)=ZU''%- R
M1PVR7$LV(G9^6O2^NMK???\ ,5];:_=ITZ_,_:ZBOY$OAM_P6M_X+5_$7]C6
M'_@H3X;_ ."6_P"SMXQ_94MO!'C'XHZGK7A_]I:/2O&DWP]^'&L:]I7CS5[/
MPMJ=[?\ B&VDT+_A%O$-W+&WAK4+QK#3I;ZUTN_1H8IOOGXS_P#!>_X-^!?^
M"=W[)O[:/PS^#OCCXJ_%G]NK4+/P%^R]^ROI]]%:^,/%WQA&MW'A'Q3X5U/Q
M!!IMZ(_#O@GQE:2>'[WQ)I>A7]QKU[?^&8-*T>(^(XI; Y7ZZVT[[V^7^?82
MDO-:7U36FG^:7J?OI17\S$O_  52_P""Q'[,?Q ^!NH_\% /^"67AJP_9[^-
MOC[1?AU>^+_V1O'>K?&KXC?"+6?$@$NG77C3P3X>O_&\NL06-M%>W-]'8QZ-
M97L5E=V^E:U/K:6&B:K_ $9?$GQ1<^!_AUX^\:V5I!?WG@_P5XJ\46EC=220
MVU[<^']"O]6@M+B6)6EB@N9;1(99(U:1(W9D4L *0T[_ "[[G:T5^*'_  3%
M_P""S'P0_;+_ &5_V=OBK^T5\3?V;?V<?V@/VB-9^(NG>$/@%=_&7PWIOB/7
M+;P=\3_$_P /-'N?#'A_QCK-CXKU5M??0(FM52Q=;[4KAK+3#<OY<9^Q9?VC
MOC(G_!1"V_9:7P[\!#\#9OV;G^++^)W^-_A-/VCQXZ3Q;-H?]F1?L_G7!XSE
M^&G]GI'(?B$OAPZ$-69],.K"Z0VM%M_($TTFM4[?CW^_4^ZJ*^3]0_;S_8@T
MCQ1\1/!.K?M@_LQ:5XO^$5N+OXI>&=3^.OPRT_6_AW;'4;71WG\9Z=>>)H;K
MPY%!J]]8Z3=-JL=J+35+VST^Z\F\NK>&3X>^,?\ P58TGX,_\%/OA/\ L:>+
M%^#_ (=_9M\<_L3^(/VNO$O[2_BSX@PZ!8^&;/2/$/C/2;1#J=_<6_@A?"%]
M9^'M)O8==N]57[1_:TC02>6EM]H=GV\_R_S076^^VWF['[(T5Y?\'_C=\&_V
M@_!-E\2O@3\5/A[\8_A]J-U=6-EXU^&7C#0?&_ABXOK%D6^L$UOPY?ZCIXOK
M)I(Q=V33K=6QDC\Z)/,3.)\<OVD_V>OV8_#5EXR_:,^./PF^!7A34[\:5IGB
M'XM_$#PM\/\ 2=3U,A6_L[3;WQ1JFF0ZA?+&ZRR6MFT\\4),TB+$"X0SVNBO
M!M?_ &I_V9/"G@KP'\2O%'[1'P/\.?#GXI7UKI?PS\?Z[\5O ND^"?B#J=]%
M--9:=X+\5W^NV^@^)[Z\AMKF6UM-&O[VXN([:Y>*-UMYBF]J7Q^^!6C_ !*D
M^#6K?&?X5:9\7HO#-WXTF^%E_P#$'PI:?$2#P=86DU_?>+)_!<^K)XC@\-6=
ME;SW=SKLNFII<%O$\TMTL8W4 >MT5\HVW[>'[$=[X@^&OA.R_:__ &9+WQ-\
M98I9_A+H-E\=/AE=ZK\2H8M6NM ,O@>RMO$TL_B:-]>L+[0K=](2[6ZUNRO-
M)MC+J%K/;1]3\4OVM_V6/@A?>)-+^,G[2'P,^%FK>#_#VD^+?%>D?$#XJ^!_
M"6K^'/"VOZM#H&A>(]:TK7-;LM0T[1-9URX@T?2M4NK:*SU#4YH[&TFEN76,
M@'T+17R]\2/VW/V-O@Y?_#[2_BS^U9^SK\--1^+&F:;KGPRLO'7QE^'OA:X\
M>Z%K(B.CZ[X3CUKQ!9MKFAZKYT0TW6;#S],OFD1;:ZE9@*[;XS_M)_L\_LY^
M#;+XA_'[XY?"3X+>!=3N+>STOQ=\4?B%X4\"^'M6O+N-9K:STG5?$FJZ=9ZK
M=W$#+<0VNGRW,\EOF=(S""X /:Z*\8\$_M'?L^?$KX57/QU^'OQR^$7C;X*6
M-IJ-_J'Q<\+?$;PAKGPVTZSTB%;C5[G4O&VG:O<>'-.BTF!TFU1KW48/[.C9
M7O/)4@UR/P'_ &S/V1OVH[_7M*_9M_:<^ OQYU7PO EUXCTOX1?%CP/\0=3T
M.SDF2VCOM4T_POK>IWEE82W$D=O%?SPI9RS2)%',SNJD ^E:*_//]@_]K'XI
M_'SX.?&?XG?M+6'[,_PX/PR^-'Q"\%VNH_ S]HCP3\;/A_:?#OP;HOAS4H_$
M7Q \;^']=U/1?!'B^VGU'61XF\)ZU?6-]H&F66FZGJ=IIZ:FD2?0OP-_:Y_9
M7_:;G\0VO[.?[1_P.^.MWX3<)XGL_A)\4O!7Q O/#^Z401RZQ:>%]:U.YT^V
MFF/DV]U<Q1VUQ*&C@FD=6 !)WMYJY]#T5\D^+/V^_P!AGP':VE]XT_;'_9>\
M*V=_XYUGX96EUKWQX^&&EP3_ !$\-FU'B3P2LMWXGB0>)_#AOK'_ (2'17*W
M^A_;;/\ M6&T^U0>9]76EW:W]K;7UC<V][97MO#=V=Y:31W-K=VMS&LUO<VU
MQ"SPSV\\+I+#-$[QRQNKHS*P)!EBBO@WP7^V9!XZ_:9_:N\#6B>"/#7[,O[%
M?A+P[H7QO^/'B[7_ .Q[=/V@M?T2T^)7B'P1I=_=7%MX6TOP;\&_@]?>'-?^
M*/B77+V.:W\2>/M%T2VCLH_#'B*>?VOP9^UU^RI\1OBGJOP-^'W[2OP%\<?&
M?0[ :IK'PH\(_%SP%XC^(NFZ=]DBOVO;SP;I&O7GB"&VBL9X+V>9[ )!:3P7
M,QCAFB=P+_K^&C/H>BOG_5/VL?V6-$U/4=%UK]I;]G_2-8T>^N]+U;2=4^,O
MPZT_4]+U/3[B2TO].U&PN_$<5U97UE=12VUW:7,45Q;7$4D,T:2(RCY5_:5_
M;*^-L/Q$^!GP&_8-^$/P^_:(^)?QS\%>-/BL?B_\0/'NN>&/V5?A5\*/ VI:
M'HEQXH\6?$7X?>%/'VI>+_$'BWQ'KUKX?\%^!_!5I-J5\]OJVM:GJ&F:1I9D
MNP5U_7]>:/TJHK\N/V;/^"C0UGPK^V1I?[;7A3P5^S%\6O\ @GQK.AV?[45Q
MX;\;W_Q#^"Z>#O%_P\L?BEX%^+'P_P#&5QX<\/\ B.\\+^+O!MX][_PB^M^&
M+7QAX>U.UET2_M+R\DMGGB_X)R?\%)&_X*%>.?VQK32/@]XP^$7@+]GCXE_#
MGP3\.F^)NB:YX1^)WCSPUXX^&6F?$"S\?^+/ 6NVMG?>"],\46NJ6>N^!M)O
M%76+KP5J>BZIKMMI>J7T^EV3L]?+]=@NM-=[_@?J917Q3^Q;^U/K?[1.F?&W
MP+\3O#FB>!?VBOV7?C9XH^!GQW\$^';N]N_#J:C:VUAXN^&GQ%\&2ZL1K4O@
M'XP?"7Q+X,^(/AEM6C6^TZ?5M8\+WDMU?^&[VZE^UJ0PHHHH **** "BBB@#
M\7?^"D$GP9B_;F_X))2^.]0^-?PY^)UO\<OBC<?"3XU_#JY\,Z?\.K".W\.^
M$KKX@_ [XS7_ (GU32$3P[\>_"UL_ARQ30[B[\1RC2M3T[3=(U*+5KR./A?V
M2/\ @C'#^S9^UEX"^-M_^U]\0/BO\#OV=9OC3<_L<_LQZKHMM8:!\!!\>CJR
M>.+5?$L7B?4CXFT^VTS6K_3M+A@\.:%(ZC3[BZG$.G+87'+_ /!?3P;^PKXO
M^'?[.]I^V%HG[3_Q1\:7?C3QEH'[.G[/?[*6J2'XB?%OQ=K&F^'+KQ+.WA:3
M3]0T_5K3PG8Z/HY_MNXB-[H U^6STJ"]N?$+V<WPE_P1]^$'_!*7P7^UA^S!
MXT^"&B?M8_#3]HWXQ_LR^-/CE\)?#_QC^(&F^+OAWK/AV]U[XD_"KQUX&75=
M(\/Z1;ZQ\0O#6A^%;[QE=:3Y45E8Z+J-I=FY;5M,NM/A#1?!=-K1I^ZG?5[.
M][6=M%T9_7C11109F1K_ (?T#Q9HFJ>&O%.AZ1XE\.:Y93Z;K6@:_IMEK.B:
MQIUTACN;#5-*U&"YL=0LKF,F.>UNX)H)D)22-E)%<3X&^"GP:^&'@J]^&OPU
M^$OPS^'OPZU)=174? /@CP'X6\*>"]076+86>K"^\+Z#I5AH=V-4M +74OM%
MC)]NMP(;KS8_EKTVB@#GO"OA+PIX$\/Z;X3\$>&/#W@WPKHT<T.D>&O"NBZ;
MX>\/Z5%<7,UY/%INC:1;6>G6,<]Y<W%U,EK;1+)<SS3N&EE=VJ>%? 7@;P*-
M;'@CP7X3\'#Q+K5WXD\1CPKX=T?P\-?\17^W[?K^MC2+.S&JZU>[$^UZI?>?
M?7.U?.G?:,=910!_,Q_P=.?\F6?LC?\ :2O]F'_TP?%>OZ9Z_F8_X.G/^3+/
MV1O^TE?[,/\ Z8/BO7],]/HO5_E$2WEZ_H@HHHI#"BBB@#^+?]K#P?\ M,_\
M$:?V[O&7[6_P<\/R^(_V?_BUXBUJ\DAOYM>L_AUJ^M?$H>/]2M?A9XOEMM5M
M=3U76/#,FE2^.;#[-,EBD]EIDL9,=K=6A_KA^!/QV^'?[0/PY\%?$'P#XHT+
M6H/%O@CPGXTETJPU.PGUC1+7Q7I%OJEI;:[H]O>W=]HEVAEEMI;+41'<V]S;
MW%K+^_MYE7G_ -J7]F#X6?M@_!K7_@9\8;359_!?B&_T'4Y[C0+JST[Q!IU_
MX=UFSUJPNM&U6\T[5%TV>26S-A>RQ6IDNM(O-1TUV%M?3JW\UNI?\$E/^"B/
M[!X_:/\ BO\ L0?M%:+HO@^^&KZKH/PZ\+6WB'Q?\7?&'@KPWJNKWW@3PI)8
MW/PQO=+U+QC9Z9JCV\W]D36MK>ZC)=/$RV\D44?P\</F7#&-Q,\#@\1F618N
M4\5/#4:E-XC+L0_:U*SH4JCIQG0J6I^XJJ:UY8N46I_US4SG@;Z0/"F0X7BW
MBC)N _&#AJCA.'L+GV;8/&1R3CC)H2RW!93#.LPP2Q=7"9M@E+'MXI9=.-1*
M"Q-:-"K&6#_K9HK^3CPW_P %J?VYOV2_A5\,/#_[7G[$7Q&N+UKVX\/ZK\;O
MBK?^*_AW=>-+Z;4K[5I)HM%?X4PZ8;_2M#N(K5-/T^\GDGMM-2XD8232$?N'
M^S5_P5"_8O\ VN?B3_PJ7X$?$W5/%?CK^P-4\3#2KWP!X[\,PG2-'>TCU"==
M1\2>'M+L&EA-] 5MEN#<2H7>.-EC<K[6 XER?'SC0ABEA\7)44\'C(3PF)]I
M7C>-*%.O&'MII^[)T'5C?E:DXS@Y?E/&'@-XF\&X2OFV*R"6=\-T99I*/%/"
MV)PW$F0O!956C2KYABL;E%7%_P!DX:I&<*M&.<0R_$."JQG0A5PV)A2_02BB
MBO>/QP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#\/?&'_*=+X5_P#9O>H?^H;\2:^UO^"H'@/QI\4?^"<O[<GPW^''A?6O
M&_C[QU^RO\</"G@WP?X<LGU'7_$_B77?A]KNG:-H>C6$7[R\U+4[ZXAM+.VC
M^>:>5(UY85^9?[4?QT^''[.7_!8SP#\5OBOJU[HG@K1?@+%9:AJ-AH^IZ[/%
M<ZSX?\?:381BPTBVN[V02WE[;HS1PL(E?S)-L89Q]J?\/EOV!?\ HIWBC_PU
M_P 0?_E!7;6I59K#RITYS2P]-7C%R5U*6CLO-?>?GN0Y[DN6XGBC#YAFV78&
MO+BK,JL:.*QF'H573E0P,(S4*M2,G!SC**E:S<9)/1V_F,_8CO\ 4?V</V4O
M@;\%/C1_P:U_%_X\?%CX:^#8=#\;?&+6?V;_ (3:AJWCO78M3U"^.O75_P")
MOAEJOB*XG:"YMH!)J=_=7:"W5!(R)'7[I?\ !='X:_'+]K[_ ((D?%'PE\(/
M@!\2-1^,_P 4O#7[,_BJT_9\T?1O[<^)'A>\?XH?"WQAXF\'WVD:6NV?5O .
MGPZI;>(%L4,4)T2_D@C,<:J?J'_A\M^P+_T4[Q1_X:_X@_\ R@H_X?+?L"_]
M%.\4?^&O^(/_ ,H*Q]AB&T_85=[_  3\NZ\UV_#3WUQ9PO:W^L62NZ2_Y&6#
M71+_ )^^:W\NS&?'KPE^WCHW_!+'P?H7["VJ:-\/OVT? GP$^"+^%/#_ (_\
M.>%]6M]5U;PGX8\*P^-_AK?6GC6*X\-Z-XBU72[;6-)TJ_UB/[#9>(X+*UOK
MO3K*XN=3L_Y0?VR_V<OVD?\ @J+#\!/AY\(/^""_CW]@;]MF'XJ> /$GQ9_;
MCO-"TCX/?#?P@/#<5POC;Q#8^(O#&B^%8O'5I<>();?Q/HEWJ=QK'BNTM]&M
MX?"L.O:Q=P7*_P!8/_#Y;]@7_HIWBC_PU_Q!_P#E!1_P^6_8%_Z*=XH_\-?\
M0?\ Y04*AB%_RXJ^3Y)];;V6JU6GGZ@^*^%G9?ZQ9+:R7_(RP?E_T]TW7X=C
M^>C_ (+0:W_P4)_:H_;8\+_LX^*_^"?_ .W#\?\ _@EY^SU<^&]2\7^#?@%I
M.I^"3^V5\4=,T*PUE=:\7?$)=+U;=\+=%\0W2:+9Z'I,+7+/I&LZ_8W]GXBU
M+0-6\)_U#?\ !//XK^(OB]^R[X)UG7_V./''[!T7A:>^^'?AC]F[Q]:6.GZI
MX0\&^"8[31_#,^F:?IVCZ#:V'AR]TV../1;./2[98;:U*QF6+RY7\0_X?+?L
M"_\ 13O%'_AK_B#_ /*"C_A\M^P+_P!%.\4?^&O^(/\ \H*/J^(=OW%7_P %
MSUO;R\U_2T:XLX7NW_K%DNO_ %,L'UY;:^U\U]_DS\']:_X)C_M7_M%_'/\
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MX*Z#>ZP@D2:WC\:?$GXJ^'?"^B3,GE74VGZXX+-IS1M^TE>(^$_V>_AKX/\
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M^'O_  =:;_\ )-7[#6='U1I$TS5M-U%X55IDL+ZUO&B5R0C2+;RR%%8JP4L
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M&?\ @HO\<?"/Q*_9F^,O_!1/X(>.OV9_C)XX\,:O\6/C)=?LI>&K']N+XC>
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M,L4?Z@)\,_AO'X^E^*\?P^\$1_%*XT!?"D_Q)3PIH*^/IO"ZSQW2^&Y?&*V
M\12: MU%%<KH[ZBVG">..86PD16 Y;VON[._>W^7X@H[-V6VB7;6[\^A_G6?
M'_1;;2O^"A7_  6V\'?M-^,?^"8?PHFEN[/PSX'?_@HU\,/BSXN^(>E?LMVW
MA?7M-^$O_##4?@36=*@LM7\/>!+?P'+IFC^#M*U?QG/K>E^"QX=LY8['5[>3
MW7XN?!/PMIW[,/\ P0ZNK_\ X*0?L]:;^TG\.?A#\<[+]EOQ/^V=^SG\49_V
M(/CY\(_%?B75I?#%IXJUWX_?"^;P[\)O&'A7P(GA?P/HTWC_ ,*QWFO:</ 6
MK>%KC1_L_@W7-6_NA^*G[+_[-7QTUK0?$GQL_9[^"/Q?\1>%@B^&M>^)_P *
MO OCW6= 2.6:>.+1M3\4Z%JM[IL"3SS7"P6D\4(N)'GV>:=]='\3_@?\%OC9
MX0C^'WQD^$7PR^+'@.%X98/!?Q)\">%_&_A6WFMK:2SMI[?0/$NEZGI5O/:V
MLTMM;3PVL<MO!(\4+HC$$YMNEO3M;JOU_P PY-]=^O7=/?OI^OD?P7_#7QW\
M#/VBO^"7/_!8W]G[]H#PK\!OV(O#WPT^/'P*NOBU^V3_ ,$\_!WQ*^.'[*?Q
MB^*&K^+[[5]%OK#X>>#-3\4V"^%K75O"&BZ7XQG^'5YH7@S3=*\<^&KX>'_#
MC6>G:;J/N7_!+[XTZO\ #'_@K1^R)\&?'WPZ_P""6W[7GB[XI_!GXAZ?\-_V
MS/\ @FU'8^%_'/PQ^&FD^"-=UA[WX[^"/AG;^$?AW86^NV]FFDSZ;XR^&FB>
M)-+DUI6TOQ%<S:?#H,W]L'@SX)?!GX<_#Z7X2_#[X2?#/P-\*[BUO[*X^&OA
M#P)X7\-^ KFSU:#[-JMM<^$-'TNS\/W$&J6_[C4HIM/=+^(F.Z$JDBN7^$7[
M+7[,W[/VH:YJWP'_ &=_@=\%M5\3>8/$6I_"CX4>!/A[J&NI+.ET\6KWOA+0
M=)N=0@:YBCN/(NI981,B2K&'4,"^^G3]$M'NMN[TT\PY?AUV_P [_P"?GUU/
M\ZZV3QQ+_P $%/VIY/#R>*;CX)6W_!>3Q+<?MA0^!1?/JC_LW1^%/ #ZL;_^
MR_W@T-/&#>"'NC+B,7[>'I)"+59#7Z@ZO+^P/K?_  6[_P""03_\$0X/A+]M
MTWPW\0[W]KR\_95LK>T^'$/[.$FD^'X;2W^,!T&WBT9?%(T#_A,++5(?%J+X
MP@\1W7@2T\2B/Q1_PB<<?]H7ACX/_"3P3X<\1>#_  9\+?AUX1\)>+[_ %;5
M/%OA;PQX(\,Z!X<\4:GK]M%9:[J/B+1-*TRTTS6[_6K."&TU:\U*UN;C4K:&
M*"\DFBC1!S?PD_9N_9X^ 4FNR_ OX#_!OX,2^*)Q<^)9?A5\,O!?P^D\03K+
M),DFLR>$]%TE]3,4LLLD(O#,L+R.T00NV2^FW2V_DEV\K^H<NVO\OG;EMMV3
MZ_U;^#O]F+]D_P#9H^)__!-#_@Y0^//Q&^"OPW\=_&#P1^TI^VMIW@+XC^*_
M#&E:[XL\ VO@+04^(/A63P)K>H6]Q?>#KBW\8:G/J][=^')M-GUMX;*TUB74
M+&QM;:+^O?\ X(O:A>:G_P $F_\ @GA=W]W->W)_9+^#-LUQ<2M-*T5CX/TZ
MQMHFD8EF%O:VT-N@8DJD2J3Q7W+IGP.^"NB^'?&_@_1O@_\ "[2?"7Q,OM7U
M/XC^%],^'_A.P\._$#4O$$"VNOZCXWT2UTF+3/%=]KELJV^KW>O6M_<:E JP
MWLD\8"UVOAGPQX:\%^']'\)^#O#VA^$_"OAZPM]*T#PUX9TFPT'P_H>EVB"*
MTTW1]&TNWM=.TRPM8P([>SLK:"WA0!(XU4 4F[V\O\DOT&HVMZ-;;W:_(_EQ
M^'DDL7_!$C_@O(->:W_X6C:?'/\ X++?\+C<*1<GX@_:_'-S9R7XD'._X?R^
M WTCK#_PC9T-;;_11"!L?%/X!? KX*_!7_@V]\3?"CX6_#[X>>)X/VP_V._#
M4'B[PGX:T/0?%6I:/\2OV4_BIJGQ!L-3\2Z=9VVKZXOQ U2QM=8\8MJ-Y=R^
M)]5@74]6:\NRTQ_:3P3^QNG@#]J;]J3XEZ5=>#M=_9R_;-\%^&-5^.7P*\5Z
M"VK6\G[0/A32+?X=ZC\0-$L[F*X\,7WA7XN_!ZWT+PS\5?#.MZ>\E[K_ ,/_
M  [KUM/=CQ!XCMU^OK[X>> -3M/!UAJ7@;P?J%A\.]3TK6_A_97WAG1;NT\#
M:SH6GW&DZ'J_@ZVN+*2'PSJ>C:5>7>F:5?Z*EC=:=I]U<65I+#;3RQ,[[6Z:
M_>E=?A;K?K<+;>6GW-?G;\3^>?XM?\$Y?VH/%?Q5^)OBG1O^"6/_  ;[^--'
M\2_$'QGK^E>,/BAX5^(LWQ+\6:;K/B/4M1L?$OQ$FM/V;]6M9O'6NVMS%JGB
MV6VU74K>37[K4&AU"]C*W,O=_M6_\%#V_P"":OP,_90_8QTC1/V'_@)^VU\<
M/"&J:=X0\))X]LOA)^P;^S!X2T2YU!/$/QA\2:_XMLO ^J+\-M!G,J>#? 6G
M:+IGBSXF^++76=#T*W0:;J$]?T&UXK\3?V;/V=/C5JMCKOQD^ 7P5^+6N:9I
MRZ/INL_$WX5^!?'FJZ?I*75Q>II=CJ/BG0M5N[33DO;N[NULH)H[9;JZN+@1
M"6:1V2M?7;J'+;;1_+;2_3R^]L^"/^"4WP__ &1?"OP?^*%E\#_VMOAM^WI\
M7?'WQ#_X6C^V1^T5X=\?> _B+K'Q)^-GC&Q0QZEXBTSP5J^N:)X \+V.EZ(F
MB_"_X=6K0Z3X5\)Z'#9:<+N[CU/4KS@O^"=KAO\ @HW_ ,%R!O#,O[3G[*N1
MNRP7_AC'X5HN1DD+\C*O;Y"H^Z0/U+^%_P "_@E\$+;5[+X+?!WX5_"&S\03
MVEUKUI\+_A[X2\ 6VMW-A'/%8W&KP>%-(TF+4I[**YN8K2:]2:2VCN)TA9%E
MD#==I/@WPEX>U?Q3XB\/>%/#6B>(O&]Y8ZGXRUS2=$TS2]7\8:GI6F0:-I5_
MXIU6QM(K[7KS3M(M+72;&\U66]N++3+:"QMF2UACA4OOYJWXK_(:V_KYGY+?
MLQ?9W_X+3?\ !5)_#?G_ -DQ_LX_\$ZX?B"0)39-\3O[+_:'FTH!E_T4:@GP
MTE\+FZ1\WGV.336;%LUOG]CJ^*OV*OV6-:_9RT+XR^,/B9XET;QY^T1^T[\:
M_%OQX^/?CGP_9WUGX=N-=U6*Q\,> ? '@N#5VEUJV^'OP@^%7ASP9\.?",&J
MSO>WJ:'J/B6\BM=2\1W]M']JT/?Y)?<K E;YMOTOT_KK<****0PHHHH ****
M /PZ_P""N/@#Q!/\8OV&OCC\ ?VGOV>?V?\ ]MSX+Z[\<1^SMX/_ &G=6@TC
MX9?'CPSX^\)^&/"GQ?\  OVF<^8GB*VTNZ\-_P!DG3=NI.FL7<5I/IUV]GK6
MD_*W_!+7_@EE^W=\,OBC^RA\1_VYO&OP4TWP!^P9\//C1X._9=^%'P<GU'7=
M8O->^/EQ=#QWXV^(GBNZMK>RG1M+OY[73K#3[F]CF:TT21++1&L=4D\1?4?_
M  6W\1_L:2>"?@I\*/VF?V(_BY^W-\3/BM>?$6P_9Z^''P1\.:U<>/=(U72+
M7P<OC+4K3QQX:U.P\1>!;"<:QX4>]N-,M=<&I#3TFO=#OK+1YC#\A?\ !&/]
MBK_@J'\"OC=/\0/B5XA\8_LZ?L'WNG:^?"W[$?QA^.8_:*^(ND#4]$N+3PNM
MCK,7A:STOP);:)JJV&L7<-G>>&M8N(XWTC5O#D[RSW2AIJH7NEO:]KM7:M'6
M]M97NK:O7M_4111109A17YX?\%,_^"BGP]_X)I?L\6'QJ\7^"O$?Q7\7^-_B
M)X3^#WP9^#7@Z^LM-\3_ !4^*?C1[Q]%\-6.IWT%Y!I%E%I^F:IJ>J:NVG:D
MUK;V:VUIIVH:G?:?877B7_!._P#X*E^(?VN_C?\ '_\ 9!_:-_9<\6?L8_ME
M_LX:)X4\9^-?@QX@\>^'/BIHFN_#OQG;Z=/H_C3P=\0/"UCINEZM;6S:UH4.
MLVD=G);V?]OZ*;35M1N9-6L]%=G:_3_AO\T*ZO:^I^OE%?EI_P %(/\ @I3?
M_L-ZQ^SU\)/A5^S5\1/VN/VH/VJO%6O^%O@K\%_!&L:?X)TBZ'A:RLKSQ!K_
M (V^)>NZ=J?A_P &Z1IXU2P,)O[20WENFKZA--IVD:#JVIVF%_P3>_X*AW7[
M;?Q!_:0_9P^,W[.7B[]D;]L']DO4O"=I\:/@;XE\7Z)\1]+CTCQKI\E[X<\5
M>#OB%X=L-,TOQ#I%^L/FRHFGQ)!9:EH%_8W^LV6K)=0EG:_]=MMPNKV^77?M
M?8^ /^#IS_DRS]D;_M)7^S#_ .F#XKU_3/7\K/\ P=#?%?X6:_\ LO\ [+_P
MXT+XE_#[6?B)X<_X*3?LS3^(/ .E>-/#>H>-M#@M]"^)B7$^K^%+34IM>TV&
MW>_L$GEO+"&.%KZR65E-U )/ZIJ.B]7^406\O7]$%%%%(84444 %%%% 'EGQ
M5^!WP;^.>EZ9HGQF^%O@+XJ:/HNH/JND:7X_\+:-XKL-,U.2VDLWO[&TUJTO
M(+:[>UEEMVN(D64PR/&6VL17\R?_  48_80_:2_8[_:4F_;^_P"">7A7P1X#
M\*^%/"'A;P_%X%^'/@W3=7\36/BGQ+::G\.O$[^&?A1:> -7\-7VAWF@W^G:
MCJ=_>-->6^H7FLZLL<;VUJ\?]7]%>-F^287-J/+)RPV*A4A7P^.PZC#%4,12
MC)4:BJQY:DE3;34>>-[*THM)K]1\-?%?B'PVS58C#PHY_D&)P>*RK.>$<[G5
MQ7#^;9-F5:C4S3 5<!5=;!TIXZ%)TI8AX2ORJK4<Z-:,YTY?SM?LM_\ !>CP
M3K7C+0O@K^V)\--:_9J\3^'/AKIMYXU^)WQ&U:^M%U[QK8Z3H(G;_A7NG_#C
M2+WP_P#\)G)>7GB'3;>.4V%A9[+:W$T+V[G]G_@!^U?^SO\ M36GB:__ &?_
M (I^'_B=:>#;C2K7Q/-H4.K0C1Y];COY=*CN5U;3M.<_;DTO4#"T*RI_HDP9
ME8 'BOBM^P1^QO\ '+QQJWQ*^+G[._PW\?\ CS78M-AU?Q1XATF6ZU74(M(T
MVTT?3$N9ENHU<6>EV-G8PG8"+>VA0DA!7\__ (#_ ."<O_!4C]B/]I;]H3QI
M^PC8?"6U^%OQ(U_6+7PU:^+]>\,&R3P9<:^=>T.TB\+:E?R+IESH88:593R[
M[N.Q2>-2B7<JGQ_K/$N35,/'&0CGN G7JTYU\#A:DLTI453DZ$JE*G[.@[RC
M'GE:;;<E*JVX-_J3R/P#\4L%G6(X7Q5;P?XPPN3Y9C,-E7%W$6!I>'^/S.IC
MJ,,YH8',<8L=G$>6C6KRPM)3PL(TZ>'JTLNA2IXJE'^KNBOY-_@]_P %VOV@
MOV=_&GQ@\!?\% _A9KWC#5_#_C>'P'X5U#X7>&?#7A30M(USPIJOBG1_'27>
MKW]U9V7B.TU&XM=(G\/WEA*T!L["^NUEEMK^"2/^K'P_K^C>*M!T3Q1X<U.S
MUKP]XDTC3=?T'6=.G6YT_5M&UBSAU'2]3L;E/DN+._L;B"ZM9T^66"5)%X85
M[659W@,XC5^J3FJU"RQ&&KTW2Q%!RG4A'VD&W'WG3DUR3G964^63Y3\G\1O"
M7C+PNQ&!CQ+A<'5R[-XRGDN?91C(9ADF<1IX7!8NO+ 8I1I5G["&/H4YK$X;
M#.=15'AU6HP]J]>BBBO7/S0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M4>TG_//_ ,"?^?DON#^S,M_Z%^!_\)*'_P K\E]Q\W_\,=?LE_\ 1LWP%_\
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M+>^TBTOK^$-86MHFU?WO<B[[>ZFY7=O+76^A_H!(6*(778Y52Z!@P1B 67<
M VTY&X  XS@9IU%%!D?F+_P6C\!^+?B7_P $H_V^O!W@:PO-5\3W_P"S5\1-
M0T_2].CFFU#4X?#>FCQ-JFG6-O;JT]W>7VD:/?VMM9Q(\EY-*EJJ.9MI_D?U
M;XI?#/\ :D^!_P#P:;?L]_L__$/P=XS^,W@3XQ_#'7?'W@_PAXAL=9\5?#;3
M?@M<?#5?B/>^.-%T::XUCPHD0\(^*-3 UFULCJ%AH6IZC;"ZL+6:Z7_09959
M2K ,K JRL 592,$$'@@C@@\$<&OD;X._L"?L2_L]_%'Q-\;/@;^RK\"/A/\
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MK-\=4_L?]O?H'VEZ/_VT_9BBBBI&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7\^GQ3_P""'WC_ ,7_ +0WQR^/WPS_ &]?BC\#
M+_XX^.M?\8ZUHOP]\*:[HLL$&M:S>:U;Z)J&M>'?BUX:EUZWTJ>]E2UFN[&!
M<DS+;1222%OZ"Z*\_,,JP.:1HPQU&594*CJT>6M7H2A4<7!R4\/5I2UA*46F
MVK-Z'VO!7B'Q?X>8C,L5PEF='+:N;X.GE^9+$93DV;T<7A*6)I8RG1J8;.LO
MS'#)0Q-"E64X4HU.:$?>MH?SJ_\ #D7]I_\ Z2W?M0?^9'_^?]1_PY%_:?\
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M_0MY?GW9_.K_ ,.1?VG_ /I+=^U!_P"9'_\ G_4?\.1?VG_^DMW[4'_F1_\
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M$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:G:7OB#6/H3]A/\ 8)_;N\7?MA6W_!13_@J1\2?AUJ_QG\#_  \UKX9?L^?
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MJO%Y3C84<3F&%P>:X/%83,*$\%',<16Y,'4J5(T9QJ4:?K-%%%>^?C84444
M%%%% !1110 4444 %%%% !1110 4444 %%%?BK^T]_P<$_\ !,']C_X]_$3]
MFCXY_%_QSH/Q>^%EWH]EXTT#1?@I\5?%EEIMQKOAW1_%.FK#K?AWPMJ&DWR3
M:-KVF3O):74T<4L[6TC+/%+&I9O97"Z6[L?M517XEZ=_P<)_\$OM4_9V\4?M
M3V?Q:^(<GP:\'?%[PG\#==UUO@5\7$U.W^(OC;PGXE\:^'],A\.-X3&MW-A<
M^'_".N7$^LPV3:99W%O!97-S'=7MG%/YAX(_X.=/^"0/Q$\8^&/ ?A/XX?$?
M4O$OB_Q1H/@[1+(_L^_&>VBEU[Q)JMMHNE6EU=W'@Z.VLDFO[N&.2>ZDBB@0
MO)*RHC$.S[/[A77=?>C^@.BOQ@_:S_X+]_\ !,?]C+XS>)O@%\6_C-XDU?XG
M^ TB;XCZ-\+_ (9^-OB38_#F:6**?[!XRU[PWI-QHFFZK;V\R3:AI-O?7NI:
M3S!JUK9796W;ZVUO_@I?^PKX=_9 TS]O/5OVD? 4'[*&M00MHOQ9C?5KJSU?
M4I]1N]'7POIGANUTR;QC>^-8]7T_4=+N_!,'AY_%5A>Z;J<-_I%L=-OC;EGV
M>NWF%UKJM-_(^Z:*_.;]AG_@J_\ L+?\%%]0\8>'OV6_C&?%'CCP#90:OXM^
M''BSPEXM^'?Q TK0+NXAMK/Q*GACQKH^C7NJ^';B:ZLHWUC1?[2L[";4--M]
M5DL+G4;*&?VC]I_]MG]GG]CS5O@%HOQX\5:KX9U#]IGXS>&_@%\(8],\+>(?
M$J:[\3/%L\-MH>CW\NA6%]'H5G<S3Q))K&KM:Z9;;MT]S&BLP5GM;7L%UO=6
M[W/K&BJ&JZG9Z+I>I:SJ#M%8:387FIWTJ1O,\=G86\EU<ND42M)*R0Q.RQQJ
MSN0%12Q /S=^QY^V'\"/V[O@3X=_:0_9N\2:KXK^$_BK5?$NC:+K6L^&-?\
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M5R[*J^+^O3P57+LGS.BL4Z<:3JTEFV78Z5"\(I.%"5.FVYSY.>I.4OYU/^'
M^L_])$OVF?\ OW=?_-U1_P .!]9_Z2)?M,_]^[K_ .;JOZ*Z*X_]4N'_ /H
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M$TE?HE^PO_P1B^$_[!?QBL/C#X$_:O\ VY_BY-I?@75?A_IOP]^/?QZC\?\
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MMVL_QUUT?4&GK:ZW2U;_ )>UWT?_  QA?!S4_P!LC]DG_@NQ^SU_P3^\9_\
M!0+XZ?M6_LX:Y^Q!\1_C!8Z#\:+[PIJ/CV'5?.\?:;!;_$W7]"T+3+SQMJ-A
MK?AFXUKPMXFUCR]8BT2]LM!N'N[?1$N[W\'/V1? _P"V/\)O^""/QN_X*"?
M_P#X*"_'_P" \O[,/[1'C?5OA7^S_P#"N#PIHGPH\0-J/Q=^'?A?QGJ?Q?$N
MCW.N_$K5M;N?%5Q+I.F^(K^]\'Z'IVA:=8CPY>'5M7FK]:O^"3W["GQ/UO\
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MB6VF\->?\$$_V&G_ ."?'B[_ ()RZ,_Q8\._"OXC_$+0_BS\4?B=8^+M(O\
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MOBK_ .=!1ROR^]?Y^:^\.9=_P?\ EYH_J HK^7__ (B!_P!L7_I )_P4H_\
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M7Q5_\Z"OT+_X)?\ _!6SPE_P4@UK]H'X::M^SY\7_P!E?]H+]F?7M T_XJ_
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MPYEY_<_\O-?>?U 45_+_ /\ $0/^V+_T@$_X*4?^$KXJ_P#G04?\1 _[8O\
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M'V-/YX@F-L(FN1%)]G6=G6 S[#Y0F:-7D6(R;1(R(SA,E59@ ?XF_CC\3O\
M@J+^QE^VK^QSX1\6?\%,+W]H[_@H5^TK^U-HLGC7_@GEX T&4_LB:7^QUXMU
M_P 96/\ ;^E3>)?#WAA_!S:1I7A::VAUB]$'C*)FN[^WO-4N?#-YX@\1M==;
M:>>O_ ]="9-):IVT_-6ZKK8_MIHHHI%!1110!\4_M-_L#? /]K3XT_LC_'KX
MM)XU;Q[^Q1\1M5^*/P4/AGQ0VA:*GBC6+SP;?WI\6Z6+&Z'B#3S<>!-!\NT\
M^Q9(EO8#.T5[*E?:U?QX?\'*'_!6/]I#X2^%O'O[-?\ P3\\5>)O"GB?]GC3
M_AG\4OVWOVAO .J#3+WX):/\2/%FE>$_@M\%M.UZ,EK/QQ\3-:UFV\5Z_8V3
M)JT'@K2[6&'[1INH^*X],_K=^'5[=ZE\/O FHZA<S7E_?^#?#%[>W=PV^>ZN
M[K1+&>YN9WXWS3S2/+(V!N=F/>F[V5]M;?A]U[DIJ[2WW?;HCLJ***105\8_
MM0_L'_ C]KSXF_LH_%KXNIXS;Q;^QI\7K?XW?!IO"WB=] TU/&]K?>'-1B;Q
M59+977]O:2+GPMI1:P$UDS1"Z@-QY5W,A^SJ_@N_X*'_ /!37QUJ_P#P5E_;
M4^#&N_\ !7;X[_\ !./]GS]GQ/@O\/?!%M\+_P!GK7_V@_#VO>-+WPII ^)F
MJ>(8_"-Q8CP38:)XNU&XM;W5-9U&YO=3GGM]/T_37ETVYBA:5WV^_;;IZB;2
MM?J_Z>O8_O1HKYF_8RCN8_V4O@ UW^T3'^UM-<?"_P +7P_:7BM["TB^-L&H
M6"7UK\08[73-2UBQMX]>MKB&X2"#4[WREPDD[S"3'TS2&%%%% 'A_P"TI^S[
M\/\ ]JWX"_%?]G'XK#6V^''QE\&ZKX%\9+X;U3^Q=>;0M8C6.\&EZJ;>[%C=
ME5 CG:UN$'(>)U8J=']G[X(>"/V:?@=\)?V>_AHNKI\/?@M\/O"OPS\%)K^I
M'6-;3PQX.T>UT/14U75##;'4+Y+"S@6XNOL\/G2!G$2 [1_.C_P7K_X*,>.?
M@9^TI^QE^P]X=_:KO?V%?A;\;= \>?&/]IS]JGPUI USXE^%_A;X-34+7PWX
M'^%=E!INM:Q'XL\=^(-"UC0[1O#>D7GB:ZUR[\*V^G@Z4OB"QU'[1_X(9?%3
MQG\5O@)\6M6NO^"AOAC_ (*-_"'3/BQ=Z=\$?B?J'ASQ'X7_ &A? 7AA[1[R
MZ^&_[2.F>)]$\-ZJ/&NG6UQH6IV$]_HYO+@:AJ\T.J7V@/H%MISL[7Z=%K_P
MWXW)NN:UM4M]-M'ZV_7\/V\HHHI%!117R;^VI\!?C1^TC\#-1^&/P$_:E\:?
ML>?$.\\1^'-8M?C3X"\+Z;XO\06&EZ/>/<:IX>31M4U;1+:2TU^!EMKF<:C%
M) (T8),ADB< P?V1?V#?@/\ L3ZU^TAKWP33QFE_^U1\<O$_[0OQ4/BWQ,?$
M4+_$/Q;<W5WK$GAV(V-E_8^C/-=S&#3BUV\2^6C74BQH!]H5_(G_ ,$RO"G_
M  4/\>?\%8/C7X%D_P""I7QX_:N_8S_8(N$\%?';Q)XU\'>&/"/AOXN_M)>(
M- UNPNO@=X;T?3=4U]KG2/A?)<C6/&WB8ZN+FP\3>'+318])2TUW2]:/]=E-
MJW6^B_(F+NMK6=NGX6Z7NOD%%%%(H*^+/@5^P3\!/V=_VG?VJOVM_AW'XS7X
MN?MC7O@J_P#C')KOB7^U?#;S^ ;._L= 'A?1?L%NVAQK!J5R+I&O+[SCY>PP
MHFP_8^H27L5A?2Z;!%=:C'9W,EA;3R^1!<7J0NUK!-, 3#%-.(XY)<'RT9GP
M<5_GD> ?^"BO_!0(^./A1XLE_P""AGQO\0_\%7?$O_!06X^ _P 3_P#@DGK/
M@JRM/@/X;^&T?B[7-.UCP['I@T5?#>DZ3IN@V-@__"?6?B5M5M+._DC@NFU[
M1K[Q5*TF[V\K^E_R5M63)I6NKOIMW6WGZ'^B'1112*"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XT_;<_82
M^!/_  4!^'7@'X7?M )XRD\+_#?XQ^#/CGX;'@GQ,WA;41XY\"6>O6.A-?WJ
MV5_]KT@6_B/4A=Z=Y49FD-O-'<0RV\;C[+K^5C]KSXC_ +;G[?/_  5T_:*_
MX)^?LY?MC?$S]C#X4_L4_L?Z3\9+S6_@K%IL'BKXG_'SQS:>#];\):=XUU:\
MCCO9O ]KI_C;2;6[\/6]TEF8-!U5S%+?>((;S2/T5_X(+_MQ?%'_ (* ?\$V
MOA-\:_CE=6FJ?&GP[XB\<_"+XG^(+*TL]/C\4^(_AWK;6-IXHN--TZVM-.T_
M5==\,WGA_4-<M]-MH--?6YM1N=/M;*RN(+&V;5EO\M=+JZ_X)*:NTEKKK;>U
MOROU^1^R5%%%(H**** "OCO]NG]AKX&_\%$/@!J?[-?[1$?C"7X:ZOXG\+>+
M;Q/ _B0^%=>.K>$-0.I:1Y>K"RU#9:_:2?M,/V8M*NTI)%(B2+XA_P %+?A!
M_P %"/CWX7^"?PF_87^.?AG]FCPYXH^*=D/VH_C<D['XP>$_@U:?8OM%G\$K
M&XT#5M+G\4ZHT^HSW-W<:EX:O[>32M*LK+6K>RU35G3^?OX(_P#!1#]J[]B#
MXC_\%M?@L?VH?%/_  4.^!G_  3Y_9CL_BE\,/CU\9/[(U?Q1X,_:2U?3M$T
MFR^"7C+QEH"1KXLM#XNU7Q+;ZYI\]Y)/IMQ\,M5TS3(]#O;K5[56D]UNK:?-
M?+=]R6ULUI_EKMNUW=M#^RK3;"WTK3M/TNU\S[+IME:V%MYSF67[/9P1V\/F
MR'!DD\N-=[D NV6/)J[7\2?[./[2O_!1#]D/XF?\$2?VD/CE^W)\3_VH_A[_
M ,%?=6M/"OQX^"?Q0L/#T'@7X5ZO\6+;P/JWPTU3X11Z=96G_"(/X93X@Z9+
MJUII$&FV%W)X>U+3%M)-+UNWM]*_MLH:MYWZK8:=UV_X9/\ 4****0PHHKF_
M&/C#PM\/?"7B?Q[XXU_2_"O@SP5X?UCQ7XM\3ZY=Q6&C>'O#?A_3[C5=;UO5
M;Z=EAM-.TO3;2YO;RXE8)#;PR2,<+0!\]?MJ?L=?!W]O?]G#Q[^RQ\>U\4O\
M+/B//X4N/$B>#->_X1GQ$TG@SQ?H7CC1?L6L?8]06W1==\.Z:]W&]I,ES:K-
M;, )2R^]?#WP1H?PR\ ^!_AOX9%X/#?P^\'^&O!'A\:C=&^U :'X3T6RT'21
M?WK(C7=Y]@L+?[5=,B&XGWRE%+X'\BW[!'_!3_\ ;#_;9_X+O>%9==U7XA?"
M_P#83^,/[*'Q7^)G[*?P/U:1M$T_Q_\ !_PGXKU/P1X.^/?C'PJX%U_PDOQ"
M\4>'/&.OZ1=:HJ7%EX>;1]-TV2\T6SLM3U/XB\9?MT?\%,OC3^RM^WC_ ,%L
MOAG^V]\1OAKX4_9._;8MOA5\&/V.=.T+09OV?/$WP+T+QE\-/#<]EX_T>9#=
M^(/$.KV'Q*TN36-8O%;57N=.UV73M1TYM6T,^%JY7MVM]\K?U\B.9:M*^]WH
MM%:_YZ']^M%>6? OXHZ=\</@E\'?C5I%L]GI/Q?^%GP]^*.EV<A8O:Z=\0/"
M6D>++*V<NJN7@MM6BB8NJME#N4'('J=27N%%%% !7@O[4/[.'PX_:\_9_P#B
MI^S5\75UYOAK\8?#$WA'Q@OAC5O["U\Z1/=VMXXTO5OLUX+*X\ZSA_>M:SHT
M>^-XF1R*]OO[ZVTRQO=2O)/*M-/M+F^NI<%O+MK2%YYY,#D[(HV; Y.,"O\
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M?MX_\%??B#_P37^!?[7_ ,2_V'_A]^RM^Q5:_M">,]>^!\-@_B[X@?&SQ4/
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MM;]NMM-5Y'EGP,^%VG? _P""7P=^"NCW+WND_"#X6?#[X7:7>2!A)=Z=\/\
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MSJC:?87-UX>LKY+J;3?$#7&F?VX44[N]_3\+?Y$\J[M.[=_7?^NA_'O\3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ggtc45pq2o35000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ggtc45pq2o35000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'K G\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLA#P)N<,63(W!25#!"2$).* .PC<21JZYPP!&1@\U1UG6;/0M/:\O9-B9VH
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MEU#K_A;_ ,E/T#_KY/\ Z U=1^T#_P C[:_]>"?^A-7+_"W_ )*?H'_7R?\
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M?M'?ZKP__O3_ /LE>"UPY1_NJ]65/XCVG]G3_D/ZY_UZQ_\ H1KS;QW_ ,E
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MY^4?\O/4NIT.F^'?_)1O#_\ U_1_SKO/VB?^1MTG_KP_]J-7!_#O_DHWA_\
MZ_H_YUWG[1/_ "-ND_\ 7A_[4:BM_P C*GZ?Y@O@9X[7OO[./_'IXA_ZZ0?R
M>O J]]_9Q_X]/$/_ %T@_D]:YO\ [J_5"I_$>&ZI_P A>^_Z^)/_ $(U4[5;
MU3_D+WW_ %\2?^A&JG:NZC_"CZ(E[GT-\2_^2 Z%_P!<[+_T77SS7T-\2_\
MD@.A?]<[+_T77SS7FY-_!EZ_HBZFYZ#\%/\ DJ>F?]<YO_1;5-\<_P#DI]U_
MU[P_^@U#\%/^2IZ9_P!<YO\ T6U3?'/_ )*?=?\ 7O#_ .@TG_R,UZ!]@\XK
MZ%^$7_)&-?\ ]ZY_]%"OGJOH7X1?\D8U_P#WKG_T4*K.?X"]?\PI[GST.@J:
MU_X_(/\ KHO\ZA'05-:_\?D'_71?YUZ4_P"&_0CJ?<\?^K7Z"G4V/_5K]!3J
M^%.D**** "BBB@ HHHH **** "L?P]_J]1_["$__ *%6Q6/X>_U>H_\ 80G_
M /0J /ESXL_\E1UW_KJO_H"UQ==I\6?^2HZ[_P!=5_\ 0%KBZ^TP7^[0]$<\
MMSZ&\&_\FVZE_P!>]Y_Z$U?/-?0W@W_DVW4O^O>\_P#0FKYYKBRO^)6]?\RI
M[(U/#/\ R-FC?]?\'_HQ:]=_:._X_O#W_7*?^:5Y%X9_Y&S1O^O^#_T8M>N_
MM'?\?WA[_KE/_-*,3_R,*7I_F"^!GAU>V_LY_P#(6U[_ *X1?^A-7B5>V_LY
M_P#(6U[_ *X1?^A-6V:_[K+Y?F*'Q'E'BG_D;];_ .PA<?\ HQJR:UO%/_(W
MZW_V$+C_ -&-6377A_X,/1?D2]SZ!U__ )-BL/\ KWM__1@KY^KZ!U__ )-B
ML/\ KWM__1@KY^KSLH^"?J74.O\ A;_R4_0/^OD_^@-74?M _P#(^VO_ %X)
M_P"A-7+_  M_Y*?H'_7R?_0&KJ/V@?\ D?;7_KP3_P!":E4_Y&4/3_,%\!Y1
M7T-^SW_R*6N?]??_ +3%?/-?0W[/?_(I:Y_U]_\ M,5><_[M\U^H4_B/GN3_
M %K_ .\:8>A^E/D_UK_[QIAZ'Z5Z,?X:]".I]#_''_DF'A__ *^H?_1#U\\U
M]#?''_DF'A__ *^H?_1#U\\UYN3?[N_5_H74W/2_@3_R4R'_ *])OY"LSXO_
M /)4];_WX_\ T4E:?P)_Y*9#_P!>DW\A69\7_P#DJ>M_[\?_ **2E'_D9O\
MP_Y!]@X>OH/X??\ )O.M_P"Y>?\ H-?/E?0?P^_Y-YUO_<O/_0:,X_A1]?\
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M#W_7ZE=^+_W>?HR8[H[']H3_ )'JQ_[!Z_\ H;UY+7K7[0G_ "/5C_V#U_\
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MCAOB+_R4;Q#_ -?TG\ZYBNG^(O\ R4;Q#_U_2?SKF*Z,)_ AZ+\B9;GT2_\
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MUZ4_X;]".I]SQ_ZM?H*=38_]6OT%.KX4Z0HHHH **** "@D 9)P!12$!E*L
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MQ<&V:WA"6.+]FV_$CA=\%XJY[G+<5\^5]3GPM)X-^"6L:++=K=/%:7+F5$*
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M 'C3#T/TKT8_PUZ$=3Z#^-D\4WPPT+RG#[+N%6QV/D/7S[7T-\<?^28>'_\
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M6*]P/*'-?/E?0WPB_P"2,:__ +UU_P"BA59S_ 7K_F%/<^>1T%2VIQ=P$_\
M/1?YU$.@J:U_X_(/^NB_SKTI_P -^A'4^X([RW,$+B92LA"H<_>/I5FFI_JU
M^@IU?"G2%%%% !1110 4444 %%%% !6/X>_U>H_]A"?_ -"K8K'\/?ZO4?\
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M\\U]#?L]_P#(I:Y_U]_^TQ5YS_NWS7ZA3^(^>Y/]:_\ O&F'H?I3Y/\ 6O\
M[QIAZ'Z5Z,?X:]".I]#_ !Q_Y)AX?_Z^H?\ T0]?/-?0WQQ_Y)AX?_Z^H?\
MT0]?/->;DW^[OU?Z%U-STOX$_P#)3(?^O2;^0K,^+_\ R5/6_P#?C_\ 125I
M_ G_ )*9#_UZ3?R%9GQ?_P"2IZW_ +\?_HI*4?\ D9O_  _Y!]@X>OH/X??\
MF\ZW_N7G_H-?/E?0?P^_Y-YUO_<O/_0:,X_A1]?\PI[GSY5[1?\ D/:;_P!?
M47_H8JC5[1?^0]IO_7U%_P"ABO2K_P *7H_R(6Y[9^T=_JO#_P#O3_\ LE>"
MU[U^T=_JO#_^]/\ ^R5X+7#E'^ZKU94_B/:?V=/^0_KG_7K'_P"A&O-O'?\
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M "535/\ KG!_Z*6O/J]!^-G_ "535/\ KG!_Z*6O/J> _P!VAZ!+<^B/A?\
M\D'UK_=O/_1=?.XZ5]$?"_\ Y(/K7^[>?^BZ^=QTKCRW^/6]?U94]D3V/_(0
MMO\ KJG\Q7N_[1W_ !Y>'_\ KK-_):\(L?\ D(6W_75/YBO=_P!H[_CR\/\
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MZ9_USF_]%M4WQS_Y*?=?]>\/_H-)_P#(S7H'V#SBOH7X1?\ )&-?_P!ZY_\
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MEWZYKJY(S:1C(.#]XUYOXX79X]\0+ECC49QECDGYSWKTK]G3_D/ZY_UZQ_\
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MQTKCRW^/6]?U94]D3V/_ "$+;_KJG\Q7N?[1$0BL-! =VS-,?G8GLM>&6/\
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M7'_HQJR:UO%/_(WZW_V$+C_T8U9-=>'_ (,/1?D2]SZ!U_\ Y-BL/^O>W_\
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MZ?\ ]DKP6O=OVBC*1H0=4"AIMA#9)^YUKPFN'*/]U7JRI_$>T_LZ?\A_7/\
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M_=9^A,/B(_C9_P E4U3_ *YP?^BEKSZO0?C7_P E4U3_ *YP?^BEKSZG@/\
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M_P!A"?\ ]"H V**** .<\?\ _)/O$'_7A+_Z":^,Z^S/'_\ R3[Q!_UX2_\
MH)KXSKZ'(_AG\OU,JAJ>&?\ D;-&_P"O^#_T8M>N_M'?\?WA[_KE/_-*\B\,
M_P#(V:-_U_P?^C%KUW]H[_C^\/?]<I_YI6V)_P"1A2]/\Q+X&>'5[;^SG_R%
MM>_ZX1?^A-7B5>V_LY_\A;7O^N$7_H35MFO^ZR^7YBA\1Y1XI_Y&_6_^PA<?
M^C&K)K6\4_\ (WZW_P!A"X_]&-6377A_X,/1?D2]SZ!U_P#Y-BL/^O>W_P#1
M@KY^KZ!U_P#Y-BL/^O>W_P#1@KY^KSLH^"?J74.O^%O_ "4_0/\ KY/_ * U
M=1^T#_R/MK_UX)_Z$U<O\+?^2GZ!_P!?)_\ 0&KJ/V@?^1]M?^O!/_0FI5/^
M1E#T_P P7P'E%?0W[/?_ "*6N?\ 7W_[3%?/-?0W[/?_ "*6N?\ 7W_[3%7G
M/^[?-?J%/XCY[D_UK_[QIAZ'Z4^3_6O_ +QIAZ'Z5Z,?X:]".I]#_''_ ))A
MX?\ ^OJ'_P!$/7SS7T-\<?\ DF'A_P#Z^H?_ $0]?/->;DW^[OU?Z%U-STOX
M$_\ )3(?^O2;^0K,^+__ "5/6_\ ?C_]%)6G\"?^2F0_]>DW\A69\7_^2IZW
M_OQ_^BDI1_Y&;_P_Y!]@X>OH/X??\F\ZW_N7G_H-?/E?0?P^_P"3>=;_ -R\
M_P#0:,X_A1]?\PI[GSY5[1?^0]IO_7U%_P"ABJ-7M%_Y#VF_]?47_H8KTJ_\
M*7H_R(6Y[9^T=_JO#_\ O3_^R5X+7O7[1W^J\/\ ^]/_ .R5X+7#E'^ZKU94
M_B/:?V=/^0_KG_7K'_Z$:\V\=_\ )0/$7_82N/\ T8:])_9T_P"0_KG_ %ZQ
M_P#H1KS;QW_R4#Q%_P!A*X_]&&LL/_R,:GI_D-_ CGZ^A-6_Y-=M_P#KU@_]
M'+7SW7T)JW_)KMO_ ->L'_HY:>:_%2_Q?Y!#J?/==3\-O^2D^'O^OU*Y:NI^
M&W_)2?#W_7ZE=^+_ -WGZ,F.Z.Q_:$_Y'JQ_[!Z_^AO7DM>M?M"?\CU8_P#8
M/7_T-Z\EK#+/]UA\_P PG\1[_P#L[?\ (&\1?]=HO_06KP:\_P"/VX_ZZM_,
MU[S^SM_R!O$7_7:+_P!!:O!KS_C]N/\ KJW\S7/@_P#?:Q4OA1">A^E?17Q>
M_P"2+:+_ -=+7_T4U?.IZ'Z5]%?%[_DBVB_]=+7_ -%-2S'_ 'BAZ_J@ALSY
MUKTCX&?\E.M?^O:;_P!!KS>O2/@9_P E.M?^O:;_ -!KLS#_ '6?H3#XB#XV
M?\E4U3_KG!_Z*6O/J]!^-G_)5-4_ZYP?^BEKSZG@/]VAZ!+<^B/A?_R0?6O]
MV\_]%U\[CI7T1\+_ /D@^M?[MY_Z+KYW'2N/+?X];U_5E3V1/8_\A"V_ZZI_
M,5[O^T=_QY>'_P#KK-_):\(L?^0A;?\ 75/YBO=_VCO^/+P__P!=9OY+1C/]
M]HA'X6> U[!^SO\ \CAJG_7A_P"U%KQ^O8/V=_\ D<-4_P"O#_VHM;YI_NLO
ME^:%#XCAOB+_ ,E&\0_]?TG\ZYBNG^(O_)1O$/\ U_2?SKF*Z,)_ AZ+\B9;
MGT2__)K@_P"O(?\ H^OG:OHE_P#DUP?]>0_]'U\[5Y^4?\O/4NIT.F^'?_)1
MO#__ %_1_P Z[S]HG_D;=)_Z\/\ VHU<'\._^2C>'_\ K^C_ )UWG[1/_(VZ
M3_UX?^U&HK?\C*GZ?Y@O@9X[7OO[./\ QZ>(?^ND'\GKP*O??V<?^/3Q#_UT
M@_D]:YO_ +J_5"I_$>&ZI_R%[[_KXD_]"-5.U6]4_P"0O??]?$G_ *$:J=J[
MJ/\ "CZ(E[GT-\2_^2 Z%_USLO\ T77SS7T-\2_^2 Z%_P!<[+_T77SS7FY-
M_!EZ_HBZFYZ#\%/^2IZ9_P!<YO\ T6U3?'/_ )*?=?\ 7O#_ .@U#\%/^2IZ
M9_USF_\ 1;5-\<_^2GW7_7O#_P"@TG_R,UZ!]@\XKZ%^$7_)&-?_ -ZY_P#1
M0KYZKZ%^$7_)&-?_ -ZY_P#10JLY_@+U_P PI[GST.@J:U_X_(/^NB_SJ$=!
M4UK_ ,?D'_71?YUZ4_X;]".I]SQ_ZM?H*=38_P#5K]!3J^%.D**** "BBB@
MHHHH **** "L?P]_J]1_["$__H5;%8_A[_5ZC_V$)_\ T*@#8HHHH YSQ_\
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M_1#U\\UYN3?[N_5_H74W/2_@3_R4R'_KTF_D*S/B_P#\E3UO_?C_ /125I_
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M/^1ZL?\ L'K_ .AO7DM>M?M"?\CU8_\ 8/7_ -#>O):PRS_=8?/\PG\1[_\
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M'_7D/_1]?.U>?E'_ "\]2ZG0Z;X=_P#)1O#_ /U_1_SKO/VB?^1MTG_KP_\
M:C5P?P[_ .2C>'_^OZ/^==Y^T3_R-ND_]>'_ +4:BM_R,J?I_F"^!GCM>^_L
MX_\ 'IXA_P"ND'\GKP*O??V<?^/3Q#_UT@_D]:YO_NK]4*G\1X;JG_(7OO\
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M\':8]]YZ&6&W:2&:6RBVB"5XON,5VYXPO0@'8N>E &E?:SI^FRK%=W(B=EW
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MI3Y/]:_^\:8>A^E>C'^&O0CJ?0?QLFCF^&&A>6V[9=PJWL?(>OGVOH;XX_\
M),/#_P#U]0_^B'KYYKS<F_W=^K_0NIN>D? V1(OB1')(=JK9S$G\!6;\76#_
M !1UIE.5+1$'_MDE:OP)_P"2F0_]>DW\A69\7_\ DJ>M_P"_'_Z*2E'_ )&;
M_P /^0?8.'KZ \ S1Q_L^ZO&[8:1+P*,=?EKY_KZ#^'W_)O.M_[EY_Z#1G'\
M*/K_ )A3W/GRKVB_\A[3?^OJ+_T,51J]HO\ R'M-_P"OJ+_T,5Z5?^%+T?Y$
M+<]H_:*FCD&A(C99&F##'3[E>$U[U^T=_JO#_P#O3_\ LE>"UPY1_NJ]65/X
MCV?]G=UCUS778X5;2,D_\"->;^.'63Q[X@=#E6U&<@^OSFO2OV=/^0_KG_7K
M'_Z$:\V\=_\ )0/$7_82N/\ T8:RP_\ R,:GI_D-_ CGZ^@M7E0?LOVJEN7M
MH0H]2)EKY]KZ%U;_ )-=@_Z]8/\ T<M/-?BI?XO\@AU/GJNH^'#!?B/X?).!
M]M2N7KJ?AM_R4GP]_P!?J5WXO_=Y^C)CNCL/V@F5O'=F <E;! ?;YWKR:O6O
MVA/^1ZL?^P>O_H;UY+6&6?[K#Y_F$_B/??V=Y%72/$2D\^9$V/;:U>$79S>3
MD=#(W\Z]Y_9V_P"0-XA_Z[1?^@M7@UY_Q^W'_75OYFN?!_[[6*E\*(3T/TKZ
M'^+4J2_!712C9'FVH_\ (35\\'H?I7T5\7O^2+:+_P!=+7_T4U+,?]XH>OZH
M(;,^=:]%^",T<'Q+MGD;:OV>89_X#7G5>D? S_DIUK_U[3?^@UV9A_NL_0F'
MQ$'QK_Y*IJG_ %S@_P#12UY]7H/QL_Y*IJG_ %S@_P#12UY]3P'^[0] EN?0
MGPOFC_X4=K4&[]X4O&VX[>77SV.E?1'PO_Y(/K7^[>?^BZ^=QTKCRW^/6]?U
M94]D3V/_ "$+;_KJG\Q7N?[1$\<]AH+1MN"S3 \=\+7AEC_R$+;_ *ZI_,5[
MO^T=_P >7A__ *ZS?R6C&?[[1"/PL\!KU[]GR5(?%FK22-M06')_[:)7D->P
M?L[_ /(X:I_UX?\ M1:WS3_=9?+\T*'Q'"_$0AOB+X@8'(-[(1^=<S73_$7_
M )*-XA_Z_I/YUS%=&$_@0]%^1,MSZ%EFC7]F)(F;#M9 J/7]_7SU7T2__)K@
M_P"O(?\ H^OG:O/RC_EYZEU.ATWP[_Y*-X?_ .OZ/^==Q^T+-'+XNTP(V=ED
M5;V/F-7#_#O_ )*-X?\ ^OZ/^==Y^T3_ ,C;I/\ UX?^U&HK?\C*GZ?Y@O@9
MX[7O7[.LB16/B)W.%5X"3^#UX+7OO[./_'IXA_ZZ0?R>M<W_ -U?JA4_B/#-
M3(.K7I'0W$F/^^C57M5O5/\ D+WW_7Q)_P"A&JG:NZC_  H^B)>Y]"?$N5/^
M%!Z N[EH[/ ]<1\U\]U]#?$O_D@.A?\ 7.R_]%U\\UYN3?P9>OZ(NIN=_P#!
M9U3XI:66. 4F ^IC:I_CBP;XGWF#G%O"#_WS47P4_P"2IZ9_USF_]%M4WQS_
M .2GW7_7O#_Z#2?_ ",UZ!]@\XKZ#^$4B?\ "G?$$>[YP;EB/;RA7SY7T-\(
MO^2,:_\ [UU_Z*%5G/\  7K_ )A3W/GD=!4MJ<7<!/\ ST7^=1#H*FM?^/R#
M_KHO\Z]*?\-^A'4^X$O+?R(7\P;9"%0X/)JS34_U:_04ZOA3I"N0\7&\@US1
MKJRU'1K&98YXHVU12^YF,?$:AU.[ ;)!Z<=ZZ^N>\2Z?K<\MK>:$U@;N!9(U
M6^#;$+@ 2KM!^9<$8QR&89% ')Z'?ZO!XK71/^$ET&Y=;U[B]M;2V>*3Y@69
M0S.5."02H^;&?>O3:Y"S\,W6EC0M,MH8);"RE-U=7LDI$\LY5LOMVD$LS$DE
ML\XKKZ "BBB@ HHHH *Q_#W^KU'_ +"$_P#Z%6Q6/X>_U>H_]A"?_P!"H V*
M*** ,GQ/IDVM>%M4TRV9$GN[9X8VD)"AF! SCM7S]_PSYXM_Y_M'_P"_TG_Q
MNOI>N%TM[RQ\:7UTEGJITF:VAB1"CX68RL&9E<DDX()8<!0*Z:&+K8>_LW:X
MG%/<\PT?X#^*+#7-/O9KW23%;W,<SA)9"2%8$X^3KQ5O]H[_ (_O#W_7*?\
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M?^CEIYK\5+_%_D$.I\]UU/PV_P"2D^'O^OU*Y:NI^&W_ "4GP]_U^I7?B_\
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M .BDI1_Y&;_P_P"0?8.'KZ#^'W_)O.M_[EY_Z#7SY7T'\/O^3>=;_P!R\_\
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MK_=O/_1=?.XZ5]$?"_\ Y(/K7^[>?^BZ^=QTKCRW^/6]?U94]D3V/_(0MO\
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MP1O.!]!T!J6B@"#[(GDK%YD^%.0?.;=^)SDBG^2OG-+NDW%=N-YV_ETS4E%
M$'V1/)$7F3[0V[/G-N_/.<4_R5\XR[I-Q&,;SM_+IFI** /([G1M3FT?Q@]I
M8:Q9I<JD6GV2R2EV9"?WI8MP6)Z ]%&:['6=NI:9<POIVI&1(U6-FB9D+,A(
M;8'!.T\'T/YUU=% 'D/CZSO++]G^.WU'SQ>QQVPG$TQD;>&4'+=_I7S=7U;\
M;/\ DENI?]=(?_1BU\I5]+DG\&7K^AC4W.M^&*"3XEZ"A+ &X/*L5/W6[BNI
M_: &/'MJ.?\ CP3J?]IJYCX6_P#)3] _Z^3_ .@-74?M _\ (^VO_7@G_H34
MZG_(RAZ?Y@O@/**^@_V?(@?#&M2[GRMU@ .=O^K'4=#7SY7T-^SW_P BEKG_
M %]_^TQ5YS_NWS7ZA3^(^>Y/]:_^\:8>A^E/D_UK_P"\:8>A^E>C'^&O0CJ?
M0?QLB6+X8:#AG.Z[A)WN6Q^X?IGI7S[7T-\<?^28>'_^OJ'_ -$/7SS7FY-_
MN[]7^A=3<](^!J"7XD1H2P!M)N58J>@[BLWXNJ%^*.M*"2 T0R3D_P"J2M7X
M$_\ )3(?^O2;^0K,^+__ "5/6_\ ?C_]%)2C_P C-_X?\@^P</7T!X!B5_V?
M=7<LX*)>8"N0#\O<#K^-?/\ 7T'\/O\ DWG6_P#<O/\ T&C./X4?7_,*>Y\^
M5>T7_D/:;_U]1?\ H8JC5[1?^0]IO_7U%_Z&*]*O_"EZ/\B%N>T?M%1+&-"<
M,Y+M,2&<D#[G0'I^%>$U[U^T=_JO#_\ O3_^R5X+7#E'^ZKU94_B/9_V=E#Z
MYKJDD VD8RIP?O'O7F_CA0GCWQ @+$+J,XRQR?OGN:]*_9T_Y#^N?]>L?_H1
MKS;QW_R4#Q%_V$KC_P!&&LL/_P C&IZ?Y#?P(Y^OH+5XP?V7[5LO\MM"1AC@
M_OEZ^M?/M?0FK?\ )KMO_P!>L'_HY:>:_%2_Q?Y!#J?/==1\.!N^(_A\$D?Z
M:G0XKEZZGX;?\E)\/?\ 7ZE=^+_W>?HR8[H[#]H)0/'=F<GYK!3R<_QOT]*\
MFKUK]H3_ )'JQ_[!Z_\ H;UY+6&6?[K#Y_F$_B/??V=T!TGQ$V6_UD8X8X^Z
MWZUX1=\7LX_Z:-_.O>?V=O\ D#>(O^NT7_H+5X->?\?MQ_UU;^9KGP?^^UBI
M?"B$]#]*^A_BU&(_@IHH!<_O;4_,Q/\ RR;UKYX/0_2OHKXO?\D6T7_KI:_^
MBFI9C_O%#U_5!#9GSK7HOP1B$WQ+MD9G4?9YCE'*G[OJ*\ZKTCX&?\E.M?\
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M_LX_\>GB'_KI!_)ZUS?_ '5^J%3^(\,U,8U:]'/%Q)U_WC57M5O5/^0O??\
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M3?B#HM[>Z#>V]M#.6DEDCPJC:>34_P"T#_R/MK_UX)_Z$U:.I"IF,7!W5O\
M,5K0/**^AOV>_P#D4M<_Z^__ &F*^>:^AOV>_P#D4M<_Z^__ &F*USG_ ';Y
MK]0I_$?/<G^M?_>-,/0_2GR?ZU_]XTP]#]*]&/\ #7H1U/H?XX_\DP\/_P#7
MU#_Z(>OGFOH;XX_\DP\/_P#7U#_Z(>OGFO-R;_=WZO\ 0NIN>E_ G_DID/\
MUZ3?R%9GQ?\ ^2IZW_OQ_P#HI*T_@3_R4R'_ *])OY"LSXO_ /)4];_WX_\
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M S_DIUK_ ->TW_H->;UZ1\#/^2G6O_7M-_Z#79F'^ZS]"8?$0?&S_DJFJ?\
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MT\A^N>]?/U>;DW^[OU?Z%U-STOX$_P#)3(?^O2;^0K,^+_\ R5/6_P#?C_\
M125H? [S/^%D1^5M\S[)-MW].@K-^+N[_A:.M;\;MT6<=,^4E*/_ ",W_A_R
M#[!Q-?0?P^_Y-YUO_<O/_0:^?*]_\ ^=_P ,_:OY?E^7LO-^[.?N]J,X_A1]
M?\PI[G@%7M%_Y#VF_P#7U%_Z&*HU>T7_ )#^F_\ 7U%_Z&*]*O\ PI>C_(A;
MGMG[1W^J\/\ ^]/_ .R5X+7NW[17G8T+S/+V;Y]FW.<?)UKPFN'*/]U7JRI_
M$>T_LZ?\A_7/^O6/_P!"->;>._\ DH'B+_L)7'_HPUZ/^SOO_MO7?+V[_LD>
M-W3.XUYOXXW_ /">^(/,V[_[1GW;>F=YZ5EA_P#D8U/3_(;^!&!7T)JW_)KM
MO_UZP?\ HY:^>Z^@M7\S_AE^UQLV_9H=V<YQYRXQ3S7XJ7^+_((=3Y]KJ?AM
M_P E)\/?]?J5RU=1\.-W_"Q_#^W&?MJ=:[\7_N\_1DQW1V7[0G_(]6/_ &#U
M_P#0WKR6O6?V@MW_  G=GNVX^P+MQUQO?K7DU899_NL/G^83^(]__9V_Y WB
M+_KM%_Z"U>#7G_'[<?\ 75OYFO=OV=_,_LGQ#MV[?,CZYSG:WZ5X3=Y^VSYQ
MGS&Z?6N?!_[[6*E\*(3T/TKZ*^+W_)%M%_ZZ6O\ Z*:OG4]#]*^A_BUYO_"E
M-%\W9GS;7[N<8\IL4LQ_WBAZ_J@ALSYXKTCX&?\ )3K7_KVF_P#0:\WKT7X)
M>=_PLJV\C9O^SS??SC[OM79F'^ZS]"8?$1_&S_DJFJ?]<X/_ $4M>?5Z#\:_
M^2J:I_US@_\ 12UY]3P'^[0] EN?1'PO_P"2#ZU_NWG_ *+KYW'2OH3X7^=_
MPH_6L>7Y.R\SUW9\O\L5\]CI7'EO\>MZ_JRI[(GL?^0A;?\ 75/YBO=_VCO^
M/+P__P!=9OY+7A%C_P A"V_ZZI_,5[E^T/YWV#0?/\O=YT^-F>F%]:,9_OM$
M(_"SP:O8/V=_^1PU3_KP_P#:BUX_7KO[/OF_\)7JWD[/,^P<;\X_UB>E;YI_
MNLOE^:%#XCB?B+_R4;Q#_P!?TG\ZYBNF^(>?^%B^(-V-WVV3..G6N9KHPG\"
M'HOR)EN?1+_\FN#_ *\A_P"CZ^=J^A)?._X9C39Y?E?8ANSG=_K^U?/=>?E'
M_+SU+J=#IOAW_P E&\/_ /7]'_.N\_:)_P"1MTG_ *\/_:C5P?P[_P"2C>'_
M /K^C_G7<?M">;_PEVF>;LQ]B.S;GIYC=?>BM_R,J?I_F"^!GD->^_LX_P#'
MIXA_ZZ0?R>O J]Z_9U\S[!XC\K;OWP;=W3.'ZUKF_P#NK]4*G\1XAJG_ "%[
M[_KXD_\ 0C53M5K4\_VM>YQG[1)G'^\:J]J[J/\ "CZ(E[GT-\2_^2 Z%_US
MLO\ T77SS7T)\2_-_P"%":!G9M\NSW=<_P"KXQ7SW7FY-_!EZ_HBZFYZ#\%/
M^2IZ9_USF_\ 1;5-\<_^2GW7_7O#_P"@U7^"V_\ X6EI>S;G9-G=Z>6V:G^.
M.[_A9]YNQ_Q[PXQZ;:3_ .1FO0/L'G-?0OPB_P"2,:__ +US_P"BA7SU7T'\
M(O,_X4[X@^YY?^DXZYSY0_2JSG^ O7_,*>Y\^#H*FM?^/R#_ *Z+_.H1T%2V
MN?M<&.OF+_.O2G_#?H1U/NB/_5K]!3JK1_:O(AR(-V1YF"<8]O?ZU9KX4Z0J
MG?ZBFG>7)/&_V8Y$DRC<(SVW <X/KV[\<U<KE?&T^M0P69TS^TEM2S?:7TN"
M.6Y!XV +)\NT_-DX)X'O0!G:9K_B&Z\8?9Y%=[5Y75[46#+%# ,[)ENL[9"V
M$^4?WSTVUW=<YX:TO4;#3;%Y1%;2.F;NR0 1*QR2R <(Q)R0#MR3CUKHZ "B
MBB@"*>V@NHQ'<01S(#N"R(&&?7!H:V@>X2X:"-IT&%D*#<H] >HJ6B@ K'\/
M?ZO4?^PA/_Z%6Q6/X>_U>H_]A"?_ -"H V**** "BBB@ HHHH **** "BBB@
M HHHH *XO6=1O(/'.CPV-_<-!+,Z7T PPC7RB5.W;\JYP2^>O'.:[2B@#CO!
M6O\ VO0XHM1U)I[Z6ZNHTD=,,RH[$$X&!\FTCID5-X(U*XU/PQ<O=WCW<\=U
M<QF1P Q02-LX  ^[C'M75TU]OEMO.%P<G/04 ?"DG^M?_>-,/0_2OH67X2_#
MA+#^TFUV\^Q,SC[0MPK1_*2&^8+C@@U+>?!CX?V%K#<7FLWL$,XS$[W* .,9
MR/E].?I7TJSB@H6L_P"OF8^S8SXX_P#),/#_ /U]0_\ HAZ^>:^C/CZD4/P]
MT:.%]T27T:HV<Y BDP<]^*^<\CUJ\F:^KOU?Z!4W/2_@3_R4R'_KTF_D*S/B
M_P#\E3UO_?C_ /125I? DC_A9D//_+I-_(5F_%__ )*GK?\ OQ_^BDI1_P"1
MD_\ #_D'V#AZ^@_A]_R;SK?^Y>?^@U\^5]!_#[_DWG6_]R\_]!HSC^%'U_S"
MGN?/E7M%_P"0]IO_ %]1?^ABJ-7M%_Y#VF_]?47_ *&*]*O_  I>C_(A;GMG
M[1W^J\/_ .]/_P"R5X+7O7[1W^J\/_[T_P#[)7@M<.4?[JO5E3^(]I_9T_Y#
M^N?]>L?_ *$:\V\=_P#)0/$7_82N/_1AKTG]G3_D/ZY_UZQ_^A&O-O'?_)0/
M$7_82N/_ $8:RP__ ",:GI_D-_ CGZ^A-6_Y-=M_^O6#_P!'+7SW7T)JW_)K
MMO\ ]>L'_HY:>:_%2_Q?Y!#J?/==3\-O^2D^'O\ K]2N6KJ?AM_R4GP]_P!?
MJ5WXO_=Y^C)CNCL?VA/^1ZL?^P>O_H;UY+7K7[0G_(]6/_8/7_T-Z\EK#+/]
MUA\_S"?Q'O\ ^SM_R!O$7_7:+_T%J\&O/^/VX_ZZM_,U[S^SM_R!O$7_ %VB
M_P#06KP:\_X_;C_KJW\S7/@_]]K%2^%$)Z'Z5]%?%[_DBVB_]=+7_P!%-7SJ
M>A^E?17Q>_Y(MHO_ %TM?_134LQ_WBAZ_J@ALSYUKTCX&?\ )3K7_KVF_P#0
M:\WKTCX&?\E.M?\ KVF_]!KLS#_=9^A,/B(/C9_R535/^N<'_HI:\^KT'XV?
M\E4U3_KG!_Z*6O/J> _W:'H$MSZ(^%__ "0?6O\ =O/_ $77SN.E?1'PO_Y(
M/K7^[>?^BZ^=QTKCRW^/6]?U94]D3V/_ "$+;_KJG\Q7N_[1W_'EX?\ ^NLW
M\EKPBQ_Y"%M_UU3^8KW?]H[_ (\O#_\ UUF_DM&,_P!]HA'X6> U[!^SO_R.
M&J?]>'_M1:\?KV#]G?\ Y'#5/^O#_P!J+6^:?[K+Y?FA0^(X;XB_\E&\0_\
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M_P"A5L5C^'O]7J/_ &$)_P#T*@#8HHHH **** "BBB@ HHHH **** "BBB@
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M_P#12UY]3P'^[0] EN?1'PO_ .2#ZU_NWG_HNOG<=*^B/A?_ ,D'UK_=O/\
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MQ_X]/$/_ %T@_D]>!5[[^SC_ ,>GB'_KI!_)ZUS?_=7ZH5/XCPW5/^0O??\
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MA?W;9_$8X_&G>?'YKQ_-N09/R'&/KC!J6B@"#[7%Y22?O-KG _=MG\L9%/\
M/3S6B^;<HW'Y#C'UZ5)10!!]LA\E9?WFUCM'[MLY^F,T_P ]/.,7S;P-Q^0X
MQ]>E244 0?;(?)$O[S83M_U;9S],9I_GIYQB^;>!N^X<8^O2I** (/MD/D^=
M^\V;MO\ JVSGZ8S3_/3SO)^;?C=]PXQ]>E244 0?;(?),O[S8&V_ZMLY^F,T
M_P ]/.$7S;R-P^0XQ]>E244 0?;(?):7]YM4[3^[;.?IC-/\]/.6+YMS#</D
M.,?7I4E% $'VN'RFE_>;5.T_NVSGZ8R:=YZ>:D?S;G&1\AQCZXP*EHH @^UQ
M>6\G[S:AP?W;9_+'-.^T1^8D?S;G&5^0X_$XX_&I:* (/M<7ER/\^V,X;]VV
M?P&.?PIWVB/?&GSYD&5^0_KQQ^-2T4 0_:HMDC?/B,X;]VWZ<<_A2_:(]T:_
M/F097Y#^O''XU+10!#]JBVRGY\1'#?NV_3CG\*;+);S1K#*GF).,;&B)!'H>
M./QJQ10!F?8-'VG_ (EMMBVR%_T4?)DY.WCU]*>+;3 UJPLH0P),!%M]PDY.
M./EY.>U:%% '/^(]*T36;5GU31XM3-EEE2:/[N>I!; Z#]*XU-.^'K^#8_$P
M\&Q_99>8XA: NPW[0W' !ZY)Z<UZ)K.F)K6C7>F23S01W49B>2!@'"GJ 2#C
M(R/QJ$:.85$=E?W-I EO'!##$$V1!#P5!4\D8!SQ@"J4I+9@9GA73?#5C;27
M^AZ5:V1E3$C6RA@Z@G&&7(;\#7RMXX</X]\0.N<-J,Y&1C^,U]?:%HEKX?TM
M+"T,C1AWD9Y""S.[%F)Q@<DGH,5\A>._^2@>(O\ L)7'_HPUZV3-NO*_;]49
MU-CGZ^@M7D4?LOVJG.6MH0/E/_/9?RKY]KZ%U;_DUVW_ .O6#_T<M=^:_%2_
MQ?Y$PZGSU74?#@A?B1X?)S_Q^IT%<O74_#;_ )*3X>_Z_4KOQ?\ N\_1DQW1
MV'[03!O'=F!G*V" \?[;UY-7K7[0G_(]6/\ V#U_]#>O):PRS_=8?/\ ,)_$
M>^_L[N!I'B)3G/F1'H?[K5X1=G-Y.?61OYU[S^SM_P @;Q#_ -=HO_06KP:\
M_P"/VX_ZZM_,USX/_?:Q4OA1">A^E?0_Q;D63X*Z*5S_ *RU'*D?\LF]:^>#
MT/TKZ*^+W_)%M%_ZZ6O_ **:EF/^\4/7]4$-F?.M>B_!&58?B7;.^['V>8?*
MI/\ #[5YU7I'P,_Y*=:_]>TW_H-=F8?[K/T)A\1!\:_^2J:I_P!<X/\ T4M>
M?5Z#\;/^2J:I_P!<X/\ T4M>?4\!_NT/0);GT+\+YD_X4=K4/S;REX?NG'^K
M]>E?/0Z5]$?"_P#Y(/K7^[>?^BZ^=QTKCRW^/6]?U94]D3V/_(0MO^NJ?S%>
MY_M$3)-8:"4W8$TP.Y2O9?6O#+'_ )"%M_UU3^8KW?\ :._X\O#_ /UUF_DM
M&,_WVB$?A9X#7KW[/<BQ>+-6D?.T6'.%)/\ K$["O(:]@_9W_P"1PU3_ *\/
M_:BUOFG^ZR^7YH4/B.%^(A#?$7Q 1T-[(1Q[US-=/\1?^2C>(?\ K^D_G7,5
MT83^!#T7Y$RW/H625%_9A2,[MS60(PI(_P!?Z]*^>J^B7_Y-<'_7D/\ T?7S
MM7GY1_R\]2ZG0Z;X=_\ )1O#_P#U_1_SKN?VA95D\7:8%W?+9%3E2.?,;UZU
MPWP[_P"2C>'_ /K^C_G7>?M$_P#(VZ3_ ->'_M1J*W_(RI^G^8+X&>.U[U^S
MK(L=CXB9LX5X"< GL_I7@M>^_LX_\>GB'_KI!_)ZUS?_ '5^J%3^(\,U,YU:
M]([W$G_H1JKVJWJG_(7OO^OB3_T(U4[5W4?X4?1$O<^A/B7(O_"@] 7G+1V>
M/E/:.OGNOH;XE_\ ) ="_P"N=E_Z+KYYKS<F_@R]?T1=3<[_ ."SA/BEI9.>
M4F' SUC:I_CB0?B?>8SQ;P@\?[-1?!3_ )*GIG_7.;_T6U3?'/\ Y*?=?]>\
M/_H-)_\ (S7H'V#SBOH/X12+_P *<\0)SN!N2?E./]4.]?/E?0WPB_Y(QK_^
M]=?^BA59S_ 7K_F%/<^>1T%2VO%W ?\ IHO\ZB'05-:_\?D'_71?YUZ4_P"&
M_0CJ?<"747D0O^\Q(0J_NVZ^_''XU9IL?^K7Z"G5\*=(4444 %%%% !1110
M4444 %8_A[_5ZC_V$)__ $*MBL?P]_J]1_["$_\ Z%0!L4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7QAX[_Y*!XB_["5Q_P"C#7V?7QAX[_Y*!XB_["5Q_P"C#7L9+_'EZ?JC.IL<
M_7T)JW_)KMO_ ->L'_HY:^>Z^A-6_P"37;?_ *]8/_1RUWYK\5+_ !?Y$PZG
MSW74_#;_ )*3X>_Z_4KEJZGX;?\ )2?#W_7ZE=^+_P!WGZ,F.Z.Q_:$_Y'JQ
M_P"P>O\ Z&]>2UZU^T)_R/5C_P!@]?\ T-Z\EK#+/]UA\_S"?Q'O_P"SM_R!
MO$7_ %VB_P#06KP:\_X_;C_KJW\S7O/[.W_(&\1?]=HO_06KP:\_X_;C_KJW
M\S7/@_\ ?:Q4OA1">A^E?17Q>_Y(MHO_ %TM?_135\ZGH?I7T5\7O^2+:+_U
MTM?_ $4U+,?]XH>OZH(;,^=:](^!G_)3K7_KVF_]!KS>O2/@9_R4ZU_Z]IO_
M $&NS,/]UGZ$P^(@^-G_ "535/\ KG!_Z*6O/J]!^-G_ "535/\ KG!_Z*6O
M/J> _P!VAZ!+<^B/A?\ \D'UK_=O/_1=?.XZ5]$?"_\ Y(/K7^[>?^BZ^=QT
MKCRW^/6]?U94]D3V/_(0MO\ KJG\Q7N_[1W_ !Y>'_\ KK-_):\(L?\ D(6W
M_75/YBO=_P!H[_CR\/\ _76;^2T8S_?:(1^%G@->P?L[_P#(X:I_UX?^U%KQ
M^O8/V=_^1PU3_KP_]J+6^:?[K+Y?FA0^(X;XB_\ )1O$/_7])_.N8KI_B+_R
M4;Q#_P!?TG\ZYBNC"?P(>B_(F6Y]$O\ \FN#_KR'_H^OG:OHE_\ DUP?]>0_
M]'U\[5Y^4?\ +SU+J=#IOAW_ ,E&\/\ _7]'_.N\_:)_Y&W2?^O#_P!J-7!_
M#O\ Y*-X?_Z_H_YUWG[1/_(VZ3_UX?\ M1J*W_(RI^G^8+X&>.U[[^SC_P >
MGB'_ *Z0?R>O J]]_9Q_X]/$/_72#^3UKF_^ZOU0J?Q'ANJ?\A>^_P"OB3_T
M(U4[5;U3_D+WW_7Q)_Z$:J=J[J/\*/HB7N?0WQ+_ .2 Z%_USLO_ $77SS7T
M-\2_^2 Z%_USLO\ T77SS7FY-_!EZ_HBZFYZ#\%/^2IZ9_USF_\ 1;5-\<_^
M2GW7_7O#_P"@U#\%/^2IZ9_USF_]%M4WQS_Y*?=?]>\/_H-)_P#(S7H'V#SB
MOH7X1?\ )&-?_P!ZY_\ 10KYZKZ%^$7_ "1C7_\ >N?_ $4*K.?X"]?\PI[G
MST.@J:U_X_(/^NB_SJ$=!4UK_P ?D'_71?YUZ4_X;]".I]SQ_P"K7Z"G4V/_
M %:_04ZOA3I"BBB@ HHHH **** "BLC5/$5GI6H6NGR)+->W2220P1[065,;
MSEB!QD<9S[<&J<?C;2I98?*2Z:WD,"M=&+;'"TPS&K[B&4G*]N-ZYQF@#HZQ
M_#W^KU'_ +"$_P#Z%6Q6/X?_ -7J/_80G_\ 0J -BBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\8\1
M_!WPS?>)KNZO?%36EWJ%PTPMW:,'=(Q("@G)Y.!7L]<YK&B7FK^*-*GF\HZ3
MIH:Z6,L=TMU]U,C'"J"QSZD<<5I3JSI.\'9B:3W/,)?@+X:@O([.;Q7-'=2_
MZN%_+#O]%ZFNA^(>B1>'/@1=:/#,\T=I'#&LC@ M^^7DXKH-:T;6M>GT-Y;2
MTMFM;J&\G*W&]-R9RN-@+$<[3D=<D5I^,XM#F\*7R>(]W]D[0T^T.2 ""#\O
M/4"M7BJDY1=23=G<.5=#XNKJ?AM_R4GP]_U^I7N7_"KOAJ=8@TG['<?;9X#<
M1Q^=-@QC&3GIW'&<U/!X&\ ^%/%&ENFG7T5^UPJV<A,SQM+@D#/(X ).>F*]
M>OF]*I2E!1>J\C-4VF>;_M"?\CU8_P#8/7_T-Z\EKZ;^)7PJO/'/B&WU&VU6
MVM1%;"$QRQEB<,3G@].:XM?V=M4?.WQ%8G'7$+?XU>!S##TJ$83>J\GW%*#;
M-C]G;_D#>(O^NT7_ *"U>#7G_'[<?]=6_F:^J?AAX N/ UAJ<$^HP7ANY%(:
M%" NT$8.?K7DUQ\!?&,ES+(LFE[6<L,W#="?]RLL+C*,<34J2E9/8<HNR1Y2
M>A^E?17Q>_Y(MHO_ %TM?_135PW_  H+QGC_ %FE?^!+?_$5W_QIMI++X1Z9
M:2E3)!<6\;E3QE8V!Q^5/%XFE7Q%'V;O9_J@BFD[GS?7I'P,_P"2G6O_ %[3
M?^@UYO7I'P,_Y*=:_P#7M-_Z#7IYA_NL_0B'Q$'QL_Y*IJG_ %S@_P#12UY]
M7H/QL_Y*IJG_ %S@_P#12UY]3P'^[0] EN?1'PO_ .2#ZU_NWG_HNOG<=*^B
M/A?_ ,D'UK_=O/\ T77SN.E<>6_QZWK^K*GLB>Q_Y"%M_P!=4_F*]W_:._X\
MO#__ %UF_DM>$6/_ "$+;_KJG\Q7N_[1W_'EX?\ ^NLW\EHQG^^T0C\+/ :]
M@_9W_P"1PU3_ *\/_:BUX_7L'[.__(X:I_UX?^U%K?-/]UE\OS0H?$<-\1?^
M2C>(?^OZ3^=<Q73_ !%_Y*-XA_Z_I/YUS%=&$_@0]%^1,MSZ)?\ Y-<'_7D/
M_1]?.U?1+_\ )K@_Z\A_Z/KYVKS\H_Y>>I=3H=-\._\ DHWA_P#Z_H_YUWG[
M1/\ R-ND_P#7A_[4:N#^'?\ R4;P_P#]?T?\Z[S]HG_D;=)_Z\/_ &HU%;_D
M94_3_,%\#/':]]_9Q_X]/$/_ %T@_D]>!5[[^SC_ ,>GB'_KI!_)ZUS?_=7Z
MH5/XCPW5/^0O??\ 7Q)_Z$:J=JMZI_R%[[_KXD_]"-5.U=U'^%'T1+W/H;XE
M_P#) ="_ZYV7_HNOGFOH;XE_\D!T+_KG9?\ HNOGFO-R;^#+U_1%U-ST'X*?
M\E3TS_KG-_Z+:IOCG_R4^Z_Z]X?_ $&H?@I_R5/3/^N<W_HMJF^.?_)3[K_K
MWA_]!I/_ )&:] ^P><5]"_"+_DC&O_[US_Z*%?/5?0WPB_Y(QK_^]=?^BA59
MS_ 7K_F%/<^>1T%36O\ Q^0?]=%_G4(Z"IK7_C\@_P"NB_SKTI_PWZ$=3[GC
M_P!6OT%.IJ?ZM?H*=7PITA1110 4444 %(R[D*Y(R,9!Y%+10!Y[KO@*[EM8
M;>*ZO-:L\3>9;ZC?$2+(RJ$D27:2-I4\?[9/.,&-/!.M".73[NYCO8[^YLKN
M\U!I-CB2 1[@$V\[C"N.?XCGISZ-10!1O=(L]0E62Y64LJ[1LF=!CZ*169X7
ML8+:WU%(@X7[=.G,C-QN]S70UC^'O]7J/_80G_\ 0J -'['#Y<<>&VH<K\[?
MSSS3OL\?FO)AMSC:WS'I].U2T4 0?8X?*2+#;4.X?.V<_7-.\B/SFEPV]EVG
MYCC'TJ6B@"#['#Y*Q8?8K;A\[9S]<YI_D1^<TV#O9=I^8XQ].E244 0?8X/)
M$.'V!MP^=LY^N<T_R(_/,V#O*[?O'&/ITJ2B@"O]C@\CR</LW;OOMG/USFI/
M(C\_SL'?MV_>.,?3I4E% $'V.#R##A]A;=]]LY^N<T_R(_.$V#O VCYCC'TZ
M5)10!!]CA\EHL/L9MQ^=LY^N<T[R(_.67#;U&T?,<8^G2I:* (/L</E-%AMC
MG<?G;.?KFG?9X_-23#;D&T?,>GTJ6B@"#['#Y3QX;:YRWSMU^N>*=]GC\R.3
M#;HQA?F/3^M2T4 0?9(?+D3#;9#EOG/^/'X4[[/'OC?#;HQA?F/^3^-2T4 0
M?9(=DBX;$ARWSG_'C\*=]FBW1MALQC"_,?\ )_&I:* (?LL6V5<-B4Y;YS^G
M/'X4?9HLQ'#9B^[\Y_QY_&IJ* (?LL6)1AOWOW_G/Z<\?A1]EB_=<-^Z^Y\Y
M_7GG\:FHH A^RQ9EX;][]_YS^G/'X4?98L1##?NON?.?UYY_&IJ* (?LT6Z4
MX;,HPWSG_(_"C[)#MB7#8B.5^<_X\_C4U% $7V:+?(V&S(,-\Q_R/PK)\1^'
M_P"W/#5UH\-P+;SXC$)6#/M!Z\;AD_4UMT4 <O-X8OY-<L=474K=)+:QDM"O
MV=B&+A<N/GXP47CZ\^DD?A5I->T_5=0O?M+6%GY,$2QE%65O]9+]X\L  !V&
M>M=)10!POB70KG4?%NG75GIMQMAE8W<P=4$T1A9?E;=NR"0 N ">3TS571=%
MU6QT?4-&ATZXBL9%:+39I&1)X<0XW3%#\WS\ \GUKT2B@#S[X?Z#?:1'JDM]
M9S65M):VD2PAN?,CA"S. I/);OU.,UBXU63PU?7,0UFVC?6+>2RL29FFA@5E
M#[R<G# .Y7) SZUZW10!YWX]EU.\2WDT2'4U:.2>.<HLJ(Y$!,?"_,1O*[2.
M-PYJ#Q[X3UGQ1\,M,TVPMV;45>"::.YG&X$(0VYCP3DUZ767XDFNK?PQJDUB
M)OM:6LAA\A [[]IQM!ZG/:JA-PDI+= ]3YJ_X4=XY_Y\;7_P*2NP^&7PK\2^
M'?&D.HZQ:PQV:0R*6CN03DCC@'-=IX5U>]GT35-/U"]OX;B;S1979CDF556%
M-SHY4$X9B<-@YR!G%;?@2ZO+C3+N*[\Z86]P8HKV1Y"+M0J_O )"2O.1@<9!
MQ7;5S+$58.$GH_(E02=SY[^-?_)5-4_ZYP?^BEKSZO0?C9_R535/^N<'_HI:
M\^KZ3 ?[M#T,9;GT+\+X4_X4=K4V#O"7B_>.,>7Z=*^>ATKZ(^%__)!]:_W;
MS_T77SN.E<>6_P >MZ_JRI[(GL?^0A;?]=4_F*]S_:(A2&PT$(" 9IB<L3SA
M?6O#+'_D(6W_ %U3^8KW?]H[_CR\/_\ 76;^2T8S_?:(1^%G@->O?L^1K-XL
MU:-\[38<X)'_ "T3N*\AKV#]G?\ Y'#5/^O#_P!J+6^:?[K+Y?FA0^(X7XB
M+\1?$"CH+V0#\ZYFNG^(O_)1O$/_ %_2?SKF*Z,)_ AZ+\B9;GT++"C?LQ)*
M0=ZV0 ^8X_U_I7SU7T2__)K@_P"O(?\ H^OG:O/RC_EYZEU.ATWP[_Y*-X?_
M .OZ/^==S^T+$D?B[3"H/SV18Y)//F-7#?#O_DHWA_\ Z_H_YUWG[1/_ "-N
MD_\ 7A_[4:BM_P C*GZ?Y@O@9X[7O7[.L:R6/B)&SAG@!P2.SUX+7OO[./\
MQZ>(?^ND'\GK7-_]U?JA4_B/#-3 &K7H'07$G_H1JKVJWJG_ "%[[_KXD_\
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M%6Q6/X>_U>H_]A"?_P!"H V**** "BBB@ HHHH **** "BBB@ HHHH ****
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M:I_UX?\ M1:\?KU[]GSS/^$LU;R=GF?8.-_3_6)6^:?[K+Y?FA0^(XCXB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_\ $UW99C*5&,O:RLVR9Q;V.'^'?_)1O#__ %_1_P Z[S]HG_D;=)_Z\/\
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M.F6+V*70=U;SKJ28;>P8Y ^M7J* "BBB@ HHHH **** "BBB@ HHHH ****
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1DY=U4 M]3WJ6B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>onct-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T19:57:53.7262452+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : e954f1db574f4cdbb446abea68e107eb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:onct="http://www.oncternal.com/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncternal.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.oncternal.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100080 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
        <link:definition>100090 - Disclosure - Commitments, Contingencies and Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements" id="Role_DisclosureLicenseCollaborationAndResearchSubawardAgreements">
        <link:definition>100100 - Disclosure - License, Collaboration and Research Subaward Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100110 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100120 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" id="Role_DisclosureCOVID19PandemicAndCARESAct">
        <link:definition>100130 - Disclosure - COVID-19 Pandemic and CARES Act</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100150 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100180 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100190 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100200 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100210 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
        <link:definition>100220 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
        <link:definition>100230 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100240 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails" id="Role_DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails">
        <link:definition>100270 - Disclosure - Stockholders&apos; Equity - Amended and Restated Articles of Incorporation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" id="Role_DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
        <link:definition>100280 - Disclosure - Stockholders&apos; Equity - Securities Purchase Agreements and Underwritten Offering (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" id="Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
        <link:definition>100290 - Disclosure - Stockholders&apos; Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" id="Role_DisclosureStockholdersEquityEquityIncentivePlansDetails">
        <link:definition>100300 - Disclosure - Stockholders&apos; Equity - Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100310 - Disclosure - Stockholders&apos; Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" id="Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
        <link:definition>100320 - Disclosure - Stockholders&apos; Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
        <link:definition>100330 - Disclosure - Stockholders&apos; Equity - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
        <link:definition>100340 - Disclosure - Stockholders&apos; Equity - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100350 - Disclosure - Stockholders&apos; Equity - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
        <link:definition>100360 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>100370 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" name="NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" name="ProceedsFromStockOptionsExercisedAndWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_FairValueOfWarrantsIssuedToPlacementAgent" name="FairValueOfWarrantsIssuedToPlacementAgent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ExerciseOfCashlessWarrantShares" name="ExerciseOfCashlessWarrantShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" name="AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" name="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" name="IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_COVID19PandemicAndCARESActDisclosureTextBlock" name="COVID19PandemicAndCARESActDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_COVID19PandemicAndCARESActAbstract" name="COVID19PandemicAndCARESActAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ConcentrationRiskCreditRiskPolicyTextBlock" name="ConcentrationRiskCreditRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AccruedClinicalTrials" name="AccruedClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommonStockSubjectToRepurchaseMember" name="CommonStockSubjectToRepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AccruedUnvestedShareLiability" name="AccruedUnvestedShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_RemainderOfLeaseTermBaseRent" name="RemainderOfLeaseTermBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_RentExpense" name="RentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ChiefFinancialOfficerSonMember" name="ChiefFinancialOfficerSonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" name="ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" name="LicenseMaintenanceFeeToBePaidAndPaymentMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CollaborativeArrangementPotentialMilestonePayments" name="CollaborativeArrangementPotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_GeorgetownUniversityMember" name="GeorgetownUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ReagentsMember" name="ReagentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_RegentsLicenseAgreementMember" name="RegentsLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ResearchAgreementMember" name="ResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyTwoMember" name="ResearchAgreementTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyThreeMember" name="ResearchAgreementTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ResearchAgreementTwoThousandTwentyFourMember" name="ResearchAgreementTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NationalInstituteOfHealthGrantAwardMember" name="NationalInstituteOfHealthGrantAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_UniversityOfTennesseeResearchFoundationMember" name="UniversityOfTennesseeResearchFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" name="CaliforniaInstituteForRegenerativeMedicineAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_UniversityOfCaliforniaSanDiegoMember" name="UniversityOfCaliforniaSanDiegoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NumberOfDaysInWrittenNoticeOfTermination" name="NumberOfDaysInWrittenNoticeOfTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" name="NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" name="NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" name="MinimumPeriodOfWrittenNoticeToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" name="CollaborativeArrangementPotentialRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_UpfrontLicenseFeesPaid" name="UpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" name="SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdvanceLicensedAssets" name="AdvanceLicensedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ResearchAgreementTerm" name="ResearchAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ResearchAgreementResearchFundingAmount" name="ResearchAgreementResearchFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ResearchAgreementResearchFundingAmountPayable" name="ResearchAgreementResearchFundingAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ResearchAndDevelopmentGrants" name="ResearchAndDevelopmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" name="DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_SubawardPaymentsReceived" name="SubawardPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_RelatedQualifyingSubawardCosts" name="RelatedQualifyingSubawardCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_AmountAgreedToBeProvidedInContingencyFunds" name="AmountAgreedToBeProvidedInContingencyFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_AccruedClinicalTrials1" name="AccruedClinicalTrials1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AwardPaymentsReceived" name="AwardPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" name="PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PercentageOfNetSales" name="PercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" name="PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" name="PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PaycheckProtectionProgramMember" name="PaycheckProtectionProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" name="CombinedPurchasePriceOfShareAndWarrantPerUnit" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_PlacementAgentMember" name="PlacementAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_JulyPurchaseAgreementMember" name="JulyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AugustUnderwritingAgreementMember" name="AugustUnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NovemberUnderwritingAgreementMember" name="NovemberUnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_DecemberUnderwritingAgreementMember" name="DecemberUnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AtTheMarketFacilityMember" name="AtTheMarketFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommonStockWarrantsExpirationDate" name="CommonStockWarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AmountForAtTheMarketFacility" name="AmountForAtTheMarketFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ExerciseOfWarrants" name="ExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantIssuedPricePerShare" name="WarrantIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantExercisedPricePerShare" name="WarrantExercisedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" name="ClassOfWarrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" name="SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" name="TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_PrivateOncternalMember" name="PrivateOncternalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_CommonStockWarrantsReservedForFutureIssuance" name="CommonStockWarrantsReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" name="CommonStockOptionsIssuedAndOutstandingForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_OperatingLossCarryforwardsNonExpirePortion" name="OperatingLossCarryforwardsNonExpirePortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PeriodForCumulativeChangeInOwnership" name="PeriodForCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>onct-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T19:57:53.7262452+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : e954f1db574f4cdbb446abea68e107eb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="onct-20211231.xsd#TemplateLink" roleURI="http://www.oncternal.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenue" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NoncashLeaseExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20211231.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AccruedUnvestedShareLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedClinicalTrials" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedUnvestedShareLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" xlink:type="locator" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationPermanentItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onct_IncomeTaxReconciliationPermanentItems" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>onct-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T19:57:53.7262452+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : e954f1db574f4cdbb446abea68e107eb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="onct-20211231.xsd#TemplateLink" roleURI="http://www.oncternal.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_AccruedClinicalTrials" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenue" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockSubjectToRepurchaseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceCommissions" xlink:type="locator" xlink:label="us-gaap_InsuranceCommissions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralInsuranceExpense" xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RemainderOfLeaseTermBaseRent" xlink:type="locator" xlink:label="onct_RemainderOfLeaseTermBaseRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RentExpense" xlink:type="locator" xlink:label="onct_RentExpense" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:type="locator" xlink:label="onct_ChiefFinancialOfficerSonMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_TitleOfIndividualAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_ChiefFinancialOfficerSonMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RentExpense" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RemainderOfLeaseTermBaseRent" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceCommissions" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="11010.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:type="locator" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:type="locator" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PercentageOfNetSales" xlink:type="locator" xlink:label="onct_PercentageOfNetSales" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:type="locator" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AwardPaymentsReceived" xlink:type="locator" xlink:label="onct_AwardPaymentsReceived" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials1" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials1" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20211231.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:loc xlink:href="onct-20211231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:loc xlink:href="onct-20211231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ContingentValueRightsAgreementMember" xlink:type="locator" xlink:label="onct_ContingentValueRightsAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NationalInstituteOfHealthGrantAwardMember" xlink:type="locator" xlink:label="onct_NationalInstituteOfHealthGrantAwardMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_RegentsLicenseAgreementMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyTwoMember" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyThreeMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyFourMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_NationalInstituteOfHealthGrantAwardMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_LicenseAgreementMember" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ContingentValueRightsAgreementMember" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="12630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="12700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="12780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="12970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="13270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="13330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="13450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="13600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="13640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="13680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="13940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="14000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="14060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="14120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="14180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="14330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AccruedClinicalTrials1" order="14500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AwardPaymentsReceived" order="14540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" order="14590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetSales" order="14610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" order="14630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" order="14650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PaycheckProtectionProgramMember" xlink:type="locator" xlink:label="onct_PaycheckProtectionProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onct_PaycheckProtectionProgramMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_AmountForAtTheMarketFacility" xlink:type="locator" xlink:label="onct_AmountForAtTheMarketFacility" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="onct_AtTheMarketFacilityMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_PurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onct_CommonStockWarrantsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_TitleOfIndividualAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_PlacementAgentMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_RangeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_JulyPurchaseAgreementMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AugustUnderwritingAgreementMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_NovemberUnderwritingAgreementMember" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_DecemberUnderwritingAgreementMember" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AtTheMarketFacilityMember" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" order="12820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CommonStockWarrantsExpirationDate" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_AmountForAtTheMarketFacility" order="13590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="onct-20211231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" order="10930.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:type="locator" xlink:label="onct_PeriodForCumulativeChangeInOwnership" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="onct_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxesTable" xlink:type="locator" xlink:label="onct_IncomeTaxesTable" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxesLineItems" xlink:type="locator" xlink:label="onct_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsExpirationYear" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_CumulativeChangeInOwnershipPercentage" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_PeriodForCumulativeChangeInOwnership" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10620.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>34
<FILENAME>onct-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T19:57:53.7262452+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : e954f1db574f4cdbb446abea68e107eb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, authorized shares &#8211; 5,000 at December 31, 2021 and 2020; issued and outstanding shares &#8211; none</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; authorized shares &#8211; 120,000 at December 31, 2021 and 60,000 at 2020; issued and outstanding shares &#8211; 49,429 and 48,802 at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NoncashLeaseExpense" xlink:to="onct_NoncashLeaseExpense_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options and common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CashlessExerciseOfWarrants" xlink:type="locator" xlink:label="onct_CashlessExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CashlessExerciseOfWarrants" xlink:to="onct_CashlessExerciseOfWarrants_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:type="locator" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent" />
    <link:label xml:lang="en-US" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants issued to placement agent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:to="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on forgiveness of payroll protection program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Noncash Gain Loss Of Forgiveness Of Payroll Protection Loan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from payroll protection loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options and common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised And Warrant Exercises</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock and common stock warrants, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued to placement agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants Issued To Placement Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on forgiveness of payroll protection program loan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Payment of 2019 bonus awards with stock options in lieu of cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfCashlessWarrantShares" xlink:to="onct_ExerciseOfCashlessWarrantShares_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital vesting related to unvested share liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital stock issued issuance costs shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of bonus awards with stock option in lieu of cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cashless exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Cashless Warrant Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting related to repurchase liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of 2019 bonus awards with stock option in lieu of cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Bonus Awards With Stock Option In Lieu Of Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and common stock warrants, issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, Contingencies and Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Collaboration and Research Subaward Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:to="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_COVID19PandemicAndCARESActAbstract" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActAbstract" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_COVID19PandemicAndCARESActAbstract" xlink:to="onct_COVID19PandemicAndCARESActAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Going Concern Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk credit risk policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="onct_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PatentCostsPolicyTextBlock" xlink:to="onct_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant activity table text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ScheduleOfWarrantActivityTableTextBlock" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Warrant Activity And Changes In Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Determine Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Components of Net Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business basis of presentation and summary of significant accounting policies line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business basis of presentation and summary of significant accounting policies table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedClinicalTrials" xlink:to="onct_AccruedClinicalTrials_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares subject to repurchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsMember" xlink:to="onct_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock subject to repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockSubjectToRepurchaseMember" xlink:to="onct_CommonStockSubjectToRepurchaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Subject to Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Subject To Repurchase [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedResearchAndDevelopmentExpenses" xlink:to="onct_AccruedResearchAndDevelopmentExpenses_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AccruedUnvestedShareLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for unvested share liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedUnvestedShareLiability" xlink:to="onct_AccruedUnvestedShareLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested share liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Unvested Share Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_RemainderOfLeaseTermBaseRent" xlink:type="locator" xlink:label="onct_RemainderOfLeaseTermBaseRent" />
    <link:label xml:lang="en-US" xlink:label="onct_RemainderOfLeaseTermBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remainder of the lease term base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RemainderOfLeaseTermBaseRent" xlink:to="onct_RemainderOfLeaseTermBaseRent_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RentExpense" xlink:type="locator" xlink:label="onct_RentExpense" />
    <link:label xml:lang="en-US" xlink:label="onct_RentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RentExpense" xlink:to="onct_RentExpense_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego, California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OfficeSpaceMember" xlink:to="onct_OfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:type="locator" xlink:label="onct_ChiefFinancialOfficerSonMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief financial officer, son.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ChiefFinancialOfficerSonMember" xlink:to="onct_ChiefFinancialOfficerSonMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer Son [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Pharmaceutical United States of America Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Pharmaceutical (USA) Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Pharmaceutical United States Of America Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RemainderOfLeaseTermBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of the lease term base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RemainderOfLeaseTermBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remainder Of Lease Term Base Rent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Discount Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralInsuranceExpense" xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General Insurance Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceCommissions" xlink:type="locator" xlink:label="us-gaap_InsuranceCommissions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Commissions</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee to be paid and payment made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExclusiveLicenseAgreementMember" xlink:to="onct_ExclusiveLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Georgetown University.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GeorgetownUniversityMember" xlink:to="onct_GeorgetownUniversityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Georgetown University</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Georgetown University [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Cancer Center.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MDAndersonCancerCenterMember" xlink:to="onct_MDAndersonCancerCenterMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Cancer Center</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reagents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ReagentsMember" xlink:to="onct_ReagentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents of the University of California</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reagents [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RegentsLicenseAgreementMember" xlink:to="onct_RegentsLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regents License Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementMember" xlink:to="onct_ResearchAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement 2022.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2022</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement 2023.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2023</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement 2024.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement 2024</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Two Thousand Twenty Four [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_NationalInstituteOfHealthGrantAwardMember" xlink:type="locator" xlink:label="onct_NationalInstituteOfHealthGrantAwardMember" />
    <link:label xml:lang="en-US" xlink:label="onct_NationalInstituteOfHealthGrantAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">National institute of health grant award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NationalInstituteOfHealthGrantAwardMember" xlink:to="onct_NationalInstituteOfHealthGrantAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NationalInstituteOfHealthGrantAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NationalInstituteOfHealthGrantAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">National Institute Of Health Grant Award [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseAgreementMember" xlink:to="onct_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Tennessee Research Foundation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfTennesseeResearchFoundationMember" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Tennessee Research Foundation</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of Tennessee Research Foundation [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute for Regenerative Medicine Award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The California Institute for Regenerative Medicine ("CIRM") Award</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine Award [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of California San Diego.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfCaliforniaSanDiegoMember" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of California San Diego School of Medicine</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of California San Diego [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ContingentValueRightsAgreementMember" xlink:type="locator" xlink:label="onct_ContingentValueRightsAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Value Rights Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ContingentValueRightsAgreementMember" xlink:to="onct_ContingentValueRightsAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee to be paid and payment made</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee To Be Paid And Payment Made</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Milestone Payments</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days in written notice of termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice in fails to pay amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice for default in payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum period of written notice to terminate agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice of termination, period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days In Written Notice Of Termination</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice, to pay failure amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice To Pay Failure Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice for default in payment</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice For Default In Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum period in days of written notice to terminate license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Period Of Written Notice To Terminate Agreement</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential regulatory milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Regulatory Milestone Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Aggregate Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UpfrontLicenseFeesPaid" xlink:to="onct_UpfrontLicenseFeesPaid_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Worldwide sales milestones based on achievement of tiered revenue levels.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance licensed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdvanceLicensedAssets" xlink:to="onct_AdvanceLicensedAssets_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualLicenseMaintenanceFees" xlink:to="onct_AnnualLicenseMaintenanceFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Worldwide sales milestones based on achievement of tiered revenue levels</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Based On Achievement Of Tiered Revenue Levels</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance licensed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Licensed Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patent costs as general and administrative expense</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTerm" xlink:to="onct_ResearchAgreementTerm_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmount" xlink:to="onct_ResearchAgreementResearchFundingAmount_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmountPayable" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate research agreement budget</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research amount payable quarterly</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount Payable</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAndDevelopmentGrants" xlink:to="onct_ResearchAndDevelopmentGrants_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones to be received under research subaward agreements throughout award project period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subaward payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SubawardPaymentsReceived" xlink:to="onct_SubawardPaymentsReceived_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related qualifying subaward costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RelatedQualifyingSubawardCosts" xlink:to="onct_RelatedQualifyingSubawardCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants awarded to researchers</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones to be received under research subaward agreements throughout award project period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subaward payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subaward Payments Received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related qualifying subaward costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Qualifying Subaward Costs</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount agreed to be provided in contingency funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount agreed to be provided in contingency funds</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Agreed To Be Provided In Contingency Funds</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials1" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials1" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Clinical Trials 1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedClinicalTrials1" xlink:to="onct_AccruedClinicalTrials1_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AwardPaymentsReceived" xlink:type="locator" xlink:label="onct_AwardPaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="onct_AwardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Award payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AwardPaymentsReceived" xlink:to="onct_AwardPaymentsReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to subawardees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AwardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AwardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Payments Received</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:type="locator" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" />
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company&apos;s SARD and SARM technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PercentageOfNetSales" xlink:type="locator" xlink:label="onct_PercentageOfNetSales" />
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PercentageOfNetSales" xlink:to="onct_PercentageOfNetSales_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:type="locator" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" />
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period from closing during which percentage of net proceeds payment would be payable under the CVR.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:type="locator" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" />
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period from closing during which the grant, sale or transfer of rights to the Company&apos;s SARD or SARM technology could trigger a payment under the CVR Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net proceeds entitled to be received per CVR</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Proceeds Entitled To Receive During Period Specified After Closing From Grant Sale Or Transfer Of Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period from closing during which payment of percentage of net proceeds would be payable under the CVR</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Which Payment Of Percentage Of Net Proceeds Would Be Payable Under C V R</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period from closing during which the grant, sale or transfer of rights to the Company&apos;s SARD or SARM technology could trigger a payment under the CVR Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Which Grant Sale Or Transfer Of Rights To Company Sard Or Sarm Technology Could Trigger Payment Under Cvr Agreement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_PaycheckProtectionProgramMember" xlink:type="locator" xlink:label="onct_PaycheckProtectionProgramMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PaycheckProtectionProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck Protection Program member,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PaycheckProtectionProgramMember" xlink:to="onct_PaycheckProtectionProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PaycheckProtectionProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PaycheckProtectionProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate, stated percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loan forgiveness (other income)</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined purchase price of share and warrant per unit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capitalization Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capitalization Equity [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PurchaseAgreementMember" xlink:to="onct_PurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PlacementAgentMember" xlink:to="onct_PlacementAgentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">July purchase agreement member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_JulyPurchaseAgreementMember" xlink:to="onct_JulyPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">July Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AugustUnderwritingAgreementMember" xlink:to="onct_AugustUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">November underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NovemberUnderwritingAgreementMember" xlink:to="onct_NovemberUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">November Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">December underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DecemberUnderwritingAgreementMember" xlink:to="onct_DecemberUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">December Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="onct_AtTheMarketFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="onct_AtTheMarketFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AtTheMarketFacilityMember" xlink:to="onct_AtTheMarketFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AtTheMarketFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AtTheMarketFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Facility [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capitalization Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capitalization Equity [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined purchase price of share and warrant per unit</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Combined Purchase Price Of Share And Warrant Per Unit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants excercisable and expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsExpirationDate" xlink:to="onct_CommonStockWarrantsExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Expiration Date</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_AmountForAtTheMarketFacility" xlink:type="locator" xlink:label="onct_AmountForAtTheMarketFacility" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountForAtTheMarketFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount for at the market facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AmountForAtTheMarketFacility" xlink:to="onct_AmountForAtTheMarketFacility_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountForAtTheMarketFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Execution of ATM Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AmountForAtTheMarketFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount For At The Market Facility</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_WarrantsIssued" xlink:type="locator" xlink:label="onct_WarrantsIssued" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsIssued" xlink:to="onct_WarrantsIssued_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ExerciseOfWarrants" xlink:type="locator" xlink:label="onct_ExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfWarrants" xlink:to="onct_ExerciseOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Number of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Number of Warrant</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_WarrantIssuedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant issued price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantIssuedPricePerShare" xlink:to="onct_WarrantIssuedPricePerShare_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_WarrantExercisedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantExercisedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercised price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantExercisedPricePerShare" xlink:to="onct_WarrantExercisedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercised Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant weighted-average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan and inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan and inducement plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan And Inducement Plan [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Oncternal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PrivateOncternalMember" xlink:to="onct_PrivateOncternalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Oncternal</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Oncternal [Member]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2015 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares of common stock a participant may receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock shares provided for issuance of stock awards to its employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_EquityIncentivePlanMember" xlink:to="onct_EquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining weighted-average period, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining weighted-average period, vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and exercisable, Aggregate intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost related to nonvested awards not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining weighted-average period</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsReservedForFutureIssuance" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options issued and outstanding for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Aggregate Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Issued And Outstanding For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for future issuance</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationPermanentItems" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxReconciliationPermanentItems" xlink:to="onct_IncomeTaxReconciliationPermanentItems_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" xlink:type="locator" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" xlink:to="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Effects Allocated Directly To Equity Employee Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets Net</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxesLineItems" xlink:type="locator" xlink:label="onct_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxesTable" xlink:type="locator" xlink:label="onct_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxesTable" xlink:to="onct_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, fully offset by valuation allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change In Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion" />
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards non expire portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OperatingLossCarryforwardsNonExpirePortion" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OperatingLossCarryforwardsExpirationYear" xlink:to="onct_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards non expire portion</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Non Expire Portion</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year</link:label>
    <link:loc xlink:href="onct-20211231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="onct_CumulativeChangeInOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CumulativeChangeInOwnershipPercentage" xlink:to="onct_CumulativeChangeInOwnershipPercentage_lbl" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:type="locator" xlink:label="onct_PeriodForCumulativeChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for cumulative change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodForCumulativeChangeInOwnership" xlink:to="onct_PeriodForCumulativeChangeInOwnership_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative changes in ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for cumulative change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period For Cumulative Change In Ownership</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Expense</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>35
<FILENAME>onct-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T19:57:53.7262452+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : e954f1db574f4cdbb446abea68e107eb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncternal.com/20211231/role/TemplateLink" xlink:href="onct-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="onct-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="onct-20211231.xsd#onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:type="locator" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CashlessExerciseOfWarrants" xlink:type="locator" xlink:label="onct_CashlessExerciseOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NoncashLeaseExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_CashlessExerciseOfWarrants" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_FairValueOfWarrantsIssuedToPlacementAgent" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:href="onct-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:href="onct-20211231.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails" xlink:href="onct-20211231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:href="onct-20211231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements" xlink:href="onct-20211231.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebt" xlink:href="onct-20211231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" xlink:href="onct-20211231.xsd#Role_DisclosureCOVID19PandemicAndCARESAct" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct">
    <link:loc xlink:href="onct-20211231.xsd#onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock" />
    <link:loc xlink:href="onct-20211231.xsd#onct_COVID19PandemicAndCARESActAbstract" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_COVID19PandemicAndCARESActAbstract" xlink:to="onct_COVID19PandemicAndCARESActDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="onct-20211231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureSubsequentEvent">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="onct_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="onct-20211231.xsd#onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_LiquidityAndGoingConcernPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_PatentCostsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" xlink:href="onct-20211231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_AccruedClinicalTrials" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenue" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20211231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockSubjectToRepurchaseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20211231.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AccruedUnvestedShareLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedClinicalTrials" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedUnvestedShareLiability" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceCommissions" xlink:type="locator" xlink:label="us-gaap_InsuranceCommissions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralInsuranceExpense" xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RemainderOfLeaseTermBaseRent" xlink:type="locator" xlink:label="onct_RemainderOfLeaseTermBaseRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RentExpense" xlink:type="locator" xlink:label="onct_RentExpense" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:type="locator" xlink:label="onct_ChiefFinancialOfficerSonMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="onct_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_ChiefFinancialOfficerSonMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RentExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_RemainderOfLeaseTermBaseRent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceCommissions" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:type="locator" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:type="locator" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PercentageOfNetSales" xlink:type="locator" xlink:label="onct_PercentageOfNetSales" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:type="locator" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AwardPaymentsReceived" xlink:type="locator" xlink:label="onct_AwardPaymentsReceived" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AccruedClinicalTrials1" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials1" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense_li0l2" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20211231.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:loc xlink:href="onct-20211231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:loc xlink:href="onct-20211231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ContingentValueRightsAgreementMember" xlink:type="locator" xlink:label="onct_ContingentValueRightsAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NationalInstituteOfHealthGrantAwardMember" xlink:type="locator" xlink:label="onct_NationalInstituteOfHealthGrantAwardMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyFourMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyFourMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyThreeMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyThreeMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="onct_ResearchAgreementTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_RegentsLicenseAgreementMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyTwoMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyThreeMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementTwoThousandTwentyFourMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_NationalInstituteOfHealthGrantAwardMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_LicenseAgreementMember" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ContingentValueRightsAgreementMember" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense_li0l2" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="13440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="13630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="13670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="13930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="13990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="14050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="14110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="14320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AccruedClinicalTrials1" order="14490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AwardPaymentsReceived" order="14530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" order="14580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetSales" order="14600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" order="14620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" order="14640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PaycheckProtectionProgramMember" xlink:type="locator" xlink:label="onct_PaycheckProtectionProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onct_PaycheckProtectionProgramMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_AmountForAtTheMarketFacility" xlink:type="locator" xlink:label="onct_AmountForAtTheMarketFacility" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AtTheMarketFacilityMember" xlink:type="locator" xlink:label="onct_AtTheMarketFacilityMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_PurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onct_CommonStockWarrantsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_PlacementAgentMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_JulyPurchaseAgreementMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AugustUnderwritingAgreementMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_NovemberUnderwritingAgreementMember" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_DecemberUnderwritingAgreementMember" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AtTheMarketFacilityMember" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ScheduleOfCapitalizationEquityLineItems" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CommonStockWarrantsExpirationDate" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_AmountForAtTheMarketFacility" order="13580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" />
    <link:loc xlink:href="onct-20211231.xsd#onct_WarrantExercisedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantExercisedPricePerShare" />
    <link:loc xlink:href="onct-20211231.xsd#onct_WarrantIssuedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_li0l2" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ExerciseOfWarrants" xlink:type="locator" xlink:label="onct_ExerciseOfWarrants" />
    <link:loc xlink:href="onct-20211231.xsd#onct_WarrantsIssued" xlink:type="locator" xlink:label="onct_WarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ExerciseOfWarrants" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantIssuedPricePerShare" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantExercisedPricePerShare" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:loc xlink:href="onct-20211231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="onct-20211231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20211231.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="onct-20211231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" xlink:type="locator" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationPermanentItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxReconciliationPermanentItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="onct-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="onct-20211231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:type="locator" xlink:label="onct_PeriodForCumulativeChangeInOwnership" />
    <link:loc xlink:href="onct-20211231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="onct_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="onct-20211231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="onct-20211231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxesLineItems" xlink:type="locator" xlink:label="onct_IncomeTaxesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="onct-20211231.xsd#onct_IncomeTaxesTable" xlink:type="locator" xlink:label="onct_IncomeTaxesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesTable" xlink:to="onct_IncomeTaxesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsExpirationYear" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_CumulativeChangeInOwnershipPercentage" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_PeriodForCumulativeChangeInOwnership" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298238344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oncternal Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001260990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text"> 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,429,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1715807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12230 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">434-1113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#8217;s 2022 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2021. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524295829640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,765<span></span>
</td>
<td class="nump">$ 116,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">92,853<span></span>
</td>
<td class="nump">118,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">93,585<span></span>
</td>
<td class="nump">118,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,431<span></span>
</td>
<td class="nump">3,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease, current</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">5,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, authorized shares &#8211; 5,000 at December 31, 2021 and 2020; issued and outstanding shares &#8211; none</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares &#8211; 120,000 at December 31, 2021 and 60,000 at 2020; issued and outstanding shares &#8211; 49,429 and 48,802 at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">202,201<span></span>
</td>
<td class="nump">195,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(114,130)<span></span>
</td>
<td class="num">(82,797)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">88,120<span></span>
</td>
<td class="nump">112,951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 93,585<span></span>
</td>
<td class="nump">$ 118,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298211768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">49,429,000<span></span>
</td>
<td class="nump">48,802,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">49,429,000<span></span>
</td>
<td class="nump">48,802,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524295787256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="nump">$ 4,315<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">24,086<span></span>
</td>
<td class="nump">12,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,595<span></span>
</td>
<td class="nump">8,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,681<span></span>
</td>
<td class="nump">20,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(31,366)<span></span>
</td>
<td class="num">(17,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,333)<span></span>
</td>
<td class="num">$ (17,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">49,321<span></span>
</td>
<td class="nump">20,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298108488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (31,333)<span></span>
</td>
<td class="num">$ (17,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan', window );">Gain on forgiveness of payroll protection program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,875<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(713)<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="num">(1,633)<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(26,589)<span></span>
</td>
<td class="num">(17,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from payroll protection loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ProceedsFromStockOptionsExercisedAndWarrantExercises', window );">Proceeds from exercise of stock options and common stock warrants</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,876<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">114,181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(25,972)<span></span>
</td>
<td class="nump">96,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">116,737<span></span>
</td>
<td class="nump">20,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">90,765<span></span>
</td>
<td class="nump">116,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_FairValueOfWarrantsIssuedToPlacementAgent', window );">Fair value of warrants issued to placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan', window );">Gain on forgiveness of payroll protection program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of 2019 bonus awards with stock options in lieu of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_FairValueOfWarrantsIssuedToPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued to placement agent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_FairValueOfWarrantsIssuedToPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ProceedsFromStockOptionsExercisedAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options and common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ProceedsFromStockOptionsExercisedAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297982184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 14,312<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 79,869<span></span>
</td>
<td class="num">$ (65,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for cash</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfCashlessWarrantShares', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability', window );">Vesting related to repurchase liability</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">113,876<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">113,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash', window );">Issuance of 2019 bonus awards with stock option in lieu of cash</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,225)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 112,951<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">195,699<span></span>
</td>
<td class="num">(82,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">48,802,000<span></span>
</td>
<td class="nump">48,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for cash</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfCashlessWarrantShares', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash', window );">Exercise of warrants for cash</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares', window );">Exercise of warrants for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability', window );">Vesting related to repurchase liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 88,120<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 202,201<span></span>
</td>
<td class="num">$ (114,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">49,429,000<span></span>
</td>
<td class="nump">49,429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital stock issued issuance costs shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital vesting related to unvested share liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfCashlessWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfCashlessWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of bonus awards with stock option in lieu of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300057064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock and common stock warrants, issuance cost</a></td>
<td class="nump">$ 11,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300243688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Business,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">Basis</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Presentation<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>Summary<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.45pt;"> </span>Significant<span style="letter-spacing:-0.5pt;"> </span>Accounting<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">Policies</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Oncternal,&#8221; or the &#8220;combined company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had $90.8 million in cash and cash equivalents and no debt. The Company believes it has sufficient cash to<span style="color:#000000;"> fund its projected operating requirements for at least twelve months from the date of issuance</span>. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $114.1 million as of December 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has capacity to issue $50.0 million of additional shares of common stock under its recently established and unused ATM program. There can be no assurance that the Company will be able to sell any shares of its common stock under the ATM Program or regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM Program may be at prices that result in additional dilution to existing stockholders of the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP.</span><span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>preparation<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">accompanying</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">notes</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities. </span><span style="letter-spacing:0.1pt;">Significant </span>estimates <span style="letter-spacing:0.1pt;">consist </span><span style="letter-spacing:0.15pt;">of those </span>used to determine <span style="letter-spacing:0.15pt;">the </span>fair <span style="letter-spacing:0.15pt;">value of the </span><span style="letter-spacing:0.1pt;">Company&#8217;s </span>stock-based awards<span style="letter-spacing:0.15pt;">, </span><span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">those </span>used to determine grant <span style="letter-spacing:0.1pt;">revenue and </span>accruals for research <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">development </span>costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of December 31, 2021, the Company&#8217;s clinical trial accrual balance of $0.5 million is included in accrued liabilities. The Company&#8217;s related clinical trial expenses are included in research and development expenses of $24.1 million and $12.5 million at December 31, 2021 and December 31, 2020, respectively.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from certain grant awards or a research subaward (the &#8220;Grant Awards&#8221;)(see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2021 and 2020, the Company had a grant receivable of $0.4 million and deferred grant revenue of <span style="color:#000000;">$1.6 </span>million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been included in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements. Under this method, deferred tax assets and liabilities are determined </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the basis of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 7,000 shares and 25,000 shares from the weighted-average number of common shares outstanding for the years ended December 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2021-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;). The FASB issued the ASU to improve transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements.&#160;&#160;The disclosure requirements in ASU 2021-10 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard (IAS) 20,&#160;Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model.&#160;ASU 2021-10 requires the entity to disclose the nature and significant terms and conditions of the transaction, accounting policies used to account for the transaction, and line items in the financial statements affected by the transaction. ASU 2021-10 is effective for annual periods beginning </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after December 15, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Early adoption is permitted, including adoption in an interim period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASU 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the prospective method of transition effective </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> determined that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there was no cumulative effect to be recognized </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">early adoption.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Standards Not Yet Adopted&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#8239;<span style="font-style:italic;">Financial Instruments - Credit Losses</span>: <span style="font-style:italic;">Measurement of Credit Losses on Financial Statements </span>(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU 2021-04, <span style="font-style:italic;">Earnings Per Share</span> (Topic 260), <span style="font-style:italic;">Debt-Modifications and Extinguishments</span> (Subtopic 470-50), <span style="font-style:italic;">Compensation-Stock Compensation</span> (Topic 718), and <span style="font-style:italic;">Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity </span>(Subtopic 815-40):<span style="font-style:italic;"> Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>, which intends to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300050856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Details</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">518</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested share liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,528</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300043768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingencies and Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments, Contingencies and Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $0.2 million for the years ended December 31, 2021 and 2020. On May 22, 2019, the Company entered into an office sublease agreement for 4,677 square feet in San Diego, California (&#8220;San Diego Lease&#8221;) which expired on March 31, 2021. On March 17, 2021, the Company entered into a direct lease with the landlord for the same facility (the &#8220;San Diego Lease&#8221;) which expires on May 31, 2022. Base rent under the San Diego Lease is approximately $77,000 for the remainder of the lease term and the monthly rent expense is being recognized on a straight-line basis over the lease term. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a 10.0% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. As of December 31, 2021, the Company has recognized a net operating lease right-of-use asset and a lease liability of $75,000 that matures in May 2022, which has a weighted average remaining lease term of 0.42 years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Transactions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company engaged Newfront Insurance as its primary insurance broker. The son of Richard Vincent, the Company&#8217;s Chief Financial Officer, acted as the Company&#8217;s agent at Newfront Insurance. During the years ended December 31, 2021 and 2020, the Company paid total related policy premiums of $1.8 million and $1.4 million, respectively, for which Mr. Vincent&#8217;s son received a commission of $0.1 million. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;) entered into a Materials Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During the year ended December&#160;31, 2021, the Company recorded amounts receivable from SPH USA related to statements of work totaling $0.4 million (see Note 4). SPH USA is the Company&#8217;s largest stockholder and an affiliate of two of the Company&#8217;s directors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the securities purchase agreements and underwritten offering, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner and Michael G. Carter (see Note 6).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300062232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Research Subaward Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration and Research Subaward Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration, Research Subaward Agreement and CVR Agreements</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Georgetown University (&#8220;Georgetown&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an Exclusive License Agreement (the &#8220;Georgetown License Agreement&#8221;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $10,000 until the first commercial sale occurs, (ii) is required to make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of December 31, 2021, the Company had not triggered or made any milestone payments under the Georgetown License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with 90 days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least 60 days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company entered into a collaboration agreement (as amended, the &#8220;Collaboration&#8221;) with MD Anderson, which provides for the conduct of preclinical and clinical research for ONCT-216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $1.0 million based on net product sales. In July 2020 and September 2021, the Company entered into two research agreements with MD Anderson for certain services up to an aggregate cost of $0.8 million. The amount recorded as research and development expense for the year ended December 31, 2021 and 2020 was $0.1 million.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, and as amended and restated in August 2018, and as amended in March and May 2019 and February 2021, the Company entered into a license agreement (as amended and restated, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $0.5 million was paid and 107,108 shares of common stock were issued, (ii) $25,000 in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain&#160;annual patent costs, (iv) certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $1.0 million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: <span style="letter-spacing:0.15pt;">(i) $25,000 in </span><span style="letter-spacing:0.1pt;">license</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">maintenance</span><span style="letter-spacing:-0.3pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>research<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">development</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">expense for each of the</span> years ended December 31, 2021 and 2020, and (ii)<span style="letter-spacing:-0.6pt;"> approximately $0.3 million and</span> $0.2 million<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">costs</span> as general <span style="letter-spacing:0.1pt;">and administrative </span><span style="letter-spacing:0.15pt;">expense </span>for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company believes it has met its obligations under the Regents License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the first commercial sale of a licensed product. <span style="color:#000000;">The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. </span>The Company may terminate the agreement at any time upon at least 60 days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000292">five-year</span> agreement that expired in 2021, the Regents was paid an aggregate of $3.6 million. The Company recorded $0.3 million and $0.5 million in research and development expense under this agreement&#160;for each of the years ended December 31, 2021 and 2020, respectively. Such costs are includable as part of the Company&#8217;s annual diligence obligations under the Regents License Agreement. Effective January 1, 2022, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000293">four-year</span> agreement that expires on December 31, 2025, the Regents will have an aggregate budget of $1.6 million, with quarterly payments of $125,000 in 2022, $131,250 in 2023, and $137,813 in 2024. &#160;&#160;  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2015, and as amended and restated in March 2022, the Company and UTRF entered into a license agreement (the &#8220;DAARI License Agreement&#8221;; formerly known as the SARD License Agreement) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader technologies owned or controlled by UTRF, including all improvements thereto, which is now known as the dual action androgen receptor inhibitor, or DAARI program. Under the DAARI License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expenses under this agreement of $0.1 million and $0.2 million for each of the years ended December 31, 2021 and 2020, respectively. <span style="color:#000000;">As of December 31, 2021, the Company believes it has met its obligations under the DAARI License Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Award<span style="font-size:6pt;font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017,<span style="color:#000000;"> and as amended and restated in December 2020,</span> CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance the Company&#8217;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia (&#8220;CLL&#8221;) and mantle cell lymphoma (&#8220;MCL&#8221;). <span style="color:#000000;">This study is known as CIRM-0001, or Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia </span>(&#8220;CIRLL&#8221;)<span style="color:#000000;"> study</span>. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $14.4 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received subaward payments of $2.2 million and $1.4 million in the years ended December 31, 2021 and 2020, respectively, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the years ended December 31, 2021 and 2020, the Company&#8217;s grant revenue was $4.2 million and $3.4 million, respectively. Related qualifying subaward costs for the years ended December 31, 2021 and 2020 were $8.8 million and $5.2 million, respectively. As of December 31, 2021, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $5.8 million grant to the researchers at the University of California San Diego School of Medicine (&#8220;UC San Diego&#8221;) to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $1.0 million in contingency funds if required during the grant period. The Company recorded no research and development expense, and no contingency funds have been provided under such CIRM award for the years ended December 31, 2021 and 2020. The grant expired in 2021 and the Company believes there are no obligations as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The National Institutes of Health (&#8220;NIH&#8221;) Grant Awards<span style="font-size:12pt;font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the NIH awarded the Company two research and development grants for up to $2.2 million to support preclinical activities for the Company&#8217;s ONCT-216 and ONCT-534 programs, including $0.7 million payable to subawardees. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the year ended December 31, 2021, the Company received no award payments from the NIH and recorded $143,000 in grant revenue and unbilled receivables which has been included in prepaid and other assets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial and Supply Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, and as amended in August 2019, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#8220;Pharmacyclics&#8221;) to supply ibrutinib for the Company&#8217;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SPH USA, a Related Party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Development Agreement (&#8220;LDA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018,<span style="color:#000000;"> and as amended in August 2020, </span>the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) SPH USA on a country</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/region-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/region</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) </span><span style="letter-spacing:0.15pt;">either</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">event</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">other</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">declares</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">insolvency</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">bankruptcy. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no significant activity under this agreement for the years ended December 31, 2021 and 2020. See Note 3.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the GTx merger agreement entered into in June 2019 (the &#8220;Merger&#8221;), the Company, a representative of holders of the CVRs, and Computershare, Inc. as rights agent entered into the CVR Agreement. Pursuant to the CVR Agreement, the Company&#8217;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#8217;s common stock held immediately prior to the Merger. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i)&#160;50% of certain net proceeds received by the Company during the 15-year period after the closing of the Merger (the &#8220;CVR Term&#8221;) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the 10-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period); and (ii) 5% of net sales of products by Parent or its affiliates during the CVR Term incorporating the DAARI technology. As of December 31, 2021, no transactions or net sales relating to the DAARI technology had occurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300203880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Debt</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company received a $0.3 million unsecured loan, bearing interest at 1%, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;), a program implemented by the U.S. Small Business Administration (the &#8220;SBA&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) (the &#8220;PPP Loan&#8221;). In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. <span style="color:#000000;">The loan forgiveness was recorded as other income of $0.3 million in the consolidated statement of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524296641736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amended and Restated Articles of Incorporation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 25, 2021, the Company&#8217;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock, each with a par value of $0.001 per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities Purchase Agreements <span style="color:#000000;">and </span>Underwritten Offering</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company entered into a Securities Purchase Agreement (the &#8220;May Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) 1,943,636 shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $4.4 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 971,818 shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.5725. In addition, the Company<span style="color:#000000;"> issued </span>warrants to purchase 116,618 <span style="color:#000000;">shares of </span>common <span style="color:#000000;">stock at </span>an exercise price of $3.2156<span style="color:#000000;"> per share </span>to the placement agent, H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221; or the &#8220;placement agent&#8221;) as part of its compensation, which warrants were immediately exercisable and expire on <span style="color:#000000;">May 21, 2025</span>. <span style="color:#000000;">An investor participating in the transaction included an entity affiliated with David F. Hale, the chairman of the Company&#8217;s board of directors.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a Securities Purchase Agreement (the &#8220;July Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) 2,581,867 shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $5.7 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the </p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants, and (ii) unregistered warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,290,933</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3825</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share and expire on </span><span style="color:#000000;">January 21, 2026</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company issued warrants to purchase </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154,912</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock at an exercise price of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9781</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on </span><span style="color:#000000;">July 21, 2025</span><span style="color:#000000;">.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, and Daniel L. Kisner, a member of the Company&#8217;s board of directors.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;August Underwriting Agreement&#8221;) with Wainwright for the sale of 2,428,886 shares of the Company&#8217;s common stock at a price to the public of $2.10 per share, resulting in net proceeds of $4.4 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 145,733 shares of common stock at an exercise price of $2.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on August 27, 2025. An investor participating in the transaction included Michael G. Carter, a member of the Company&#8217;s board of directors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;November Underwriting Agreement&#8221;) with Wainwright for the sale of 7,258,065 shares of the Company&#8217;s common stock at a price to the public of $3.10 per share, resulting in net proceeds of $20.4 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 435,484 shares of common stock at an exercise price of $3.875 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <span style="color:#000000;">November 17, 2025</span>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;December Underwriting Agreement&#8221;) with Wainwright for the sale of 19,161,667 shares of the Company&#8217;s common stock at a price to the public of $4.50 per share, resulting in net proceeds of $79.0 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase 1,149,700 shares of common stock at an exercise price of $5.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <span style="color:#000000;">December 9, 2025</span>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, <span style="color:#000000;">which expired in 2021</span>. <span style="color:#000000;">In December 2021, the Company executed an at-the-market (&#8220;ATM&#8221;) facility of up to $50.0 million.</span> During the year ended December 31, 2021, the Company did not sell shares under the ATM. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:85.12%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Underlying Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000376">2.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031,841</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000377">4.40</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(796,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.56</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,234,910</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000378">3.31</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, all warrants met the criteria for classification in stockholders&#8217; equity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneous with the Merger&#160;&#160;closing: (i) Private Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) 1,678,571&#160;shares of common stock, (b) 275,579 shares of common stock previously outstanding under the GTx 2013 Equity Incentive Plan that were cancelled became available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At December&#160;31, <span style="color:#000000;">2021, 1,842,432</span> shares remain available for future issuance under the 2019 Plan and Inducement Plan (as defined below).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to 631,120 shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a <span style="-sec-ix-hidden:F_000385">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan was terminated as to new grants in June 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire ten years from the date of grant and vest over a four-year period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 11, 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan. As amended on May 25, 2021 and December 16, 2021, the Company has reserved 2,800,000 shares of common stock under the Inducement Plan.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.7%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,884,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.78</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(439,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.84</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444,744</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000398">8.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613,190</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000399">6.8</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488,187</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of option grants for the years ended December 31, 2021 and 2020 was $4.35 and $2.53 per share, respectively.&#160;&#160;The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at the time of the option exercise and the exercise price of that stock option. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $419,755 and $10,413. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000410">6.2</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000411">6.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected term assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term</span><span style="font-size:9pt;font-family:Segoe UI;font-style:normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <span style="font-style:normal;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield. <span style="font-style:normal;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,136</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, the total compensation cost related to nonvested awards not yet recognized was $17.4 million and the weighted-average period over which it is expected to be recognized was 3.2 years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297310168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19 Pandemic and CARES Act<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_COVID19PandemicAndCARESActAbstract', window );"><strong>C O V I D19 Pandemic And C A R E S Act [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_COVID19PandemicAndCARESActDisclosureTextBlock', window );">COVID-19 Pandemic and CARES Act</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#FF0000;"/>COVID-19 Pandemic and CARES Act</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#8220;COVID-19&#8221;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., the Company expects that COVID-19 precautions may directly or indirectly impact the timeline for some of its clinical trials. For example, some of its clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Additionally, the Company&#8217;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy in China has been delayed. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its consolidated financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at December&#160;31, 2021. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP), and authorized the PPP (see Note 5).&#160; The CARES Act had no material impact on the Company&#8217;s income tax provision for the years ended December&#160;31, 2021 or 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_COVID19PandemicAndCARESActAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_COVID19PandemicAndCARESActAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_COVID19PandemicAndCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_COVID19PandemicAndCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300195928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.78%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,579</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,013</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,254</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,852</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,051</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,540</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company's deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of the Company's deferred tax assets, management considers all available evidence, both positive and negative.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#8220;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#8221; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2021. Accordingly, a valuation allowance of $41.8 million has been recorded to offset this deferred tax asset.&#160;&#160;The valuation allowance increased by $9.3 million and $5.0 million for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, the Company had federal and state net operating loss (NOL) carryforwards of approximately $81.5 million and $59.4 million, respectively. Of the federal net operating losses at December&#160;31, 2021, $55.2 million do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in 2033 and 2029, respectively, unless previously utilized. At December&#160;31, 2021, the Company also had federal and state research and development credit carryforwards of approximately $2.1 million and $1.3 million, respectively. The federal research and development credit carryforwards will begin expiring in 2034 unless previously utilized. The state research and development credits do not expire. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a <span style="-sec-ix-hidden:F_000475">three-year</span> period. The Company has not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study and the fact that there may be additional such ownership changes in the future. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December 31, 2021 and 2020, there were no unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#8217;s 2014 through 2021 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated statements of operations since inception.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298207240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297818632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had $90.8 million in cash and cash equivalents and no debt. The Company believes it has sufficient cash to<span style="color:#000000;"> fund its projected operating requirements for at least twelve months from the date of issuance</span>. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $114.1 million as of December 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has capacity to issue $50.0 million of additional shares of common stock under its recently established and unused ATM program. There can be no assurance that the Company will be able to sell any shares of its common stock under the ATM Program or regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM Program may be at prices that result in additional dilution to existing stockholders of the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP.</span><span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>preparation<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">accompanying</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">notes</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities. </span><span style="letter-spacing:0.1pt;">Significant </span>estimates <span style="letter-spacing:0.1pt;">consist </span><span style="letter-spacing:0.15pt;">of those </span>used to determine <span style="letter-spacing:0.15pt;">the </span>fair <span style="letter-spacing:0.15pt;">value of the </span><span style="letter-spacing:0.1pt;">Company&#8217;s </span>stock-based awards<span style="letter-spacing:0.15pt;">, </span><span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">those </span>used to determine grant <span style="letter-spacing:0.1pt;">revenue and </span>accruals for research <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">development </span>costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of December 31, 2021, the Company&#8217;s clinical trial accrual balance of $0.5 million is included in accrued liabilities. The Company&#8217;s related clinical trial expenses are included in research and development expenses of $24.1 million and $12.5 million at December 31, 2021 and December 31, 2020, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from certain grant awards or a research subaward (the &#8220;Grant Awards&#8221;)(see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2021 and 2020, the Company had a grant receivable of $0.4 million and deferred grant revenue of <span style="color:#000000;">$1.6 </span>million, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been included in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements. Under this method, deferred tax assets and liabilities are determined </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the basis of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 7,000 shares and 25,000 shares from the weighted-average number of common shares outstanding for the years ended December 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2021-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;). The FASB issued the ASU to improve transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements.&#160;&#160;The disclosure requirements in ASU 2021-10 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard (IAS) 20,&#160;Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model.&#160;ASU 2021-10 requires the entity to disclose the nature and significant terms and conditions of the transaction, accounting policies used to account for the transaction, and line items in the financial statements affected by the transaction. ASU 2021-10 is effective for annual periods beginning </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after December 15, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Early adoption is permitted, including adoption in an interim period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASU 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the prospective method of transition effective </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> determined that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there was no cumulative effect to be recognized </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">early adoption.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Standards Not Yet Adopted&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#8239;<span style="font-style:italic;">Financial Instruments - Credit Losses</span>: <span style="font-style:italic;">Measurement of Credit Losses on Financial Statements </span>(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU 2021-04, <span style="font-style:italic;">Earnings Per Share</span> (Topic 260), <span style="font-style:italic;">Debt-Modifications and Extinguishments</span> (Subtopic 470-50), <span style="font-style:italic;">Compensation-Stock Compensation</span> (Topic 718), and <span style="font-style:italic;">Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity </span>(Subtopic 815-40):<span style="font-style:italic;"> Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>, which intends to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk credit risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ConcentrationRiskCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300245816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297679848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">518</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested share liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,528</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298010152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ScheduleOfWarrantActivityTableTextBlock', window );">Summary Of Warrant Activity And Changes In Warrants Outstanding</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:85.12%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Underlying Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000376">2.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031,841</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000377">4.40</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(796,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.56</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,234,910</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000378">3.31</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.7%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,884,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.78</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(439,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.84</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444,744</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000398">8.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613,190</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000399">6.8</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488,187</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,136</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000410">6.2</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000411">6.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300117304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,579</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,013</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Significant Components of Net Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,254</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,852</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,051</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,845</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,540</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298107720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (114,130)<span></span>
</td>
<td class="num">$ (82,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">90,765<span></span>
</td>
<td class="nump">116,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Accrued Clinical Trials</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">24,086<span></span>
</td>
<td class="nump">12,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Weighted-average shares subject to repurchase | shares</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="nump">50,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business basis of presentation and summary of significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297841336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">10,680,000<span></span>
</td>
<td class="nump">7,273,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">4,235,000<span></span>
</td>
<td class="nump">5,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">6,445,000<span></span>
</td>
<td class="nump">2,226,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember', window );">Common Stock Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298000472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Accrued Clinical Trials</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedUnvestedShareLiability', window );">Unvested share liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,431<span></span>
</td>
<td class="nump">$ 3,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedUnvestedShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for unvested share liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedUnvestedShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524291400232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember', window );">Shanghai Pharmaceutical (USA) Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=onct_ChiefFinancialOfficerSonMember', window );">Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Insurance commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">San Diego, California | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_RentExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_RemainderOfLeaseTermBaseRent', window );">Remainder of the lease term base rent</a></td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RemainderOfLeaseTermBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remainder of the lease term base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RemainderOfLeaseTermBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=onct_ChiefFinancialOfficerSonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=onct_ChiefFinancialOfficerSonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524221774248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Research Subaward Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,595,000<span></span>
</td>
<td class="nump">8,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,315,000<span></span>
</td>
<td class="nump">3,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_NationalInstituteOfHealthGrantAwardMember', window );">The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAndDevelopmentGrants', window );">Grants awarded to researchers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials1', window );">Payable to subawardees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AwardPaymentsReceived', window );">Award payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember', window );">MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Aggregate cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_ReagentsMember', window );">Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_UpfrontLicenseFeesPaid', window );">Upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels', window );">Worldwide sales milestones based on achievement of tiered revenue levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember', window );">University of California San Diego School of Medicine | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAndDevelopmentGrants', window );">Grants awarded to researchers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod', window );">Development milestones to be received under research subaward agreements throughout award project period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SubawardPaymentsReceived', window );">Subaward payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_RelatedQualifyingSubawardCosts', window );">Related qualifying subaward costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement | Georgetown University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LicenseMaintenanceFeeToBePaidAndPaymentMade', window );">Annual license maintenance fee to be paid and payment made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount', window );">Days after receipt of notice, to pay failure amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment', window );">Days after receipt of notice for default in payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement', window );">Minimum period in days of written notice to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Agreement | MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember', window );">Regents License Agreement | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember', window );">Research Agreement | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementTerm', window );">Research agreement term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmount', window );">Aggregate research agreement budget</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyTwoMember', window );">Research Agreement 2022 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyThreeMember', window );">Research Agreement 2023 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="nump">131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyFourMember', window );">Research Agreement 2024 | Regents of the University of California | The National Institute of Health (&#8220;NIH&#8221;) Grant Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="nump">$ 137,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember', window );">License Agreement | University of Tennessee Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights', window );">Percentage of net proceeds entitled to be received per CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR', window );">Period from closing during which payment of percentage of net proceeds would be payable under the CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement', window );">Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AmountAgreedToBeProvidedInContingencyFunds', window );">Amount agreed to be provided in contingency funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Exclusive License Agreement | Georgetown University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdvanceLicensedAssets', window );">Advance licensed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdvanceLicensedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance licensed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdvanceLicensedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AmountAgreedToBeProvidedInContingencyFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount agreed to be provided in contingency funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AmountAgreedToBeProvidedInContingencyFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AwardPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Award payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AwardPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones to be received under research subaward agreements throughout award project period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LicenseMaintenanceFeeToBePaidAndPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee to be paid and payment made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LicenseMaintenanceFeeToBePaidAndPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period of written notice to terminate agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after receipt of notice for default in payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after receipt of notice in fails to pay amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysInWrittenNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days in written notice of termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysInWrittenNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company's SARD and SARM technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from closing during which percentage of net proceeds payment would be payable under the CVR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RelatedQualifyingSubawardCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related qualifying subaward costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RelatedQualifyingSubawardCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Worldwide sales milestones based on achievement of tiered revenue levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SubawardPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subaward payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SubawardPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_UpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_UpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_NationalInstituteOfHealthGrantAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_NationalInstituteOfHealthGrantAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_ReagentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_ReagentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_GeorgetownUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_GeorgetownUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524299180616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Loan forgiveness (other income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Loan forgiveness (other income)</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onct_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onct_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300494040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Amended and Restated Articles of Incorporation (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524294561608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">5,031,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,234,910,000<span></span>
</td>
<td class="nump">5,031,841,000<span></span>
</td>
<td class="nump">841,424,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock | Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,943,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockWarrantsExpirationDate', window );">Common stock warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock | Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,581,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">Dec.  09,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">1,149,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,149,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="nump">19,161,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketFacilityMember', window );">At The Market Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AmountForAtTheMarketFacility', window );">Execution of ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AmountForAtTheMarketFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for at the market facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AmountForAtTheMarketFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined purchase price of share and warrant per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CombinedPurchasePriceOfShareAndWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=onct_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=onct_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297848872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">5,031,841,000<span></span>
</td>
<td class="nump">841,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantsIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,265,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfWarrants', window );">Number of Shares Underlying Warrants Exercised</a></td>
<td class="num">(796,931,000)<span></span>
</td>
<td class="num">(74,781,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">4,234,910,000<span></span>
</td>
<td class="nump">5,031,841,000<span></span>
</td>
<td class="nump">841,424,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantIssuedPricePerShare', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantExercisedPricePerShare', window );">Exercised</a></td>
<td class="nump">2.56<span></span>
</td>
<td class="nump">3.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">3 years 3 months 22 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant weighted-average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ClassOfWarrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercised price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant issued price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300459336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Incentive Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,522,000<span></span>
</td>
<td class="nump">8,196,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,755<span></span>
</td>
<td class="nump">$ 10,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">1,678,571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum number of shares of common stock a participant may receive</a></td>
<td class="nump">275,579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance', window );">Percentage of annual increase in shares reserved for issuance</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember', window );">2019 incentive award plan and inducement plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,842,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan | Private Oncternal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember', window );">2019 and 2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298141656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted-average period, outstanding</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember', window );">Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance | shares</a></td>
<td class="nump">2,107,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted | shares</a></td>
<td class="nump">4,884,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, cancelled | shares</a></td>
<td class="num">(439,684,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised | shares</a></td>
<td class="num">(107,997,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance | shares</a></td>
<td class="nump">6,444,744,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber', window );">Number of options, vested and exercisable | shares</a></td>
<td class="nump">1,440,122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">5.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="nump">5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">5.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable | $ / shares</a></td>
<td class="nump">$ 3.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted-average period, outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm', window );">Remaining weighted-average period, vested and exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 613,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue', window );">Vested and exercisable, Aggregate intrinsic value | $</a></td>
<td class="nump">$ 488,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524298170280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.80%<span></span>
</td>
<td class="nump">91.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297824936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,875<span></span>
</td>
<td class="nump">$ 1,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,136<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,739<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300053912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-Based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation cost related to nonvested awards not yet recognized</a></td>
<td class="nump">$ 17.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted-average period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524300355096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockWarrantsReservedForFutureIssuance', window );">Common stock warrants</a></td>
<td class="nump">4,235<span></span>
</td>
<td class="nump">5,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance', window );">Common stock options issued and outstanding</a></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">2,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="nump">12,522<span></span>
</td>
<td class="nump">8,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember', window );">Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock options issued and outstanding for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297825176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes</a></td>
<td class="num">$ (6,579)<span></span>
</td>
<td class="num">$ (3,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions', window );">Stock based compensation</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit carryforwards</a></td>
<td class="num">(1,099)<span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 9,306<span></span>
</td>
<td class="nump">$ 5,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effects of employee stock option transactions that are recognized differently for financial reporting and tax purposes, occurring during the period and charged or credited directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121829988&amp;loc=d3e23586-113945<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121829988&amp;loc=d3e23594-113945<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297968712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 21,254<span></span>
</td>
<td class="nump">$ 17,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">15,847<span></span>
</td>
<td class="nump">11,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">41,866<span></span>
</td>
<td class="nump">32,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(41,845)<span></span>
</td>
<td class="num">(32,540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524297868328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, fully offset by valuation allowance</a></td>
<td class="nump">$ 41,845,000<span></span>
</td>
<td class="nump">$ 32,540,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change In Valuation Allowance</a></td>
<td class="nump">9,300,000<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 3,051,000<span></span>
</td>
<td class="nump">1,952,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CumulativeChangeInOwnershipPercentage', window );">Cumulative changes in ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PeriodForCumulativeChangeInOwnership', window );">Period for cumulative change in ownership</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">81,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsNonExpirePortion', window );">Operating loss carryforwards non expire portion</a></td>
<td class="nump">$ 55,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development credit carryforward expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 59,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OperatingLossCarryforwardsNonExpirePortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards non expire portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OperatingLossCarryforwardsNonExpirePortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodForCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodForCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>onct-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:onct="http://www.oncternal.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="onct-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001260990_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20220310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="C_0001260990_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001260990_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-22</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:ChiefFinancialOfficerSonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:RegentsLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20211202_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyTwoMember_20211202_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyThreeMember_20211202_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyFourMember_20211202_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210801_20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:NationalInstituteOfHealthGrantAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-02</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20210525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-05-25</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_onctAtTheMarketFacilityMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_onctsegment">
        <measure>onct:segment</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_0001260990_20210101_20211231" id="F_000001">0001260990</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_0001260990_20210101_20211231" id="F_000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001260990_20210101_20211231" id="F_000006">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001260990_20210101_20211231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <onct:CollaborativeArrangementPotentialMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20211231"
      decimals="-6"
      id="F_000271"
      unitRef="U_iso4217USD">0</onct:CollaborativeArrangementPotentialMilestonePayments>
    <onct:ResearchAgreementTerm
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231"
      id="F_000292">P5Y</onct:ResearchAgreementTerm>
    <onct:ResearchAgreementTerm
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20211202_20220101"
      id="F_000293">P4Y</onct:ResearchAgreementTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731"
      id="F_000385">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <onct:PeriodForCumulativeChangeInOwnership contextRef="C_0001260990_20210101_20211231" id="F_000475">P3Y</onct:PeriodForCumulativeChangeInOwnership>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="INF"
      id="F_000478"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001260990_20211231"
      id="F_000059"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001260990_20201231"
      id="F_000060"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001260990_20211231"
      id="F_000061"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001260990_20201231"
      id="F_000062"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20190101_20191231" id="F_000376">P2Y9M0D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20200101_20201231" id="F_000377">P4Y4M24D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20210101_20211231" id="F_000378">P3Y3M22D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      id="F_000398">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      id="F_000399">P6Y9M18D</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001260990_20210101_20211231" id="F_000410">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001260990_20200101_20201231" id="F_000411">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001260990_20210101_20211231" id="F_000002">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001260990_20210101_20211231" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001260990_20210101_20211231" id="F_000003">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001260990_20210101_20211231" id="F_000005">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001260990_20210101_20211231" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001260990_20210101_20211231" id="F_000018">000-50549</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001260990_20210101_20211231" id="F_000000">Oncternal Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001260990_20210101_20211231" id="F_000030">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001260990_20210101_20211231" id="F_000019">62-1715807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001260990_20210101_20211231" id="F_000020">12230 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001260990_20210101_20211231" id="F_000021">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001260990_20210101_20211231" id="F_000022">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001260990_20210101_20211231" id="F_000023">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001260990_20210101_20211231" id="F_000024">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001260990_20210101_20211231" id="F_000025">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001260990_20210101_20211231" id="F_000026">434-1113</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001260990_20210101_20211231" id="F_000028">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001260990_20210101_20211231" id="F_000007">ONCT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001260990_20210101_20211231" id="F_000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001260990_20210101_20211231" id="F_000010">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001260990_20210101_20211231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001260990_20210101_20211231" id="F_000014">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001260990_20210101_20211231" id="F_000027">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="C_0001260990_20210101_20211231" id="F_000012">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001260990_20210101_20211231" id="F_000013">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="C_0001260990_20210101_20211231" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001260990_20210101_20211231" id="F_000031">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001260990_20210101_20211231" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001260990_20210630"
      decimals="-5"
      id="F_000017"
      unitRef="U_iso4217USD">212200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001260990_20220310"
      decimals="INF"
      id="F_000016"
      unitRef="U_xbrlishares">49429054</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000034">Portions of the Registrant&#x2019;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#x2019;s 2022 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#x2019;s fiscal year ended December 31, 2021. </dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="C_0001260990_20210101_20211231" id="F_000035">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001260990_20210101_20211231" id="F_000036">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">90765000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">116737000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">2088000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">1266000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">92853000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">118003000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">75000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">657000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">766000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">93585000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">118809000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">1959000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">1143000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">3431000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">3042000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">1633000</us-gaap:DeferredRevenue>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">75000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">5465000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">5858000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000073"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000074"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000075"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000076"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000077"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000081"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000082"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">49429000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">49429000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">49000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">202201000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">195699000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">-114130000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">-82797000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">88120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">112951000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">93585000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">118809000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">4315000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">3375000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">24086000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">12544000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">11595000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">8373000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">35681000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">20917000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">-31366000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">-17542000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">301000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">33000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">16000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">33000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">317000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-31333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">-17225000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001260990_20210101_20211231"
      decimals="2"
      id="F_000106"
      unitRef="U_iso4217USD_xbrlishares">-0.64</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001260990_20200101_20201231"
      decimals="2"
      id="F_000107"
      unitRef="U_iso4217USD_xbrlishares">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000108"
      unitRef="U_xbrlishares">49321000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000109"
      unitRef="U_xbrlishares">20305000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-31333000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-17225000</us-gaap:ProfitLoss>
    <onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">301000</onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">5875000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">1556000</us-gaap:ShareBasedCompensation>
    <onct:NoncashLeaseExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">169000</onct:NoncashLeaseExpense>
    <onct:NoncashLeaseExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">150000</onct:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">713000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">529000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">816000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">272000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">399000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">739000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-169000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-150000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-1633000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-2007000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-26589000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-17495000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">301000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <onct:ProceedsFromStockOptionsExercisedAndWarrantExercises
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">617000</onct:ProceedsFromStockOptionsExercisedAndWarrantExercises>
    <onct:ProceedsFromStockOptionsExercisedAndWarrantExercises
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">4000</onct:ProceedsFromStockOptionsExercisedAndWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">113876000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">617000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">114181000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-25972000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">96686000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">116737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">20051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">90765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">116737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <onct:CashlessExerciseOfWarrants
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">1836000</onct:CashlessExerciseOfWarrants>
    <onct:FairValueOfWarrantsIssuedToPlacementAgent
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">5325000</onct:FairValueOfWarrantsIssuedToPlacementAgent>
    <onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">301000</onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan>
    <us-gaap:StockIssued1
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">415000</us-gaap:StockIssued1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000145"
      unitRef="U_xbrlishares">15387000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">79869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-65572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">14312000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onct:ExerciseOfCashlessWarrantShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000153"
      unitRef="U_xbrlishares">36000</onct:ExerciseOfCashlessWarrantShares>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">13000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">13000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">11103000</us-gaap:PaymentsOfStockIssuanceCosts>
    <onct:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">33374000</onct:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">34000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">113842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">113876000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">415000</onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash>
    <onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">415000</onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">1556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">1556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">-17225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">-17225000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000166"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">195699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-82797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">112951000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000171"
      unitRef="U_xbrlishares">108000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">415000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">415000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onct:ExerciseOfCashlessWarrantShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000174"
      unitRef="U_xbrlishares">459000</onct:ExerciseOfCashlessWarrantShares>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000175"
      unitRef="U_xbrlishares">60000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">202000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">202000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">10000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">10000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">5875000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">5875000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">-31333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-31333000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000184"
      unitRef="U_xbrlishares">49429000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">202201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-114130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">88120000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000190">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Description&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;Business,&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Basis&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;Presentation&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;Summary&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;Significant&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;Accounting&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Policies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Description of Business&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Oncternal Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;Oncternal,&#x201d; or the &#x201c;combined company&#x201d;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#x2019;s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the Company had $90.8 million in cash and cash equivalents and no debt. The Company believes it has sufficient cash to&lt;span style="color:#000000;"&gt; fund its projected operating requirements for at least twelve months from the date of issuance&lt;/span&gt;. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $114.1 million as of December 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has capacity to issue $50.0 million of additional shares of common stock under its recently established and unused ATM program. There can be no assurance that the Company will be able to sell any shares of its common stock under the ATM Program or regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM Program may be at prices that result in additional dilution to existing stockholders of the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;prepared&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;accordance&lt;/span&gt;&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; GAAP.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;preparation&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;accompanying&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;notes&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;requires&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;make&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and assumptions &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;that &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;impact &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;reported &lt;span style="letter-spacing:0.15pt;"&gt;amounts of &lt;/span&gt;assets, &lt;span style="letter-spacing:0.15pt;"&gt;liabilities, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;revenues and expenses and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;disclosure &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;contingent &lt;/span&gt;assets &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;liabilities. &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Significant &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;consist &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of those &lt;/span&gt;used to determine &lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;fair &lt;span style="letter-spacing:0.15pt;"&gt;value of the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s &lt;/span&gt;stock-based awards&lt;span style="letter-spacing:0.15pt;"&gt;, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;those &lt;/span&gt;used to determine grant &lt;span style="letter-spacing:0.1pt;"&gt;revenue and &lt;/span&gt;accruals for research &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;development &lt;/span&gt;costs. &lt;span style="letter-spacing:0.15pt;"&gt;Although &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these &lt;/span&gt;estimates are based &lt;span style="letter-spacing:0.15pt;"&gt;on the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;knowledge&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;current&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;events&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;actions&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;undertake&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;future,&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;actual&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;results&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;ultimately&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;materially&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;differ&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;assumptions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accruals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. As of December 31, 2021, the Company&#x2019;s clinical trial accrual balance of $0.5 million is included in accrued liabilities. The Company&#x2019;s related clinical trial expenses are included in research and development expenses of $24.1 million and $12.5 million at December 31, 2021 and December 31, 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenue from certain grant awards or a research subaward (the &#x201c;Grant Awards&#x201d;)(see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2021 and 2020, the Company had a grant receivable of $0.4 million and deferred grant revenue of &lt;span style="color:#000000;"&gt;$1.6 &lt;/span&gt;million, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;been included in the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;financial statements. Under this method, deferred tax assets and liabilities are determined &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on the basis of&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 7,000 shares and 25,000 shares from the weighted-average number of common shares outstanding for the years ended December 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2021-10&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance (&#x201c;ASU 2021-10&#x201d;). The FASB issued the ASU to improve transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements.&#160;&#160;The disclosure requirements in ASU 2021-10 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard (IAS) 20,&#160;Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model.&#160;ASU 2021-10 requires the entity to disclose the nature and significant terms and conditions of the transaction, accounting policies used to account for the transaction, and line items in the financial statements affected by the transaction. ASU 2021-10 is effective for annual periods beginning &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;after December 15, 202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Early adoption is permitted, including adoption in an interim period&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company elected to early adopt ASU 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;under the prospective method of transition effective &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021, and&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; determined that &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;there was no cumulative effect to be recognized &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;upon &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;early adoption.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Standards Not Yet Adopted&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&#x202f;&lt;span style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;: &lt;span style="font-style:italic;"&gt;Measurement of Credit Losses on Financial Statements &lt;/span&gt;(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share&lt;/span&gt; (Topic 260), &lt;span style="font-style:italic;"&gt;Debt-Modifications and Extinguishments&lt;/span&gt; (Subtopic 470-50), &lt;span style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/span&gt; (Topic 718), and &lt;span style="font-style:italic;"&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;(Subtopic 815-40):&lt;span style="font-style:italic;"&gt; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;, which intends to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&#160;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000199">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <onct:LiquidityAndGoingConcernPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000200">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the Company had $90.8 million in cash and cash equivalents and no debt. The Company believes it has sufficient cash to&lt;span style="color:#000000;"&gt; fund its projected operating requirements for at least twelve months from the date of issuance&lt;/span&gt;. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $114.1 million as of December 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity or debt offerings or other sources, including potential collaborations, strategic alliances and other similar licensing arrangements in both the short term and long term. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our pipeline development programs, extend payment terms with suppliers, or liquidate assets where possible. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has capacity to issue $50.0 million of additional shares of common stock under its recently established and unused ATM program. There can be no assurance that the Company will be able to sell any shares of its common stock under the ATM Program or regarding the price at which it will be able to sell any such shares, and any sales of shares of its common stock under the ATM Program may be at prices that result in additional dilution to existing stockholders of the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company's ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, its ability to generate positive data from its clinical trials and preclinical studies, the condition of the capital markets and the other risks, many of which are dependent on factors outside of its control. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&lt;/p&gt;</onct:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000223"
      unitRef="U_iso4217USD">90800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000222"
      unitRef="U_iso4217USD">-114100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000224"
      unitRef="U_xbrlishares">50000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:UseOfEstimates contextRef="C_0001260990_20210101_20211231" id="F_000201">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;prepared&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;accordance&lt;/span&gt;&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; GAAP.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;preparation&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;accompanying&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;notes&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;requires&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;make&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and assumptions &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;that &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;impact &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;reported &lt;span style="letter-spacing:0.15pt;"&gt;amounts of &lt;/span&gt;assets, &lt;span style="letter-spacing:0.15pt;"&gt;liabilities, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;revenues and expenses and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;disclosure &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;contingent &lt;/span&gt;assets &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;liabilities. &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Significant &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;consist &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of those &lt;/span&gt;used to determine &lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;fair &lt;span style="letter-spacing:0.15pt;"&gt;value of the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s &lt;/span&gt;stock-based awards&lt;span style="letter-spacing:0.15pt;"&gt;, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;those &lt;/span&gt;used to determine grant &lt;span style="letter-spacing:0.1pt;"&gt;revenue and &lt;/span&gt;accruals for research &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;development &lt;/span&gt;costs. &lt;span style="letter-spacing:0.15pt;"&gt;Although &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these &lt;/span&gt;estimates are based &lt;span style="letter-spacing:0.15pt;"&gt;on the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;knowledge&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;current&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;events&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;actions&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;undertake&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;future,&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;actual&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;results&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;ultimately&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;materially&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;differ&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000202">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <onct:ConcentrationRiskCreditRiskPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000203">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/p&gt;</onct:ConcentrationRiskCreditRiskPolicyTextBlock>
    <onct:PatentCostsPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000204">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;</onct:PatentCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001260990_20210101_20211231" id="F_000205">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accruals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. As of December 31, 2021, the Company&#x2019;s clinical trial accrual balance of $0.5 million is included in accrued liabilities. The Company&#x2019;s related clinical trial expenses are included in research and development expenses of $24.1 million and $12.5 million at December 31, 2021 and December 31, 2020, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000225"
      unitRef="U_iso4217USD">500000</onct:AccruedClinicalTrials>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20210101_20211231"
      decimals="-5"
      id="F_000226"
      unitRef="U_iso4217USD">24100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000227"
      unitRef="U_iso4217USD">12500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001260990_20210101_20211231" id="F_000206">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000207">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenue from certain grant awards or a research subaward (the &#x201c;Grant Awards&#x201d;)(see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such Grant Awards is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Grant Awards have been met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Grant Awards are on a best-efforts basis and do not require scientific achievement as a performance obligation. The Grant Awards are non-refundable. The costs associated with the Grant Awards are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funds received from the Grant Awards are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Grant Awards are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2021 and 2020, the Company had a grant receivable of $0.4 million and deferred grant revenue of &lt;span style="color:#000000;"&gt;$1.6 &lt;/span&gt;million, respectively.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000229"
      unitRef="U_iso4217USD">400000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000228"
      unitRef="U_iso4217USD">400000</us-gaap:GrantsReceivable>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000231"
      unitRef="U_iso4217USD">1600000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000230"
      unitRef="U_iso4217USD">1600000</us-gaap:DeferredRevenue>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001260990_20210101_20211231" id="F_000208">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000209">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;been included in the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;financial statements. Under this method, deferred tax assets and liabilities are determined &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on the basis of&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000210">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001260990_20210101_20211231"
      decimals="INF"
      id="F_000232"
      unitRef="U_onctsegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000211">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 7,000 shares and 25,000 shares from the weighted-average number of common shares outstanding for the years ended December 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001260990_20210101_20211231"
      decimals="INF"
      id="F_000233"
      unitRef="U_xbrlishares">7000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000234"
      unitRef="U_xbrlishares">25000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000213">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20211231"
      decimals="INF"
      id="F_000235"
      unitRef="U_xbrlishares">4235000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231"
      decimals="INF"
      id="F_000236"
      unitRef="U_xbrlishares">5032000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="INF"
      id="F_000237"
      unitRef="U_xbrlishares">6445000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000238"
      unitRef="U_xbrlishares">2226000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231"
      decimals="INF"
      id="F_000239"
      unitRef="U_xbrlishares">15000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_20210101_20211231"
      decimals="INF"
      id="F_000240"
      unitRef="U_xbrlishares">10680000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000241"
      unitRef="U_xbrlishares">7273000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000212">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU 2021-10&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance (&#x201c;ASU 2021-10&#x201d;). The FASB issued the ASU to improve transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements.&#160;&#160;The disclosure requirements in ASU 2021-10 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard (IAS) 20,&#160;Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model.&#160;ASU 2021-10 requires the entity to disclose the nature and significant terms and conditions of the transaction, accounting policies used to account for the transaction, and line items in the financial statements affected by the transaction. ASU 2021-10 is effective for annual periods beginning &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;after December 15, 202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Early adoption is permitted, including adoption in an interim period&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company elected to early adopt ASU 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;under the prospective method of transition effective &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021, and&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; determined that &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;there was no cumulative effect to be recognized &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;upon &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;early adoption.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Standards Not Yet Adopted&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&#x202f;&lt;span style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;: &lt;span style="font-style:italic;"&gt;Measurement of Credit Losses on Financial Statements &lt;/span&gt;(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share&lt;/span&gt; (Topic 260), &lt;span style="font-style:italic;"&gt;Debt-Modifications and Extinguishments&lt;/span&gt; (Subtopic 470-50), &lt;span style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/span&gt; (Topic 718), and &lt;span style="font-style:italic;"&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;(Subtopic 815-40):&lt;span style="font-style:italic;"&gt; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;, which intends to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000191">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Balance Sheet Details&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested share liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000214">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;154&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested share liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">779000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">412000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">518000</onct:AccruedClinicalTrials>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">980000</onct:AccruedClinicalTrials>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">154000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">77000</us-gaap:AccruedProfessionalFeesCurrent>
    <onct:AccruedUnvestedShareLiability
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">10000</onct:AccruedUnvestedShareLiability>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">1955000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">1528000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">25000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">35000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">3431000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">3042000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000192">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments, Contingencies and Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense was $0.2 million for the years ended December 31, 2021 and 2020. On May 22, 2019, the Company entered into an office sublease agreement for 4,677 square feet in San Diego, California (&#x201c;San Diego Lease&#x201d;) which expired on March 31, 2021. On March 17, 2021, the Company entered into a direct lease with the landlord for the same facility (the &#x201c;San Diego Lease&#x201d;) which expires on May 31, 2022. Base rent under the San Diego Lease is approximately $77,000 for the remainder of the lease term and the monthly rent expense is being recognized on a straight-line basis over the lease term. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a 10.0% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. As of December 31, 2021, the Company has recognized a net operating lease right-of-use asset and a lease liability of $75,000 that matures in May 2022, which has a weighted average remaining lease term of 0.42 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Related Party Transactions&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, the Company engaged Newfront Insurance as its primary insurance broker. The son of Richard Vincent, the Company&#x2019;s Chief Financial Officer, acted as the Company&#x2019;s agent at Newfront Insurance. During the years ended December 31, 2021 and 2020, the Company paid total related policy premiums of $1.8 million and $1.4 million, respectively, for which Mr. Vincent&#x2019;s son received a commission of $0.1 million. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#x201c;SPH USA&#x201d;) entered into a Materials Supply and Services Agreement (&#x201c;SPH USA Services Agreement&#x201d;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During the year ended December&#160;31, 2021, the Company recorded amounts receivable from SPH USA related to statements of work totaling $0.4 million (see Note 4). SPH USA is the Company&#x2019;s largest stockholder and an affiliate of two of the Company&#x2019;s directors.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the securities purchase agreements and underwritten offering, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner and Michael G. Carter (see Note 6).&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <onct:RentExpense
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20201231"
      decimals="-5"
      id="F_000256"
      unitRef="U_iso4217USD">200000</onct:RentExpense>
    <onct:RentExpense
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20211231"
      decimals="-5"
      id="F_000255"
      unitRef="U_iso4217USD">200000</onct:RentExpense>
    <us-gaap:NetRentableArea
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522"
      decimals="0"
      id="F_000257"
      unitRef="U_utrsqft">4677</us-gaap:NetRentableArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522"
      id="F_000258">2021-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317"
      id="F_000259">2022-05-31</us-gaap:LeaseExpirationDate1>
    <onct:RemainderOfLeaseTermBaseRent
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522"
      decimals="0"
      id="F_000260"
      unitRef="U_iso4217USD">77000</onct:RemainderOfLeaseTermBaseRent>
    <onct:RemainderOfLeaseTermBaseRent
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317"
      decimals="0"
      id="F_000261"
      unitRef="U_iso4217USD">77000</onct:RemainderOfLeaseTermBaseRent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231"
      decimals="3"
      id="F_000262"
      unitRef="U_xbrlipure">0.100</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231"
      decimals="0"
      id="F_000263"
      unitRef="U_iso4217USD">75000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20211231"
      id="F_000264">P0Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="-5"
      id="F_000265"
      unitRef="U_iso4217USD">1800000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000266"
      unitRef="U_iso4217USD">1400000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:InsuranceCommissions
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20210101_20211231"
      decimals="-5"
      id="F_000267"
      unitRef="U_iso4217USD">100000</us-gaap:InsuranceCommissions>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20211231"
      decimals="-5"
      id="F_000268"
      unitRef="U_iso4217USD">400000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000193">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;License, Collaboration, Research Subaward Agreement and CVR Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Georgetown University (&#x201c;Georgetown&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2014, the Company entered into an Exclusive License Agreement (the &#x201c;Georgetown License Agreement&#x201d;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $10,000 until the first commercial sale occurs, (ii) is required to make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of December 31, 2021, the Company had not triggered or made any milestone payments under the Georgetown License Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with 90 days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least 60 days&#x2019; written notice.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;)&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2014, the Company entered into a collaboration agreement (as amended, the &#x201c;Collaboration&#x201d;) with MD Anderson, which provides for the conduct of preclinical and clinical research for ONCT-216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $1.0 million based on net product sales. In July 2020 and September 2021, the Company entered into two research agreements with MD Anderson for certain services up to an aggregate cost of $0.8 million. The amount recorded as research and development expense for the year ended December 31, 2021 and 2020 was $0.1 million.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Agreements with the Regents of the University of California (the &#x201c;Regents&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, and as amended and restated in August 2018, and as amended in March and May 2019 and February 2021, the Company entered into a license agreement (as amended and restated, the &#x201c;Regents License Agreement&#x201d;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $0.5 million was paid and 107,108 shares of common stock were issued, (ii) $25,000 in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain&#160;annual patent costs, (iv) certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $1.0 million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: &lt;span style="letter-spacing:0.15pt;"&gt;(i) $25,000 in &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;license&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;maintenance&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;fees&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;research&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;development&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;expense for each of the&lt;/span&gt; years ended December 31, 2021 and 2020, and (ii)&lt;span style="letter-spacing:-0.6pt;"&gt; approximately $0.3 million and&lt;/span&gt; $0.2 million&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;patent&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;costs&lt;/span&gt; as general &lt;span style="letter-spacing:0.1pt;"&gt;and administrative &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;expense &lt;/span&gt;for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company believes it has met its obligations under the Regents License Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; anniversary of the first commercial sale of a licensed product. &lt;span style="color:#000000;"&gt;The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. &lt;/span&gt;The Company may terminate the agreement at any time upon at least 60 days&#x2019; written notice.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement with the Regents for further research on a ROR1 therapeutic development program. Under this &lt;span style="-sec-ix-hidden:F_000292"&gt;five-year&lt;/span&gt; agreement that expired in 2021, the Regents was paid an aggregate of $3.6 million. The Company recorded $0.3 million and $0.5 million in research and development expense under this agreement&#160;for each of the years ended December 31, 2021 and 2020, respectively. Such costs are includable as part of the Company&#x2019;s annual diligence obligations under the Regents License Agreement. Effective January 1, 2022, the Company entered into a Research Agreement (the &#x201c;Research Agreement&#x201d;) with the Regents for further research on a ROR1 therapeutic development program. Under this &lt;span style="-sec-ix-hidden:F_000293"&gt;four-year&lt;/span&gt; agreement that expires on December 31, 2025, the Regents will have an aggregate budget of $1.6 million, with quarterly payments of $125,000 in 2022, $131,250 in 2023, and $137,813 in 2024. &#160;&#160;  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;University of Tennessee Research Foundation (&#x201c;UTRF&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&#160;2015, and as amended and restated in March 2022, the Company and UTRF entered into a license agreement (the &#x201c;DAARI License Agreement&#x201d;; formerly known as the SARD License Agreement) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader technologies owned or controlled by UTRF, including all improvements thereto, which is now known as the dual action androgen receptor inhibitor, or DAARI program. Under the DAARI License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the DAARI program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expenses under this agreement of $0.1 million and $0.2 million for each of the years ended December 31, 2021 and 2020, respectively. &lt;span style="color:#000000;"&gt;As of December 31, 2021, the Company believes it has met its obligations under the DAARI License Agreement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) Award&lt;span style="font-size:6pt;font-weight:normal;font-style:normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2017,&lt;span style="color:#000000;"&gt; and as amended and restated in December 2020,&lt;/span&gt; CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance the Company&#x2019;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia (&#x201c;CLL&#x201d;) and mantle cell lymphoma (&#x201c;MCL&#x201d;). &lt;span style="color:#000000;"&gt;This study is known as CIRM-0001, or Cirmtuzumab and Ibrutinib for Relapsed Lymphoma or Leukemia &lt;/span&gt;(&#x201c;CIRLL&#x201d;)&lt;span style="color:#000000;"&gt; study&lt;/span&gt;. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $14.4 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received subaward payments of $2.2 million and $1.4 million in the years ended December 31, 2021 and 2020, respectively, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the years ended December 31, 2021 and 2020, the Company&#x2019;s grant revenue was $4.2 million and $3.4 million, respectively. Related qualifying subaward costs for the years ended December 31, 2021 and 2020 were $8.8 million and $5.2 million, respectively. As of December 31, 2021, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, CIRM awarded a $5.8 million grant to the researchers at the University of California San Diego School of Medicine (&#x201c;UC San Diego&#x201d;) to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $1.0 million in contingency funds if required during the grant period. The Company recorded no research and development expense, and no contingency funds have been provided under such CIRM award for the years ended December 31, 2021 and 2020. The grant expired in 2021 and the Company believes there are no obligations as of December 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The National Institutes of Health (&#x201c;NIH&#x201d;) Grant Awards&lt;span style="font-size:12pt;font-weight:normal;font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2021, the NIH awarded the Company two research and development grants for up to $2.2 million to support preclinical activities for the Company&#x2019;s ONCT-216 and ONCT-534 programs, including $0.7 million payable to subawardees. Under the terms of the grant awards, the Company is entitled to receive reimbursement in arrears of incurring allowable expenditures. The earned NIH funds are non-refundable and the Company is required to provide periodic progress performance reports. During the year ended December 31, 2021, the Company received no award payments from the NIH and recorded $143,000 in grant revenue and unbilled receivables which has been included in prepaid and other assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Clinical Trial and Supply Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, and as amended in August 2019, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#x201c;Pharmacyclics&#x201d;) to supply ibrutinib for the Company&#x2019;s Phase 1/2 clinical trial evaluating zilovertamab in combination with ibrutinib. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;SPH USA, a Related Party&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Development Agreement (&#x201c;LDA&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018,&lt;span style="color:#000000;"&gt; and as amended in August 2020, &lt;/span&gt;the Company entered into the LDA with SPH USA for: (i) the territory of the People&#x2019;s Republic of China, Hong Kong, Macau, and Taiwan (&#x201c;Greater China&#x201d;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#x2019;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;i&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) SPH USA on a country&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;/region-&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;by&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;country&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;/region&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;either&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;party&lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in&lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;event&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;other&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;party&lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;declares&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;insolvency&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;or&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;bankruptcy. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There has been no significant activity under this agreement for the years ended December 31, 2021 and 2020. See Note 3.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingent Value Rights Agreement (&#x201c;CVR Agreement&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the GTx merger agreement entered into in June 2019 (the &#x201c;Merger&#x201d;), the Company, a representative of holders of the CVRs, and Computershare, Inc. as rights agent entered into the CVR Agreement. Pursuant to the CVR Agreement, the Company&#x2019;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#x2019;s common stock held immediately prior to the Merger. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As amended on November 1, 2021, the CVR Agreement entitles holders of CVRs to receive: (i)&#160;50% of certain net proceeds received by the Company during the 15-year period after the closing of the Merger (the &#x201c;CVR Term&#x201d;) from a transaction, if any, resulting in the grant, sale, or transfer of DAARI technology to a third party that occurs during the 10-year period after the closing of the Merger (or in the 11th year if based on a term sheet approved during the initial 10-year period); and (ii) 5% of net sales of products by Parent or its affiliates during the CVR Term incorporating the DAARI technology. As of December 31, 2021, no transactions or net sales relating to the DAARI technology had occurred.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <onct:LicenseMaintenanceFeeToBePaidAndPaymentMade
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231"
      decimals="0"
      id="F_000269"
      unitRef="U_iso4217USD">10000</onct:LicenseMaintenanceFeeToBePaidAndPaymentMade>
    <onct:CollaborativeArrangementPotentialMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231"
      decimals="INF"
      id="F_000270"
      unitRef="U_iso4217USD">200000</onct:CollaborativeArrangementPotentialMilestonePayments>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231"
      id="F_000272">P90D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231"
      id="F_000273">P30D</onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount>
    <onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231"
      id="F_000274">P60D</onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment>
    <onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20211231"
      id="F_000275">P60D</onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231"
      decimals="-5"
      id="F_000276"
      unitRef="U_iso4217USD">1000000.0</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731"
      decimals="-5"
      id="F_000277"
      unitRef="U_iso4217USD">800000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231"
      decimals="-5"
      id="F_000278"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20211231"
      decimals="-5"
      id="F_000279"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:UpfrontLicenseFeesPaid
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="-5"
      id="F_000280"
      unitRef="U_iso4217USD">500000</onct:UpfrontLicenseFeesPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="INF"
      id="F_000281"
      unitRef="U_xbrlishares">107108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:AnnualLicenseMaintenanceFees
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231"
      decimals="0"
      id="F_000282"
      unitRef="U_iso4217USD">25000</onct:AnnualLicenseMaintenanceFees>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531"
      decimals="INF"
      id="F_000283"
      unitRef="U_iso4217USD">10000000.0</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531"
      decimals="INF"
      id="F_000284"
      unitRef="U_iso4217USD">12500000</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="-5"
      id="F_000285"
      unitRef="U_iso4217USD">75000000.0</onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels>
    <onct:AdvanceLicensedAssets
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531"
      decimals="INF"
      id="F_000286"
      unitRef="U_iso4217USD">1000000.0</onct:AdvanceLicensedAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231"
      decimals="0"
      id="F_000287"
      unitRef="U_iso4217USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20211231"
      decimals="0"
      id="F_000288"
      unitRef="U_iso4217USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20211231"
      decimals="-5"
      id="F_000290"
      unitRef="U_iso4217USD">300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231"
      decimals="-5"
      id="F_000289"
      unitRef="U_iso4217USD">200000</us-gaap:GeneralAndAdministrativeExpense>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20211231"
      id="F_000291">P60D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <onct:ResearchAgreementResearchFundingAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000294"
      unitRef="U_iso4217USD">3600000</onct:ResearchAgreementResearchFundingAmount>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000299"
      unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000300"
      unitRef="U_iso4217USD">500000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:ResearchAgreementResearchFundingAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20211202_20220101"
      decimals="-5"
      id="F_000295"
      unitRef="U_iso4217USD">1600000</onct:ResearchAgreementResearchFundingAmount>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyTwoMember_20211202_20220101"
      decimals="0"
      id="F_000296"
      unitRef="U_iso4217USD">125000</onct:ResearchAgreementResearchFundingAmountPayable>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyThreeMember_20211202_20220101"
      decimals="0"
      id="F_000297"
      unitRef="U_iso4217USD">131250</onct:ResearchAgreementResearchFundingAmountPayable>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementTwoThousandTwentyFourMember_20211202_20220101"
      decimals="0"
      id="F_000298"
      unitRef="U_iso4217USD">137813</onct:ResearchAgreementResearchFundingAmountPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000301"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000302"
      unitRef="U_iso4217USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831"
      decimals="-5"
      id="F_000303"
      unitRef="U_iso4217USD">18300000</onct:ResearchAndDevelopmentGrants>
    <onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831"
      decimals="-5"
      id="F_000304"
      unitRef="U_iso4217USD">14400000</onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod>
    <onct:SubawardPaymentsReceived
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231"
      decimals="-5"
      id="F_000305"
      unitRef="U_iso4217USD">2200000</onct:SubawardPaymentsReceived>
    <onct:SubawardPaymentsReceived
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000306"
      unitRef="U_iso4217USD">1400000</onct:SubawardPaymentsReceived>
    <us-gaap:Revenues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231"
      decimals="-5"
      id="F_000307"
      unitRef="U_iso4217USD">4200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000308"
      unitRef="U_iso4217USD">3400000</us-gaap:Revenues>
    <onct:RelatedQualifyingSubawardCosts
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20211231"
      decimals="-5"
      id="F_000309"
      unitRef="U_iso4217USD">8800000</onct:RelatedQualifyingSubawardCosts>
    <onct:RelatedQualifyingSubawardCosts
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000310"
      unitRef="U_iso4217USD">5200000</onct:RelatedQualifyingSubawardCosts>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031"
      decimals="-5"
      id="F_000311"
      unitRef="U_iso4217USD">5800000</onct:ResearchAndDevelopmentGrants>
    <onct:AmountAgreedToBeProvidedInContingencyFunds
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031"
      decimals="INF"
      id="F_000312"
      unitRef="U_iso4217USD">1000000.0</onct:AmountAgreedToBeProvidedInContingencyFunds>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-6"
      id="F_000313"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="-6"
      id="F_000314"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210801_20210831"
      decimals="-5"
      id="F_000315"
      unitRef="U_iso4217USD">2200000</onct:ResearchAndDevelopmentGrants>
    <onct:AccruedClinicalTrials1
      contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210831"
      decimals="-5"
      id="F_000316"
      unitRef="U_iso4217USD">700000</onct:AccruedClinicalTrials1>
    <us-gaap:Revenues
      contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210101_20211231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">0</us-gaap:Revenues>
    <onct:AwardPaymentsReceived
      contextRef="C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210101_20211231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">143000000</onct:AwardPaymentsReceived>
    <onct:PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101"
      decimals="2"
      id="F_000319"
      unitRef="U_xbrlipure">0.50</onct:PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights>
    <onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101"
      id="F_000321">P15Y</onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR>
    <onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101"
      id="F_000322">P10Y</onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement>
    <onct:PercentageOfNetSales
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20211002_20211101"
      decimals="2"
      id="F_000320"
      unitRef="U_xbrlipure">0.05</onct:PercentageOfNetSales>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000194">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Debt&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Paycheck Protection Program Loan Payable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020, the Company received a $0.3 million unsecured loan, bearing interest at 1%, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;), a program implemented by the U.S. Small Business Administration (the &#x201c;SBA&#x201d;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) (the &#x201c;PPP Loan&#x201d;). In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. &lt;span style="color:#000000;"&gt;The loan forgiveness was recorded as other income of $0.3 million in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531"
      decimals="-5"
      id="F_000323"
      unitRef="U_iso4217USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531"
      decimals="INF"
      id="F_000324"
      unitRef="U_xbrlipure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20210101_20211231"
      decimals="-5"
      id="F_000325"
      unitRef="U_iso4217USD">300000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000195">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Amended and Restated Articles of Incorporation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 25, 2021, the Company&#x2019;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock, each with a par value of $0.001 per share. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.78%;text-indent:-3.78%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Securities Purchase Agreements &lt;span style="color:#000000;"&gt;and &lt;/span&gt;Underwritten Offering&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;May Purchase Agreement&#x201d;) with several institutional and individual investors for the concurrent sale of: (i) 1,943,636 shares of the Company&#x2019;s common stock in a registered direct offering, resulting in net proceeds of $4.4 million, after deducting the placement agent&#x2019;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 971,818 shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.5725. In addition, the Company&lt;span style="color:#000000;"&gt; issued &lt;/span&gt;warrants to purchase 116,618 &lt;span style="color:#000000;"&gt;shares of &lt;/span&gt;common &lt;span style="color:#000000;"&gt;stock at &lt;/span&gt;an exercise price of $3.2156&lt;span style="color:#000000;"&gt; per share &lt;/span&gt;to the placement agent, H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d; or the &#x201c;placement agent&#x201d;) as part of its compensation, which warrants were immediately exercisable and expire on &lt;span style="color:#000000;"&gt;May 21, 2025&lt;/span&gt;. &lt;span style="color:#000000;"&gt;An investor participating in the transaction included an entity affiliated with David F. Hale, the chairman of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;July Purchase Agreement&#x201d;) with several institutional and individual investors for the concurrent sale of: (i) 2,581,867 shares of the Company&#x2019;s common stock in a registered direct offering, resulting in net proceeds of $5.7 million, after deducting the placement agent&#x2019;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;warrants, and (ii) unregistered warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,290,933&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3825&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.32&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share and expire on &lt;/span&gt;&lt;span style="color:#000000;"&gt;January 21, 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company issued warrants to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;154,912&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.9781&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on &lt;/span&gt;&lt;span style="color:#000000;"&gt;July 21, 2025&lt;/span&gt;&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, and Daniel L. Kisner, a member of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;August Underwriting Agreement&#x201d;) with Wainwright for the sale of 2,428,886 shares of the Company&#x2019;s common stock at a price to the public of $2.10 per share, resulting in net proceeds of $4.4 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 145,733 shares of common stock at an exercise price of $2.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on August 27, 2025. An investor participating in the transaction included Michael G. Carter, a member of the Company&#x2019;s board of directors.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;November Underwriting Agreement&#x201d;) with Wainwright for the sale of 7,258,065 shares of the Company&#x2019;s common stock at a price to the public of $3.10 per share, resulting in net proceeds of $20.4 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 435,484 shares of common stock at an exercise price of $3.875 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on &lt;span style="color:#000000;"&gt;November 17, 2025&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;December Underwriting Agreement&#x201d;) with Wainwright for the sale of 19,161,667 shares of the Company&#x2019;s common stock at a price to the public of $4.50 per share, resulting in net proceeds of $79.0 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase 1,149,700 shares of common stock at an exercise price of $5.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on &lt;span style="color:#000000;"&gt;December 9, 2025&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, &lt;span style="color:#000000;"&gt;which expired in 2021&lt;/span&gt;. &lt;span style="color:#000000;"&gt;In December 2021, the Company executed an at-the-market (&#x201c;ATM&#x201d;) facility of up to $50.0 million.&lt;/span&gt; During the year ended December 31, 2021, the Company did not sell shares under the ATM. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Warrants&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:85.12%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares Underlying Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Remaining Contractual Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000376"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,265,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000377"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(796,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,234,910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000378"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021 and 2020, all warrants met the criteria for classification in stockholders&#x2019; equity.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contemporaneous with the Merger&#160;&#160;closing: (i) Private Oncternal&#x2019;s 2015 Equity Incentive Plan, as amended (the &#x201c;2015 Plan&#x201d;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#x201c;2019 Plan&#x201d;) under which the sum of: (a) 1,678,571&#160;shares of common stock, (b) 275,579 shares of common stock previously outstanding under the GTx 2013 Equity Incentive Plan that were cancelled became available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At December&#160;31, &lt;span style="color:#000000;"&gt;2021, 1,842,432&lt;/span&gt; shares remain available for future issuance under the 2019 Plan and Inducement Plan (as defined below).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to 631,120 shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a &lt;span style="-sec-ix-hidden:F_000385"&gt;four-year&lt;/span&gt; period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan was terminated as to new grants in June 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants. In general, the stock options issued under the 2019 Plan expire ten years from the date of grant and vest over a four-year period. Certain stock option grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 11, 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;Inducement Plan&#x201d;). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#x201c;inducement exception&#x201d; provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#x2019;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan. As amended on May 25, 2021 and December 16, 2021, the Company has reserved 2,800,000 shares of common stock under the Inducement Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.7%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,884,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(439,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(107,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.84&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,444,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000398"&gt;8.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;613,190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,440,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000399"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;488,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value per share of option grants for the years ended December 31, 2021 and 2020 was $4.35 and $2.53 per share, respectively.&#160;&#160;The intrinsic value is calculated as the difference between the fair value of the Company&#x2019;s common stock at the time of the option exercise and the exercise price of that stock option. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $419,755 and $10,413. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000410"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000411"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility. &lt;span style="font-style:normal;"&gt;The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term. &lt;span style="font-style:normal;"&gt;The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected term assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Segoe UI;font-style:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate. &lt;span style="font-style:normal;"&gt;The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield. &lt;span style="font-style:normal;"&gt;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,136&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,739&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2021, the total compensation cost related to nonvested awards not yet recognized was $17.4 million and the weighted-average period over which it is expected to be recognized was 3.2 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Issuance&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock available for issuance under equity&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; plans&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20210525"
      decimals="INF"
      id="F_000326"
      unitRef="U_xbrlishares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20210525"
      decimals="INF"
      id="F_000327"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20210525"
      decimals="INF"
      id="F_000328"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      decimals="INF"
      id="F_000329"
      unitRef="U_xbrlishares">1943636</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      decimals="-5"
      id="F_000330"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="INF"
      id="F_000331"
      unitRef="U_xbrlishares">971818</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="4"
      id="F_000332"
      unitRef="U_iso4217USD_xbrlishares">2.5725</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="INF"
      id="F_000333"
      unitRef="U_xbrlishares">116618</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="4"
      id="F_000334"
      unitRef="U_iso4217USD_xbrlishares">3.2156</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      id="F_000335">2025-05-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      decimals="INF"
      id="F_000336"
      unitRef="U_xbrlishares">2581867</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      decimals="-5"
      id="F_000337"
      unitRef="U_iso4217USD">5700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="INF"
      id="F_000338"
      unitRef="U_xbrlishares">1290933</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="4"
      id="F_000339"
      unitRef="U_iso4217USD_xbrlishares">2.3825</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="2"
      id="F_000340"
      unitRef="U_iso4217USD_xbrlishares">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:CommonStockWarrantsExpirationDate
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      id="F_000341">2026-01-21</onct:CommonStockWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="INF"
      id="F_000342"
      unitRef="U_xbrlishares">154912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="4"
      id="F_000343"
      unitRef="U_iso4217USD_xbrlishares">2.9781</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      id="F_000344">2025-07-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      decimals="INF"
      id="F_000345"
      unitRef="U_xbrlishares">2428886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="2"
      id="F_000348"
      unitRef="U_iso4217USD_xbrlishares">2.10</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      decimals="-5"
      id="F_000346"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="INF"
      id="F_000347"
      unitRef="U_xbrlishares">145733</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="3"
      id="F_000349"
      unitRef="U_iso4217USD_xbrlishares">2.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      id="F_000350">2025-08-27</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      decimals="INF"
      id="F_000351"
      unitRef="U_xbrlishares">7258065</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="2"
      id="F_000354"
      unitRef="U_iso4217USD_xbrlishares">3.10</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      decimals="-5"
      id="F_000352"
      unitRef="U_iso4217USD">20400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="INF"
      id="F_000353"
      unitRef="U_xbrlishares">435484</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="3"
      id="F_000355"
      unitRef="U_iso4217USD_xbrlishares">3.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      id="F_000356">2025-11-17</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      decimals="INF"
      id="F_000357"
      unitRef="U_xbrlishares">19161667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="2"
      id="F_000360"
      unitRef="U_iso4217USD_xbrlishares">4.50</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000358"
      unitRef="U_iso4217USD">79000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="INF"
      id="F_000359"
      unitRef="U_xbrlishares">1149700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="3"
      id="F_000361"
      unitRef="U_iso4217USD_xbrlishares">5.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      id="F_000362">2025-12-09</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <onct:AmountForAtTheMarketFacility
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_onctAtTheMarketFacilityMember_20210101_20211231"
      decimals="-5"
      id="F_000363"
      unitRef="U_iso4217USD">50000000.0</onct:AmountForAtTheMarketFacility>
    <onct:ScheduleOfWarrantActivityTableTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000215">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:85.12%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares Underlying Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Remaining Contractual Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000376"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,265,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000377"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(796,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,234,910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000378"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</onct:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000364"
      unitRef="U_xbrlishares">841424000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000370"
      unitRef="U_iso4217USD_xbrlishares">37.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:WarrantsIssued
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000365"
      unitRef="U_xbrlishares">4265198000</onct:WarrantsIssued>
    <onct:WarrantIssuedPricePerShare
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000371"
      unitRef="U_iso4217USD_xbrlishares">3.47</onct:WarrantIssuedPricePerShare>
    <onct:ExerciseOfWarrants
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000366"
      unitRef="U_xbrlishares">-74781000</onct:ExerciseOfWarrants>
    <onct:WarrantExercisedPricePerShare
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000372"
      unitRef="U_iso4217USD_xbrlishares">3.22</onct:WarrantExercisedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000367"
      unitRef="U_xbrlishares">5031841000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000373"
      unitRef="U_iso4217USD_xbrlishares">9.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ExerciseOfWarrants
      contextRef="C_0001260990_20210101_20211231"
      decimals="INF"
      id="F_000368"
      unitRef="U_xbrlishares">-796931000</onct:ExerciseOfWarrants>
    <onct:WarrantExercisedPricePerShare
      contextRef="C_0001260990_20210101_20211231"
      decimals="INF"
      id="F_000374"
      unitRef="U_iso4217USD_xbrlishares">2.56</onct:WarrantExercisedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000369"
      unitRef="U_xbrlishares">4234910000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000375"
      unitRef="U_iso4217USD_xbrlishares">10.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607"
      decimals="INF"
      id="F_000379"
      unitRef="U_xbrlishares">1678571000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607"
      decimals="INF"
      id="F_000380"
      unitRef="U_xbrlishares">275579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607"
      decimals="2"
      id="F_000381"
      unitRef="U_xbrlipure">0.05</onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20211231"
      decimals="INF"
      id="F_000382"
      unitRef="U_xbrlishares">1842432000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731"
      decimals="INF"
      id="F_000383"
      unitRef="U_xbrlishares">631120</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731"
      id="F_000384">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000216">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s stock option activity under the 2015 Plan, 2019 Plan and Inducement Plan is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.7%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,884,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(439,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(107,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.84&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,444,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000398"&gt;8.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;613,190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,440,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000399"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;488,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000386"
      unitRef="U_xbrlishares">2107625000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="2"
      id="F_000392"
      unitRef="U_iso4217USD_xbrlishares">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000387"
      unitRef="U_xbrlishares">4884800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000393"
      unitRef="U_iso4217USD_xbrlishares">5.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000388"
      unitRef="U_xbrlishares">439684000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000394"
      unitRef="U_iso4217USD_xbrlishares">5.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000389"
      unitRef="U_xbrlishares">107997000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000395"
      unitRef="U_iso4217USD_xbrlishares">3.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000390"
      unitRef="U_xbrlishares">6444744000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="2"
      id="F_000396"
      unitRef="U_iso4217USD_xbrlishares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">613190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000391"
      unitRef="U_xbrlishares">1440122000</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="2"
      id="F_000397"
      unitRef="U_iso4217USD_xbrlishares">3.92</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">488187000</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20211231"
      decimals="2"
      id="F_000402"
      unitRef="U_iso4217USD_xbrlishares">4.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231"
      decimals="2"
      id="F_000403"
      unitRef="U_iso4217USD_xbrlishares">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">419755000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">10413000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      id="F_000217">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000410"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000411"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001260990_20210101_20211231"
      decimals="3"
      id="F_000406"
      unitRef="U_xbrlipure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001260990_20200101_20201231"
      decimals="3"
      id="F_000407"
      unitRef="U_xbrlipure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001260990_20210101_20211231"
      decimals="3"
      id="F_000408"
      unitRef="U_xbrlipure">0.928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001260990_20200101_20201231"
      decimals="3"
      id="F_000409"
      unitRef="U_xbrlipure">0.916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000218">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,136&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,739&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">3136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">2739000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">1012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">5875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">1556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000418"
      unitRef="U_iso4217USD">17400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001260990_20210101_20211231" id="F_000419">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000219">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock available for issuance under equity&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; plans&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000420"
      unitRef="U_xbrlishares">4235000</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000421"
      unitRef="U_xbrlishares">5032000</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000422"
      unitRef="U_xbrlishares">6445000</onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance>
    <onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000423"
      unitRef="U_xbrlishares">2226000</onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20211231"
      decimals="-3"
      id="F_000424"
      unitRef="U_xbrlishares">1842000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="-3"
      id="F_000425"
      unitRef="U_xbrlishares">938000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000426"
      unitRef="U_xbrlishares">12522000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000427"
      unitRef="U_xbrlishares">8196000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <onct:COVID19PandemicAndCARESActDisclosureTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000196">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#FF0000;"/&gt;COVID-19 Pandemic and CARES Act&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#x201c;COVID-19&#x201d;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#x201c;stay-at-home&#x201d; orders, and restricting business functions outside of one&#x2019;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., the Company expects that COVID-19 precautions may directly or indirectly impact the timeline for some of its clinical trials. For example, some of its clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Additionally, the Company&#x2019;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy in China has been delayed. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its consolidated financial statements and determined that there were no material adverse impacts on the Company&#x2019;s results of operations and financial position at December&#160;31, 2021. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP), and authorized the PPP (see Note 5).&#160; The CARES Act had no material impact on the Company&#x2019;s income tax provision for the years ended December&#160;31, 2021 or 2020.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</onct:COVID19PandemicAndCARESActDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000197">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.78%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,579&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,013&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;484&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021 and 2020, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company's deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of the Company's deferred tax assets, management considers all available evidence, both positive and negative.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#x201c;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#x201d; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2021. Accordingly, a valuation allowance of $41.8 million has been recorded to offset this deferred tax asset.&#160;&#160;The valuation allowance increased by $9.3 million and $5.0 million for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2021, the Company had federal and state net operating loss (NOL) carryforwards of approximately $81.5 million and $59.4 million, respectively. Of the federal net operating losses at December&#160;31, 2021, $55.2 million do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in 2033 and 2029, respectively, unless previously utilized. At December&#160;31, 2021, the Company also had federal and state research and development credit carryforwards of approximately $2.1 million and $1.3 million, respectively. The federal research and development credit carryforwards will begin expiring in 2034 unless previously utilized. The state research and development credits do not expire. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#x2019;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a &lt;span style="-sec-ix-hidden:F_000475"&gt;three-year&lt;/span&gt; period. The Company has not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#x2019;s formation due to the complexity and cost associated with such a study and the fact that there may be additional such ownership changes in the future. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December 31, 2021 and 2020, there were no unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#x2019;s 2014 through 2021 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated statements of operations since inception.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000220">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,579&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,013&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">-6579000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">-3617000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">-2013000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">-1113000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <onct:IncomeTaxReconciliationPermanentItems
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">4000</onct:IncomeTaxReconciliationPermanentItems>
    <onct:IncomeTaxReconciliationPermanentItems
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">-65000</onct:IncomeTaxReconciliationPermanentItems>
    <us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">512000</us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions>
    <us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">226000</us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">1099000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">505000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">-131000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20210101_20211231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">9306000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">5074000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000221">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:3.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;484&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">21254000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">17852000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">3051000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">1952000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">484000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">367000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">15847000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">11987000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">1206000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">303000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">24000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">90000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">41866000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">32551000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">41845000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">32540000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">21000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">11000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <onct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">21000</onct:DeferredTaxLiabilitiesRightOfUseAsset>
    <onct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">11000</onct:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001260990_20211231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">21000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">11000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20211231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">41800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001260990_20210101_20211231"
      decimals="-5"
      id="F_000464"
      unitRef="U_iso4217USD">9300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000465"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000466"
      unitRef="U_iso4217USD">81500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000467"
      unitRef="U_iso4217USD">59400000</us-gaap:OperatingLossCarryforwards>
    <onct:OperatingLossCarryforwardsNonExpirePortion
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">55200000</onct:OperatingLossCarryforwardsNonExpirePortion>
    <onct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000469">2033</onct:OperatingLossCarryforwardsExpirationYear>
    <onct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000470">2029</onct:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000471"
      unitRef="U_iso4217USD">2100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000472"
      unitRef="U_iso4217USD">1300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000473">2034</onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
    <onct:CumulativeChangeInOwnershipPercentage
      contextRef="C_0001260990_20210101_20211231"
      decimals="2"
      id="F_000474"
      unitRef="U_xbrlipure">0.50</onct:CumulativeChangeInOwnershipPercentage>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001260990_20211231"
      decimals="INF"
      id="F_000476"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000477"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001260990_20210101_20211231" id="F_000198">
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:AuditorFirmId contextRef="C_0001260990_20210101_20211231" id="F_000037">243</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\3GC\7@R.W#Q2Z8 BKP7>2GG3JK4]MYU99Q"P>0=WT*)7]9<%$SA4&Q<N17
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MEGBUY.P(N$8K;_JBSGYMK?)%2UTH]Y*KMU39R=6:E8+E-,62I.!>JC]5!5(
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M=,#PF :CDI*-4!\VHL_JOL_G?-2.FF4;$JUYGB#,T..>@:/=&"H[96J!N#N
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M_$Z<_P.5";[U>76T A^*@"+*LXIA [?ODL9+%'Q%22]\PX<B84V%D+XFZ1U
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M:^3OIL@'A#K^6R5SV[9VQ?^DV].ZH0'XO;1@W_X#+1#_>,VK?P)02P,$%
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MXZS=K U8GA.*"ZN966CU)5(I!7<.:^43KDZ65.PTRP[?K?5$?-B.5^FL:O-
M;S@BLRSRSLXR5*JI5!Z*>"Y!,E=,&&_2A^V878YQ+F75TMV@&KD.C9&(4[>5
MK=R 9VV\*.62N"15W50J4UQKG'+GA87G\19'&#8\B4"WF*9)^@.JPF6FU?%$
METH5W<).2$<>WP'C8-Z771A]K:U,6^41#XH-$3 M*"OFTXBYL:Q&0"KKX(S0
M'Q6_N1]US X&"BN 1;=\"10.Z4'F%/I<VMOD*[VQBC1K4ZL,Y;]4UF@V&I@$
M_GL:<+=A2NC(1IE(H9$O7#P0/B<UXK2A:$SQI.7>=XY3JGES?%TI.8^M W^/
M#O9#%0>Z0&7+#:(ZL4E9;B+A[%B*59C=[!AQXBK2%?VMZQ PS*;)WBQJ6_*0
M4K[6XA>I(43KK:JV@(M<O*55 98\=F.FA#H%&(4\-%;Q!0EX^Q=S:V[(QHYP
MAI50O =\"?7XA'8 T7=\L$!,#YX[<5XJ*L1+I6%%(>_O@H+:,5^&.%RW]13@
MZ= N]R$FXJ*US,L_%_F[T3=203.,!QC;$=B@7[,UMTNMVCJ4RZ-I<CC,%#:$
MA;U^88R3KJ%PG:O6XZ!4,9N7H*CC8PC&A<MC1MB<A_+&^'/A2LE^TF3:FTW$
MBZ*(5L/DH,;'B.ZGD!%=EU(O2JG$%=)0RXQ:KS)$]?CC]>D.",/-9!@S5Z\$
M5@?9_FH\7'*[(3M.7+=-4W7FR2Z1*MQ#AB'WE;DM6WH/8]&TUK42A^ A<G,/
M?V=EA>BAV92U4)JEM,JT(,T#4R<*1;A7#_/ <Z$745UZ&]AS0RS_H7+B1<)@
ML^76B[&-P^(PZF*@.(=J]&@UX?I@YNL[4&^]C+E<(3$ UL3"B5.MTZ&BM>PQ
MM$LGZF]@D"<1[[@@%(MI I&WE,[)KXCT-\FAH2)D8.(MA+"OB<-[O?"M5KA;
M/*QSEO=%179==4I<:@2ZK1Z<]_T!"K;D(_00>T<-#ZTA'CLBH$0J]W:2P9+:
MWN<0[07/%'QD9#>EJ7HV>5I *""H<?CXE>DI_=I$O-H8UD.('K*CNZ^MX9KC
M4%E6>;Y?HBBA69L7MU@J(8\K;/(4+GG$K(Z["E)Z"8SPL#GW<[54><LM8YAU
M'^T/H//H_D)BEWB9B%>RPDP>ZNA":D65>).(7Y737="7K*=8_3G!3=&B:C>X
M?+J3;+OG3S8^NVH"E_QQR36*M,8OL&%U^'X]C9]MM]OCQR]NDPO(/<9-@:-I
M<K _BO.N?_"F"1]Q<^/Q21A^EO@&)\L;\+XP -H]L(/AJ_[D+U!+ P04
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M2'YYX@-)_]":AN]B9Z9M3<4_5XJ:B#0 WQ<&H38\$(%X.?_M_P%02P,$%
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M!N(-NW]GM:,I\D1F^91T>?OV!_'3[96)@Q<RURH3_Q.(_]85G #?BK5:SSD
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MASDF/,@Q']%-UP:PROH"CR[61H6/'>A[_[K-#@N9 ,L"U-+<CGNS1_&@B\>
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M8!ZXP?DK,)W3E8]X"P$JMJE:TY@[5T53]5*;*I>*#BDJR&82$'QE2S'X)D_
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M?"9*\RL4\T==;/B7'_.BKHLU?UPI">9I 9XOBJ)V?] ![4^!GO\+4$L#!!0
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MGSC28BC( KRO')#J_XB#X8)^\3=02P,$%     @ X8EJ5&?2'@^S"   X!8
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MD41?-4SUX1I-TGAV!JDLGL+G7WI2?TI')D2>4SHU27 %?-/T$%V4\ASU[*0
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M1YP\DQ)=R_O8E7!Y7^ LZ1!SS66:7-^XX*#!&]SJ')-'.8=DJ>.+L33.=5'
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MQ$V_'+![7%\Q5JL=E^95(F@< /IM/#J/S<>0_Y/:/J1JX1B?%6P<%ZO56G4
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M'P<J*. OY??8"0E:X*(S.#+I$JWNUD9<C0BK9+2HJ>9NJHG)086MJ]C3=@;
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M3W]_D62ZJ=<:^E>^_N#WEY*=R^1],'<1:(A0;F+0!60^ROLTJ][V]9/A^&R
MRL*J'CLUZ/.''TU.GB0VJ-[=(0=:;1=\1CK4'-)0LSOGW.']AX_T^U>(;!VN
M;/I\9WE=-.'"NSN>&Y">O:^5"D4OPQU>^BE]+OZLT2@J<8G%N ME?5762?*7
M;Y:JGM/?]Z'5Z*KA/X(3?@U_0^B"_W).O)W_ -%'6<_QY;A2%?#H>/3T_%#4
M_#=]^ N$.OH[.C/3-&9)'_$]"57C#7"],)!]NR]X0/C+2J__!U!+ P04
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MT Y',1P;?/O > ?\7FOM=A=/T+^FXW]02P,$%     @ X8EJ5('<Y([,!0
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MRP]\]X2Q)\@)3C>@?71"F]OQ.Y5K5BK"884RYS;"'F5]X]0#+3;5H;T4&J^
MZC7'2QJD"<#YE1#Z,##W0'OMC_\!4$L#!!0    ( .&):E06L8K X@,  ',-
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;+5748_:.!!^;G^%E=Y5
M6ZE'X@ ;M@=(%%K=2CT5+;?7A],]F&0@5IV8V@86Z7[\C9-L MU@]F7W87$2
MSS<SWTP^3X9[J;[K%,"0ATSD>N2EQFP^^+Z.4\B8[L@-Y/AD)57&#%ZJM:\W
M"EA2&&7"#X/@VL\8S[WQL+@W5^.AW!K!<Y@KHK=9QM3A(PBY'WG4>[QQQ]>I
ML3?\\7##UK  <[^9*[SR:Y2$9Y!K+G.B8#7R)O3#)SJP!L6.OSGL]=&:V%26
M4GZW%[?)R ML1" @-A:"X<\.IB"$1<(X?E2@7NW3&AZO']$_%\EC,DNF82K%
M-YZ8=.0-/)+ BFV%N9/[/Z!*J&_Q8BET\9_LJ[V!1^*M-C*KC#&"C.?E+WNH
MB#@R".D9@[ R"'\VZ)XQZ%8&W>=ZZ%4&O><:]"N#(G6_S+T@;L8,&P^5W!-E
M=R.:713L%];(%\]MHRR,PJ<<[<QX*K.,&ZR\T>_)5.:&YVO(8PZ:L#PA=R"8
M@83,F3('\I=BN69%A37YC4R2A-LU$^0V+WO6UOYJ!H9QH=\-?8,16C]^7$7S
ML8PF/!/-GTQU"(W>DS (Z?UB1JY^:4.97D(YD#"T(/2F EF9MV]H-/B]!6SF
M!IM!W"%=>BFD3\]'"5I1?"Q<7;VPKEY8P'8O5X],L%RG!?SG"VXGMP8R_:_#
M6;=VUBV<]<XXN\WU%AL@!H*2E/%MIMO8+#&B L.JU&Y,!X']&_J[8[Y:]O5.
M]YT$V:N#[#F#7*0L7Z>,DWG*L"%CV!H>8X->W2\F[[!-XXZ#B7[MI/_RM%_7
MSJZ=&4TRN;6.%,3 =VPIH(WV$J-_1*>+S:CV';E]8T[&D<.@QAF\/&$WM;.;
M9_9I;-UJ>Z:UMNK-$\ZH@S,:-)(:N'N0Y63&82U149G@J(PY9^0_\G6UXAC5
M8H-MZ<B3'FDW?7E::2,V-'3F=8>."#S@C*);>[ R/WZGP[97__*^TP ;@:)N
MA;(!VA>$,)R9D'"'ZD\KJ),WYCJ*SH30R ]UZ\\7P*G%DL15>1HF>'ZV'H1N
M''N&X7GQ^M4K/#'"U@0N :A.@T!=#=#('NU?X->.G@DH(E?$I$!$D:T!E173
M&FK4SW)1)=M_4O$H>M(8TXO;3N-N%)2Z);0L2L)U;*64J/:2S"Z@T* 3!+^Z
MB&QDE;IU]>L&;'ODZXI!P=F2"VX.K6%%3UGIGV>ET60Z< ;QK1BB<;AC.XQF
M;:MGR]M$9>O:&I ;MT\RU*%4$XK-?VCCRS^:5^WG"/;JFN-(*6"%B$$GPCY0
MY81?7ABY*4;8I30X$!?+%+^*0-D-^'PEI7F\L%-Q_9TU_A]02P,$%     @
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M8T#?-X*N;KTQ#IK1'?T&4$L#!!0    ( .&):E1J-;]:< (  -<&   9
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M2_SR@+( O+^2TNPFME<-W[+T/U!+ P04    " #AB6I4_ZK(F@4(   =,@
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MK8C6.J+P-[0=TL)%A?B)%6_R\'Z!D1M,\<1UW;FS;T$+*[3PK6B)-I(^1KU
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MFO9VHYM[*LP$_7[-N3H]F VJOPL6_P!02P,$%     @ X8EJ5/GANL6\ @
M1 <  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC55=;^(P$/PKJTBG
MZTE7$D+AV@J0@'(?#U41J+V'TSV89$,LG#BUG5+^_:T=R-$*4E[ WGC&,VOO
MNK^1:JU31 .OF<CUP$N-*6Y]7T<I9DRW9($Y?4FDRIBAJ5KYNE#(8@?*A!\&
M0<_/&,^]8=_%9FK8EZ41/,>9 EUF&5/;,0JY&7AM;Q^8\U5J;, ?]@NVP@6:
MQV*F:.;7+#'/,-=<YJ P&7BC]NVD9]>[!4\<-_I@#-;)4LJUG?R*!UY@!:'
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M]C3!,\#71&!9PW-8=O1K$% RXP-O;0^/D9(H3D_ /5)Q?"3U##SKP;.KX ^
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MJF^!]<#(H[M(/4B#US+W6.#-&90UP/F]E.9E8.]F[5U\]1]02P,$%     @
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MV%,214GB1P#S*X@B#(&G$4<P!: !0Z*HW@=W]J-PO4^%FW_)QK\!4$L#!!0
M   ( .&):E27BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%
MT)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI
M&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17
MB%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)
MT:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L
M?@!02P,$%     @ X8EJ5%B)?@>J P  DQH   \   !X;"]W;W)K8F]O:RYX
M;6S%F5%OTS 0@/^*E1>&Q&B3;(--%(FM RHA-BUHK\BUKZLUQRZVLP&_GG-*
MA3/:$R^F+VUCN\Z7<WR?G;QYM.Y^;NT]^]YJXR?%,H35V6CDQ1):[E_:%1BL
M65C7\H"'[F[D5PZX]$N T.I1-1Z?C%JN3/'VS::O:S=*#VP $90U6!@+;A4\
M^C_U\9 ]**_F2JOP8U+TOS44K%5&M>HGR$DQ+IA?VL>/UJF?U@2N&^&LUI.B
M7%?<@@M*_%7<1,@O?.[[DL#G-QQ!)L7)&#M<*.=#WZ+OGR/C V#C]5$7['NE
M [@I#_#!V6ZES%WL!J]BE%Q&'X?-]SJ(9^Y?PF@7"R5@:D77@@GK.#K0$=#X
MI5KY@AG>PJ38-&'<2'9I @:)S<RZ*VP;KQ1//9/KJPZ(F\30G2FL<#/9@^>#
MO,!CJY7$LTMVSC4W E@?7)\ 5@1@M3= =G#-$\B:@*S_(V03(>(?/+,+=K4"
MET >$9!'>X.\X'Z90!X3D,?[@[3F(8$\(2!/LD-*,!X)M^(FD*\(R%=Y(:?@
MA5.K6!ZC=]YY9<#[%SB)O/(L@7Q-0+[."SF8T&P*@2N=)IY3 NTT]R"WK0K]
MW?<BCG- CX 1"GR?T-/T/:;R]S@OYB=LAK=B1-2:SZWKF_2(-^ AQ20UD]DS
M4YB'E(4R2IE9*4VPXGYIM03GG['+;QV:.66C1%+F-LG5[6QZ6)ZR:QQ!:)7H
M1_+BW<UEP]Z)00@IE92973(SPK; OO#OD$[7DC)'F5D=33?W\*V+*Z[+!_Q,
MN2A9E)EM02;BKU6*2>FBW*<OOM8I)B6,<A_&8 >X_M?@GZ>4E#O*S/+8EF*V
M05:4.JK,ZD@G\58X2AA5=F%0M^-1BDGN3C*[A,8\3C$IK529M;)]UARB4H3K
M0*:8E%:J[%L48LTU2)4599HJLVG(-=<0DQ)/E5T\\Q#'6$H5Z[A.'S^P@Q23
M$D^563Q;<R5BX]\D#!;:%26>*K-X=F V(#J'\4TQ*?-4^S /8G9MR]V/-)HU
MY9XZLWMV8/[^,4LQ*0O5F2U$1G,PTVO*0O4>=C01$[N6G4XW@37YE"RSA79A
M+KF#P_/!LSS*0G5F"^W"C,5/,"D+U;GW.]LQHT,QO3<I)F6A.K.%!JO,/XD(
M%TLW( :/P6O*0G5F"^W&;-2=2=-[35FHSFRA)YA/W9YB4A:J>PN--B]!)"QP
MV2H_XRD\E@NNQ;5C\6O]L.;H..ZF%IW6%UAV93Y9+C?O5#;O@][^ E!+ P04
M    " #AB6I40+O#+8<!  "\%P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSS=C+;L(P$(7A5T%Y )R9X5H!JV[85KQ !.8B<E/LJO#VC6 !!W71
M#?)91;:5R;_Z%'GQY<LBGIHZ'$]M&%RJL@[+[!AC^^%<V!Y]581AT_JZ/]DW
M757$?MD=7%MLS\7!.\WSB>N>9V2KQ?/,P>;:^O],;/;[T]9_-MOORM?QC\'N
MI^G.X>A]S :;HCOXN,S<I7QL!W=[R+"?G W6NV76K7>2N=1!"D&:/L@@R-('
MC2!HE#YH#$'C]$$3")JD#YI"T#1]T R"9NF#YA T3Q\D.<J8$R2]8$V@M2#7
M0N"U(-A"(+8@V4)@MB#:0J"V(-M"X+8@W$(@MR#=0F"W(-Y"H+>BWDJ@MZ+>
M2J"WOOQL$^BMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VH
MMQ'H;:BW$>AMJ+<1Z&TOER4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;
MZFWOU#O$:^G#H^>^QMO(=U(=^W?]X_.WY7T3<1[=<'9P6;_Z!5!+ P04
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M6?=78/8%4$L! A0#%     @ X8EJ5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #AB6I4K]ETWNX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ X8EJ5"5S*,6] @
M1 D  !@              ("!B!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( .&):E02AL?+NP,  $4,   8              " @7L7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #AB6I4#7V7
MTX4%  !J%   &               @(%L&P  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ X8EJ5,>/.KG&!   CQ0  !@
M ("!)R$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .&)
M:E08:TVK3 (  -4$   8              " @2,F  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #AB6I4XI"C*]P8  #(1@  &
M        @(&E*   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( .&):E2[OEI+&Q   !8T   9              "
M@4=?  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ X8EJ
M5'Z4>9<8!P  K \  !D              ("!F6\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #AB6I49](>#[,(  #@%@  &0
M        @('H=@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( .&):E0C5"+;U0$   P$   9              " @=)_  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ X8EJ5!"BM.+?%P  94D
M !D              ("!WH$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #AB6I4#7X-GC8#  ":!@  &0              @('TF0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .&):E2*I]JX
MH@(  %D%   9              " @6&=  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ X8EJ5('<Y([,!0  8 X  !D
M ("!.J   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #A
MB6I4)B=,M0\$  "+"0  &0              @($]I@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .&):E124N1-V0,  .D+   9
M          " @8.J  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ X8EJ5($&*3!2 P  Y0H  !D              ("!DZX  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #AB6I4MP ?Q] "   "
M"   &0              @($<L@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( .&):E06L8K X@,  ',-   9              " @2.U
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ X8EJ5!)F
M7<Z>"@  >#T  !D              ("!/+D  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    " #AB6I4F2=M&L,"  #&!P  &0
M    @($1Q   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M .&):E1J-;]:< (  -<&   9              " @0O'  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ X8EJ5/^JR)H%"   '3(  !D
M             ("!LLD  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #AB6I4D/B*RXX#  "]"P  &0              @('NT0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .&):E0VLX?9900
M .@/   9              " @;/5  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ X8EJ5'A-V%I(!   .A   !D              ("!
M3]H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #AB6I4
M^>&ZQ;P"  !$!P  &0              @('.W@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( .&):E1PR-0<Z0(  ,P(   9
M      " @<'A  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ X8EJ5"AK4ZQI @  2@4  !D              ("!X>0  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #AB6I4^.$GWKT"  #6!P
M&0              @(&!YP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( .&):E1^OZAF0P,  "@)   9              " @77J  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ X8EJ5/'3FYV#
M P  EPL  !D              ("![^T  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #AB6I4-\)>.PH$  !6#P  &0
M@(&I\0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .&)
M:E2(W3&>)P,  #(3   -              "  >KU  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ X8EJ5)>*NQS     $P(   L              ( !//D
M %]R96QS+RYR96QS4$L! A0#%     @ X8EJ5%B)?@>J P  DQH   \
M         ( !)?H  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .&):E1
MN\,MAP$  +P7   :              "  ?S]  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( .&):E3_>6J2GP$  !T8   3
M      "  ;O_  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\ P P
' (L! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>114</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Commitments, Contingencies and Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - License, Collaboration and Research Subaward Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements</Role>
      <ShortName>License, Collaboration and Research Subaward Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - COVID-19 Pandemic and CARES Act</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct</Role>
      <ShortName>COVID-19 Pandemic and CARES Act</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails</Role>
      <ShortName>License, Collaboration and Research Subaward Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stockholders' Equity - Amended and Restated Articles of Incorporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails</Role>
      <ShortName>Stockholders' Equity - Amended and Restated Articles of Incorporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails</Role>
      <ShortName>Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="onct-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="onct-10k_20211231.htm">onct-10k_20211231.htm</File>
    <File>onct-20211231.xsd</File>
    <File>onct-20211231_cal.xml</File>
    <File>onct-20211231_def.xml</File>
    <File>onct-20211231_lab.xml</File>
    <File>onct-20211231_pre.xml</File>
    <File>onct-ex10181_736.htm</File>
    <File>onct-ex10182_1014.htm</File>
    <File>onct-ex1018_739.htm</File>
    <File>onct-ex10191_735.htm</File>
    <File>onct-ex10193_738.htm</File>
    <File>onct-ex105_807.htm</File>
    <File>onct-ex2310_945.htm</File>
    <File>onct-ex311_8.htm</File>
    <File>onct-ex312_6.htm</File>
    <File>onct-ex321_7.htm</File>
    <File>onct-ex322_9.htm</File>
    <File>onct-ex411_404.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ggtc45pq2o35000001.jpg</File>
    <File>ggtc45pq2o35000002.jpg</File>
    <File>ggtc45pq2o35000003.jpg</File>
    <File>ggtc45pq2o35000004.jpg</File>
    <File>ggtc45pq2o35000005.jpg</File>
    <File>ggtc45pq2o35000006.jpg</File>
    <File>ggtc45pq2o35000007.jpg</File>
    <File>ggtc45pq2o35000008.jpg</File>
    <File>ggtc45pq2o35000009.jpg</File>
    <File>ggtc45pq2o35000010.jpg</File>
    <File>ggtc45pq2o35000011.jpg</File>
    <File>ggtc45pq2o35000012.jpg</File>
    <File>ggtc45pq2o35000013.jpg</File>
    <File>ggtc45pq2o35000014.jpg</File>
    <File>ggtc45pq2o35000015.jpg</File>
    <File>ggtc45pq2o35000016.jpg</File>
    <File>ggtc45pq2o35000017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="334">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "onct-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 114,
   "dts": {
    "calculationLink": {
     "local": [
      "onct-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "onct-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "onct-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "onct-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "onct-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "onct-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 395,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 9,
    "http://www.oncternal.com/20211231": 8,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 21
   },
   "keyCustom": 68,
   "keyStandard": 269,
   "memberCustom": 34,
   "memberStandard": 13,
   "nsprefix": "onct",
   "nsuri": "http://www.oncternal.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Commitments, Contingencies and Related Party Transactions",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions",
     "shortName": "Commitments, Contingencies and Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - License, Collaboration and Research Subaward Agreements",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements",
     "shortName": "License, Collaboration and Research Subaward Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Debt",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Stockholders' Equity",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:COVID19PandemicAndCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - COVID-19 Pandemic and CARES Act",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct",
     "shortName": "COVID-19 Pandemic and CARES Act",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:COVID19PandemicAndCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Income Taxes",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Subsequent Event",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureSubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GrantsReceivable",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Details - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralInsuranceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralInsuranceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchAndDevelopmentExpense",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
     "shortName": "License, Collaboration and Research Subaward Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctNationalInstituteOfHealthGrantAwardMember_20210801_20210831",
      "decimals": "-5",
      "lang": null,
      "name": "onct:ResearchAndDevelopmentGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherNonoperatingIncome",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stockholders' Equity - Amended and Restated Articles of Incorporation (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails",
     "shortName": "Stockholders' Equity - Amended and Restated Articles of Incorporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210525",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
     "shortName": "Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531",
      "decimals": "4",
      "lang": null,
      "name": "onct:CombinedPurchasePriceOfShareAndWarrantPerUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "onct:WarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity - Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails",
     "shortName": "Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails",
     "shortName": "Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Balance Sheet Details",
     "role": "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20211231.htm",
      "contextRef": "C_0001260990_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "verboseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "onct_AccruedClinicalTrials": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials.",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Accrued Clinical Trials"
       }
      }
     },
     "localname": "AccruedClinicalTrials",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AccruedClinicalTrials1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials 1.",
        "label": "Accrued Clinical Trials1",
        "terseLabel": "Payable to subawardees"
       }
      }
     },
     "localname": "AccruedClinicalTrials1",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AccruedUnvestedShareLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for unvested share liability.",
        "label": "Accrued Unvested Share Liability",
        "terseLabel": "Unvested share liability"
       }
      }
     },
     "localname": "AccruedUnvestedShareLiability",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash",
        "terseLabel": "Exercise of warrants for cash"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash Shares",
        "terseLabel": "Exercise of warrants for cash (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital stock issued issuance costs shares",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Shares",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital vesting related to unvested share liability.",
        "label": "Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability",
        "terseLabel": "Vesting related to repurchase liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdvanceLicensedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance licensed assets.",
        "label": "Advance Licensed Assets",
        "terseLabel": "Advance licensed assets"
       }
      }
     },
     "localname": "AdvanceLicensedAssets",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AmountAgreedToBeProvidedInContingencyFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed to be provided in contingency funds.",
        "label": "Amount Agreed To Be Provided In Contingency Funds",
        "terseLabel": "Amount agreed to be provided in contingency funds"
       }
      }
     },
     "localname": "AmountAgreedToBeProvidedInContingencyFunds",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AmountForAtTheMarketFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for at the market facility.",
        "label": "Amount For At The Market Facility",
        "terseLabel": "Execution of ATM Facility"
       }
      }
     },
     "localname": "AmountForAtTheMarketFacility",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees.",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AtTheMarketFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market facility.",
        "label": "At The Market Facility [Member]",
        "terseLabel": "At The Market Facility"
       }
      }
     },
     "localname": "AtTheMarketFacilityMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_AugustUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August underwriting agreement.",
        "label": "August Underwriting Agreement [Member]",
        "terseLabel": "August Underwriting Agreement"
       }
      }
     },
     "localname": "AugustUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_AwardPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award payments received.",
        "label": "Award Payments Received",
        "terseLabel": "Award payments received"
       }
      }
     },
     "localname": "AwardPaymentsReceived",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_COVID19PandemicAndCARESActAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act [Abstract]"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActAbstract",
     "nsuri": "http://www.oncternal.com/20211231",
     "xbrltype": "stringItemType"
    },
    "onct_COVID19PandemicAndCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act Disclosure [Text Block]",
        "terseLabel": "COVID-19 Pandemic and CARES Act"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActDisclosureTextBlock",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_CaliforniaInstituteForRegenerativeMedicineAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Institute for Regenerative Medicine Award.",
        "label": "California Institute For Regenerative Medicine Award [Member]",
        "terseLabel": "The California Institute for Regenerative Medicine (\"CIRM\") Award"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAwardMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CashlessExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants.",
        "label": "Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "CashlessExerciseOfWarrants",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ChiefFinancialOfficerSonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief financial officer, son.",
        "label": "Chief Financial Officer Son [Member]",
        "terseLabel": "Agent"
       }
      }
     },
     "localname": "ChiefFinancialOfficerSonMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ClassOfWarrantWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant weighted-average remaining contractual term.",
        "label": "Class Of Warrant Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_CollaborativeArrangementPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential milestone payments.",
        "label": "Collaborative Arrangement Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialMilestonePayments",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential regulatory milestone payments.",
        "label": "Collaborative Arrangement Potential Regulatory Milestone Payments",
        "terseLabel": "Potential regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialRegulatoryMilestonePayments",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CombinedPurchasePriceOfShareAndWarrantPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined purchase price of share and warrant per unit.",
        "label": "Combined Purchase Price Of Share And Warrant Per Unit",
        "terseLabel": "Combined purchase price of share and warrant per unit"
       }
      }
     },
     "localname": "CombinedPurchasePriceOfShareAndWarrantPerUnit",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options issued and outstanding for future issuance.",
        "label": "Common Stock Options Issued And Outstanding For Future Issuance",
        "terseLabel": "Common stock options issued and outstanding"
       }
      }
     },
     "localname": "CommonStockOptionsIssuedAndOutstandingForFutureIssuance",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_CommonStockSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock subject to repurchase.",
        "label": "Common Stock Subject To Repurchase [Member]",
        "terseLabel": "Common Stock Subject to Repurchase"
       }
      }
     },
     "localname": "CommonStockSubjectToRepurchaseMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CommonStockWarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants expiration date.",
        "label": "Common Stock Warrants Expiration Date",
        "terseLabel": "Common stock warrants expiration date"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationDate",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "onct_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CommonStockWarrantsReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants reserved for future issuance.",
        "label": "Common Stock Warrants Reserved For Future Issuance",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsReservedForFutureIssuance",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ConcentrationRiskCreditRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk credit risk policy.",
        "label": "Concentration Risk Credit Risk Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_ContingentValueRightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights Agreement.",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "Contingent Value Rights Agreement"
       }
      }
     },
     "localname": "ContingentValueRightsAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CumulativeChangeInOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative change in ownership percentage.",
        "label": "Cumulative Change In Ownership Percentage",
        "terseLabel": "Cumulative changes in ownership percentage"
       }
      }
     },
     "localname": "CumulativeChangeInOwnershipPercentage",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_DecemberUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December underwriting agreement.",
        "label": "December Underwriting Agreement [Member]",
        "terseLabel": "December Underwriting Agreement"
       }
      }
     },
     "localname": "DecemberUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research expiration year.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year",
        "terseLabel": "Research and development credit carryforward expiration year"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "onct_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business basis of presentation and summary of significant accounting policies line items.",
        "label": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business basis of presentation and summary of significant accounting policies table.",
        "label": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones to be received under research subaward agreements throughout award project period.",
        "label": "Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period",
        "terseLabel": "Development milestones to be received under research subaward agreements throughout award project period"
       }
      }
     },
     "localname": "DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "Equity incentive plan"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license agreement.",
        "label": "Exclusive License Agreement [Member]",
        "terseLabel": "Exclusive License Agreement"
       }
      }
     },
     "localname": "ExclusiveLicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ExerciseOfCashlessWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants",
        "label": "Exercise Of Cashless Warrant Shares",
        "verboseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfCashlessWarrantShares",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrants",
        "terseLabel": "Number of Shares Underlying Warrants Exercised"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_FairValueOfWarrantsIssuedToPlacementAgent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants issued to placement agent.",
        "label": "Fair Value Of Warrants Issued To Placement Agent",
        "terseLabel": "Fair value of warrants issued to placement agent"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedToPlacementAgent",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_GeorgetownUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Georgetown University.",
        "label": "Georgetown University [Member]",
        "terseLabel": "Georgetown University"
       }
      }
     },
     "localname": "GeorgetownUniversityMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of bonus awards with stock option in lieu of cash.",
        "label": "Issuance Of Bonus Awards With Stock Option In Lieu Of Cash",
        "terseLabel": "Issuance of 2019 bonus awards with stock option in lieu of cash"
       }
      }
     },
     "localname": "IssuanceOfBonusAwardsWithStockOptionInLieuOfCash",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_JulyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July purchase agreement member",
        "label": "July Purchase Agreement [Member]",
        "terseLabel": "July Purchase Agreement"
       }
      }
     },
     "localname": "JulyPurchaseAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_LicenseMaintenanceFeeToBePaidAndPaymentMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee to be paid and payment made.",
        "label": "License Maintenance Fee To Be Paid And Payment Made",
        "terseLabel": "Annual license maintenance fee to be paid and payment made"
       }
      }
     },
     "localname": "LicenseMaintenanceFeeToBePaidAndPaymentMade",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy [Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_MDAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Cancer Center.",
        "label": "M D Anderson Cancer Center [Member]",
        "terseLabel": "MD Anderson Cancer Center"
       }
      }
     },
     "localname": "MDAndersonCancerCenterMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period of written notice to terminate agreement.",
        "label": "Minimum Period Of Written Notice To Terminate Agreement",
        "terseLabel": "Minimum period in days of written notice to terminate license agreement"
       }
      }
     },
     "localname": "MinimumPeriodOfWrittenNoticeToTerminateAgreement",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NationalInstituteOfHealthGrantAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National institute of health grant award.",
        "label": "National Institute Of Health Grant Award [Member]",
        "terseLabel": "The National Institute of Health (\u201cNIH\u201d) Grant Awards"
       }
      }
     },
     "localname": "NationalInstituteOfHealthGrantAwardMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.",
        "label": "Non Cash Or Part Noncash Gain Loss Of Forgiveness Of Payroll Protection Loan",
        "negatedLabel": "Gain on forgiveness of payroll protection program loan",
        "terseLabel": "Gain on forgiveness of payroll protection program loan"
       }
      }
     },
     "localname": "NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_NovemberUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November underwriting agreement.",
        "label": "November Underwriting Agreement [Member]",
        "terseLabel": "November Underwriting Agreement"
       }
      }
     },
     "localname": "NovemberUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice for default in payment.",
        "label": "Number Of Days After Receipt Of Notice For Default In Payment",
        "terseLabel": "Days after receipt of notice for default in payment"
       }
      }
     },
     "localname": "NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice in fails to pay amount.",
        "label": "Number Of Days After Receipt Of Notice To Pay Failure Amount",
        "terseLabel": "Days after receipt of notice, to pay failure amount"
       }
      }
     },
     "localname": "NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NumberOfDaysInWrittenNoticeOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days in written notice of termination.",
        "label": "Number Of Days In Written Notice Of Termination",
        "terseLabel": "Written notice of termination, period"
       }
      }
     },
     "localname": "NumberOfDaysInWrittenNoticeOfTermination",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "onct_OperatingLossCarryforwardsNonExpirePortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards non expire portion.",
        "label": "Operating Loss Carryforwards Non Expire Portion",
        "terseLabel": "Operating loss carryforwards non expire portion"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNonExpirePortion",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs policy.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program member,",
        "label": "Paycheck Protection Program [Member]",
        "terseLabel": "Paycheck Protection Program"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company's SARD and SARM technology.",
        "label": "Percentage Of Net Proceeds Entitled To Receive During Period Specified After Closing From Grant Sale Or Transfer Of Rights",
        "terseLabel": "Percentage of net proceeds entitled to be received per CVR"
       }
      }
     },
     "localname": "PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_PercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales.",
        "label": "Percentage Of Net Sales",
        "terseLabel": "Percentage of net sales"
       }
      }
     },
     "localname": "PercentageOfNetSales",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_PeriodForCumulativeChangeInOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for cumulative change in ownership.",
        "label": "Period For Cumulative Change In Ownership",
        "terseLabel": "Period for cumulative change in ownership"
       }
      }
     },
     "localname": "PeriodForCumulativeChangeInOwnership",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.",
        "label": "Period Which Grant Sale Or Transfer Of Rights To Company Sard Or Sarm Technology Could Trigger Payment Under Cvr Agreement",
        "terseLabel": "Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement"
       }
      }
     },
     "localname": "PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from closing during which percentage of net proceeds payment would be payable under the CVR.",
        "label": "Period Which Payment Of Percentage Of Net Proceeds Would Be Payable Under C V R",
        "terseLabel": "Period from closing during which payment of percentage of net proceeds would be payable under the CVR"
       }
      }
     },
     "localname": "PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_PlacementAgentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent member.",
        "label": "Placement Agent [Member]",
        "terseLabel": "Placement Agent"
       }
      }
     },
     "localname": "PlacementAgentMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_PrivateOncternalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Oncternal.",
        "label": "Private Oncternal [Member]",
        "terseLabel": "Private Oncternal"
       }
      }
     },
     "localname": "PrivateOncternalMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ProceedsFromStockOptionsExercisedAndWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options and common stock warrants.",
        "label": "Proceeds From Stock Options Exercised And Warrant Exercises",
        "terseLabel": "Proceeds from exercise of stock options and common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantExercises",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement member.",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ReagentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reagents.",
        "label": "Reagents [Member]",
        "terseLabel": "Regents of the University of California"
       }
      }
     },
     "localname": "ReagentsMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_RegentsLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regents license agreement.",
        "label": "Regents License Agreement [Member]",
        "terseLabel": "Regents License Agreement"
       }
      }
     },
     "localname": "RegentsLicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_RelatedQualifyingSubawardCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related qualifying subaward costs.",
        "label": "Related Qualifying Subaward Costs",
        "terseLabel": "Related qualifying subaward costs"
       }
      }
     },
     "localname": "RelatedQualifyingSubawardCosts",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_RemainderOfLeaseTermBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remainder of the lease term base rent.",
        "label": "Remainder Of Lease Term Base Rent",
        "terseLabel": "Remainder of the lease term base rent"
       }
      }
     },
     "localname": "RemainderOfLeaseTermBaseRent",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_RentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent expense.",
        "label": "Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "RentExpense",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement.",
        "label": "Research Agreement [Member]",
        "terseLabel": "Research Agreement"
       }
      }
     },
     "localname": "ResearchAgreementMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ResearchAgreementResearchFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount.",
        "label": "Research Agreement Research Funding Amount",
        "terseLabel": "Aggregate research agreement budget"
       }
      }
     },
     "localname": "ResearchAgreementResearchFundingAmount",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementResearchFundingAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount payable.",
        "label": "Research Agreement Research Funding Amount Payable",
        "terseLabel": "Research amount payable quarterly"
       }
      }
     },
     "localname": "ResearchAgreementResearchFundingAmountPayable",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement term.",
        "label": "Research Agreement Term",
        "terseLabel": "Research agreement term"
       }
      }
     },
     "localname": "ResearchAgreementTerm",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_ResearchAgreementTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement 2024.",
        "label": "Research Agreement Two Thousand Twenty Four [Member]",
        "terseLabel": "Research Agreement 2024"
       }
      }
     },
     "localname": "ResearchAgreementTwoThousandTwentyFourMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ResearchAgreementTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement 2023.",
        "label": "Research Agreement Two Thousand Twenty Three [Member]",
        "terseLabel": "Research Agreement 2023"
       }
      }
     },
     "localname": "ResearchAgreementTwoThousandTwentyThreeMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ResearchAgreementTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement 2022.",
        "label": "Research Agreement Two Thousand Twenty Two [Member]",
        "terseLabel": "Research Agreement 2022"
       }
      }
     },
     "localname": "ResearchAgreementTwoThousandTwentyTwoMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ResearchAndDevelopmentGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "Research And Development Grants",
        "terseLabel": "Grants awarded to researchers"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrants",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide sales milestones based on achievement of tiered revenue levels.",
        "label": "Sales Milestones Based On Achievement Of Tiered Revenue Levels",
        "terseLabel": "Worldwide sales milestones based on achievement of tiered revenue levels"
       }
      }
     },
     "localname": "SalesMilestonesBasedOnAchievementOfTieredRevenueLevels",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of warrant activity table text block.",
        "label": "Schedule Of Warrant Activity Table [Text Block]",
        "terseLabel": "Summary Of Warrant Activity And Changes In Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shanghai Pharmaceutical United States of America Inc.",
        "label": "Shanghai Pharmaceutical United States Of America Inc [Member]",
        "terseLabel": "Shanghai Pharmaceutical (USA) Inc."
       }
      }
     },
     "localname": "ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Intrinsic Value",
        "terseLabel": "Vested and exercisable, Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableIntrinsicValue",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number",
        "terseLabel": "Number of options, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining weighted-average period, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.",
        "label": "Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of annual increase in shares reserved for issuance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_SubawardPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subaward payments received.",
        "label": "Subaward Payments Received",
        "terseLabel": "Subaward payments received"
       }
      }
     },
     "localname": "SubawardPaymentsReceived",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_TwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen plan.",
        "label": "Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2015 plan"
       }
      }
     },
     "localname": "TwoThousandFifteenPlanMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2019 and 2015 plan"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandFifteenPlanMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan and inducement plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan And Inducement Plan [Member]",
        "terseLabel": "2019 incentive award plan and inducement plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 incentive award plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UniversityOfCaliforniaSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California San Diego.",
        "label": "University Of California San Diego [Member]",
        "terseLabel": "University of California San Diego School of Medicine"
       }
      }
     },
     "localname": "UniversityOfCaliforniaSanDiegoMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UniversityOfTennesseeResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Tennessee Research Foundation.",
        "label": "University Of Tennessee Research Foundation [Member]",
        "terseLabel": "University of Tennessee Research Foundation"
       }
      }
     },
     "localname": "UniversityOfTennesseeResearchFoundationMember",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UpfrontLicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fees paid.",
        "label": "Upfront License Fees Paid",
        "terseLabel": "Upfront license fees paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeesPaid",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_WarrantExercisedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercised price per share.",
        "label": "Warrant Exercised Price Per Share",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "WarrantExercisedPricePerShare",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_WarrantIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant issued price per share.",
        "label": "Warrant Issued Price Per Share",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "WarrantIssuedPricePerShare",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_WarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued.",
        "label": "Warrants Issued",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://www.oncternal.com/20211231",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r87",
      "r161",
      "r165",
      "r170",
      "r316",
      "r317",
      "r321",
      "r322",
      "r351",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r87",
      "r161",
      "r165",
      "r170",
      "r316",
      "r317",
      "r321",
      "r322",
      "r351",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r45",
      "r85",
      "r86",
      "r176",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r175",
      "r211",
      "r239",
      "r240",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r399",
      "r401",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r175",
      "r211",
      "r239",
      "r240",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r399",
      "r401",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r175",
      "r211",
      "r237",
      "r239",
      "r240",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r399",
      "r401",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r175",
      "r211",
      "r237",
      "r239",
      "r240",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r399",
      "r401",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r44",
      "r45",
      "r85",
      "r86",
      "r176",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r235",
      "r236",
      "r400",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r235",
      "r236",
      "r400",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r142",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r19",
      "r84",
      "r348",
      "r350",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable Related Parties",
        "terseLabel": "Amounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r272",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r269",
      "r270",
      "r271",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r241",
      "r243",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r225",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r243",
      "r266",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r122",
      "r131",
      "r136",
      "r144",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r316",
      "r321",
      "r329",
      "r352",
      "r354",
      "r380",
      "r391"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r42",
      "r81",
      "r144",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r316",
      "r321",
      "r329",
      "r352",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r244",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r88",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r28",
      "r68"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r64",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r330"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Common stock warrants excercisable and expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r233",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "periodEndLabel": "Weighted-Average Exercise Price",
        "periodStartLabel": "Weighted-Average Exercise Price",
        "terseLabel": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "periodEndLabel": "Options outstanding, Number of Warrant",
        "periodStartLabel": "Options outstanding, Number of Warrant",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration and Research Subaward Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r158",
      "r385",
      "r395"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 3)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r159",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingencies and Related Party Transactions"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock available for future issuance",
        "verboseLabel": "Number of common stock shares provided for issuance of stock awards to its employees"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; authorized shares \u2013 120,000 at December 31, 2021 and 60,000 at 2020; issued and outstanding shares \u2013 49,429 and 48,802 at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r189",
      "r196",
      "r197",
      "r199",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r80",
      "r87",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r201",
      "r202",
      "r203",
      "r339",
      "r381",
      "r383",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r172",
      "r200",
      "r201",
      "r338",
      "r339",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36",
      "r80",
      "r87",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r201",
      "r202",
      "r203",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r80",
      "r87",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r226",
      "r229",
      "r230",
      "r231",
      "r337",
      "r338",
      "r339",
      "r340",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r293",
      "r382",
      "r389"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r298",
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development credit carryforwards",
        "verboseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, fully offset by valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Aggregate Disclosures [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Compensation cost related to nonvested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option Grants",
        "verboseLabel": "Common Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r106",
      "r145",
      "r225",
      "r232",
      "r269",
      "r270",
      "r271",
      "r302",
      "r303",
      "r325",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r402",
      "r403",
      "r404",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Aggregate Cost",
        "terseLabel": "Aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "Patent costs as general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralInsuranceExpense": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).",
        "label": "General Insurance Expense",
        "terseLabel": "Insurance premiums"
       }
      }
     },
     "localname": "GeneralInsuranceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r287",
      "r291",
      "r297",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effects of employee stock option transactions that are recognized differently for financial reporting and tax purposes, occurring during the period and charged or credited directly to shareholders' equity.",
        "label": "Income Tax Effects Allocated Directly To Equity Employee Stock Options",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination Penalties And Interest Expense",
        "terseLabel": "Interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r99",
      "r100",
      "r121",
      "r285",
      "r305",
      "r307",
      "r398"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r281",
      "r282",
      "r291",
      "r292",
      "r296",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Income Tax Reconciliation Other Adjustments",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Income Tax Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "negatedLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r66",
      "r344"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Change in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceCommissions": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.",
        "label": "Insurance Commissions",
        "terseLabel": "Insurance commissions"
       }
      }
     },
     "localname": "InsuranceCommissions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r58",
      "r120"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee Operating Lease Discount Rate",
        "terseLabel": "Lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r81",
      "r144",
      "r329",
      "r354",
      "r384",
      "r393"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r81",
      "r144",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r317",
      "r321",
      "r322",
      "r329",
      "r352",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r65",
      "r67"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r48",
      "r52",
      "r54",
      "r67",
      "r81",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r102",
      "r122",
      "r130",
      "r132",
      "r135",
      "r137",
      "r144",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r326",
      "r329",
      "r386",
      "r397"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Rentable area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r130",
      "r132",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Lease, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income",
        "verboseLabel": "Loan forgiveness (other income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Common stock and common stock warrants, issuance cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r244",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityAmendedAndRestatedArticlesOfIncorporationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, authorized shares \u2013 5,000 at December 31, 2021 and 2020; issued and outstanding shares \u2013 none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock and common stock warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from payroll protection loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r48",
      "r52",
      "r63",
      "r81",
      "r92",
      "r99",
      "r100",
      "r122",
      "r130",
      "r132",
      "r135",
      "r137",
      "r144",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r315",
      "r319",
      "r320",
      "r323",
      "r324",
      "r326",
      "r329",
      "r387"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r238",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r238",
      "r347",
      "r350",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r279",
      "r364",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r232",
      "r272",
      "r354",
      "r392",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r145",
      "r269",
      "r270",
      "r271",
      "r302",
      "r303",
      "r325",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r53",
      "r81",
      "r118",
      "r119",
      "r129",
      "r133",
      "r134",
      "r138",
      "r139",
      "r141",
      "r144",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r329",
      "r387"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Capitalization Equity [Line Items]",
        "terseLabel": "Schedule Of Capitalization Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule Of Capitalization Equity [Table]",
        "terseLabel": "Schedule Of Capitalization Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Summary of Significant Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r243",
      "r265",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r243",
      "r265",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r244",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r250",
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r38",
      "r78",
      "r107",
      "r108",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r218",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r206",
      "r207",
      "r208",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule Of Stock By Class [Text Block]",
        "terseLabel": "Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Maximum number of shares of common stock a participant may receive"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of options, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r252",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of options, ending balance",
        "periodStartLabel": "Number of options, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, exercised",
        "periodStartLabel": "Weighted average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r242",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r260",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Remaining weighted-average period, outstanding",
        "verboseLabel": "Remaining weighted-average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r40",
      "r50",
      "r51",
      "r52",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r106",
      "r145",
      "r225",
      "r232",
      "r269",
      "r270",
      "r271",
      "r302",
      "r303",
      "r325",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r402",
      "r403",
      "r404",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r106",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "positiveLabel": "Payment of 2019 bonus awards with stock options in lieu of cash"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Common stock shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r225",
      "r232",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of options, exercised",
        "terseLabel": "Exercise of stock options for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r81",
      "r143",
      "r144",
      "r329",
      "r354"
     ],
     "calculation": {
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r210",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r280",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Change In Valuation Allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation",
        "terseLabel": "Weighted-average shares subject to repurchase"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.oncternal.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121829988&loc=d3e23586-113945"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121829988&loc=d3e23594-113945"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-03.7(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r426": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r427": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r428": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r429": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r430": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r431": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001564590-22-009702-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-009702-xbrl.zip
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M93AA\_R33)IKON[XJEY,_LTX8MH4_EX4$$Y7 +@Q;D>W)[FQ9XYZZ\*IA79
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MBY[5EDEI/D(T6&UT7]U?IIL<0R#;[RNA"96FV(Y- ]JK.6E_DT[]"VR*4:.
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M9T=>!E*17V+C=9'WO.Q/'T=,EE64Y+?;8^$/)#](/JS/7RG1LYI D@N2PI[
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MVPO(2LR;YOT<.!2)=<ZK5E-?9O/&F4_!";=63RXIE0A_P;F2T7UIKN06G-
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M?4&6.[7E6]WZ)1-?&TP<K1VAZ*]JJU,8T]Q]F5FL2*1:5O$Z[;G4)"*#OBN
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MD"+OX,622EDD #M1'@E(1W%!FNLX2CH<:D:\O&3-*NF'?'DY@HO6%\GV5YO
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M.0@E[1&D17OV%CUV%/E!<Z&&DI;++1(H?9?=Z<R*O#J^ZCP\;XA3@6ML]=)
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M,SE[QN\Q.>\:0K"U /D (T/XFS8?_#G2HJC'/23@187^V2QX1;)*-W6V/6[
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M"SIG"JA%R].XWQ4U3CDXI&CW>86>2U\<NMU:9^OYRJAMA=HY.IB5WIL)DZ-
ML<T:%P$K)*VQ?X%TKUHEE[.V]@ILBB^>GIM=Q]C>?J$$MG&$[UU?98X42$LM
MFCP@4VA+6OUXJ.I,N#W+R?1]]VPHG@Z"]&_"MD36K-D63;C ?]4=DT90@-3
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MWP;;@&],JQTU&Z;.IG_RH5O<S!L]D!+12=8 '-_P6__U7+%3?B0N_ A_.C9
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MM@=(&(SZH]RH&PJL? H<P/'MD>?_))C^TZ.3.:1EZL-5]#8OOH2.0L\!K.>
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M +3WT=W$*N8!@R*G'M'F!_)58[4*U'4\WP(7F?8T]Q$)Y+[N8O"E*6+60R+
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M)9*F1_@&_0'.%(WT*KR#G'CJ(F93V^<]N;"6&;HA%MFW.(&';J9CK]:> Z;
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M+*RR48PN6<,R)*TR;?R8T9:Y+M-@:.541;QUUJ7X): X6N*] HIK=:UY0H&
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M_ :JKH19?6W>.1J\:O2$<&!?"9J;M9M^;F&HI+^9.[&^X39_5U*C2,_6P,?
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M_!\,UI'CS=%B>S4]C4*[D^L--*6V)LSE&*$@F+?4%GF>TA/]=+<N!M+5/).
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ML_#$G"5_T,P%]KXL!+P+U&EVD2\E,O<\#T!99WK.,09! "8R]]$"G\]/Z][
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MSH*ZI"_,SIVG-*?IJ)F!#5( . "SMU8>Q2(N;SE1E0>[;K"#2LW>Q8A4_KC
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M<IQC0C9/MJ1]NLPJSU2Y)8C-:9_66YXB4B)_L!!(,?GU*&N&!(J9+, */T
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MBEJ$W $>Q;,-3RUJQ6;[-]#NRR\7?&+Q5/3BRL-\PHNF'M$.0"7[Q#4]??_
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M.:F*1Y"<K/202&ZQ]IZ)HI::R7!KP4TRU^R</L8+XL/0YLGD@JD.*Z9L?YY
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M_D&>PHR+_/8Z<-$8*O/)1*S5F[I>9:"?<E.3Q];CSQHKH<Y=A">*FF,?TQ&
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M[ 2DI&ZR9V!W%NW>>"$3A1U%%,F.62J$7!;Z$:1RN*6%\0% ?KI>K*O]X :
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MO"C7FU.SZCO92-R?-,'-*412OHXEAUPG,7AI.5+Z+4A3.W0*&K.?>+7+CRF
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MRZ?:(RS>4ONZVO@&<,LFOW;= %!%ZEZ*;+3!>1>7]3*PX25HNX;:*1/ EU/
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M7Y: CYY U= ?P4M@8 6+($A*J-C^+.H-.25D7/TRV==ZR($\74O/6!+?X\B
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MUZ]_"]! ;,Z4$+@M[(@6B@?T4?QD/')C]@=<CAQ]4J:-T"($!,F10?ONV76
MUUX Y#*H82&5'K%NH>0/]$'B;8#2X/<MT-0C%:RG42RP H+G_1\=?F6B0]^C
M^.", YUBR"8@$? :1,A/C9!7R5^%+MJ@DC5T,'7 &GQ*:40VX?]A(!T;/<$2
M?+O_DQQ0(=WX8[!I8(*#'H>UZQ;W_ &\3R0OAC0 =?%I<]5UJ/9@=G'L&&VD
M\_/J.+#T=R<Q];F'-#M @7NA? #)5-^+2FF\WHFY2SM[/ I^"_6ZU*D]0):.
MQYR7*BW!L[8O VF]2?WPMW:!M0S/_Q?P.W1NCH-M(&=, &$"13,1;;*2<=GT
MMH\0<8P+ @"74%QR249?7=0ZYCHP2^5]<C1$#;7YMB2&>X]]#7;=NNX( //N
M$G+D 2M2KMD3^LD"H^$"@2< H1P?5OF<J: :C_ES%;\@+@N(\7)":-;#DL.3
M2"#)-6K &I*C\T9;4-) O+&7)(N)/X/[G-\#8IS\#/QV!&;$GA?2]3TC]RP$
MP;!8M0NKB$?Y>D=@ZA50Z8U$3:<G "3%:UY.4Q6<-%8'.R\\OIN[S\)8 .DR
M/\<T<P+8&:N[K7^L>48\"X&W92 I"SX6UL?O9:]%^F7\B8D&9JF ;@U:LSCN
MZ[F4";^U?$LJ="TZOVX-C M>RE_/..YS1M..BG>"SVZ=6ASODF-"'_T;U@+,
M"8?H&NOCPR@DW3P=ZG4L!+V9@:;F72WXY35/1<:<@,4AD5^&+%G(%Z"VXKO
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M!;+<?H_?.Z_EPGR$(P!ZW$ Y(I-G ?SSRLB^(9U=]D?395YU?A?2=0P@\V-
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M2M@,[X"0YM0\7L?^1OK0A4[YJTA"GA<8Y5[/;,9[-VUT[XX",P3W,E2R+^Z
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M61$\ Y\7_:%F 4HGF^DJWZ;=0G7O,6R82UMI#G1U:2X%C/X6)_XK*LQE\Y'
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M'=2\0+&"."_LV=3:6EXCEH)$H*-?8M,0/$3VOYU%;)J$E91/HB:'YVKS2R'
MQ,4&_"(_B'QV!^0%DI=2WP'=7":ZZ%1<")S'=.R 8*@X@V7[I?)!^&+\T0?O
M=T!3<3(:HG-#/@\A-7BV/B05JHB4+(:,2!S_K+H#ZA#U;&*VGQ<2L<9=W@$A
M-\: FY<L.IA@S_WGW@/ED_,;CK^?;FR"JB&C/8O%AWX3"_#4/[R/=G M831
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M1/>)XU@L*DX8U9T8-'3D;9C&2"!K>*3=+1(W)>>(W^9O.[W_!U!+ P04
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MN?F%Q:7E%<3FUO;.IUWDWO[G=H$ ;-"7S^^VB_2H75@X.-@X>)_;!<)R^9R
M%.?$^:NX9%*J>$9V9R[P^)XDOQ[ULK@1GXE7#4YQS[Z/X"PS'_0BXG/3?FS9
M'VN8WS_4LJ\-^Z5=8\ I;-#1X&&3 A+ [CY;F@_!,?[R.#5;R'C7_;25A.X9
M.BY#)O&[U%1%#-#8*J\\PY57!KB'S5![<^Q^"WSLW%9NJ7AHK0*,.F.D<%M7
M#^9-/5(&N(!\EZ3VU4:2=%<%O&F&9 H7%L-E"0H6ZDC/N7.XA_9B]25NY^G4
MU.IHM$0=SE^7,5H>:QYSU> N(GFO2QL/K)@7*%&V:([E<"RP/17E<A^>/ ND
MA; =X[\36.?2GU@0VVW&;QD&S-%YZ._YBMO:%KK3Y]-N?I"/G>4A]=43\*OE
MR',%:]=6Q8I>[%RW!+;9Z6X\( 3L5@TTZ(V009:L!ZUH-:OJ(6M^? BV;FB6
MK&5L'=3?P\$V5]?_4P?E//:PC]#&X_"GEF/V<ELE[ZO&Q^KH10^C19T^2,38
M"RL'9,7O0?AEQ$WM\>J<[P*IQ#[W? 09R!2*.#.GXWA/OG(MHM2N&H+"3RDS
MMW=.]]>EZ[WILPGO]98>J^UL<\4  ;?QWS#4%;)A #(6)V_<A^+D0TXL"*("
ME6ZI>QS+(@PB'X,7$]^&*WD.S9#LT95^Q "N6@-#?:$*2MJ=IPZ'R55E[)+.
MRY"K@([Q7PU<YQH,P*@+V25RBPMMF'O6B 'TK0:<WMP*<\1SY)\7OUKO@Q((
MZ9#/,F*YZ=]E)8>,VN'-A_,^AN.APL=L#YKJDR%QJ).KE*';N_844M0L]2E:
M6BKOI-F7I H1#30\3:C+.FQIE=V1W\&J/L:_%MB\+5SWX(?;/B8%-T*06VHC
M10DM/*4E%3&588_@'!_U'?!DJD_Q9)[DWVIX+$ZNMZ(9I%G\$%M@$BN/9SXZ
M,E[I3F(MSXO3"F>>V;R,RX%(]WMSKKC?BB.*&-6T9;LK/ZGD$(_GPR\2>';3
M)G1[HJG:%*G@F<U@<W/[_FT2U2UYV%P^I?G'.T>:;S0/W"LN+ %UMDS9)@G/
M S=EU6. E,%T- 7_+@J=J01/+[.?1G%UW4;[(OHP .%K=0R0ZNET^^?[#/!<
M2,/B#EL].:=>Q=?;CN"FCT,22PQT1U<!2EX80")7#G7):F/O\"9W *$6)P;X
M^3X#O(9?>1^O74,">ML0W+.BB@$(X@_08+4GT.M#G>"?[\K]7/^0,E)]9'IK
M_]D7*=.0*O\<Z221BIZWQ,>>&1(P-/PBG>,4,3*!^[$3>4EUP(6H'D KUM6_
M:<#5T?N3$:L@K,!3& -$K;P?Z@YCQ6-[*9LIPY?AQ3D5^USYO8R@5JP+X7>@
ML([Q)Q6^3=V1PE<\4OC&KHI)("D5V=GA<J>-/:Q)<*451V-GT@F)*3Z0I:.!
M<UO^-H7"T.NI"F9_?E 9_3-06%G=TM@.Y)/4LMPH7B9@8NU^K<[J,-)=]>@_
MDM3G#,(@.AC A/Z95Z2["J[L2+K5<,-1.H:C_X"BRO['G#&J%<1EA4<7-SFO
MH[J:PK-\1&UA\HRG,(#[JWHZ< ?"3)^R%7^-=N_A>PBCC;J6&'S&K%WS7MU]
M%$E4\VUDQ[XRLDM0S7@A6RO:Y02YJN0Q_B_B-MF-R,@"8N%>[*6TJ$E5Q:MO
MZ,Q!YED93RZLJYWD6P&Z1\!SA$YH:,$T+@DR,ON@K;1L^J=Y*] (W@0I[X8!
MCB<LKA%$AP 1=]/OYK*EGOQ$\(<NBPAA<<%S\'7?2^-DK^6#C+8A4D4,,*V
M<RWQIYI.ZT!//U*=\A$W'G#27=-!*VR8\O ZL=2 L0WDLEV;AE=D+H>X856.
M2Q"OQ!.G+>?HEDK:=3G7@\H5>VATI%@GC TR+G9)SST<1/.(1[VN#?]$$7OE
M>E14_&M5*2S=-K*K 727=#:[9[Z#'?P8_X#5\P0!?CQ7]MPBMJ6P>2:0(L+)
M(=?5U$O<HDC'I*K1:%D%F2G:\/CTA#S)L].G/N77B[^@H;MZYI0) Q<;=NWK
M6L5._BJIS:AXZ [XM&*N:S31A2ECDN=V(X6.:.K'S:G-M$%X]59)(Z+4',C
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M' S2;_UWQAT?X[L :#:%5GBY(>P>ZAP&B*JWW5^PLIH-TA= %!CZ@S<%NC"
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M*!BMAM_)K_!&[6NQ7PN"5HJSBH=X"MIHHBDJS9@?53!YWXQ83R1&T>.EKDI
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ME&-*4D;JHBDP0')<RN[L$1-7Y^NA0RJVTK.4>M3<8:PF%:LUM JFN3:A'I'
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MJT^\$2%2^?%?#,<S]O\L_@4S%KNS5NN,U&REK;[R,W(L#PT(G5X&8MGNS8U
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M&3 6''W]KS^]^!?]HE_TB_XLR>P-_P]02P,$%     @ X8EJ5+9?3Q+J;@
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MUWW#Y^O67;?;-=*#*544TF*A /+"!R@@EJ]\<\I$YKP@Q(ZJ+VE*Z*^*4VI
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MG\^]X$ N]Z2DRC^NA"L#ZV/[VBR^B:J)]'@E.(3;5990WVQV)1N #0?J/>!
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MU$OQ=LG!\18H=UX:SI4TS[QG?CWMYOK6_\AO%SWM"0I*CGK#/F1%W0\*R+2
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M]M8G<1"<,S0@&/>.M)& 95<L:K#_?Q, 4$L#!!0    ( .&):E35S-83XV(
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MQ@=O%/E:/09="NV4S7+<0T,&;\W7E+O80(JRZ'=[A#VJK953YN>)71P/R-G
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MG%!"[L +>Q!^FKM;(!E5@OB/#*.XC1/_V70%\MAS)9J0!0%+S/!<]9]<:FK
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M(V)2&:Q:]FGFM4?KE:&K2XN:-ZV7&"@E[JXY1\A9/0X'IVB$G9NR:H'7U[[
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MR1<ZP7_+%&N,_CQ&;EI3ET6M7M5*JVV'#$$;C&E_V?!12/&,_(UIHF:!9;W
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MS78XW/Q3D[TJ9O@-A[?WI@F$F>.]O#R$I,YJ3&X]\8YHTK6\7<I$OA",.3?
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M="5]>!(.4_Y&+?0 "1@,UYS(9U'8ZH-5,EFUA:]'7%A+?WL$:DC.UC'.ZV]
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MK   !C;&?Q;@?UD8CS"QL'%P\? )"!\N@)$!'F%@8C["PL3&QL)Z..O_<!Z
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MBJF2H],JL-[S&89C].=K6:Y/XLL;.PT#G1#E"0<8X]=-P@?HP1-RPO&ZJ.)
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MY.?UL'DO_>\E(U2>-\],/0U,&97:VPSOQH&P%DW@V,T(+KS0:P;J[0OURIZ
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MXD#/N$G1F\7R7(G.G5,8 UZ"[M,/-SRQ%Z[QS^UYIL U,S"I+KK.;_:\"=N
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MZ[8@O<JC^J-:\F?094KP8:&1L+%+EWNY"JJ/N$Z.TQ=[:4 6DB\ASES:#GS
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M+19[+YQ R@7\9.696DMN>C.K$&S4?>R&!/XBX]9A>M\QY:^Z,W'A+QIX+?N
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MOIF'E(^7CD[2K8/D5VC#P7/R6-ZR17!A90+,.@.D)^\0 N:><]<W&$-<GC^
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M&J/I[.FWDAK&'KH _P'F-1'0@6 E1\.%,!!"Q@-$.,'EOJ'85 B':7A5*7#
M2:""N_;WX*1\*6^#5-BT6@ 8JK/WQT?<_JY1%VJB@9H<=W:F/5@B//CC/ @=
M+?H" 1?W+A<2":$P!I5/DM. '=KV$6B G:PB3WJ[&Q<Q+0&"0L/3.9MB&R'!
M(BX=F%%AGS7=!^3;N]AM92AL$P!$J\O/P+HG7Y:E6>\COVIIBST'2B\ZS^\K
ME1<.I[\02^2VCWO%;;S.HT#8DQW 0$MI2FJI8/I?K^!KHM0LS_5*!P&%"F/;
M#<,9E.]\"+X.DC:J8R=$7[Q[PKQGQ5!U]IY-77./$"7]\C Y73H[86FRL-L
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M7:YCG]4V^8Y."N@1CJ;&V(H]A;:%F\0?-UCK1/6QUE[?Z\=)%"NGI<>BOI_
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M']BW>K[9] <W$K4O)0U;^$A]*->KT9D4Q&@]0-G.$+NX9R1\?'A-_[I1^N6
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M5U"8_H51FX/56#A]$K=Q_-  J!F8"<-A8%&Y_._G,>)[+;A^ /?&TU+)^0'
M*+2)+#/I]=33]WJD+=JHPCZ^KQOZ#:Y%-U1&P(.MD"B:ROYW\>G=]\:3--'U
M+>=3IC91>V0JSNB!]9 -,?+Y4D..,67_U.B0DF/1(5-QO7V2_#]@MM5V6"9
MF\)I)E&JXZEJ4=V^K*:9BVF5RK>[#KV?K/9NR!R_!R.6GIHWL,GR;-(J^ 10
M92W;39T<5PY97<[)]%;C3\F:DGDRWV T7U,^Z?V*FQJ^P<O3LK<VI,IV%)S6
MVB^HW!K?,&1V0:+3OG7&I0?ZAY4 :Z:>.=+-S_V!X\<WNTY;WYPB6_V$,_8D
M:\#E[DP=H[UK=4:IW'#HO=KSY'=A[P=^ZW"HUCN[^:1/U3 3P^[?_-8P\LHC
M^[&WA0L?06U:?Q73/OVOQC;<WXUM?C>V^=W8YG=CF]^-;7XWMOG=V.9W8YM?
MK059L6+]RO%]7D\Y-BKD&-E1G_!,X\'0I.H:^/J\G2R?-1NKJC^YO$BN<K+V
MU#ARR6A(+%^[C]E?I#*.&]H]?.YW/[&>J<4XZR&L-EJ5?+/*I%!8^/6FS9#4
M81$YC_ "YEA_UCW6+2=W_Z0;]>?W%5FW$ZMF3M(B6K*K<G=XYY<?]"WD>#8N
MUB</FYF8))^4Z!%KO:VTFJB3._SQKHZKA8?O=ISPD[N;=@=0/K4GU]5H7W?:
M//G4N0=.<<\VO**V\^EUTJYX%U4&:]$\X-/$<;VW(343=_^\(XS6O[;\*/F^
MY4>QE0IK)<)W[Q#S1T04];:: VLU_6P?#X^?\%O=2W![=(%1W=Z#_:_M/8Q4
MMPU.I*D&1IM?*7!]@41/;@W4^K,]//ZJ^%8555$:_O:.'O>2X-=I$'H(+YV7
M[<&X:Z::0O@+#5_^%^IN57HWU\ JJ.MOMWI19;6NU4-?F*54MR@@)P805!A'
M? ]S?$JMP%FY?6]T'_QEDY>_47+[W^1 9]9/NK_412D34:5P&/&++<%%\MU>
M0KFPZ+TFVI_WHF<NX;_[N^SA=N_OTGU '0H4L&]<$["V+0^  W@&Z9DGV,0$
M"BZA#I&*P7M8?H\2^Y>1S6XD5L;\DV*-!HG>>G%1SAWI)G,ZOQ:XB$YTR9CK
MJF%.<E!!G>TGR_/C>NP<[-AC:^%?;^W2)C_&@'ETD0ZI$R"@L.^12 $L= X8
MJ\^'/Q5RBJW,N!19CSS!A\;5[0!R.VJBIY0P-8]Z#TR/#SU&3AN\**8,VM.F
M$L ,\/@ADS!I30Q:[O\DGF+KV?ON&^:]$UJK,9LP(3H:>_FU7'738)>MJO%-
MU@T%3LDI7-8\\TK)Z$V& *A*.J>T*G4)*3\<6:,N>VK9ESS2,N,G>VZ4_VR?
MX>>SV(+9<>C1:?*!!8P[V?V X 4!D6QB2V=F!_8XT"V6N:?W6&9/T/4784P
M(%[W+T$^/P)VEL\R!QY(?__5@KDY%/=R#96$P?*:GA%-9/@]?D&9;(%\^N<>
MY;9_O0='+\'+:[WR62YM_5N1/*DA3<F)?E%%5E_=>]MY(UME!^$4U?V%&:^2
MV5V-<F12X%%GK U/_P:M4)+G #X?A=&^F7 ]27YUW&HL+4_)I7<.[9W7:GUN
M(CZDP*72=.=ABR0&<,_.S:/_ISMNZ'*F'0Q4[S53\&^4W_[0LJ4'\LITT5/@
M_.AB>-/1W6QEOXB=JKMJQ">I;KJ1[1^;SUR''[R0WB-QL(AB 4X\DX5E? :O
M4F(2QRC;H\ -LSHC&4S7'ZS2GB7)G'Q"@<LS,/08MB30+W;OLV<\ST#+F'[7
M' XO]S1Q,[YK<NU%\P"_^!'RF8]*Z@(4.'5BP+U]8=..V*?[34PS#!L;W[QD
M(_5Z\1ZUDCT/6]3LQ]0<WQEWI@IZFCLVQMONLT_;S=+O^Q4/'E,1?W/*9:N8
MR8G5[W-"<]P&77-XK?9U RN)>B/)H*MN #WID]D)HF>4JU/U^?4:*W.WKF-/
MG\U)]@PK&<#UI-L^F'E@?/K9]YO+4Z<Y7>UW;(]:[EP-60"[#V5!J</6@(B]
M(JUQHN<3I+K>I'%IN"^B)%Y.__W4J;Z,%4\OS)^^?!YKZ>B2J2,67GQK:7K<
M\1K6[\,,BJ%;[4>CC LF4[;,: U[57SAX>9YB_-MB!M"':Z=O6,='9%&+??R
M\_$C1'AZ'7Z1<7'6 &T<3@V'F]HGO.J=*/%3SK#C@=YCZD<N+PTZN,CU^$-G
M$[N,Y_S\NX(]7=<XE9^2*O7F#&A<4$O#USKW:(VX6-_4::5VX5GWZ?'5SBM>
MH8?W7*M;T3K"+.6:]<$GTT:3&0L2M-?W]YLY:?6],XYON-6N_0[@D_:XGQW5
MN'W4DR<&3T[,H['^/_;>.ZRI=.\:#H*"T@1%.I&BHJ HB(*4(%5$1$"(U(@(
M"$AOH88B(%U00$&(=*F1WHGT*ATBO4LOH886WN"<,T>8L<R<>:[G>]^//_9U
MN7=V0LS>^[[7O7Z_M1;O(V] FC$;]2-@1ITBUF[4"&L;,TOIB*C=Y"P$C>=(
M#HR'I4L P&I>I%W/NNN.P^H5)-LVO@2>"TSKYM%G>3]YA<-MXTM*BPA5=$3W
MT/"U($F?M[?,LI&L88-;$)[Z$48AS?Y;95T-^%=H3")N/$1%H^![JJ]%,SW;
M=0E1';A;!^KUXSPZ!\G?"JQB7PNL/)A)CGHT 4\9FD*?IAM3.[I4:1OQYT3@
M.E9O5]TB-7B>8V3]UN'G&2^<!18Y(C'QL^<J4O6[K_F^ 8\]?>P0TUKP(ZYP
MK\S%9&9NC(MW];X>"\U"<ON/XNAD3J&M,RIOOW2\@D,[;SMEG^ZU,/S&L%#.
M.>BJYC$4(XOM PW'BBJY&B'#\;A?"2 1AU)*!JQ"BWM.U!9P?+0>&:,UMMTU
M;_BKBA=:[.G T%7K;A8;4D+.*^Z[?7IU/ZN^FOBDE0]B/5S/7E#^'#J"/SH)
M$<S]!W0O =U7/D<<%LPY1A(+TEZ#(H[^2@5V?=A&%[WUKJJ.^J[O(9C/6D -
M O_OE&%_LRG\(9R%C2A28^(2*7U?^U.X#:QIARUM_'(P">SX9V0%Y#@/LZ@)
M9$Q(P@;^*Y78@9F)6VU%MT38/-U<!L;L%FZO-74U86]B<2@X[05L@DM-#S@W
M</6"?1@=Q3FI9R_NA[QTZQDW:/FA$J;H6J7#F>&RX^G4)QZ2[0#R;Z\KE*3L
MIQ(WJ8EAA8B%ZD5A*?HM%;L/B!C!:Q5.C<U;L:NXV7$D;+WQ6__"S.<@YQ)8
M8#"Y;]$^MC!Q;V )1MV)S3'S,S+URJX_X>W <!]C(6'EI.VISOUL8HFG%ZR?
M>3="0E=QZ[S=F^XU.E)T%<P2F@3/HCU75L)4%QCN:CN[69#[?5H1E5Z*I-XN
M\K^S6RYKRLX?; 57;5 <>^"#,26$O55F_"%_:+++'U9O??B%@)*>H:,<:$4Q
M9AF'11+RC=&5[%W^\/((5CT:AU]Q4]XO563?;^$_$F:]?.SNTU@"_]Y46ZL?
M5F1G#0/6GWS3K/=[[U[61UBA6/,9-$\/2$^2%8RBUC]="OSTV=RP;@NWA&%U
M^AV]_J6L.3'@;M9<(;W)ZVH;DQ5'CO&-#>)!N:WGFKCA,0VW+(N>OC.^W6>W
M WBMV+N^ZLV.N O_6$RDU]Q/86W2A512I&=7$RBZ4D4_;XF(-/RQO<RGPLRM
M(RW7)6NS'N"]=2AO"@B$\(!_!G6!OP1UN] GLB)I%UY>-:)=>K2NAD-+"OW!
M=W^FF;$:E@QD!J132GV<7_*NWXZF*<YQ;O!]EI6O/,5'E?RG6!A<6&J/0#L]
M']E=4D$O6N+ DT8,QN==054KA76>4I7<N'KE=_0S2Q45<(;TTZZ6RWQ")19*
M23^IV(8Y^%'[+BO?BE3T\NBH<IK7_.\BY]H1P.<KIA^*7%)C"-*$(:\7+33Y
M_YDLD[7YKFZPQG557Y&95 NFQP1:3F*H8K6_EV>2@M'%W<O/P)4MMERYL]12
M#2,F&\]&.I.5_AGF\5SY&XVB,P2ZA$HJ:5>864DWUR;["PP-O<[I$X1DB%)\
MB*M9WZXBM1C8%X#RGS:],F_V5"(<3G;>W?B$U.304>BT&*NA_*QZ0Q6CB\&C
M[<PVE-QOH+()'P3'VQ6=JM%@K.NN%.*C/K(J&9/6WU8AS(-MZ.1=BM.W<\RX
MP^R]-#-OP>;NS#9J&D4N-Z\40#1]0]G//OE)ZK"A?81P2[0A_R4$Q5N.1,["
MI26 E-.;2H )AJ5UJKI4539U69:JW?1P,(TVZ<NP@22[NPE&J?K*W<%OM$U,
MPT<X+]]*?O57HUCPFEOVY[?LQ7?%AXIV -^REN.Z W-*0F0IU)L5=[I_(-$8
M_I>(F>% Q'P@8CX0,1^(F ]$S <BY@,1\X&(>;^(F<EQ6!94_A(SR=+AP&6;
M"M'L3G@E4:0@<=(LI->\X=CB"/]T%7^:O:);F1G48^EV<PE-:2JI('EN$XD^
MS;-(Z_=:2SG\'],0%9TEE]JL?%+ERCJM;6;?JTD]G33C"C&*(*9ZH><)>3L&
MY<?OC]".,\ >6U#H>K)AVFGE15Q_-=) @O[N5F;.%^ E>ZX$ T#/@J^J@S!E
MZTAK7)#:81<'ST#K=,TN&AK6A"$UI>"A\"-M@KP)78(*XFA1?"D.#NY<A:.:
MY/R3JED'P.L >!T KP/@=0"\#H#7 ? Z %[_%P OBB9!Y69IP46V>U5Q$;V#
M[(S2O'4[@+*6!=S5[X9M;R4S\4:VSI=&GLY588T8S-&^>J7.)=3OXS6H^@C2
M8&E:[GE(6U<I!Q3_+B<ZF3)WU8"?=O!$(&9)A"DWSB"DH#/8*%&%WU[M%:5X
MY:TS<F)N8 ["4K#\ )1+NL"CD9YO+!>L!I6K/0XJ$TJV<_Z-8DL##4MY7=KB
M&3*S>;0H(?@R%O9$3?'&QS?UA>]G3@*K3^)]EM<T)/>Q F$D+:&#Z,,>">^G
M53V[C+*)+IJ=E/'-401! 5#AZ-PMGE0(Z+D5G'0J5-K&-F'=XDR=*.O 23>.
M/++K^(&5 "NK/48RQED+,4;Z\@^L.0\_5)&AAR[=YV"A6*5W\@45GP%86BJ<
MNF?ZX)#=H2><[P8_$*Q^ EP\&?[J6FOYN9PGO84Y<[3+7X^$6O>5V\1_/4)?
MS"-"+'%VK"_7M EW)"['X^LYMCL /]BH<2MNZJDSV2;E0)+$#EYFL_ZT>YP&
M2*W_^O1PW=/!'4#.'J@W];>A7A1ZP@U-<0LW6T95MTT9UD^O.61N=X)0BB/G
MT$QQWQ.F*J]]!*VS<\-0;^$-RH25KN05VT_=X/VXR>D;ZY,J\#[KDUQLHR>=
M1X'<UF+ >M@ #N):.;V_CV6MVR]/A7S-WH#N ."[N$^%JLL=2R!$/2K3N\&Z
MZKB;R+P+"1';\1SC.E\+ITY-%>2$AH]?$'87XN[G*Q !Q,]T%=%; )'=^ V1
MK_$;OS?\+?QJPU\KX<R7P< &?.#:*FZ_+X-\2&9L'4BA-DSQA^X^<..G-;G6
M$B],GM36^8CCC_6VZ0,PA[_)=Q/H^#OY;B.K?JRZSCR-NE@93?*_86S2?YX5
M>Z)SM>UK! ?D8A6L%!Z]U23&@15T@@4JP'$X'C><.NXVTQ_FWK/G9/42AE1<
MV::=']D!](W:4N_K\%OF\D-^4R#-_FZ!%(F#9Z.Q4$\L4K,0T=6#E?RDABV2
MPGIPN&/\;V("ARGY=P"R_SOM?KAO1I3POZ93U=NK4U7^:SK5[R1P_$RG"EL4
MG/AW\,;_G$[U">SOZ50S_L=TJN?_IDZ54FKKM!,SXU;G[H_[GPBWS1\EN$D]
MJ_D:O5%EI_(K2E7QFQCBJ(<[@,.>V #__+P #$<K)#">?D3SO>:?&98T_9IA
M"?;L:8Q%V8,=0.0/XC;^++HM;K?TB7LFOM8^F[IY7F<QP/X ^^C^ /MN 2D=
MA*4_;C[ZODAU]RO:P_[5^/=7[$D>MMYBNM8B?=H,!%G[6R+5TU ?U5K\:^DC
MV W>5=O<K_8X7\2&!:>K!Q;O;>'&8RW<<[G,HSYK^8?*9P(A=IY<8OV8&OPF
MMA&R> 2%G/X"V@:T]S/@9BCK^NWRW;O(;=7B]).-";;'O=756X!V[+>O;2%]
MUW8 N0-3]K:@JFW2V\6X@>B$(&ZU!@%#-I@O^&DLE (7/#!YC_5FP>JP'@($
MM0>L7P\+[&!\D[NK Z2E^U:9FKQ'M8J(3$1GMGF6^2<,C6]Y62-7^G'+&JE:
M#5GS ;+/L#): V[N<_DU3=O7@PJ<Z[I*"1E-OREG5D9[<XCN-N'M;B1=1:!8
M];/1&9.=XYO2HOT1SK0?:>@#',@.:U<NH$KE10,#2/2?4HBZKDY5C+1'2J^E
M1M@KRQ*+%G>P><6I/?#UX#U]:K5V$,QH,LQ%+14W/?L^QX<L*OYY&JLXV:,G
M73*OZT^L?;B21Z*7_HYLX$Z;D:4C]\#=]("Z[-R;#-)!UN\GN WZ=#'V*CX5
MPDP?.IF]AOT7J=YHFW/G,Y)QW/Z*"-D-585"D+%-\09$\X;"UY-NU=PETEHZ
M3V!^V*)SPQS#1'.U&+\<'.;QQGQ1QGP2FM9RK0-@%.PQ^'E&A$8X^[.\").)
MV6!]O2/7W8Z+G,>G3H45&J0FB+%4/0/5U<0NT!N3JQLW\54:0?5N%9F<G(X\
MB\P,J9)!GSS>7<LB0#1"0])CCL<6B2?XJ&"*'?_"?+GJF>VVWKY)Z\R[N%61
ME"^EX0F9YJQD.08#^9[)531+5T\>D3/)W$MX,UA+?25A*Z @81O:@[LC%>X=
M:<^Q;JL+JC\DZ+6FXLGBQ3D;'Z$;=%)?<2Z?P3O2&^ R,QN;I^;I3J>SF2;%
MXI&98Q]HVLS\QH[_ZZO.73WT@>8/Y01A]7<LI#[/EK2MPL\(XL;C27\#._9#
M>'I/<\^.:=V\,H49;0ZQKC5%'3UT-#S9I39QXAT1:V:.MW4D'X4.K&C0W- ;
M;>WNU+T=$A6G#]&7)TC_-';K>8_/>8(Y5B%2FU?*2A-EQ=?OVG-/M@?SGZ^V
MM+59A>$F] DUW*SV\3D,DQ14+H&:$[P96R_L=S'E%$K8,JA6\#'@I+]WQ7A8
ME V:OF)IVD)_PV!"WC%^<;B_H:^F])V:Q6;5:_R6],41Q@)4%$9.W802"K[;
MR41QHD\B_P6#\\W3@QN/S68UK1A"CTI&)Q+,%34FO7&WK:R2DX1*5<&.3:&<
M^%6R(HYM#'_N?L=E:#!7F&%1YY\]#EOP@"9@W5-Q( >@LP,8-IP]SR!UHD92
M-%$; \:/WH(L?(G7DEDI:!F%OY;=LF=]97UAM]D]U5&"I#6;SN"M0@9N"<_3
M9"K;NR3GJDG?F35/7W\M+@;2W1-^773M6A-=T*T1SL-F<"H6?W(ONW:ST^(J
MX&,Q+HO>&RLJ&E0M;APDKN0$X!KD-^:!&K2.MN"J36GCYOA4^J\MAO-T,O8(
MW/64]+A\<\*6=UAIC_!XXLO '**#0FY8,+3R0N+PK#Z%:-+ '0"CQY(*[_?Y
MT"AAO/*3V&.=(V^HFOO,4_@V74OL?HT3E7(>\C;I&M[\Y =Y"O;%/65J8>O]
M?SV=#HXH9X!GYJQ)Z-WBCO4'KQ4GCU_8$-MK&%CX&%@66K\HS));P>K8MHR(
M*KDD08L1BJJ3O^.L!O@\2AJ\5+][/-KI$JR6M@4VB\)-;:D\7&O>PLBDL_0\
MXW9[1,CW#?8:!=J]#AAL:L&*7VQZLAW#*F))>\AY1N=PX8MKJ&>HHCWJ&4\<
MD+%>ST@R_LI2_%MZ[( 6?!(I'!@LPI4@^<!_O,%N ?1=,<U87A.&9QGR9D('
M5AW0M'A!<1F.F[- .-R\ 8C_;4?NZPZB,<-D;<H)&2.T!=LL"CB-0=%)H644
MB*)N>E.:36E3C7?\NM'+():%I1I-74'D324Q/7AL'O1M+#+U,&CK50 .-**F
M453DZ[1-;5O>L$/\=FO(KN8C;46WB&JX *S80RN#P=\5)E\]32WE?O_AD1<
M 2=TLN0/M<F:"ZT<&+E*[[ICX5X9Y+#>.(=$B#)4&RL!H<)]A8J!C3,<8S>V
M?=R1?2B,]CJ0U0_+6?P W%)"KP3*+.+'CX<!!<&-2O^-0+ER6_^^ ]_"QV,
MZE.?5W?]_WZ!-2V_03HA1"*9Y-1L0.CN( C IR8@-^GK*/XU>7+3D0M(_ZM4
M#X^%8VX2(ALYR/;9 T(2'^&62.,3N&-E_A,KY-W7=SL*0<O_L0.<_XX=(.S9
MA52THA@)'MZHX,;S7;CL\C7YN$MBJSL=^WU&M0RR>#4@8:)ZE?P20AYS)&F
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M,S\Y&KAMB0,_-^T6;GQ/N'+CW)8K#A4YR6W3=$2I;'R[!W'#_;/_@AVR8=,
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M/KZ0XT_X0E!<-=:98RDE?'L#CIAH@@&Q\ZPU)==AM8KML&E?X 8G.!+\SL&
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M0RW/#NN?]K'KJ2#KFY^1.XD'+OTTG#G,"(5&: '.Y':5U!?63&SFS,VO66#
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M4ET!K"Q\!EO3 ?J]\WL.-QYT1'3$PX=/6!A=I1_U- FG51^"\'VR"=JZNY
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MR_?F:7_/=QL6JO?O'28%27YHG3,QYARD$)IQ5?D Y3S)_G&"#S\.@OL#@U9
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MH!>9M\/LS@%[/Z !,Q>/:6+T<6::PX]CJN=HAMU[UWB%'X,ZPTXXP/H*E2P
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M.L<3^K"Y\J)'T'HBZ=/34R)\.%BUYHC)_6/G;+C6U2<DH'D/RR39U.V.,P,
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MT*<3!H2A;KV"-R+^GTS(FQTQR/>1I>?U9=;3OQ"C-5*Z"#<,1>, FMX[45;
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M[,IX#-OCW<K>;\:,&#@9FRHWS\L#^IDP>!WA*#%1^;0VF(?(UJT'LSP2XP+
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MLP; "R;(&>K#4AG;.4E1[VC),/@\.!)>),R?A]A<XHMAK-=#8Y:2NHC4(Q[
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M?LW]QDPWZ^A*@R5FO"Z46A1>C=:O^W?6Q([F<2Y]?K1VA#""WHV]3_4FA75
M& /G#W7&0I3K4#OE;+&%Y@YTCW(_F5E!MM-KQDQ1870P\#ID8(4E1-3LXW,"
MG+KJ?5&+#3;OI8SUM&/TABM@J'IL4 GE3M[)HP.U$^=4XOI1FH,HR* N% %=
MG4&25!D:34#I,4:>%F1?*=@1FY,3N5YS^HHLE&\%_^7 W?I&'XJ+">9DN] )
M#S#@%IB_&W&FO*B1_'5R2C233.HN;++2G(V-"+)?^DY"E-A:G-HUS7#HQ.;3
M:6Y@$<MA+\206KZJ(7:8P2>>KS\ZBHA%02UB%@Z0$([_>S[/<Q:S?DSXJ67!
MILNX"]]QI*Y.=B-1H%@E2^M] OPM$B3 "#!-%52]I-X%!P5YJA59$ME-=5">
M*X%OXTG4=*.B6GO A10??@,[\=R(D1")\YWHD_--A&UU8R^FHZ56F-*<NKK.
MI<;K]-A;U0O="F<WWP\\C7]:%[+8I0.)%#>*Z%5^W?>5#ZW7-'G"Z!K.LVB[
ME?K8N^V"PC84V?1Q4E&T7R@:XBB,#Y6OPR.$DL"?NWQG7DRHU->HCEA;O;=^
M_,;-ZH44HEVK4R<VCN=EIFP(<-!0^JK>^ K ,=I=3;A=_TJ]$$*5+TR>I43'
M9<L=6<<:, !,I+=AJ@]*(3*6=9"]>OS4IP 9N'UZHW(9]';/.\ )A[#5<65T
MN_BPFRY0JB.?'V_+%MH;XXHN\_3S2+C[L<D5X,-3F$:T=GK45)7=&,=/H/NY
M$)BQW;^/$'R$=6":"G8:O1E.ZL:?WZU/&7A3Y+1YH3PVI1#BNAT]._2>BU2<
M].V.D)^/ . P0,E<?'U(2E%=791VU\;4]X]ARS:ER\U43[!(I:+*V^(>4,4.
M#_U46H6TH"=CRJ2E2$%,[^U"%_4])'?&GDL,[RA_+1W[V@62ES@3ZK!PDGOJ
ML4"_G[V_K67@QXGW9DE^"?ZQVVK?#DHXNL;'KZWO;V+HPL/="T%O6Y$@!1MD
M G,QGU&*S89NI(-)!;?#<[TM[HR4%&5H:,BHPT?[BE#G0@7G_(_Z[32H,1@B
M%&O*1XY\<-=:ODPHVI&^,&OL/QM!\>.: W6B'I;*O?>A];M=4Q..VDD;=HOQ
M&'0KZ^>L7/2>8D 5.^ZFME[/,QA;6FY-:C4_T=8FW:*07DAMU]-0'-U5$10=
M,&"?V!)01>FM/D*M/%J<)#]2A3AJ&,BLKO7D-78'>V-8>IF8"X/OAJ+&+S5X
M00LIP$G0$QVPO)BK5R_]=BY,N 1U^DVM8:#[86$B591-NIFZ(#C#V>\S80#I
M0%\KIO%BW:;V+_D 7;Z*.30GD9>G<-9' D5.][=6&X/?T[=-I<4;F8)LT;&E
M2 ;<X68W[TJBWG+%&J!'^>&X:S."HD<:D7+,1?G(+@*:BBN9<]\\K@[!;2!W
M>SX7H23>*:2A\\NJY=3]3C=EZFM&K(<_[TOW@&V'=O X+UGK2&EKFDQ<V=NB
M3S3$Y=EDTM_1$AUD2FK$)L6YL/3',:3.Q@[]6@1-=7]W;*4LSUP[-<F%L.DX
ME0T/<4V+\EZ$I2G%$FZ6%^=LO3LCB+NMGN<EU2X\+0M\)XIE3K/Q$X>N;S?4
M*M4BWK=E26+0>_,3]06@\:.WZJ>QTA]L^/G_]+^!4%@-%ZFK/<5'SUE.W8*M
M%K3P=_J[WL9*,M=0WT>X4+"UL&0G]*J!\E]2R-VEK:C&3VKA#_*.9R2F]"]]
M<%QR[])FZRN):YM^&_76FVW1%?%,AFX.J_CP$RFC:U-/>+O^9<&0?G%>I"7Q
M)6E=/=,K.'XOWT6!E^1VYAHC:&3+:896I2YQ2G',RAI.<P7H$39]DAXZB'@'
MBAJ@&%<O791G5VBL*:^NKVAJCCYFEBDVJG_&A;5=X\#8O4CKAZ)?U;9>GJ)\
M!;1QF">N)/".A7*A;E?V<V9&#PE'9[-A*,PJPYDX-.A]6N<6," 2CZ\]'L6/
M]=P\8E/5VMEYM57,9V=NK][%3CLI]2GVN4+:8J+$J;(2.RJ=OTWPQSOCZL">
M#'4SS01JMH(N#&D0K=WT[:#"PU.6,)%E_V>PC7'NR<PMR]<E>)GJ<P8?! 9H
M(^STC5P\C@F\F8N3[7"(FS>GYK:1$O;CK<(+>G $0 X &LIPV<ZJW!0U9:'%
M=E%67+WU604^G4,:9VRH(8 D,)5<MH@4S@B".5Z8RHTEFHQ4,0MU^E;WL>9J
M89JFDIL+"%,UQZIT:.^<TXH2C_*65GCE;D5]3U5,J/"F,7+&%CPEZ]H?9G^C
MOL"C2OV%K?9I..)U[$XJEL+0H?C]'MD5<.'AO?7)AZYQ3[3B_47XHO:0U?,/
MM77ADSD5H_JFP5E":B$\C'QP&@J*T$.>N)?W)JH@$AK^<D,\$T$*399\T9LJ
MK@F3:CIWU)$!PR#W9%>I;7LMF8+-^IQ<K,I".\JJUAKIT#??M!KS(JMQ: A"
M?3^6>']*1$K-+SII]@BNNNTT0:_$6L7\Q@D:3[ILY(1X,!HZB"+CM4!^XB0D
M0C3PI*9V_%XUOXKDMT"!.^*/TF;=3-[!!:@9A&-"RG(MRYNJSBR=Q2:Y-/D8
MHF6XK;I#@\)?H)/:3=#@VJ/"[80U1'V$P8;$P9#$SEF!-Y.6C_;E#,J3@U[U
M!,CBIU-P&S9QW4_%'=-&XW7R<CH2P_H"Q:L>*]5[(&##Z3EWJZLP0.A"!C%:
M -B.'1L4Y# QC'S8=;=.#.MD@QW7U5)I3/03I(3E5>AQ&-M"3WJLP1=J9HCP
MHA_JMM[S\D;#(7]FS$ 4FI!]<@'ZD4O"R9/ 83[GP,\;L\<"$ZRL#<+)%T_#
MKX"<*T ;V%3I=(\]SLC27'?G+:K8(%,:[:YO,8OC[0E+T$PN^PX5(!PVC['8
M#Q:KLK*"2$/CCW6@:2XE+H_?;6_JJX#6AD[\/Z'HCHE5%'O/$^J57P%F37'/
M'%WU-C8421=%ZNWT(^8+2W'D*';7!&$6#Z7=O!<LOA4ES-G#EQ]"%9  [3$G
MW]SI+UIMJ+7-S?'&2@E\GF_ZPA6P"36^+,52'F@2N,)5_:X U3<R^&9D7KTZ
MNK/DR7)O(27K1--<S$[T'UOI0+X);"Y2>PZ*YK[[RT,Y<O;N-O@9MB+'L>>%
MX7MT?,79)T%M9/S!M"^:ZV(UP&?WSPQ2/J^@RG2]*IO5Z:4UM^)[ %#.0%\[
M:9V#G;+-ZM528#"=#IZ1F6<\& G\AJHLBJG$(O4A07I[ 9UO[ >QN![T9P<=
M![X'=S_%U*E.8U^Z6/0L$1<2W7F:V#D&.<>S\<X'%VMIYWRX$V:4I#2UHAM%
M@C[>$/R@"V,?<$'XBAPGC[2RJY^2[QJX<.$DD0,V];(!I5M>M$/\'O4HR%'6
M*>>N6IN!RFO& E:*QN.&T&A"D*)UPLZ9^=!I2)9B>ZDD$?2QX>QR++:/]GOF
M:<$L6U $\:48?:F2BY9'+74U,2JU-:-A;_G)K&P5AJ3<W/>CF )0\.=0(VF1
M8>\6F]R=&W*;B^?[Y124B>0:9 P04Q&,:4\'D6^Y-FC6#Y/KE>U^3<N$'!C=
M.X!,#QZQ16XQV7.I/?&)"G^U4#G5?NTHH['%9+%F78=*#ZS;R_'#2.33[C_B
MCFFI(X'*M@X)VV2NB^)45#2ET(P708RJ8Z09B.6Y\I2"B6<A4!(:W(<HV3@B
M8P/MI>B*'A:L;%G#;+,Z=@P)RYP<RRX&IE2UZ=@PV#[LF"]Z>(%T4<-L\KUM
M*U<R5[20_T?*PH11X6?>N1B%WP\9(L!5=43[NG(/9*96,%;HZ#F&X")R?N)T
MH$YW2\M>RR\P.;G7IF%ZF2^"VX >VQYI. ZB<ZGP7F=IM@5,;Y1C@+<EN(BA
M,RU7CHTNT<1NN;9F6EWU.0*FZISQ>18%X!@_2S>*M9)IDV'.:2'U!-#['B^)
MKUNR1V%DA +)(HC.7'F:6CM;6:_3@,IVGI^N]5Q+N&XP,T?2ML<=;UHC+D5(
MO'Q"6-G3D/*]GKYL#1&&^T-U+/1 OKDKH%=^T[]B95YLLF2Q3:,"YFHD63VQ
M0RMO\(4E!LKCWP\IX"^C5.#BIU81)^6[%*E+),=2EB?H&62'CX_/[L[@"*U"
M\FDE*H'0:=LEGX<=NFD=-?!X#9A^H!,EV_!\\4KT_:EM[*XI8TZ)#T'H]J(G
M#)8&C@/\N2=)$GO--:;>>9NG>LUI$'OR)\/-,R2)"TJVT7UUGQUZI$9-&5*1
M&8Y?Q.:<F.I^J)76Z QVL8<][VG;UDE4WJVJ?FD01'/>PN:R>I('@@71\@ZX
M0CM0/KF;5*U]B/[VN4'.@<*FRL<JNLV_U@>GM]/+4A\&OQ>I)>< >@9%E^%A
M7+3W[]QN$J>CH+98%7:::'MV3%E]!4SF@60WVY7:"LSXXO:*VP7K(J&VT;8%
M93N(F)ZM$79:@M3!YU(+K!P6?&3(;ZO[6<IRTPJE2YR%[M!AV"/+IJY\2$5S
MM E^2388"CF^G0A?^?AI7OG>*WC0)3 )/6/)K#(YH?)&S@U4<[(AN @YU-/]
M'NG]"<Q;\O5KLYAS!:-N*)7_@P%WX##_*)^%5X1K0*E:6OWBB;FP@S6X%N02
MVQ.>3EG\U9R$PO1Y;2E%+^%.X*'-UF1 V[1%G&2/9O8L.3XR"WER6,BJ:$+)
M^'__"S7_!&*T<']"ECNI+15]OYA!:R[Q+JBSC6:1)I20)0MO*,*3K.4W6H^T
MK)[KR<I=?!X1EB-"^Z[VD,$7KBCV\&__[II1/NNC0Q%LPT$X@KZ ZR,I[7.B
M^61,4SL*XU1DN]#DKW^!*_6_1U>3_P=02P,$%     @ X8EJ5)+]GTKNKP
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M3L12H=Z[:HBGFD\1"SDR7QVYZ*[C(UC?]Q;:]344[X+\2S8K)6,6\"3>),(
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M[[S8L?6RQ,IER03R,[=-Y@QK3XTZ1B=M1X<HU@B5Z$;=NUFYDZ1%^YOWRUW
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MZ= GHPEM%BLK)$6-UIO,G^Y7%8^V)NN#Z2^C#LF'A,/H%*\]J"=8V*J\;8Y
M=\]MJL*<T<HB1TZF\%X6+.,U3&5-<C7I[\G4)QHZ/@G \4%J8'PLV?18E*<J
M3+5-!"6\S74V:\R24Y\G5:DEOI91PY5_F']!3P]7K4]!83^W4T+KD6]+?Y#
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MD;JW5)5?/Y,WL;(G[A:NY.AJPEO#0%ZV0 Q-O]&L^N3^]N<)X0WJ7KALF00
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MHFEZTK9XPJP-;KBU&O9TN /0Z@_?H  _'7+&^@C<6VR"/#POF5EL"UG_ %Z
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M,W)-X!!%+-@()%)A\A-7[PON 9-PA>FG_F#^]?-0#$&6?*E"BU]$$3^3GH^
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MYOSXP,6E(=CC='R*%-%AO76)N0.($"SZSDA"N2,]\OJM*!*L[-:+(MC5/^,
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MEJY^L#4AL; >$:,+G9P=/]HVF%\UQ)5:CGRBOX/5*E_3CW++Y]M7]F#,8YP
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MI+1>4A;HOXGYF'W^JN<.0,6%L67IQ7DPOBQ<F/09WJ4*!X-.65 &43?P]TX
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M!]85K!2JR&J\NPY#QPO;9I05:J%--R1<+&N?;979(VSISKX#^">HW0&@#'>
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MK@&B$J=%6YY<!9<;MG6@'RNM.Q)JUCG3C=D'V2[GT?UEPC)9<;^0J!ZTA#!
MCU7@YI]KOYHS[O[7&S8,&HL7[J0MS=K$)8N4+*&VXZ[8\_],JQPFE6J]WT>E
M#A-6WK6B*O<:ZCFQO.<8_X:.@?DH,WLO,4^T1C19<.!N"![F'72SZO=^X4X%
MA^Y,3L:GV-< ?70F\)R"BBN4TZU&?) G.;EB#+0FGO!#W=%8[6RPQA^T:JA9
MT!+O;5("\4FP4#<8]B2+4/KUH+^><D/JO\'3/VMH'0EP R#^6#PK.KSKQBN(
MW?0X4SDH@8[N25Q&5@7*8"H3C!R,H]+M@JX!'F%9?'X"-T+L;OY%QQG58?<^
M[.F1VY4",$]JD2<V R6JK3PK6J418L9U=<RV7FG6V??UR%9+/=*QQ#TOMII3
M?S$A+^F6W+GY/K:]B5Q6N<2"IT[@#[(-# 9F)?%A_KUQ1&R]R8#F7PO*!G8,
MN7O8%99CTPYZ/-YN,G:#ZN@X*P9AY\JC0 116%HE34&*]<;=-XJR4<C1T^(I
MAI_:W=R_DG0-,+P1VI)\G>.&NU,8T$T_M0*88!L-#*._BB\0LZY]R;4O'G>C
M+'Y*_*GZ8LD6R'#8#?$$O4YRK.K2L9L7Y]BI'AM19QE%NNJ3WV;E,+B.O/"]
MS[B$N54K\4#2;PQ'=20O5C$Y3?/Y O'7VY4V;-SOO'-,\5ZQJ<12I?Y&HJ9+
M\S?I0$85&1,;JJ&I'MU-+F!TY<#3+XLP"ONR&L@VT: !! <5L64-UZM6<&?J
MA^?.6+MIM/43+<]X6%$YB=H(="*?=:0O,GE=V8S-$M8VU) +;ZVGA,0\3&/_
MFI6-?N9XQ+B,/F3?<%&<5A /H7\O2*]S8[5F8[V8UUC+JE-'?EB>_@>Y= 1A
M?*R7('R$^SU,AWT/_?=ID@X#;=M]$*U +=S'4;#/.>!9=770PW9SC=NI\_CW
M:,,FD^B3*WCS]=R<6(ZT'H_5@WP8K>?%95>66+L8;J><NU\6"T]BUM+3=.]O
MU(E&Y )L='$+F'Q1I6.(6$*7*?]=]JPN=NIQ^V'$>*FI8;F"X;WO<DN:5/EA
M3GZ@XBFTGO_^9&71F>G4RJ,C1M^#PP+4.])^U[H&ZS5'^I'+"H9-9T01$L
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M!.WB#'N.8<Z>G@Y6.4JY4Z81HB5/:=YPO^C'8<2 G\)0!_@QV?*YNO[%JF.
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M2KW&PCT_-;[D :&75;I8T3://^*QSD/"H([J:B?NI((MK@K9Y3MVF+MU#J3
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M,_F! VG%2V/;BPR6G4[R?-HOB=K<H\D@*)@,)#9J)E%K?B#S\$X4]NB-4C7
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M LXU@ZJ[>)K*D&@P_I\ZL/=?@>N)_P502P,$%     @ X8EJ5"Z[O)JT-P
M)3H  !8   !G9W1C-#5P<3)O,S4P,# P,3 N:G!GS;ME4!S1]_<Y! ()&MPE
M>'!W"2%X</<0G,%A< L$@LL0(+A;8&9PEQ <@L, ,SC!=8+[YO?4(_MBG]K_
M[HNM/5V?%UWW5M_Z]NE[SKG=?9\6GM8 KU05510!:&AH@(__#L 3$B />(&)
MB87Y_ 46%M;+ER^P<4GP<'%P<"F)B E(:*GHZ6BI:&@8F'G8&!BYF&AHV$7?
M</'Q"PD)T;.)2XL)2/$("@G\YR)H+U^^Q,7!I<##HQ!X3?-:X/^Q/?T$$+X
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M?J#9 0#UV;%H^[J!%Q56V^?B*G0#S1R2[&7Z$29IC0LL@@::G"8TU4,6]Y\
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MNXMM'B=^0QO>[2;<SM?(6]5M;HVZ2'@"++K)C$O%X.+N.(4M,K/3>N30.3W
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MD-_>L\Q?*C0/V ;%SE7-FVK>V;&F0L7&5=S25#GNJ/N'C$061W#%>^06+UQ
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MC<NDK/JL*\<\<@<1/:1;MU>1C1"B?TX//T;G&"BDJ&K:#.-3LE@&SGC32C=
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M4.5>WAM%G*PLKKN0E TQG>QX7K#+Q9JXL&P! F87;XO+=)S*8B/PU9OFHM/
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M*&8N5\VKZ5 FEOV'X/\G6]8^Z$R]Q4/JE\] H';&MM&"%0/!(8VNL9F_! W
M;50NS@91 ^RT"^0^'@V9%$WD,WES8F\E 'Q\;V9UX_7TDZ..BETD8C^*NE [
MSFJA^TPUY2H _N=)+.A__3_XWT%[6OP_ %!+ P04    " #AB6I4-Q6HC)5Z
M P!OP 0 %@   &=G=&,T-7!Q,F\S-3 P,# Q,2YJ<&?LO'=44]V[+KHB)=(,
M($@G* %40)0BG:!^-%$!%8.TJ'01D-X"09 J-7R(TH*"(@I$I;>$WBQ40>D0
M>DVH 4)RXF^?N_?^?KN,<\\=X]XS[O@6X_DC:ZZ4.><[W^=YYKL6])_T28#[
MJKZ1/@ "@8![C#^ /@)< 8ZRLH)968Z"P6 VMJ/LG'Q<G!P<G$*\QR%\8L)0
M<3%A45$)V#D9B5-RDJ*BIU7/R)V_H*RL#)51UU93U#JGI*SX^T- ;&QLG!R<
M@EQ<@HHG14\J_M\^Z T SU$6Q6-]3*!3P!$>$!,/B-X"0 $ Q +ZQP'\SP-T
MA(F9A15\E(V=@W%!.3=P!,3$=(29B86%F9G1&L)H!YAY6'A/7KC$>MSL/OB4
M)Y_BDY171R4O?VKDO]E+@BD]\ IG8S\A("@D+"4M<_K,6665BZIJZAI7_M#3
M-S TNGKKMOD=A,5=2SM[!T<G9Y>'WCZ^?OX!@4$13R.CHF-BXS"I?Z8]3W_Q
M,N-U7OZ;MP7O"M]_+BTKKZBLJJYI:FYI;6OOZ.SJZQ_X,3CT\]?PU#1Q9G9N
M?F%QB;RQN;6]LTO9V__=+Q# !/J_CO^T7SR,?AUA9F9B!O_N%^B(_^\+>)A9
M3EY@Y;UD!K[O>?R4XI.C?)=37GUJ9)-4NDGB?^#5RWX"ICPE1?[=M7_T['^M
M8^'_6SW[UX[]6[^& 4XF$&/RF'@ .+"[?_IU&/O?^!M_XV_\C;_Q-_[&W_@;
M?^-O_(V_\3?^WX7L/%?P3A19ZBT![7K_S:*Q*_,ZWX,IF/_)&XJ&OJ)$;;7O
MZLMWZ0"I=_P\'<AUCZ8#H=)T@%@&VCKDWP13E?WCX0LBK^C 1"R!LAK4WJ00
M8YF>M#5VP^;F<)_0JK0>\G/>V;1[GLE?V]7!6[D0@]=UR]-#+<^PT<.AV!T1
MM7,*"CFZ.:&K,>\$8$_" QW6-(=2VP\,*!\-WUY7T'-N%$E[D&8D1D(U1U"$
M@7V_N/FZX]/+<!&*(Y?C-]3KEG8MD4I!>\&NU"<YN?.BX;*O<H_$D= Q<%$5
M.L 9\)T._-'O,Z;RJLP!J3AK[^=E;@67/2T6LMQ/$PMX.]]FR_9YL&1U.GSZ
MP?*IRS>^?N#OZ)80]>G<[P'?TD/M$B%)XE(]J/OO%R]J^&'<BM:$^93:)=5'
MVHR.@66&/\&G\NKNTP'=,0B->IT.M#LS+>[+SD$HSNN"Z![5*W2 <!Q-'AXD
M$=KI .\2_FR?S\BJTM4#^=E1OPV1@#<(T,]SE\Z-*6799=DE,D;S.I^9+@O_
MYG/"@9[K8]?T9.=AOS\'N;O(K;!I(V%S3EW4AW>-@FKMTZYV4^OM-B8MH>=*
M>WV_<.D(XC@,1 <;AUR)9X\Z/IJ)]YN-?@,$%__^M/\._--P:)U=R0)7OLNP
M]FKK4_\SL-3K3&[^C<#I^QUM1I.[XFE?4'SDB=AU5(A;WL12949DVH!7NE7A
MURC%=Q;GY5.I:@UJ>[&YD#<+K^. T[]1Y,$3\.$/4C;&9CE]T8DSH9Q-_T%[
M#PLSMJN0XCT-B:RS\MNID<:)_6@ZZ1?30J[HC4\6TS>0? /XE)GI 7S_C%M2
M:1*1LVGA;7%W7^PP85QCD/%8R/#R"K'%S&,4(3U^[R4="'8<#9[G XV9&18)
M73G#8M@A07)Q!E['G?X75)G$Y>A@&\3%*^M*R^+FUI;0TBHODN,N8BR(J>%@
M(;&@H00ZT&P0T$Q[4@,]I&32@<0></\6XB55EH*C VS4=#^!"L_AAW<ZYT''
M>3$&6;Q*'1+)$-O7]8J,Q8.3IA22HY#,#\V<]_6RRP=?V_%V[7*VGF0FO4$P
M8]27+K1;]X"+>I'GT7_]BB%\ *05W&;+^7%(F"7\;K/<IS,PV0_\:CMJ'8S(
M,]![##VAA0Z<Y#HRN&Q2%CZ]M(0^P]5V58()EGQ4IO_=]@X.2@>B$LG1ATP^
M\ .R*AT0RX44+.!>(':2R'Y3M==ZV>>33_[)"U^?];%46)4YWI&RG,&68 ST
MW_U6RP0=O;],&T*[ZVIOQ'60YN.4T?R+K^F ?GWBG#C3DV9]S^RB^DM%="!&
MYR2!A OWY7*]5I8X-_?S)-MI*=USH <@YK!C :?"-()DYYY!AJ^TN*)! \K%
M9XVUB=^M F:,V'>'[W9T#R#Z4JZF-F%:&O-\.8LT(SJ4@?W3)2;3JO'M3U"2
MYTH^PG;ESS9Z',^2U;3?3'S,=X'87VD)+)_&Y:"DR,16R]UG9=G2(0I&SA[G
M,$):,?D(<QF6)XH\#9V+P_4>TZK/'$DF$>?*,UV=U\[Q/U?#7+[,:A=F)9JL
MS:JTI-$#1NBA&ND EQ@1LL^Z@-Z=]J!I&OQ3G@)"X'JHP]>T/G?W$]K>E_0B
M8[A4L@I.*W7^' O8%=.F[*R"6X21L64ORK5/K9YS@\%832_=U/C U*'3%J;\
MKP'_-_X3U-E-8]NT[1I#SUP7,>I?L6<[\D6N\N%Z5:7NJ[N>89KSZJN)NMHY
M<7L1-&'--N@65P\=6&^9H/HE_5/B!/9#X\B0**10^;H@I4],X/:G?KMP9WN'
M8(LQ"\7XS>J.-M#JHNTK(I(7<I0"-QNZ=LKN85B^_:22$HNIR5L+4U8&/7&$
M]M+.C?HM9DA8DS@5,>!#*@Y!09!OP*'-GBZ!;OQOBQ\^&5=[\6>:&LN N"YS
MF+Z)6;<R:&'+S!9)]I]V+R =EG7X?)$UFJF[*Y0S[\G.AP/.0,>W<R&FK^MJ
MIR MWQ#MZ^^;W__ZU2SU(B%E]<KI>R-11QW=0VVKU_O>HZPI'XHH');]*\H?
M--F>!WLK)_DDMJ]S \-?$J.'BH&@V?_(G]#_-9H-$9E:-5W.$>G;MA/ >+B=
MJKHPDQTY<%'1,\L)%P3TO8XCX^(8 P=A#?C3.4,E.Z'E4PO&VMB[NJ+4?F6X
MZ+S?JKH,X<86:*4,\74'718=>V=-*21_4='*7?Q! T8R)>>Q<4J64WF(C)LG
M_UB1ZL4U6)0]KSXQ[XP0>".7S?F_G?ZJI&>V)P>TE$AK=,"T;[35SU(-<P]T
M@?4>AY>VHDZ^,+"Z@(LO0\:&*GT<7%U+;Q%.^[6)\*UO[=?RXFJ6C>H06DQ6
M^Q:2^3^)RES>ZL['GJW.<OD;L_)%DT"G[#P'!EA<,H0F #:OJU8EIQDI:NRJ
MO.:-(3O,FEV%VCB;W7C0/0%3MIV2MO]"[R0.AIZA*#3O9]6X%Q3GJWIZPEP]
MY#)-7IW-=QJNT9:TZ-]>590W,*Y)7/INO9*F(2HJ7I>H!]C^*ZG$=9$OEN%%
M26T%166V'C]7Q\V3U,8;'BN-R# I@S[HH5IE5J'3S9*"6_7\=K#5.W%W)/PZ
M-UE-)F4+29#V#]^"6RJ"=.H++"\KB%[A;WT[RW%2S=0\=C+K6#U:%^+S+[2U
M'BNN$S%%!Z(Q>\6#2VN!6A^"O0[\1>T_J6F!J U$=1S/?\H RA0#LN+N- O^
MS8D"%S>/0'NS""O6HPL'M1=@W(BAK*2KJUJWBNE D^J4F_'=#:U-)Z:KI\8J
M/<58@[UUA;<07_]C]*'_$W+\GN&T>N9=WI/WE-!!AW;I0<?X^861^H/=G?DA
M+1&R;'..*E+A>HTS[K:[JV;8"5/-9*4H\<D>,%)/Y8O<(S/_C\R1WQ5#9.?N
M$IP)@JU:*16I>?H=K5>UCKO?A%PY:/P&A*CK>>-9R;=#E4B1SRN28\3O?9$[
M6?II($U2)\L^F,>&'^ S=[N\SZ5TO890_:!BYV-=7\JOV[SH2\B+W0>& 6\*
MO#W>./<VF71@#&0_BJ^(,NVQ _ON<5T??SAD-OG5M(Y5IBG]?#/0<^8@WE3I
MM$[[*7Q )H,Y[V9<.9;^.E\O5B_@C:/Y"ALO)Q8%R66,ZVG<BW^6>@]IV0=&
MRSP=V.$@KGCR_-R!<A)/N[;JB1UJ/078OQPWJ\5/AEPB__AP\:6FU*BA<+!1
M%"Q)^U#0J6KGNY*-S7_4.G_C?PLHR6G(GI"*R?Y!.AVXHK).!SA"3U!46]#'
ME+.M[O3B>T/@V7/&.X6I?K^R#=@GCP&B["0(-[JC\SUZ:)2P+X1#4ZS(QHUX
M48IG_J)&1>E.\(+6NJ+"YZ\'_M=6U&]+D"[]#EPZP&X\-7_(,;&GZ<F8?-DW
MI*&G/@I'+:^[OK)X9NB8^C4%-93J;2=FG=I7C:/8$"#P!4:P=,HFT51MOJ7-
MXE_9>02[2#P?GI9Z?@90L[^?'+C-; J.H/4C-V71(Q.T7AQ'9=]:25GMV&7^
M.^$=;3)[U:8S89ZC]G9D_C5LV1"U:V)GEPZ4N>90^%];!B31>.O%][P]_.^E
M?&J0ND&,$B*>?6Q0Q0<RF71*,(G6LE9^]A+H+W>T2"2V>'.NW%_$^&'?;>$^
MR$ZN.AG5]OA^^'9V[Z*-Y=5>P_./#;7U=3NT+ZT=5=D>:L(),7*#R^2'X,*9
ML4)+.I W[AE?M4##GF\D5DN6 Z@)<C3M:AN!#MC<H@-Z;T) )%F:D0XC+]@X
MT8'>!"2<RN@VYA-#. _=9IQP0>JBV!DG3-XR3C <Y):=*6O.!Q*V47B\T+/P
MH;#P%W^O@]D4=\?KWY8C'\.O%OSS./?(/J44$\M)\$AA0Z$;A<$U(LK:B3I.
M^Z<ER:?"=((HI6Y3\K*M8#U22<;S97MVF^_G8*FH^A[W!^?K(5>R$G_X3Z9'
M.) 5$NX-Y(\^U]"*]98\QF%XS,Z,#AP1TFE(W)X?#HF<*W\_\G-8?W/<YBH/
MG]?=V'5J)ZZ,RC.EB62AW.DWJ!C^'A'2DFOW[<63:L(UB"ZPJBO&Y3G!A[JA
M=89$!V[6&XSX*H8\'TG!7F@$XK<;OJ ;7#_ALNB "X1;J-Q-MKE7_9<'3\T+
MOW,39VD2K'0 3P<D(-(D;)2'ELVTH+*KN'0:[%Z+_;D!^>Y<& A[4_9BWQ+Q
MVL"]VK RQ,52N7=!_+[JT!3^-4*I1W2S45% XFVPNURN>X"65L[$9O<F/"D;
M9</X(51) J^OH=E%JS'5$8FF2;?4U"<+(H^IIYF6$P3,(ZQ[5GRM'@6J)L.Z
M0-]5 <]M,3@[P5;E0).24@YE'W?V[JRQN6C:$QZXD=_9L'_>XV !\;D'I,=G
M"K+8M94CS28LW[6A1%RMK+W,GYNQH>PKDWOV1G#<3UR,EC\=D(*T3.SPUS F
MO%@7ZK <*ME+56?,N//2?OR)YX2FM0D44<U4W2[Q,4@E>XH I2!;AVX.+P1]
MMNGF%1*'GS7\>5K"Z5B>)"S4=R-D;#U61W+YQ)T[@[L"2:Z/DBV'+RM^;,L]
MHQ,!.V*QGQB$>$L5HX1,8[E0^JH:;2GR^3R6AL)W?.VE/H4)&3$?0@1S(:]E
M7P[B3U(,FH<@'H7+.X]']1^3/@B)05[=9HY8T0O$MB-C56NT4BAV?]0$!\<>
M_UJ?<\J\UV1,S_V7*$;SGK_*+!V A/(MT>!&):^K$MMO1+:X>9\](3?6=+IM
M&FR=,F *[JV "J!8WG7/-$X;VWM8/<6P,*8UWQQ:[.>\*.<*>U02SR1[ID-B
M2V*H"Z]).?D^0%,O%5$Q8#>P,B79/0)*-&RDR5??N^VO3MQLQ3VA ]PX923W
M,,5QQVO_.A5O?9:Z=UQU;&1!D&10V%VBJ_.Z*,2_-0@<97ZL_(/E+R'0:0SA
M>X,_N[KD!+]5N^TI-!M%TGR0J!=8_/JPYW[*G!+SM0/W^QF4C>\C%N2)9].5
M2IG9B%M8+N75-I,[,!]3L*X:$^##!]J^AA;"0XT>2R!Y]$6SJUU=TM#KKU^T
MXUUQ_;XVFA;E I8.V^4SX/SG&]'(KXCPS@.E,0Y?9^HM#I,GU<(=D>*$BQLF
MLWL(*Y+3%(TP:3S!+?U18J-$*S+*$';L\^JXD9B@G9\ZDU8/V(TH+]D4A'\I
M:BMO#/V<MY:P5K#AEU/@.L/3, _.\KX[SM&C W6I5/PV!7K3^?BX/<9R[/#5
M#^\L^U)NI:3^X;K-'49N3W:*1B^7_2.I'N:@9_*_T(%[>^@M6"ZD<)G)FDR(
M0JFH15@,%LL[2?ICNJL;5J[&)\,ALQ98 2T;W\F)(]>#[S4JE#A:604>[7[^
ME4T^R?3]SVZ4[R+R7(!QTSXV"76[QJ%L>2=V]YOVM^;CY09R*X$P#)I7W[.3
M\0WRH1<H1S9\HQ1XFHJ"A'*?2S'F^Z7NH>NG"GQ9?9E5K?$[F8K[U8YQNAT&
MUFNB#_#HNL,,A9N\CU F'EI5:G=7.8US1J,\9FVBFR> Y7U($QW@I?B;;4S6
MXS&S;G&&0J'.=U1"FK-XE2+"@8733$F'KU0.12S[MZ3ZRH,Y=N+NQH</SDJ=
M/FKMY**V:(UKR+YETJ<C8>1=.#'\RRI3B-O86[&M]IDTJ\63'"ZO'&F20JP6
ME+\N8R=SYX]J1XLDK&AF3%LH4=17["$V&J7T@8*[J>$7Z[+SX970G^USIU"Y
M83<LGHR:@H=K/&)]Q!RGBK?J/:[CLV\%&[CZ8#Y:/\'PI<:G=%<5R_C$7<3H
MW]9C>?EB$M# N,[3@0B&R]:RFD*+E104NUP>['7+-SD_VK)G%\\I>_P6K0=#
M"9\W[U5.4+,U=O+F^%A1H6^G_"1,G5WGT9$ZO^YZ(,CQ#=FD8?]:Y+DZ(_N[
M0<^\^HFTPZAW<GB% %;:+5$=6.4=)O4<]9/0S'?\DS7(!KC(T@6YU"MV!5$V
M#3:CWGL2CZ"X I4$(CPR5(JDDN5?@[$R<5S_.&II:&.6I/L+B-\G0M\ (<^8
M2:,-J2-=F&:)48Q^8UKT.\EB(^0Y*C,Y83Q]>H&JJ=*<K6K&R2L]:_>",TK\
M)3LBL5H\;2NGDI&JN0QH]0YTH.<Z8%Y!]H_"*=S\/M2B<6WWQLB)HS@[)\<M
M]F-&A>4$[@6::.F![:=W([\NW^#[2CD7PN=KMP+"19=](+Y9/F$9W@9SM8J9
M/WI#U>W>S^XI&]5?6BYD9(L XN/PZ$.$^A?^DR?#_'0M(LV>-'R_H9F5 >P[
M=D^OA^%*:%\@L?+/;P1FPR+AZY6FA/^88YKV&5:@',OQ$'I_< 566B5;;]YQ
M,GW@/(QG2V456MH>[SY;6TLJGFWN=/^8^4R"NA< UV : C]66VS<GF$:1+E-
MBQTW(>W@[@<7N>P,87Y>GQWYYA4K.2O(>49=78N=\K:>0!1H]N!?RKGX W7E
M_H-S/A5/I!0/7ZMLA.LS<14UT $VK6.T\FD^T,XW;"+J5,7%I?&SO4Q'![A]
MCWY6HP-!-0\I>SKLU$L8E10M>-J]H_!'E3-0BEB(QUO=G1KS[+JJS5-/>#YZ
M=YAR ;<'M*[GNJA"G0;*OUWL>N3TI;HV\6)[;XS*VT1,VV?]KH4&Q<]9X9#+
M7"BEZ<+Y:K)?J<H7I1N[_0)RY[WK=E:W<.]"6:][JS;5:XT*"<(^YU_;FV7*
MLM-^TD'L"],6CSN="^$Y? .?L>J%+Z\R] @[R8;I2JI-B/YI?Z'B(H=:/6CK
M[-2+8&HM031$=IS@8K)W8HLA+=&'1^IV)T_!",=YU?EMA+L<'.XG7V*2B -F
MM4#3TJ3*1.5BQ%?[*/4FZWO;L7A$-XX9^XY_9PQE1%R'8#DH\XB^R_Q19[[H
MPA=349T,$Y4,9]]/FI*)S6R%'BL[B#54O1.QXDVLU0? 2[<+=69ZP$[>WBS9
M14,(Q?P[I#PCN<3'[W+M,<$ "PH^S75SOG7\ GZ !X8)T5]Y8=<P%J7V![%*
MQ& *:8SR(Y]U1D/>]!/3W>;>TP&G! .DW+V.T!=-V-W6 $+#.@3MCC(JRS'<
MM5I\YSXAFU+U.$([<5H07>/,E$RVC=/2G';]!O6;*Y,5J=S%WAM%:PWU,Z02
M829UD; ]B#X4_+'9WNJQ=U;G)!W X0[_1/3\I74 ]#6T#[LAOX#=WJ$#^RP!
MNTUCQV^0H2TA,D8_BFF]=@PIKE>?ZO?3)OKL)=&P )45>%D!]5F0S&$(@?;$
MUH9D3+NZ$TD'/*#[IZX"NYVA8*HV1EJO9UA:,MJX<T/GI1?\Z@8R%LD,(U5D
M>Y8XJRJ.+7Z<>EOYIZ,%HM:>4S%B*$QWNU%E:]5 B\=ZI--#RQ6F^,I 7X@S
M_UX$Q13<DL-)=J,#X50CCP\6M6XW3P1X;WP3.NA"%[QJQ'VV.M!LI?'YZO,N
M[K]Y91WQ0\SSY[;0]F0<!=LB_+A/R^B]R[/XN^/&[N>]=T5QR"9\'@42NHOE
MD)M&[_E490 A^HQX.M"!LP-[M\P^88T'UK8.DEE:B[J9<WTXBV[37N.K*4K%
M:#>40I]Q!TXEHSSK"3KZ?A/3>NE]JFN+CDX :A'.G6F:<+3RQ\F[3U;G%+HF
M0Z].D,XNP!T9^D#0UPW1W%?]RY.[YJG?,8)L*(R?P4#P\Y \V7F386-+HW(;
M@3\2-MRF@U^&J0MY\5_:DI"$YB%Z?<DR276Z*#-B-O+.,4LA)UD0'7AKO%%
MTP!1G9EZ"4Y(+OGUF/6Z*XJS/@LMIM!]%PD);*,7?-)W80(*GTFW1@\-P/?Y
M7:ABI#W2;O-U%=CE2H'<\:^0HA<CC#AFAD8ZHE ,@6_#4.M(4SJP<!NT"7^Z
MXK8-%W+V$TC9>UYI^93[:V;,:,*I*"'1^/ @Q "&"J$$PZX]>U5VS>!8>NI,
MB.),:-H&@TEDHH;:;<6KJIZKW7MVJR(0EA+^_G2:$2P'8*H/0:NV0%D;A?S)
M=^)U:;,K[F@)HUQ(.NUL (L6T[3A:K&[L"M'U=?!6=H^\-B\WG-YW29ZA5AL
MW3P=8JQW;JYO;F"4N9OCE&+\DY&3B2&/M=7F\!<"]KO;&?Q"^\KI,W)T6,W!
M]VR_DFCIO0TP.Z!%SJ&(>:P0IT8*!GT5>#HBW4Z%#?]A"*]+>7GW(_H71_<!
M(YOHQ/_;=M#?^&?@_@R%,[2:23JM_B1-'U_RU]=A"E1.DDDTRNZP_I!0<%BZ
M0G#:0(? @OT#,_%$SGGGY45;PC];P0X=UH"19OPQVCAM8D"G?0=7N@>OQEP?
M07V;\+QQH<IW&\=PZ9$CI$U:%)2*J:(#1!_0AZGUJ'%>4DG!X9O7BT>&U^\G
M?57E[=S(<HIZH'D'T3:Q!]-8/ZQEA"UEN9"T'KOE<<*E^)VS_^NU'U(7E&)^
MG9\\HB_(U),XMOR<P@AW6+0-':A$'T+% -3+-R[^EM_SQ"(Q'ZRO"KXNM?,T
MEP\+N7%>FVPI#B&K##W5NN50;$G]QHC.S9:4E*A;V^"D*Q'#Y:%\C%$P(^T>
MAJ!7WA93K4G^U),T]>K$<?D,MS5WMXLE_)?@BL< $2L)4._5_1[PD&7(845A
M@17R5P>LHCK6(;;=]WZ*+=.!,1WHN-*,W>Y"SZ6].M *Z/[^N8J4,(/5QKO+
M!2P]G?N#*K@&78=>[3Y\0P=F3DYU[\_"-Z\"<,>DO:,!2;3J2]3Q^J06_!%2
M^[,UB:HAG_+:#.8S(GM]^I=3LU#Q2MTX0G' _$HO'3@)X6%X]]/PS*&>+1!#
M\)'R\>+HGGHZD%H)I7K5$8@*452FR>*SX\V&O68JM<WU%F-?:7_H;E#.Z1N)
MZ.OK[+X)WB$4_Z)X7*H;5 '_<G,5W]'N7. +QNB*S^'/D UB<%J(:>.QAP='
M7-,[=+TDS9K>[0 @77 D53-PFL![U[E"[;@UGB,E13CQ;M)'(./ W[@_MT_Y
MF;SB"/K7RJ1Q0&56Q8!IGLS0D;KN2?\PPI00:7%P?6KD_9+S4<XJYWN3[_?#
M3;ZB)W72EK9 ++.C&B$)K:M?8E97IUT<O +,S3#HDT@(Y1FBFHR(6]_6-W#!
ME1CGW[,/N\'#JC%Y+Y1_:Z(=R2TF,-7:6G3C#O%6FAM"+'4=/E5^E0XT?&@*
MY:*@ B*F;3,P$J[!<N-=QX*D+S(B;_8T4Q89&;56)S5M7'^"%)4QBOO.RL1J
MVI!8GQ"B3;K2 A_!<A5-I>Q:NQ0]FI!/+0^\H7TQ&3XI74<'=E(89CX].)\2
M!]MSN.6DR4+TFDV5J98@3.:1&@^Q=8;#B$2DP?-KEDLI_.PW@#20 _SYU'J*
M+O1FKQX?8*;'!\HN7-Z_&-=;\N'#3POEW!>M/[K^0(IY5L433^4G(?JE^D5N
M/3,K"]&^76LCM_2 70.SUP8>Q+L=YA%F7BTROI\]B0[H?[$-PDO^*$$IN$YI
M7E'X.;SXUOE!IVNLB+.I[@R1B6E@ON0\:#LDNA7-M!149FF34\^7[M5U*D'K
MY6W-U# F?G:O(.]O?N8;XL](!>TGAL<3O.'1:Y)1QN\R ^TU^<[#JL!GVG?#
M<+EXV8 %BDB3F^=#TZ5TMYEAL'48.K:##M@'[9X*T]#V;K6$1/5:W?U1+/<L
MH0/3P52US3% .U)=15-"Z6 F=?&GXM4UO0;[S]*!";T+2:BAKZ%BI!T"6:;5
MS8-OW3/PO.+HV)CF>3U1=\>9?4 GO!YZZS"SW-A&?KY_>SGX2]GUMK'5^$LQ
MHN\KYCJ7&>3 L H<!0^?"[=FC+M45NP^__I8JC)98[ZJ8WWUSO(TFH72?H<$
MB6F=+?2U&;>9S0MG?@\Y:^ H.KD-'I$X?&47S/JF8 1IB3\(?O'<.?.@JX$;
M+:G+LQ14@LVSJ%\K"&;)?A^RZ/3X _9&$-;];37;[UY4)K?13L5_7!<K^PY7
MN2P[!Q>G]-&!-II4#FW)\>*[E>>/?2Q>=XL&I82;>*\ X@FO:=\MHUZ]'AE'
M+I/OVEP73%WI?.C EI(L5(G33@0Q?5(&K6O(Q&U!> HU='!. 0WV^3<3EK=M
M\\C\'G<J^TNV/KQ0<5Z=,/$YY5O5GEXYH07!/63$&S-5F"P3@9=V$<[L=O%]
MVSQ7EGZ^@MU1VIKOD;BQ73RYLS5(M94.[$D)TX%#3Y-#P3)0^JL XRFQDG(V
M1I+XY#A@EZQLEF#<_7B2_-1%)#FD9KK^'%Z0E$Y-#!(X?"K/D-H/AD8L\7GB
M2:^12UZ%SBNK,U6^8H9Z<@:+NCS+&K24J67SZD$5$=?3%JMW<G1KDW+%C/81
MIR>$=:!RXV9D7O<.H1.E/'LKK:CBHF7+[H2ZJQX*^:[9ES?TXF"B9V>FS,#W
MNZ$O9U)M:P56>H,>\<^1M6ML^;_\\3PRCVM!]",L>!7*4)0ADBW".@10IN'
MJH(=-*#Q] ."J3IXV=:#3&C1D&IO_G;+.-JB?V;@A'-:,>\L9VZL@$2N.I'
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M>OIQKQ-Z[#C7)K?:3P/<M^U<"!8O83TR3KTTM.;F%!<<Z&'O/!O;+!L^RFW
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M.:G:O5N[ERM9H1J/@V*A<Q+$?DTT^R9V&-Y,"TUX0PF'B:R^N5C*,Y"W4;#
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MO2D,;'937'#[?Z(W&*)^^$,%Q8WLHG/R87H%6,]->_75<=8#DPQ1]T:HK^=
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MW)-)3XC8RDU][)PJ*BCM0>34VYO;SQR::+$7V^316*?I2,FSTX;V/2^.&C4
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M6"// 5(A2A&2BO\TA?GP7Z\P_WX9BIH*J=+06WA<,96D7A_U2/!F3<K#[Q*
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MN,H^R9%.\Y6U_9 ,#7;:N?,^<N>APQ!! LI]\JJCG+'A:5%?"X7_]+OEN8%
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MBF'7XIO1-YH26P#GF>!\T],QD5W: #6,WTSQGMF&MU5E\JPD,EJJ@H6U4 H
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MT$(<)RMAK[IX*/>NE&UJ;0OTE":VS=7Q@[(;%/8.C@5^CZ!N^CU^ O)[_$3
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MZ"LOHA\F78#<OI1!H.*?'ZQH[E\+ 4]+%9W<Q(0(9_9$77&3?G1 NISZ29/
MKA3P "_&?[!3[+S& H3,:I6;IZ'GM1.OE^:+K=WO7 ]RU*7F<VA:6,ZR8<^
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M[-E[TVB *B5 CUB#395>C5Y0/9;)4)TX=(A(YVW/Y3,1H9)\JI)KO;QC;-X
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MJF-?*E7V]P?? 6]CQ3<[%$I>7O9.; ^(2/&0+8AW<--P3Q=$X)[O/<@^>S@
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M_EI6OY E^[3@4 [R7=!]>*SW[2[L8>SN4G[P66S#^4KP&9> Z[<NP&7NS;H
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M<2Q#HD%EZ9X6$RA#X#]T_>0__9KF_]_^=VN,1L:WRT>5?N^2KTW)R4H:)=W
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M*/G^^6=\_;?F9/B#LUNQ3T(U F26T/&Y;;6VEL:JT4_>W\'XL_^^SIL0Q<M
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M!#XR?(?0) ..I+YI.]TI];&\H?J7+ZC-UNO:7'<QMH1I^Q'8V;WG.16?;:U
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MTT638Q,^DK;JTJ86VAQ0O3P*@!A^)D3>*<4+A&)VX=6'TLX?.JDZ4G\I-C1
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M+L(335]V1-7DX\;:8V$*^7"$.8;LAK#8AY.?,C=.5)3I7M\M5F)N9Z;@O]I
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MJ*OBK&//E#CQ/Y_7#Q(;VX->7,%:=2C)I7R0V*&3UOWAIP7ZJNS5AY;H9R$
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M6&!09 @4LPE&]4V#"$#Z*R+E]KE& .9+2=;U$A*&&6*,C!19&5"YO^W]Y*X
M>?GM1"Z660L^W3UTPN.4_K1[B(*>D#KW'*-!O^T>/LFHA>*9;S<2@#W*$<AV
M"P3G4E'/C%G!'.JBSW^A>ZAH=4F1OO96O=J5-P9^#5Q8#W)@[]^Z\?>_\I"U
M/ CJWZ?45NE[J%U<5?.L\GU116 6OT14):M^#Y'UA&+B\($G1-H $,V3_#@U
M#,!P[+1M:Z?]J"M+'7\BNMC%I-(. XES1\7EV::^./!)<W9=G(>.S=I(+']]
M324:<*2?Z45D%+$I/"<>RKA(Y[0226P/[8D0]* 0<.O!<?@0R?P7Z&,B'^"#
M--7G8H1?.%N@$/<K:LN3IYW=*U1OT5DD&40$=+GN_=<;!P^(WY1]!UH)C5?_
M\Z^ %R4/M@V;? R9=<7%"1-M:R19O^T_D?YQ_IN^$\U>1'X2JPV'CD@1C=!6
MW\E$LDWXB M[>.)$7,4JV8!7:#8!^&'6B:_)P;\3V";>@AY"T?S\ZM\2=AW2
MOTP4"O3(2T([!(8@T^%$)T"_XKR(9"U+D0$'CXS;F;8?C!G)%9$F-#QYH[ B
M7_I)XTWF16VU_#3>/F6ZCM.YDBLYL"< ,9\," !<F0#TYJ_*'/WMG_XM)6=_
M&K/B\""9ZP@TB?.)5I- +G/GSUB>-V2?"R2J2%GJ[ZCR@'GGX- _2V_"RL.
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M9\*>)B_[Q:X:P/-'U'EN\"[ZM[F_;[Y4JTR-2[>%S_X*/Y?7+O;OP%4I4+V
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M>G'UOF;TR(UP%58WUH!L O$]31CI^?[UY>X)L=B80"WS%,(GK BJHXH.Q):
M*6X5SJJ&15T>P\X:]3*2?4/RX>=V>(=2[[+'Z$WU/9/^CZ;)S# <,FW<AUOZ
MA:+R]JY#:I.:/Y&B)WGTW\?I;#YC.@VX6V=75=S5*O\05'WP:BN@_8]298_V
M3&ZO:!Y8O,L&'.8  H@,C1"A9@ *WE2^.(RPQAJ/R5(,ES;_XDG6)QS+OB"B
MWBE>7AGG/%4.>U,8R@25D)^WO4Q4&SO7+U:N&C\$B6%\0VII2]W ;3)G[]Q^
MU?-0221%9XX 14%D4J;O6X\8^GF?K5WM:I>-]U*+%Z_"3[2_A(9ZH(M&H9&Z
M*UK^47:VC51#7%=I2C#V.*T+*S"Z[%-8[#HB=4SLC3<9-+>)>9SOSP/:]9.)
M7GZJ^P@WXEC%5T>623!B$)0NC7/_/J?PMTJ'21X")FC+X/$7^Z+0RSD>3H>/
M/-OC/?-,MM*."*X)9(L0SW*S70F9_E'"E'G7+_H-MU^,5,L,];-T7=N O[14
M=0IVI]H*O+HLNI7;?LB?KX>"H ,\BA%%JJ^"=]9>.@6II6[:B]T[J,(N<KFK
M2AST' ]*?R4Z__UF#6FZ\MT).N#_#9P)*/[""5#.3OJ]6AYR\F@>/-833F"%
M:82/1Z^T'=[$Z/QL5.)7-_")SR;P_>SORQ/^^+'MXWGPA6_6%>-[84>9:;ZF
M[2&*Y+RWB25!\L/H0OR\RPO!#V#\L%*3B&]T]_#S-EE-D>!_T;/-]ALLB)K&
M(%*VUQC<132?#FP_I /O,VBCD.VB)__D,R#@WQX/]D\&L\W5C//S-3Q3T&T7
MPH0R;;#79V>_2 S&@2'(W8ATH%KXQ"^-0SV>S0:&1HE^MT4&9LX7KD8;S1T!
MZ<I/#GE^'WOD%9]_([=;[$%4*A=K@"L10]/CK=@,H@/0!KB$(VK]DA-N:XN/
M%G*.>?[YGB+2%;S.WXM28NBF1#S!NSI2L#KYS&O+[SV8N42Y!X<56C]=JIY/
M[?]T[$7\W]<'D]B.IP-O'$)Q2X7X1JEVC8.H1E@W:ND#GBR=TT$'G%QW#R+]
M:!4&E)C*C7$'2ER (JVLE7%'AIYIE/TU(3/'%C^X4#P[N3TKA83"XGZA^RKW
M;$BX+,O5U[K%B$;H :<KT>B:-7#7CVQ+;IJXU\259;/+0R\%-Q9VEGWU3AW0
M XY]ZA?-I^@1ME^7RY7N>?Z>:BJN 0*&4ZF&1<BVLBEA[UK6X*V-70F:N<ZZ
M+H2IG]CZ8'!@=%'QJ.M#9^G:ULXSV@V;&(W/ZE7G,Y:>^)\]=-'_ 4U?9\.5
MQI9M-;D6D5]IXYFEUM=I5>,Z>RA#6V_.Q<UO4SC8)].7K19S9#%9J*3K8<_4
M]<2EEL'C 2VEP_U"WEL82/ZR:M+G#SL:<,4H$:7&!@X7'825<QP=.,XP*7:M
M1\@9VWX,2L=@$5M4F77+75OL%VHR Y.2<%24/B7^F;KM'XQ86_L%X_KTY%L6
M&=]44\Y8A6+Y9&4HWXNH$Q0RJ+;O[7S/UUVGNF(;E3M?5EC=LSX;R)D1Y7XT
M1>MF7%BMUB3'VJKF4&Q[\A6AF98ZCA\_)>R@=SW T?E\M_L\I6WALD95R3,_
MWHBY:9*/!1$P]T-T;'U[_7/6'+*@YW*D'ZD&7MANA4]ZAQ:V-K*THR[1!)_&
MM>\UH)OE?S+FP[/53&V\'^U$% D^N$,'L&CP&YZ&!?*MM*^M,^86[6Y42J$8
M*'L>(K#J@7YIF=<W**__)3>VTFFO@:H$?H_1N;M.X2VRP2?C0BG,%8L#%RX6
M"3/>//\Y.C8*;W.H+(N?O-,[X]:P(>]]@S!6D/=-P"M%KNF66FNI%ATXH!98
MM$*&UN"..0E:6U#S[]$!Z8M1=(#BO4J+Z_GZ]9PIDPD[P';@6UZ*ME3\2PV&
M\+F<\T%7LL>.,=/HZ41H]0+^<6)]:H$,,B]D=G_RS.OR8PLB1SOD#/*<LNJ[
M92C%27/^Y!>^@2?SR%+UF'?W$0O*3H..Z(O%"E6NX98\11P:W:;=<]^PSR6*
M/A[1.Q%U$M:&520Q?1EHE=\)GK:JT+!:_EYJ82=22ZA9AUB2;Z4RT!@MB"9/
MXYM*H^Z,NUUZX@?[C#PQCBV9)$EO2;V__ZWK[&[\_>KI:#=H4RKQ-^U"H/PL
MYH_2^PTD'8:B^\&X[GPV.J MQU0R00<.SX_Q=\!TNW,[+(\]X +JS=0M-GI2
M-NKN(E*.RAD8>A2K%BZT4S8$,R"$$]V$,Q5?I1XIA1<*+S35%^;T?%ICLYMK
M=9_8QJ6[1.<%]KM 9HJ*K9E65=#-/"U0L3<WOE];$0IWR\UB ><%F%K3RL;S
MCL)'=KQN)' P5GIB%ZSQ*0HTR>%7ZK]+D9_:@$_[;LI&Q26THJ)G+,%UPN[Z
MPSP3-KI,]>)*;T .C*V+Z"J$O$H\6%0,*:1&C1-GK"?< I+2*!LKUL?*" DF
MWT<OQEV!7U->'SY\BD*"O"/#F#T=W.V>=-@,-[,T]Y[5_A1XL#PSZ*==@KR$
MPPPY(VWB";*HU6!P%Q6]I70J(DJ'9R,D;$K=6U.RV#NW [1[3[$=/,VX=9@;
M'33IA82D^[VI?N<-1>X_G(+T!$*7;'4EQ&MO]VFLK^-7Z4"HVM"NC:]OPY@M
MXS*DG\ %(-,Q"/QJ#1W(R,@#\5"N=:B=G^C,:?84'G@;5QPR6B/7HLH\<&RN
MI/\ ]B$QH<[U!++5OJB\S,I901O2D5=__)F;HDC>;[;8B*BX&;GN'VJSB5X.
M?*YT 'P9A85\#"B:3#FA-1' O&(84NHYZ,I)$V]8_PL9.LWRXI"2:%K^-]*>
M)2X1O%+1Z-HEMM[Y2=D#CD$UI/CB#WTI[]QNZU2H^>KR=1LSJC)<41&IO6Z5
M\U[ 8M:MK2%;O.K'1'L0[ELA'5@Y.D#\,H+15@Z#5&RITX&+O;_])0FYOC70
M2:DXT(-0A28HUWX*,@335?6YZ@/^DD& [>ON/)QH=TM!&,9.WP4WS>#5_L3)
MX+]&:?]=!G+EG[*4 1],-6I7RI=OKQLUGX#YEC.%_Y/+X=^.K_N#53! ?*@?
MANU)8W6HNAY_K_YD_<F#"Q\FOOG,9Q ]9_,^+RSS[A@5%MMU&%SYC)*U!1/A
MD\5YXA4R+]5$NG:_^.<DO3:R=$BH?+HR;9<F^F&:W2Y9H&$<C2Z*<7%Y/%7L
M=&QRIU_4SZ&,V=UA4583;&XU:C5:>[8X^7R&NH@B.VA2LJHOP=7GRP#\NF![
M@8/CJP9BMC%(^))[O?(!K,L/DB)1]M=& .Y:18E5W!RO=R9_P<#JD4]^(E)]
M6 '2GA&1I9\Q(_E8<V1,M;>^H'BU6H#B\X'--B5EEB=/ '6N_]MFX*\#<X#Z
MF9^2PB%#X"V36-K[NC.T 8I*/AD+)YRPM=(5F--'%4X)O2.&,A-J GB?:1C^
MY7OQ0V.(BG=Y>5-.XG&_=,.O6(3]//!,%<UQT)EK5%-LYADSK@41*"UKE")B
M$-GR?N$[KS)5:M[U(#) 36:"0Q9JJKE-./<V2_?-^AR-+%Z"P&<FJYAD&%Q]
MP.!*!-#]Y,<+W1'<"F9X&M/&-5M>(LO(Y[ O;W2U]F2?[T[F0\<AW/H['HCG
M]8'..936 #X=B92^!5924-NCS7"U@Y 0VPON&TZ-8'7+2<A\?;X.(:$V)F"V
M )TR]8X.Z,BOFI@9JM>IQ\!E2.*NBK4:^/X6XBOL,02;B%?&_>0*Q9)-GFD(
M-X7'>QS/6?NC22)DG5/RQBOMZ2?-6R?9B#S;TFY8"$$G(8JB0@ZH'UC-:!X:
ML7N70@%I0W["1"0N8<+0TM"LM%:XH&6EC_VFAF1ZL9K>1 #\EV]N8B#&D7 ]
M:]I-0X]M)ZZ<TWRKUHW5@PZ Y/C]H5.M9ZJ/%Z(<+>PW.=-&\+<.:GPR$TGZ
M#$?P$<T7^KZ/6C<]B:X-#J,#2W[]O;C#-/ZLYQX-%;CUZ;[\!*[R]=.WL.80
M6[W5IPN)P&9@T'_T-CDL?6]D"RU23O?2$RV,BWX[GGWH^AFL$H23XL38L#RZ
M.73@N31-?CMXY2O<W-JBR1RJ9G""1^W9SR!T(**1#DQ\V*^RIR7M3J,##(-?
M_X5YKLJPWE:L+S<R.2L?/CK,RWX_T?ZAF(>2?*R3]U,[;Y[13^T<M1=$E(]/
MQ(5J@_("9.D ^]0X'2 ?1J3LT, T>2A%%KW?V/)L/@I/0I%Z 224<@$E0 <Z
M.O>KR.JC(GT3?J)XD4&VQ(];Q7FY8V,_X]F7A#;XF$I2VT#^)VQD_O0#'M@C
M),,TY E8DG'7ZA;_YWAF9NF>5TW<;Y!#X>[K49M,HYW_F;/1UH<H,QE*D2HK
MG*<#!72@4&,@?W#/,.Z'"V3@\58^B": H&6"*=FH[:_ !N0U?-VD:(U,H@.#
M.GZ@Y5$Z<"8JCP[ &<^Z :):S0I#!W[=F4RB(I;Q#_>LDR@ILH%M0/TR^^9F
M?L-$21V&!"O7&0W=EABF=4(^XE8"S?!OV>WL'#*! "<=)!M%KI]Z [)KS+ L
MIBO)PKUTH(2B^'F1!HW>'O9(:<)7V(\?DWV>7/7D'/.M_V"C0&\K_?*19B"1
MI6@;DNH*[+#/J1C4BO*=%N7I%6;F!>NZMJJ)\\[B4?AJVVMM$07-U!RIQ_>5
M'G,&!;5)I1+Q+_'&Q-DRGV-EJ9_<QJY7/^CA-/=O>*$J,)M%,"%HB358=0CI
M9H9_3@^..OB$S5U3J-73K'SGY61AB"J:=7?C#&N,ZXH>S(^I^2X[.QDF906S
M%8KI:SL:TBN7K39^*$KJ6UNEPRQSUM1^7R&CEUD7S5<=B_-2;>&#G]]/1&==
M%YLU+-&[K/%!D6<4":_I%Q'O/_TM5#)T-O$F*D>KA^H'<K=]F.G4A4)8LB:.
M#C1]_1)SP#SV&;"%P5".3IA39-(EKW/C#4-+GRX-0K_1 8&)'!VSW I/#8Q,
M2V;\PVX#2^>]"J]1L@]9<)M7@>S\4L&LX-5X\($S:"TSQ_2*KN)7N\IZC67Z
M9K\8"ZGU[T)<:\7ZH_PR-+ZEHT*!3L%VI0_:%,7<I"#J6"-$V>=RL8)"MW,/
M[IJ^C7@!>@1D?WKD9=D6C?BRT/6IV)LS-"SVL[KZJWGH8],A O@X19W8\,QU
M51X4FA@\DFB=_T"!\YM7*&VP^%K0MU.\#6SJAH?]B-Z3GA%YK@$Y(U;Z'9_*
M_2]_HTRQ&+'U\9&#DQ,>GIVA]ICU=;)7?B\UO;TE/X/BV)J8,@S'2A*%$Y6Z
M18M"V@X^K'[ZX45@A?G4MS.5H8:$DEIXV-!+9U]/?N>=!Z./V!M9-'>,D)!K
MPHS;07:HM@5U4S@G!@J3V,O:WZLM7^J^KMD,OO6,:8!)4YCGSWEN)CU%)STJ
MQ,L35<.XCZ=)CSO9A"D!DB]\:<Q8R5%NIHVY6E2DQOEN5_CU;YT/.RS>J+3Z
MILUYJ//#WMJ^1/'=2NTO)&FO,F0CJZ-B@O%[EXMR2SX/H\LK"A_I08P1M1 G
MQ[>/DD7>!LR&/(1H_H9NR*]HL#!HFL]$RAZK)<.@9*8>>U&Y,0FI+9A0SO,P
M$!ETI>CXFYXJD9A!/QW*K-)3YQ-=5-WQ[G^S,!30NM7\^,60>**N>IR6V'_C
M[CVCFNJV->"-*"@*$95>HM*4*M)KL  "4D3I)2(J38KT$HB @/0.BM)$F@@1
MI+=(#0A()]()O9-0 X3D"Z?<\[[O*?<[8WS?./?>'VL,(&'O[*PUG_D\<\TY
M%_%VO15>0WQ" C^N6)<'V^)V@3+P7?&^ZK^:^1V\'@;L)&!#FIGZE<?2('$*
M3XM( (_@C.3GR;'6FZKVOPC7_3AAZLG-WI$+P81;MDF<7,7/C;C,+SCEGBSR
MIA]S07%%S/06S&M'S,-/PRQ*<'3O#ZOF@@5J%X+=>$YS]7R..)@][*'N=YL=
M03=K0IOKQ17/8;D:V'L=I*J_?.:PT).V#^^9BKGI$O=RPP1"#WN1HMT8*C&N
MJ!NWK*.2I/WA_#/3 (5&!\?&RLGA;QJ1X@IV!OSGXDT+ORKZ7Q(E$!KV:8!%
MMS4!U 1]WRQ:',F@47B4>*Y"GVDH/U3'N85F*L+9"33S:\?\)*X^?08)XLU^
MGL,2LUI5_KSC-O'=.DC')_I.C.QSG1]ZK_A53G,%0H5AB@/OO\/9A4LEG*M]
M6U937#)EVB;NJJZDUAZ(9H#R_QK;^U]=9T!>#J$XD]9JIN@=7S'-H=IP.:^
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MV?.0Z.]T7%-!T/.5FEJ37%#%/H_,F<C0*#"1_IAXAXHB48F+*] 0@JTD@DE
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MF.X#+)FCWF(8Z/DM'E 9A")G'PU!5EH=CP!T8VZA[^"TXSZ#1/0![CT)4)+
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M/GS440-0-%92OI*EZ4J>RFT:#/KE"3]YG>M(\B^M^=R<.: /*T*?A#RH"9/
M/.![3-U#J6<*K%(KV2TA*&"\6)6R*3.P[H"XMNSZ]+"YD2+ZYKKE),5W\*L,
M$$5O69=1V;B"R:,Z?@?+DVPA"_.<.WLGCGJWBRZ  CF!\LHHSU+:$I6&WOIA
MF09J+OQ*[:+H[Y]-!KG&][F@A$RK%:P:4 >[)("F">>!XKC34L]8UY/3:U\X
M4WWZ7+[ A1HSDTSP:C]X"A3%JF+!F1Z@1@*BTXEE4D2R):/ 6]W:9$Q%$,L
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M><F+<OTQW4VGP9_+X%*1-VX<DLNMFESW#=<M/(T2U&*8S]_;KUMQ;#GNDO@
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M_T# +RL0ZHENA3# 9_,\ XGUT9N7@.YS,'&<:H0X:L#5[EI.N=I]P2[9*V,
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M:<HA]JVS]**R^Z-_GF'ZH)L$<&["*^&):G_[$8#1\AVT'J0<0C >A'@1LK1
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MH$=N"E::O1E;96R_[.,KWOX2VN;0QIB+%A*,T!(<O4LKG*EGUM/E0X@GO?T
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M2< 5)<Z90UDR"LC5D-=O0OJ!L.S.R*;(,)JH-CYY]/KXH/:7Z*+?%0)00"_
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M]X[002=HE(C.X.EP>HZ85J9"T^?X/;(ZG +L[("V)  D#EU]C@(H;J!QERA
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MN#U,F&U4W8:YD,17]#M33W3<A<SM<3FED'B_%X])%<E6?W28;8T-\U(TVCZ
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M? K]N(TKCMJL.&4KN^BF/D0V1,:UF)?_LL!GC*[]('[0468J7#AQZ;WW:5Y
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M62&VX"O=#M\_J$[7>4#%F%>[)NTVX(^//Z-*M7A>Q!3<JV3[W"6:)E=YC':
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MU:U1>L+CUTO0GJ(7.C[_7;(H?C<5"[5V+3-<JL.?289-=",RM5&&"\5)7!3
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MHC5@#&=3W.1%+C9TZ.I!;3"/T7B=^YJP 8=[+FW]AI_)(0#?HOJ1;B?J$G\
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M>"E0@4>B60/QL1\BQ^R^77;N0]DV4H"_5;4\(GZ6=%=R.>\8.7O5M(TJ&%<
MDX/1XZCA4S,F,]W+IL;=+KR'BZYM^^D]C;M/$G[^*$U$0[9:6"SP>E6V,-H:
MR6Q'6\%4"FW4$Z;01F@$?1?KNN#FEY*W"HZG7C;+<-LP*<\*L%;NWQ0RO(V<
MC<BUVD,7J$D2Z.G[24RXL&,ZU^^CK;Y=1PZPJDJBBTE6 B9:L71\/*BE93<J
M#RY(/RM-M.^U0?"7.8?E'53J)>R[]>1]-O]U4;C5*\D @VHDGA%\X'@]?MJV
MI>S6EP<+<59'X1<_!,FA[(Z46PXYKM9@3QWZLX0=G#_70T%%4P]SS2V&].PE
M] :RLQW@7_UE;1*S:F?M[YK<:$0?S(G?7+"9C:@^?;']7/UF#%CF:)[$U!8)
M6]$;@F%8D(TUJVI:GK'54B]X>3UZ3,/6P'/&7B.D(#\],G BZ<^]-)=Y,SS3
MOAGAC#,FYX_4,TA,:QSZ;"F(86+&Q&CB/=;(Z&'$#ZE5I!N"JE :Y2]#])P#
M,>GC4/>B#0;2*\+&E2W/O\Q%Q$G)\G'M(S[ _M*\P"HLD%4W+9T@75H\N+%4
M4FFP:,'8KA,@V'8F0.Y_"WF#:YZYS6NXD9!+OTY'F@^/A).!A5<CX'42C$@[
M+/CGAKDMSF/U5HU&YI3:E3:Z2:W;FCU4)UW,5.Q@+ O2)@)J.GLQJ[MD( J!
M&^FJ<A5+3,GEC/>(>Y ;$>/6JU=A"Z>#0G(<P<^.N:UQ6TE6X%G9\E5C_<IA
M#:7/>T=GV(1S'KN[%-@,%6[BW 76_.6Q$GF55D,\87_J/1EX)?_9%(*V3_:T
M9:\NLN+ECHVQ'WF%"F1>+RW5T%*E]]I\3Q%K79(T(<C#T/HU5#SS64/F@QWZ
M(UNI7:/U76M0D&O^59^H79CW-N3=CQK6A28E,C"G:Y:]@(*7;%+K#HW2@1]7
M5E#C8D1+_(R^%'8^PBD43LTALLJ*%(;4O:/ I^?W$2\!_J G%#]Y8;"TC[8N
M$9>"8F-H&:U*U P+.YXY\J<^D07E[!64*-U(D.R1"78,/1(&%RAC!1[V[\&#
M9/"K>+_2<KQ,1-L56G_W-1]X:^V%/#M6]]2"Y^)!Q"ICPZYJR]!6A0LU(\8W
M!T(:H^'-2U+Y$&RNY.[ UBCN1M@QF,1D]AJV8D#!MW407!\9H$'4(_=NC5)<
M!B_!7B$"U_A/?F-#U0*VIC^ZN@\^II8D1:CAG;[O0<[@/)L\[QBOX!5+D_MO
MM'DEQ%3VR'\^6?ZO7XC\5Y=O3EN;&[>6:JKBGI>_D8@Q8)_E?!T#F=/6.X$M
M]-XD,=AKG. WZE#F^E'RC7XYV5_LQ#Q)!'>,IE,CJ4 EYA\-]+U3I;7;59-3
M??: "+3OBV_!Z<0%NBWFAB._V5VF=_&4?=2O1M3??DX(>H)I:Z* !4B3^MF!
M B?W$TZ/#HL?%FX=>S=(CU>N4*]YY\A?A'7P_TK#_-*92/?M9'GX$M;Y[;5J
M+$?<-SHSC;>?"TNJ!W5LYM=:^1A/WKXKX46-4.C#05I\K"-*KI0Z"CWH*YK@
M=CR<>WE&,^1;._X-G3JZ>L(1W"C3,C5_LSRJ1^NXFO#58C+UTR'B/#%QV]K$
MVOA[)YMG>92Y:/T+!_^TZ(6;5"M5_\ZCN?+W<!-D@,?7F R4PX@7KU)00K$P
MH1MTL$H&2O,"_L'#;U0K_[VAKY[Z?2FC_-\ZS%\"7T[GCN"#4C_;C>B-B$S4
MUYHJU>-]X79S4 VL5M/C&<>,W!GC*-ILHA8)W()SV395SUOWB:_V/$A16EV&
MS9V:>^)SHE>O*+ C3_<PU[>( ('0Q0WF;4.FS$*["&9U)4.D:R9KPQS/RZI4
M,#W5KIHGV6$SUTCB#2,_# AWAVI<[+3Z3S"JJ:I7_BC*\[%F 0>(+^+)0(@[
MA-;NAVU5:<;$I/)8".U=)KFSATS=G^;20@KG-*;\3;/E)=[:Z"P&5MU924]A
M=Q8+9U?IV7B9F\$-OV],?=U994!(/,4<]:C$9.2R]BW-J#&+*+^\E3V<B/^[
M7'%[XYOUQ(FGX#/RC*BY0[-+ZYA/^[P/!!V-\FF4SDL>6[);?.>5397+JOH^
M^G/4_IC7/H511,?&;*P6Q0*F%H_ ?AN=)U&3F-@('".!T(1Q6X[,2=A&W.93
M/?.>(K^1R5=DP [MBZC GI._Z!5T1K$G>;HB#D?HKS"JB!_>,G(1T_9VT.MZ
M&Q.Y)\7"L;^*O%3C6]/]Q?8.(8//4X:C[EOVP"")HW1I7/Z#=^':R]4#$98;
M[TDT=XOD @II")H1V@O9UCOR*+Z&IZE7T2*H.*?X89,Q:X7>??J+9G[1&@&=
MUTRZ5!N_[?.6OJ*>@X45DP$.3="Q%P2+>(Y!!CL0!+\6I'R?$H .="G?D40,
M],+VUYVJ5ZTK>LS\E$AP#.1SJ_7Y"?%@TV7U+0+JS?Y=EKU:W9W&50ECHT>8
M]LH>%M53_N:Y>I507QQ,O.SKM-! FJ"]2ZFSCC*^4H8:+TFUOL\T5[I0"SGU
M:\]_C<2ZLEY(>-CGP!W=%50H^?-SJ^8)*^)IO]#G::N&^J#G P6.[:2;Z!-(
M^=(%V E_4/=70U5TRN-+"9(N&\61#;0?.-0_D$:N'.!'RG3X.H2>[O&IJ1K\
M\K@YW/_J\PS_?RN8"G]&7*V\*/Q2R@.NY\2T@^)75G?'!<=VRO:/D;Q98/Y#
MB2=K.L$ZP6?W,RF6ZGXM3A5M%,VZ[B,1GLTR]QT>RJ&C>%'>4#2>B]=)-&(W
MD:*9-%QMR+T+962@OH(,M-8AU-6]MF]4J\0YW7BHRN[^K'("GC5_-#AX8D>/
M<#.:@P*B9"@&[N0OAK%"NH*[W.Q/BRO*A#G9+DU+SR4K\K<71CRTYN)_3%_4
M@/B:R^+X+-77.S-"+'[#] ;O5DRF*B$4% EH_.?<HM(+@7K@HN4_4@>)A8X+
MA&;0^XHY!C^4X[K:P!6[H9R#<$$$UYCEJA9XM>D/6KJV^E:R>*]41_7*!=1_
MH34MH0!)&6D./F:5J0^#BP:/SXKOP9I0D66[./N-U&N7&>S* FYZ#3*\3/D4
MH\R5MC^[&VLFJ8L,AAYBZ;Y*8&MB'DUKM0;$-.\!%VK0Y4U*EPJN#([5:MC<
M5,M_>N" 9WB*:_C6_7'@UK4RL^V?CR*) /'7=I-&@?W=(%*FRQV.HJUQ^&%[
M/5'@2S_ILE?TD_&!%J8(ZYKM70MB7^P1NEI#>.["!\>00:="86-W'6*__V=P
M@1]X^,XDJ,&*\&?,_A6Y,FHZS#C)$(DDG4.OY7<QW;_U&*"*->%(F!6^9%=M
M*"BA8@'>Z9\_M%@/[""<]FU-^K(J(_,Z>_7@8('6Z2%;]% 5O*?$/JH,QIMY
MTX\"LUV'>BSWLD$U.P7"LV@Z1)Y=4*U%J3%LOIO$-+[J?Q:S%5M:L-=N>I\,
M"-[@L+ >65K%F5?1"'04?#*WA[IY'".Y>O(B$7KHA!7@V;-7Z6$"$8O_YC]%
M",KH%+9&PU>>^,7E,4'+CP\0B[*?7<]1G3VWDKU3:$:Z[-R$PE^![:A1-#5R
M&+3)P!@+E2_2S_!\GJOT,I>B*3J"T(Z#\ZBC/3B)F C@9_Y:@P(QSY?/+1-I
MP4<\+I1YL;X@S1G//''+F>UB\IWWMN9O#$(O/MRY.&(>&P;@M_]:=\3H"RY$
M'2O_,3$UVOT@2=)*)[;3LH.:.A@@Q6%F1H7!R_VPXP/[M9G7(AV7&X\??F!A
MVV1XV42]S0KLY?X%;.0[6K3X<+P].RA^Q8+"O7GN4M2Y3EGL5S+W;CZM'%WC
MC^B)C5()VW/ I<? FH:W1#$V85LY?76ZT3Z#\!ZTCM.#KW/PCXCW*Z5]Z^:V
M)AGP_5(2=,6:14[;W"!>%D0S+V"OVVOJ@ZST+^"8SR<H8)8B*SEP)H_ BW'?
M=NF7#Y71]BAW> 1KYO#*7IY^?H8<-VQ:%4_(V!%??MD@WM5)>U'V1U'C5SN#
MZ%Z:C3WGH-3K@P<=;JRVF%2WE_Y0WVO+NRVNLH\YBTLN3Y&L>Q5X?KJN[*(M
MDTB[A(P1K"R73J)ZBNF.=W+-CT<;&SX4VI_KGHD^#_GN%:U53(]LKXR1&VW=
M$&%IL1I!L(T9$W;RPG-XKQ8VAMW,LG+ *9.4!1E(R#2*36KQZQZO8\%$$Z(,
M>8DP!3*0%G:<5/K?XXH&S1OE;-2<1Y@8_L1,*CP7^] >0AOQQ_O[^P7CF?FV
M[]<-!;<27/NY+[^7O21F>8:F/C#BC2@J$X#:4]0 U(K<$[-#XB[-S"L3;L%8
M*:_K^W6,7QT6Z8LDB$8'DH$5GD+8# Z&&WIIQNS/:&-*A1G*RLR<6A/5$!]]
M';_V\ 6-9E+DMVQIS>D *3.</DF<\H$9.A23&T\QH^ Y"]P(*3B2PG)/&A'L
M0"=M).IN8LL^IT]WB'F,:-VI?E O=4(?H\)5GNF[_=O[ "LH@)6H1-,I&&N8
MZ5;7Z9N_;17B$2Z)&6OU?U/;4X&B(HCVU9R06QC7&2)T>^3^.)]S,>!\LH6=
M<(''JW]Y1)-_==&U?E>B#KN(\R #RE7<"M[G'^K3QO%FT+]\":,9^,K-'V\.
M4'&G#IY E\&9A:!L##B]MD3'2<_AOD_FR/(GV,EK5_06 MO;N&3W@04:CG.X
MOCGG\U"Y_I+.S+I4_/@-O;"S2J(U'W9%J&I]!A3GG$$K<^-WZ:SJI75<TQJE
MU@.'( -,G1H8KGHMU4JQ]4\AAUI;C_R_)@(4/O0.QK0/>T?'D>3LY+!7=(W/
MELW9.PG,YQ;E]]$%KG4"88WCF16 G_7R\24^YF+.S&&R"@VYW5HYGCVY$(N[
M,#2(\YU#O:T1E*KH?Z7/54G-Z7U>G9/(TB& ,R]QAS-[P9KZN7WJBEZ\X X4
M8.\/:/:9+Y1;H3(/*WC^S< NWM8S>ZK!TX$,>.AS7\C&LNLD_A-<4B2KCIZB
M;Y3@W#8:Y"I3DGK88/V>#/S(X";I7UVA<@J;>X8KG_.H#IXFK+%"X*0L$[7N
MV2C(R[8 N1Z!2MT+:1_??+7\PXLS@/D_;I_RYXBL<J:7ST3/H%/\'26MZYW(
M/AA";0?$ 'T\)!YY@/=8/R_:JH/TF9^J]J->LJ\^EZ#7<K?%P-/WJI<#D['"
MH4Z"6W^-^OP4J.EUNJW\D(^,4:,W-3&C#P8O]=I^1[#/]XH;<[+:*1#=F5!L
M] =/@\WZOS][XUL=%'SV:Z+M!::+ZJ*@9P+]!'%,HO>!\?K.%8LU07.P-!GP
MKJ+_TG'(M'>[Z=G.Z.Z@9\+\CME(SJ92\&4J#MMJ9-M"-+C_E8FR<37SN'M^
M;,>,S=%3GU_WCGU0P?Y,^JO'0NY91A.OV]_"<K6WIY <<GG5 WL3@OQ]C@Z"
M&>6O?3AI_7D'CQ-+31^+2N<9365OM6%E-Q[;:B&J*6SPW>##2"8NG:=_7N76
MN6KQH+_T&/S#;MRO=N/J@Z[79:F?J;_)HTMN(J[LH"229B$!BY]4JMR;U2Y
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M&E4YE4QI/JVPFL32U@K:N]1+!K8),P2[*N>Q#)(L5)$,F#PC04QW[['/!-2
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MO[_@>_$>QXE_+G_P;\%9;_X>E_5_T;O?-76/#!#XA$/@>\*PA<TV,L">\=<
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MO"\\W[[.;B.?#=  Q8K: Z4F=_4"4%EVS.7? P-Y2CHYE]>^#OW\W]ZY%_B
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M"6!.VJXK?^<K77], >T!HEGXGJU8"NBUKR_1H?C\]J[#&-:C'M"\/T_ BE%
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M_?)H@BZTU"./*N,DUB?AHP7]5I]VW*/JYZY#WG]E84$7!IPZ&\"^0I6U*7'
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M@<8_M23WC&X#;87H;YT4D)5BUK8QW'BO4*"@*IP"*C<GL2(EGSZS\-/#]5-
M;=@FZ3.ZJT\"Y<BN22-E!"1NXL<^.O3A-9_#APK;P-728'><7NM[VH4Q\S]>
M+"VS_WBQ;*LD/)ZSN'N8(E#U'.@1+ *6A?M(7]X_)(APK$#[9WH>"'QRF@."
M!N9^X6KCZX"EPBB&-M(V\W,+!/R4,V;H-\$56"O\\(,"6C8*Q^FAF B!/60U
M#]4[?$"/G@Y\44*R;\XM5DCH3&H(,TNPVVK50/*A' 6DOK]C@3*V,".*U]27
ME^#\WE+-<9,3JI.[P-Z/>SKY[10XI 8J3@%Y7[GX^$C2+\A QVM$1E;B3+ !
MLSLLZ!&9L<LGCYR-.'L,>4A -M71XZBC5I[9?*UQE*<%07L;Z+UX,OJZX<L]
M49!O$J%W[WI!K;'UT*728[JD^/F$C<[F@1^:*S&?'_+[A3Q^:WKW5K:8NT5.
M'X.[!.J^WZ5^%<BL2VB2?W,=7]]2=?FIT86%HK#Q]MJ?$K&W&XB(\G\!FNC$
M.BZB3@7N3*8;,WIT'<W.<&%'X7&H-AC\F>W:E-K0%@^LE6J)5GD?;FR6K+#
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MVX5H;;JH=/[<+:(8!00!>BNA)!+R?SKE8Z> D)AE2Q293&VZ%L-368WHL&&
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MY\M4L\]\7IF^G9'G+B)+Z' 0/F:.)M%M 5O'0)3_!11=#6=40FFUZS)6$CG
M(4H4 ^B 7@47(F,<T9X",I=I*8&03V!^J;X]1E$QT<D1LWN.BHJ8#;(\7U(\
ML:!*;RSQ@HVD!&0-?A=H3,3ID&B?4?LK!]J:B9Q>>F/T8E3VMOM0X2(Y\C(U
MMZ*%W+=U"^3'ZZ+CA\!&.;"SIT@BROF7;9$#OE$S#:E+H^(Z=!IZ1 /,CU-
M1"L(+HL(IL*9-#$910%%I).<J((H%NX!'%[8/[?I5Z@K'*LKFB,7O_>:8#SM
M"6(^(:!J^YZ*D8,87&X-*_5!>F!K'45\ %D+83D4(0 ?_:VM>N)R,XG5-JQ!
MG9Y')MA[?C(XD0R8NU3H\YCFS(E)G=&OIV/=1EHEYC$<CISFJ##T9DGGK=+O
M#K?+@T^=^#H=(.SFO];SB_ M08A97$YP("'QY5AA5SPC\YWUMBPA]A=-V7*C
M$G-"HMQB.AX>7U1#DK,=WQ78//9TK\Z*8X)N<_3^)LKAO^RKH%BLI8"EJG?
MKHQ$%>E+C26CM=?#5>/XKJYO<V.$P8!0@0WK8[B5U-5FMTP>1_(K8-Z=9/5*
MS:Z8P#W']-F[L7$ VUW1#=UZ/=1K1NXQ<0KRG3TOM'=VC(NDQ[)@C==Z,3C[
MN14X_<&?C>1\+Y7.6QY5#SG3$O0JQ]&$[J7V;2J:S&602WO-B!"<5@K+OL:7
M4#Q,)>K(#I+Y2LX$97R];9"0IS>_<6A::L"4&F$WP\(\8K->=2;Y',LL9T[U
M3BOB,:N-87;J?0_0(T9/C@:EXNRM&XJK]W0%F(]O>55WE!7C"O(Q<A45-8Q
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M+D[00"WG;WF67U^8T%LA*,6J[X/BS\4&XQT@I0RRR!QZ:")@_YN8,1FVHS4
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M/+TTO;2X$*90I2-Q_E#A?!\(A$%EY:1#WG2T.$4_?FPGF@XYBH82N)$X72)
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M^]7,W>*HB*RPHWV1*9K//K?;%>^U!AH?/R;;,NW_+^SK_ZM0^;^)W@4T+)0
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M(P&^DJN3TI.IR:^,4J1OF4_W2ZM)B+ 8!UPR]XUI88$%='(R-U14C7QT=GW
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M. E(M' _I<BZIPK?8'5O!<$F,7!BM=#<59-FZ^[GOA^9UE<;T[MT;BF</17
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MKW"%8_  \Z9G@KGS_CM?K/[B1,34U@=G071.9>^M'V:5SEYP-Q,W;<2L#(<
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MPK:0>\U.BVI=O%B1!-A^@Q=]==/_U]YU1375;>N-- 4$05K $&F"($6*@I2
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M:4X14+M2U68_.U7"O%1XZ^51DA &4=G-,_C*:_N]W!!3LESR69":M 'LNNR
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M&G90=.BZ786H]<!'+->60#TDIDMET(N2=RS9VG4O7/'ZM8\V,EY>CV*7C)E
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M0L9]6#ZD)&;$PW5G=.2;B/22]1\\!E-VJ]'+9+YT4QZ\@S?B&Z!RJ.5S6]F
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M2+\^AL.?T _3L/,>-^=7V+_F,WKXPB4$>^=3U*Q961XGC_(>NO0JM1K4(^Z
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MS^X 7,6PVX)'J2Z4"I,%I"46V#(!30\/B2!?D?5@>Q=XKXH=8[0^TTFRF,N
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M,O8-^I@"ZSN %-57H-\%L=UZX5WXE7,S()UK]YH!S5UC<6&Q:^U61CP';_\
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ME&9;S1X =3@RI\4R/78877VRQ[0^UA(/@'6-"RIEY*V/(^TT)^W _49];D,
M7+W[(P%3!J'0-5-5.M0EE6K(.&ZOOW(R $%1D S-0C;[. #5>GSH13^$G8'N
MV2U"Q-UP>[*D )./K[.WH#W;<+X.*TB"KB*;C;5Q%&YQSG7AHPOLE]NKG2XD
M<!)M6XXG?R2]UHA#T+PDQ -MQ/O8N!G8TYV\L$PK\?LI(%EAM:%LQY4,F=^N
MH?3Y-LC@ GRVWL+X@"D:#((T_6CU3HOQ9JE7 Q$:"9L$]N^+]-\S0KJ[F;MS
M.HF7/-E@:"N"<,+0SY7)EIW'6;$-/O:TZC=:+Q2%N1,+?Z9>V 6>L//B/[-P
M=75(J62LDX[%VJ32A' Q3Y#%,4^]?16H(HRBG$_WKU +G.6I TON7V@/YU64
M5)[*CIJ KF^&*IZ'?8CO!SB<@[.+L_&3(.*/9HB@G*>YK+E5#;T^B.N4N2UF
M2\80<[LQ^@F(OF>%0Z][_7;@J ?-K?F8@G6G2,(1J(.HQK+U9"SM1E-F!5OO
MAX0G&4?Y:@UFD@+#:/!(427'+CR^.D1SNR0!!?:N8J"^0K0(M2S"]ETVNP=
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M.NGMU<^*O<?0/2LV7+<D2,QS<SU"C-,$##_KF([TL T:Q_M)$/ZSMI+92$:
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M@K%C47^6RHE4=:YY"PSDC_-NPF6"C\W2%1NKD_A W^J:/A&;#HB<TR]ID>>
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MZ"G:/ZV67?T]WPV[64\'0LA(.%ZKKH:=*2^\[JK7HOT*9ZQ59%!]/7\L'Y%
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M40]:6!)Z8U>3_+W8/8N%KT(?K+1WNP]O2S#*/P*BZB)=!O.  %%,34<*/.:
M,O5<?83?P:I6A*\#Q 6L9Y9X&ZQ;DN/%"(R8G;7H^O1$/-S=1M!!"),5=#\
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MM8>#(A/R5W!V)A-"AS)?2MLF'["P\V.N'7RWQ S*WR "&<?(X_TFETA@&<^
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MG9C&"PO!<Q;;)B6UKSL8-!NO[(IN09D/^JUFH98=@?=D=ON&9LO6=ZC7"HA
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M%BC3TW6Z8TTH0PMDKDLI82CSGN^IKPO9^CY#$QH4Q/H*7G"'4.=WGG^;MAN
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MUP1L*:7L%COZ.#,2%SE<5PS>G?^6#G%=<HTQS1\:(A_U,.H+679MCP(?UGO
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M?"<ON!*Y"&9/IV&D&;QQ)#DDQG2_U5!U[D7AG);'P7\-05RW:U&\+W=%-90
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M'/0MH73V01^P9/Y$DF<9]>9TB-S<=D60\W3E681-"OAWN=)<PD]LKLW;X\\
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M:E!98J/#XA"KA>]&IPP;@7/2-LSB[F]TD@+50XL[Q:KDURGYFH(BU8% 52)
M*?0*MGIO"H:Q(+D>LXEGFW1)9_41DS8M5DZ;+U'GVPW9B^&]%P_+FC=0##Q$
MH$\-*W/VTJ5EW\D ,KO_3S!=_W<"J['Q6-9$Y6PL3?CE#ODM3R[G9P&<->J
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M:(M]7663O )'Y15I*-\5GA\U87*\-X(M%C4T-A^=ET]W$]G!2TV=Z<".C8C
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M]]+2/V#%4&H=G]<?C*RE:2!7D!%:A!:=0V>P:@5F.]0I9T;H1*DQ@&);^V
M\)MJY7J7$"90/G2B7M41#3^M$ZP?BJ[Y\ABS8OH^:N@G)O-(CG7%-"$TT&)1
MG]7<29EZUMWZ>==*36(D^=XK: F\";/2"8V>.AQV6DUSB:79?OZ 0VAM/D2!
M(;0Z#M(1H/TA=_,'C.+R6]1.B+05[\,UMS7/V<[);PHMZ9U/;P#6P D\Z+-#
M]8S&!]?'#NSQE(PB!>Q%ST$D#B/9$]NRRI>/6)CZ8UTV#CO5\<NLU?5I?=Y
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M7*3I;B%%MT2'&[_5(36/M^9#%/,)'#UM1&#__!1L!P_#.R;@[*!_%*YUS8E
M"X8DQ J7JHC #,1RO$JP$I.:FMB6Q.?W1%)?J'G83?D=S%1/!K72>793]68)
MLJ[,&=0?+75\Z5F Q"N&3DY@&R^ *9QJM6)TWJDLBNW_P!5+A7J[!8A'=VC
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M3L3/;6FS 16ARP%HW@,#H$TXAN'.TM*NASVX._C&+!%P##3#W/U ]4M2@LW
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M7I*GG9IWS&%K\GL)=QJU@O9H^;E\U-0U:Y.^\9B\3^?!?NM*NC!!@AUR\ !
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M;(RU,PJ$H$U<[D[J&;'_4$84?\UB[14>F+@+0=.-3)0!_MI,A[VA@7Z()?I
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MZX@$E[,/"2!XNUPI$? ZU,OH!9W\]5]5\1>3R>"]5)!-$O*&N17?_\L;'OS
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MJU&?J8%(1N0P6B#(S.\5P! .D9V[I$B'4YRZ>98NB\KM$U]TPJ+@('=:>3+
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MN"5)>@%*,FEU+XC Z<.<F3"_R3C,HDIA35GDZ(+0G<B+>M87QSV#@56+O_3
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MZ+<Q?[^@QDO=.NDK]FNS<M/%B28ZMTR:EI'M?67!VDE 4\7=D C05]G-YKU
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MKZQ/J3(/8I_R76@K*KSS62E,29R7BVYC(.BZ\ZPPM^I()1BT06_BM];)0?6
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M"[&OP9X['_LA=[)1J>VE6@9QLX[*8F4Q/:*2+*>,S2D<K8MA2YV;3US9.A6
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MW# 8&U=Q_Q/<#FJ5S\&[7N248W0@[5(H'Z8GA\:-'&HVA+?T._N(Z2M85[G
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M#(*C(_%(UXV&"(XA^(1"26&/Z)H\=_BM^K;3&A$U\2OH?[;.>2]&_)TO&-T
M]ON]A6/*\R(%\RP^C\ ?&<?^P'Z",95X"(E@Y9#<"=D B?!^1O]"!;^L5E^D
M8^.H%5_W/UNO5W +4YNW""W]-V6\VB&X3RW_A8[U%A*!TTML:5_9!>^,NP;;
M;G;5/I9]FVDL.!EIENJA5!Z4$3X^?.,<;_PM*BEX,TK_9U>U)G%2X7I M_+*
MPL=&E'-ZN?-_ZE#2KO^+W=4_FCD#AM>'-R$B_=.\,^T2=Z<"/$7XK/ZIX_5\
M[*UO\O.3UA\TWN"R9#G??$'A/I5#@YH\8+Y8/A\W+2@BJ*I<&;[<?[ONPZ+G
MB650WGPA_\M^#W+!W$SA5]+,SO&R^?B.DX^&Q[?>J_A]6-FB<Y5IMQH(P'M2
MIG_DH'Y4:,U<KW0SK_3QW;K#3K0B%56F-&=I&^ @*XB)]KB/G>N/]/S4:IEF
M\>)KX_@$^US,@R:$- #4<'/B-I2)  UV$LUCGIAM,Q)Q?8T:B1IM1)PJP_+7
M&(RCLD@L_(350[V5+W*SWX*NA3Y2H+O5<<\O"415?<W8<A<=02TQ)+Y<4;V^
M<?$,>F_\&F[>6PH*PO&I^Z-/%[YRS-&!Y8 ?B8RHP>PBKAEQ63(V7F5GMWM/
M8UX-&\QNE67'4=6+N]7!,QN'0V/CFV),BGSFMX[G?]D/=Z.4N5I)EG0?OB/Y
M;XRT<.>.KS) E];OE?IYV+(FNWB_0J$* 5:91>VXMZGMGM$1\=*+_D"RNJGZ
MF:4'/:[.TJ//S!5!Z_B'JVA-Q$.LZ%6;\.\GTY;0.$7<@!_^167\EGH/Y[2.
MR_7JZYVTJ9GI[O<3IH*>U<>FU2=ZY.U%#'27HB+&.<[ C_6OM_1:]ZS[*1?:
MYY7RZ26AW1_C8332U[0_?2IR#%XZ\LH49TJZ3F\@ME*MEQ.+!VW)FJ0$\_?)
M?$&5B8YP0/0Q ;&T.XE5<]G#=Z:E7L7(0\[7UAWCGU:3;?14?UB<5Q3:;&?'
MU\ &FGYVXUCU6L\:4YU:4<&]YR7^%Q_1O$@&+=TZ*T>C@TF[>C?RKI_5Q2O:
M&HO DOK?B3Y[#*H_F'%8D?5_(@G\>/M.0.-1T48]E$;?%&$1-(J@.=&!;&(Y
M@KVOPC4\BV-BT]H\$-VD.**$E<?HAV9C>A RD+_$)8^3A_MO-"!.C\X:AAC*
MKSZ4:2,"$:9>;WT@KZ25<R!O#OR/FFWWS=C%0?CC\"/^KLRZT@#40Q7^#4+U
M)H=VYP'EGEZ/XQ0A 6%MNR;P*7/S<F7F]$2#(!^(:LS237 !Z>E%<SR2A2+T
M:"OJJOV-F</QOG8#.'/]P(3DDL/=*OWU$R&<"W:4E3!HU:$-ZIHNB.&Y22CJ
M#MFR;!6,QH;JI'_Z>N\"TLRV"?'=[DW:+M]2?%A[Y">#97';_/E^[?C+VV8W
M&=>B/%2Q3&CS<RM9194/<STJ'G/5KHO(VO977JZJV(5C&=/8^@8"UZ?\VLHX
MG=*^^\&=P"(VC:[G? C-.[F/T,SJU!)\KQ\2 9%,9L$X,:1_I7*N\GQ#IE$+
ME&"HMNE'\D'/GY7G2$U1IHJS:_2>+X:NUV<H$/SV![YT&>V4^IV5X4UGW",@
M9N^D<V8R9WH(8>9BV. 957;CKE>O;S_R*LO]U*J6UY.ZN?IYLABJE$J-;,G1
M,%9[;N0V49^ N"[/4$PR^;+&OVP;3$-9JEEPT8W5@H6]CO"<^'%^!I_0 @JI
MEU'79A:_5A4' _MR! ;F<-)L\\,W!N(T_H,#3 OH /0):=TIQ"LVXX*/<A;%
MSN.V[TS>7_?HD@R7_<R_J/+OWC'Z%Z8R]"OZR@E0T>+,P_;^A\<U1J?+54P[
MT^N%:3ZQGF-\[!X,;$YXBUS N>51<CY5OSRW+FMB9%L/>UF$<\UIXQDS-$%^
MUXTR!)W!<V#-,"'W$S2[A--$GC'PF'/O+BI8>BA/(QCP6E%@T.*P3%MX(A<B
M35V$D4:&3@%(INN9O =BKBOE?N+_=A U#Y.:Z?#?09^U/!!P$TH46ZD3"+C-
M)/O@5J/#-DH9T^YG.X6D&UIB2J4WS)#<X8D^B#;H)</&XODB2!ZULX@TOY/\
M:!@8\^G'R=8[?1L$*8+8KC7#GUG^VV4QA56?QE(%F 2HP523FGFX%4R;OBL:
M!XY7SZ).'*6C9W]$JCU8$]XT #:I08&<5_M$<<*KCM0?U\R-L"H5+^H&<D@0
MUU]C!GW A$)@)["H3 (SHODJ9N/(%;636^XM*_+3WZD$1D52LXL&542@"=%8
MW9;R9X[?F^-CCBPK_*!]6>H5_KJS\?7(UZ4$IUT9AA[+,7)=6742)%>?5C\Z
MU8.8X/_?9.($LAYYP)A!!*I_[.FA/E_)\<K3W0\]>B,%YB%Q8AXL#\'?$KWQ
MEZW"7Y76[6?0V DFH7@SNJ9F(H )PI-@X <#V\.YOVQSGL7]V*<MG-@C$0&L
M]HX_@^=3U!95?J#)+!' W25PD^PN1^)H\R],ZZ>B!U^#94E]\!N2R]M$X"\B
MSB 6=1((^R1Z$O%S.<\G\F"];'SMZH?!?0B!'A($V>97(P(>/TB7WO &_I(7
MR]4PF/(A_?NSS.]2YYM^6'(S"@FQM,7A?FSH%R#$4E<8$>]DWDB=HPLQF8'2
MZR6,<<G!*A[/T41F-4[UVGNN*/ZJ7F/4H30))]Z,):#3"*K&!8K]?"2ZYG[%
M^9\2[E^;^Z=ER]G"$4$2X\_")+&V7Y;-7CEUY: !.@_ZU^C!GR1>W/+>5&;$
MQGK\-)1F+-#FPYV9_3X$3OO'P:P/5GM$@.1$V [%@YN+QX8L]?7!K(BO6=B)
M(VI=-&X#1R):IU*;$-N"QD1@!CT#?=:E9-X(_:4S$OUE]H&AP@=4?_#_BP1&
M^!*WCBQKU:0?'C(#->NZ!18=L2#(%-R)J6;OF[ICK\T*\&Q]K&[ LA.\)0>.
M=I$S4"4-;1[6:LL[@J3QA8CD$^2_3-CUF-@5?C6Q3=:/WB Q5C;9G_.KD#CQ
MPB@"PTB0*T3'':WNHU>A].A%\AS$A"5!U#-D6N((<$(=KD$:JU^GA&B2J+$=
MB7'J[A]/QW=LF)/ ZE-<&!&XQ0$C'*IC4W]15FS;G\$ B3^,(!Q#?Q,4GD>X
MR]H>,M?;'@ KT+UA$CW]94%4VI64OW7DMB7B^N'0%F*PF@O1265 LL0>/ RB
MC\8B S_+CF5;#A>EYV*23*.$)#C]_* /=-]Z=2(VU2!KN\*SO3^W*#V@6(W-
M?"6Z@^XN'#-8[WN7%7.3F2(\-5J7\ LI&/MAJ G*CN"='8DMQJ7M/Z[3%K\L
MZGE!GBF3",C.$ %OU":UZCYRO"/AE]U0_.E[ETY=*8+L[X'QQQ&O#:#?_Y$:
MY3\2@8Y2$O'GQ_MV$\SW"N:)0)Z' HG1TQ41 <],7-=/I0_N! NJ$SQ)&)8,
M.LL4NP6I0O+!QFFQ[44VVI7"'UGCZD2C&&X>P1)_GAH++#)Y;]K0!RO^Y[:L
M%8IK_=GI1_S]N /^W\RS9>MK0)D]-4'1:IX]V&S^8L!F^N:UJ#1A2+J;VC\=
MT+LY(WS\)$_<5WFV6&<9@)R[DWR%O3Z)L5M:/_,H0J?HS'&IE+=T0T]L-[CH
MM$B*WD>=Z7-"!4^<,76/H!D:6XJGOLFT<:[5IOO*XO?9@.=$H*#)QBZ^HQB#
M;B0"=/>$K6ULUYUI"LT?*/>&2S:N.N".69#W,.MCP7517^"O.W)PUO (O2#J
M1X;"MH57Y@(@H6X.S0UNM/Y'&1_-&-?\O^N*Y^<NS@7Y\8.R/H..P;-PK740
M6$4^3'71%&:XHLP0(:1-SD7U_O3MVJ7WSI]5-\BM9-FJH_4P%%W#UXL/$\]H
MAJBBC-!;S=C.\!L<E/9DBXZZ@E.VYY8(W/%JLA9I/4ZM=H3H#"./_ S)MX0#
M(E H1=\CUOMON2_VP!AJ8-F/<O)THBTJ]UQZ]OHBJC>)OU5:$;OW]<!TXEGW
M]X/0N#HU&D0%-&-:PNN<>V_+HT^SI+3P<<RHUIPYSHXO9;=#<YMC)0P+"GO8
MW>@>+3PD,/VH^;KGJA>'K%]\6X_-//;1 ZB!U&CZ5RI=Z<=@J'KZ<RL$Z+E3
M!]W8DMN;CO(Y ,2,SW]\F\)MTJ>_,L+Z54-'#'6,#%3S*SS46-+C3<]+X>R5
M!2) 4VT>L )E)1.(%_-YBIBK&B("0[<)YIC<:Q[*,V!ZJR[!]-U4L:GG#8R1
M9N</^1"2>S)4NXZ8HY?C-@4?'RV70@24D.9W9#"JX%I_MXS(Y"7)XZBAPD3)
MX1;.%8HG+N[1O4@'8_]SE]@@%$[K;F^NWG!C^RJYM\P3&)!6?:Y'X<OM7O]"
MA!47>$4\;.S&2M);^^5^ZA7E')L4Y9QYN7.1I=_,N"C8XH.7)#O>X1TP[/H]
MPF85F'ISC9YW,:=MCEE4??'";#?)CJT$%N+,9V CD;;, 6*B]G9QR=>$C[8'
MP3F>2 <[VO3/ Q)G!![<"5#F-O'^1*DL6Z,;Y7$5A^()\;#,L71I9^(=[<C@
M DZE8$SVI&[9UF8=L_5'4&G6;N46?&[F:$05ODJ->%-"A9(9.6>>O( RV/G$
MF[O"QNQ\*O6CB?<5LEX=CHU0#ZG,V4=6NQ6!VF&57R''FW/M]Z;' RGE<XK&
M>N@"+>0A03>/^'-CR!EU)S,(TX]2RA./&&=*T"QB-^T%"E<,7[A_:[P#>7W$
M_[X2NQ"TT0[6CK\*IP;H"9_(CF#=Z76#97CGB [\*Z>GGN1B]>)=<3SQ-UX[
MF3].W1+S<9]!TPR:*F?+<8&F_$3,"?O?4 R!=03N_K0M775T&6FV%333J24"
M/A+@'-LACRM8VG;:.H-AX1>;-D]P5[AV<HA _E4MQ#@__FWL?LBP\FKXI[UI
MPELF^1BDTPM%UU.-H"U(NH,+FEFL;+,XICBFQ8TC?="+>V8[9T38K]C2#_&I
M0_A3+8MZ[WRYE'"@,4M^+:'];"F!=PP)"; [T-P=D@$%T-D>;-A^$]1(DG&:
M)@)GK5!SS9_&\FR.W7(VQ]Q[%@(] 4_0\L0NZ3XW3-RBC<-#65').<^?KVJ:
MI:<QK2PQ/*%:TN&5/:_5]V7[#0+%3Y5?O8J%";]T&\7!*A)4M644IE<AP+6#
M 44SC)]J".7>@_)2KD*K/#]\QXIQF/R+OG9LD6Q?%?-VJ]9TN'UKC1?KE]H(
MY0 %<(.L6<?D$".:ME*\Z]5DP(W7CGJ]5_#^RO*N??Q]GS8>JAWD1ZF:=%2+
MKL2Z,=?!!@I8HM;ZN]+:I0M?N( ]O'4)QY/Z-IFH]@)7H%;X6QA;/(\QBZ3$
M"*$N+@HJU;SEM0YOG-O90?$2@0 S(O"Q@@CPHH^*\UFWB(!7:7:Y\0>[U.7B
M\K?O:X6LS?1-;.#G%S91#C]GCL ]@QXDH#<3B,"(!?F88VLQNOOS!J<P;^YY
MY7NN[=TM=-<G6+.UC;\.K$HZY60<$>ZJ<N)-G#LI[7#:__[W:_X="9:BE&XD
MQ[M\XEM& \4#7KU4I=[-.[E\*K_QM* L+A4S/S/-6)S(P!;J_*QK+"A*Y+ $
MD*)?,O:3!TS@ZG<1M#A-M:ZT1'/W&W<5M!]1-GGHM/W3\_;_/1G;816GWC;5
M\SH.^&D&=ZSZU(+H/4?R%CVSNQ:3Z:2F2GSG,3P!4.6D':&A7#;;:Z>S .]K
M?MNYC7_$JV&*TQ"_9]@!?Y)ON%"IJKC5#;W6^67?H9&JOWSY"OD;G,O420_Z
MJ1O;EKG=2_WFT6UW^61->BC+R_]%*W?95N*P+,M8Y_L-#Z>9_5^MLM ?6;4Q
MD$VQ01L-(\A&ZJ:@3'!GQXH>+D,[P53:_(NA7,>?O[AUSL]O45*[ CFL?D=)
M;]C"(#1_9D[?B.NA5W+))DJ_W^-F"BZ ,5"O>\U6PVLCD>4I6J[7BS$N#2^-
M"0AR+#% !*ZFE,J]>9.Q*[><7A#QU9O70R)$!ZE4/>!4H5U0W9_;-C&D;3?;
M2,]URWW!ZIA7%5F;LZ/&+=:!<KJX+*L8R<2V][:>3QMRUB4E31FYN++.)X$X
M#H*[_IEGG_Z0O9/-C2 TB[4TXX7N[4&3JGZE5G[DV(COC;%P$B4U-1F0K2H)
M1:V+HBE68G>C]G7%=Z^K,KRC@E%P<\)7H*?'QCH0KF)CO3F"]>NF,0HW!>IG
MHW&=5*X0$AY\=694-#OG\ZWWGRTMZ?IVYY0AX;!./#EV?WTCI4?:\-RU("6M
MWHOL6ISC3[<!(@ WX4QLZM!Z0#51XTM&=7[[8AGB'"[&&E3']F98YW*?B4_H
M-?^QHBJEW7,SU?S?O1C@!09H#)?!Z'AEB+6]];0]Y5R0B=I'Y.WHC3:7>.=
MEZS("YQ:/ 2#&RLDC/0=%8XLVA4U<8X GXW3TJX*X#S7;4@$H!\W9Z-PJ*;X
M=R*RJ=EC9WVBVL_*!&*R\/YN4))1FUOK;%]J>K5#T3,MG>#NH<R[R[..(LA
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M=<:<+KUZU9D(WK)RP3[]O+=X_L+?O M29OO*H!B5 A<_.)0O.3/:^'*A'/1
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M-?=2HXNNS0V*]#3;ZRL.V]X(@:T(#9>3&T:UJO@D7V+%O11#/&A77895)SD
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M@%.E](7-J1MR@SBF3,?UC,-MUXIK:Y-,'KZ-">3BC]K9QI2PK'')XPDJ4_>
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M\#'KGU,_AW:"7:Q>RYG/<WP(:;EQ_.[&TQ8;\30IJ0L93\,+!9@Y[IJ\J8Q
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M^V)&I<5RAN,>UW18,S=W9UB+6[/0Y]1W# +96QY+PXYF;H@1.SOE>;-JIU=
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MFL#;M$GBF;IPT7S.#@_S;Y5)TBK 4[^:Z"]OHW1U0]%&,3R!I)!LR9JRGX^
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M7*49Z.WYJ"WE^"3;Y)<1A#%L"=4&(U1LZXW$LTJS1=EH55F\QI:5AUK<%3P
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MH?/R'//-0X7F:O-YF^II2'D-B&L##BD]#^D2%IJ)C.#97S@E9!R1F.+,<G@
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M_V0JRI$T$ _$2H12Q.1>\0_7X"!GDII/$OK*;P#$Z4IW [M)*Q0U(*LA3\E
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M4LN>]M,%VI2:J/HR>*5S)<"9&CA)RK3<A_!"DHAN\K?5VU+"%56WR3_:M3P
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ME%QOAJ5M'E<#2/HSBF"*5.%;JUYCE,IZP_WK3[Y!34\M'6U(NQAL&L=GO&&
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MM&:2WRG5F"T#.J#*OW@#N FF V87UJSID;P8J]A,K(3M4SJ]Q+U*/_5ZJ<$
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MZO413]P<GJ,%BS:$GH:P,0.'=8UUY5NK^S7JY\\E$TC#'Q]%M)&?BN\8 -@
MUM#-95%R.TLV7&2^.ZU@:CPCK&#E,7+I7(HI2*2N#$.ZE#(MOW^I+YVV[AGX
MM.6,.V)1-)$-;4S^,:#""LTV:-TU2PV]-(&QD4 A(Q;R;D:AD@O^IR:&45H@
M3:NELSKCLV.]>?,=D%[O4.D6\NCQE%4+ANM4(*1OH.C'T+;=H':+'?4:U'QH
MN(C2'3Y_;(+]4-.SM+%<5K<>DV^X?"+YV:/L>XN5B$=Y>_K:C:!!6SIRTP@
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M7O.&![",_96'WK-.OVGLLRX6@ J!@C-WDPR3&BR[I5[KVPFL7P94\(O6SI6
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MY6;UD9#N]O]<:W(A>-Q6>:G6C,#4?;/ C%%_O4&3LU0HNQ/>NKS*,CS.\NW
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M"/;.G]F#A8^Q*!?@\)0SR\IB(.,%3B<6 M\A1]_!7E"SCR;VB6W0>%K&&B?
M)JUZ@W^H*KK+,W-W2!;D\B9[W8=J*9:9'SX6[N \I1(TPN2"O4T<Z78U'*Q1
M"F5!]9[#+SV5W4H+.WDCS/I<I$3&]0Q_K,&6)7BRBLF/F@/K7>CHBH8]XPII
M,!J(HL@;GM1()U3@ %]<-WZ'/_+:?TUN()!ZJ-D!!1X(6.?X#63.#3&*]_O^
M'K5>##'M@T_6+W452W,CIO5_I?5S!U[4P)N1*;7E#[,/C+=:GQI2R</G'V0Q
M[HAN^L,;P_@:9=\M*->68S?(;9T:=?49]@@8R+U<R+,__;D/#Z]W0;A%D Z6
M[VO3D%BGN$6)9:WWD@PL,_2992Z]\-*4.)_"L8-W/)P9CU\\T<\P:Z&D&KGQ
M/1V]"1;QF2 $?J@5ZJ] 0+36RW=8.-2TQRI.)S+V8K1RY-T4V3?WY54')]7W
MO(%\:8@#A+=X1UMT2$M;0RWE-_T.I&$CWA)0@[,^RH,DBW/+ZZ\[.% ^(3!:
M7$G.#>A^WRWG\@A(EJ5"7WTN15T=K:"N^C=(I+U1A\-=_&B<OJ*8O,6HCE!$
MQ$N@^*+?9(3:PIUJ]222SG!CP'3R8CVVF+4BL&;IH'+AAK7 K52QQ(P9;:Z.
M)KK\>U_\P'ZG@$I-NF!X^C!E25S4U_VR0PRMKC_?10_D*^KO8L84(2-PX IV
M6U [Q%!-*,+"=F_0QR7'Z[LX,D9#<,EX4J2@L[&!RY6G*Q$-OGN5NA7X)6++
M&V/6;]681"^*&41);;W$K"$? 3&FN;T1%$$,'V# YUT,LW<:(F-WBBV+C8\
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M4=UQY)IXDB\'.5H\/U1&YX>8Y\D4)0 E$$4O]BW94:=QT(9EOD;1^G\LK[[
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MLJKDG'!2%!-04UI8I\(J47IRK?G?:]\A-[N^P!I4&0.9VU6@&(7H6+<]2K/
MESDCK&3 ]SG>[S=>B'ZUN.\K%5CLAL8V\B9?P:(667:^J^-/LJT1>W&#MF^4
M[J"5^JV9$%./J3EG6-+!U V[LL9'SI8$<34#[^P,_:T7_B[MK<L^+&$28%[C
MTJ[9XVXK]#0R,+[ZPJT(!V.EUSK+[2?XL9%0'N:4L'NJEQPQJ\LQ$Z_8V%'4
MDIS59U'B>+9&X"'KESK\S^ES]Z3P4;F!!-5+\Y+G*@1&>@KH=5FMLKTR[%\(
M?.+B\Y\?S3G8*30Y8<T(WLNN^SLM]<WQV\HM3.5H0CE ?%];W6.P![!5FR(N
ML4=%>7$ZYYWP,#B.L7HS+G@C3DMO$>GG=5ZLJ0>)*3:%!BNR<"XE9+_>T06I
MAI[Y_+9@+^]5XOH;TEHFVQFH6\U:E[\"K*W0Y2_[WF'WWY"JHJ(SM#K7O3EP
M6>R?P[E9@[C<Y"9UO/.UWO:L"U/:.ZJ6:YD)+C0QP/Y$I2GEP[% ;4N2,MJZ
MS:F>V=)$9&B7H3(MG9YO:)EMO^GQAX+VF/Z.8;I<MFO^SW^_I+T:.Y[SI+^O
M\_@&(E&36]#\4?DUBO@!S/W2^GGOH)]\ 2T/G].7_M_]NN[-!#+4^AP5+D[L
ML*17F8OZWYN.J0R@'.-Y4-7Y/%4V7=T*U@;8F?M^]_O&,/]_Y?%+PR/@Y7[3
M)=RA7KV2F^1=^3Z,-&V]]EL>5^)_2XYO;3@S>O]*MN6^[6VY[K? :)7!-Q*_
M<D]]KS2V8+Z\,BST**ATN8DN_>G,ZUX-S:-IYSI41:I:MT0C6IH+A3-84Q0)
MK7YT/WL@'T1F(HF(76\"4T^!(IM\N(>6[(4K6^LI>:F)THJ5^Z*C_DY;?'B=
MVTX:$:0';[\)=PH:_;W +3%S?IBJ;SQN3MH(4A@NY/=\>=A%A3%#NS1\UW R
M^?2N&F.X^\_DP0T:LW<&O%<P'1AW?W?Z?JOFIGC-&C?"6Q (-DUE_?*SN"QS
M"A&=%6^*2)^?L]Z@X9[/%_:A3F4\KX)@-7Z?3$W]_3NU@FIXB/,OLLHMFZ1D
MMJ,#A,.7R 3=;)?94K!.7Y+'JFV> 4O]=Q>N(0T@%[+H*5 >?1]3LG5*__"[
MNU$KH8,%<IQH@HJ-BW#Q3()/?[F !)W8MIGQV/6W%255-X1I#CK%4$5#+PH&
MGB"2FSP4W]3>O4!9['WQ(WJZYAK^NA-E%>U/L^;47XB]T&&!H-/JR3/L+._U
M=X^H60J2/=7-[+\TO3^B:/8R/PRX<745ZO?WIFTFR%1C6#V6ID!V4_]W I38
MDB,]#'AUT"_?W#%S3F>DW]2R &K.N)1AY$JD,=D*TSE"9*"%M^T"%FI'O=Z<
MZ:SZ\=^]0M>M',+6@\2&=(CP?M%SA*82'@J 8\;-0,L6P7F_E5*&%E1.O,MI
M["Z#F7+OS;B,:O&N'>G1318QKB"\BS=*,23YV6HB'&UD3I1#8@6<V:_W-4W[
M_)G&YD TK483NQ6#BT-SR7O4ZG##K.#*(3]7=HN5/*]H-5^=^BP;<;5]5;Y1
M.3CY(0+<.]HAL@5E0*8.XUM%YE67X,3X>T86H5IE&<7ZEH[YF-(W4S518G?,
M5JBD1X"]6BUIKCJU2SV>VG_R#CB_"XDQ\5A_ @)0=0JD 3.#V-XVC,;I3W]R
MEN,54_S<M"8(,:H"AM['-3 DM['UW%L]D(L-:#P]U<9TE^Y+-L6ZH58&:C%*
MGD2#0*:N4+Z$O(+LX<CJQL/$-^*UO[E-K_1@'F,;5BZYAN17Q.I[# U&1[\1
M-<N'B.XA=YR>!S),>LW="XP!0H.F/V>#^ *B<O'G&/X(Z"]DF'L?SK4H+5/\
M3RH+PGA+(.INCC5E^Z/,\O-/Q[EB<[L)\^W)?#FL?Z%!"OR#50:NV?1D6R4)
MD-RY,6?$]:%^M(ADQH!3$/N,JX&-)4CM(&M'TI_XL(VLME63!&2ZOF"LJ"8[
M#>?0)$7[3'1!R?Z;;&;38AV:JG05BJ;V<YV2G?+;?<C"*"#OZ1\!RA:,"&.[
M.;];2 ;9M_<UV">PY^;YHU2C3( L]Y[+85A(V$YV7Q1!<3YO0*MV$.VQ3<$R
M6_$V,B5(+JW)$ANS7^F\("N*VNB32R3!N"+5OUO!@ YNFT6O3/Z$%":[KGB(
M6+PR*]*,TEHX^NF(=[9O))9>_[*$)UI.&<B* 5=:F2P/5EB*3"3%$90>9R@!
M@!/\ -M@-@!)\&[CX.:OUB2T4!^2_^^ S8&/[9]9J&;5G_EYG_DD-@[=[UDL
M(?ZD;$%C<-94HE>1D"])G.*JORNS?JR:6W&WVH-PW<6%SS,"=G8T#XVN;G[E
M8]/D26\3I CUPJ7<]YB8#E4KG+UB,R@]2 ZX>4=A$HS*S][9[(R(%2M=:R+Z
MN;)M_Q.9P.@-OERKL@U"9$<^ BC&=PDN')5&'9#2]A?'EC_X-O-(XCT_1G]Z
M4J)K_I0(+<30.9<?E82DK$FOB2V@[JC34IJOH3>JO&KR='#C\JP,,2L4,M10
M75N&TKAP.3>INH=N&-A?*2/9CG^7_)%T&D@%'!C!$M4A-42'.E:4)0H\DTU%
MH1]GA$AZ?9+9DRW&.:^_ C87]RA2[_PWA[1^+5\S&C]YLK"I[F-5='&@^K[G
M3WD"8%@O0P;Y@%>!QCNXO4Q!;40)0^K=GT>C+F%FNW%ICP#7!7^IU@66C];$
MS]K&N=B9KW\1)!D5/@)Z1;L 0&G,Q:W;'2'&#NW4KX$DB@T77NC0<$- <1O=
M(]Z[Z](0/0TJ,JY+;HP@= V1;76UF>?F]E!?.@BH8<NRSBYMSC"VOSX*"\1;
M^J87Y9$L,5=8XTHJ U6DA/AJZB25T#N1[HP59&]'A&/\!\D$M7!]$N91\[4"
M8W7FPP)#&B;S*23)0 ]18=1<_OX02*NRI3(<WLCI<C:$3NT("HQ^X&Z.I7:V
MR3.(#'R2,#:>%E!A\E2<M]3+R%MF^IUE"<6@LX@9;D.["=G"P_N6S''[L;'*
MWTGCD;<![2>)7DK,KW), X^?/ *P;^]_R3G=3F-; M7N"X$F6Q9<2)QD)E1L
MWW=WR4? 6[3_>C>"T#4P@C!(>K^+?/%.$>HBRSYWM"XR"Y1!F+F+#5"<]0:2
M!OB:+VU4T<]N66'8K([E;F4>9N3J+%*/K5 49JCF/KGDC0:Q/L\8HWJYA X1
MR#Z\5)83[9CY KSU_=AIJSFQT5VA+Z\+LH6$R#06W)]$5:M[.E68[[,=4VNL
MYG3Q$HGU(2WQ[TN(GB4/_.[];5"I!Q9'NH99+DDFYFG85MR&X%7321A$0; 1
MUYN@*W_Q4YQ<[<I#.R_*&^%?2Q-]6?S&>61HR@YR<\@X1=SXUK'=1:5^%]2"
M,SU\3! LH@L2PQ4_^F-%W^VL03$<@1?.:7QGW%6'7NPEBH5']%M%F4*;HSNP
ME?LWGAF;'AKFP#E-Q:*_:Z+?AGH2N^[[>R.EK$@L+?J!*$OS:6I%TG!WQ"G)
MG3'Z(1WUMR^<&ST'!\?(DF[<*2P"<4KVUZE03E^..R2J[W31]$6(&EK7$& 7
M,6HW.I#BLKJQS&61W-1NFC5]:PG*6(^:C$EV:%OKJL&,HA+[J9_GHIN-,8$H
M)*(J,RCP >\=VNA2&27=IM2\V1FZE2]+A[H+9RKJZR;R>P00K;O!BX8[0Q&K
M9RXWP?7=84PZJ.R'2(T.^.HZ9[I[V1^1[B6SRUJ44?(#Y9TT6J[7W4T='3O$
M=VR \2\I".UMAM1,%N]#JMP,ZUTE(^(]S@N>_U6%?;]5UJY#LURF^KHYT%Z]
MZJM])S2<@D.7B=C?K,?3*58"J>H-61\8Z;,CF.(G4$$>K_/_P#W4R21-JKR_
MYFIZE%;:<AKE[U9R-LK<$7K@^8#CLNJXR4R%T3/@B]8=C.DYJI5'>IHHQ>_G
M 8<R3HY-;>LD-2RY?!/5,C&6K:B9PT2&&UPSP "/NBS'I)8%56X@E(<)]0;@
MW8/36"9 7DP\9'0S-?K&L!AZQ_3;WPQJ.-V38?G'$F^6K:ZVK;NS*]=H7GBQ
M?O%BI(P\;Z$BPK'V;=<3*% ;\P]+8IKEL(%L-<E\FSN/@)2/#\P'#SA-J,5H
M#W=/H+<-B#76#4'I#YG$.QR BR#^H)7!YF715?LY-\D_$\.4:%JZ3&_9AB)J
M&8YUMJP2+9]C%!!642'SL2E 7Y"5%49./=8,%0-R@.SGX>&G$A\PH#)<)!^*
MM]3Q+<@<4]P=+?3,ZBU8UQ%C%NI'ORQ-1[V;-VN6_EY&HE,'3ZF!C"BM/JC"
M(#TWQK_LC^1PXCD=EQ4*NXWWNQTBE.B8Z$53,W+T3O_AV=?#2S=OV6P7!X14
M8CO&W3-O;".@*(BG[/M(B48;/H_?H27$#QR]G>\5G&QN6@[W0/<Y)C2]45W3
M'AYJ-$3&[:;KL_68!- 7F,NRQ7B=L\^6Y/W.EK8T44JA3^+4'D-)1$O\+=<&
MC:!:-2E(\SG:O(L_15LY5L!DWZ/HCA>*K>WG]S(6=HX=(JGP<IWA;^W>ZBQM
MD06])@#XE(CXK%]J-4R"+4J]H*E?TP<)5&D_,NO$]R9A<61[*61H,;_*CX)A
M'@$]#]P8'20?"5 6?1KK><> Y,,[P+6I"?+4,1Y<S_66:9",+B<Q&Y=I7&O<
M+0AV*7=IOC2B$)4L+ ATB0"OKBZO]DL7>3W Y.KD^E._6.'XG5)@% 9E^1:[
M>._8T<I]IS@/<Z8O:F2_/-"@Z#O1=EM5<L32(O31;@YE9JXS^Y>!BZ+TKSHS
M3>8\+?\:S6V:.4,GC 38#(##./(I%&2<Z ("_X\\!")J@@8V>H?^Y5NHBXJQ
M[QE^=!\-J;,.V3A=@ZHD?2P7<&_%)TZY>NS.\ED^.C5 BX::+T/ SW23]K?*
M9\L/ACJ9M]3RN^IC06J!66Z& [!HN92]'M8A_#5\P_F85C?/<A>CIK1W6\M,
MZ1X7^!+]81#MIB)6\ELF]U=F3<P"=V-FV/BFALGE!Z)$OF2-\0TN)&M\_A))
M =X3D%TR@D#/W!_$V$XVR96NT?<GL?Z!-&;.>5\RU=X)* 20=B0GC]-Z][*-
M3:AJFV@2F?.ZG=]>OKK/ID',3^;&=UB!ZC *O0^,15:I:ATIRHW=<QJ?H[3J
M"N*(-<FWPZH/^"=(:$0_C\F,&4K$2!::1-<D#<RKY3.(E!5/97[1=^E5!(MQ
MQONT-ISJPH 53+D)046$_2:R7(*#1LER]G/%\I4@3MAN61:[-DBMU/Q L\JV
MF+-..ZGRX0P83\=V] VEIXZ)^#F)QAGX:[R.F=:979>AT$J96U$HWJ>H+1(,
M>MVB C9;TZ588@VZHC%T;S=\[WHQ_3S"3;:U(LZS(3'(H[$BS43+A2#WYQO&
MZ*#M;[T?3OAHE'[8>\ E%^?7)3!Z 3;MH3+DZI +6[3E\K,$ SC>,&7:1YJG
MQ_I?=EF>: -^V(T+UQ#N.P5\JW*N-W.]%1PZ(*9;]OHA5%JLX(\-@:1I4>UV
M8TW54R\/B9:)=EHZR*WUD>]&4WM'M(/)',@H.\V2]'RR2N>WIS=/6!'FTXE"
M^4INW\;T:@S*=<IV3FQ^_8*E4"=H?R%UJ5#3W?EBH%9?X,(;DG0YR:"E@6,X
MP]LPE+S@F#.VZ12<.V'5@$O]-L@^0Q2G,F/)@.RH;5;5EX!D]>F(XUNFZ[?:
M/<]6C8DLEJ?"]69LN\PP 9K?():84.VV0OV830L7H565080\5K!]P?+9]-BW
M;0B9Q"C3G[EY#\>DGG'/U]&?2-Q'X.^N$S*\5R2P+Y"_T,[52EN\->H@-^%V
M][*%X^YP:@T1OU:]QL6\QHO#KLY3A\"ZU24S5=H$1JOZ+YQVUOR!SU>/2HKI
M2[)E)'9;(F?V'\):/U*>,3EM-SBQJ$BPI*).+F@OAU6#RZW>"4-VXE_[,PGD
MDWI^M=[T*?41Z.U%9IH#SW@F1DY:\O@GWF%)^0317C%%7US6V!'9YU;^=J[.
M,/7<AF^X+>7N==T&-EO)$$"^YAD\^0R(G-Q@R67KUHQZ!$ '?4*BJZS%QEI.
M>X:"1Y 5=UH1:L<U)\7.5V\HAYE>V^W0Q7YX*KZ)"CW?]'1R43^BPJ']F]*R
M=W?1<U5CF?%;)KM[\^KZ$9!&JP3Z&,_95C/V!(>A3U9A2.K5XJKW)PU%\A>R
MWT9.QP,9XJ&M6WP%/9F%UT=Z*VQRY56C3&<KK[U3HC[/G5_NMKF'-E;GS&KX
MM:NM6-V=SSP)_W/W")#[^^"K ]8[?_B9'YLZ?(/G^K_$"M?[D^;N+=@CH)SD
MMR)IS_\;KLV%OKI<NX^4<W0GVCP])D+O:: ":H@&2L!!8 3197M0_\!?DT=
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M L?)NN)N8@H(Y[L*0G*ITS,.C!%Y--KAL.Z?EO_=MW8[:I$<R)*@PFI2D#-
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M\T) @HS @4"6.@=?I+*KG?KK3N[LS[I'P/PC "YVN8C1N94L$-*<>[:7?&<
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MJ:++%&8[]EJS+WS\!@\/;FO_5ZN7-1*303Q3CN8:0K5($3[]EY7I'S88-JC
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M@>.+-\B!*[<.WT]^1HX?R1D@6@,9!R5^'@$" 9M<ZE0J75=I2HY*KRZ@1>5
MX7*9'%B/='9S?Z]VJY%\<?Y0YAL58WZNG]9??*EFG I72;",'4"X=!E\VT%(
M;RKQ-J/$(-7W(Y<[$?R/<'L]PPA)'%]*Y^M+&?",(3YVW1/6RB@I-EO-/"S<
M_/M]!VIKT<[94MXBZ]&!P"W["LHFQ/AJDY= 4//'?(>FKAK0C(%LN,WB3H&A
MU#:3W.KIEM6^:]G86LF<PRJJ[8K3BQ&54>UH1MU^ZY;:T!V\D=G">K#\1"U]
M;G^]!F^M3?SOGA\\;S9:C0-FY.YNKCLCW?!TEVK:N*$>J,KC&=_@\D/+Z>7=
M"Y^NOL\^CAY] ]*=@6ZZWEMF,0)9OW\BZ#\]HOM[M"(D8*M[Y\?/-'\)TKLQ
M,5#!^;MGC]Z0G=9-?]T9..;7VZFMD%L\0^88V!WN%?]&!5GPY/-RIEW8*G@"
M5]>VYU^ A_H[]+L9O"POGAS8:89T%)2HBM,RB \^5TPZ_-W=*?A[C?5/[E"\
M-,OO6:%<.1$=C]I,I0$96F,I7X!]G>G^0XSU ]";A62A(B/"*UPSHA=!L0*>
M/AU1+-#:7YUX7O=?MDTM2I*GE8E7Y[]?=EO*(QP4,Q-W[^M8FBDYI3K1JWJ(
M)JV*MW_:Y>2_^3)E]8/NY\&]ZYJ:P=92.O5V0P]_)O6I[CQQ]RXX^'4W:A_-
MJ=W_:7$.AQ=@9GYC76'69U4H WKMV(G-+#H4$TA5J'7LF:L@;5]N$C ,A+.T
M?URN(+2$"G&;P$QA%LEE!9I_IS\Z5VKEFM2,\<Q+O'_ST4G*U!"5NW51=F35
M$?"$/>;'-CNN<+-0?(@D]E^YE=VWZ<>IKDD8:XQ;)C?9>=[=]XSW O78CQX
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M\P]78;_D=7H15UO";KKTL[L@@$)2R,&>)_ LJ73WE5P\L\=DA<)#F_Z&']<
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M9YU[@O/[HRS;PT4*\DM<8R%R>4:18;?[1>D)-P2I'4OD@@C/J8CM<9'O$X7
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M-S#X3B'-FWS9 8A1&MI[6R#-)=L9B__IZ)1D(8@67R!=WZPTJZ!PY"P5C!#
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M;UD[FVL4\O\>H-Z5#0)_ZJR])U N(M-??AN$NA&6^#+8\^!O9UX]S:QTY1%
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MZRXEH%S%05%#>P[8H72^3O9<W/'^<)T.3A)R$T0BFP?</&2J;^N 8P:(HT"
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M=,1@7R E/"+JRQS33%OKCD.^P=IQ..-">:5-75@]1[N 88U1IM26#UD90XM
M#TLB;?D5)SE+KPS@200."KNYN4 @-BZR#=KG!#%.LY2Y&.KK9^LRU44=SC,9
M9MI YC;OU^V\R-7K:H[Q2X]XY<&.&I:5/ (]%CNZ[TJ_=5MI$TKEY:NH+NU8
M!%<4AN><%JN0AD6EDFF[Y*.TET[KJJ;*>&WI$5X(<W ,Z'6YZ)$A2OM$82:4
MJ-C<-J'_&5]RP<T1=UFTV90K9:!H@6TMJQ56!.?Z5)/*(]CO9^=CK%TR4V@R
M(C 8(.3U*&@7A.?!@U#M>(-(/5> 6R[$@OW V\<9#F:R2;U>T^7KA84?:\$D
M(M\%['B-3 9=.&M7V>]'F#CQ1=:H,>%J=]^$C$Q HU$G@AQ.)4L5NR&WZ(LS
M>7[1/Y:L9(7*H(R\(PFMZ,NR3V<77J>YMNZ36/UP].Z6T_#22O7I6 O@C&7#
MQ<U=Q&X[>4!:Y/4/#XZ"61ZZ]!-CHU$;0,K"B>NJ$@<FP9I4T(Y3_SG!D_"<
MNRH5[J!\2[3FS!EWH8/A\HL/@;+C1_9J"BGU;IVWL"KWA&A74EP._^/H)IE0
MA!?_-J65L8)D!AXGJJ0G"99<.7BK9%_(7"54GZ)'^TBWV!2W[O?Y6;'4E_.G
MP<%5O)V(=W 2'.=&ZCW$)S-\'6-Y)89MF(-]1P5+9!79^]SP@<^E?3_ <UG@
MM-US])/+$>^\$G-=[IJHO3XFFKFA%SYO9C]D%^+?\[7VFO-I#5KETT/X5GHG
M4\;RS/,C9=&L5WQ-)=BL]SL#,OCU7+Y''ZO:VQIGHFJ2&>6NT+=",9:BE!I9
MM?S(D"P8\'L$G_Z]8>%%B-!7P(<@M%? 9J?1*V _/ YA%Q<I<XU^X?2"==/Y
M8@NY7)8!@C!8)0:)LH;7#R>9RT[]/-/;Z]<?O*8Z25Z8<OL6N&V^#6<<CL,T
MP XUMYX=Z2*>K6O, 3?//C):LR^">EV=%W,T^$%_\38WGDB.@Y[^3+T"<#3@
MZ"_!+SBO@.[ QE? .(YG4-\40N,5(.MS\$(&";J</)H<N7D%$"QL!SV_V=U
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M^2IS2TM4M*OE?5P44K%[Q(G2L8)Z8NY*N(1Z Y%27\:+AEQYQ.I\4R^ES@+
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M-M"$CPZW-/*4#2]XV)KEE*.I>9,)<7K?B1X&-<Y(#[@<,2B8DV<WFAEDQVZ
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ML6.C9THRV3!UU&FP]_158<Q, X'Y$B&V_01=F:Y;HS9">6)BL!!+1M@%T:7
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M9SJ39>'QH-%(S%8U$"S1JYP_Q6IKZW<"V<X4#ZLX,,CE97D2_X+TS6^7^LI
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M.S@Y+ZO[_.#=OUAW]Q?^PM^#]';J?P!02P,$%     @ X8EJ5*('@,<3M@
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M>T _TCT>W0-.FR[K#[0,MD"_'!0M(CWHOU?2'+/JL!<44II/4*]BB'TG2%'
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M3VH?8S+:8 #G[(@'5>6+H0DR9M;C%X0X4W>\AF5*NI"M+/41;N%Z74M!Q%6
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M>7[?K+K=X%LZ6/<N+58 KX$^ V:.,'.[&^&3R\_73+6[G^05=2=#/P:8RNF
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MY]H+.:6N15^?G&%<01%2L^>^=_MRVV0GRQQ'O8&:C6]TZOUZ8AF*C*+.,EM
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M3"2$3IE=4$&A[[04S?9*K,DWT$?T<B4)=%B:2!,W^?[LVELF679'&=@?1/H
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M0.N$W]';5F+^(\OPIIPB_W^BH)\YX *-^#ZWDBSQ?R_ZUH3_V$A7-I!)AQ"
M:!!/D_8SUYR 8ZY*O8XEK2S" ^$.]V0=,LM1'YE+7YZW0W0][ZWQK9+Q:Q<
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M/9WF)65KPR$FR@6:^U1X:HLYJH8&WA4NH(+:.4%_;E3.\5$ ^O2UT-!-<8D
M%E]6_QO8#M?CE A)!&8=7603@0>7YO\B3]=4G+'J&^'$6NEYK03*'08&HR_L
MPLF'UMI-^4@=FJ"-0Y,/ ALJ@1.3?/B+A4]8+!$:#,6.%8DL5S12GR+)]P>G
M]N:3"]'"$+(R5L5D%;)J]CI-T\>[/EP=L(V/ D0#(KXO+J72GC?."O,J"["<
M?/W*]/_R5;>=?^8+X=_OQ3PG"J_FNOGYE[\!*G\Z7#S,I\;X?"2&&H0),[7O
M%YR1BQSE2QA?ZP<\-VJ;WU%WZ0FY 5OBE7!*\':1OP"@LH_6S@KF&6D:C%P
M[JORDW=,)%2T=K'MK@2OR3A$-A$@>\*F$S3ZDXO%?1[??M35];3U2P85 CA6
M2]?)-[">CVUK$^PV</XFP[5XO8IG<[R59&)D[+#?@%M*Z@4@_=<I0W%3]\&P
M[]AN[*G.&1#M+UP%R_FTKVM&%IG]HYIZN2\ )UG)P-7'&J/XFG^G2;'^#:E
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MT\-2NEH3@T3]/3V]B8ANB\P(P?;C8PP>+ISWXT04SKGTM6#A4B'0.A %\1,
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M=94GX4;3U,(H](Q&!+.=R3NCAC>Q_%.]:3C;K$* XFY4\O@R7H^_6%9%=!U
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MDO.7#Z+5+,1F.%E1&J1'R^CBM8%.^G)CGY\A"H2[/1/W0,-',LX-!W,I^I5
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M$MY4#%^[G,WE0#K*%P#;"\!FUI<?"(I\WQ$=R^83K.D=#MA!A3D7@,N%Y>$
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MG!F?VN84-%)N3*8_5W>K0T5B5M,(4AE3MVFS'IHBCIB[P+>@;R LTFJ:_V&
ME*)J(,A,Q4%3K#@>?];;+OKQ\S6*(:NVIJ>!) ?TS=8FP9%45(;2/;@X5#W_
MJ[VOCHK[6_+L! +!"2&X!1JWX*X)[@DN"<&M<6LD2 ()H;$F0' -[NX0K''W
MIG%)@,;IX"R_WYMY.^\W;^;-V]VSLSOS_JC3W>=;Y_8]WZJZMZINU>?R[R1:
M08W\JH\Z^3/$6,!/3<<: &O.;,VG3[6I0@!N*!H1E:A'\)^D:,I*CE;>+W%
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ME@&\MNHZ7H08CWAEZ0" C+1$QJ]51%NZ$PY[#'6-DYQT2?(11")6.E;6'(0
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M*OHJHJ1=L30[:=FI&R24!$MRX<)*ISB**0N<^09,.I)N@ %:YOUH&9S)8#R
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M3.G;D!]\R0DK;1?N_6&#%G7P.L(>=!@ HS&N@^VFFQY=#9RO(UHQAJ^'_49
ME[6H;O>DG@B\D0B0@ 2S877Y(5!0C;A\.-A%(M'A:LQ)%Z 43*VX1;>5L?!;
M+Q2UN=9420GJC=UKO?F-1=C@T8R=LSK&/1C ND6AZ,Q7=>;UM,H9D&]>3*+Y
M0 -(U&7@63O'8&GZ4)A!6-PZ(X. [*Q.Q%?"5WT&5,(XPUG=RU5<PREA$611
M8Y\?LQK/BX0"T0-5RD0H-5[O?U>3:.L*H+*5 K6F]?3J^R>Q%_4YBI<<\@GB
M0F"Q(V\TE'^0?I>DIGB79\Z4COKDH>I?4YH+!3// TS&Q4C/I2G!YQH,F$D5
M'BO^3+]Z+U7Y^C9>E%,A^L7/8"^2\2XW-NICG<^3+X>B"5@.2IN*[6FHSMRR
M$'9UBZ]K!"Z73!@[PQ-)$',QZ T+A=Z89 ZX]S%<C6SJ+KP@DG2I)+]TZAO'
M2ZN'Y(634/)0)(F09ZUU)U^!;&_&5G0B,Z9D6AK6P>X[JII1AHE:VUIH&#+&
M*EJ<%Y.+&HAH,7(1#QT!NJ]6[HGS$'S@]W?<^MXHL9 TG0_!#7=G-!><865/
M#GLF;;5%SNSU7/K1V7.M].YW+%-^6J!\]1L:?2A,-<QO=BT=(%[%[XBA+W+4
M"7$N?K@F@-DS<@X4W;\NOP6,'<XH+"/NW2GA-;L<#IFOD8=!<ZV5[I>K\6><
MPSCQ$HTGU&R;=5FVBPSCS.,U1@'5^B-U@^&^3,AB,M><1[V8[Z6I KK!W%)5
MX@*VU@5O;&\!CC-($%-2CQMQFM%'7#2"]N.8:.'B:]?5(^Y/AEX?2K)GN$Z*
M0*PU)*&=6JQN_!'L\N)]&XG&/1GK+,ZN\JX M%$!D\?JTR'1DYQ7^Q4F"F"G
MX\K=1+Z:UI=\D#1\A9K_J3M4(S:[J./OXM$JCRSGX181<8%TRY#EP[3@W]8C
MM:FM6\ 'B5T_E:)MS6K1?10H8;:,WA=>7F]3LA7/9 JM8X.Y6P?%DP.7O8-*
MWQ@>,H73>P=W:KS!&LG'$4/J;%JEDD]*;B1I1(?298)*HA+5[Y7I!6#^(%BY
M5'MH6P'+FVM4 E&ICU5SY;']V'Y>M,7L+"(BPLS,T[U<@B'6W>1KL,>%_E)Z
MW&11303*#.#7V!19HB5_.*>I1'=?*8. ^R T?B:-XZ#GBX>_*Z?PF>R2%G2:
MVG#ET2;'XZH-/73"0FV\[%J9V,Y%X'360?H'<1V70I-%.\.]QB3_U05EOR T
M_ABDHM[##V [>""B201(1)!O^YIP],0([CN HZ 2;L^]>V;A&V;!ZM3F';5E
MWNZ8VMY.A:OM?,;<67LAF9#3G8>L&-^;1@USBS[?4"7_*NAE<;3KK$1UDH'/
M][)M\DKFD*"K4:QS%:OX)-F;OE8-_T+L.>40#2I>=CS3"_VMPF &6EQ?7[^)
M@LDAXU*GF(F1?MJBRG$ "C5V"@AS6P_4X\9Y(@(?GNC91+/]^3-IY@._%.$"
M3H3\N'SZ[K[=>*<+!QZ0PW6L(>)+X^,KSIB^4P$S#7Q;HC<_A7)[!)(5]50(
M.+[H/YED !3*KMF@H5-Y=@.\85U*.<G29^^SE"3@\S9X>351B6"^6BY<AYVG
MUI(VZ$1-OYXL.$NWTVR\M29)MZ0NYA;K2?R>YI5X+K*Q$"_AFR;J7CQ0AOF#
MM-*>VR,7QC,-Y6];W'W1(3"?8HVM[<[^/H4F6Z#""=O(2 [=2C:&3HY7<;CK
M7J1!&(=_'_!7!M9_MD/]WX%NY_X'4$L#!!0    ( .&):E3F'TXMJ%(! (9S
M 0 6    9V=T8S0U<'$R;S,U,# P,#$V+FIP9\R[>3B4[_\W/$H)2;(34TF4
M4-G*,E,)(4TH0DR2;.$C9&3,E'V)^;3@$S%E39:Q#669B3%4*MD9,8NR+]<4
MXZK9GOG<]W/<]S_W\QSW]_X]?SS7<;P/,Z[S.*_S?9[O]_OU>IW7.<)Q(0.R
MV\'6WA8BMD4,\M\NX23$&B+V7[S^[>2_VH>8\!U$;H?8=O&&K6('(%ODQ+;*
MB0F[(5 (1&S;?V\ ^;\OL2U;Q;=ME]@A*24M:D#<#=DBMG7K%O&MV[:)BXON
MQHON0\3EMNW9?_S,=GEG7XD#$0HG'CQZN4/K;'VGHLL <-#HQIT$22DE9155
M->U#.KJ'CQB;F)J=/&5N?<[&UNZ\O8/KY2MN[E<]//UN^M\*" P*CHR*OAN#
MBKV7F)2<DIJ6GO'XR=.<W+Q_GN47EY26E5>\JGS=T-A$;&YY\[:UB])-[>E]
M_^'CX-#PR.C8^ 2-R9KY_F-V;GYAD?WSU_H&9Q/\_>=?O\0@6_^'Z_]+O^1$
M?FT1%]\J+O&O7V);8OYM(">^;?_Q[7O..$OX1L@?./%@A\+91R_K.R6UC%P
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M!?W0G6CWB-K:3%8X5":@1U.=O?UMC($(-^7!CYM=R)U-4$VPWPG0227"%7U
MC/IAXZ21^,V9BA4CH)<AVWD*9HG*#XVD^LAWX-^U(A.:L*GF5]GA#V$Z8 DK
M+\T8+LD[!H13LO:H5YWGV; 04#"ONW77(^:XYI]>)\-7Y26O%^_=R@K!5GIB
MK@J&\9)"2!!^*UK$>A*>+B"EL0%P-73,()Q1(D*$34K_%IX>NR+)T@X00BX
MA"YRIII.9[\:;PM[5PY[$*F*:J&TKB61H.,+GKA$P?YQL*0K7SDKY66PX/@
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M18-[&@$,<5+X;RT]&!KR+-E4["W\3A&=-$Q5X_12%W0>K,?R(F$O:_DX3W;
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MUL=I!. \[95JM#V.H9QV$V?GQ87O1FWMRB<]M"E_&:M)A&8:TV747\V-SF5
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MK.V^!T_8'=&3?<;T_-4Y8_2MM3@5)F%&2,O(P'#DC9%>92)Y,)9C$[42]63
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M*[600@^+J=O&PH$[LB:G ;; 6ZP"R,Y($*GI[8Q5U0"IO0D3EW=0(LT53FN
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M)$9YS$ ^N*;.]7755;,(G,U(*VDQ]Z?>.EFQ@]2Z K6/$"EG,"^2'S#,D]U
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MR?1Z9-OQ%=)P^4OB+N@\R.3CE-[?4$F(AFT4;68@<C6Q[['=CX[*+40CO+N
MG@3MDW2S4 B)AH(JI,9FUN)[!5/YRSC,S\;FC0-U(\%7S[AAIJ8:JUH.\KK_
MW9I#@V1VX?69KDPG[,S7J]!Y>3KS,I+KQ"=/BF0!A-!!4K!2)/=.3@"%TH.
M;@Y D>)K@!**Q !#1NV4?!C5>HSD4L^ N!+TO<IFDF2DW7]U7F?OB7K)SC&%
M(7 U%YED^?6@PR=:;80M>M_B+*!64\6QREA[('^!4O?%=Y\#I#3! HQK*LT<
M8 ;RXD8W<""G%U"D,B[#\63!C[3X=OBP-Y])CL#I+!%^A0N[)B7"%FN6_V97
MT^3N[COP5>/<R)C)B&@,:TU\@\S55?Z0=!7^.;-+ZMV//L]#$%"@" C@1TY2
M!.AA3!>IAB/>(DJ]PU=:(<BU$F^,1]8AN-@W"[#5D#H@$A;/Q3-V3&A;Y1>
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MZMG=_4ZN<.1]_N*] '-06OGV2+,%V#?*("^#"2<)?G,0,X%H!%.R %-<WKX
MB^\]1^I[ A$78%T+L#__4+_LW"Y]39I768"]G[5M;J;P_D7\_RV9IDDHD,[B
M7LJ:R9F6@T($I,T2XL@6<KCO*XE5<H (O6K,>'MMOZUS\6WF<-Z&?C&M5X5W
MJ'0B*C+7^K.E[Y$X16]/UN3<FC]D"L_F_S/#\E]NB0&3D]%7&]!8M#9(9^$
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M-R6C6-_AZ_XZ;DA)]JTHQ#M>>RY<VK!8/@TZ"_(D=P1Z+/>_QC!+%;L)+DP
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M!'R/@F9"]^$%& ;(BK,TT^SR&9RU.SJ1W<%+"Y>37(?"(K#J.RPF>E25-+P
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M<(TRZY28TVU!?;M/MNP^'_8\LOCX:1!.?/OWXVM9VR]?>9!RKINX*(?S96%
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MV581V"(=P8)YJ*NP^^(+;"!-]80)#BV^E>&5F(&1+6_FO\KF$8Z$_S'<?!2
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MZ>T31_1@<UDHT.1.-PM78BHNY9;2WRLQZ[FH<1A4%YNU,@5#T@L*QD6Z!7U
M6'F)"U80[V9BJ[S3MH-(-<3EC6C"B>63>.LJT/V>QN?<OY=*DT1#6OI3=9O[
M3\ZNLC.@OI"3X.7\9#T*#B%$.$@1JTDN0UE2+GI9+_I[;+56ZYY2(+2>G5"W
MT$:*%6[D!I'40H4;([&Z$V@7T0A0&9?;P"R1BIBUQ\E(;+QZ27@8\H[7F(N/
M+"'K]UV[[SLOMP5NO<KJ<(OV[^^:9J'VB/EAIYZ\P%\>K*AW0GW&JD$0Q5=L
M"Z%:B6F-H;0)XA)X<P)R.[,\M(>S!>#M<)-9H+H;N1UFWT19!U\GJ#B/#6NU
M<?1@>[&Y6Y0[W(1+K];2#L]SZ"Z[T#<3W&/K75.MN#C L8?'1EWDND,B+1YS
M([7''R+.S"T7*81_$D]R=">6YJ?]S]*PBD)",%]S<L2L_SMNS9N]1Q3W1%KI
MW%6V9*YVIVAP5YTK!2O?U1\9L_= $)3YXE;M/-N5]$V^:6ZZ!QJ">I#515-N
MNAZ__#\EG]5&T:EBAQLZ+)/&0]7CKPFP1=3,M$Q7?A T:.:NIK+;"*OQIE1[
MD0E7C%6='!"\\S?,$A.3Y@F;P^P%-?=$3#TJP^?#-3\KV8E7M=U#I^HJ>EB7
M(Z.T^8OC(G8BL]8B;_L'TY?+6^\(OTGH(VYDUV/?S4GJ]$YL6'] ](2^G]70
M3-W)<P_GQBS)ZX8:KMK<?Y;^RZ<$DH )[XF*)?PFO,U< 80QAXC2/$6.?!]T
M)0S1H[J(:AF2(W<?4)GBLCAL"[#:C[8?#K#L&=[9V!C7WNI*4/$O@&_59%CE
M4$J.9R456I8R.VMRBF C*;67MA;B2M')''L-T47XW I2HE/@J,)*)IZ[*P]%
M]D)93;T0O;%H$M&##!A.)I%#K!-# A+IC&^XU\V1V%''8EQA>O,:H&;6HL&1
M9MA^NF*F47!ST+P@\OH\A>U>BDSL+LPO3:PP7>UR^MIO5S:?6>VE]G+K':W'
M12<NZ'TVT8 U0'L1/T7N :F(%IJ8<?A5T%R:P 5BIC48@W/-^$U05(I/6/<7
M+\@^R<;-I./L0&KM/I>KV_IPEQHZ[IX=VG]K?NK[";4]CZA:KQ&=/AJ13?5M
MRM,%^U^-11RU)+7=?'];-&QZM(_F5_)CY0Y#9M*\L<-[P3=2;X!K4K?YL!>Y
M_J_^L(R=*UW6XVX[:>;MSQ+OI=HW)T&K(S;2;.W3LWAUA^&W)$W+9K^RV[BD
MUK_Z_^G2G[6I\]O#3DM\^?-?/WW9'=#7]2-6'96B1-0>&P&U0L5#ML12B7D>
MU:;W%9 ;H>YU=Y#B#C#SYS1WJ9(623H#_.]^];24()G[X.>=+Q?_5P'B_W7W
MCA/QI"(;"+$,/,'IFP=N85?-^WF?:GC5&WF(>!(^/>HJ<?;HQ85$YW1,3P^Q
M5OOFU'?4/[SP\M6KEYG'QO-<,KUO&/^%6N]X;\5?P,0GN@H@>K2\8^+=?'2G
M7FRS**>>]R%B:BC??6$.7#0=8&P(Z4H-W#)GGWK^S\!-7\ZT;FHUW]VZ]\V.
M^\=VE&8F(F>L$%/Z>V;Y@MR@5IS.'8OP1D7M:TK<=:"R,..IX$U$O@ .:0:G
M;X[?1K:,' FC%%&C?_4-9=ONV=98=]WWU+=_TD/N.YOO!@:Q<#16KI.%I M%
M)$253)(7E2V,X>0Z7*FEXI$\YCG- ^X 59KQAR!I=42A3WC>SCX*S4U5(N&D
M%0U-^ERXTEI(KK$#)K(C"ZJ?7LI\*]'=F+3Y;:R_KQ*C&8M:N@B@JXBJHL2L
MIMLJ,5\*.8$:69"^GR=VO9K4J%E<N<7?X7Y+PY62->+@O\/>V@08DN_O.]Y5
M1SRRJYK$'6\(&P6,1E\2=-H\H.M9&WY'!2K(7QLX=>&$:-U#NE7-D=AKX6-[
M3G5>SKA<;;*]T:='FI%[T'U=3L;>JU>/LN6'&,A:5'BY4$"V$K.RFHUX=J'&
M,7#Y59(2TS4D-T?'C$568OZ<S_C/K67 U]#!(2-ICJ^QL#6$GL76MD^)V1QU
MR0C]:24!<1E8NDF;YZ0J,=^^M9/D>J^Q\GKT$$H^O(^H6_B;^_TZROPHY9G[
MH"%X" M*"; 93F',;>;*U_5S%XEG2> $ =XUH#",ND4 0\9(2/CR4ZZ?T/BV
MXT[T-*Q D8)@B)[>TT4>-/R2@O;CG1*SB"5-3OA.\)48@E,D^M5SZ-<Z&H&B
MPO\[?;8!VOR&4$<+6J!7O#>/Y,7]MQ[?-+A-&"W OBAJF=L$4T0+MU#03##9
M#3%3;:,/J?'P)CV7(KVX_;9I1X-JRWLDJP3G?LA)*1[>GGC,(KQ[?]G,"[59
M0\2#<)$]6(LR=#IW])D0_)4+>W)4P 24QL@F/]1 :JESIOTXB4W2A>X&2L%0
MT[.I[(2DR)3ZZ-VE$O]3WVBRT#L'OZD;/P6.$\!NH)*M,!#>X<+7Y!KHX @:
M\FU:O4L>!E2ZW,I/ZH"N@4K,3&6QX6E3)]OU+ON76AKS*UD=]#,E);XEGR$<
M[SWV#;A%E4F-)J9>=7J0=H"R.?<EI&F@2MK7Y-4<LEAVS.(0<<8!ZWDW1)$]
MW8;OK_H4?N15:^T:V6F]?Y9<VKFWZ5M[9ZZYJ8VY-$=0SO99G:_HL4DS%=O'
MSEL2/1IR[_P4%A@05.H6%775^H][/U%T[_^K9>^V'>OFDQ<>G\S]>?A@<YBC
M_=JCQQS].UOK'6T46NV7#S@%K_.(MU9/:G:_/'YWG\W>#W^*HDQ"VTJW?C:Y
M,+#?S<\V^M&3Y+WO?WO"S>/"N\WD>@3I.+R<1,X47EY?.:U(XEY HPFH(J33
M=],[Q\;Z,@9:N,D&0DVK[0@?PK;$V+?XA#:^?-G3<$@CC_F4:B)8ZG9-^78C
M.BKF\L7RW<DZ9I6T'8HRPBC+Q! FR<[2SBA09@V8NX5=Z80#':7!<"X4*\H=
MN(4_-"AWR6HG;9"KB"0N+9DCZR&-])3G9/MLJ]LQ16%9)_VF/=IU/^QWT:@X
MYVJW_3K=YSNG3B",46+VD7S)"V$]['>*LB?<>[AX(>@CA"U)+:2/_5AX-Q&-
MP=%,)::R-A4(<J6LHK:+TXM85$":R3@./47]SA:RH31CK-.?WRS(E2@QB1%/
M/W!%^I#&I_+:^&KUMA<]!9SJ[KFNQ\D4#GTYKT@TH@$;(&N'9;L0 6$]H@F/
MB=FMS*&2$Y6@P4RCS'QRH<L'YK4*-QVMO2S"ZL+>GM JPX@)!H^S%LIXFH=M
MA'9E/29](@_4(IMCCW>)\:;)OBH92],1CG.4K$6I]OUO/J13_=E MG_17(&>
M_-UR<8"3Z)1K07WQ!OSJ*0)X0@O>F15?2@CAIG'P771C?Y@K/0J-L* 2L7VS
M94C++=<B/VI/$]Z$"S74M>C;=?E_$KH$FJ0%1>ME#',R6$1607S2<R7F*$F;
MYG%U%$CPQT.LC*<&"WE:H'=R@T=88.2./X;\/\' 86[?HZJ7F3O#SM_YXOMS
M_%E3KWNFUR^<?+W.V5V)L9+ELO3@QVB8M*+->T?;H*A08H* P2$Q6Z('V4LC
M%'\#H5H"T[-P2A'5>51/V$;2F.28#E@V&$.$%A1@;**9ZZE FT,G(WG>:T#X
M8Q+KM(4?I=H\OJ)'HV/Q,K,\2)'/V6\FUST\)/4A:<I7$52"%3E,<0><B]C#
M;H10:.PI=%& E5X@52X.J*5^AL,4>??^1=^&2]"\:QL<\\-4\Z0&2U_X+QVW
M7=7N0@; ]9Q];OZ/PEGZ39%HP]"E_0RZLV2_(>]\O%.0C;XIW&3_S;V(@WQ_
MSSPWX7J[1W77"+!Y<B!O5_PT[]Y/)<(SD_9NS]O#+6U=AP[AI]\TU-7&$Q,X
M^Y9KG=@P8PF@Y]Q=)::\*,5@%$5C(%BX!6E!MBK*&EQEKJCG7>^@RHB_^)VQ
M >8?JW(N%G[RA;?1ML6$B"2[I,;7YTZ3J@#R+Q^.?2ZH%1@S*80.^0<_"F?H
M1CVVPL8[2XZ%AT&*-!9TRVIAWR;HX4WD@7#,LV&_,X/4 5%6J@W6"#XO7FJ]
M1RG5\04_(_E%*=.[[N^+NM##ZBN_3W#8\4WG ',+-XPP."T-!/NR4KFA_'3"
M6HXJU=.3:^CU4(Q- 38X68++VZWG]^MQ*ZN&A+KAV1<<XKZV35MDUD0X08=_
M[=[>HG[76C#!7HV*H'!@\$%SWCH0V\+6I7=A55#U/2[.F"_+ OGM2W.ME)63
M^+5P;+'PB$V_3]0=N3=0-C2!-^,TQ N^^/JZ&2)2L=B1G)5L[WLCF1).PG)4
M40K3?@K;EM!"X-.%-/\4GCW=)D<4I,2T8-?YT'Z.;>K7?T 24BL 57Z)6>(H
MV)>;T; 0Y3!3%Q[VNV_+-]=KY6F]*Z:O>;^U$]8FS+A$B[7B.3H5"I2+@EV%
M.K2@Y+.(]H0=R1B_V6^*J_TXQ:ONPWJ.6D4-9%,)9]L/E.*JS*.ZM267JNO-
M.W=]['CFPX_ >D*NTEI%)GX-B?K %7XC^X6V'CY;0B7P!,04FO=3VH]PR2BP
M-AS9 M9P2YP?A?J;]E>QKOI6]-I(=,X.6&WM^LXZ.24P/^3LF>UH=*S@563J
MK1CU([1&R%3Z29'&T23)\=V(!=+'K&3SW%S$;0\+IYGK2QLBH2S17%R94_1C
M\G;3_&F.#L,'4LTA9YN4C/]L,QS,X_?@LG_V)1>?O54V-$:0F,F<D/=TC0HX
M 9*-9343[XRH]LY:SGSG&J!"+$Y$7 E'>S74IP775'9'DK3#ZR+S2J(NJUBV
MV-71:JW?4!YV6Z^QPAPJ2X88JY N8>5X"SO.FV!,-Y%?@8^,4>YDVF6G(8^A
MJ\W"C0W;RFAV/:7?$[W&O%_U-D04A2^8;.EYTOW;M9Q3Y.&C6C,3@_[?WIS4
MN$) Q<5%_J"1-)\[4+7,SW_#ZM#X:;!A;:3X$$YDT,I0D?_4^]WQX"[7T+EJ
M-T+STDC1C:  RY9[0ZV TYX0B^X='N_>3SU5F?0Q_\:7:BE*Z7OD-/@@Q!1'
M22P#9-;R X3U'!O:8="O+!^TEB:"Q#9^@I2I*3=Z E\]R6@A;7"BB!11GEVT
MC6)9V+SQ!6I.\\V^^33I[<*S875Y16%%A87WS#YP50 R<Y DS6&VV'$KF1(L
MZ#C&$M[]9)8T@VC33H+>+>I\K=D_?]I2UUH4-\]R'R?69 ?^,S1\KM6XNN5Q
M_ITPXS.88R,CX>,?OGN_P5LLK_H,8*X0"$C4'FF[(JO!/ 08RPT1913T-T)C
MHOBL54K,1B>[")<D)^V*83AOAXD9*.*4*S%W$XY<J5W"#EU48JH#JF2G3$+Z
M^K.NUTIK!OKM[19JO&O X<$1'S?C3M8PZQW9MK&SNL4"Y%.<K.[S;-RA#J.2
M_/TO=FP^GPS;-P$U%TP<%(5 ^)R*C]D=)UO9?J25K@W.QD'<L?:4:E3"1%]3
M/*I6:/>(O1-I&PN$P^=\J;ZN(*6)&SLPLF4 V0UGG6M,)P/:5-F1+LO\"@;/
M9'L>0 9#))&RO;2C<-%SN08<(SLN5X7:VV(T7X=GMS<SULC/@0:)R/;)NJC!
M[5SR$'_UI.'\>.*VFN0V*B[DX<S*G\*<#*PWB;+-?L<M(8;6$S?-QQ6>TG)%
MIHT;T:,KDBWPE0+=MFDF2W.N?56YGF,X'HO@V3U_""]V=54X>KRHA[9X>WGW
M>WNX1D2%7=7UUA_8>&Q]U]/$M_C3B@+@(COMA?QG>#-H)-6 G4&9-!'.@OA-
M_C9P*1TG_Q&:?25B#'J+O)L9*N$^)DF7Q0Q]VA$X1D3$AOOC(+44F@O;!P::
MZ&K@Z:>"C&]#4X+^HF=AV4<S+]2K1BH _U#%WB=<*T(P'][]H9]F+KL0!M0,
MQ#GIR?;14)%^AT9V,&9*CEP6<8V$<F?8*D\3 G@=V&1_5;@<Q=0V;Y,MRRG+
MYYQPXKG5(X?FY-N7A/&6M "1Q+W?3QOI_OK5-20/!YNA7'>/._K8_Z"BG&7#
MB!WY 3XRBAL<$Y-XS%5R!TI2W:Y7(FS2B!,XD([?',;<8"$'Q/P5Y)J:J!'U
M'B</\O.STYS5W12]R!2V:OA-J^*RH;";!=^7_!Y4#G3,?[2J&HA&U*:"]"#B
MC*_,<QJH<G\(U;[FZC0<?$(UD"8KLNAVU/S1D'9@%7Q]5CK'*WXF&#I#K1<5
MM9!6NY9L9+F.8E.Q:VFNH_Q$_.8('UM.3U%?-4-]Q#42$-4/%=/[G_[P/PNS
M[E:!HI!U/YDU_<6]1(%W_,EQ[,7;R@_"N12H0YS6WDQ, S3+:-9%<H<7Z4(>
M1[L.CD4G'VHGDN;=MNGPN"9RRXO(EG(W3?%<RY4T<\^>JF'3DRE>#>EX ^ER
M]9U]/)D=O=]_)3P$R$@H$K-1-1F9,^;&G[DJVS=59UD=?QO<0+OI4$$5]]%<
M#9+F3<41^*%?^]G?)5:;G X^_F7*1I92W.)PY>,YU.6 ).)JI)F#@Z-DC@+Z
M1Q\S"0%R:<NBVT"9MV4.=#Y0D5F\#4Z"**V"MAQ1!UO[_8C^ V*OC<*GI_FZ
M SX=J)G=;E^'&?A<V?VH\16D/M@)9LDW+HC4Y-I934!UPDS3&/&.H9DD$.R1
MIL'MLOUP#PK5)"V4QF\7PO6BD4K1T'"TF-C,-J9NCO0SY2T=X91#ZCP?;!RE
M(2CRZ:+'V3,3=6D%@Z\B?'^MZQ%I&#1=$W05S1;%^+]?J,ZM\MNLH"YGYWJ(
M^KZ$[UK+.]_B&SP?3YKL!+^\"L+GL$(-D9R@THGLMMQK\8XY&I['>W][5=YK
M41:XZZ#DTFCVVC_^O&]W\LAE_&IX#T@6)=QATPWEMK KR!?-\5C'(O5Z:2JC
MC!6P;W.>>J_!F1K]FR\X(">VX$QH5."IJI4#)V5'4IF7:E<:L>T(F8UVR9CQ
M!G,1;AU5A[=$N2O?*&)H4>V;ZVRN.C^EDIOKK')$<UJ3'N?.==YP\KF4]M3W
M[&3_/OZ-JY<C]_L,_5QQCF\S:WC63U 41U,=I:Q,NT@U;:+K@+]#5M518N)&
MQCHXR@4$!^1'@%K)$E)CD^*X[_FT=[V.Y&;! C/F:C5M4AC:?O;_;(/H[B?)
MSO^N")4""'A-2DP57[ZQ2#H+94DHX%7>5Y@A!>!JL67XUU\H7P9*$>/PI8&6
MQV.*XP.BD)3/-7T1D8>\SX#OLD]Q#KZ0V;PY_V P['[;K]=KO1*61+ .-"02
M2E3 \>6T[2KB-'6?V%;.&I"9MK.[U-9Q[7R:]D#KS2.<XK"(L@GI0FV48*=@
M<U!-9H?'QD]#Z)]/ATQV(^.&$B/(DOX&GY7])C<<0%;3 JKZ0D!2(N6[L7MT
MVLHIOCNT.A<0#0?S?5[4=57[=CJ>\K.[L;/2SJ"B-?Q"73?.UMCVHR_)G27O
MGR*!QXCP;L:,"0%58<G+FYDD>D\F.%H<0T[)([D#6%V;2"-!46TFZ\"1DA(A
M5:?Y_IE/\GV-W?.X38.3V?E#G8I[MBS6;/[.GI8.R@X/%Q#B?3FW+ZV%KQ+;
M$GQ6W\JSE:AQM, ^L:-<2]!;.G'RV63;M;T^S)?/"ZL_I_SIPYSO_'7\-N</
MISU_B*BUR?LOJ4"Q\<]$!Z+5F<$?G2Y<<3_PYK%%K>J?/(=W/[@:>*_-^>W/
M<HDXT^] [W%U'1^;O6UG"-/!R8B[DSUJEHH5K[@7N'&D]4X$F3^]A;2Q#.<C
M'>,ML=OFDFL1<S@J<LQULMI<XG/L21=)]*M# +>[RC&1Y4GLF3.['QUA:[4C
M8$?W1EF"S!9H.L$]CP[SN)@HWTNZC=6)).K!TS*54] /W6S:BC'N^N9K:<82
MTUXS/Y>6/)/N&<,S;M]5(S)'/QV/&SDP&'B%TZ^2=(5&&SN\J2"A]8T'42WU
M+O@7,\S?/FVW)WM3=%C1[)L/D8%TKZ=C!P[2/=M,5*@Y32^/+]:8;\V,XET+
MRC[NY-G\\6][[0LXU0ROM+V+\>9&?YY&W=8%T?.COY<</=BR7^Y\IV3SA[AS
M=KMTN3^A,;O :/^O^LS_>Q\MGG 3\/8:1T^)&6R<PB[%RX^QJ[FCSTQ4H*)6
M+&R&D[P!A:+VN'FV$2QK)U5PV[764>V;D"T5,2XDB) 4*4P0S.;FA]ZTO4MJ
M:.BM=IQ.C+"0Y"]^R3N5=B. ]!"HQK83$["567)]Z]<$/8[YU$"=V9TJTJWR
ML^&&:?&,XNG*UJNE,- N<+M[GO=+37WC'ZXWHB^E=C4W[P3VNY7'7Y86R?&^
M4E4EYDFNF"%'Z6$#L/B37W7QZ6S>V]R#G1:';*FM;_R.^SCB;!>8>?\<G'7-
M%%/SM?X*'KR^NN%ER?X2PP.EP29QWNZG?O@AM7=O;^K?6\9V%_MTMAT[9,S]
MB_\Q78GQ4/Q-",+=YJKB;8 F%F" .-'.P.31C]<(1K3S_4 P*L\$\:RQQNN6
MQ!,<A_D^E*(XF\,YVU_F/GI5<^M8L7#8[U'M*>W].R)E!6C\=<%DJ$.**L$[
M.V@>8%:SUBVLMBTV=;DPDJW,&G[>(Z5U?:=(^$DF!@U ,E:=%B"FJ G##'TD
M3"]0DZE9'"%6+7?6-?N9>W_-N\O/F<\ T5?A"YQ"=TX7$+'A6"7F[3K"?S_4
M_O&\$?'CZ9'E[,+U;-LAL$=X[FRSM':I]7[]4^X_0;%^VDH,DT,&K-Z%M+/7
MTD<<[.7:[4U+!C.6ST.%6MP([$K:*G@[HHLJ%8;\H"C&1WBZK\%,Q%C'&P/B
M:_OS;)/'>#?M$ZO]K(;.=%\K49PGO!BDIJN;^TXW.KP5CWM6(B> B]S!#ND]
MM.M/>*".:+Q9"][*90"_48:"L<EY&,BLE3F4_NUP-UZ+9@_> C]YJX]1-GR$
M4WB&N+CS4%]!>^+.6@B?%%7\B6QB7E7;Q1*!I0[2\BC5MTK,&0*X2/EH@"1'
M)1-0[/])B?FLBOWOA];%;P,ZDCG$^S$1C9DEIXN8S_#FHI @I/Q"307IZ_ZF
M1:!GV)Z4$+@X@;;R QD 3S %^=*/('=F3,R%S908"6\YE\;:&[)#YV#*20B(
MI:\(<V#>(4HR()=?/Y3:9O0W^$%KKS7Z1C4/&[38'WLR.''S5\LK_*=D!T6:
M@IE8;:GB!3+G-=#[\ UFBW$IPHJY.Y&Y@/0 U#YC;!!7Q(&C4#%:W]Z?Z4 O
M%FFMAG<YNF%YUI/9]-S\";L:DRV-/8'IA_3?'[(:#*BI-M^<B;/RAK1@6NV,
MNA)SQ!&=EF1DJQ+S]0[C/QTK$1MS+WNC8<CW'>KH!%R/OJR,FQ6B03"MQ'A:
M8/U]R1+:@/ ??I."C*QER+R1+F"+$C/ZA9W0);>'2#PW:VE'-WT%<Y I)J3;
M=,QIPNKB0BXH/ %II>JX=CEY["!&7,X/SR[,*J!>]>N5]'\QWC7@;V#_1YWI
M:\0:JA?QY;J!R+H0F3'RF@ >.^2+K"V >J0>?4"(T%"^JE;QA!"&<LP&F/(K
MK"726HN\1U1[\89$,2G61YH3?5DKS1:G'78S5="?^W1"AVAA'V:04)44.6RX
M]*W5A_0=)7*M3,5M8**(FJ_$:  M6.2$QW\Z-K,/^TW,=J7/WB1$DBAN2LP[
MTC1IW:02LUG?;0@Y2CWDB3:#/R*)B."C4;HG1*XM0TWJ<BDV!FB5!7)%"<E.
MWC+4KS7]Z$2486F'%0WSP]:'ZQO F,P2&9;*]"5W8ML$!75I]BYX*Q"?^[0]
M /]8M^C,0(/S]4!GI_6D$&3-<GVG#XKGB-IR.2+\ 2I#F@G'B.>TZ'S""[58
MQ!9Y3P")PX&MA@<K/L@]1MEIPBI""R/Q 97_6I#:53RPK1(,9K$F:Y?2JJY/
MDXNHT\>ZF"M;AH[(_M,PG&3 %K4SZWY1$4<EK]V!(8B\Y3_^DQ>;B]%Z)V:^
M:+&E!'@'488[8BRD(YVXOP 6S3):B2D]:[6@Q-S+TZ!T<.>N-S)+\)O_*Q=K
M ).!>E%V$V/065PT,R<B)@(Z#4395GH/WAAN%0OO FOD%^DFM',0D_<J\RU.
M)YRD)O>Y/6O#2![1C\&ZOP+C9G-UE][GV1I[>GV0V!X*=*_HFL?]@<9:KA*S
MAD9$31I3\01U.UG,%UIRO?1._!KDG0__#GX+M5WZ2?%$[@R1I56*QY%N[GZ.
MWLQ1XEUN2*[G+P,XKL@HP?L.F:$!9P-)9CP']Z<U-ZO S?.'@K74@3,F*Z#V
M!/PN*K89NY&&O6'U6$3< E..0B'Q<U^J7I5G?W,>^"Z+\71%V_SUP"7)CKSW
M7S:;C'S9713W5_M>\V*/_GZ-ZME&R\B0?)\I9F?D(=@A4I?L^7?(NGMIO[A;
M'M=)??*WV6;SHLU'.VWFW6SXHPO2W8K[RWN9RNTEKT >HJX#J4E_(!G\)+LI
M_Q4>$C$%15(/^""82J*1%.EX+.TXE);.%A&-8<"EQGI**#!P??)&3- WQK_M
M./VJ2_P2;$]Y:K(;6GQP;!X8+)*^A(6R[6CX_ :,-J+BQ4^F);^FJ'(BB$E)
M7#4;B1=/>KT*E#:.L56I2_QFCNU+."Q(3%$/OYD17Z?$:#J%6LD]*6*2 ?4F
MW_\E>/K][?,+=)/>'._:)*"F;M%ZE#%S3.9$YV--"&%, 5$4$A<982 >D$2Q
M8,\6PI;Y#J$>S/!Y >TJ'BV)"1[@]835Z9<\&PXS,7(]$RGYU54S+BS0N.NA
M1O.;?WXTC1(>J:Y;\.(THDSCR+C?>;;>7,IY$U;D2P8R&&-L'FJSCC.& !'N
MWPM1[X &21P5:F4+5N<1BL5-,%G:!D^#<Z\% = I;.4<CZ0[M71^T61_SO'[
MT^Y=WQ5:/W5=K"9M7)7GJJ&IQ)RJ[YHMBNYPC#6;8,@-L-(]BD>T(^CT7:E(
MY5*X"=SU2LQ%K522*AJC6R'&:ZTT_'+%'[K\%RX<(?.G:MA&N"Z_>1XC)BSX
MN.<7DDVV=E47.U&N/H4?'.VY)(D(Z;GFR[(F]5ZKM[S>OX2;$B0?S)TK(K4)
M_TG^["6KGBY@+=)#H B0*UT!C;"7DU$L9^JA'>X%1N^C=L&^%;>1WLLTX!B%
MUS%GYF5!]$]Y._L(X6P&5@O9,&6":_B =_@TG3+ZK)H;!VR1'XP43[(OTLRB
MQ6[D$] =7[(A(+ ]9"+\L8=&P<JU$Z0ABBJ./C)\4X,Y\P;\AJR["E8B:ULI
MH+7XI)P*H[-6U:L1[&>,3L\E9=?>=7(N0'4[MFE8Y]<Z:$5OU<]0('PR(J3M
MILO=F7DCROJ/U/L]/K+3N?T/"Z8)@@C=LOGIZ+FHQ<8!EY=_1D3XI[PAS?K>
MP(Z3HF6:]$&2!BVLB"O7 :2HN[SS'&BR!R[Y,M/- TI1+4C2NT9))(#'J\!2
MSB[+9W AD,HQY?:P;0%U?*RN3RQ,\>UN."UZ^'#\@^3BK.1Q3ZFOM*.=\((B
M,8<&D'5CRPV/B&[*LP0!'D[ 1-9BN)5:=Y684-&C\)N4Y@XE)H6S!QQH%FH*
M!R<$S9L_/ZP:/JIQ?NF;R^U";HIK=^2F"QT6$?;SAXYLX2.:M9-]M1\/Z@L$
MDT-=OM 4L)IN#H<LKQ2%Z]%;E -?1O^C8Y7@*P\!0UH5ZJW^&G"$F"_(;QG(
MVPP,FA^#@5%"Z@_R$PGBP@3(ZCTYQ5?AZ7&G[7V/9X^-L&:X@VQ7'I7?44(>
MD"*Z*?,]TIN*-,Z!?Q>30L*PVI?H6ZAS9Q1,F@IZG7LP179PDENE,1!?%D%3
M9\M_!+VXHQIX/^U#87G1OS2X/ L3[!PIMKJ?I7/.>?W5A.MI7L<(!<E[:O_)
M$O:/T'W4]C;.#K,BJEP+!4C(MR'TC&L5>7@'.E^"=N@(P0C1@<=% 7#)<G4.
M> XBB-Y -;%1CY689C(H:U$C(FU00@*]OUA1]"C<_Q0SL)>U,$2,__KTXI9H
MZ4.*?3,;QF%3<$Z_,H.["&0A;&9P]R)';]H[O7AUP1A[T'N,DE1&WTE5<;5R
M/O;<%[8>\[XKO])_[T)'(:_$_S?6W7?<B@PQ=A,AA!W/-)KGQOKO@5CQ!5HI
M"(9VL@>/D^^&@(1(WS2UECQ]R*_P7@D<XEV5X%FE^"R,DX>-HD)^&M& ^'%L
MKQBC%L2H;_;BG,1'K(&??4/ZZCI;S=WA>'9''9Y3AV@PXP M()C-$%#DVB1$
M/0!,_S8ZSKC(V4V[#*.$KGIE@+,1UJ=HG6L5 TDW"6U&<UOLFR6^S3>#A573
M=GF.\4@KS?JR-E/R<Z96Q5S2DV#951[S!2X-;TG34V1%:H1(FQ2-0% NT"2L
M$+YF)W"VPT102\R^C9A0/=TAM;@&C:+64K_I/!/(K)EA-+5G; ?G5<[1_MG5
M%9E?C$V:!8Z[+]1D^C+Z;^[FC+@K,5F+:GM[WNQ<<,R'VJ7IBG1Y&)@EW0HO
M@DOM[O!RO >_0!%C-,:YG8 A7 22\PP@7)*3*]A^;*!J#B96X6(-YQ*<C,&V
MCI_AV,!'*<Q-5&U'V<M+P=#[V'Q\1NGDTO./J^53BC^YRU2J@;=&/C(U.!:T
M+8IT;IAPT%%Z%=8 3:6)8%8R?@<BR,(?JE<\I1^BG4%)=85!DT3G=;8F$XH5
M8UN(R?JDU?A5-*M>>41,T.68Y_#5I@'__= # =7[2%\0XPRD!YRZYA%%IK,1
MHZ7O!GM[W@[7192-?PV,&64,F8MQ<AV5)B;HG!8HM5,\DEM#[WM^AB-EN^!Q
MZ=\OP3)40:R_7(B*'4U:E*BG&/F0AX7?<;;9(:;XG;"YZ%_>1^  2L&0W"6A
MO:XA6[_@L6][04=DY-)I&3G40[Y<M3,'93X3_#KJ0?^QT[!Y&=)#J@88;MRL
MWVE8,.4U5]5WM"PVNG3KO5VUC#:F-GTO'-6\M.-=WNE> ?WE:&58IQ&]VSL1
M)DJC43^GQ*03]('0#G4-H@?\"GK 0S @)8E&9(?7.M1/("IP2,1SQEI8K>EZ
M%F%B1!ND&0XDTHAB!=&E^^3. :< L9^O?]_GAE=VVUNXQ*G9D=PR[HG/WR3<
M"W-=)L-'=$_N_G\3S5B@+2]!VE&Z.TD0C/#$#!XECE %S&2!WZ3[H"Q>HWY/
M:]YZ>&BT\>18B^!HM6CHMMB2V!;;5H/?T.=[&&GNKV)A6Q"3_H !2]*/W"[6
MG+S^ZL5NUT5OR/LU%CS!3C=9 4>!?&DR>J'WZ!#MQN^2;P&Q:8@1-;_-1+=/
M3A(=C157#_  [0G!0L(U?K**,]B6%C/F>Y4]Z>-?%"GJB2D<I*:<JRG/.7UG
M]G/ -<5']%3]<E.8"_&1M?=D'C0;>/-C,F(.(=6/J>8GB&KP";X2L]8^U<E<
MQ$SBK(<(#-J^QT?(.27#Q#.@.X,M& KSNN?G1[XH_-C?[]TSM7&0+_\#Z1*6
MLU_S!Q?$9:Q1QET2Z$9D+&#U471GZ".MV*H0N0[C1&\5R1!N;QY973Y@ R3<
M9+1S!X>D*3VV7#W2A/<]JB>I6^X;(;8T.E$!V=46L)/TYTC]#=://X8)"CZ0
M-0+KA@>OM#?H1$6'*C&KYYX0/E1A5F->;\$XK)@\8JO^I_/VN#^>9YV.>%OV
MXZ?G+2M?V_UX<7WZ[PZ>S_:O,^_D[)?[@/:OB7>9.G1[N5L?]P7'6+X=Q"8C
M.ZC",QMM6[*!N(;-CT?@6-]7=P;7W)^=M)&M1=Z$;/Q6-ONKUX=8BV=:H]XS
M*.2J8:8!(XX=_2U="_XF4Y-[*#+QJQ#A0MZN'NYYHD"M!="1;QOKT$IV*$K8
M&2\8.@ZQ8VTTMO,\X:@H<4I.CGH,AO]L>FWDU;)0W 5;@I8_7YSB$BPE#4SM
MZD:%!:E8@?4@[:1_$M9@>?R/YE(?F"4[)7?O<O(6,]?+]W67FC&:_=5Z-%EB
MOCXUUK_?PLE1Q-:<D+:4ZDN*I[,+4KV7JJ<+F8_#4"WIVVLT<Y/V&O%%WC%!
M'V8*YP?%<T((8_"J%.68.]%R%T6"+3!DW<S9 0$S#\<LO<7C=SD_A!(VL.3V
MCYK$9*X&E3/$N[GZ=@RHQ+2:/R%2+):"G]8Z9#*?30DTLU@32P0IJWHZD[*$
ML+^J%Q1-+$TPNDCP'B5&GD^1RI282EM% 7?>'6[F+*>:OXG:]O7<%T3%_=PH
M)<:+DE[RB3M:"N@A^E1K9*U"%D$EM)%T\":P2RO'4I%."-LMWR-BZ,(#/']C
M2"OI<X[():5T:PI/8%=>/#CET#M@>/?>I+0KK&9@_SE2A]Z?>Q?VM^M0*?]]
MZ1YQ!A@2/HHIF%!BI#W_,Z/R_\=G!1@B 5 >'E'\Q;U$V$"U;Q%B;2CZ4]GL
M6]]CG)W!;_#5U@'$*-[(V%UZZ/#$.><0HZ0O]AOW'$OR.O76^+65$$5$,98-
MF]DKU@&Z*#Y,37/EP=R+$VSSC?<N?*SK:3E_I4%S>Z-7[O&^WWN?G\KQ2/7\
M\[/^</ZF5K\95OG2T6-C!LD-]AFB_>Y82"OEZT7FBK4]34$/+T7_%?##F3.G
M69X;3]K\\)W<G'O@?6-X]85\O<Z33_^9?Q#R=:/L,+T%6\F?L5S6#NAM#IO
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MP:'TM;HQS4,UF8/5V-B^%A<U3UR:76I[_74B]W@(#]]$Y. 1A>5MB$<@OIU
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M'R^KMTT,/ABW(WX<FED&O!.@7;700(''F$T ^]RDF0WV_*ZXNL#Q9*H>Y<P
MHU3=$RI-27N:,(*H?J>#PK.-H PCT;WMZ4FFV=:F.%V]ZE/!^6RK,/)&2H=7
MB%V0CS),M5%A LK]?&281"H.SO;CC23O'6KYZ7MAJCM9.SKHV*_0%]]=G/NJ
MQ@E!MO@+^ZOT]P*YY[<^_D,N$2X5KZ:VR3#;&H*+*>?@-^)C$A-(ADDU^E3U
M*0Q0(=.LTZ<O]>_H/3QBBSMO\R1]RBC8)__3\*?F.RL-9I^=.GN2V"7#_/&O
ME [@Q=1/J:)TZ3,S/_&Z3Y1=U; [I$,<-* 8!0BD4>RU[\RV!C.RHRRJDIHY
MCR5)!5<FKL8]]C:K_RXLMQ8Z)H3OI>.FS6S2+K+;MZX;?[U^J-@N##SB]JAS
MC\/%+Q/G\O=2/\8T/->.< NLW;6W]+7)4MH_):L@FS79UXX05=V;D/W-7W[=
M.*3X.#A\\^]^9"#UPY37"_;19W<_!"=I_6V5GNS_H[G7J;GY\"1_JK?CV;F<
MO7\"Q77ZOTS@Y=1['.E3E@^@0?D=5)>H8/DW&H6*1#9B0GM+5>TW5R?[L#U5
MNJN20YHS&8FA@-:N,080YN,M.&9[1C!TELY>3%>J6ONQ>6G6.YV#K-=!2B@$
MQL38WNY0>Q5RB%/E8,-Q@:V.[="\EH]==E"HU/W,X#Y^?VBC7=M7<YND8V+-
M>,-2'_MTUUW6ZG&JL]Z7QU8=22:^M/.O5MAW1J/1Q&;SR?=AVW%^:S]'C]O9
MWK:[X^ST->TK00_2;/8\"-9OOINJQ+\5=GMF[&".#=U[RS]O;-4-UB!?43-L
M>+4E7^,2_56<>>S1$CO-#>,.%\EA;@^.%P_E)NH/$0[_=VHSFP'MN,KQMZD)
M=9]07$B*(2A((@2;?=;^;=2E#BNSS74&8F.+SXD&3Z$<JR_H>VP)UJQSPTJB
MH7'ZJ42%&C)JI[T8PW@D.8N'1S1(*V68'RG,?^06V058'MU9<\[6'?I!#'YG
MQEKA>+O(:<W]HJ.U>^S(_@?_SEO\,W^W\4A%?6 C%J4Q_!36==:2,>D/%NS7
MH"##O#<E_/NMI5.)U%Z@BR!9C[+41^)XY$,',$&\*\,TG\-)&.^BVSME&+"=
M6$&4:IJ\)4H.CZV18;YJX?[]5O1V2^W_U%",^)"!#/.,*B?#K-\-_&#M6L29
MH'!=B_H.F+_)70& ?61U&>;/4.#?;H7-QZI$6<LP9FC'>@C5YCMVYD,M$@OC
M)#N?H2.69'RF<&68#6'B73),3R4%[9QMRR,B#CW_U<VA7A6'63W)3QGF+?W7
M+_QK0N5![I(Z#P ?T608?70:?P*2 T,S&3+,F4X0[5W1Y"[PR\KJ_[S'^F5%
M/.M@547_B2KN2F#\"Y/W?TY4VXVDW ED6^_A+BP,V/3-VRJ<?E75.Q^M:5U9
MVS??B3]??M>@I$IJWC9XI+1D9M9 F*(0$$ 6QFUYJ).L>G%%H:6JG/^Y/6?V
M[,Y[9+WST;EW.ZNL#93<=J(N8=7_I"PXX0"!5\:JZFH!AAFB]=)\LPBQ.?DY
MNX[8WK4!-CF=Q09\F3V&U7/K40>?)"$\(]<+M#+B&&,1U>L;L+Q2BQ9/PRI\
M ;=)8:( L5$\H["GI%"B!C>"+J(GTKM4+<E6:1EJ,EGPOKG6KA&<,#S%? ]E
M6T_5W'!?.VZSLD".C>?4" 7 @U MY<O@$#MUW16RN*7()U [NY@8,'Y);2C$
M%U'IK;;I, A@1]Y7"RF<MI>HXI'URT&,+Z"<AY"-2")EFFO":6Z$#<QMD\[(
M'L@P%M(3D&AE9?,$[,?0+GDXQ!+LBC6[RI?N$+>XC566NI$!RV1A3;25\\"^
MWQJ8]Y2&-@/&7#DF#FC2G2<E &LIUF(+U'%O16GF\"J>>JO]-MC=&K867Y18
MP'SQ27^J7*"/Q^M[XTVF&<FATR-T["03UVODU]K85-_78"D(33W_R-;!8*XJ
MR68:MG!UX^@.2.=N&XJCBMYXC'1XD)XA?YQUS57W2+ED\_3WIBU_7 ['K H\
MJOD'1GAD:Z&#Y5JK;WB)6NI;J@&,"M7JYU)F@Q8O0*'3I651AJET:;&UL.^=
MG_B6=:&?#XYEFMF^]!LT%DWUC8X1_32.2TNK_S[[P]-VK]O+HUE^B-4"*9&X
M08;QMU\N]>E7.[,H)D@LP/ 'R"&RLA#'U@IO'\."M/B;8715BG$?5>$*Q8@8
MO\@\TA/J5V:4*K_3HME\=__;P<";*<^N/O./3'Y5]ZHZ<Q+H]GY\^=RK#27R
M%:_67#[;M%I[G<X][.I; 5](,:Q7>C,VXN,2!\BDK>LNJX+Q-O6^#*-&^=UH
MYY $X!'BQK: XPE!N8,^8N=*4L +/PX%F^<VK7[D]<!L:/!54M&'U1D]5XZL
M=KSSRX.16<,:&L^KOD//7YCIDV*/PZ/_*BN4@,A)=DE+S?>1TX1 C,0ZG]H:
M2'I.[<Y1 U.>^Y61ZYNUC0?+YD*!]12C^AXW]S"B!LQMN7,;]F)G7NH'W3]/
M(3?#,^[<J:FM-99A/BZ''XJ28-2*K#FY7(MA^7C8O11DF%M-F^'S68E+N^C)
M5&V@R83%^SMG$US*+XUJQZV;-Z".7*X8HH1!FN<2OQVW<(3+!3C%D:D,/7OQ
M2N*5TZ*Q[0TUW8>E<DU,#=3:O""J($TR3#DI99_YODGJ 6DZ=369;@O_%!['
M"O3:BA5#^/38,'W[1.8Q\$-M)1S5.G;\WK3M(X(*.<:2[MBOVV=TW".HK.1;
M8]VC]9O''V8EP-ZH>+2C0[TC48?FXIA[)#NE"80;N#BNDIEFM&X^WUZ+K,]K
MOTLY*F!LG%*^_'GRQ]C$TEC&<W?BIROOO"+"?7^Z=VE6J2N?MAO>HAKFT\CU
M'"'.#7V=:O?Y*CU.P+:#, U10"W?ZJ_2%,"?/FPC2I+F,X])MMMOH_A*_P:N
M$U+K,IJZMJ!6S4M(Q[[CZW.Q9)U6;9.> N2?(#=^OE3!S1VOXL8NB@^3'G)*
MO&(=L->HI.)T)!<V82 7.L2K4Y?R3>>0$JZ6RR#*9&287V>XLZB4WP@0VP!3
MV5 LA8Y"^P74CF\%?J>+=_W'LTYBG&AQ N<729!62?_*3=Q[YK];S$=5LD1!
M>[F'0YUFZW)P?3L^E8NJ!XF82%B%1X[ TT0HI3I7<APLJ,_M6*TQ6!E1ZCZ1
M&5?-YR9Y:F1XUO86-CXVN%%??O?V^8Y E4=GW9<4<ALD[+UOOSU\OB%LJ_/%
MO:95$0$NSW9?#+YUVXD]D&]P=8]E :<R$A?0Y+D= FA_/>A0;;Z<O:VFC!13
MF/'-9O.?7X8;MWDJI>NF'\S6^.OF-/[#K7<6RJ<>>Q]Q3+;SM1JKH?TLEF$V
M6DH+459AP*V60ZX#"- /L!\N5^=:L@F?147V"<K/Z"C,ONCR!'EYG3BO$#\I
MPQS:UY7/FCHD+H;,?R*Z)JW<)=QU.GR7'"W#=-=FC(_2/S(D1]5%Z SGU5+[
M<;\>HM,OPSC\>V<#4E4'JZ6BAT"WH4ZAY$.E>3HJS5W?&2T$@1?% W7;(E1S
MXM5I7*E"!#5Z6#*%NM-_'QT._$+D ,BC4?$%X!O*OL>EQ)Y+*L#+)^K2E0)3
MX$/'H4G2T@-D2F+Q___!YM!?$68N02:BHY7PLP ()RJ'L\2.A!8%NEQ7GCVT
MC?P'X5X&^P#\!/^\=R-+R-AV#N!O-UUXQA*;<2)7Y+K24O@U581GH0Z>8\KK
M+5;1"F/99RX\L[8^=:C(N2KC\->CGOE^_47Z[QVI\Z-I7YT3K:E.+13++.A&
M6+)@P^)F*]7,;QMC6H?8O(.2BF2KN.;NIIXO;[^B>'4ES1"'/:=T<7__8^LS
ME_Q#!HL<\Q)WY]9A-_U/JV B#JC7=4+D45.YI@(*;R>E,#=+F91HL1S2QI2'
M.X2L>RCV:5@#:MKW"Z"YE,,R#,WMOK')V!'()^$P7@7&NE@.Z::/1;V>:[ H
M/A&VXL4$YPXMWR_RNOI2.Q-IIV^288*XGS01^>T@%UG?)[Z&]!ZD#M-1A.B/
MC?,TA\9G^!"KI>XZA]@RIP _Y\<F#S($A'5P-0-?G>W\XZ/P1)^A&S^,N G.
MU8F.X$]+L:Y]L>WQ\V?)[G.?HA"%Y=HRTW 35#..K \6$(9_"EUF&-"X(",>
M.= *Z@@EE7YNC&:L!OPZ06(5R!?S2V'+H*JC^2F]O<U3[6TKR@Z/FMC$7 3K
M_.]D,'\;-+\O1=W<[_21^E9NC6KMOVH\/83T^(,,B/Y6AL$:,>*(*,BGQSR,
M@P&0=@:Z&#)"+O9L:' =&[.]@[3-7>KCU58/4)R"P]5J0R**X8+@ E]3Y[\
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MHYIK)<-LN$K9UB_#W$P=UD,4RL7'@29"PW):PY7PI-@9^:@Q/G,2P@G7I,1
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M81<7 XHAC%>$_6YYBE_JK>RTAE-^['=VWPT.7SNGI);].M54/<?8<1"^V'9
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M4.H48KIM)"I-*"^U6:/+3 .((9R,!=]KXGJS2-)S1[JB83;3V=W12)366 7
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M[M/^YLQ.X>00&DLZ;-%5.OQM4V\4*5<9-%FF7ZW*VWTZ"7]ARM'#[/[;88Q
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M,U:^N58//@6]JJY+58WNR]X-WT_X\Z\H%V2)M^8K3( [A5'L-V1U!_; M7
MJO],"5R5 /AY7$P=\#5BHGTZ'4=M=!5^)58T3%TEKHD-H62S[."4@U?'!9:0
M]R4F27Z!MN*FQS6J:U9YK#JPVL\F?1FC1H-B8$,C_G+7!7"T'*OD2^3 .I()
M$$4>[$3U+^A.Q"&AZABX2QT(9VF8# /U[[JI:DQ[[:WZ70^8^ :Q4+$5!%3&
M8)!B5D1+M\%#I"SGLE]&-?Y&"^$,4MI<>,6#"6@PS,N:=SG!+4=IO4MTKSU(
M&Z4[HD)%7!V9Y7+_/J-:B+HUQA0S3_3/R*R0(W#NG2-#1\:-&4'-P,J9%RX&
M9 /RPS&)6R*K$(L6EOPN9^W9"?)3+MGRKY";@KPS2<<6\V<Z)Y--*;Z)U+%[
MGU9E^*.U\4'\>1SAM[\I9X9RN]U%QMW;NLHWVPS%@0W1&^(C?6YN6.(6_4?Z
M4GF!V8(+![U\,=R4S[X"R/,I-6WI\[@(@M0(U<=,H=')PPL*55? E9I?W%IT
M=MSHIYK!?T4&I1,_".%,!<64>]5RMM5O[ZX18 4CVW/AWCYGBR[[>GZ?HLO#
MI]3S=8['KA5W[TP I7B\X"O6VWD<Z"^#O_$O^;O%%$GCB.A:(IQG[%*G:\_7
M;]80$&_2TAG/[4Q P6.S<-VH=70B+9/I>S^6IYX&Z9F%<)0B:_=LLSE(L?L]
M47CE(\%R>-9;7,K7W:(MITZ'LY)HO.O2YD].4X758Y\J9U"NDJNK2-,8,'4P
MBH7MP$V 9ZZ'9R)I!<Q8J"T+2<!B2E"J:FIRA@+OFA'BAV+ &(%%76_5V$;Q
ME$L6H4EJE,YI=CQVAAX1I]1/\+5R&)SP#:9MU);>R_ ;JGE;>,_W,2;K\\C2
M)]K;1*+NP'O=!)Z?BSA"WZ"O,54WNAR#O2Q:>FZ1P P?: ,S0)Q0J3"[H>+2
M=CSH4=P"B]_4WUUEOO73,R1->T<8*8,WC4ZR1XQ@1_ID">B@MH5O:OS^GD!8
M#=<<A(3/\5DR0S[/8)"!5YPJA*[4AQV#*/M@$;'R00A9<<39T[W5[6Q.Y.L'
MTN34#DEZ*>_Z>)Q;L^'I(N"4:4!=@Y9D %SS**GS5\DDP,1=).GO4)_ ZI.!
M_H0,+N@E'#22 \\)QJR!8K6)]F8";\!7G0\'@>$?6_&7Z60E>RGCS5MX0M%_
MK<SOU+!=3QP2 >UJHW\U;*N6]ULN#[I5W1_2]['PGNZ493$I8AXGQ<NC,*LZ
M19/FJ@MA>C(8JI0@IGKJIYB/+;9H] L]).;')2EJSCOQV<;C^29B9@#QC^,U
MNI9]&'=@^MH-7?BC<\DUVEW?Y+BB<8[%7&3Q] (O"]HG82@&GO[8='^*=_U#
ME>\G2KD"XSF;'$:FX$WD"TQL56I#;171BND!8O NLSYI1'<P/B)+85HHPAPF
ML86Q-D!!5U@6,->[R]G1714P&)I<<[B/X'@RCM5]>A&1.?:^P_+4:;6AJ:-E
M\GDTIM[!#3&EJ=?.XU*222> _ZN]:_]JXES7="M%" K(Q1*$5.D6+6*\@%B2
M)L=2BD@A*K7<A&RE&B"&M')+)21>"<@E1SV2"D(6*D((ER*$*$(BA$ M580H
M"!'(95= B)FQ$$8R&?:PUOD#S@][_W;6FO>G66O6K&>^]WN?9];[/6\>;L7W
M3Z&?=$4FLJB8CD @K_]Q6/5T4&D#$']D.!/G,DE?MEI/#*].Q=:?#1D%*GFI
MT<'W2W7(2YC: !U[NY3Y[JJ7^-0DRK"Z7#GV*YUC=@R8:MX#GT4_R2&.BKRV
M(]O\ T36798;RM&4\8$&04&WUSZ05DBD-+"<E5*#J=/7O,K,C  :JW68WN=$
M/ZV:[$0-7]?<T*6C.+VFMY>G!NK-KJB,E@B:J-")[XZT-8V'^;51_2;C8U"U
ME8!F.HJ+]2Y0.A<";$#6?*%W>"7NXVP$IKKEZGM3.EX)-\V6&*H=L=R2X$='
MB8?U?-<$.H+K",][&4!Q3@WT"GB)ST#??'5$YJ>J><;NO\(OQK[$,UJI\Q_=
M;Y&JY@S;_;P=QV+4^VETQ\_R&PRW#QPO6A^VR3OD4-AGYY]LJ1\,SH:I3]_9
M[94_85^[;_>_+3@?_:>#.F #NZ:;?K,TKYS3ETL&YNZ8X\>AI=E>(1!.S2?Y
M#")K.,,XNX'SL'<F%R#T(-[FR'*ML2B.6G1Z?DW':7^/YI\8XJ<UDW0I]A_#
M'7^O9='^*=39\*I4RU952Y #8B<"WN *5WZ8J\5:,VLS)7]D;'&N&11U$#3]
MC'7ZGK+2%KV?S^/V9P\UYZNF2W\\-DF%KBF42VD%(BCU2Y)MYIH%L]]>^NK
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M7UR<)>R)L8^,#[2_J+YX^)T68;S(VT1W,L>[9N)R]LE7[HOF[J'C\0?(AZB
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MFWQWG3ISRRB,L.(^<'PQ[NU1K%<O+*TSD;S=?"T8\3Y!%%?!4WH8?A96ARJ
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M_),EN*P/\T/A+^<ND_K@^@P'YY0O1 5HK/X^,G1 A$@4(0+1,T-.PU_X9G=
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M'$G0^E$DF"<4*S(>"T:YK-C);FBI<JDF!C+1.TB ^3+H@SP+7LT.%4VO4SE
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MK@4MNF4ZV5AUB 4-/"?>Z6PB&T .$N!NG6*>TKP.!$0]X8ZEB78H#+O.J%L
MI:<-^KNVY@8,AC<T[I]=43+@2P$]D!F8#;Z*YU":\B*YWQ%H)0@<I'63\1)A
M?Y%X+I.T$_3$0N'@C&BZ&6_L:?.J(NPZZ2!7%?B2E4KRDR ,,(JO5, RV>YL
MW;WP(8-3W\JOUH5O9MTL\Q)&Y8Z99?-8]E./JKPNC%Z#+& =@PIHCK.?O ;?
M_TA*^9V!E0<KW.0YLF#E]B8I8$3:I2U=T$IB(,6QF'47H=\\O2Q;8@+%S$K
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M+R_-W%+@M1>YKN7V:^(9B>!3W'Z-49.*%XS?0L'AH_\P^#(-:U]6#'&E^!2
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MUE#_>#'R/78 JU"J'S&WC!K5WZ(I4:0SS"RQ>PMJK>NS_O,3.)2&RIV,[DP
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M-0IX32C;ISP)/9+P6Q'I2/JY_$Z9O2AK)<F+7L]7^<KW#[8(YEINPQN)KA?
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MRA[K:+,C7,ANL8\FW&F^5?,ZHYGD*RJL,DCSZD8V8R4Q-_JK3*K4)>1U<*>
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M;,1CW)0;M,#&H/$]AD.H8D%K'9'=F@L_$A-T0O:CKUV/J\/)5[R+"7PQ=JN
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MCOA_T?:=44UMT;I841!!JB 0%1#I*DT!B>4@*D)$.@A1$2%$B$J+$!*5$HK
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M(^=A^'D/FK@W75\:@7/MX69)QC41L"W[(N*Z__:^8+@=]1+':B #GM6ZO%V
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M3MG*8OM.J^=N5S2'('Z*0:-%Y'/L&LB_1[QNMI8^YCZY?_6HYV,+7ZH7UIC
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MMMXS6& (MHHQ\RN. M^0N%X[IL#S$I:0)-#M4RJ)-@'\\P(8J,6%L@,3L5M
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M&AO)GW%HSG&GAS8YQ!I<>;;(N_SE&7Q@VR9KIN]BVP19K-Y*FJ^?/W7-[4'
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M32(9S$6@M NJ)H #YZJ!67"M![NM#7Q2,"M2XL;KGN9^<&1;0^7!BS&=#BY
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MJ9,8>VS<.7V=/FET\*MG;FJ=277;&-E(#?;3?LY.'/2[4OYCX<H!^PFZ$ZN
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M'Y\$MPE^VQ#PF-3J0_BJ)& S+\63BYB'KOQFJ]&0=9LKH2SJIVS.78"\LEX
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M4WJA183K/4\ 3Q!79I@Z!O9MP^$D&7#=H2%NEF$.4.,Q*]5&H@^.'(EU8B<
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M':P( L#G8N"SS[_'NUISHJ"XD#W1>*GV7I2S*X]9]48<E7B$71XR+$%+@D*
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M%'S]K#KMI=>CV>/-L <VS>DYP_QDE.2G \J#OR,VZ?M=CXN:[B7DOFWKZ-T
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MC?>U?AAQ+5IU)%;]+2WSQ?"4=_G$<WK#C\GR@%!3D)^.-Y!R]&E[6L4FMZ3
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M3/;FOMSPBV-*(-M21_ESOO<J\O3.*,Z]MR=K];=ON>Z]+:#G#EU[[#U7"FP
M6E^$ZD+ZSU[Z>XI4*^\#K>N:L1KMNL&M_@V)Z>DE?PX0;"/G1U?^.5!=EW'N
M<?#0;-/,2DFDLXBD2.O)*72J*3QP+7\A!A)>H:^'W%IYMG "9-HFULC!KQX/
MT?<%15G-FV1%VX7!J'+$$ZN&#X=7?EQX=>N!AWM>284DJ'N+BXEHS?,-U[NL
M-AI\(4X7_N?HU5(WGE-))-,AY#E0*T3=EV+5-7\IOGAW"\@N4W?6RFSZ"B9F
MNWV\R:(X77)P_N'>T06%#^Y R#['Y-W>W4]W_!S]S],[11)ORB)&/QJ9F6RO
MCT]V);\;%E&MWRJU4/K]T;^;5<^?C@/-%1+X_%WZ9O5]O--#VK TYQIDV(;*
M#QQ>/U*6# B"3&\X,36\*A<Q9R**O\T2B!;BNC)4ZT2N=_C]S;; A=CL($67
M3_)![>OL%;@YBQ5GUR1:ZF( 5PE(N=W24J%:6[BOKI:;TML[K,A5E\OET=&E
MAZ+9;"E<4NFEV]*\Z_+-?3I1CSO68FYV/LS\YK+=PC:.$;Q<N9>NK\YC6':
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MD,!OB# .>]41>%.+:)DKC]._4Q?/D5;!'Y#57Y0_T%B*4(CX+ ^^;5)22?>
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M    ;VYC="TQ,&M?,C R,3$R,S$N:'1M[+UI<R+'UC#X>29B_D.._/B^W3%
M ]K5=K]!(ZG-M;9'T/;U,S&A2*H2R*NB"M<BB?OKYYR361L4"-1: *5O7%M
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MUH3GDA,-[35]$?K6/)<<0JEO]XT@FR"@Z..R\Z1MPQ(>1HZTI':[,UL.,9<
M,Y<2VVG>EK>^9!V*N4W_\JGP%9.<(K^PS4*$AFU+%2FYXM)NN4T^DB%WW@]2
MS 6 09#1M0BY=(5]PGWT%@7O!S.*=VY0HE!XO+F^L^E29"W4L^>4/.\'HU9
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M=N!<A]SO2[?<]<+0&QY51^%G_4WHC>@C/KLL73S4H^K/GWOPMG*/#Z4S/NK
M207L0MRS:V_(7?5;(/\CCFIXY]:7?_Q4VZM^_N73*/=*>B)W9-\]PB"$\#]W
M/1_6%R_BV(NZCF#U2GT7GC+BMBW=?OQC+5WA<FNF==676E;FJ?7"UQ:]YUY@
M0OU1UW/LSY;G>/[13U7Z)PN>';CY<4CBNHY<SQ]R1[T*5'$WZ,$7\*TKU%5W
MW)<@O(Z8OG#KR_>+5N?DF+4[C<Y)>^%=+@?-M]]E^Z3Y_;K5:9VT6>/BF)W\
MJ_E;X^+;"6M>GI^WVNW6Y<7;;'TQVOBAK?_9:/_6NOC6N;PHL>-*L\+JU=V=
MPV7)K(U91JQ:V2^@LNHB5*8_.J(7'NT =/1GG\"#7TQ ;Q:>;"^")AKJ&@8_
M!+XGD/_V&I'_Z>7UN=XBL'ZX\B(:@MBP2,$XO:'%U+>8RU&LVT("O[4B%'PX
MIWZ+:7%R+7I%0]'SFD2M6OZ=!$SZEB\:KEK.A!Q9N4*\7[>J\'CA.,&(6X!L
MR6>-?/0Y)Y:.>!1Z,=H"-!T^"L11_,=G=B_M<'!T +#?HI>1B MM=D?G"&?J
MC9(GJFMW*M4#??6/\(4LZN/G1W ?KU@][/_E4V@_"K##W<IA_6T@EH=1T<H_
MZ1-_VKD_*MZGUER\Q,4$0EOT/<&^MUA[/(1+GU4@S"3T[4)";[ANQ)UK,?+\
M<"F"9[@2'OZZ)6%I8 ; GCVGRQW'"[O> Y[0X?[.WN<BEO "R/9*!_>2DKQQ
M<?&]<<:N3ZXNKSOLZOMU^WOCHL,ZEPS4FP[H, KG:]OL\IK5=C\<?U1?7)ZR
MSF\G+*,#)?I/H]EAEZ?ZOL/MG0)Z^41<^<NT,?"*,O#P146@Y[-P(%A/!F 0
MLK'@/@.#2MALMDC<+J*4*[*W3I0M]F12.<)D[B'<.[#Y&!<CW*TO<=&O.JGM
M6FGVTG:+EG9*>_L+GG8*WP3+"6Z&?TZ3Z7I)\MH\CEZ,K1O T0OQM(,/E>CQ
M>"FNOO-#7/U@.:[^"H?WDER]<]VX:+>0?;]'SG[PDIP=NQ/( +V#[%0"/P)D
M1)_A3'*I'63)Y81\>7BCNF\YI@F_EG>5I5W(*(WEO?J6]]Y+(N=L"5Z=QL)K
MT:?8NAMBMN1RF)A4?['.0/A\)*)06D%)@;?E6I7E,?3%O( OR@X^G#QP*V0(
M0>;U6 I3Q@/6'@D+XQ VDRYKA0%K#K@/>_UHZ/6'Z'595%G)W;RB5ENK3JFU
M.?UHMUJIDWZ4T:9R%U0KA_OS?M\YJ!S4LA<D?I'XNH&"8JU6J>V2+V5:9WMV
M!\^3M+.79QFS->L")HV!1Q\4:LJ3HBBC#E8W/?OI]B IV0$^;>1[=_A.91 Z
M_!YLPR7T[.7(\@DG-'$H"W@/WST:U0ZGT:C#'UHZ*JY2[IZB?N[5R[7]VNX!
M=I68C2$S27^_LKT&I+__HMH"43#SP%X %N_&.Y[$<2\$I8K].Y-&\,LGO/X+
MJ!C/H$BM"[1DEO<AT#R_SUWY'_K\<46XTO[:<:67Q?#6=9N=#$>.-\:TEW>#
MJWGNRBZ\RL=EO",;H=$^^VX6BE*_G7=@W;(V9FH,]0+%LV';O@@"_9\SZ8K:
MDJ'Y>GV[RDX<UH2=N1Z8QMR9U!M*L_UF]=HB:ZHOMZ9V)$'\;E>K4PI,UV>?
MY@"H/G,Q3?CSTN]X]^Z22P'Q?RQ%WUL&)MLSET&*Q:5_!>H\B,TEO3G-QN0B
MYJQA9^8:KCPP*9S_D:.E;9,OA_7:]HQ#^3![*;FP%!Y$PQ=\^9<?[!Y,OOKC
M(_DK];WLJRGK\VH I/<4M7IG>Z=<J]6VWXW+3*-+B0&F.A$Z-MA_Y A@9HL2
MXZ[-0N&($8*3N03/[)5@GW)]J==C?N)O^\=/!_7:_N> C7RX6(ZXP\2#L"*L
M'((K03*+X.,,K3N1FGE9D@H$4KY?Z#P*\TLV,2;>AM/PJ9N8/C;A"YN-(C^(
MT%\:>@RN0.U)!YCJ'[J:#.&@,9C>L,(CXPI\/E?@A(%^4-F;99_GO7W;NY7#
MGS^SO(LZR+BH60S?=V/V=&3HB!A9U7]/N#50?U'#\X6#U;5*_6 ^=&E)(TSB
M"(O3#][8ULWOI[Y;V=LQZ))'%Y^3,%-Y&^Q#,,^;L2QZ_'1*_ZP!:AA&,H49
M&$B<Q4=.'JP!MI77OVLY^>= QA=<)V)U(8=L_0G<'N&Y\B?T-G[W>B[30VL[
MXUJ]2\)A28N,9F P&EI08L#K\8 BP?ZK6H'[V CKX@;+A6J*V,@JQF_F2@^#
M?K-3//:SZ*<EC!(P2^9V7#0[*XE73\<BP\,F] ^PIF;SL<,B/A8+GZ5SA:;B
MS@*>%(><+WA@\[^GO$]-/I(A6/!J/LO[=:1OBLMG>=._/VWZLPMX@\F<>KW(
MS$YE=V?VAA9"F&?<4,NU,;HF6'?,K(&P;ADL_99)A2"I(Y#)@'%V+QRG?.MZ
M]RX+! _@N3;\$$3H3.0!LT5/NBHO[SJ*+?>=ZB[3^)9!6$"]BOI]^M]_P>_3
M/L49V?F9/';R)\YZZ.S$CH(PS9^PS]]QFVV]RQ9M<CF)?S$5A%AZ5WOQKBHS
M4&XQ9^7ZHISKA?#-WY%$S@8,K8?)X3[50@1S.-TVYC7DO]K]8$\QOU7!P(*@
MW!^>$[DA]RFKW5^R#,A@WE*8=S\0E!HT@7X?:AIA!L#:$/%LQATGP;XL6G:%
MO@ >7(")T\B7X82Q"H@(B8P22T"8#;^Z?;ITY M+D%^K5F=4;1:P#_!0V"T+
M(FL )JN'Z<],-1&!>W@XN95['DR3$=VL=_-1A8@^U#-;[H(N"1=U_PT;PIOH
M>K@3EZ(?AC5* :V$5LJ#D!U6F<W'064QS"\(>S8C'WVPJN )C:V0A\O6P0']
M/A\%S*+G"^_I/.+=$A4B%N#44(8AH*)P +=\SX4'.,Z8B3OACUD+%4YN48CQ
MF(=<501-D%OZC*P40*V#:87C6O0C1^4-M<L=]@$/;?\SJV_7*XE* A(&B&^$
MQ0,O37)JP0D1B>#C8B12WR]*7TX@A #2%//#)*)78NAD!>B$U&T'MB<8MRR@
M$Q\'1Q'FH*[M%GX++W/+A3\$L ;X4[-[Q&S+&P* QR643_ X8.4(RC[K^]Y]
M.(A_KH"D$K0VTNVI%#5 VL'$@'KU\XP5TJ^USZ7XLD<OF+F^Y$(43_KB&6O5
ME\;6!]!NMUR/38^LE)VETJRW>V,UPMV'E<.%XA\OXL]<%5(_FT45R[E7Y]16
M_SL*0MD;/X?O=%&@%9;%/RLR:\:_*'A6T".^T5C=5CQ:@21AU.ICPH)_#,,W
M")UGVSP%6:\$VJ]1(%T1+&?J/$/KGEF1;,/*L9./8>*&B6\0/I_,TIT-XWZ4
M<1?4"<3@_$;0;"I@OG:7'L/ GY3945#02\[V)C#[ON?_X#&J_M(D,BS]0 K-
M%UGH,QPQ1L;,EC%[1L8\>SK/!G.!F3U&WTG*RSK[37MS_)-8P[1@-!DC#Q1O
M *Z+8>708U&@?)NP&-5&,DSZ[<6N?73YX[N<,;[\7L*KX;7,A>UZZ*Z\DP%Q
M<9>[EN0..GVPDPA>C,-';.[;6#SEW4F[.#>'U;8_\(^%;LJGN\W9\U00SV8H
MFX);2\>N=!Q8.ZH9G!\ZIGD8"FS\@N<)1RO# ![D\CX%2),:.AX$8-[C5_%Q
MBUY/4!@'[7[\$N^4KFX"ANJ'[SG,NX.UI"B6^L@C@&F2Y\!VJCL?N@DFM;G?
MY?#8\N6#(\847/Y0VV7?*VWL++]?W\-"L(^X\727.G^LZX"BE$'DGO2'*L8U
M@G=SO APG_)^;%HQCVP9ZG7EHUJ+(_#L_CVY[(B6U?,;^#K/;Z1 /W5X_W6T
M[GE1J9>AJQ^60*M-5!3H"@;"<6*>SCYD4LG@&6DJ6:W>+6*4'V?F\?Q 3L]L
M,W"WP'^'ZW]5Z^^Y(ZY[&QAQ;1!+_6?D:O39KI:H07*),,C!;)6N]KEBSDJ,
M6@75ST,O0/Z&N;#.6.D# O4(.#'/M>-^U']'U(=0/9[W^_ @)(,AI5OK4I/9
M[[!4<4J Q2D,\(EPGP*Z/4RZ@2<%TW=3F@$?@8+Q( &/!*SNOS3FGE*& #PQ
M<J7"Q>\W,O!VX&W?V\=;68PN2#&X(BEPZGC\T;R"/>RP9@L+%N $OVZ5@3X0
M'/"XO:TO]5J]4H_1-U[2%P;G[\ ?)=;EJ#^AV(1]68X7H, 9 8XO#"I]K\IY
MG\AQQQ^GSQ^?_%\[E?W=M.)GD[+<L Q!5?CC1KTH)$64-%+<:@$6%0.6TY7G
M. :9U13HZH1O<Q",1E>IU^0P;*\@SXO>1;58;;KA,EWI?)2K@TZ00[G6Q6F^
M,3MLW_9"?<'6EYW#TD[]L%3=W9G"Q*F#?\6^ "]:''!\V?Q^?G+1:;/61?/R
M^NKRNH'3H[[^Q:Y/3D^N3RZ:)\\_*6M52&"V,KE3U&8]2/M!"OOK&) .-&'7
M$AUXXU<'$'2YU*HK5,]UG@P2VG51.PWO8<R">&1O+H>4C,R))%$T,A*5)],L
M.Y?\EB:\U78:F 8#BW:U<9 \M& Q1-AJ> @[%X)T?E@ZD>8 $%CX00G4-PE\
MX![X=KK2(.H&XN](;X"RA%#@@98GO%X)FXHPF8$L"C0_ABV:.1Z[ HG)6JU6
MDHYW"D?(</Y0A;4Q56X24/D%+ ,JM/D!/*2!@FI4JZM$5> ;H&W=QZE_ NZ>
M?6S3@R?B<0]LNZ:$"UCMCW2<66(JWD*U-.OHB'KF&7\O\]2Y_+"V^.C QT<G
M/GW]M(QYQSKQRD$2)!KQOBAW?<%O0<.$S1UQYQ[H88M]^O&E_=@@R3=XY>N4
M!+Y"-[H%6LB_#)*__=;3 7DH/RA9M%;_S'*SF#;VW./12&I\$,/Y0>PD)Z&2
M@43J#S4I:%-QH=/X>G;"+D]9\_*B@UKPV_&8M^U(#Y>@6^?7K>VM>:-\MBN'
M.Z_1N*+HC%^DGP-G Q]U]9^N&M>=FQ9\DW6(T9/ /-1=D-6C0'&':UDK<83Q
MQ1LT[%6J>W.B\%37_&R-#I:@GV?4Y^I/F]!X2)U&7@:SW@802X;5J^0<>L<
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M;J6^4\COWD9:= 8R8 W7C;@#>Q]Y?HC- =%F4P>-AEN)>3X+IRXL,>E:3D3
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M.VDI6YKFDP@?>R+8,SJKQ[V?+UVPAWV7.[\$T6B:.Q[L_OP90Y?E@=I*K0[
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M#"4J]8/;DJYA>#R5N&N: F=R/ A,+*O)EP &PNF58;GB'KD1UL%CUP<B#E_
M1GSU;I1+:-V4M6:B6NWA\[UDZ@J@PU!_29WC<%@8P!1]?K!&A*A2BE23.CT
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M*9 G)$TV^0<I]\[$$0-'&3!,#P\2_,&'(V^(JTP#$"CHW%4A8DF.<3A D5'
MK43[4!%C!#P9WAGQ@K>[T;"K"E)392:Y0[T'2.PT\LEY."H@M2#J]T50[,!
MK\%4N50:1$G0?V:NTOH%+1+XO'#VX=NDG>2V>C5 _*JE6PY]J7C:5$1SO0,U
MC62KMH=1Y@##?D2O$UN?X-"Q?Q#)H!=1P#Y-PP!VDR3R*LQH79^K#M<YKEG?
MFP"GXNW..#6]56]RG=1ES\IUTPPA8^$ -0MY1V4LD4]["Z8%FSV$+0)]HP,7
M,_#&E*$("N<M<0K+P^A'H%B3+X1.BAOEWT'!)0TV+%ZA5P'L*5VMYWM#AEU[
M4/Q@HES_TVW_$UXS67'B]J* ,O)(!<8XE4^>7^)H29)8G!=*%[D>O:U,<7X5
M8*;Z%PKRPH\!)B]$%,7*I! H+03O1>\UIAA%J@:&@*NC1_E;=/9,)G4I_[L.
M7I'H0@])B:35L(N)+AX(*_R&7BHBX(CZ"XT_N)%, D\(V-:-PM2/C;CE.V.-
M"!4=.+>\6PFL%F4!5BUIU8*#WL"#(:=<AC+J)930D$L@W:[#+6- 6B^M3YV-
M(2&K[:E#6S+G=.4(O>5J+WZ.K$NL7L_0(.5S48H"&E\](K)@!+A!P42@QR'I
MD:AM$-1R29<I/HE)Q88R0Y!X, MXJ,N\,)X &,I5HDA,\!GG@D;R4)5QV9I,
M]>HJ[,)+WX^)C[GGH0WIB)"BB)2?0GVDAU)Y\]+#)YAT?2EZ:7I,A;4)KZEL
MNH<02F&2O!&Y4:"R8I(X*KRK?0PJ!6XB=V'![B8SS-(4)#MUG\0*"VAAB?*3
MII Q2A$,="05'30Z2QBT4.I +C.V14_K.<DN Y7\XR:IX;C5/44=I537&WD2
M-4U%5ZFW**\+X<N14#&931U.P\'#[D_HBDD/=9 $Q+44G:<4"#!T$]@15B6,
M?)(P8VY* .9@M<&^*(T MK1;_3GO@R*@<:!$#W5F3*O*N#94WE[LS""6K93$
M3)*PQ+0V+Y-"I5E.QNNENVNA+CD)+65$*K^&VK*.8C'@2M: :I8HK2S(B# R
M8G%S$XZZ@GDATVZ[B8[X<= \>7\74!"#WB6M&-.N\V=% +53("1,-@?9_&J
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MDG[/CZ\RNE<D_,O ,B,.GFF%D"+'((N'4I/>)'I>O3LZ/GH15;VB3&^9<7N
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M83H0U_:N%=ER+-Z\.N#W7I Z@(#7AF>:\46G:YND%W<NRC'=3E*4B=<,T-I
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MF8; ; C(LQ$\,+4QA#L4);':@VG).M5#]>VIJ#^K]".4.QD$#(T<K-E:BD;
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M- YFO1'&%I%JTA\H//[B0X-I=+9O!PB]?NC>[X6A%GL3SD[V [=)O\RN2&A
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M;;2WGP7U5?UI:5/0UH1J'*K_<DRJL]7>U15A7Y-OA\NL[$=_3LE@33DDZJ[
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M&<O1%:C1K4C_6Q8F>G65715B/K,=E69L 24Y4H%%V1C?(@L<JZJ]I?85MO7
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M!;Y'6<Z5N9,U5)3D_20>5)W7PN(%"XOS*BVO9$^3<RB[32E^MP(H8C'_#+H
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M2+8),N>%80@BVV3HVC,_B, -TY)%*>Q^T2KZ,J4]D][*-,^&J!E#QF1>6E7
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MA3SZP?*16'R__Y"><7-Y64X_DJ6*[5OTOJVY]VWO+US??;N^;+FLL+Q&"X<
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M< L-P)?G]TCK^>(\CF^O^XK4NBV_DOB5$E!S4(QNA'QAR,GE._>?P,T5AN-
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M1FSM46-WRVV[6&YY6"QP<;V-S^KD)KKF*W G%_2(3W5,RN# ]:<]$9IB/"D
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MR%_4;78'$,X\S54PV$LI/-6%0#8AQ7!UVPU,/%FY!^#MD?HPY+?*;OLPR<2
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M*&LU"-5-I-XF",XWJYQ ,%@.J^-@AG,]A+O)XS@!\X8@."]3CL^?2M7@L[=
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MF1.7TK'J8]F6,/B7]:,"(Q!IWB9)[*G/X()#GGF (1X#A(<O<O-49$7L;0L
MJYG<OC)8FO5%FC//GC=!%+6[[5^'?G26[UFGQ7'*0*JKU7*"Y%0),3'+="U0
M 1T6FJKVJBI8]W-,(7+@#LA-IQ\-FV%X,83'^C3A6.)56^47K<!%[<_[.Y/M
MQT&OGS2EZR5]G)ZG:4)HS!2''7E0Z:V8<<D-]VZ \2@TSX8 =8 +O"8E3(3[
MEE;FBV_)Q2^6+R,+D4^86P'7B3+E#182XJ:)%1A(387C*=]E)DE:4W!YK,FY
MF,76E0DY'!!"TFF5'A,LYF:QQQ7DZ4F&:7=1)"S2-?G%^Q1OKAM:(@J+I-\R
M>C!JM*&Y<J&EI;1%54C?$0%.RIT(.Y([?CR=MC9(%E@!XV-9<$X?JLDFD9[2
MVKYT%X#C:7'A!<+L==\@2UMA-YRH075<JRU'@@_:]M)+AA7;M!+4H]P:TXT3
M$;+/0CNG3&=1+F3 ;+#$.'=@I;Z2EH%N?,YMG.ZS0PP[S8)HL8:'.ILE?5JM
M5_ '$F$%N'E-$%J#PN#):H#C>^'$#)=C@1Q*RB\7;OY\FY*M,VLW%9,JRU B
MQ-/!X<RA+I7/J<A)M.INZ@J]86EJ0C4'5ZIOBL%3K,ML?))@\!F%(:KNG/H5
MML,5BG&GD=AK?5? ^/5L\.0!_#\A:*WB&618& E#(F.U/I'"\Q'%4SMN8S"T
M/T:AW8&JC:9!=\8"SVBM!??-)[3MUR0._-3$7CDK3THW YIM=9J&CWN),H3]
M&G>R==,EDTXA3+Z1<M)_R!2[F2$/V$ +<Y"X3[U<[N&O]&8)]SQ$I\ >;39C
MJ\,6L :47>*<AC=I'0X8)&%[:/(^(G7BW\0NL?[TY!I7,-BT[2,BR^O\?<'A
M!UYFMIQFOO?DQ'69:JT45\L68FA"Q+85=F%CG,1U!73+2!6MY0HL*[5<$/MR
MFUXB*5$3@W=:RJCP8*HKYKG)N2$TL_KA0K,R/B_28Q4[78$X):PSPPC"J5@#
M8!\T8;YBLI?72I;+Z%YAC25BAN(4T+M8H#P^D-<[=DD35@[8(+2OICJ*J(5[
M;&NVP7B+]F=O>Z"UW!$U,L8UR8EY4U-O-LGMHRQXQWQI1,6YY&7;'8^E]YZ@
MI:AE;9AOG&+ERO] ;=:#<APR_$2)9V1D*O'DN6?Y><EYC$T<&R\A-78^JTLQ
M]QQ*UC\SFYTILXR1!'L!Y=J..3;D,+,3XEY.IAO[2<>BGUMNGKRXJD\J(<7E
MSDNL<4NZ"KLHCS_NR29=+7+OV%[9E1TT[&4<*M]R\G'TDK<YETNUETDF/RFD
M8%)UV+%M3E@%80CPXQI V:19\P"A 53#P/6F95+S+3898X1'PM4"O$[DMV52
ME[_VA'8SR38YYVB%>!G*[D[\4$HEWA3+OA60D#"&J0>6%$@!).0(B>LHI/SG
MLL&.NFA/%@%-9_5J$44["59E/3,Q[Q*802*[7[1%^7<NKNWJCCF,R>)&\_J>
MV;[93W/>C+>^&317_57JZHC]F:KY,UT):+I3NCT5]AC>3PX0V9K"2(#[3NH@
M3H@DXH;;1]=SIKU:%"=Y(V4:Y&)V,IHPMM.Z.;4JVS#R9=EQRX7Q=CL]=L>B
M[8_N?+3]>G'D=!<^7[3]2XP"L3NI G#T^R\===?E,6Z-:%^^T%]<]?+4$DHR
M9T0[C$]O6<KO7QP?P3I>!+.>#3Y/!-*DH6X'G9D$D$RS+1T?>>Z499!<>P ;
M<)P1@)ZZVJ.BCP28XJ?A$KQ0FA+D8X:2J,V(MW) N!?[OD>B_?E9L9;JL0Y*
MZHA]3F37)S[@Z=(4[>$LFZB,C.[2$$K"EV_]W8CV3WC^UW591#;-4N+[7'S+
MO!<(*,#Q,W@XMB,A9$G[B.W/7D2S(3D(6.PTG^&I.C70+TPTKE"8U.C)28.H
M8[%PX"O??X]*1WY^<21(::QWQ,+P<7LK8<RO#[Y^</+PP:.'^+#]-,/7XY>(
MJJG2GB[LE7+:.])]$*M/##5,K2T3#:VD0X!O6:P;/N+(&M*,"@+(:J5+Z3!Q
M'O'/?ER^6T/L!Q>/J#DE9 LC 4^*G)T_9NWCP"406'.FS).""+#86PK (WD=
MU^6@A6PL8=+N[[ ,EQ0L!&A#BNSEG#* OND<DA:,>\Q[$-YDE5=T9<MJ26>M
M4.(/X'W%DL9W@@M:MDF3>G0_WTK< 0LI-?=DEDWD\(>NS@V7P.]4X+EJR]4V
MBC]"W12R\$D"TE_5I=VA+#5]I0&U$=70NI4,AS3S-LD@D!DG)YZ@@F6=%(=:
MFS<)^'/[4%*2G)N,(2?9L7B*@<5AT*&+Y'!O!2)=,_#_4'T,8''<_D3TQ3C%
M)_V_,!AI8MZ*1+=%X$Y+P)%B=5FW^/6$.]IJ**O@$HII<E57R%HXWG&1,$PB
M)K.X9-4Y+JP77>.-MDSP+F,[U2/P*PQ%(0=].!$X4"(BXYC$7<66DT\FNA)*
MD#!LI'"^-_W+4:'))3,P_"ZS(.TUL>Q7:"$S*8<J@T5*OQ#YL#3:.TG3FEHI
M64?NW%UB$<#)47^P6=(9=ZH^==C=HRK(;::J%S2]=W11.[K-W'8I%2%5"7MM
M:TI,&Q],RZ?IK@G3#S7)IY UUZRE_#"+1"8[7M5UA'U8>.AO-!L'W+L1DFV=
M6X=;3=E#@1M*O(A[IH*)\*(A%5E%WEN- B$$2J*=JL(T&3S^O(LW3A9/PPSJ
M**K.=38:O1W5;B?UNSO(A@%1CL_(3X*0XS@/N%11#A9.Z]#2GEQFSYIN]*1)
M3/7VXKV>EW5;AL?F M%P3M_M!C31>3RB5/H"5_&85/(1P+K69S"(782V%'Q+
MQ^ZYY=1>-Q3G/A9N=$WWI0W4Z,@\.CCX%H;(\]?'KZP9VASPX<70.XC!2*FA
M7]93I/XNDW%B&\1M!S@?Q3 +S(RQ2Q6358<A5V3S1TTP?GB,UI.SQEUJC5K8
M>.X6=3C?L%&YV[?T6\$$J)V7(VOR+4C"@L01WWH2NG@[7&,'XP?0VCD 6:@(
MSQ$@"LXZ*'.K%YFCIJ*[**2YRT0O!R4IB=NG?R%54C1KZ +6NYI)=.DU2B]*
MT0LU;Z#7< EE'A3*MDN;%X?QK=.?%YXYAGZ_9<M2^HJ^\@>/3>1T*6+V@+AD
MDW,[/2F=KN'N"".34B<3W8Q5\G!W(U9W_!UM>[>.[).2[VC5,YU<2S*.3LE<
ML>PU($Y+5YCLLK(2\4<7HS7UD2=KG(MDV.6(%0!9LK43&VI_$M=3/2'Q*<)M
MAD)G/Y0\1KJD: WK0RI^1-JU-$@VHN5!N35;9M3T$Z:S_(.Z.."+9X4#<'#&
M^EQ 2<J5[YJUC@<_:!ZQ"MY&Q]7G*:\>?3N<@--"Z 2XUH')0OE[&7DN/;(K
MK0B/H2Q,J#KEN)!%6@!IQW=2:^F%R*1)P(1A8X'\\HR%9SWB'C3G:;J&2Z6V
M'8W@U #\(^V,A5';I89ON0",]1JBW0;Q$PX:NKON(;3&;CC!V4E9I17B+*X]
MS51]E6NW,+S'5%+!(4[3>SXI/Z)Y29VRRP>-;JCFU7@OGD=^^"@9MYK"7!+F
M"XNN,FP7E0R2\_#1;&"5IG;M(.J'W"6.H69CM:%+>"!H@7S_L)$LC*%;"76V
MZH,2XZ.ZS_&)5M2>.MUBQUMNGU/9T?M$< Y^/_V#7?SK.*$#UY.EOE>#":!F
M"!M@DP='F &E:IX9YFP4"F[5-(OFL<6QVY$1%N$)1QWO(I*8#-_KN,7'?$6[
MJD%6$U82)Q*<T^#!6MCFSA_%'BA+2H0NQ!=:H'DHE:,ARDV92[X(P2\*MYAA
MS'P>26)Q^I0_P8AD^1R1#%S<M2*AQ[<O;7E;5,--(7H[FC*DR6#$19<@62S?
M6X^3@!*FN6$$=K_NO[UA(]H1Q +/D14$!97;^M@5C$J)14])68AMSJ# P9%8
M=7C"'IXPU5JOZ2NG<PL8EEI<D@;7NL)0)NXEV;")<Y(H.Z]70<?G"HHO(@>R
MZP\-[ZA$/I!"# :V9T=\3[QJ$>J_223L#4?"5*@[=A\\;__C6?;K1),\J<KO
M.S77*>,.&NI-A+R'93N&G1)^N!SL$"M57C!=>'!7VZM^Y7<5PD\!0-RB/+TS
M)'B_](T7D-(!*BG5$:\O+/I$W:4_4'_X3\*7EL%<DRU0EG<PB=727G<IV?]-
M4\+2&"/%89E1-77<]$S<1!BKDO90WFXZ1^EGN>Y+*I70S$%0ME0'-.>XA47A
M'>1"N_N:]Y<6:TA A(7*LE@@.(8R!-A,7+5>C"JRQ+R:AE"G(Y/J<"'Y-.!B
MEIC-0$F;*5Q C.(3HL9@4W+(W>,9N?BMB652JU*^FM1]9:[$H>WJ!HS$'C67
M@.0S:=X\K.J@\#A5F5@50]-I3,H(/(D]^;P(EBN#,'ZM5M( J_A G/1E;+24
M36XTYFZU$2Y,/[D 26I"RL\8:JH$FW[\[!QT%[4P.VS39@Z7%  I4!7ID<'N
MHM;#]BGX;)93S<0%X:#SUX<'#]X_C//0R@3]9MS4,(G7/QUE#M7PSQ5'=T,(
MOEJJD)L\9]0MPR?HR<E,,YPF(W?V38>4J>S\1=9@I(WU#,=H1.-/L:"6XHC(
M*2[H5N55P=$_CY5.D .=8W,TS_>7:G;4G_9D=M#N/25.B<,G$>DDIDJ.)KD3
M"0"-:UE49M"^9(2O)K-&#)^/*I$@F__BE8@9"[-H!5"+1TARM9NLRE(#2CIF
M#N!6002OO(*S1K^3^B^3@,GH*.A%%D4!8#'E0Q<*JTCVWO6H.=/$O44,=(N!
M3QYN9W#$M8L-3:9O(YFDE:Y,[*S);I9?MF_<!/G#9@6\D@3F+YL@,3IQ >E[
MWS202EL9&5F.^+/=^1^<[I/"^M!Q]BN!?IAX)-(PJ  .CH0%6=5;16U5$75&
MBS& H/"@*1N_HL#'=FJ5@])?IO,B$E69P&B"KO6.&"@M:A M<#A>L\MGG42:
M*?9N2^V I9'']M5@B?B\SUZJ:H3H?_7B99;4?H==[X4ETE&/30]7!YDB2=+"
MB_""]/F77#.@"::OBAR+G*L[*/S+K0W#3Z<"+ZR!V4)W& 3I7"6L5=5FLZ!/
M7$A?TUKRL-)A&H<G#+Z4M2=D3XUY,?%(CH.ZHA)9M<'\+77SZN<7PW5WM\U!
MUT#X,RB17Q0=.,YK/YAP-=DJDY*3UM/E(9Q;%.]YF2AR3A>"!H&&;S@+F(?^
MECN.A='#TOVO/NQI$/!/)P3\HLF7W82 3QFFF>@A;ZG@4$>E$QC*(*G,=1^Z
MMMMPB61"C1)&W_HBUGF]-R \[)0Y]5-*Q.[MHJ35\*C'P0[/*SDU+"\5V2K]
MI\]J-7B@-;%U=/ :)X-W(-+)T!6%B*K,CQE#EQA"?%^3MGKAK'R68\J:L;9Z
M)==RV[_.+LV$2<)%IA>%($9QJEUO/UI[R&"+ILB38S[ M,@QPO-8-11TO(P-
MO'+TQ6Z#:J2W5HN/?5UN'[Y&/6LTNOICD:^Z,UY1VB&KL8O$=M 3.<U:2@H3
M5W8R(S1 3R*COAA/E*$-P(<I6$6 PHVP'P<!V,65 RZR;HC4+WI3RM+.Z;9H
M540L)C (X0N;7%AH1,*[_ L8C*3_3<$=VQ/;'<MG"[L+)<F&I:,+X/I79^-$
MRS.<^ J7B@'[.ZD@DLC"R-E'(,",1MK I(P0$R;CT1%9#-.]13'(JX:G")6-
M9-)4=&,=HS#1FD:^'0S0@)<.;L"6.5G3N,=U\X-&\>.R@Q/+GNP2XZL)SS39
MHCGAK*&H-'HP80E0V(@^<)GQPJI@R*;.U C7,C#5!-!">\S_++FPE]?J0CU*
MF#PM \()T\WUZ0-42K@U]AOJ8XS*6?N-]:<26(_O\Q4[671RR;4]I<\_4H1$
M@$Y"?,3(\:DJ;^D[L8ORB+[WW\)F\W8;)K-V\6-8.__]]HU5 0E'1B%3*&),
M3,Y&9F9-%'U\1Y0R)][7E CDWFCXI&"*'HO8+Y)Q/&IJ#\2,2?R4@,H=$A)#
M2VH(R8VZDV-7E!W3$%/W"<]6Q[7),\_[">',O]?CHVTWK9I'%8GC2N4V''1A
MT2D-:+&@@L5O*=!+@L;$T9*AX8$ G2IWY5H+3XAQ5A2.2%MXA_9.6'1<FV37
M<YS?&)\T,;"=@X)#K$L99BL86)-#+IAI/4I0>@7D65B&P4;(#C@[S44[DAH5
M@<-*YSE"?MTQB,&3NP(QN-+*W7T\@7:B04T8V^=:/$08&^[".*SXBC;Q/+=&
MY)P L=LX%#)ZH83R95!H$XPB%357,V6NP!.6LG]$23)(\8PR/)^G\]B_O(Z,
MC:N2WLJJ)1.ND8%2%'+477HQS'0[)?91+R"B.E8S.\U(M=V3?^#G,O1?"W*X
M8]B<*;+\^5?%KB6]&R+E(/LP$VVAR> +:1^:G/2UEOR(J2 #F6@)H.U;M<MF
M5)]#=P <4/J2+%*]SXD@>_"NE:)!4,PG06BU#+0"2\N!PV-6_ 3WIE@6*M9-
MI6#0W*%?N2]V,-^KA<8^3#N#?M<P-%.#4^X63R,XQ:U+,B=^>4BX9Q+(M2V(
MO2&OQLLKK5:%IHCF+_M;8NT4P1LV!$DTRY_NI_.2YY[V.:8M-*,V-9HV.2S4
M01'!* LBL=7A;"-A[QV<X[37KR%\KG",8XINUP&+2X8]9IM1>A%_V(@_FPN[
MYQYS[4D@7;KD%9%TC#2&ZS6_VDI5Z4?SO%>TC[ZX!!2B8Y>ZF2)!!%"6 C4P
MS&,((LFE3--<[<]^2D$?NAG6U /%S2[#IM$7,U33+-.6K[6D[ Q9 *0V3V*"
MW)43;Q:$&&$P9/H"Q4@YB$D.#P $D\[T)&UOH<F*FC/3Z$+? T[1C(F1+R'<
M E>H(Q1TGC>*Q'FWBO"BA19Q>U_;S!&./CFXBK(]97'(YK&'?XU<<P],V>3S
M]_FI!;#:LW*SD=CB".KSHEX7"*:(ZMPF#*([%V\GOW-+M3C]:B>_<]11V'PZ
M=1H/(7YC@O<X)8[;+EB96&54&SKI'X7[^\2ZTNO<<!7JKP4#\$O?4394C\2O
M%4SJMX2=:C\+6.^.0?-<$$[(RRT/67KXVD7,Y?HH+3,]=EM'ZJS?937UUW#F
MVX4:_PQ2V^DH#(RI;!<$*ANV:!Y1UTI34$5=3>/' -Z=A&;LSYX7\YPP !'B
MS3Y8,T=;EXO88'EXB_NJ_%M?<*C'K #4P662=J;GBIY0UXBM-!#Q,QGS.$(:
MI!];MJATDRZP3$]#<96PKLID29I^CQI'0O,7\[.*YA"L4?J#)(;D)T6X*>9.
M?]=HTH:) 2.3H[-,_'Z;B\>,=TJMX7@21>0)??F%L$(1\\4M-S)^D[H: (#
MSRZ)Q22&SY'ZT4G#Q8(2ER\92*"EOI^1ZQLI"V>%R'T0VF 3^G9X(OBP.Y,.
MW^&,6)^](:JF2>DX9<^&@-U2XQ+NC+X;HAHD=05I;/==1B$4(J,!1"9'KDP3
M[4VMG$_%,"[7)WW3\@S.R8%CCGUA+H=Y@7_NY/ATYH:NU@ZKSE#Z\59/RRLA
MB?04DT/V4K]E$6(R(K(4 DM'44EHY W:6D.^Q0A*-F P;FJ*P2):<C.B)"ZL
M^M=PLH/[_8EQU2]!2?C&";4?[/1&;L*C!(H;MNLG[CC.)@A;5G*-7_9-V,'@
M8_TZ*D*0YG<'^-^41/IHA<$5*6V^;$W&ZQTL0(/;_[F.[1TSS=YR_>=JZTUU
MCK_1AX$O.,NE:^%.[+YI\LE3B9#*RU]';7=V^+[J.=UVG3UY,-%LKZ'O2L^"
M0=GO&4 H(&2LSLNF!A4PC,NE6, )167*KV)$D,2\/O%V3?S%B-Y$0Q56RV4U
MIVPZMOV'/[]&OJZ W]=AEU_^.GM1*A7QHX.#)U\='GSU\G@$'IC@Z!+PX[5!
M2G3BKO:E<_U.9E,F5"*B>[;Z:$M3=C48%-B1YG^1!RO!3CK3I?1P&M;"T3K1
MRL2UTF@"!>&J B1,3%S6JV-@V4>VU#0RT#(R(+*YG>:52'^'/-?XX:#W^<0*
MW_:;P^:>"82P=8MVGF^29A\3Y%Z0/+]&2A$G:HC5CRBU.6?-!F7XZ+$^Y!T_
M9(#-.'YG$2+TU%W4&[DT1V'75R@U$,LQ2+M5JR,8/M9N"A6TS\%4&NW$H.'_
M*Z]ZLC8?'Z(EYB,>7W@[C,BV -[+D?5A%=F=YG .?P%@(TR7QQQLR5IMVX2P
M4)9,?6U?--_)B^%R"Z/OZ'LPSX_?'6%5P"41H=\[YZY=L8:3S3[R-8S2MY:B
MM:/6J&%-[EBR_>O;EVR_9&'OL^W_&2]J.-E,(,I"WHA@]V='%NR@MFHWK"C^
MIA7I*Q8_TL+,S^J:.1RUG@"2B062(*HN%S"B=4GJ,?N-EU W;/Y!8#Z^84/B
MU#C5S!C%?*;([UT*9N=>C#<@S/CK_=ES8:7B<!9Q8JMR2W79G(*;3N]+C&G0
M2BIL]<= '[?%5/JU6I7O"VE]%E90:J;H, =AP[]FEGJU-\B4#6L5S)0U-^)&
MS7=K1&OT]:H0H$#Z$5=!8X7EJ'&KPE\JM5>):,<,F*JFC.%V1BP\P=S^>\%&
M4DYQVM:J+-L^V#&\22Z,NYRP/83S3P<:9G$>S.E\=*1>.>@Y V]CKL^1G5.'
ME16Z(H0GD>$OGBTEOBFI?NNST[\9HF/WI;/\*7DLP7DC7W2 "!C2_0<1FVD%
MG(>  &SN#PU_2N&R3+1%NVZG11Q>#35OM>2+%I#*S>C#R$IP1RUZ$U'=$H84
M)U\1%: O??/<E=N1.K6[0"$%!J"GV^Z=*Z31'>EC,8"H4N5C=;I*$15"T9]>
M%,F5%(MX$7)"CK2QFDRA0?;0M$AD8LE&2S1<EAT;L"("+89GV,NT.I3\A^3C
M.N C]IP%Z[>C:5YX]4;IR.2@$"M-/:]7<1O3\L6U13(U/+V@GEJ$8J8RT)]>
MO\@\^=IT!<FPE;+ZT3*2\3O8&DC&PA-U<@@G82'Q\4X6P7Q)DU\+Y6OT=4'Y
M[*]!&77^<=3!8O>Y4$)2NV_I-T>[J'4Y4HU01Y1UDA9Q_C'!)$"26C0-13FV
M?KQR<A"8V)^]'+[- !EV3$K?SRYR'6II+LE@'-8I@2KX+UW2,G+-94-"5E_Y
MR/T1PY[0+;H928?;%=J5I$%X)6K%)^K<K1# L8E.A;I^^.EUV$3<?9/;H-/^
M=>^B7%S>GP_0$;CLUV0+_>9&91EV)&=^UPEYMO_L;B857FDL+G,EL!-)2B%C
M&NJ('='M5)@'\>(!G3#QH),^PFAC)LQ/1T<Q/&Q&S+[+M4TDIPG-"#/A9%>O
M8V8V/E$%MG,\,@960YY<9%$;5RI;0.VT]I7W2M?H7:KO7G1^R@$6@I=CI\Y^
M.FJ5H06@8*8=$(?6\EW'9(N)$2?LY$.]:'9&EA+S46FTPQD>FU5'AT(1H);^
MI5_^V*\IQ=8R;<+QCS^]SO3;-J"H!(Y.F4*=<G$@6D)^@])\JW*06$DSQW_X
M3^=TB=?,UYL/[^3DQ&+8]$'\-]NDAM;XI^)A7>LHK3KLC[,'Y</Q<:8[T2 C
M V1&D X1>N31EUICIE"CH@IGK2BX4OA!.?UH9W=R)SCIM6-I-<=<H[F:6.SO
MVN,MRK;(DW'\^.HO7QV]>O$V$Y( :KV9GQ0@Z*F*L%F+0J#3:"UFWP\BHR[)
M[BI<K:?\8K%ME[UOP'I>-DS^)5\.\PP39<"J4+"CFXA;;?K:@_+\X>QH<4X#
M6]".$G)K G+ ?=[>_?1ZL+X1[-769*K/PSIPTS(\B!8*MV5/-X$J>G4(EQTA
MF ]*C\U=5M(F4I7 DD^*:.+(%@B+-"T$%\ZW,[0E)I]QM8TE2M-OYN9$G&B(
M420^)2,Z@WL1^ZDYOE3&#8X@,L4DUX[>9;1]OAGB+F8*DH%V-=,Z)!Q<\6Z/
MW@&F#SZ\TLHOTCZ++951@-9NZD'*]T \"JV1SY@(9XDN;FDV*''CO@1$?$Y^
M%SW.P?-SLDM0C!\M$AES9!^7UW#72&:-J#@(1Y9[7UD%']8#Q?6G)=J-D5?(
M9;24\2:\WD*PHTJ]P/=K"$!RS2\HP6[L'T&%K90=XB3( NH>S!E1]&2(I3/[
MLZ,5Q1=%(?KII&OGIZYWS[8UK0#.XA])5"P*%/='MGK_W$Q:'1JC$7,746^8
MN-&,)!,C4=:=GDX3HD-C'!+# \-/I=4C_B&"]C.]3SPK*#=&9VRTIZCZ=0'R
MCOAY[Y^;=Y\^SDE;0SE%4:M(R;;P7U."#X>I-8XD.:?D^B$DI4(QV >6=@7M
M%[?+6EG$BPLA4J:\7;?DTA 22]8Q4B4IZ3C+J>*NH-0"/_=__]O7WWXWB 1I
MHEO00TGD"!.+Q'5IT=I5' 9^H;%^QNJUH&G1V\./5V ED2O(K0Z'08C098_J
MMZ(X,'Y_5)5I*_5@7&A%JTJP>UWS>_I\3*M[/J;2!TU\4#:AHH!!%T(!#Z'2
M<1ZN'FK=C,T'<C)<G?"HJF8V )19'WY],%ODVW;V@+#;\9;/5_7\/5'3;MJ'
M^]9[Z]S9&GPCJ<4,>-+ZBB@;M"X(29H[AH!X>OL0$/=T Y>,0YU,W]OJ1+I+
M_I5D)&G$N2:!T!Z$S'RM-@WGV'3L#4M[YZ3#*6)>+V_8R+#8"Y2D#76T"*H@
M7TZ;?.W\.))SK]^\^NGEC(H"UX4F2\U<"E*+=!,1.0P:G^%NNF 'G#YU.F'1
MN3ZAKRJ"N8<'1Q)',C96>3#ESY12E2JK&2V'85&-"65W?HIN*Y%%TV@S&V[N
M&AOP[V9Y21A;*DJL@A2>JVT;WA?9RX2I4XW^ ?.B>:F)(!Y+87,Q+: CW<I@
M8H0S+4W;80@ ;!V\_U5]VDM\7>CW8)4:21[15C!/N?/7*9P:5-2:3*'.]P!*
MADY@5R6O)"71;^3#SD8+3SHK5OC#&G;&6318:(PET2>\3A]>J)$HIC[;VGQN
M_([/07VNJ:KA1?::,Z:];M@ERF[8>&8GO;1>&C$+[(<K56V=^S6?-XR4]-2E
M$\%LG+W1[GD_A%Y*+S/6F#J3 RP%6+DB""P2GYYLN7!9."D4P2%>XK*=]VVK
M-"T#G &/HW7!KN1<L]P*QTEKJ*!?W'DBY]FE4FM01FN*.4$&JW/]"I3^824)
M+D!5_!KA0S10VC@&F094>-]$]Q)F(2<S*?=;Z-46<>>EJ99)<YU5E W(9("+
M8J(D+EPS+ZIBEG]%*Q+\:165*_#_1E**CL$+;6$N&U65)\X8\,1%6$D2<L1#
M0;M2!G>G(OE)5[?IVIGS!KDE)1S)H?=8@TID-:%K'-T&[<YI"99S,J74H+JG
MW?G4W&YP+FITJ"QCKBU78GJK$,A7FK/XZ6C8%8AB:"CL85:;G.,(T9.="EHQ
MJRFQSP2AL"6G1+N!2QPWOAB.4$)UX1FBH!66_6I9@N^2U(+&OT5-(XU"5/3T
M2I3#M.SDQ^LC(U0GW.*\2&C0(ZG!J#6[UU1?$]YS 5.C8KX\:=;(@U'5K\L1
M!^U@#$J#G53U\/589+&C*\"(MBG*.1-WQ/49%3IOMT2ZRG&12* J87XX;<L&
M7)F%!?L@9^D?Q-.%%("LL\QX?_8]@_?(,\WT1&@ 78^%C%;PL]XC]CW!=1)&
MW!DC\B!\.:LO9MK>%NT!M9.(2A$R>9KB3,AD>)/Y24E(1+:81\.G?\#S0W7N
MU.M<,J]>@IJXC\A43TR>P&@L&-!*OU-#C"VD9Q<6JRD)UJJ3-I)H3[6"G!JE
M&AKAV+4[NJ%:#N+?!Z*'6AW'T./[JKX(FWQJ'15I[S>DMRY=N(18$4'DHO(W
M"0LK%Q^1,6&EBM2UI#U1U2*E_ZZ>22;.%WF^$IAU-[[GN78ZH DVYQ(&&R?8
M^#@:DZ(Q4<6,%\UAPKZVVJ=XS!9UP8MT5J^T+@K]S)29*CP#Q 41TQ>S=CCL
M&J]QU["O#%.83G'(>1O?GI\GVS,27:#WI5AJ1:_0SP_"X6$-KW?OPEKKA46U
M6>D!CQ1[WU,3W07HI[%QV#9R"[U,U/7FO8_L7*(TQJ\!$Q"?6^&KCG1N]S'+
M3]'P1RT?ECS:>4$^68!]2==?2TA4]%$_$?M]-I'*,480UH'2D(2./1OXVI57
M>KBC8@77I"G&M'Y3Y^QZ>WUUC-<GQR.OL>0O]+Y&L-?+V'#QQA>0?YF0[3M&
MX<.,L&A1#7>IKR(Q]K@QZ?[LUPT2C_."<Y,D96,+YPGU$946,JM+AI5@*KY=
M-36"IYWTS3(%C>R28-U%/?C2U!!?N=Z?HX=2RWK$2S"PH,23ELI16QBQRFKK
MFJ?L;H3'GC"]31 IL26,>K([.U[#  !P 1R;*#.>'AXG*J2(0EH&Y+XM-S(>
MOZL#N+.[[%6N&W@QVH]O'AU\^]V@/?AX6[(XIZ_2"6D?'77O(^EBR=D5U\/;
MFT8VB? -CGE,O<"WW_7T>](S_4 6"U([>-Z;5F%*/ "6X:/4^O0BNO5ZYYSL
M8&]R"?!X573)C*DQ-C"A>7XHUSW\_6(%<YG'6BXSW7MD@K%M?N<Q0++\='KF
M8I#=95!'=#M,IZ8.&%W^&H2E%Q(>YGXAWF;&<4I&,@V_\'Q#93,$5)*]?5:L
M.,D@Y]ES3-@-4YTE[ =DU2N*Q+KYNIRZF8<=/&4V<BS^-I,F9';\QRVSU$'[
MU0[?#I(E,9 3CH>O' 26E@3GGZ-O+!9IP\D4]4)Q**L^'T:)M<RCCVB9SZ[;
MOHA!\ OCY<90N%N^F%_,4$CX+RSF#.2&.D I1C&J?_-\3&>!349$<UE%OY7E
M0XU&@S'S=#3A^A@SLB$DJ8\B#Z!DIE&M<$%*P[5@R</4'AP^Y(WQ08?2]8ZR
MM!+W02E!R@6;06B\$O1H/@O7M]BCXG!JYBTL=_.SIJZ$&G!1G,0PLCFH#$YY
M\$@&(S7/#W+Y&2D^^_ L!\=ZFR(4EAQ+"$(^.S@X($W2.G+&L-;#.$\G4"TB
M?T#@X<&)6XL[!DIX=N= "5]F(2?(>[[(.*R1K2]YMO19 C 788"&V,3O P@9
MTF]*=-WV2Z;<)@ZKKF\J=VN"(!)R.JEQH:L>L60/'L<[ XQ$V?+%;,/]:AF5
MMQ5&8G@U5Q(CP_L>;?#HAW& TQ('Q*,O7\SU?3P:1>BEI@V]Q=E5:DZ9W&49
M$PT?&\UG;[7PCXOZ?#DEF;0D(R.:SR :C_HL^ZAV21EVAG)Z*95&O^QX$*Q*
M4%2!N@L!8D+:5J"U]<@/08L$FY89KQ&(*CAL&_X;7+_R'*S<DI9MC0%Z$G@G
M*15/'+%+_7-<74;*P."B^J@#/^[>,^V!)$[IQWVLS.+-:65VR15BH.I'6)WA
MW+A@''+.$>40$,2F&W:@H\XH\-OD@P9&YTZP.MR,\;A<#"R%Z6P'3=1_N2-5
M==JSDF(NY&C0IL7=U-<!@LZ>Z:[#9[D5"X\H5J#T/.EF*#!9BR;.)+-,::SX
MPA'F_;(8 /HJJXM+8B8-Y[A[,Y6'((^-@ZOH50\&/,FP84M.FP+!T"!QB1(U
MK5 $O(8Q2*]>[\]^KK7+G[9WW#(_/3 *E&^AFGAF5T=Y"B/,"PTC:!Q_&'.-
M;]<THYN4<YYWWVM+4@3Y>TZL_]1&A8HLNF"^A$=PNZXS C9(="G&ER63X M[
M 1V;ZHE^S<+>&Q=JI[-V>."C3Q/GS2)%R DR?>4'?^0HE"+GFBZP1':6Y;([
MBQ_3[)ZY$L4BPNY5S<84"C=V[H:>DUY*#]I!*/0#.B=:.MGY)-%,6>% !GV-
ME"P=#V>FH ]*46G&:"KVQEE&43-DA^2KPB68HN5!(B(FZ_.3^EQ:RP0'IZ7H
MT8![? Q1$,:*-/JV0R;2VM,!ATP)\P_.&7^LH!$-\M.I)P='SXS"7!-S\F(4
M'U$>NLG88[(N5=8GY8*RPAI=6FV9SJ:D6*-X9L,4>;BV"!SS!'F$N\35N Z!
MW*W'HV>RWH'DV883B"G\K:>N*]!+=2+/)_3$D< 0^:@KFI++H]8UM(5M@08U
MY6G<#*1H[A-]GVKRD=VV9H.>J3.$,S0<-Y>J3TB<8+QKF>_+<(3J== 51^&Z
M<8WORR/'>-3"M9 S\.C9F/UI$RYX4&5-<&.SV9_+8GY&*JTK2D:MOIH7Q,)Y
MO\&?L,$[J.(I@D6P),_RLLHOQ#I):D\OX[0?5$!9:1RU1UM.VM'H%>-X^&'5
M1T)X, ^))P%MC^2R(2;87!N^E^P5HLC)YS"MW?LR=IYA0QC,WQKAG#3E"6%E
M.#_7E7OSNFGZC3JV6"C&@;K#?QG=B&\BL0Y+Q3V*"$L^#_H+E!*1U3XHNE7G
MRN;L%]*10CL=HF,5G)RF6/8MK7X=O9:/;A&G+'@%:>FB.ZTD_E(SJ43]^@$A
M[$_8_[.$^[\!46N22P)8I>[XKZ!B!C-T[!Y@6& \S?<J&>WJB']M=[^ TLIQ
M!\T*EM)NH=!>!H/6 K8)MT2VR(^K8MG]\6#_:7CKE=H*?"IMS2>U%:!5/^:B
M@O##"VO#[4*ZPWE3M>C>&8_Z\' R)/OE@Y<W2JX[EIMK<YF[SNB#-E_2T0P[
MR:YM).K[]INOGGW[U<MCYDK[RXL7JN'U\^PK$#&- QJLI0$=0.LO\2-H,."I
MM*V4G*:]242DT1I(Z[(135IK+F)L!%<'H_K4M9QSQ%*MZQ+7*H>:EAZ=EZ<E
MP]1<;.BCB_KJZHN*6-FP-URB/!2_BW'++7&\W0SC"U]4 LSDR\:&R05'D0J3
M,/&S!S)+(.?8Q7GX.Q.R_XKW[5T,2(B(FYN(6S@1-]%";'+3:H5SAPGC'%UV
M@)QL_;FFZK5G7SU[\E0OXILL(:!-V=U_"CO^Z*DRNQN8(/SEEWE7D_%W^ 1_
M/<Q2H]Z1"873N:GA1FN>%+4PX5*&TZFIT:9>K?8HGR&6  V,L:E(%I"J5]M*
M#KAXB^'SGU&"";N^SN(U%9/E5A9R7 <SH5P9F;[$*7AV?GN#WBKF;!P??LWK
MPT_&M+#<RU[=HNUPH3,IF*) A1Z(?!;L#)0V<+\%CA]JV#?89W.+.8KPVMK^
M/V NKBA6RP;XQV @!>%HI!$/70Q^:^!@KG58;:W71N>%D$[Y]QE _ZH2 :<A
MH7?E5@=^5WR#C1TR@\E74'-Q854!DG1? H&7M_[,4S\[<=6TB)2#4LLB;66.
M @6.T6NMP<@IRTC-:QMIU'YJ)2;[@FB;(P$[ .3MIZ7/_NT[FV\D$/4L F!^
M6H.\U?3['4O8?W/G$O;_XBP"*:TN!:VY'_=)O=A2&TV(7*F[TH[PP=1UV196
MK<D7V2ALB^(]7<Z(-U0F(HMR4@%DK0J3+E[IV8:C0)%HS3B":[2_&I@??V1)
MGK\%V@LQ4U5-SX,JM?=-4IA8HG,(+UTG5?,[2T#R5;@<BZV'"UR!P!#P8DK>
M+7<^>UQS^_$'<]L9COO$GE936XAB,]I!1*/]QN4WC3#"G(+)O/$-&ZR>E7#T
M]W= -I* P<%]P. ?'.E_>71]^_!JH:I_V7C9\Z;X4'96(O FAI6_I]K:B[IY
M;Q!2;O']IV"<+>KU?>SL<UR%=$VA3'[]$[4K6%IOCW%OM /*=%,K!3*3V6HW
MR#Z26D/]LZ+XE/B4VD5L$=N(Z?[^R1<?C/JKN?YF1-MFF;27O^Z%;_X6 _)'
MA!QA6_S=U(,T8,>X%>_CQODA!\]5/RF&*LQ/VC<HV71E%(FGJ_H$4?H<^0I*
M*53%:0TZ"%> 0*\\*<[RU9*F0'EOSC^U.\8;PV+(JZN:#Y-F_G=ZO;V'\$1V
M<9:2?0@BC>@G[*O+OH/I$-OJ=80MGC?!10NRSQ<+O<-D.&@@:0?B5-0EQHEY
M=RQ4QM)8SR7G^2%Z?@Y]""%\*U)A^!IP;10D%AM\L22O94T>-3<$JR?,22@U
M3ZM2+:\?B!^DXFXD4JR>IE>$%<1*Y*9S=?2813WO)=((WFF.;AB^1[H$4F.^
MH$ORU:X1Q6T;).M<E_7[P.2UA5E83R1N^6# T8;%BV]S8 ODK&'YP^?,_&7<
M!YW-*1D5B^75$@A716)_32'R@=\L\3\76Z00B'^HI_FB_I3O)(!&AR=Y"5^/
M,%!NV067BRSX#;E@"PFN1$YQ%,M*].^%1,J.@M#E8*9>%(O-+ JJR$>=<1AI
MPTWEJ4I<Y>G;8DYS:^!<O66:A$:+0PZ??H?T]J9A8:/M<*2H"C)]#>A5XP!X
M43VX0ZX2)EA=^65I\G%@$ZX2.OG02K#MQCL5"2/TZ2SJ2/A>Y)C1Y([K.N7E
MNI5N0O7%;+D*XQ9'$\GL!8*]<1IDIISF0NLC;Y+VIO;^LE@M('?.P!3O7,%A
M)Y"IV=YR5-\19CX0_U*]F!S@'X%*F N)"^^^LP4=;_Y//[XYRH1V.5R22",'
M:I<553NNDT</LPBV=_NSHQ95]4 KR.G_N4:6HIJ]:H"VL69*E*5?HD*TDR.'
MVVL6S.B+'6-$9R^#M0 &DM_RE=*]OYW7'?^RJT\+^EXV^X%"B+/GX3;E @O]
MX3ECS4Z:.E\0L<3H':.^K&R7J8Q)0!JG)7'TD<XBD^,23WBK .5U+H>8UIRE
M$OV+A9'1*.<)&Q61SFC3\AQZUPRU(-%& _)*5Y>4S0QX73\\5U[8T=2C!8H<
MZH=-V5@X2)R*L24U9>SQQ&P.9I*,4!<E6,J0M@VOTW_BC+ FKV,*%:-&+ZB"
ML+Z*23[I6YHG28?S>G4>Q90V;\\\A1<. 1C"&ZH"F HH1=N9IT$"T:9"AMUI
M287&;)%9BRAN6A%OX!LGE1\<D?QFJ=W-]Q_.'H2#]#(LY\/D8X\.#K^U:!;]
MV?_UFO;+S9-;R5%W2D6%>])J$<@:88NTM'SD[W.L1L@#@DF3($O1L:!=&_!<
M2KZ,BWHT%9&V.SO\^F!OD6^'?1QSY"!92RG3J(;TCL)#O:M&!"?<%@01P%42
M>W3=%AJH>NXLD7,2K0JV"?>S *IJL<R1Z(MF5GAVYEP!OLT/J''/0U 1(IA*
MO.*G2?]M4Q)]M<+RG/E*=^XTVPH')R5: 6"FOO$ >/7"BS,=H(V-D, 1[1=:
M&,N&K2T)P!F90;7:QR/'76P(31,0!\\$L<>"R#]BXJMAK2B$&A'G.HFP09=Q
M9;==D8-1([Q;JM)YA&!C(G'COQVV(UTJ6PGLE2 C3=0X/6S#S%RI##6'V[T:
MXN3@$Z*20$-@BB"V,$MBY>ZN*'.!DC.LI2L,R-]%P(/7U6FRZ*#&!SF]Q=A$
M[5MN??6X=<,E781J*[N-';-P9Q],;L]#6DX4ZRX*BE1(-YMJ5 ^60[_Y!3!L
MN1X!&K?O!.C>1XIS[&&Z%=0H!QP7NNE6@$56R1!\_(!0%(PP'H"/,\$D/Q0C
MVY$7_O!\9*'>\K3EMW<E;3E2JCNCO-=0L9\OB?DE1L'=$[\/\CF<SL2:^0&>
M-@B0IGL,TIV?HJ"X?B'MS3-V8IX/?6L:5*KT'1&GQ!AKI"F/'R(QDE/-225B
M,P@.@B7/@@G9!$&'7E5MF2M(T>&^3FW!/P;<MABRFEGTJW*NK4;"7JY/^J;E
M.,,Y61!(/?(HMZS6\$^N=%I96XG\%'X6WC_TQ!L;TXYFG,>OAW2(EX'B]:-C
M>L=9+(-D/%,X<>&D&/BQF*_RR#?W8[$**_"^O.UA@5=+ZN"US,O5L"##+>92
M[NF.1<WH$5*K%E&&TQUNEMK6+B+BFP3"OYSJC.D.GU4%2#6  _#OA.,/(/9-
ML%OG_648,^NX^DD*\GH"]7=)4!>L^3/%7#D[P*BZ.>7PW-&_UDE]>M,.ZNLT
M1!_->(:#&;;5<:B=Q<5Q2$K T0CJ-2\40@-+F%AQEL6"4LY,BXMX:PS\\N*>
MI Q5&EJ4"_+7OBG;A9ZZTA'#;4VRLG"Q\ /7'^'/A!NW6*7R#>1-0XYN'$'*
M8J[1<\D?^?"% Y6W:-#MTF16YE+ .S$'(W9>"X\2MV0]W1!J?_867>?IV%E3
M*Z40 8&FQ'-Y(1$HLN7MRKWWY?S]23Y_3QYHWC,5<1Z6)3QE&6X\J0** 0O1
M8)#3Y\:"'&YO8\1?G%;(B2]NRZ-Q=.O8!]<&'$7A7FEM\FU<6A%5.(\%DR@0
MV5H!7A^$#,ZV;?ANGE#RGR4!4TH/4O[P+V4=D=D=ZJDP.-/P\62E&:=!W985
M!+F(PXYU]MQN5-V519F'Q4TJP/R#%_DZ6-91.@ON2K%#<:1[RQZ9VG3*@^8I
MG $1WYA_*#D+$4N7\959;$P9K9TFO409/,M3Q$)I&"W(^'B')?"7E%ETZ$9'
M 3TR, K]==B#(%SVYB8:4>EU6C>GDCLMUQO0WO%/S T]ATMGBQ->V'?JX9(T
MHF=@2<_8Y[1N?S!D>NJ\*03J#:NCWM4'FH.\,[-P"Y30,8@83WFKWR3VW^W6
M-F_=7>HKZ:+:;964*(]$+GX%4@N869*XJ?=VF&*>[N4])7XGS*$@>BF!88^V
MMC2$R0<;"D$-K"<V@/U0COQL7^'J^!G/(SECV2SVF/LFR,>Z<9=;1+A(=9;
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MW'\4^Z(A*BXOUM?%W\@L\'SF)C),7MU.W9#!ZMQ>Z?V],:;>_JLVKQM*DG;
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M4/E4)E!:X@N;" DSU8N+"=^QO/;CVY?7_KT5L/^$N.@5N@_^<Z*S5['E)5=
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M;L- ALB_"=*N_A:XF4D[KN_!!1"1A'1&>SG=EAL#@=H<!LHM @0ZWB(FY (
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MCX[&T]6\'=31?U\1 T5WWG8"2)P@=I+7D&\\R<0XN'L"SQ3U]YZB^AZDJ1\
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M^PW'*XVBI8VE(!=7F^[&>G_E9'23U*0XXV^$F,L0N8XI/&D="]!HD.&@1W/
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MK[>&MB:\KU&"07SRR!]<)@PF^JNS;=72+KAW]5HC!35(/#4W8555\'99O>?
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MV^KI&M*"9UHUMGT><#+PCXJ7(F?=:@\G8J*@NB</HT4;ZN1'&DEB!(XB^.3
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M; <D;?US)_,0B(7VM!CJ>&J9,O5<-$'"!Q_8X9)SL5ZHT8R[SW;CN_3\2*S
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M]TR\7DO2'$+,9U?W7$Z TNQP($:O#W\WD'1H\6R:)DEK@AZ<8\PIL+*[=Q)
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MTJW?!8 V&O'@T=C M?\$(<M_?DOO6\@E&2 7 YL,=,MSIA[PV9IWT1V6"8J
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M>L FL[[<U-E]&?$%)'='NXJ<'/.6M]E=5:OIO6X/YY7*J\-8W/2$BC@_VH,
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M$77U2)8;7L3*B;:!<I5O] _V8-R*S^D9TWL7;UQU"ST#G<RY[2KU:6UK1U*
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M<*HKQ1NH!-^$M\+FU+E;>?1>>2.-;&AVXE%XQC^D>ZYR"@AN\[7VK@;(DT?
MANA (Y!*HDO^.B21Y2#3ZOTWQ\V![.YJ!VH,+#%X+\EI!T 2"B^Y%0N37.0-
M<\E31/\.;5LY@)^CF1M40,.[VD.0]Q3[3+1D&&$C;^6K:FPMY E#2L;V7O9C
M9,MRV?%T"I"]@:ZTQ(N/(7<!VKF-P#.,4D3RNF049'*/G,D-.G"E'KFOFE9:
MD 5^,FMW*:E(K"!(=3,4&?UE+PC'J&#XD4\_"G@HLK64UDCDR &3F0TTXU9\
MYF_I*)8*O9. N7 R0GW=)B3+#))G2R(C,TW-!+Q"?$IDD$5\+(S_**J*Z;6M
M ?0S<$H,$;+X(GXD/BY39RIJ:(]Z#BM?/J+SB-(BW99#,??8:3D>?9)U,) @
MO,FF_WRK^/E$>(\I#,VO&JKCL*P\"LJN-0.2VCYH>_!9VFT,%#4,MENZ\.QN
MQ@"2&QH9Y=@]8DJ.%V<P*6<%O(E9N:B._ZO&YBR1>^+XQ_OW[@;GM"5QG:OZ
MB'?^BATJ:PDW2$L_T9G)D (/IV?,G^?-SS1038L"MK19^Q$RV04HW@A-VB/&
MJ'<3!/M@T  JQ7<5;:"KK]W-H2/P[).GSY:+%R1T@/:*AD],@MGAO,_JS=0B
M",BAV*TFYCV8V*H(P,AZ0FQR(X)O\UT?P(&F@*-FR/E>*[&AK.$<F+V.!S($
M,,FIUA K&T/4G7[4IH_J)FJHC1Z5Y[3TW<G 5N82-]KT$@KO(VZ;_%J'&\:?
MP&8://!<,T">2RI+<DG=&*T62^L&J51)%[7^(4?DVNQJPU#5/$T_"9\>)2H#
M2O2KU(.9/JV\%"8'4:?"E(CA'46DZ8>/@IM ^KS)"B?-7OZU*]\WJ%N38#V_
MBCZJT>U64M#^%K43:-3@';4XF!&:FUV!Y\4:N-P-5+=U3]DRD%4V7\N_ (]Z
MV;1E<&)ZS7L!TMQ7>FA1*J[1EL?)A=+.M%/KGB Q^R_>LR_"QYQ=/WD\SUL2
MPV^HU^2G)$/U1>LKL)MA./W*->1/O]H"G<#&#* D@I&Y7.QL)NN$U;IWO@/:
M>MDL!3DE%L&_">B=39A3B[RB^*"$$1)O'M2]WT!+E#R"AGFO)FHDXF'!CGTN
MM20F&I/68%R05;_J RV^*\FQ7SL<QV=_6I+9>O:).%DO^;K?^^M^H=?U8#XO
MY;K_J]?]7DT,RSL*!1LN1O^HBMWYIBMY#4ZE]%^4,RB8WOR!FX/Q1+__!$_T
MAZ4_K\*9 K,9]'%HAI1U/]] ]I$A68.<*8<661L<2M:FD'81Y!_)P?"=* P:
M?]M/EVE?O[QL>7SD3C<W_[6J%Q\/\G]7GA/_\]7FQ'^36Y[<W7&JPC,V=Q"L
MG'S(-]S:ETQ#1FK%]U<QCCO]F$L9MV17ED["]UPP8_:4:9CO\X7X/0T*U5QI
M1/*:W^@@;Q2/F.P36)UAK1R)K[18+EPB1K:T8F:IF#@WNGC2)6+=R9:2P0#
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MNFT 5Q\$FUA47R]-:-&.N@OO!<*:3>KB9J#STNQ#$',VK1T+D#L +#&R&>9
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M%M]C\5FDU'G55;0!+]P&L&I[V32T;?CQ^0JFY-F3)W] $_YGKUZ\?!XAS?E
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M7/PNTZ'.@M$-3>8L?AR:ZA^#;#Q+$P/0(/6,.\"=T+A%_0CQRR"U4U[#V%?
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MK&^"):@SV5R,A1-O2&$?<I/(-8K'7[6,6<\PW#XGBQOQPE;[/9)^\KGJQU'
MO=5%UA]9 ZE)^\G*./^&+LYY:^GW[^',#L[LX%SBR?D%_9L-A?!D .JRVFJD
M3E:Z7I W$_92?*$@'YX+AY4^FD46$A_^$M=X(==XSK6=1[E'HTZH4R[2CN/E
M1IVB#K0@6JY;!OLC []J=<U>[(;=EL:Z?/!HFS9B=\##,!QQI$?93LMB<!:
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MW1\NQ!"9ML=2?KWXDCY_RX,V:_(.9**FO"G)!Q/X1]G1E6HY<I&7PN+-0T
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MXCAHJVXRU_R@P&>#NK.3(^,/;F7&[Z/89%GK\[[LWU@S!((^0P>+?83PL32
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M.\/;."[:N8TW.H8^9O?[H\+.6/'@B_@W)W%3@V/J#Q*0O] DV#_U>,F/H>=
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M5\0'_;%AF*-_AT:=<2DFH?*]2Q,ADK;8DF_!L_>"/(8]5H0_7OY &J0]A&"
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M$@<+]T#=A82Q2^:X9T2^8S##%U___>7G5T__L."\&</Y1Y SY##&)*S9WC&
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MT[.O\.BFB$XIX%*Z'(PHB"3:7TY8'B,KM43%*BJ'Z\57Z5-2$^:ZM 9L,:9
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M$B8>=F>.YK9=DT<L2]>%N_:-B!("K,!N8>_;9\9/0E?@ GFL!>J^(2<?NY:
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M. 4($( :A,3@)CMGO2GO$R\7TW)(HP 5@+&O=?_/'9S_D^M/?F(FD,>+XR6
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M.U2FI'/)A=*:.A_*;YZ7'/VD!;+?5$PG:Z/HN]DE%-)Q<-P:."%H,7J/9+#
M154D-=;16G(1B8_@=K(:]Y.&X5LTMI#EJ*#1^L(W5B5*OUX=R[9-L5'BO/8;
M,7T^)E6E\&</^I6]I3+%.*X7_F6>,+;PE67)=ODT>N6V]'G::"\#63?PQL&E
M._+$Y/T[E9@\*/EV**E*A_9*ETM*3$*C"!0*F4"C0M@OQ^J7>8=W29%+^T#T
M4H#BRZ,QH-FQ2O[XT)"##VP\X#;T.+T$9EXM2]\N[D'R>AT;&0AU= 76UO[-
MT?C ?S$H_VO?%VE:]!2N-I*E:)2SV6U@R!,U=X>)2J_TE 6%?D3IX2E':P3[
M07&T]>D8J[>_]2BSD@C>0%1LHP$U/6R\@MZ:RB_J:,>JWJETUJ47LACW'6VI
M#]H(0F'0+FJB*O/XNN=H!&5*X*%6<#=FN,W!&D #QP_C"*>8\GX\OG^?3G:Z
M@$6B'\^$#43#K=:",Y@/0?M$XA".QBO!$S^' 6,P":TQ+ 8\F25X+FW:$\MQ
MPX@31YZ]L>$,7/J\3XS"-LEH>ITL>HR[XG-=(2L.PY:P.OJSJ4OE5B>60UP[
M4,)WNHB:B^*_^>7A8;F\C=;1%6#3O/5N@(<@TF>PQQNA/C\^IE6QUKL.>I)'
MKD6/%:KQIKZ5I6]=U>]03FZE/8O6<*/ENB*ZO1NQ?295EHXUU?3G:)>GYU!M
MY=(R2^(XLD;)2/AEU0N]_I!L%B?/*K 9SKD7Z.S)XWMDF 1_(;W1#(=HN3/1
MA3-^07D?[Q]_IR@ E%@3NZ;F0ERT6F!QBVR-O0@>2Q2%Z5Q&>2ZQ,C<&7("N
M1NJ=7J7(V)*BO+5>9BRNJ2ZOFG0]+MW6\=!RM0:7!KL)LAM-=:'>+S$I.5@,
M_I7EIB#>+2^"[$VT7Q:-AF+>VA(PX>#X/OHJ_UHH*S,8)(5T6[-J7)*#&[[
M52V']5<2R>9W,@K#5[D^T%LV#L]0B:FE<D9WU" %#R&S10N#')M4CY/,3<NA
M4$;6P5_"8V_YW$#C4*R27T3LK;1O8ZKN*^$-AE,FI ];]9Y3>*(#O^;*Z?Z9
MH2<&!X<N#SK_;=ZRM3W8/BE3TBKR-%]1C!U#MLPPH2R8P1;HK?3>CL%?_9*D
MU8)&*3J=5\@D7.^0VJ@CL9AK!2.9HX2@:BTZ\%1@-?8=)X]YN9/M%HDM3AZ1
MO.,V1#S(1;G\:GC;E+3#"T383,4>-UX>IM20Y<9UP)"XW'A1[\$NVGZ9<:6T
M[6LSXW.O!F,O;#"$!OH6>8E'#"GX4-:!9[!1"V^=Y->.WDI/?H)05I*!L/5N
MK&!9/<HQ) P A[UB;M#QV#37+*A\,VE]PAPLONU*SS,Q<QAQZZ<>J>3'"DF?
MA4>K'#G;AS$Y6W=C.6@EF:*I_2)_AT%DBK79]=RQG K<ZT#< UD>95@- %YU
M\#C;G..1!,UASCGU.^RW0Q]FH:I^#BQ5EG4CO&;;J5M@E"PW!!1YF$S:2I%"
MM_9#+*]8JSJN\T9#]T.#@K("O.\%<VMOABTDL#NM<<\5(97R1LA!OD9*27B\
MQS#YHH2M;#'1!:\F6DJM1'F%_2J@(\F.>?KBXI4(%Q3BBO,_)\[,><7'I&F[
MC-8L,.PX8S[3@FL24_FL!J^XS&?B!97P\8+X)4]2/&08^S-+PAD21DZ^DG6R
MVL1.)QA#H[$U!!Z.GO:O\++(#/C ^%_1P'Q@Q/:?']+NX%HODFW'P8_$>U%P
MZMJ+O3,"1Q%'="(J0#_*969^X!W7S^W7B*SV-M,[8"D1AN)5I'Y25M?6TARS
M@D;M",WQ<MF5OS"H3\4V2!?4.+#":TI5U[YJE1/M3]:/NGDO<$_T&18IV2'O
M295#:%7CT>PK0^Y=H\=ML8E@Y6IZ1L_@@B?4K 4RD\(U<TJ"EQ3S]CXQZS[L
MGT<06ADW6>202#V/KE].':NR?'XCEQ1VV]3%>-OS5"(\7JB=&2KUPS)76Y%N
M2[;1+O"*[W?&$JC)4,6:+<W8]0T!R[&AR]C& :A01#PA+H:P52<VXHKZE>IQ
MQ,(,L73&6]\]*?O]D5!N/3K][C 8I0X5A^[!H2S0CJ3E!$1W?$!T1WEW/C<:
M*/?!]0 OM'[,NCMLS5%GF3B+U;9()OJB]N,6YL"9/U)Z&/3%;8,MN4, T)]!
MZA_VP?WR0G^2^9/,/\:;\[D9NT9Z[JI>O1I77]OF"PM.-\_KIK4U=D&,O.D+
M>@%INZ'_8A+\=^WX3H)_$OR3X+^K@I]RG6."W+:J]/KOG(*XA5"_*Z7'#PZ_
M]'C2GP<F!3Z9_MPA/2=SZE_O.$SFU&1.3>;49PF=HAX6*"./GV%/Y-^L8RLJ
MX!,(/J3(:@X,^,;DW>1 '^^YG23^)/$GB7^ $C\?017;"7HE;!>CO?S8DH]^
M=F$2JD4*PZ63_#[>4SC)[TE^3_+[$.5WF)':395"H,(*03@"/QARGS#F4<B
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M@?JY@QMAZ6$$>)8  ,GIDF_UREMH,W=4()*G83<T-P7+!$OBCE%MN9L>7U-
M5,U;*V?$']L-3=]D=#H.,J4@;0BK;JF@L7&T-*#?,I(Q/C(DFI7R%P(*1/--
M0$4#;AA"2JS#KVYEW3YR)H[SYH;CC?95@G*?(+FJVA/LM3;KQX*EV[S#NX
MHZK^=Q,Y#\4Q\^ELT27;5<</@C(VRM1(1XTAP<CW1"$\9])CF"<A4#LS'^WF
MC-Z0(P<XB!KT(3D88A ^+( 4Q+)>9B(R/1]ZG=2.9;-WNGT)J;,E?3#J@=Q
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M<>F EUBCXE&DD@B\$0RQ#I].[+$5#+2@LWH 3\68D!9;8 LVI!<LJ!,$!O%
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M%](BR9<>=0W(5I"96 C>U5AU;F7K3=(Q_K 2#SU@.U:?<!'W'3[M$"SY%:J
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MARSZBOS@>W_]^?5+^M?97[\&Z[*N-_!\D/.9+P/:Y#WZ'74^(^DD$4@!KY^
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M3E56\B3X 9S/!_0]F/B3<&P6I 3!/! "&\;7(?OA/^'&1CL#.%OAQ+<N+&*
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MIKUS <1O#S^ >.C<?V?W3A]^=S.YW:VX/,D:_S@?_].UDGSY,;UHS3(Z^V%
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MP?Q>!_*6+/+SG;B'*\*LM_).;R%C]8L7#;>U=#/69HN(+5Q$;-L6X1Y+#PQ
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M'+31\7QN!;KV+[R*/SMXG)O&W+6\8.I9[D?SXE'DI5 4L+(PD*MB+C:D(D;
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MBZ?"[2X]L5+9<*!D9U8O#-+88L\L<F/KV4L&,CO."D7[0\L++-_CJ4B>8_'
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MG&F9I)/":R[E"P\6V[ 6P!$"8,1L"\/(L *03I3G,,7$"2[FQJ[O2GEF&2/
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MTO;ZJU,XEN<;<C5!J.59'LT&'@6UO'5M'N>.M=+]0EJ-#)P!0)0DI(U*B?<
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MZ7-!O7?X>03=9TG0;=GA-(>%+/_/;!1_=B.D1$#W/:#NDP>*R';Y_0S /L,
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MF?+HILX[VMZRZ+3./?1Z<&NCVZD-S=<F5Y8E_Y;I1.3@U'DW^VE#FR4CG%S
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MRKP6X'TAXBRETE9*B/76FX_%EJ]_1<@A'*V'AY ]H.3PZ:CA]TOH4R7*E A
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M$@Q*0T1FKX26C8D5969GJS9H-FL@J)<)A(P_+BR_(>,393I3R^P5="9[PAP
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M'P_6JV^S5[9F2_LM<OALWR6S!-[[I>0VC)S7HX@\WJ61%>]4&C5B0V9J?6O
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M-<Z<2>F!!JZ]5,K)ELI):YER(G*%KXGY7?B.DC3\8O9]K];I',Z^KUC B;.
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MSQ:\9F?IC0VOY*(U65/_;[_@JK1<6T.NK5PE0'(Y/!WLMMBMN$0.UJGZ0DN
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M'<^!U H:!DH1XI$B*(,L9X80#L$)P8N".EB!#QV$]R#JRV(G1Y#@KSQ:Z#'
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MY:6I"Z%Q''4Q#I/3;D#!,*E.<(?+D!R2L"ZL7)B=GIX\PQ9@PD!"^78NE2[
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M]3TC0Z_T7C!!I\&O6().D^1/QZ!O64$L;";NIL(+][=M*04B:G4[V2(U8*!
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MQJ9E6]OTZOX,77/%T#TT^K$_MQK%X;*CJ;&"![SG<1#&F,]#ZG<"V 1(PUV
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MSL(6+)Z8^S(0$ J >>"!R+<Q9[1DP+#2*/G -)]SH-GYP"T7Z<OM"+TL)]O
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M?)3 :Y-BO/FV'I<)$;5E"Q>5H3(U"Z*4],V6H<C600 #7L2=DZY8+ ;W.H&
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MPY1-_2*&0<R#&4O*4[O$I^J8K!.?JC.ZQ*>6 &0((%HTB/7%MWQ\*OS#AZZ
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M!SN;+N^LP&+HJ$#N-3OG18D/U3'9)CY49W2)#RT!R,B'$K[ZXDM\*/&AJHA
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M]K/)O"^.QSW+X>[^R3RB\=0QGN2;E1>A^!(0" I(4#00*$HMBJ,C&D\!"2A
M(K=0!K= (*@I0O$E*!H(%""5B\8S:\9??^J:9NM9D=G^@2XWF6<:5YU7J,R;
MQD$8PZOQN-J!L.3EO7H[(_D&/!AR3X35LSM7S#)FSJS736+C%+*!Y&*5%Z'X
M$A ("DA0-! HV"R*HR,V3@$)*$ BMU &MT @J"E"\24H&@@4()6-C3.)C2L^
M&V=>]5ZAM([8. HVU9>@:"Z60%!3A.)+4#00*-@LBJ,C-DX!"2A (K=0!K=
M(*@I0O$E*!H(%""5BHTSZD;MY'1 JUR+"NR)YSJ>8/_W^>(K._'"B'N68$>^
M%4^@K0R)5L/X)+DS)_O5SGZU?6BIYT>,3Z>"!W"%O/ $QRZW9)7<$8\X^^*X
M@@V%Q>,P?5/$KT/& \'$9"AL6]CLUHG&\_L73<K>11&GRA*0GU5!A.)+0" H
M($'10*"(LRB.CB@Y!22@ (G<0AG< H&@I@C%EZ!H(&@8(,$_?.@*^*_MW&S7
M8FR?84X?\,]J5DX99A.E!QG'02;DE%^+ZC 0_$>5CT#&C]R]Y;/P'3M0Q*U#
M*U)@)$YLZ >V"/[QKOZ.6<)U4>,<[WK^><IM._N\U/://([\3\G=5<MW73X-
MQ<?LCT\L&Y'9D"P]3[M43*=,JQYBCP>'O_YM7GM')'(AM2[/V%[R.]_S)S-V
M?!<)+\0"S($U%A,^9Y4I55%9 @K05!"A^!(0" I(4#00-$Q5B,M5503B<BE
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M#+.=]._0MV>R:\?1Q(4__C]02P,$%     @ X8EJ5&X9O0(+%0  %=<  !$
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M@L[U'1/LGSXJ]C(Q0"*&4_O$L,-=H<5170+]\P>&GA>2)^C//BKZK5S*&V9
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M;BLL):%%@%OD>0AM\T"5&EW+][!\920IIZ7D@ [?KD4#H\G[I>7"]T@L8B%
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M"__Z?3046I_Q3QM3'5%VZJ^(S%UCM:#6EYP>+"#00Z8;5=-)I5MZ7!E574!
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M5#OA3A#E65]8%7CY\FPLL1.U(@9^V'4"].(/D QYOD)"AC1I+=;Y=\=-?'_
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M13-LEZG:9./+XW19(V;12@4?Q!CQ+4)W#+8="CJH)>?4WK1E:8V/-^L58Q@
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MKU\C+T67V,?0"QC]X<TK!,KE\Q'[X?5?49@DL%'"JV'+QWJ;I"(Z]W-N,D9
M)=!Q$'#2Q%H\H3Q+ 7GET6CUZQDGWQV7!E1IV4G/:-3E5W_M\:LW;U_W>]:?
MBK^K^-CW/[SZ_NT/_%/?_^757UZ_[7?=5XA]>8]YBV/BR)E^I_70(61=LQ12
M,Y(9'7(5!/S*K4=NO3"XCBZ\?<C6UDHG*ETD1NSBMY.T<)I2,$)P*> LC) O
M>+EA\4/P4$F=.0H%.4$!F*#K"%T,H6#''>YPZH41#MYY<<1B:++R_</N0*#]
MT27>A'ZHM&*2H::/S#!U*Z>/.0\4""9N.(H"<%1=A>Z#E'E2S@[E_% 5L<LA
MQ*;:?ABW[6!V96MK=SKIW&QPPV-Z4.G=8S"_MV![3\&UXF+-LYD.6O;*3VUY
M1N6\AB\W7/<4:3P52HAMEPY/73(\[V;=K1>O8]Y1*."KJ%L<W\/J5W__KINB
MJ1V>+@X3[/(5VQ!N^)<BEIW;</T:709N'9MUC"F\0"S8BIT"Q!@CSGE>W^,B
M)*MB.TO?YTXIF<*L27D"'\MVW\IM/A=]K1.[3A]KUZ3;.'7XE&"&5A((3>='
MUWPO=ZP/Y53,XB*H3N<[8E_;7;]I8#7@,U7MN8M+OZ]<#R RG9^LRX..L<Y2
M(V46F0KIZ=RF<@;DKN^TX3?@0"?*=!RK?E=:RZ!D_1#6Q,))BIR1 [CIEDSU
MTUO'UDLJ^+6?C-I:*4V&5=OYJ5-KI(HFQBR0>LD8P<G^TJCN2XZNBV3P:O<E
MTRLBZ]BT^<[L:Z&34:LOA#I)&,3"UA*HU4=<6O\,X=/G&V96/E:QZ/&)>=8\
M)Z/57/#TTS&(AM6E3JM[.+?.D<*LSU$,KG#LX]/C,C.N;>#!LATN'I?0N>?0
M24(?C0Z29E^SY3Q0^7Z(:R^%#$%#)?4UR7L@V>5GI5MEY7?&U L)&N9CZ$_N
M79P_43+M4H0K"BW*K 31V>[&9\VKM1ZLZ2%BX/9UDZB%WJ'%[6N<\7+D]M8P
M.FV7X=L5YBP2I E"SF;&FUMW.,$,)WBGX9)Y)J%[F#4RP=Y]]LD!4I&5__LA
MC'%P'=W&U,=)<D$3Q7+>$6S&1#!MMA9Z6F?"\,*MH!3'#0\T80C4H.87##II
MX UU7Q5)BN<3"EE0+@R4[V?B()!GZFCP$XY8;"),X%6P"Z,0@A+<8LHD5O'X
M05+Z  ^0MI#_"8;<<;T:2S=\5Q8VJJA#QR$B=73 S>K<<D^;/=<<E6,:S6AL
M%2;3D\S2#=?HAJ(OH32>2%I.(&<S<+';<$,3/1.O?MV MDMRYLT<J"*PK=S4
M:>2:B;> T6;D32TYJ/@30\]VZ(##+ ^-?* 1K0\V?W1+9Q=!DN+(-S$&.=AZ
MFR048'V=S03?N++'H 9D\]T2274N S12Q:O*,_>T?(TRW\Y$ASH,.)H%D.RZ
MDM/^H^ PECQD&I>8_CCN&2>\#9K@?QTQ\\!JVV[=-,8<R+73-.\".66GO& 0
M%BJK*E<A* Y%<R;YG)"S<60FT-B4&J)D:_*VMNINS;?<<!1)U*33++OIU;1I
MU=0>] &G>BOUQA?UM5\C9-X=&'E$>A>'4YI^N[IIKS:<4BTIM3KCRCMOQ)+7
MOY][2>C#J4Y(#JE:@>L@*7WU#Y VGQ;EMHY8<!$%?:_0(S 5!XN"K1N.((L@
M552GXVAE[E,T$BJN4B#.3AP(#N%DQZ=^P?!R+PY6SVQFVN(/!VAAN-YPZ2JU
MAR-<39>#/J9Z',T[9B['F2<$::FV==931]H%-8/&,FV U.%'F0Q(" &O9 OG
MK\@Q(A P+%/NW6_>9KX-O_D;RS8OO.1I'=]Z<0J/%+-__.2%$4S<Z\T5DSA\
MQA&&?]QZ1R8WN8UI"DU**?N,%\FXN"%&ZB@;86P&[(#Z!U@4\Q,@-AG3Z P$
M032&NXXI]&,6O]@RT<0\33=H4TH'_]P+^="^$)!]THN^G3<6F+4C:A2V_LKE
M;I\ ;ORE&87=@N[OZEMNDY8M8^2F1_C3.MEV@"-&U0D$'5*2%O2\B@H'R143
M@E^P6._YD>V[SSCVPX1-%%'PBQ=#87?^*ZF%\0CBFL:CP\R*=>6"B%-PG/&"
M<,8O%R$JY,I>5"EO':%/0KK$!4L<91=T-"1:M@SAD[  F=-:;S+B\A;;1T+3
M+KM)6K&^G%W-\%RR+ F4J*3JM*SDR@MC?G._I";N7S[06^+YXC;05O)],U6*
MFC8DS<&*20%WT9RB:DOYFP I1?M<!N2!$"Y8F3K*5$_7DUP5*ZZIK3?@$U>$
M?M*ZE]-/9TS#W6ZZAEOOYE</V6H16"'.R[F+B%* 414%3F)G'W *[-F\_1P&
M.#@_?DR@\K^H+UO!6QVB(ZR&]>E0'[7=K\C-PJ5RL- -M]!J262T15[!W0V#
M'8$\':_SY:%<.?GA(.<"H/,C A'@ADI9EEE*,>OC8W03IJHGF]5OC>F&EE.Q
M=\[CAB.U:)EVZ\$=C68&+<C.<HRY"OY^$(4T2;;'<<WFQ.2!WF'0>TAP[03W
M@5J<JNS+,N:Y'+NRV7@"J9 8E@MQ+B>*\B-:]EOXF>_*'2!\AE'K9.E(B?1D
MIDJGAOVEFR4YM<A\-YB+BQXH*@1&C<(.^*/YV7XAYSH_" 5&> O-#S//!OZ(
M1A+G-NS';>SM^/G-XG712 )I),QB'4.'R+2P**X=;CALM5H1"OZ9B85*N=!-
MKVHL[2QDQ1TXN* [.$P0>SXJ>PH=%$;L)K12M/16\]DC,(*-^(*3&W/, #)4
M3E]NHI#OYN2U/AA>+Y<%8-:3Q-K"H^T8T6'925ULSF"N2ELVJ\; _Q*+_U:F
M_NQ=1LV^:M)41[5:D^1B84?IB8D'C3MK^7&2X%0<*%8>OG(D5]9 FNKK>CFH
M9MZ8LT4YWWHNF;&><=OH5"^W,8:7;"^SIO/YQ<LHX/7\*VZ,X[Q6CH-)K&4X
MVDB@,[[B96U^'4(XLZN^JX1]KQ_+:WQA.$OX=XYZ+D9QC1@*'<6MF-6 &4SE
M["O?IP>V3&;K%>^1*-TBDR!F$MH&<2LO$W,&L+P%#J[Z:!=DO>[8JCWGX>ES
ML@*NVR&X)O2E^,!"?YFCC7:G$WJ&(6O0M^)4P*.:N#KL5UWP#;E6JQJ7 -6
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MSB'Q7/&\\Q>6=E8*'J^C&Y9QBEE.VA/4"6O:O2HC*U9^7:GGZ\_@FPF\"Q.
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MZ][S52]6MGQ3<\_DA)*5C2S!!27 QH5]JV[-TWZ]N*7EVF&R4#'G,7['R9+
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MFZ+B)$R/B@EA'PG-9*.;I)4TL&2'2GXN)( 2Z%!)E3F*1.-MIE,8QN=ZMH=
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M2%739I2X6''B>@%7(0,J]DQ**5QP;SVPJ;ZZEP-L-48HH#H^>LPP5G(RS/7
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ME,&%U8HRPE1+T5H/(E99K#9,<?PQT'VZW@@^#Y39^947DD.,Q4NN6G8H2]J
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MEQ-FDLE=SISL&X7DXL$!M!>R9W7P+KC.)&9+)[,$O0J,C%%>>)I+(U]CT4E
MMXJB@Z 5<\^9%47(A8V[8*"#X% IG6DNTPE+BH/_?8"VA$>69>0\H(Q2)0_H
M)Z.="?21M90+<):0568\R[C'-VU=L!A)U*B"&IW-U:I+ $%7S#0,(S9=Y9,3
M^Y#!]-_:8$ZR_4;YI> U?B3N)R2U&Y,392-?@E[)J4HK)[:B@5<N+.+2E@O-
M8IHL!4:EQ%E/ZTSF[(J?@8-MJXE U<RZLP#71T$: \BY%$B:B'WVI]KZ;L[
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MIDBW8:JU-A8857F:=/*)1D0D!F/,X3_09T[(A,M+T=*T)@G:5MP^Y^NPXZM
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MUC;+3HP^U45377E/J=4.IA.5H*U.6S]NJ/*RU@WM.E(K.YHRW&N#3<<J>FG
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MD)HA>X^DA>R4'/ZQ\!JU_\:8?./UUB*'P4M[[7K90] 2P4TI+TEOL Y$B!R
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MM]7"\GTJ[.6X+FW>T]85"<;@H:)MR;@A57NQ(,0"GKB&8&T7"T;1U5-)1LM
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M]0G?:)UTRR;DZ:& -VW2#3XFOODNE^XE0[6_:4L3DS'9=6EY'G N=H< MYY
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M43 6,<"9'H>_+7&OA3.)E!<<#,0B_G)/4!T'XU#ZT\I+JUSKY6,G $[8O0J
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M7+&>91I2L@T%MCB,RFETY*A?L(F%KV4A3%&E/%^W'.M+(Z@KX8K9*9TGSAN
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MZS0)/L]CB6W2@S_][:#3:1V?X-0.8_6T;* G0 ( JHQQ?.(-C=4^WF(C?B,
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MZ_$O['?0 :"ZT;1MLB?KWJSNIOA976/_H-$)FM4&V<WQ7+!)P3LQ$9Q @ S
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M=K^0_G%TUPE?=<SIG)'U1&_Q%,</O]O05ARL\/Z9[G,UJ ^PL^LHFQF=] S
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M(Z2<E'Q@X,#DEYU":Y2%<XUS.W,4#4(\AXV=>V8J576 _^#:* V)TF\KX=9
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M_!Y$0JIV:-).K-:0:KJB^0FG*.9YK%+X,4Y%26_$?67HM?7^1B<LHW:D=)J
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MRCOZDK#A(&P6KL:WL96ZN5/4(9A"$; ^#"YOM9^ IBE6+3Z+P2K[(4*[[P,
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M,C!X"; CDI<)_.D&F4?OQFL29#'0/UZ,6[0V00XFS@@N6 #&+SV!UPN6*-Q
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M /%E&=(TH"H[E*S2&_<4>V6MPZ;]D L]PUYYUU_LE3R@_#3 *PP>VFVH47N
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M3E;(RFCOYQL@3RF.OET]4*.X BWS6^B#09*0,)B"SAZ&,@$=!9.2A 2+A6:
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M0\#'/0FO]E/NJ!9-1WKK#7GHW5.51'?XG++CT0]PAW_J@E7>SGP6]]239.*
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MW.$WCUG:Y.Z^))NP!P_ONXL/RO!:6X$88?<H!DRSR6*'38_"Y3.3:.$\6<-
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M7P>+'7YH!0?93VPV38EVM1<+U+N1*"B?(^[^9*U9.<WPW6!'ENVYJ7(U*T!
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M88T&]63=U)/MDQL&U-SS8<K48*+8S4GC^;\:']BL'?1[7]Y*#<1]8G[]V0]
M[J -4>P'\&I\V*[$<+@UZW9K!J7^<4K]G]NMNIY-$58K;Y:B$([J6OPDD<;
MW*IJY<;&B!<:EQ;8<,HZ_)'"$>W0,*2TV35XMT:IEZKY4 Z,Y9I6!(B#J_OG
M,!Z;PLO"/Z9&?N0_RIU B94X !ID!=],G%+B04V.005H/$<L-_AQ"/-F4/@P
M%<'+$"...W#^7P28GTYAI-A.D&K&WAV *A](UT<*J/*M^'IT=7I^);Y>?+D\
M/?YV=?;E?/T5Z$X4TM..@$\ZB[?C@X>V'W[<!O]\&7C!;3&0_YUD&+)[/ZC
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M%QF*53'-8K0#=&]T$I<DVD?MUXUV3/M,-ZQ60=,%O6H)"\;.(//M1V.9RTU
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M8]YG,IY;7*XC%+?"E( 9VK#@:$GC895%H&NJZ[,()E@L;'(OUC7W(AMJ[GU
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MD]4&8@ U%".!^NQ1XS68:C#58'I:8!(UF"H#IN/"Y]]D!YTU+#>4PIU; ?6
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M&[Z%[D?E/^+=C\I_^/LG4$L#!!0    ( .&):E2+M$3=FP@  #Y8   0
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ME@6#XL":-:=?!TX)(^<D!U0@Y9!^4JXP5A'$>CU658-&S.?,ZRA12!  =FD
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M(Q86/:"U6O9TI4Z4YD!TG$G87,YA<2P!=,P 0+ 0J!8"H:C.(W/MS*290CC
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M8DU_AID/#)[R^IT2+_;M1@QWO#*4/%L^[W!F@U9,AS,=SG0XL_DX4W'4V9P
M-BL6PD\5+]SI?/32%B?3BUQ3&+3C$<@9UFI^5'NP::V?U?D(N\W'QK-W!PH=
M*'2@\%\#"NL-2@07>$U*F4VPYR)6HB6C'&C^6\_E3\'\B+ZJ>O+$(H]GX=.B
M[0MTQEW DE5W,HV>3$0BIC*PD2JW\/W0;3$=YFS.ZNDPI\.<#G,V'W-LAME
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M,# P,#$N:G!G4$L! A0#%     @ X8EJ5%@4Y!F\?P  :=0  !8
M     ( !ZC(! &=G=&,T-7!Q,F\S-3 P,# P,BYJ<&=02P$"% ,4    " #A
MB6I48",18AA:  #7\P  %@              @ ':L@$ 9V=T8S0U<'$R;S,U
M,# P,# S+FIP9U!+ 0(4 Q0    ( .&):E2V7T\2ZFX  &.E   6
M      "  28- @!G9W1C-#5P<3)O,S4P,# P,#0N:G!G4$L! A0#%     @
MX8EJ5.8'B=PV10  TGP  !8              ( !1'P" &=G=&,T-7!Q,F\S
M-3 P,# P-2YJ<&=02P$"% ,4    " #AB6I4U<S6$^-B   #G   %@
M        @ &NP0( 9V=T8S0U<'$R;S,U,# P,# V+FIP9U!+ 0(4 Q0    (
M .&):E1)U2;+?OX  $*R 0 6              "  <4D P!G9W1C-#5P<3)O
M,S4P,# P,#<N:G!G4$L! A0#%     @ X8EJ5!K=2]:19P  Q9,  !8
M         ( !=R,$ &=G=&,T-7!Q,F\S-3 P,# P."YJ<&=02P$"% ,4
M" #AB6I4DOV?2NZO  "EW0  %@              @ $\BP0 9V=T8S0U<'$R
M;S,U,# P,# Y+FIP9U!+ 0(4 Q0    ( .&):E0NN[R:M#<  "4Z   6
M          "  5X[!0!G9W1C-#5P<3)O,S4P,# P,3 N:G!G4$L! A0#%
M  @ X8EJ5#<5J(R5>@, ;\ $ !8              ( !1G,% &=G=&,T-7!Q
M,F\S-3 P,# Q,2YJ<&=02P$"% ,4    " #AB6I4II9@=H3%  #P\@  %@
M            @ $/[@@ 9V=T8S0U<'$R;S,U,# P,#$R+FIP9U!+ 0(4 Q0
M   ( .&):E3E-+!Q_%4! %T2 @ 6              "  <>S"0!G9W1C-#5P
M<3)O,S4P,# P,3,N:G!G4$L! A0#%     @ X8EJ5,^;?<09<0$ ") ! !8
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M-7!Q,F\S-3 P,# Q-RYJ<&=02P$"% ,4    " #AB6I4GD Z1K_Y P"R5"P
M%0              @ %<Q \ ;VYC="TQ,&M?,C R,3$R,S$N:'1M4$L! A0#
M%     @ X8EJ5&X9O0(+%0  %=<  !$              ( !3KX3 &]N8W0M
M,C R,3$R,S$N>'-D4$L! A0#%     @ X8EJ5#;&YK2'"@  AH8  !4
M         ( !B-,3 &]N8W0M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M .&):E20*J*->R   (X+ @ 5              "  4+>$P!O;F-T+3(P,C$Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " #AB6I4K856MYMB  !SU 4 %0
M        @ 'P_A, ;VYC="TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @
MX8EJ5 *EY&='-P  4OT# !4              ( !OF$4 &]N8W0M,C R,3$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( .&):E08;_E+TQ@  +.S   4
M      "  3B9% !O;F-T+65X,3 Q.#%?-S,V+FAT;5!+ 0(4 Q0    ( .&)
M:E1-)_]FA!L  -2H   5              "  3VR% !O;F-T+65X,3 Q.#)?
M,3 Q-"YH=&U02P$"% ,4    " #AB6I4ZX?M?N)A   +3P( $P
M    @ 'TS10 ;VYC="UE>#$P,3A?-S,Y+FAT;5!+ 0(4 Q0    ( .&):E1_
M>".BM18  'J?   4              "  0<P%0!O;F-T+65X,3 Q.3%?-S,U
M+FAT;5!+ 0(4 Q0    ( .&):E20S+U< P8  *PE   4              "
M >Y&%0!O;F-T+65X,3 Q.3-?-S,X+FAT;5!+ 0(4 Q0    ( .&):E3*<K8R
M 7L   K*!  2              "  2--%0!O;F-T+65X,3 U7S@P-RYH=&U0
M2P$"% ,4    " #AB6I4DFZL]B0#   .#@  $P              @ %4R!4
M;VYC="UE>#(S,3!?.30U+FAT;5!+ 0(4 Q0    ( .&):E23+EG.J @  &%8
M   0              "  :G+%0!O;F-T+65X,S$Q7S@N:'1M4$L! A0#%
M  @ X8EJ5(NT1-V;"   /E@  !               ( !?]05 &]N8W0M97@S
M,3)?-BYH=&U02P$"% ,4    " #AB6I4;R>_[P<&  "'(   $
M    @ %(W14 ;VYC="UE>#,R,5\W+FAT;5!+ 0(4 Q0    ( .&):E18W*P.
M$@8  $,A   0              "  7WC%0!O;F-T+65X,S(R7SDN:'1M4$L!
M A0#%     @ X8EJ5+H,M_J7$P  ":4  !(              ( !O>D5 &]N
F8W0M97@T,3%?-# T+FAT;5!+!08     (P C !4)  "$_14    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
